

YONGHE MEDICAL GROUP CO., LTD.

雍禾醫療集團有限公司

(Incorporated in the Cayman Islands with limited liability)

Stock Code:2279

GLOBAL
OFFERING



Joint Sponsors, Joint Global Coordinators, Joint Bookrunners and Joint Lead Managers

Morgan Stanley

 CICC 中金公司

IMPORTANT

IMPORTANT: If you are in any doubt about any of the contents of this prospectus, you should obtain independent professional advice.

Yonghe Medical Group Co., Ltd.

雍禾醫療集團有限公司

(Incorporated in the Cayman Islands with limited liability)

GLOBAL OFFERING

Number of Offer Shares under the Global Offering	:	94,424,000 Shares (subject to the Over-allotment Option)
Number of Hong Kong Offer Shares	:	9,443,000 Shares (subject to reallocation)
Number of International Offer Shares	:	84,981,000 Shares (subject to reallocation and the Over-allotment Option)
Offer Price	:	HK\$15.80 per Offer Share, plus brokerage of 1%, SFC transaction levy of 0.0027%, and Stock Exchange trading fee of 0.005% (payable in full on application in Hong Kong dollars and subject to refund)
Nominal value	:	US\$0.0000025 per Share
Stock code	:	2279

Joint Sponsors, Joint Global Coordinators, Joint Bookrunners and Joint Lead Managers

Morgan Stanley



Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited and Hong Kong Securities Clearing Company Limited take no responsibility for the contents of this prospectus, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this prospectus.

A copy of this prospectus, having attached thereto the documents specified in “Appendix V — Documents Delivered to the Registrar of Companies and Available on Display”, has been registered by the Registrar of Companies in Hong Kong as required by section 342C of the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Chapter 32 of the Laws of Hong Kong). The Securities and Futures Commission and the Registrar of Companies in Hong Kong take no responsibility for the contents of this prospectus or any other document referred to above.

The Offer Shares have not been and will not be registered under the U.S. Securities Act or any state securities laws of the United States and may not be offered, sold, pledged, or transferred within the United States, except that Offer Shares may be offered, sold or delivered to QIBs in reliance on an exemption from registration under the U.S. Securities Act provided by, and in accordance with the restrictions of, Rule 144A or another exemption from the registration requirements of the U.S. Securities Act. The Offer Shares may be offered, sold or delivered outside of the United States in offshore transactions in accordance with Regulation S.

The Offer Price will be HK\$15.80 per Offer Share. Applicants for Hong Kong Offer Shares are required to pay, on application, the Offer Price of HK\$15.80 for each Hong Kong Offer Share together with a brokerage fee of 1%, a SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005%.

Prior to making an investment decision, prospective investors should consider carefully all of the information set out in this prospectus, including the risk factors set out in the section headed “Risk Factors.”

The Joint Global Coordinators (for themselves and on behalf of the Underwriters), with our consent, may reduce the number of Offer Shares being offered under the Global Offering and/or the Offer Price stated in this prospectus at any time on or prior to the morning of the last day for lodging applications under the Hong Kong Public Offering. In such a case, an announcement will be published on the websites of the Stock Exchange at www.hkexnews.hk and our Company at www.yonghegroup.cn not later than the morning of the day which is the last day for lodging applications under the Hong Kong Public Offering. Details of the arrangement will then be announced by us as soon as practicable. For further information, see “Structure of the Global Offering” and “How to Apply for the Hong Kong Offer Shares” in this prospectus.

The obligations of the Hong Kong Underwriters under the Hong Kong Underwriting Agreement are subject to termination by the Joint Global Coordinators (for themselves and on behalf of the Hong Kong Underwriters) if certain grounds arise prior to 8:00 a.m. on the Listing Date. See “Underwriting — Underwriting Arrangements and Expenses — Hong Kong Public Offering — Grounds for Termination.” in this prospectus.

ATTENTION

We have adopted a fully electronic application process for the Hong Kong Public Offering. We will not provide printed copies of this prospectus or printed copies of any application forms to the public in relation to the Hong Kong Public Offering.

This prospectus is available at the website of the Stock Exchange at www.hkexnews.hk and our website at www.yonghegroup.cn. If you require a printed copy of this prospectus, you may download and print from the website addresses above.

December 1, 2021

IMPORTANT

IMPORTANT NOTICE TO INVESTORS: FULLY ELECTRONIC APPLICATION PROCESS

We have adopted a fully electronic application process for the Hong Kong Public Offering. We will not provide printed copies of this prospectus or printed copies of any application forms to the public in relation to the Hong Kong Public Offering.

This prospectus is available at the website of the Stock Exchange at www.hkexnews.hk under the “HKEXnews> New Listings> New Listing Information” section, and our website at www.yonghegroup.cn. If you require a printed copy of this prospectus, you may download and print from the website addresses above.

To apply for the Hong Kong Offer Shares, you may:

- (1) apply online via the **HK eIPO White Form** service in the **IPO App** (which can be downloaded by searching “**IPO App**” in App Store or Google Play or downloaded at www.hkeipo.hk/IPOApp or www.tricorglobal.com/IPOApp) or at www.hkeipo.hk; or
- (2) apply through the **CCASS EIPO** service to electronically cause HKSCC Nominees to apply on your behalf, including by:
 - (i) instructing your **broker** or **custodian** who is a CCASS Clearing Participant or a CCASS Custodian Participant to give **electronic application instructions** via CCASS terminals to apply for the Hong Kong Offer Shares on your behalf; or
 - (ii) (if you are an existing **CCASS Investor Participant**) giving **electronic application instructions** through the CCASS Internet System (<https://ip.ccass.com>) or through the CCASS Phone System by calling +852 2979 7888 (using the procedures in HKSCC’s “An Operating Guide for Investor Participants” in effect from time to time). HKSCC can also input **electronic application instructions** for CCASS Investor Participants through HKSCC’s Customer Service Centre at 1/F, One & Two Exchange Square, 8 Connaught Place, Central, Hong Kong by completing an input request.

We will not provide any physical channels to accept any application for the Hong Kong Offer Shares by the public. The contents of the electronic version of this prospectus are identical to the printed prospectus as registered with the Registrar of Companies in Hong Kong pursuant to Section 342C of the Companies (WUMP) Ordinance.

If you are an intermediary, broker or agent, please remind your customers, clients or principals, as applicable, that this prospectus is available online at the website addresses above.

Please refer to the section headed “How to Apply for Hong Kong Offer Shares” in this prospectus for further details of the procedures through which you can apply for the Hong Kong Offer Shares electronically.

IMPORTANT

Your application through the **HK eIPO White Form** service or the **CCASS EIPO** service must be for a minimum of 500 Hong Kong Offer Shares and in one of the numbers set out in the table. You are required to pay the amount next to the number you select.

No. of Hong Kong Offer Shares applied for	Amount payable on application	No. of Hong Kong Offer Shares applied for	Amount payable on application	No. of Hong Kong Offer Shares applied for	Amount payable on application	No. of Hong Kong Offer Shares applied for	Amount payable on application
	<i>HK\$</i>		<i>HK\$</i>		<i>HK\$</i>		<i>HK\$</i>
500	7,979.61	7,000	111,714.52	50,000	797,960.83	700,000	11,171,451.62
1,000	15,959.22	8,000	127,673.73	60,000	957,553.00	800,000	12,767,373.28
1,500	23,938.83	9,000	143,632.95	70,000	1,117,145.16	900,000	14,363,294.94
2,000	31,918.43	10,000	159,592.17	80,000	1,276,737.33	1,000,000	15,959,216.60
2,500	39,898.05	15,000	239,388.25	90,000	1,436,329.49	2,000,000	31,918,433.20
3,000	47,877.65	20,000	319,184.33	100,000	1,595,921.66	3,000,000	47,877,649.80
3,500	55,857.26	25,000	398,980.42	200,000	3,191,843.32	4,000,000	63,836,866.40
4,000	63,836.87	30,000	478,776.50	300,000	4,787,764.98	4,721,500 ⁽¹⁾	75,351,441.18
4,500	71,816.48	35,000	558,572.58	400,000	6,383,686.64		
5,000	79,796.08	40,000	638,368.66	500,000	7,979,608.30		
6,000	95,755.30	45,000	718,164.75	600,000	9,575,529.96		

(1) Maximum number of Hong Kong Offer Shares you may apply for.

No application for any other number of the Hong Kong Offer Shares will be considered and any such application is liable to be rejected.

EXPECTED TIMETABLE⁽¹⁾

If there is any change in the following expected timetable of the Hong Kong Public Offering, we will issue an announcement in Hong Kong to be published on the Company's website at www.yonghegroup.cn and the website of the Stock Exchange at www.hkexnews.hk.

Hong Kong Public Offering commences 9:00 a.m. on
Wednesday, December 1, 2021

Latest time for completing electronic applications under
the **HK eIPO White Form** service through one of the ways below⁽²⁾:

- the **IPO App**, which can be downloaded by searching
“**IPO App**” in App Store or Google Play or downloaded at
www.hkeipo.hk/IPOApp or www.tricorglobal.com/IPOApp
- the designated website www.hkeipo.hk 11:30 a.m. on
Monday, December 6, 2021

Application lists open⁽³⁾ 11:45 a.m. on
Monday, December 6, 2021

Latest time for (a) completing payment of
HK eIPO White Form applications by effecting internet banking
transfer(s) or PPS payment transfer(s) and (b) giving **electronic**
application instructions to HKSCC⁽⁴⁾ 12:00 noon on
Monday, December 6, 2021

If you are instructing your **broker** or **custodian** who is a CCASS Clearing Participant or a CCASS Custodian Participant to give **electronic application instructions** via CCASS terminals to apply for the Hong Kong Offer Shares on your behalf, you are advised to contact your **broker** or **custodian** for the latest time for giving such instructions which may be different from the latest time as stated above.

Application lists close⁽³⁾ 12:00 noon on
Monday, December 6, 2021

Announcement of the level of indications of
interest in the International Offering, the level of applications in
the Hong Kong Public Offering and the basis of allocation of
the Hong Kong Public Offering to be published and on the
website of the Stock Exchange at www.hkexnews.hk and the
Company's website at www.yonghegroup.cn⁽⁵⁾ on or before⁽⁹⁾ Friday, December 10, 2021

EXPECTED TIMETABLE⁽¹⁾

The results of allocations in the Hong Kong Public Offering (with successful applicants' identification document numbers, where appropriate) to be available through a variety of channels, including:

- in the announcement to be posted on our website and the website of the Stock Exchange at www.yonghegroup.cn and www.hkexnews.hk, respectively⁽⁹⁾ Friday, December 10, 2021
- from the "IPO Results" function in the **IPO App** or the designated results of allocations website at www.hkeipo.hk/IPOResult (or www.tricor.com.hk/ipo/result) with a "search by ID" function from⁽⁹⁾ 8:00 a.m. on Friday, December 10, 2021 to 12:00 midnight on Thursday, December 16, 2021
- from the allocation results telephone enquiry line by calling +852 3691 8488 between 9:00 a.m. and 6:00 p.m. from⁽⁹⁾ . . . Friday, December 10, 2021 to Wednesday, December 15, 2021 (excluding Saturday, Sunday and public holidays in Hong Kong)

Share certificates in respect of wholly or partially successful applications to be dispatched/collected or deposited into CCASS on or before^{(6) (8) (9)} Friday, December 10, 2021

HK eIPO White Form e-Auto Refund payment instructions/refund checks in respect of wholly or partially unsuccessful applications to be dispatched/collected on or before^{(7) (8) (9)} Friday, December 10, 2021

Dealings in the Shares on the Stock Exchange expected to commence at⁽⁹⁾ 9:00 a.m. on Monday, December 13, 2021

<p>The application for the Hong Kong Offer Shares will commence on Wednesday, December 1, 2021 through Monday, December 6, 2021. The application monies (including brokerage, SFC transaction levy and Stock Exchange trading fee) will be held by the receiving bank on behalf of the Company and the refund monies, if any, will be returned to the applicant(s) without interest on Friday, December 10, 2021. Investors should be aware that the dealings in Shares on the Stock Exchange are expected to commence on Monday, December 13, 2021.</p>
--

EXPECTED TIMETABLE⁽¹⁾

Notes:

- (1) Unless otherwise stated, all times and dates refer to Hong Kong local times and dates.
- (2) You will not be permitted to submit your application under the **HK eIPO White Form** service through the **IPO App** or the designated website at www.hkeipo.hk after 11:30 a.m. on the last day for submitting applications. If you have already submitted your application and obtained an application reference number from the **IPO App** or the designated website prior to 11:30 a.m., you will be permitted to continue the application process (by completing payment of application monies) until 12:00 noon on the last day for submitting applications, when the application lists close.
- (3) If there is/are a “black” rainstorm warning or a tropical cyclone warning signal number 8 or above and/or Extreme Conditions in force in Hong Kong at any time between 9:00 a.m. and 12:00 noon on Monday, December 6, 2021, the application lists will not open and will close on that day. For further details, please see “How to Apply for the Hong Kong Offer Shares — 10. Effect of Bad Weather and/or Extreme Conditions on the Opening and Closing of the Application Lists” in this prospectus.
- (4) Applicants who apply for Hong Kong Offer Shares by giving **electronic application instructions** to HKSCC via CCASS should refer to the section headed “How to Apply for the Hong Kong Offer Shares — 6. Applying Through the **CCASS EIPO Service**” in this prospectus.
- (5) None of the websites or any of the information contained on the websites forms part of this prospectus.
- (6) Share certificates will only become valid at 8:00 a.m. on the Listing Date provided that the Global Offering has become unconditional and the right of termination described in “Underwriting — Underwriting Arrangements and Expenses — Hong Kong Public Offering — Grounds for Termination” has not been exercised. Investors who trade Shares on the basis of publicly available allocation details prior to the receipt of Share certificates or prior to the Share certificates becoming valid certificates of title do so entirely at their own risk.
- (7) e-Auto Refund payment instructions/refund cheques will be issued in respect of wholly or partially unsuccessful applications pursuant to the Hong Kong Public Offering. Part of the applicant’s identification document number provided by the applicant(s) may be printed on the refund check, if any. Such data would also be transferred to a third party for refund purposes. Banks may require verification of an applicant’s identification document number before encashment of the refund check. Inaccurate completion of an applicant’s identification document number may invalidate or delay encashment of the refund check.
- (8) Applicants who have applied through the **HK eIPO White Form** service for 1,000,000 or more Hong Kong Offer Shares may collect any refund checks (where applicable) and/or Share certificates in person from our Hong Kong Share Registrar, Tricor Investor Services Limited, at Level 54, Hopewell Centre, 183 Queen’s Road East, Hong Kong from 9:00 a.m. to 1:00 p.m. on Friday, December 10, 2021 or such other date as notified by us as the date of dispatch/collection of Share certificates/e-Auto Refund payment instructions/refund checks. Applicants being individuals who are eligible for personal collection may not authorize any other person to collect on their behalf. If you are a corporate applicant which is eligible for personal collection, your authorised representative must bear a letter of authorization from your corporation stamped with your corporation’s chop. Both individuals and authorized representatives must produce evidence of identity acceptable to our Hong Kong Share Registrar at the time of collection.

Applicants who have applied for Hong Kong Offer Shares through the **CCASS EIPO** service should refer to the section headed “How to Apply for the Hong Kong Offer Shares — 14. Despatch/Collection of Share Certificates and Refund Monies — Personal Collection — (ii) if you apply through the **CCASS EIPO** service” in this document for details.

Applicants who have applied through the **HK eIPO White Form** service and paid their applications monies through single bank accounts may have refund monies (if any) dispatched to the bank account in the form of e-Auto Refund payment instructions. Applicants who have applied through the **HK eIPO White Form** service and paid their application monies through multiple bank accounts may have refund monies (if any) dispatched to the address as specified in their application instructions in the form of refund checks in favour of the applicant (or, in the case of joint applications, the first-named applicant) by ordinary post at their own risk.

Share certificates and/or refund checks for applicants who have applied for less than 1,000,000 Hong Kong Offer Shares and any uncollected Share certificates and/or refund checks will be dispatched by ordinary post, at the applicants’ risk, to the addresses specified in the relevant applications.

Further information is set out in the sections headed “How to Apply for the Hong Kong Offer Shares — 13. Refund of Application Monies” and “How to Apply for Hong Kong Offer Shares — 14. Despatch/Collection of Share Certificates and Refund Monies”.

EXPECTED TIMETABLE⁽¹⁾

- (9) In case a typhoon warning signal no.8 or above, a black rainstorm warning signal and/or Extreme Conditions is/are in force in any days between Wednesday, December 1, 2021 to Monday, December 13, 2021, then the day of (i) announcement of results of allocations in the Hong Kong Public Offering; (ii) despatch of Share certificates and refund checks/**HK eIPO White Form** e-Auto Refund payment instructions; and (iii) dealings in the Shares on the Stock Exchange may be postponed and an announcement may be made in such event.

The above expected timetable is a summary only. For further details of the structure of the Global Offering, including its conditions, and the procedures for applications for Hong Kong Offer Shares, please see “Structure of the Global Offering” and “How to Apply for the Hong Kong Offer Shares” in this prospectus, respectively.

If the Global Offering does not become unconditional or is terminated in accordance with its terms, the Global Offering will not proceed. In such case, the Company will make an announcement as soon as practicable thereafter.

TABLE OF CONTENTS

You should rely only on the information contained in this prospectus to make your investment decision. We have not authorized anyone to provide you with information that is different from what is contained in this prospectus. Any information or representation not made in this prospectus must not be relied on by you as having been authorized by us, the Joint Global Coordinators, the Joint Bookrunners, the Joint Lead Managers, the Joint Sponsors, the Underwriters, any of our or their respective directors, officers, employees, partners, agents or representatives, or any other party involved in the Global Offering.

	<i>Page</i>
EXPECTED TIMETABLE	i
TABLE OF CONTENTS	v
SUMMARY	1
DEFINITIONS AND GLOSSARY	25
FORWARD-LOOKING STATEMENTS	39
RISK FACTORS	41
WAIVERS FROM STRICT COMPLIANCE WITH THE LISTING RULES	79
INFORMATION ABOUT THIS PROSPECTUS AND THE GLOBAL OFFERING	82
DIRECTORS AND PARTIES INVOLVED IN THE GLOBAL OFFERING	86
CORPORATE INFORMATION	91
INDUSTRY OVERVIEW	93
REGULATORY OVERVIEW	106
HISTORY, DEVELOPMENT AND CORPORATE STRUCTURE	131
BUSINESS	151
FINANCIAL INFORMATION	247
CONTRACTUAL ARRANGEMENTS	306
SHARE CAPITAL	319
RELATIONSHIP WITH OUR CONTROLLING SHAREHOLDERS	322

TABLE OF CONTENTS

	<i>Page</i>
CONTINUING CONNECTED TRANSACTIONS	325
CORNERSTONE INVESTORS	329
SUBSTANTIAL SHAREHOLDERS	337
DIRECTORS AND SENIOR MANAGEMENT	341
FUTURE PLANS AND USE OF PROCEEDS	354
UNDERWRITING	359
STRUCTURE OF THE GLOBAL OFFERING	371
HOW TO APPLY FOR THE HONG KONG OFFER SHARES	380
APPENDIX I — ACCOUNTANT’S REPORT	I-1
APPENDIX II — UNAUDITED PRO FORMA FINANCIAL INFORMATION	II-1
APPENDIX III — SUMMARY OF THE CONSTITUTION OF THE COMPANY AND CAYMAN ISLANDS COMPANY LAW	III-1
APPENDIX IV — STATUTORY AND GENERAL INFORMATION	IV-1
APPENDIX V — DOCUMENTS DELIVERED TO THE REGISTRAR OF COMPANIES AND AVAILABLE ON DISPLAY	V-1

SUMMARY

This summary aims to give you an overview of the information contained in this prospectus and is qualified in its entirety by, and should be read in conjunction with, the more detailed information and financial information appearing elsewhere in this prospectus. As this is a summary, it does not contain all the information that may be important to you and we urge you to read the entire prospectus carefully before making your investment decision. There are risks associated with any investment. Some of the particular risks in investing in the Offer Shares are set out in the section headed “Risk Factors” in this prospectus. You should read that section carefully before you decide to invest in the Offer Shares.

OVERVIEW

We are the leading medical group in China specialized in providing hair-related healthcare services in terms of total revenue for 2020. We offer one-stop hair-related healthcare services covering hair transplant, medical hair care, and routine hair restoration and other ancillary services. According to Frost & Sullivan, we are the largest player in China’s hair transplant service market with a market share of 10.5% and medical hair care service market with a market share of 4.3%, in terms of total revenue derived from the relevant services in 2020. Among all hair-related healthcare service providers in China, we ranked first in terms of the number of registered physicians at the end of 2020, the number of clinics in operation at the end of 2020, and the number of hair transplant patients for 2020, according to Frost & Sullivan. We adopt a standardized and scalable business model to operate a hair transplant chain consisting of mostly self-operated clinics. As of the Latest Practicable Date, we operated 53 clinics in 52 cities nationwide, making us the largest and most extensive hair transplant clinic chain in China, according to Frost & Sullivan. During the Track Record Period, we opened 29 new clinics in mainland China and acquired one clinic in Hong Kong, achieving the fastest growth among all hair transplant clinic chains in China and further widening our lead over the runners-up.

Through decades of dedication and commitment to China’s hair-related healthcare industry, we have made *Yonghe Hair Transplant* (雍禾植髮) a well-known and highly trusted brand among its peers, and have promoted many major developments and advancements in the industry. In 2010, we became the first ISO-certified hair transplant service provider in China, and by the end of 2017, we had successfully opened 22 hair transplant clinics across China. In 2017, we obtained investment from CITIC PE, who helped us enhance our corporate governance and further expand our business. In 2017, we acquired the mainland China business of *Svenson*, a globally renowned brand originated from London that had over six decades of experience in offering hair restoration products and services. From 2018 onwards, leveraging our strong medical service capabilities and *Svenson*’s extensive experience in hair restoration, we strategically took inroads into the medical hair care service sector and successfully established a *Svenson Medical Hair Care Center* (史雲遜醫學健髮中心) in each of our clinics in mainland China under a “shop-in-shop” model. During the Track Record Period, we derived a majority of our revenue from providing hair transplant services, and a substantial and increasing portion of our revenue from providing medical hair care services. We also expanded our footprint outside the mainland China in May 2021 by acquiring the Hong Kong business of *Nu/Hart Hair* (顯赫植髮), a renowned hair transplant service provider originated from the U.S. In addition, through our cooperation with prestigious universities such as Sun Yat-sen University, we are blazing a trail toward collaborative research and development with academia and showing the way forward for the hair-related healthcare service industry. We believe that by breaking those new grounds, we are enhancing our core competitiveness and further strengthening our leading position in the industry.

SUMMARY

We have been persistently specializing in the hair-related healthcare service market. Driven by the soaring prevalence of hair problems in China, the increasing disposable income *per capita* of Chinese residents and elevated self-awareness of appearance, China's hair-related healthcare service market is expanding rapidly. According to Frost & Sullivan, the size of the hair-related healthcare service market in China reached RMB18.4 billion in 2020, and is projected to grow to RMB138.1 billion in 2030 with a CAGR of 22.3%. China's hair-related healthcare service market consists of two main parts — the hair transplant service market and the medical hair care service market. Hair transplant is a surgical treatment for hair loss, i.e., alopecia. According to Frost & Sullivan, approximately 250.9 million people suffered from alopecia in China in 2020. Medical hair care integrates various non-surgical treatment methods, such as medical devices and medications, and is able to address the diversified needs of a larger patient pool with various scalp and hair problems. According to Frost & Sullivan, China's hair transplant service market reached RMB13.4 billion in 2020, and is projected to grow to RMB75.6 billion in 2030 with a CAGR of 18.9%. China's medical hair care service market is still at an early stage of development with a market size of only RMB5.0 billion in 2020, but is believed to harbor huge growth potential and is expected to grow to RMB62.5 billion in 2030 at a CAGR of 28.7%. We are the largest service provider in each of hair transplant service market and the medical hair care service market in China by revenue derived from the relevant services in 2020, with a leading market share of approximately 10.5% and 4.3%, respectively, according to Frost & Sullivan. With our industry-leading prowess in medical examination and diagnosis, and continuing innovation in product and service offerings, we believe we are well-positioned to capture the huge growth potential of China's hair-related healthcare service market.

Our in-house professional medical staff is at the core of our hair-related healthcare services. Leveraging our standardized and proven physician training system, as of the Latest Practicable Date, we had built a professional medical team consisting of 1,233 members, including 246 registered physicians and 919 nurses. By standardizing our diagnostic and therapeutic service system, we are able to provide consistent, high-quality medical services and achieve rapid expansion of clinics without compromising the quality of service.

Leveraging our standardized and highly scalable business model, we have achieved industry-leading operational capabilities, enabling us to effectively control costs, boost operational efficiency and improve profitability. During the Track Record Period, our gross profit margin remained largely stable, while our administrative expenses as a percentage of our total revenue continued to decrease.

We have built a one-stop shop for medical hair care services to meet the medical demands of a wide range of patients. We continue to improve our diagnostic, therapeutic, and research and development capabilities by collaborating with experts from Class IIIA hospitals and renowned academic institutions. In addition, in order to continuously improve medical service to patients, to stay ahead of the technological curve and to propel business development, we have always been actively promoting and adopting new technologies in our business, including data usage and analysis, intelligent services and online services. We believe that such strengths have reinforced our industry-leading position and will sustain our growth momentum into the future.

We experienced significant growth during the Track Record Period. Our total revenue increased by 31.1% from RMB934.3 million in 2018 to RMB1.22 billion in 2019, and grew by another 33.8% to RMB1.64 billion in 2020. For the six months ended June 30, 2021, our revenue amounted to RMB1.05 billion, representing an increase of 75.1% as compared to the corresponding period in 2020. While our revenue was generated mainly from rendering hair transplant services, revenue from medical hair care services grew rapidly over the same period. We recorded a net profit of RMB53.5 million in 2018,

SUMMARY

RMB35.6 million in 2019, RMB163.3 million in 2020 and RMB40.4 million in the six months ended June 30, 2021. The total number of patients receiving our treatments increased by 41.7% from 35,177 in 2018 to 49,851 in 2019, and further increased by 82.7% to 91,069 in 2020. In the six months ended June 30, 2021, the total number of patients receiving our treatments reached 68,112. Our clinics' average initial breakeven period is approximately three months and their average cash payback period is approximately 14 months, better than the average for private medical institutions in China, according to Frost & Sullivan.

OUR COMPETITIVE STRENGTHS

We believe the following strengths have contributed to our success and differentiated us from our competitors: (1) China's largest hair transplant service provider; (2) nationwide footprint in major metropolitan centers with great growth potential; (3) industry-leading operational and medical service capabilities; (4) one-stop-shop hair-related healthcare service system rooted in tenacious innovation in product and service offerings; (5) industry-leading technology; and (6) visionary and seasoned management and strong shareholder support.

OUR STRATEGIES

Our mission is to become a world-leading one-stop shop for hair-related healthcare services. We plan to implement the following strategies to achieve that goal: (1) continue our network expansion and upgrade, and strengthen talent development and recruitment; (2) promote further innovations in product and service offerings to expand the one-stop-shop system for hair-related healthcare service; (3) continue to adopt new technologies; and (4) integrate industry resources and promote multi-brand strategy.

OUR CLINIC NETWORK

We own and operate the largest and most widely distributed hair transplant clinic chain in China, according to Frost & Sullivan. As of the Latest Practicable Date, we had 53 hair transplant clinics nationwide, 52 of which were self-operated and one was acquired from third parties. We experienced rapid expansion in recent years. The following table sets out the number of our clinics during the Track Record Period.

	Year Ended December 31,			Six Months Ended June 30,
	2018	2019	2020	2021
Number of clinics in operation at the beginning of the period	22	30	37	48
Number of new clinics opened during the period	8	7	11	3
Number of clinics acquired during the period	—	—	—	1
Number of clinics in operation at the end of the period	30	37	48	52

SUMMARY

Geographic Locations

As of the Latest Practicable Date, our 53 hair transplant clinics covered 52 cities in 26 provinces, autonomous regions and centrally-administered municipalities (collectively, “**provinces**”) across mainland China and in Hong Kong. We typically enter a province by setting up our clinics in the provincial capital first. During the Track Record Period, we primarily focused on establishing our market presence in regions with huge hair transplant demands and high *per capita* income. We are striving to achieve regional concentration strategy by opening clinics in more cities in such regions. The following table sets forth the breakdown of the number and revenue of our clinics in operation by geographical regions for the periods indicated:

	As of/for the Year Ended December 31,						As of/for the Six Months Ended June 30,	
	2018		2019		2020		2021	
	<i>Revenue</i>		<i>Revenue</i>		<i>Revenue</i>		<i>Revenue</i>	
	<i>Number (RMB'000)</i>		<i>Number (RMB'000)</i>		<i>Number (RMB'000)</i>		<i>Number (RMB'000)</i>	
Eastern China ⁽¹⁾	10	259,128	15	369,918	21	563,896	23	363,024
Southern China ⁽²⁾	4	174,960	5	261,075	10	348,583	10	249,233
Northern China ⁽³⁾	4	191,221	4	208,752	4	234,407	4	128,929
Southwestern China ⁽⁴⁾	4	97,950	4	121,176	4	184,969	4	100,996
Central China ⁽⁵⁾	3	120,146	3	126,507	3	143,004	4	96,804
Northwestern China ⁽⁶⁾	2	45,463	3	72,122	3	93,740	3	67,553
Northeastern China ⁽⁷⁾	3	29,146	3	53,285	3	57,359	3	36,418
Hong Kong ⁽⁸⁾	–	–	–	–	–	–	1	754
Total	30	918,014	37	1,212,835	48	1,625,958	52	1,043,711

Notes:

- (1) Including Shanghai, Zhejiang, Jiangsu, Fujian, Jiangxi, An'hui and Shandong.
- (2) Including Guangdong and Guangxi.
- (3) Including Beijing, Tianjin, Hebei and Shanxi.
- (4) Including Sichuan, Guizhou, Yunnan and Chongqing.
- (5) Including Henan, Hubei and Hunan.
- (6) Including Shaanxi, Gansu and Xinjiang.
- (7) Including Heilongjiang and Liaoning.
- (8) Including one acquired clinic, Nu/Hart Hair, in Hong Kong.

SUMMARY

Development Stages

Our clinics can be categorized into three groups based on their respective opening date, including mature-stage clinics (i.e., clinics that have been established for more than three years), developing-stage clinics (i.e., clinics that have been established for one to three years), and newly-established clinics (i.e., clinics that have been established for less than one year). For acquired clinics, we regard the date when their financial position and results of operations are consolidated into our Group as their respective opening date. During the Track Record Period, we only acquired one clinic in May 2021. As of the Latest Practicable Date, we had 30 mature-stage clinics, 17 developing-stage clinics and six newly-established clinics (including the acquired clinic).

The following table sets forth the breakdown of the number and revenue of our clinics by development stage for the periods indicated:

	As of/for the Year Ended December 31,						As of/for the Six Months Ended	
	2018		2019		2020		June 30, 2021	
	<i>Revenue</i> <i>Number (RMB'000)</i>		<i>Revenue</i> <i>Number (RMB'000)</i>		<i>Revenue</i> <i>Number (RMB'000)</i>		<i>Revenue</i> <i>Number (RMB'000)</i>	
Mature-stage clinics	10	555,038	16	831,989	22	1,196,970	24	722,954
Developing-stage clinics	12	300,766	14	338,917	15	328,511	17	234,541
Newly-established clinics	8	62,210	7	41,929	11	100,477	11	86,216
– Acquired clinic	–	–	–	–	–	–	1	754
Total	30	918,014	37	1,212,835	48	1,625,958	52	1,043,711

SUMMARY

OUR BUSINESS

We are the leading medical group in China specialized in providing hair-related healthcare services in terms of total revenue for 2020. During the Track Record Period, we focused on providing hair transplant services while constantly expanding the boundaries of our business. Since 2019, we started to provide medical hair care services by establishing a *Svenson Medical Hair Care Center* (史雲遜醫學健髮中心) in each of our hair transplant clinics in mainland China under a “shop-in-shop” model. Our *Svenson Medical Hair Care Centers* provide patients with non-surgical, effective and affordable medical solutions on various scalp and hair problems, including but not limited to hair loss, soft hair, itching scalp and oily scalp. The following table sets forth the components of our revenue by business line for the period indicated.

	Year Ended December 31,						Six Months Ended June 30,			
	2018		2019		2020		2020		2021	
	RMB'000	%	RMB'000	%	RMB'000	%	RMB'000	%	RMB'000	%
Hair transplant services	918,014	98.3	1,197,775	97.8	1,412,744	86.2	567,225	94.3	789,522	75.0
Medical hair care services	–	–	15,060	1.2	213,214	13.0	30,687	5.1	254,189	24.1
Others ⁽¹⁾	16,312	1.7	11,642	1.0	12,339	0.8	3,651	0.6	9,689	0.9
Total	934,326	100.0	1,224,477	100.0	1,638,297	100.0	601,563	100.0	1,053,400	100.0

Note:

- (1) Others mainly include revenue from *Svenson Hair Care Centers* (史雲遜健髮中心) we acquired in December 2017. These *Svenson Hair Care Centers* are not medical institutions and primarily engaged in providing routine hair restoration products (such as anti-hair loss shampoo and head massager) and services (such as scalp cleaning and massaging) without using medicines or medical devices.

The following table sets forth a breakdown of our gross profit and gross profit margin by business line for the periods indicated:

	Year Ended December 31,						Six Months Ended June 30,			
	2018		2019		2020		2020		2021	
	Gross profit	Gross profit margin	Gross profit	Gross profit margin	Gross profit	Gross profit margin	Gross profit	Gross profit margin	Gross profit	Gross profit margin
	RMB'000	%	RMB'000	%	RMB'000	%	RMB'000	%	RMB'000	%
Hair transplant services	703,767	76.7	886,700	74.0	1,061,144	75.1	417,519	73.6	572,306	72.5
Medical hair care services ⁽¹⁾	–	–	4,816	32.0	157,305	73.8	17,781	57.9	197,817	77.8
Others ⁽²⁾	(1,648)	(10.1)	(2,418)	(20.8)	3,181	25.8	251	6.9	5,294	54.6
Total gross profit/overall gross profit margin	702,119	75.2	889,098	72.6	1,221,630	74.6	435,551	72.4	775,417	73.6

SUMMARY

Notes:

- (1) Our gross profit margin of our medical hair care services increased significantly from 2019 to 2020, primarily because we started to ramp up our business in medical hair care sector and formed a scale effect corresponding with the growth of our hair transplant services. For details, see “Financial Information — Results of Operations — Year Ended December 31, 2020 Compared with Year Ended December 31, 2019 — Gross Profit and Gross Profit Margin — Medical Hair Care Services.”
- (2) We recorded gross losses in other services in 2018 and 2019, primarily because we incurred more costs as compared to revenue at initial stage of *Svenson Hair Care Centers* (史雲遜健髮中心) and its business integration. For details, see “Financial Information — Description of Selected Components of Consolidated Statements of Comprehensive Income — Gross Profit and Gross Profit Margin.”

LEGAL PROCEEDINGS AND COMPLIANCE

Legal Proceedings

During the Track Record Period and up to the Latest Practicable Date, we were not involved in any litigation or arbitration proceedings pending or, to our knowledge, threatened against us or any of our Directors that could have a material and adverse effect on our business, financial condition or results of operations. For details, see “Business — Legal Proceedings” in this prospectus.

Compliance

During the Track Record Period and up to the Latest Practicable Date, we experienced certain non-compliance incidents, including performing hair plant surgeries without the supervision of a qualified physician, failure to obtain, or to promptly update, certain licenses and permits necessary for the operation of some of our clinics (e.g., the medical institution practicing licenses, the fire safety procedures, the water discharge licenses, etc.), and non-compliances relating to the Advertisement Law of the PRC. As of the Latest Practicable Date, we had fully rectified most of the non-compliance incidents identified during the Track Record Period, except that: (i) with respect to a few clinics, we had not obtained the relevant water discharge licenses or had not completed the relevant fire safety procedures, for reasons outside of our control; we had either ceased the operation of such clinics and relocated them to new locations in the same cities, or were in the process of obtaining/completing the relevant licenses/procedures; and (ii) with respect to the lease registration and potential title defects concerning certain of our leased properties, we and/or the lessors of the relevant properties still need some time to complete the relevant administrative procedures. We currently expect to fully rectify all the relevant non-compliances in the first quarter of 2022 at the latest. We have adopted a number of enhanced internal control measures to prevent the recurrence of similar non-compliances, including (i) establishing a Regulatory Compliance Committee at the Group level, which is headed by Mr. Zhang, our founder and chief executive officer, and comprised seven Directors and/or senior officers of our Group; (ii) establishing a Compliance Management Inspection Team comprising staff from our legal and compliance department as well as audit department, which team will assist our Regulatory Compliance Committee in monitoring and supervising the rectification of the identified non-compliances, and in preventing the recurrence of similar non-compliances; and (iii) arranging our Directors, officers and other employees to attend training sessions conducted by our PRC Legal Adviser on applicable laws, regulations and rules in relation to our operation. See “Business — Licenses, Permits, Approvals and Compliance” for more information about the non-compliance incidents and the rectification measures we took in relation thereto, and see “Business — Internal Control and Risk Management” for more information about the enhanced internal control measures we adopted to prevent the recurrence of the non-compliances and

SUMMARY

their implementation status. We undertake to continue to use our reasonable best efforts to rectify our historical non-compliances and to prevent similar non-compliances from recurring, and expect to incur additional costs as a result of our such efforts. See “Risk Factors — Risks Relating to Our Business” for the various risks in this regard.

OUR CUSTOMERS

During the Track Record Period, substantially all of our customers consisted of individual customers, and none of these individual customers accounted for more than 5% of our total revenue. We have not entered into any long-term agreements with our individual customers. We generally do not extend any credit periods to our customers.

To the best knowledge and belief of our Directors, our five largest customers during the Track Record Period were Independent Third Parties. None of our Directors or their close associates or any of our Shareholders (who, to the best knowledge of our Directors, beneficially own more than 5% of our Share capital) had any interest in any of our five largest customers during the Track Record Period.

OUR SUPPLIERS

During the Track Record Period, our suppliers primarily included providers of advertising services, IT services, pharmaceuticals, surgical consumables and hair care products. We have maintained a list of suppliers approved by our senior management team.

Our headquarters is in charge of our overall procurement strategy. Pharmaceuticals, surgical consumables, hair care products and other products are centrally procured by the headquarters. Most procurements have gone through a tender or price comparison process except for a few local procurements in small scale. For any given type of raw materials or supplies, we typically have multiple suppliers in order to obtain competitive prices from suppliers, maintain sourcing stability and avoid over-reliance risk. During the Track Record Period, we did not experience any interruption in our supplies, early termination of supply agreements, or failure to secure sufficient supplies that had any material adverse impact on our business or results of operations. Our suppliers generally offer us a credit term of 30 to 90 days. We typically settle trade payable obligations with respect to our suppliers through bank transfers.

For each of 2018, 2019, 2020 and the six months ended June 30, 2021, purchases from our five largest suppliers amounted to RMB186.4 million, RMB280.6 million, RMB278.7 million and RMB217.4 million, respectively, representing approximately 23%, 25%, 20% and 23%, respectively, of our total purchases for the respective periods. For each of 2018, 2019, 2020 and the six months ended June 30, 2021, purchases from our largest supplier amounted to RMB119.2 million, RMB168.9 million, RMB114.9 million and RMB71.3 million, respectively, representing approximately 15%, 15%, 8% and 7%, respectively, of our total purchases for the respective periods.

All of our top five largest suppliers are Independent Third Parties. None of our Directors, their associates or any of our current Shareholders (who, to the knowledge of our Directors, own more than 5% of our share capital) has any interest in any of our top five largest suppliers required to be disclosed under the Listing Rules.

SUMMARY

PRICING

Pricing policies are determined by our headquarters based on cost and market positioning. Our headquarters has adopted a uniform pricing guideline. We generally apply the same prices for our services across all clinics in our network. In line with industry practice, the local clinics from time to time offer discounts to customers for certain services they provide, as part of their marketing strategies. Managers of the local clinics have the discretion to determine the appropriate discount level for the relevant services, subject to a maximum level set by our headquarters, and prior approval from our headquarters needs to be obtained if they, in exceptional cases, intend to offer discounts exceeding the maximum level. During the Track Record Period, we recorded our revenue based on the actual prices we charged (i.e., after taking into consideration the discounts offered, if any), and did not record the exact amounts of the discounts offered by the clinics. For details of our revenue recognition, see “Financial Information — Significant Accounting Policies and Critical Judgments and Estimates — Significant Accounting Policies — Revenue Recognition.”

Our internal pricing policy provides reference price points of various treatment options across our operations in the PRC. We set this price taking into account certain factors, such as experience of physicians, customer needs and operating costs. Our headquarters and regional managers strictly control and monitor clinical prices to ensure they have followed our pricing policies. We also closely monitor the pricing of our competitors in the same regions to evaluate our pricing.

MARKETING

We believe that ultimately, our reputation has been, and will continue to be, built upon our service quality, and that the most effective marketing channel is the spontaneous word-of-mouth referral by our satisfied customers. Based on a survey conducted by Frost & Sullivan among over 1,100 patients who received our services, 29.7% of the surveyed patients first learned about us through recommendations from their friends or family members, and 88.5% of the surveyed patients indicated that they will recommend us to their friends and family members who are in need of hair transplant services.

In the meantime, we recognize the importance of long-term investment in brand building and consumer education. Therefore, in line with other players in the consumer medical service industry, particularly the hair-related healthcare industry, we made significant investments in promoting customer awareness of our brand and our services, and expect to continue to do so in the near future.

We have designed a comprehensive marketing strategy, and utilize a combination of online and offline channels to promote our brand and our services, using various forms of advertisements.

In 2018, 2019, 2020 and the six months ended June 30, 2021, the marketing and promotion expenses we incurred amounted to RMB328.1 million, RMB458.1 million, RMB507.7 million and RMB389.4 million, respectively, among which the marketing and promotion expenses incurred through online channels (e.g., Tencent, Baidu, Bytedance, Kuaishou, Weibo, etc.) amounted to RMB177.6 million, RMB365.5 million, RMB382.0 million and RMB314.8 million, respectively, and the marketing and promotion expenses incurred through offline channels (e.g., subway stations, office buildings, shopping complexes and cinemas) amounted to RMB150.5 million, RMB92.7 million, RMB125.7 million and RMB74.7 million, respectively. The marketing and promotion expenses incurred through online channels can be further break down into those incurred for brand advertising and those incurred for performance-based advertising. In 2018, 2019, 2020 and the six months ended June 30, 2021, brand

SUMMARY

advertising accounted for 52.9%, 39.2%, 37.5% and 35.5% of the total marketing and promotion expenses incurred during such period, respectively. See “Business — Marketing” for more information about the different types of advertisements we use to promote our brand and services, and see “Financial Information — Description of Selected Components of Consolidated Statements of Comprehensive Income — Selling and Marketing Expenses” for our financial performance in relation to our selling and marketing efforts.

INTELLECTUAL PROPERTY

We believe that intellectual property rights are critical to our continued success. We primarily rely on the applicable laws and regulations on trademarks, patents, trade secrets, and confidentiality agreements to protect our intellectual property rights. We have registered or applied for registration of certain trademarks, patents and domain names in the PRC and Hong Kong relating to the names and logos of our clinics. As of the Latest Practicable Date, we had (i) 186 trademarks registered in the PRC, two trademarks registered in Hong Kong, one trademark registered in Macau and 69 pending trademark applications in the PRC; (ii) 24 patents registered in the PRC and six pending patent applications in the PRC; (iii) 17 computer softwares registered in the PRC; and (iv) 130 registered domain names in the PRC. As we direct more resources towards research and development, we will continue to patent new techniques, technologies and other innovations.

As of the Latest Practicable Date, we were not aware of any material infringement or dispute regarding our intellectual property rights. We believe that we have taken reasonable measures to prevent infringement of our intellectual property rights. For more details, see “Appendix IV — Statutory and General Information — B. Further Information About the Business of the Company — 2. Our Material Intellectual Property Rights.”

COMPETITION

The hair transplant service market and medical hair care service market in the PRC have been competitive due to the abundance of medical institutions. According to Frost & Sullivan, we were the largest hair-related healthcare service provider in China in 2020 with a leading market share of approximately 10.5% in the hair transplant service market and approximately 4.3% in the medical hair care service market in terms of revenue from the relevant services, respectively. Our major competitors include other private hair transplant institutions, hair transplant departments of public hospitals and aesthetic service providers.

We believe our principal competitive advantages are our national coverage and footprint, brand reputation, operational and medical service capabilities, one-stop-shop hair-related healthcare service system, technology, strong management team and shareholder support. For more details of our market position and the competitive landscape of the markets, see “Industry Overview” in this prospectus.

SUMMARY OF HISTORICAL FINANCIAL INFORMATION

The following tables summarize our consolidated financial results during the Track Record Period and should be read in conjunction with the section headed “Financial Information” in this prospectus and the accountant’s report set out in Appendix I to this prospectus, together with the accompanying notes.

SUMMARY

Summary of Consolidated Statements of Comprehensive Income

The following table sets forth a summary of our consolidated statements of comprehensive income for the periods indicated:

	Year Ended December 31,						Six Months Ended June 30,			
	2018		2019		2020		2020		2021	
	RMB'000	% of Revenue	RMB'000	% of Revenue	RMB'000	% of Revenue	RMB'000	% of Revenue	RMB'000	% of Revenue
Revenue	934,326	100.0	1,224,477	100.0	1,638,297	100.0	601,563	100.0	1,053,400	100.0
Cost of sales and services	(232,207)	(24.9)	(335,379)	(27.4)	(416,667)	(25.4)	(166,012)	(27.6)	(277,983)	(26.4)
Gross profit	702,119	75.1	889,098	72.6	1,221,630	74.6	435,551	72.4	775,417	73.6
Selling and marketing expenses	(463,681)	(49.6)	(650,262)	(53.1)	(779,611)	(47.6)	(246,631)	(41.0)	(577,947)	(54.9)
General and administrative expenses	(93,952)	(10.1)	(129,962)	(10.6)	(162,022)	(9.9)	(69,443)	(11.5)	(91,142)	(8.7)
Research and development expenses	(7,807)	(0.8)	(8,869)	(0.7)	(11,815)	(0.7)	(5,456)	(0.9)	(6,151)	(0.6)
Net impairment losses on financial assets	(1,633)	(0.2)	(34)	–	(487)	–	(279)	–	(376)	–
Other income	933	0.1	1,443	0.1	6,304	0.4	1,354	0.2	2,133	0.2
Other gains and losses, net	(7,021)	(0.8)	(3,373)	(0.3)	(7,738)	(0.5)	(5,766)	(1.0)	7,211	0.7
Operating profit	128,958	13.8	98,041	8.0	266,261	16.3	109,330	18.2	109,145	10.4
Finance costs – net	(17,669)	(1.9)	(26,518)	(2.2)	(35,347)	(2.2)	(15,789)	(2.6)	(20,270)	(1.9)
Profit before income tax	111,289	11.9	71,523	5.8	230,914	14.1	93,541	15.5	88,875	8.4
Income tax expense	(57,789)	(6.2)	(35,899)	(2.9)	(67,582)	(4.1)	(28,082)	(4.7)	(48,434)	(4.6)
Profit for the year/period	53,500	5.7	35,624	2.9	163,332	10.0	65,459	10.9	40,441	3.8
Other comprehensive income										
<i>Items that may be subsequently reclassified to profit or loss</i>										
– Currency translation differences	–	–	–	–	–	–	–	–	710	0.1
<i>Items that will not be reclassified to profit or loss</i>										
– Currency translation differences	–	–	–	–	–	–	–	–	(1,657)	(0.2)
Total comprehensive income for the year/period	53,500	5.7	35,624	2.9	163,332	10.0	65,459	10.9	39,494	3.7
Profit and total comprehensive income for the year/period attributable to:										
Owners of the Company	53,500	5.7	35,624	2.9	163,332	10.0	65,459	10.9	39,494	3.7

SUMMARY

Our net profit fluctuated during the Track Record Period. Our net profit decreased by RMB17.9 million, from RMB53.5 million in 2018 to RMB35.6 million in 2019. Such decrease was primarily due to the increases in selling and marketing expenses and general and administrative expenses, both of which were generally in line with our business expansion. In particular, we had increased marketing and promotion expenses as we continue to focus on brand marketing and advertising to enhance our brand recognition. In addition, we have an increase in overall staff costs to support our business growth. Our net profit increased significantly by RMB127.7 million from RMB35.6 million in 2019 to RMB163.3 million in 2020, mainly due to an increase in gross profit, reflecting our business growth in all service types. In addition, our major costs and expenses, such as selling and marketing expenses and general and administrative expenses, had increased at a relatively slower rate during the relevant year. Furthermore, our net profit decreased from RMB65.5 million for the six months ended June 30, 2020 to RMB40.4 million for the six months ended June 30, 2021, primarily due to the increases in selling and marketing expenses and general and administrative expenses. The increase in selling and marketing expenses reflects the differences in timing of brand advertising placement. Furthermore, the increase in general and administrative expenses was primarily due to the listing expenses incurred in relation to the Global Offering. In addition, we received certain rental subsidies during the COVID-19 pandemic in 2020, however, such subsidies were ceased in 2021 as compared with that of 2020. See “Financial Information — Results of Operations” for details.

Cost Structure

Cost of Sales and Services

Our cost of sales and services primarily consists of (i) staff costs, representing wages, benefits and bonuses for our business operation personnel, such as physicians and other medical staff; (ii) amortization and depreciation charges, which primarily include amortization and depreciation of lease and medical equipment mainly used to provide hair transplant services; (iii) cost of inventories and consumables, primarily including (a) hair care products and (b) sterilization supplies, reagent and pharmaceuticals used in providing hair transplant services; (iv) operation related expenses, which primarily include utilities and maintenance fee; and (v) others expenses, primarily including non-deductible input taxes and surcharges. The following table sets forth a breakdown of our cost of sales and services by nature for the periods indicated:

	Year Ended December 31,						Six Months Ended June 30,			
	2018		2019		2020		2020		2021	
	RMB'000	%	RMB'000	%	RMB'000	%	RMB'000	%	RMB'000	%
Staff costs	105,807	45.6	145,445	43.4	165,946	39.8	64,781	39.0	116,881	42.0
Amortization and depreciation charges	75,423	32.5	114,948	34.3	141,686	34.0	66,190	39.9	86,802	31.2
Cost of inventories and consumables	25,941	11.2	40,405	12.0	63,951	15.3	19,831	11.9	46,307	16.7
Operation related expenses	14,430	6.2	17,212	5.1	21,164	5.1	10,437	6.3	12,387	4.5
Other expenses	10,606	4.5	17,369	5.2	23,920	5.8	4,773	2.9	15,606	5.6
Total	232,207	100.0	335,379	100.0	416,667	100.0	166,012	100.0	277,983	100.0

SUMMARY

Selling and Marketing Expenses

We recognize the importance of long-term investment in brand building and consumer education. Therefore, in line with other players in the consumer medical service industry, we made significant investments in promoting customer awareness of our brand and our services, and expect to continue to do so in the near future. Our selling and marketing expenses primarily consist of (i) marketing and promotion expenses; (ii) staff costs; (iii) travel and transportation expenses; (iv) operation related expenses for sales and marketing team and (v) amortization and depreciation. In particular, our selling and marketing expenses increased significantly for the six months ended June 30, 2021 as compared with that of 2020, primarily due to the differences in timing of our brand advertising placement. In 2021, in line with our marketing strategies, we strategically focused on brand advertisements during NBA season in the first half of 2021, and targeted NBA audience, which consists of a large percentage of male audience, as our potential customers. In addition, in the first half of 2021, with the development of our medical hair care and other services, we continued to promote *Svenson*-related brand awareness and had more promotional activities in this regard. For details, see “Financial Information — Results of Operations — Six Months Ended June 30, 2021 Compared with Six Months Ended June 30, 2020.”

Summary of Consolidated Balance Sheets

The table below sets forth selected information from our consolidated balance sheets as of the dates indicated:

	As of December 31,			As of June 30,
	2018	2019	2020	2021
	RMB'000	RMB'000	RMB'000	RMB'000
Non-current assets	581,798	752,780	1,156,744	1,211,143
Current assets	152,647	178,433	437,612	785,651
Equity	203,496	239,120	406,058	534,333
Non-current liabilities	325,726	411,365	683,098	645,345
Current liabilities	205,223	280,728	505,200	817,116
Net current liabilities	52,576	102,295	67,588	31,465

We recorded an opening balance of negative retained earnings in the amount of RMB0.4 million as of January 1, 2018, primarily due to our relatively small business scale at the early stage of our business. We improved our financial performance in the following years, primarily attributed to (i) our significant business growth in relation to the number of our clinics and the number of surgeries performed and (ii) our cost control measures and the improvement of our operational efficiency. As of December 31, 2018, we no longer had any accumulated losses after accumulation of earnings. As of December 31, 2018, 2019, 2020 and June 30, 2021, we had retained earnings of RMB53.1 million, RMB88.8 million, RMB252.1 million and RMB292.5 million, respectively.

SUMMARY

We had net current liabilities during the Track Record Period. Our net current liability position was primarily attributable to (i) lease liabilities in relation to the properties we leased for our office premises and clinics; (ii) trade and other payables; (iii) contract liabilities in relation to the advanced payments received from customers for services or products that had not yet been provided to the customers; and (iv) borrowings, while our current assets increased at a relatively slower rate during the relevant period. We had a significant amount of contract liabilities in 2020 and six months ended June 30, 2021, primarily due to the growth of our medical hair care services, where we offered medical hair care services in service components.

Although we had net current liabilities during the Track Record Period, our Directors believe that the working capital available to us is sufficient at present and for at least the next 12 months from the date of this document, taking into account the financial resources available to us, including internally generated funds, the proceeds from the Global Offering and the available banking and other facilities. Details of these factors are set out below:

- *Cash flow generated from operations.* Our net cash from operating activities experienced robust growth during the Track Record Period. And we had net cash flow generated from operating activities in the amount of RMB194.6 million, RMB182.5 million, RMB501.6 million and RMB218.3 million in 2018, 2019, 2020 and the six months ended June 30, 2021. As we optimize our product portfolio and cost structure, increase sales of higher-margin services, and continue to grow our business, we expect to generate a steady inflow of cash from operations in the foreseeable future, which will be applied to our working capital.
- *Bank loans and facilities.* Historically, we have been able to obtain our bank borrowings if needed, including short-term working capital loans to support our cash needs. We do not foresee any impediment in continuing to do so in the future. In addition, we plan to negotiate with banks to restructure our current short-term bank borrowings by obtaining better terms of loans and take systematic steps to restructure the composition of our short-term and long-term borrowings, such as refinancing certain portion of our short-term bank borrowings with long-term bank borrowings. As of the Latest Practicable Date, we had unutilized banking facilities of RMB15.8 million.
- *Proceeds from the Global Offering.* We expect to receive proceeds from the Global Offering of approximately HK\$1,356.7 million.
- *Stringent cash management.* We closely monitor and manage our cash position and cash requirements to ensure that we have sufficient working capital for our operations. Our finance department is responsible for managing our working capital and the collection of our receivables and payables settlement. We review our cash position and cash requirements on a weekly basis to determine the usage and allocation of cash in our operations, optimize our capital structure and meet our working capital needs. Based on our weekly cash requirements, we will manage our receivables and payables settlement schedule. We also prepare cash flow projection for the next 12 months on a monthly rolling basis to ensure our long-term funding.

SUMMARY

Summary of Consolidated Statements of Cash Flow

The table below sets forth our consolidated statements of cash flows for the periods indicated:

	Year Ended December 31,			Six Months Ended June 30,	
	2018	2019	2020	2020	2021
	<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>
Cash generated from operations before movements in working capital	218,011	228,529	437,159	191,197	215,732
Changes in working capital	(5,181)	10,477	104,144	22,622	74,918
Cash generated from operations	<u>212,830</u>	<u>239,006</u>	<u>541,303</u>	<u>213,819</u>	<u>290,650</u>
Interests received on bank deposits	139	210	941	218	2,408
Income tax paid	<u>(18,402)</u>	<u>(56,736)</u>	<u>(40,673)</u>	<u>(40,146)</u>	<u>(74,744)</u>
Net cash flows generated from operating activities	194,567	182,480	501,571	173,891	218,314
Net cash flows used in investing activities	(102,789)	(105,352)	(142,388)	(44,802)	(97,174)
Net cash flows (used in)/from financing activities	<u>(69,689)</u>	<u>(55,815)</u>	<u>(156,116)</u>	<u>(83,877)</u>	<u>38,341</u>
Net increase in cash and cash equivalents	22,089	21,313	203,067	45,212	159,481
Cash and cash equivalents at beginning of the year/period	46,387	68,476	89,789	89,789	292,856
Exchange gains on cash and cash equivalents	<u>—</u>	<u>—</u>	<u>—</u>	<u>—</u>	<u>763</u>
Cash and cash equivalents at end of the year/period	<u>68,476</u>	<u>89,789</u>	<u>292,856</u>	<u>135,001</u>	<u>453,100</u>

SUMMARY

KEY FINANCIAL RATIOS

The table below sets forth the key financial ratios for the periods or as of the dates indicated:

	As of December 31,			As of June 30,
	2018	2019	2020	2021
Return on average equity ⁽¹⁾	30.3%	16.1%	50.6%	17.2% ⁽⁷⁾
Return on average assets ⁽²⁾	8.5%	4.3%	12.9%	4.5% ⁽⁷⁾
Current ratio ⁽³⁾	0.74	0.64	0.87	0.96
Quick ratio ⁽⁴⁾	0.67	0.58	0.81	0.91
Gearing ratio ⁽⁵⁾	N/M ⁽⁶⁾	0.19	0.06	0.40

Notes:

- (1) Equals profit for the year/period divided by average balance of total equity attributable to owners of the Company at the beginning and the end of that year/period and multiplied by 100%.
- (2) Equals profit for the year/period divided by average balance of total assets at the beginning and the end of that year/period and multiplied by 100%.
- (3) Equals current assets divided by current liabilities as of the same date.
- (4) Equals current assets less inventories and divided by current liabilities as of the same date.
- (5) Equals bank loans and other borrowings divided by total equity as of the same date.
- (6) As of December 31, 2018, the Group had no bank loans or other borrowings, so the gearing ratio as of that date is not meaningful.
- (7) Calculated based on annualized basis.

Our return on average equity decreased from 30.3% for 2018 to 16.1% for 2019 primarily due to (i) a decrease in our profit from 2018 to 2019; and (ii) an increase in total equity resulting from the growth of retained earnings. Our return on average equity increased from 16.1% for 2019 to 50.6% for 2020 primarily due to an increase in our profit from 2019 to 2020. Our return on average equity decreased from 50.6% for 2020 to 17.2% for the six months ended June 30, 2021, primarily due to (i) a decrease in profit and (ii) an increase in total equity accumulation of profit during the relevant period. For details, see “Financial Information — Key Financial Ratios.”

CONTROLLING SHAREHOLDERS


Immediately upon completion of the Global Offering (assuming the Over-allotment Option is not exercised), our Company will be held as to approximately 34.91% by Mr. Zhang through ZY Investment Capital Ltd and Yunuo Technology Holdings Limited. Yonghe Hair Service and CYH has been forming agreed-upon decisions amongst themselves before general meetings of the Company were convened and casting the same voting decisions at general meetings of the Company. As such, Yonghe Hair Service and CYH could jointly control the exercise of the 35.34% voting rights in our Company.

For the purpose of this prospectus, (i) Mr. Zhang, ZY Investment Capital Ltd, ZY Ventures Ltd, (ii) Yonghe Hair Service, Panmao Shanghai, Shanghai Pannuo, CITIC Private Equity Funds Management Co., Ltd., CYH, CYH Cosmetic Medical Investment Limited, CPEChina Fund II, CPEChina Fund IIA, Citron PE Associates II, Citron PE Funds II, Citron PE Holdings Limited are our Controlling Shareholders. See “Relationship With Our Controlling Shareholders” for details.

SUMMARY

CONTRACTUAL ARRANGEMENTS

Due to foreign ownership restrictions under PRC Laws, our Company is unable to own or hold 100% equity interest in the Medical Institutions conducting our businesses. Rather, we control the 100% equity interest in these entities through Contractual Arrangements, through which we are able to consolidate all other economic benefits enjoyed by the Registered Shareholders from the VIE Entities. The Contractual Arrangements apply to the 30% and 10% equity interests in Yonghe Investment and Chengdu Yonghe, respectively. Yonghe Investment is the holding company of our Medical Institutions (other than Chengdu Yonghe). See “Contractual Arrangements” for details. See also “Risk factors — Risks Relating to Our Contractual Arrangements”. The following simplified diagram illustrates the key aspects of the Contractual Arrangements:



Notes:

1. Mr. Zhang and Mr. ZHANG Hui are the Registered Shareholders.
2. “—>” denotes direct legal and beneficial ownership in the equity interest.
3. “<--->” denotes contractual relationship.
4. “----” denotes the entities that are subject to the Contractual Arrangements.

SUMMARY

USE OF PROCEEDS

We estimate that we will receive net proceeds from the Global Offering of approximately HK\$1,356.7 million, after deducting underwriting commissions, fees and estimated expenses payable by us in connection with the Global Offering, and assuming there is no exercise of the Over-allotment Option. In the event that the Over-allotment Option is exercised in full, we estimate that we will receive additional net proceeds of approximately HK\$213.7 million. We intend to use the net proceeds of the Global Offering for the following purposes:

- approximately 42.1%, or HK\$571.2 million, will be used to expand and upgrade existing hair transplant clinics in our network in China;
- approximately 17.5%, or HK\$237.4 million, will be used for investment on further innovations in products;
- approximately 9.7%, or HK\$131.6 million, will be used for investment in research and development to upgrade our service system with cutting-edge technologies;
- approximately 23.4%, or HK\$317.5 million, will be used to integrate industry resources to raise brand awareness in China;
- approximately 1.6%, or HK\$21.7 million, will be used to settle the outstanding balance of the acquisition considerations payable by us to Xinsiyu, a related party, for our acquisition of Nu/Hart Hair in May 2021; and
- approximately 5.7%, or HK\$77.3 million, will be used for our working capital and general corporate purposes.

DIVIDENDS

During the Track Record Period, our Company did not pay or declare any dividend. We paid out a cash dividend of RMB70 million, being approximately RMB0.1645 per Share (after the Share Split), utilizing our existing cash at hand at the time to our existing Shareholders on November 25, 2021 (the “**Dividend**”). The Dividend was approved by our Board and Shareholders on November 12, 2021. We believe that the distribution of the Dividend will not have a material impact on the sufficiency of our working capital after the Listing and we will be able to maintain sufficient funds to meet our working capital requirements and debt obligations. Our historical declarations of dividends may not reflect our future declarations of dividends.

Currently, we do not have a formal dividend policy or a fixed dividend payout ratio. Our Board may declare dividends in the future after taking into account our results of operations, financial condition, cash requirements and availability and other factors as it may deem relevant at such time. Any declaration and payment as well as the amount of dividends will be subject to our constitutional documents and the Companies Act. In addition, our Directors may from time to time pay such interim dividends as our Board considers to be justified by our profits and overall financial requirements, or special dividends of such amounts and on such dates as they deem appropriate. No dividend shall be declared or payable except out of our profits, retained earnings or share premium, subject to a solvency test being satisfied.

SUMMARY

Future dividend payments will also depend upon the availability of dividends received from our subsidiaries in China. PRC laws require that dividends be paid only out of net profits calculated according to PRC accounting principles, which differ in many aspects from generally accepted accounting principles in other jurisdictions, including HKFRS. PRC laws also require enterprises incorporated in the PRC to set aside at least 10% of their after-tax profits based on the relevant accounting standards set out by the PRC regulatory authorities at the end of each year to fund certain statutory reserves until the statutory reserves reach and remain at or above 50% of the relevant PRC entity's registered capital. Distributions from our subsidiaries may also be restricted if they incur debt or losses, or in accordance with any restrictive covenants in bank credit facilities or other agreements that we or our subsidiaries may enter into in the future.

LISTING EXPENSES

Listing expenses to be borne by us are estimated to be approximately RMB111.0 million (HK\$135.2 million) (at the Offer Price of HK\$15.80 per Share and assuming the Over-allotment Option is not exercised) among which (i) underwriting-related expenses, including underwriting commission and other expenses are approximately RMB55.1 million (HK\$67.1 million) and (ii) non-underwriting-related expenses are approximately RMB55.9 million (HK\$68.1 million), comprising (a) fees and expenses of legal advisors and Reporting Accountants of approximately RMB32.7 million (HK\$39.9 million) and (b) other fees and expenses of approximately RMB23.2 million (HK\$28.2 million). We incurred approximately RMB16.0 million (HK\$19.5 million) of listing expenses during the Track Record Period, among which approximately RMB13.6 million (HK\$16.6 million) was recorded as expenses and approximately RMB2.4 million (HK\$2.9 million) was recorded as prepayment.

We estimate that additional listing expenses of approximately RMB95.0 million (HK\$115.7 million) (including underwriting commissions of approximately RMB48.7 million (HK\$59.3 million), assuming the Over-allotment Option is not exercised and based on the Offer Price of HK\$15.80 per Offer Share) will be incurred by our Company, approximately RMB39.1 million (HK\$47.6 million) of which is expected to be charged to profit or loss, and approximately RMB55.9 million (HK\$68.1 million) of which is expected to be capitalized. Our listing expenses as a percentage of gross proceeds is 9.06%, assuming an Offer Price of HK\$15.80 per Share, assuming that the Over-allotment Option is not exercised. The listing expenses above are the latest practicable estimate for reference only, and the actual amount may differ from this estimate.

SUMMARY

OFFERING STATISTICS

	Based on an Offer Price of HK\$15.80 per Share
Our Company's market capitalization upon completion of the Global Offering (Assuming Over-allotment Option is not exercised)	HK\$8,215.3 million
Unaudited pro forma adjusted consolidated net tangible assets per Share ⁽¹⁾	HK\$3.78

Note:

- (1) The unaudited pro forma adjusted consolidated net tangible assets per Share is arrived at after the adjustments referred to in "Appendix II — Unaudited Pro Forma Financial Information" in this prospectus and on the basis that 94,424,000 Shares were in issue immediately upon completion of the Global Offering, which is assumed to be on June 30, 2021 for the purpose of the pro forma financial information, and takes no account of any Shares which may be issued upon exercise of the Over-allotment Option. For details of such events and the related adjustments, see "Financial Information — Unaudited Pro Forma Statement of Adjusted Net Tangible Assets" and Appendix II "Unaudited Pro Forma Financial Information" in this prospectus. The unaudited pro forma adjusted consolidated net tangible assets of the Group per Share have not taken into account the cash dividend of RMB70 million approved by our Board and Shareholders on November 12, 2021. The unaudited pro forma adjusted consolidated net tangible assets per Share would have been HK\$3.62 (equivalent to RMB2.97) per Share based on the indicative Offer Price of HK\$15.80 per share, after taking into account the declaration and payment of the cash dividend.

The estimated valuation of the Company upon completion of the Global Offering has taken into consideration the business growth potential of the Company and valuation of comparable publicly traded companies listed on the Stock Exchange and mainland China. The final valuation of the Company will be subject to various factors including market condition at the time of Price Determination Date.

SUMMARY OF MATERIAL RISK FACTORS

Our business faces risks including those set out in the "Risk Factors" section. As different investors may have different interpretations and criteria when determining the significance of a risk, you should read the "Risk Factors" section in its entirety before you decide to invest in the Offer Shares. Some of the major risks that we face include: (i) our brand, market reputation and consumer perception contribute significantly to our continued success and growth. Any failure to maintain, or any damage to, our brand, market reputation and/or consumer perception could materially and adversely affect our results of operations and prospects; (ii) We may be unable to retain our existing physicians and other medical professionals, or to attract suitable physicians and other medical professionals to join our Group; (iii) we are exposed to inherent risks of medical incidents, malpractice, medical negligence, misconduct claims arising from our operations, and resolving such incidents could result in significant costs and materially and adversely affect our reputation and business; (iv) failure to enhance our sales and marketing efficiency could harm our ability to increase the sales of our services and products and achieve broader market reception; (v) we have significantly increased the size and capabilities of our organization since our inception, and we may experience difficulties in managing our growth; and (vi) we conduct our business in a heavily regulated industry, so we expect to incur on-going compliance costs and may face potential penalties for non-compliance.

SUMMARY

IMPACT OF THE COVID-19 OUTBREAK

Since late 2019, the outbreak of a novel strain of coronavirus causing coronavirus disease 2019 (COVID-19) has materially and adversely affected the global economy. In response, countries across the world have imposed widespread lockdowns, closure of work places and restrictions on mobility and travel to contain the spread of the virus. Some of our clinics experienced temporary closures during the early phases of COVID-19 pandemic. Nevertheless, benefiting from the significant growth of the revenue from medical hair care services, our total revenue increased by 33.8% from 2019 to 2020. The Chinese government has gradually lifted domestic travel restrictions and other quarantine measures, and economic activities have begun to recover and return to normal nationwide during the second quarter of 2020. As a result, we recovered from the adverse impact of COVID-19 pandemic and continued to witness rapid growth in revenue for the six months ended June 30, 2021 as compared to the corresponding period in 2020. For further details of the financial impact of COVID-19 outbreak on our business, see “Financial Information” in this prospectus.

Since late July 2021, the delta variant of COVID-19 has recurred in several provinces across China (the “**Recurrence**”). Our eight clinics located in eight cities (i.e., Nanjing, Wuxi, Zhengzhou, Xi’an, Dalian, Harbin, Luoyang and Xiamen) experienced temporary closures in August 2021. Three clinics located in three cities (i.e., Xiamen, Quanzhou and Harbin) were temporarily closed in September 2021. Four clinics located in four cities (i.e., Lanzhou, Xiamen, Harbin and Xi’an) were temporarily closed in October 2021. Three clinics located in three cities (e.g. Changzhou, Dalian and Lanzhou) were closed in November 2021. The planned opening of three newly-established clinics located in three cities (i.e., Yangzhou, Zhangzhou and Shantou) and the planned upgrade of one clinic located in Urumqi were delayed. As of the Latest Practicable Date, three clinics in Changzhou, Dalian and Lanzhou were still in closing and the opening of the newly-established clinics in Yangzhou, Zhangzhou and Shantou was further delayed, while the other clinics mentioned above had resumed normal operation. We currently expect to open the three new clinics in Yangzhou, Zhangzhou and Shantou by February 2022, and resume the operations of the three clinics in Changzhou, Dalian and Lanzhou as soon as allowed by local governmental authorities. As a result, we expected that our total revenue for 2021 would be adversely affected to certain extent by the Recurrence. However, we do not expect the Recurrence would have any material impact on our business operations and financial performance, mainly because (i) the Recurrence is far less severe in terms of suspected or confirmed cases than the previous outbreak; (ii) the Recurrence was effectively controlled due to the quick response of the relevant authorities, and substantially all of the Chinese cities had eased or lifted domestic travel restrictions and resumed normal social activities, work and production as of the date of this prospectus; and (iii) the government authorities, and our Company have developed corresponding systems in response to COVID-19 to relieve its potential impact based on past experience.

Our Directors have carried out a holistic review of the impact of the COVID-19 on our operations and confirmed that as of the Latest Practicable Date, COVID-19 has not had any long-term material adverse impact on our operations. However, we cannot be entirely certain as to when the COVID-19 pandemic will be fully contained, and its impact will be completely alleviated. There remain significant uncertainties surrounding the COVID-19 outbreak and its further development as a global pandemic, considering the situation outside China and the occasional regional resurgence of COVID-19 cases in certain areas in China. We are closely monitoring the development of the COVID-19 pandemic and continuously evaluating any potential impact on our business, results of operations and financial condition. See “Risk Factors — Risks Relating to Our Business — Our operations and business plans have been and may continue to be adversely affected by the COVID-19 pandemic.”

SUMMARY

RECENT DEVELOPMENTS AND NO MATERIAL ADVERSE CHANGE

Share Split

On November 12, 2021, the Shareholders resolved to conduct share split on a one-for-four basis, and the nominal value of the Shares changed from US\$0.00001 each to US\$0.0000025 each. Immediately after such share split, the issued share capital of the Company is 425,531,916 Shares of US\$0.0000025 each.

Dividend Distribution

We paid out a cash dividend of RMB70 million, being approximately RMB0.1645 per Share (after the Share Split), utilizing our existing cash at hand at the time to our existing Shareholders on November 25, 2021. The Dividend was approved by our Board and Shareholders on November 12, 2021. We believe that the distribution of the Dividend will not have a material impact on the sufficiency of our working capital after the Listing and we will be able to maintain sufficient funds to meet our working capital requirements and debt obligations. Our historical declarations of dividends may not reflect our future declarations of dividends.

Regulatory Developments

Regulatory Updates Related to Internet Information Security and Privacy Protection

On July 6, 2021, the General Office of the Communist Party of China Central Committee and the General Office of the State Council jointly issued the Opinions on Strictly Combating Illegal Securities Activities in Accordance with the Law (《關於依法從嚴打擊證券違法活動的意見》). It specifies the targets in upgrading the securities law-enforcement and judicial systems by 2022 and 2025. The targets include effectively curbing the frequent occurrence of major illegal and criminal cases and making notable advances in the transparency, standardization, and credibility in the securities law-enforcement and judicial system. The document also calls for improving investigation, inspection, and trial mechanisms in terms of law enforcement cracking down on illegal securities activities, strengthening cross-border oversight of law-enforcement and judicial cooperation, and stepping up efforts to build the credit system in the capital market.

On July 10, 2021, the Cyberspace Administration of China (the “CAC”) published the Measures for Cybersecurity Review (Revised Draft for Comments), which stipulate that if an operator has collected personal information of over one million users and intends to be listed in a foreign country, it must be subject to the cybersecurity review. On November 14, 2021, the CAC, jointly with the relevant authorities, published the Administrative Regulations on Internet Data Security (Draft for Comment), which requires data processors who carry out certain activities to apply for a cybersecurity review in accordance with relevant regulations, and such activities include the proposed listing of the data processor in Hong Kong that affects or may affect national security.

As advised by our PRC Legal Adviser, we believe that the above-mentioned regulatory changes will not have a material adverse effect on our business operations. For details, see “Regulatory Overview — Laws and Regulations Related to Internet Information Security and Privacy Protection.” For risks related to the above-mentioned regulatory changes, see “Risk Factors — Risks Relating to Our Business — Failures in properly keeping and maintaining patient records, or in protecting our patients’ information from leakage or improper use could expose us, our physicians and other professional medical staff to claims, regulatory actions or litigations.”

SUMMARY

Regulatory Updates Related to Medical Beauty Services

The PRC government authorities have been stepping up regulations on the beauty surgery industry recently. Specifically, on May 28, 2021, the SAMR, SATCM, NHC, NMPA, CCAC, among others, jointly promulgated the Special Rectification Work Plan for Cracking Down on Illegal Medical Beauty Services (關於印發打擊非法醫療美容服務專項整治工作方案的通知), which stipulate that in order to further safeguard the legitimate rights and interests of consumers and protect people's health and life safety, the SAMR, SATCM, NHC, NMPA, CCAC, among others, are scheduled to carry out special rectification work against illegal medical and beauty services nationwide from June to December 2021. The work tasks mainly include: (i) severely crack down on illegal activities related to medical beauty, (ii) strictly standardize the behavior of medical beauty service, (iii) severely crack down on the illegal manufacture, sale of drugs and medical devices, and (iv) seriously investigate and prosecute illegal advertising and internet information. On November 1, 2021, the SAMR promulgated the Enforcement Guidance for the Medical Cosmetology Advertising (醫療美容廣告執法指南) (the “**Enforcement Guidance**”), which stipulates that the market regulatory departments shall rectify the chaos of all kinds of medical beauty advertisements in accordance with the laws and regulations, strive to solve the problems of great harmfulness and concentrated public response, and crack down a number of illegal advertising activities. As confirmed by our PRC Legal Adviser, the final version of the Enforcement Guidance is substantially the same as the Enforcement Guidance for the Medical Cosmetology Advertising (Draft for Comment) (醫療美容廣告執法指南(徵求意見稿)) (the “**Draft for Comment**”) previously published by SAMR on August 27, 2021. For details, see “Regulatory Overview — Regulations on Medical Advertising in the PRC” in this prospectus. As advised by our PRC Legal Adviser, the regulatory principles of the Enforcement Guidance are consistent with that of the Advertisement Law of the PRC and the Administrative Measures on Medical Advertisement, and focus on cracking down illegal medical advertisement activities (e.g., guaranteeing cure rate or effective treatment rate, using the name or image of patients, or using advertising spokesmen). The Enforcement Guidance stipulated detailed provisions on the enforcement and application of the regulatory principles set forth in the Advertisement Law of the PRC and the Administrative Measures on Medical Advertisement, and clarified a number of ambiguities and resolved many uncertainties previously involved in the interpretation and/or real-world application of the Advertisement Law of the PRC and the Administrative Measures on Medical Advertisement. Our Directors are of the view that the enactment of the Enforcement Guidance, which explicitly stipulates what types of activities are illegal and clearly streamlines the interpretation and application standards, would actually help us in ensuring our ongoing compliance with the applicable regulations, and would significantly reduce the uncertainties faced by us in this regard. With the assistance of our PRC Legal Adviser, our Directors analyzed the compliance status of our advertising practices shortly after the publishment of the Draft for Comment, and revisited such analysis after the Enforcement Guidance was formally enacted. As advised by our PRC Legal Adviser, the Directors are of the view that our current practice in connection with medical advertisement is in compliance with the Enforcement Guidance in all material respects, and the Enforcement Guidance would not have any material negative impact on our business operation. In addition, with the assistance of our PRC Legal Adviser, we designed a number of training programs, and plan to conduct such trainings on a monthly basis, to familiar our employees of the applicable laws and regulations, including but not limited to the newly enacted Enforcement Guidance.

Based on the due diligence performed by the Joint Sponsors, including reviewing the enhanced internal control measures specifically designed for rectifying the non-compliances relating to the Advertisement Law of the PRC and/or the Administrative Measures of Medical Advertisements as stated in the section headed “Business — Licenses, Permits, Approvals and Compliance — Non-compliances”, and considering the work results of the Internal Control Consultant, the view of Protiviti, as well as the

SUMMARY

view of the Company's PRC Legal Adviser, nothing has come to the Joint Sponsors attention which would cause them to disagree with our Directors' view in relation to our Group's compliance status with the Enforcement Guidance.

Hair transplant services are deemed as a type of medical beauty services pursuant to the applicable laws and regulations in the PRC, and in line with industry practice, we heavily rely on posting advertisements to maintain our business growth. Therefore, we expect that we will be impacted by the abovementioned regulatory updates. Medical advertisements have always been one of the focus areas of the relevant government authorities, and we have always been subject to extensive regulations in this regard. During the Track Record Period and up to the Latest Practicable Date, we experienced a number of isolated incidents of non-compliances in relation to certain advertisements we posted. See "Business — Licenses, Permits, Approvals and Compliance — Non-Compliances — Non-Compliances Relating to the Advertisement Law of the PRC and/or the Administrative Measures of Medical Advertisements" for more information. With the further tightening of the applicable laws and regulations as discussed above, we expect to devote even more efforts and resources in order to ensure our compliance. We have adopted a series of internal control measures aiming to ensure our compliance of the applicable laws and regulations. See "Business — Internal Control and Risk Management" for more information. We believe that the further enhanced internal control measures we adopted can effectively mitigate the relevant risks, and that we would not be materially and adversely affected by such tightening of regulations.

Estimated Decrease in Net Profit for 2021

We currently estimate that our net profit for 2021 would decrease as compared to 2020. In the six months ended June 30, 2021, we experienced a significant growth in revenue as compared to the corresponding period in 2020, while due to the regional resurgence of COVID-19 cases in certain areas in China as disclosed in "— Impact of the COVID-19 Outbreak" above, our revenue growth in the second half of 2021 might be negatively affected. Meanwhile, we expect that our operating expenses would significantly increase for 2021 as compared to 2020, primarily due to (i) an increase in selling and marketing expenses in line with our business expansion and (ii) an increase in general and administrative expenses, primarily attributable to the listing expenses incurred in relation to the Global Offering. As a result of these factors, we currently estimate that our net profit for 2021 would decrease as compared to 2020.

No Material Adverse Change

Our Directors confirm that there has been no material adverse change in our business, financial condition and results of operations since June 30, 2021, being the latest balance sheet date of our consolidated financial statements as set out in the Accountant's Report included in Appendix I to this prospectus, and up to the date of this prospectus.

DEFINITIONS AND GLOSSARY

In this prospectus, the following expressions shall have the meanings set out below unless the context otherwise requires.

“Adrenal Androgens”	steroid hormones with weak androgenic activity that is normally secreted by the fetal adrenal zone and the zona reticularis of the adrenal cortex
“affiliate(s)”	any other person, directly or indirectly, controlling or controlled by or under direct or indirect common control with such specified person
“Application Lists”	the application lists for the Hong Kong Public Offering
“Articles” or “Articles of Association”	the amended and restated articles of association of the Company conditionally adopted on November 24, 2021 and will come into effect upon Listing (as amended, supplemented or otherwise modified from time to time), a summary of which is set out in Appendix III to this prospectus
“Associate(s)”	has the meaning ascribed thereto under the Listing Rules
“Beijing AMR”	Beijing Administration for Market Regulation (北京市市場監督管理局)
“Beijing Hafada”	Beijing Hafada Hair Growth Technology Company Limited (北京哈發達增髮科技有限公司), a limited liability company established under the laws of the PRC on May 9, 2020, an indirectly wholly-owned subsidiary of the Company
“Beijing Haiyouyou”	Beijing Haiyouyou Technology Company Limited (北京海游友科技有限公司), a limited liability company established under the laws of the PRC on September 2, 2015, an indirectly wholly-owned subsidiary of the Company
“Beijing Haizhousheng”	Beijing Haizhousheng Bio Technology Company Limited (北京海洲盛生物科技有限公司), a limited liability company established under the laws of the PRC on April 26, 2021, an indirectly wholly-owned subsidiary of the Company
“Beijing Maoduoduo”	Beijing Maoduoduo Skin Clinic Company Limited (北京毛多多皮膚診所有限公司), a limited liability company established under the laws of the PRC on July 18, 2019, an indirectly wholly-owned subsidiary of the Company

DEFINITIONS AND GLOSSARY

“Beijing Xunyi”	Beijing Xunyi Technology Development Company Limited (北京迅翼科技發展有限公司), a limited liability company established under the laws of the PRC on November 16, 2016, our subsidiary by virtue of the Contractual Arrangements
“Beijing Yunmao”	Beijing Yunmao Chuangxiang Network Technology Company Limited (北京雲貓創想網絡科技有限公司), a limited liability company established under the laws of the PRC on May 4, 2018, an indirectly wholly-owned subsidiary of the Company
“Beijing Yunyihui”	Beijing Yunyihui Medical Management Company Limited (北京雲醫匯醫療管理有限公司), a limited liability company established under the laws of the PRC on October 13, 2020, an indirectly wholly-owned subsidiary of the Company
“Board”	the board of Directors
“breakeven”	the first month for the revenue of a newly opened clinic to at least equal its expenses
“Business Day”	a day that is not a Saturday, Sunday or public holiday in Hong Kong
“BVI”	the British Virgin Islands
“CAGR”	compound annual growth rate, representing the year-over-year growth rate of a value over a specified period of time taking into account the effects of compounding and calculated by subtracting one from the result of dividing the ending value by its beginning value raised to the power of one divided by the period length
“cash investment payback period”	the amount of time it takes for the accumulated operating profit from a clinic to cover the costs of opening and operating the clinic up to that point, including incurred capital expenditures and ongoing cash and non-cash operating expenses
“CCASS”	the Central Clearing and Settlement System established and operated by HKSCC
“CCASS Clearing Participant”	a person admitted to participate in CCASS as a direct clearing participant or a general clearing participant

DEFINITIONS AND GLOSSARY

“CCASS Custodian Participant”	a person admitted to participate in CCASS as a custodian participant
“CCASS EIPO”	the application for the Hong Kong Offer Shares to be issued in the name of HKSCC Nominees and deposited directly into CCASS to be credited to your or a designated CCASS Participant’s stock account through causing HKSCC Nominees to apply on your behalf, including by (i) instructing your broker or custodian who is a CCASS Clearing Participant or a CCASS Custodian Participant to give electronic application instructions via CCASS terminals to apply for the Hong Kong Offer Shares on your behalf, or (ii) if you are an existing CCASS Investor Participant, giving electronic application instructions through the CCASS Internet System (https://ip.ccass.com) or through the CCASS Phone System (using the procedures in HKSCC’s “An Operating Guide for Investor Participants” in effect from time to time). HKSCC can also input electronic application instructions for CCASS Investor Participants through HKSCC’s Customer Service Centre by completing an input request
“CCASS Investor Participant”	a person admitted to participate in CCASS as an investor participant, which may be an individual, joint individuals or a corporation
“CCASS Operational Procedures”	the Operational Procedures of HKSCC in relation to CCASS, containing the practices, procedures and administrative requirements relating to operations and functions of CCASS, as from time to time in force
“CCASS Participant”	a CCASS Clearing Participant, a CCASS Custodian Participant or a CCASS Investor Participant
“Chengdu Yonghe”	Chengdu Wuhou Yonghe Jimei Medical Aesthetic Clinic Company Limited (成都武侯雍禾既美醫療美容診所有限公司), a limited liability company established under the laws of the PRC on April 18, 2017 and a subsidiary of the Company in which 90% equity interest is owned by the Company and the other 10% equity interest is controlled by the Company through contractual arrangement
“China” or “the PRC”	the People’s Republic of China excluding, for the purposes of this prospectus, Hong Kong, the Macau Special Administrative Region of the People’s Republic of China and Taiwan

DEFINITIONS AND GLOSSARY

“Citron PE Associates II”	Citron PE Associates II, L.P., formerly known as CITIC PE Associates II, L.P., is an exempted limited partnership registered in the Cayman Islands on September 30, 2013, the general partner of CPEChina Fund II and CPEChina Fund IIA and one of our Controlling Shareholders
“Citron PE Funds II”	Citron PE Funds II Limited, formerly known as CITIC PE Funds II Limited, is a company incorporated in the Cayman Islands with limited liability on September 26, 2013, the general partner of Citron PE Associates II and one of our Controlling Shareholders
“Class IIIA Hospitals”	the largest regional hospitals with the highest standard in China designated as Class IIIA hospitals by the National Health and Family Planning Commission hospital classification system, typically having more than 500 beds in operation, providing high-quality professional healthcare services covering a wide geographic area and undertaking higher academic and scientific research initiatives
“close associate(s)”	has the meaning ascribed thereto under the Listing Rules
“Companies (Winding Up and Miscellaneous Provisions) Ordinance”	the Companies (Winding Up and Miscellaneous Provisions) Ordinance, Chapter 32 of the Laws of Hong Kong (as amended, supplemented or otherwise modified from time to time)
“Companies Act”	the Companies Act (2021 Revision) Cap. 22 (Law 3 of 1961, as consolidated and revised) of the Cayman Islands (as amended, supplemented or otherwise modified from time to time)
“Companies Ordinance”	the Companies Ordinance, Chapter 622 of the Laws of Hong Kong (as amended, supplemented or otherwise modified from time to time)
“Company” or “Our Company”	Yonghe Medical Group Co., Ltd. (雍禾醫療集團有限公司), a limited liability company incorporated under the laws of the Cayman Islands on September 17, 2020
“connected person(s)”	has the meaning ascribed thereto under the Listing Rules
“connected transaction(s)”	has the meaning ascribed thereto under the Listing Rules
“Contractual Arrangements”	the series of contractual arrangements, as the case may be, entered into by, among others, Beijing Haiyouyou, the Registered Shareholders, Beijing Xunyi and the VIE Entities, details of which are described in the section headed “Contractual Arrangements” in this prospectus

DEFINITIONS AND GLOSSARY

“Controlling Shareholder(s)”	Has the meaning ascribed to it under the Listing Rules and in the context of our Company for the purpose of this prospectus and the Listing, means Controlling Shareholders: Yonghe Hair Service Holdings Limited, Panmao Shanghai, Shanghai Pannuo, CITIC Private Equity Funds Management Co., Ltd., CYH, CYH Cosmetic Medical Investment Limited, CPEChina Fund II, CPEChina Fund IIA, Citron PE Associates II, Citron PE Funds II, Citron PE Holdings Limited, Mr. Zhang, ZY Investment Capital Ltd and ZY Ventures Ltd
“core connected person(s)”	has the meaning ascribed thereto under the Listing Rules
“CPEChina Fund II”	CPEChina Fund II, L.P., an exempted limited partnership registered in the Cayman Islands on September 30, 2013 and one of our Controlling Shareholders
“CPEChina Fund IIA”	CPEChina Fund IIA, L.P., an exempted limited partnership registered in the Cayman Islands on April 24, 2014 and one of our Controlling Shareholders
“CSRC”	China Securities Regulatory Commission (中國證券監督管理委員會)
“CYH”	CYH Cosmetic Medical Holdings Limited, a limited liability company established under the laws of Cayman Islands on November 21, 2016 and one of our Controlling Shareholders
“Dihydrotestosterone”	a male sex hormone which is the active form of testosterone, formed from testosterone in bodily tissue
“Director(s)”	the director(s) of the Company
“EIT”	enterprise income tax
“EIT Law”	the Enterprise Income Tax Law of the PRC
“Extreme Conditions”	extreme conditions caused by a super typhoon as announced by the government of Hong Kong
“Frاندor Limited”	A company incorporated in the British Virgin Islands on December 18, 1996 and is wholly owned by Trident Trust Company (Singapore) Pte. Limited, as the nominee shareholders of The ZY Trust and The ZH Trust

DEFINITIONS AND GLOSSARY

“FUE”	follicular unit extraction, a sutureless method of hair restoration in which hair follicles are extracted from the back of head under local anaesthesia with the help of special micropunches and implanted in the bald area
“GDP”	Gross Domestic Product
“General Rules of CCASS”	General Rules of CCASS published by the Stock Exchange and as amended from time to time
“GFA”	Gross floor area
“Global Offering”	the Hong Kong Public Offering and the International Offering
“ GREEN Application Form(s)”	the application form(s) to be completed by the HK eIPO White Form Service Provider designated by our Company
“Group”, “Our Group”, “Our”, “We”, or “us”	the Company and all of its subsidiaries, or any one of them as the context may require or, where the context refers to any time prior to its incorporation, the business which its predecessors or the predecessors of its present subsidiaries, or any one of them as the context may require, were or was engaged in and which were subsequently assumed by it
“hair follicle”	an organ residing in the dermal layer of the skin that regulates hair growth via a complex interaction between hormones, neuropeptides, and immune cells
“ HK eIPO White Form ”	the application for Hong Kong Offer Shares to be issued in the applicant’s own name, submitted online through the IPO App or the designated website at www.hkeipo.hk
“ HK eIPO White Form Service Provider”	the HK eIPO White Form service provider designated by our Company as specified in the IPO App or on the designated website at www.hkeipo.hk
“HKFRS”	financial reporting standards and interpretations issued by the Hong Kong Institute of Certified Public Accountants
“HKSCC”	the Hong Kong Securities Clearing Company Limited
“HKSCC Nominees”	HKSCC Nominees Limited, a wholly owned subsidiary of the HKSCC
“Hong Kong”	the Hong Kong Special Administrative Region of the PRC

DEFINITIONS AND GLOSSARY

“Hong Kong Dollars” or “HK Dollars” or “HK\$”	Hong Kong dollars and cents respectively, the lawful currency of Hong Kong
“Hong Kong Offer Shares”	the 9,443,000 Offer Shares initially being offered by us for subscription pursuant to the Hong Kong Public Offering, subject to reallocation as described in the section headed “Structure of the Global Offering”
“Hong Kong Public Offering”	the offer for subscription of the Hong Kong Offer Shares to the public in Hong Kong (subject to reallocation as described in the section headed “Structure of the Global Offering”) at the Offer Price (plus brokerage of 1%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005%) on the terms and subject to the conditions described in this prospectus, as further described in section headed “Structure of the Global Offering — The Hong Kong Public Offering”
“Hong Kong Share Registrar”	Tricor Investor Services Limited
“Hong Kong Underwriters”	the underwriters of the Hong Kong Public Offering as listed in the section headed “Underwriting — Hong Kong Underwriters”
“Hong Kong Underwriting Agreement”	the underwriting agreement dated November 30, 2021 relating to the Hong Kong Public Offering and entered into by, among others, the Company, the Joint Global Coordinators, the Joint Bookrunners and the Hong Kong Underwriters
“Independent Third Party” or “Independent Third Parties”	a person or entity who is not a connected person of the Company under the Listing Rules
“International Offer Shares”	the 84,981,000 Offer Shares initially being offered by us for subscription under the International Offering together, where relevant, with any additional Shares that may be allotted and issued pursuant to the exercise of the Over-allotment Option, and subject to reallocation as described in the section headed “Structure of the Global Offering”
“International Offering”	the conditional placing by the International Underwriters of the International Offer Shares at the Offer Price outside the United States (including to professional, institutional and other investors within Hong Kong) in offshore transactions in reliance on Regulation S, and in the United States only to QIBs in reliance on Rule 144A or another available exemption from registration requirement of the U.S. Securities Act

DEFINITIONS AND GLOSSARY

“International Underwriters”	the underwriters of the International Offering listed in the International Underwriting Agreement
“International Underwriting Agreement”	the underwriting agreement relating to the International Offering and to be entered into on or around December 6, 2021 by, among others, the Company and the International Underwriters
“ IPO App ”	the mobile application for the HK eIPO White Form service which can be downloaded by searching “ IPO App ” in App Store or Google Play or downloaded at www.hkeipo.hk/IPOApp or www.tricorglobal.com/IPOApp
“IT”	information technology
“Joint Bookrunners”	Morgan Stanley Asia Limited (in relation to the Hong Kong Public Offering), Morgan Stanley & Co. International plc (in relation to the International Offering) and China International Capital Corporation Hong Kong Securities Limited
“Joint Global Coordinators”	Morgan Stanley Asia Limited and China International Capital Corporation Hong Kong Securities Limited
“Joint Lead Managers”	Morgan Stanley Asia Limited (in relation to the Hong Kong Public Offering), Morgan Stanley & Co. International plc (in relation to the International Offering) and China International Capital Corporation Hong Kong Securities Limited
“Joint Sponsors”	Morgan Stanley Asia Limited and China International Capital Corporation Hong Kong Securities Limited
“KOLs”	the acronym of key opinion leaders
“Latest Practicable Date”	November 22, 2021, being the latest practicable date for the purpose of ascertaining certain information contained in this prospectus prior to its publication
“Listing”	listing of the Shares on the Stock Exchange
“Listing Committee”	the listing committee of the Stock Exchange
“Listing Date”	the date, expected to be on or about December 13, 2021, on which the Shares will be listed and dealings in the Shares first commence on the Stock Exchange

DEFINITIONS AND GLOSSARY

“Listing Rules”	the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (as amended, supplemented or otherwise modified from time to time)
“Medical Institution(s)”	Our medical institutions in the PRC providing aesthetic medical services and are subject to foreign investment restriction in accordance with the Special Administrative Measures for the Access of Foreign Investment (Negative List) (2020) (《外商投資准入特別管理措施(負面清單)(2020年版)》), a list of our current existing medical institutions as of the Latest Practicable Date is included in the section headed “History, Development and Corporate Structure — Our Corporate Structure”
“Memorandum of Association” or “Memorandum”	the memorandum of association of our Company, conditionally adopted on November 24, 2021 and will come into effect upon Listing (as amended from time to time)
“MOFCOM”	Ministry of Commerce of the PRC (中華人民共和國商務部)
“Mr. Zhang”	Mr. ZHANG Yu (張玉), our founder and one of our Controlling Shareholders
“New Tier-One Cities”	Chengdu, Chongqing, Hangzhou, Wuhan, Xi’an, Tianjin, Suzhou, Nanjing, Zhengzhou, Changsha, Dongguan, Shenyang, Qingdao, Hefei, and Foshan
“NPC”	The National People’s Congress of the People’s Republic of China (全國人民代表大會)
“Nu/Hart Hair”	a renowned hair transplant service provider originated from the U.S.
“Offer Price”	HK\$15.80 per Offer Share (exclusive of brokerage fee of 1%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005%)
“Offer Shares”	the Hong Kong Offer Shares and the International Offer Shares

DEFINITIONS AND GLOSSARY

“Over-allotment Option”	the option to be granted by us to the International Underwriters exercisable by the Joint Global Coordinators on behalf of the International Underwriters under the International Underwriting Agreement, to require us to allot and issue up to 14,163,500 additional Shares at the Offer Price, representing up to approximately 15% of the total number of Offer Shares initially available under the Global Offering to, among others, cover over-allocations in the International Offering, if any
“Panmao Shanghai”	Panmao (Shanghai) Investment Center (Limited Partnership) (磐茂(上海)投資中心(有限合夥)), a limited liability partnership established under the laws of the PRC on June 24, 2016, the sole shareholder of Yonghe Hair Service Holdings Limited and one of the Controlling Shareholders
“Panxin Shanghai”	Panxin (Shanghai) Investment Center (Limited Partnership) (磐信(上海)投資中心(有限合夥)), a limited liability partnership established under the laws of the PRC on March 24, 2016, a former shareholder of the Company
“PBOC”	People’s Bank of China (中國人民銀行)
“PRC Government”	the central government of the PRC and all governmental subdivisions (including provincial, municipal and other regional or local government entities) and instrumentalities thereof or, where the context requires, any of them
“Qualified Institutional Buyers” or “QIBs”	qualified institutional buyers within the meaning of Rule 144A
“Registered Shareholders”	two individual shareholders of Beijing Xunyi, namely Mr. Zhang and Mr. ZHANG Hui, Mr. Zhang’s brother
“Regulation S”	Regulation S under the U.S. Securities Act
“RMB” or “Renminbi”	Renminbi, the lawful currency of the PRC
“Rule 144A”	Rule 144A under the U.S. Securities Act
“SAFE”	State Administration of Foreign Exchange of the PRC (中華人民共和國國家外匯管理局)
“SAIC”	State Administration for Industry and Commerce of the PRC (中華人民共和國國家工商行政管理總局)

DEFINITIONS AND GLOSSARY

“SAMR”	the State Administration for Market Regulation of the PRC (中華人民共和國市場監督管理總局)
“Securities and Futures Commission” or “SFC”	the Securities and Futures Commission of Hong Kong
“Serum Ferritin”	widely recognized as an acute phase reactant and marker of acute and chronic inflammation that is nonspecifically elevated in a wide range of inflammatory conditions, including chronic kidney disease, rheumatoid arthritis and other autoimmune disorders, acute infection, and malignancy
“SFO”	the Securities and Futures Ordinance, Chapter 571 of the Laws of Hong Kong (as amended, supplemented or otherwise modified from time to time)
“Shanghai Pannuo”	Shanghai Pannuo Corporate Management Service Company Limited (上海磐諾企業管理服務有限公司), a limited liability company established under the laws of the PRC on March 24, 2016
“Share(s)”	ordinary share(s) with nominal value of US\$0.0000025 each in the share capital of the Company
“Shareholder(s)”	holder(s) of the Share(s)
“sq.m.”	square meter(s)
“STA”	State Taxation Administration of the PRC (中華人民共和國國家稅務總局)
“Stabilizing Manager”	Morgan Stanley Asia Limited
“Stock Borrowing Agreement”	the agreement expected to be entered into on or around December 6, 2021 between ZY Investment Capital Ltd and the Stabilizing Manager and/or its affiliates, pursuant to which the Stabilizing Manager may, on its own or through its affiliates, request ZY Investment Capital Ltd to make available to the Stabilizing Manager up to 14,163,500 Shares to cover, inter alia, over-allocations in the International Offering
“Stock Exchange”	The Stock Exchange of Hong Kong Limited
“Subsidiary”	has the meaning ascribed thereto under the Listing Rules
“Substantial Shareholder(s)”	has the meaning ascribed thereto under the Listing Rules

DEFINITIONS AND GLOSSARY

“Svenson”	a globally renowned brand originated from London that had over six decades of experience in offering hair restoration products and services
“Svenson Beijing”	Svenson Hair Care (Beijing) Company Limited (史雲遜護髮(北京)有限公司), a limited liability company established under the laws of the PRC on November 5, 2003, an indirectly wholly-owned subsidiary of the Company
“Svenson Yantai”	Yantai Svenson Hair Care Co., Ltd. (煙臺史雲遜護發有限公司), a limited liability company established under the laws of the PRC on August 17, 2021, an indirectly wholly-owned subsidiary of the Company
“Takeovers Code”	the Code on Takeovers and Mergers and Share Buy-backs, as published by the SFC (as amended, supplemented or otherwise modified from time to time)
“The ZH Trust”	a discretionary trust established by Mr. ZHANG Hui (as the settlor) and Trident Trust Company (Singapore) Pte. Limited (as the trustee) on March 25, 2021 for the benefits of Mr. ZHANG Hui and his family
“The ZY Trust”	a discretionary trust established by Mr. Zhang (as the settlor) and Trident Trust Company (Singapore) Pte. Limited (as the trustee) on March 25, 2021 for the benefits of Mr. Zhang and his family
“Tier-One Cities”	Beijing, Shanghai, Guangzhou and Shenzhen
“Tier-Two Cities”	Ningbo, Kunming, Fuzhou, Wuxi, Xiamen, Jinan, Dalian, Harbin, Wenzhou, Shijiazhuang, Quanzhou, Nanning, Changchun, Nanchang, Guiyang, Jinhua, Changzhou, Huizhou, Jiaxing, Nantong, Xuzhou, Taiyuan, Zhuhai, Zhongshan, Baoding, Lanzhou, Taizhou, Shaoxing, Yantai, and Langfang
“Track Record Period”	2018, 2019, 2020 and the six months ended June 30, 2021
“Underwriters”	the Hong Kong Underwriters and the International Underwriters
“Underwriting Agreements”	the Hong Kong Underwriting Agreement and the International Underwriting Agreement

DEFINITIONS AND GLOSSARY

“United States” or “U.S.”	the United States of America, its territories, its possessions and all areas subject to its jurisdiction
“U.S. dollars”, “US\$” or “USD”	United States dollars, the lawful currency of the United States
“U.S. Exchange Act”	the United States Securities Exchange Act of 1934, as amended or supplemented from time to time and the rules and regulations promulgated thereunder
“U.S. GAAP”	generally acceptable accounting principles in the U.S.
“U.S. Securities Act”	the U.S. Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder
“VIE”	variable interest entity
“VIE Entities”	the entities that we control certain percentage of their shareholding through the Contractual Arrangements which comprised, as at the Latest Practicable Date, Yonghe Investment, Medical Institutions (other than Chengdu Yonghe) wholly-owned by Yonghe Investment and Chengdu Yonghe
“Xizang Yonghe” or “Yonghe Yuhui”	Xizang Yonghe Startups Investment Management Partnership (Limited Partnership) (西藏永禾創業投資管理合夥企業(有限合夥)), a limited liability partnership established under the laws of the PRC on December 30, 2016, now known as Tianjin Yonghe Yuhui Enterprise Management Partnership (Limited Partnership) (天津永禾玉輝企業管理合夥企業(有限合夥)), a shareholder of our Group prior to the Reorganization
“Yonghe Investment”	Beijing Yonghe Medical Investment Management Company Limited (北京雍禾醫療投資管理有限公司), a limited liability company established under the laws of the PRC on September 30, 2015, an indirectly wholly-owned subsidiary of the Company
“Yonghe Research Laboratory”	Beijing Yonghe Hair Transplant Technique Research Laboratory Company Limited (北京雍禾植發技術研究院有限公司), a limited liability company established under the laws of the PRC on May 9, 2011, an indirectly wholly-owned subsidiary of the Company

DEFINITIONS AND GLOSSARY

“ZH Investment Capital Ltd”	a company incorporated in the British Virgin Islands on March 25, 2021 and wholly-owned by ZH Ventures Ltd
“ZH Ventures Ltd”	a company incorporated in the British Virgin Islands on March 25, 2021 and wholly-owned by Frandor Limited

The English names of PRC laws, regulations, governmental authorities, institutions, and of companies or entities established in the PRC included in this prospectus are translations of their Chinese names or vice versa and are included for identification purposes only. In the event of inconsistency, the Chinese versions shall prevail.

FORWARD-LOOKING STATEMENTS

FORWARD-LOOKING STATEMENTS CONTAINED IN THIS PROSPECTUS ARE SUBJECT TO RISKS AND UNCERTAINTIES

This prospectus contains forward-looking statements relating to our plans, objectives, expectations and intentions, which may not represent our overall performance for the periods of time to which such statements relate. Such statements reflect the current views of our management with respect to future events, operations, liquidity and capital resources, some of which may not materialize or may change. These statements are subject to certain risks, uncertainties and assumptions, including the other risk factors as described in this prospectus. You are strongly cautioned that reliance on any forward-looking statements involves known and unknown risks and uncertainties. The risks and uncertainties facing the Company which could affect the accuracy of forward-looking statements include, but are not limited to, the following:

- our business prospects;
- our business strategies and plans to achieve these strategies;
- the actions of and developments affecting our competitors;
- our future debt levels and capital needs;
- changes to the political and regulatory environment in the industry and markets in which we operate;
- our expectations with respect to our ability to acquire and maintain regulatory licenses or permits;
- changes in competitive conditions and our ability to compete under these conditions;
- future developments, trends and conditions in the industry and markets in which we operate;
- general economic, political and business conditions in the markets in which we operate;
- effects of the global financial markets and economic crisis;
- our financial conditions and performance;
- our dividend policy; and
- change or volatility in interest rates, foreign exchange rates, equity prices, volumes, operations, margins, risk management and overall market trends.

In some cases, we use the words “aim,” “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “going forward,” “intend,” “ought to,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “will,” “would” and similar expressions to identify forward-looking statements. In particular, we use these forward-looking statements in the “Business” and “Financial Information” sections of this prospectus in relation to future events, our future financial, business or other performance and development, the future development of our industry and the future development of the general economy of our key markets.

FORWARD-LOOKING STATEMENTS

These forward-looking statements are based on current plans and estimates, and speak only as of the date they were made. We undertake no obligation to update or revise any forward-looking statements in light of new information, future events or otherwise. Forward-looking statements involve inherent risks and uncertainties and are subject to assumptions, some of which are beyond our control. We caution you that a number of important factors could cause actual outcomes to differ, or to differ materially, from those expressed in any forward-looking statements.

Our Directors confirm that the forward-looking statements are made after reasonable care and due consideration. Nonetheless, due to the risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this prospectus might not occur in the way we expect, or at all.

Accordingly, you should not place undue reliance on any forward-looking information. All forward-looking statements contained in this prospectus are qualified by reference to this cautionary statement.

RISK FACTORS

An investment in our Shares involves significant risks. You should carefully consider all of the information in this prospectus, including the risks and uncertainties described below, as well as our financial statements and the related notes, and the “Financial Information” section, before deciding to invest in our Shares. The following is a description of what we consider to be our material risks. Any of the following risks could have a material adverse effect on our business, financial condition, results of operations and growth prospects. In any such an event, the market price of our Shares could decline, and you may lose all or part of your investment. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations.

These factors are contingencies that may or may not occur, and we are not in a position to express a view on the likelihood of any such contingency occurring. The information given is as of the Latest Practicable Date unless otherwise stated, will not be updated after the date hereof, and is subject to the cautionary statements in the section headed “Forward-Looking Statements” in this prospectus.

We believe there are certain risks and uncertainties involved in our operations, some of which are beyond our control. We have categorized these risks and uncertainties into: (i) risks relating to our business; (ii) risk relating to our industry; (iii) risks relating to our contractual arrangements; (iv) risks relating to doing business in China and (v) risks relating to the Global Offering. Additional risks and uncertainties that are presently not known to us or not expressed or implied below or that we currently deem immaterial could also have a material adverse effect on our business, financial condition and operating results. You should consider our business and prospects in light of the challenges we face, including the ones discussed in this section.

RISKS RELATING TO OUR BUSINESS

Our historical business growth, revenue and profitability may not be indicative of future performance, and our success depends, in part, on our ability to execute our business strategy.

We experienced significant growth during the Track Record Period. Our total revenue increased from RMB934.3 million in 2018 to RMB1,224.5 million in 2019, and further to RMB1,638.3 million in 2020. In addition, our revenue increased from RMB601.6 million for the six months ended June 30, 2020 to RMB1,053.4 million for the six months ended June 30, 2021. While our revenue was generated mainly from rendering hair transplant services, revenue from medical hair care services also grew rapidly over the same period. We recorded a net profit of RMB53.5 million, RMB35.6 million, RMB163.3 million and RMB40.4 million in 2018, 2019, 2020 and the six months ended June 30, 2021, respectively. However, our net profit fluctuated during the Track Record Period. Our net profit decreased by RMB17.9 million, from RMB53.5 million in 2018 to RMB35.6 million in 2019. Such decrease was primarily due to the increases in selling and marketing expenses and general and administrative expenses, both of which were generally in line with our business expansion. In addition, we have an increase in overall staff costs to support our business growth. Our net profit increased significantly by RMB127.7 million from RMB35.6 million in 2019 to RMB163.3 million in 2020, mainly due to an increase in gross profit, reflecting our business growth in all service types. In addition, our major costs and expenses, such as selling and marketing expenses and general and administrative expenses, had increased at a relatively slower rate during the relevant year. Furthermore, our net profit decreased from RMB65.5 million for the six months ended June 30, 2020 to RMB40.4 million for the six months ended June 30, 2021, primarily due to an increase in selling and marketing expenses, reflecting the differences in timing of brand advertising

RISK FACTORS

placement, which was in line with our marketing strategies during the relevant period. Therefore, we cannot assure you that we will achieve similar growth rate like 2019 to 2020, or that we will be successful in mitigating any negative growth rate in the future. Our revenues, expenses and operating results may vary from period to period and you should not rely on the results of any prior periods as indicative of our future growth or financial results. Our ability to achieve profitability and positive cash flow will depend in large part on our ability to successfully execute our business strategies, which in turn depends on a number of factors, including our ability to:

- successfully improve our existing services and products, launch new services and products and continue to increase our market share in the hair-related healthcare industry;
- develop functionality and features that address market demand and preferences;
- maintain effective operational, financial and management controls across a larger operating scale; and
- respond to evolving industry standards and government regulations that impact our growing business.

We may also encounter fluctuation in operation costs and expenses, as well as other unforeseen costs and expenses, difficulties, complications, delays and other unknown events. In addition, our ability to execute our business strategy is subject to various factors beyond our control, such as changes in the macroeconomic and regulatory environment and competitive dynamics. We cannot assure you that we will be able to respond to these changes in a timely and effective matter or at all, failure of which will adversely affect our business, results of operations and financial condition.

Our brand, market reputation and consumer perception contribute significantly to our continued success and growth. Any failure to maintain, or any damage to, our brand, market reputation and/or consumer perception could materially and adversely affect our results of operations and prospects.

According to Frost & Sullivan, in 2020, we ranked first in the hair-related healthcare industry in China in terms of various key financial and operational indicators, including the total revenue for 2020, the number of registered physicians at the end of 2020, the number of clinics in operation at the end of 2020, and the number of hair transplant patients for 2020. For details, see “Business — Our Competitive Strengths — China’s Largest Hair Transplant Service Provider.” We are committed to establishing and maintaining the market recognition of our brand. Over the years, our brand development has set us on a course for success. For details, see “Business — Awards and Recognitions” in this prospectus. We believe our operational and financial performance is highly dependent on the strength of our brand, which is critical to increasing our customer base and forging long-term relationships with them. However, we cannot assure you that we will be able to maintain and enhance our brand, and remain our reputation and market leading position in China. Any negative review, comment or allegation against our Company, our physicians, our clinic network, among others, or services and products offered by our platform, appearing in the media or in social media forums may harm our brand, reputation and public image. We may also face challenges from others seeking to profit from, or defame, our brand. Any of the foregoing may result in loss of potential and existing customers or business partners and, in turn, have a material adverse effect on our business, financial condition, results of operations and prospects.

RISK FACTORS

We conduct our business in a heavily regulated industry, so we expect to incur on-going compliance costs and may face potential penalties for non-compliance.

We conduct our business in a heavily regulated industry and therefore incur on-going compliance costs and face potential penalties for non-compliance. The laws and regulations relate mainly to the requirements for medical institutions and equipment, and the licensing, qualifications and number of medical professionals. For details, see “Regulatory Overview”. Accordingly, our clinics are subject to periodic licensing renewal requirements and inspections by various government agencies and departments. During the Track Record Period, some of our clinics were subject to administrative penalties due to certain non-compliance incidents. See “Business — Licenses, Permits, Approvals and Compliance — Non-Compliances” in this prospectus for more details. If we or our business partners fail to obtain or renew any necessary licenses, permits, approvals and certificates, or if our medical professionals become unlicensed at any time during their practices at our clinics, or if our physician fail to obtain or maintain a valid license, or if we fail to keep and management the medical record properly, or if we are found to be non-compliant with any of these laws, regulations or rules, we may face penalties, suspension of operations or even revocation of operating licenses, permits, approvals or certificates, depending on the nature of the findings, any of which could adversely affect our business, financial condition, results of operations and prospects.

In addition, there is no assurance that the governments of the PRC will not impose more stringent laws, rules, regulations or industry standards in connection with the provision of hair-related healthcare services. Any changes in laws and regulations, or any change of interpretation thereof, could require us to obtain additional licenses, permits, approvals or certificates, or result in the invalidation of our currently owned licenses, permits, approvals or certificates, or result in us being regarded as not in compliance with the relevant laws and regulations thereby subjecting us to penalties and/or other legal consequences. There is no assurance that we will be able to adapt to such changes in a timely manner. Even if we are able to be compliant with such new laws, rules, regulations or industry standards and the regular audit of the same, it may significantly increase our operating costs, which may in turn lower our profit margins. Any of the abovementioned circumstance may materially and adversely affect our business, results of operations, financial condition and prospects.

Non-compliance with the PRC advertising laws, rules and regulations could subject us to liabilities.

In line with many other companies in our industry, we rely heavily on our sales and marketing activities to promote our brand and services, and in particular, we made substantial efforts in promoting our brand and marketing our services using internet platforms. We are obligated under PRC laws and regulations to monitor our advertising content to comply with applicable laws. According to the Administrative Measures on Medical Advertisement (醫療廣告管理辦法) and Notice of the Ministry of Health on Further Strengthening the Administration of Medical Advertisements (衛生部關於進一步加強醫療廣告管理的通知), our clinics must apply for and obtain a medical advertisement examination certificate before publishing a medical advertisement. Violation of these regulations may result in penalties against the hospital, including rectification, orders, warnings, suspension of operations, revocation of relevant permits to engage in the provision of specific medical services, and the revocation of the Medical Institution Practicing License. In addition, if the content of the published advertisement is different from what is approved and documented in the medical advertisement examination certificate, the competent authority may revoke the medical advertisement examination certificate and refuse to accept any applications for advertisement examination for a period of one year. In addition, if a special government review is required, we must confirm that such review has been performed and the approval

RISK FACTORS

has been obtained before we publish the advertisement. For advertising content related to certain types of products and services, such as pharmaceuticals and medical equipment, we are required to confirm that the advertisers have completed filings with local authorities and obtained all requisite government approvals, including review of operating qualifications, proof of quality inspection of the advertised products and government pre-approval of the contents of the advertisement. For more details of the laws and regulations on medical advertising in the PRC, see “Regulatory Overview — Regulations on Medical Advertising in the PRC” in this prospectus.

Whilst we endeavor to comply with PRC advertising laws and regulations, we cannot guarantee that we would not inadvertently become non-compliant with relevant advertising laws and regulations. During the Track Record Period, some of our clinics were fined for publishing certain content of medical advertisement in violation of the PRC Advertisement Law (中華人民共和國廣告法), the Medical Advertising Management Measures (醫療廣告管理辦法), and/or the Interim Measures for the Administration of Internet Advertisement (互聯網廣告管理暫行辦法), and/or the Enforcement Guidance for the Medical Cosmetology Advertising (醫療美容廣告執法指南). See “Business — Licenses, Permits, Approvals and Compliance — Non-Compliances” for details. In addition, any changes in the existing laws and regulations (such as the newly promulgated Enforcement Guidance for the Medical Cosmetology Advertising (醫療美容廣告執法指南), or any changes of interpretation thereof, or any promulgation of new laws and regulations in the PRC in relation to medical advertising could require us to obtain additional approvals or permits for our promotions and advertisements, or incur additional compliance costs, or result in us being regarded as not in compliance with the relevant laws and regulations thereby subjecting us to penalties and/or other legal consequences. If we fail to adjust promotions, advertising and marketing strategies and policies in a timely manner in response to changes in the existing laws, regulations or rules; or if we are found to be non-compliant with any of these laws, regulations or rules, we may face penalties, which could adversely affect our business, financial condition, results of operations and prospects.

Any lack of requisite approvals, licenses, permits, registrations or filings applicable to our business may have a material and adverse impact on our business, financial condition and results of operations.

We are subject to extensive government regulations for all material aspects of our operations in China, and are required to obtain and maintain various approvals, licenses and permits, and to complete various registrations or filings, to operate our business, including but not limited to business license, medical institution practicing license, environmental impact assessment filing, fire safety inspection, and permits and filings in relation to relevant constructions. For details, see “Business — Licenses, Permits, Approvals and Compliance.” These approvals, licenses and permits are obtained upon satisfactory compliance with, among other things, the applicable laws and regulations. Complying with government regulations may require substantial expense, and any non-compliance may expose us to liability. In case of any non-compliance, we may have to incur significant expenses and divert substantial management time and resources to rectify the issues.

RISK FACTORS

If we fail to obtain the required licenses, permits and approvals, or if the scope of our operations exceed the scope permitted under the applicable licenses, permits and approvals, we may be subject to fines, confiscation of the income derived from the related clinics, the suspension of operations of the related clinics, and adverse publicity arising from such non-compliance with government regulations. If we fail to obtain the necessary approvals, licenses and permits for new clinics in time, our network expansion plan may be delayed. In addition, many of these licenses are subject to examinations or verifications by relevant authorities and are valid only for a fixed period of time subject to renewal and accreditation, and there can be no assurance that we will be able to obtain, renew and/or convert all of the approvals, licenses and permits required for our existing business operations upon their expiration in a timely manner or at all, which may materially impact our operations.

During the Track Record Period, we were fined by relevant government authorities for certain isolated non-compliance incidents relating to our failure to obtain certain approvals and licenses necessary to operate our clinics. For details, see “Business — Licenses, Permits, Approvals and Compliance.” In addition, we identified certain non-compliance incidents relating to our historical failure to promptly update the business scopes set forth in the business licenses of some of our clinics. We have resolved substantially all the non-compliance incidents identified, and are in the process of rectifying the remaining non-compliance incidents, and have adopted a series of enhanced internal control measures aiming to prevent similar non-compliances from recurring. We expect to incur additional costs as a result of the measures we take to rectify the remaining non-compliances and to prevent similar non-compliances from recurring, however, we cannot assure you that we will be able to fully rectify all non-compliance incidents in a timely manner, or that we will not be subject to any future regulatory reviews and inspections where other non-compliance incidents might be identified, which might materially and adversely affect our business, financial condition, results of operations and prospects.

We may be unable to retain our existing physicians and other medical professionals, or to attract suitable physicians and other medical professionals to join our Group.

We believe our professional medical staff, including physicians, nurses, and other medical professionals is at the core of our medical hair care services. The qualification and expertise of physicians and other medical professionals practicing at our clinics are vital to the quality of services provided by our clinics and our competitiveness. For details of our current professional team, see “Business — Our Professional Team.” Our future success depends on our ability to retain, attract and motivate a sufficient number of qualified and experienced professional medical staff, which is necessary to meet the demands of the services at our existing clinics and our future expansion. The number of qualified and experienced professional medical staff in the market that meets our Group’s requirements is limited in the near term, so the competition for these personnel is intense. Our ability to provide our services is reliant on the services of these professionals. The ability to attract and retain them is dependent on several factors such as our reputation, financial remuneration and job satisfaction. To compete with other medical hair care service providers for these personnel, we may need to offer more competitive terms, such as higher compensation and other rewards, which would increase our costs of operation. We cannot guarantee that we will win the competition in retaining and attracting these professionals. We may also be subject to the constant risks that our competitors will poach our experienced medical staff with more attractive incentives. Failure to retain, attract or motivate qualified and experienced professional medical staff could adversely affect the operations of our clinics, and any material increases in the turnover rates of our professional medical staff could also have a material adverse effect on our business, results of operation and financial results and prospects.

RISK FACTORS

We are exposed to inherent risks of medical incidents, malpractice, medical negligence, misconduct claims arising from our operations, and resolving such incidents could result in significant costs and materially and adversely affect our reputation and business.

The safety and quality of our hair-related healthcare services are vital to the success of our business in the industry which depends significantly on the performance of our physicians and other medical professionals. As a hair-related healthcare service provider, we strictly adhered to relevant medical standards and the safety of our customers is of utmost importance to our operations. Our major business sector, hair transplant services, are the least risky surgical operations to address the hair-related problems. However, we may still face the risk of exposure to malpractice, or medical negligence or misconduct and claims on account of alleged deficiencies in the medical hair care services provided by us. We may not be able to avoid malpractice, medical negligence or misconduct exposure, including on account of error by our personnel, machine or equipment error, or the lack of pre-operative advice or post-operative care by patients. We cannot assure you that we or any of our physicians will not encounter malpractice, medical negligence or misconduct claims in the future. These claims may be brought against us or any of our medical professionals by way of legal proceedings or lodging of formal complaints with the relevant licensing regulatory bodies. In any of these cases, we may be required to pay monetary compensation or damages or that the qualifications or licenses of our medical professionals may be suspended or revoked or otherwise they may be subject to other disciplinary action. Negative publicity associated with these claims or actions may affect our business as well as our business reputation.

In addition, we rely on our physicians and other medical staff in our clinics to make informed decisions regarding the appropriate treatment and evaluation of our customers, particularly due to their position as the front-line staff which have high degree of interactions with our customers. However, any miscommunications or misconducts between our physicians and other medical staff on one hand; and the customers on the other hand, and/or incorrect decisions on the part of our physicians and staff may result in undesirable or unexpected outcomes, including complications, unexpected side effects and injuries. Any medical incident, malpractice, medical negligence, or misconducts occurring at our clinics may result in claims or legal proceedings against us, which, regardless of merit or settlement status, could adversely affect our industry reputation, divert management resources and cause us to incur significant costs, such as legal fees.

Failure to perform hair transplant services in accordance with various evolving laws and regulations in the PRC could expose us, our physicians and other professional medical staff to penalties, claims, regulatory actions or litigations.

Hair transplant services are deemed as a type of aesthetic medical services pursuant to the applicable laws and regulations in the PRC, and the provision of aesthetic medical services in China is subject to complex and evolving laws and regulations. For example, the Rules of Aesthetic Medical Services Management (醫療美容服務管理辦法) require aesthetic medical services be conducted by, or under the supervision of, physician holding the Aesthetic Medical Attending Physician (醫療美容主診醫師) qualification. Any non-compliance with the relevant regulations may expose us to regulatory actions and administrative penalties. For example, during the Track Record Period, we identified three isolated incidents where physicians at our clinics performed hair transplant surgeries for patients without the supervision of physicians possessing the Aesthetic Medical Attending Physician qualification, and two of our clinics, namely Kunshan and Nanchang clinics, were penalized for the three incidents. For details, see “Business — Licenses, Permits, Approvals and Compliance — Non-Compliances” in this prospectus.

RISK FACTORS

Such non-compliance incidents may also involve us in medical disputes and expose us, our physicians and other professional medical staff to claims and litigations. For example, we have an ongoing legal proceeding against our Kunshan clinic brought by a hair transplant patient alleging that, among others, the handling physician did not possess relevant qualification of Medical Aesthetic Attending Physician. For details, see “Business — Legal Proceedings” in this prospectus. In addition, the laws and regulations regarding aesthetic medical services in China are generally complex and evolving, and there is a trend of heightened scrutiny in this industry. Any actual or alleged failure to comply with the evolving laws and regulations on aesthetic medical services could damage our reputation, expose us to penalties claims, regulatory actions or litigations, and negatively affect our business operation and financial position.

Failure to manage our customers’ expectations may lead to complaints and legal claims by our customers.

Most medical hair care services we offer have the objective of improving our customers’ physical appearance. Our customers have varying demands on the improvement of their physical appearance, and would have different expectations of the magnitude of improvement that may result from our services. Therefore, sufficient communications to precisely acknowledge the customers’ expectations and managing the same are also crucial to our business. We rely on our physicians and other medical staff to engage in detailed discussion to identify our customers’ demands while understanding and managing their expectations. In addition, we also had a team of around 100 professionals who are responsible for client satisfaction, as of the Latest Practicable Date. However, there is no guarantee that some of our customers may still find that the results are dissatisfying. If we fail to manage our customers’ expectations properly, a discontented customer may request refunds, complain on the internet or media, or file legal claim against us. Such actions from a discontented customer may materially and adversely affect our brand image and cause deterioration in the level of trust among our customers and potential customers in our services and products, thereby resulting in reduced sales and potential loss of customers.

Our operations and business plans have been and may continue to be adversely affected by the COVID-19 pandemic.

Coronavirus disease 2019 (COVID-19) is a contagious disease caused by a novel strain of coronavirus. The first known case of COVID-19 was identified in December 2019, and the disease has since spread worldwide, leading to an ongoing pandemic. As part of the intensified efforts to contain the spread of COVID-19, governments across the world took a number of actions, including imposing lockdown policies, quarantining and asking residents to remain at home and to avoid public gatherings. As a result, China’s healthcare service market had been negatively impacted, which in turn materially and adversely affected our business, results of operations and financial condition. For example, some of our clinics experienced temporary closures during the COVID-19 pandemic and many of our customers avoided going to our clinics in order to avoid social gathering and prevent from themselves being infected. As a result, many of our service procedures were delayed or cancelled and the overall demand for our services and products has decreased. Although we have experienced a strong rebound of our business volume since April 2020, as the Chinese government has gradually lifted restrictions and quarantine measures in China, we cannot assure you that our business volume and growth rate will remain robust in the future due to the uncertainties associated with the development of COVID-19.

RISK FACTORS

The exacerbation, continuance or reoccurrence of COVID-19 has already caused and may continue to cause an adverse and prolonged impact on the economy, geopolitical and social conditions. Our business operation has also been, and may continue to be, negatively affected by the outbreak. Should there be an escalation of the spread, China may again take strict emergency measures to combat the spread of the virus, including travel restrictions, mandatory cessations of business operations including our hair transplant clinics, mandatory quarantines, work-from-home and other alternative working arrangements, and limitations on social and public gatherings and lockdowns of cities or regions, which may impact our business. In addition, our customers may hesitate to visit our clinics or reschedule their visits to avoid social gathering and cross-infections. Meanwhile, newly-established clinics may not be fully utilized due to the decrease in customer volume. As a result, it might take longer time for us to achieve a utilization rate as expected. Furthermore, some of our suppliers are based overseas, we may experience shortage or delay in our supplies due to COVID-19.

As a result, the extent of the disruption to our business and the related impact on our financial results and outlook cannot be reasonably estimated at this time. We are continuously evaluating its impact on our business, results of operations and financial condition, which we believe will depend on the duration of the pandemic and the government's responsive measures. The potential downturn brought by and the duration of the COVID-19 outbreak may be difficult to assess or predict as the actual effects will depend on many factors beyond our control. If the outbreak persists or escalates, we may be subject to further negative impact on our business operations, results of operations and financial condition.

Most of our hair transplant services were offered in one-off session and failure to attract new customers could materially and adversely affect our business, results of operations, financial condition and prospects.

During the Track Record Period, our revenue was generated mainly from rendering hair transplant services, which were generally one-off in nature. In 2018, 2019, 2020 and the six months ended June 30, 2021, approximately 98.3%, 97.8%, 86.2% and 75.0% of our total revenue were derived from the hair transplant, respectively. The medical effect of most of our hair transplant surgeries performed may last indefinitely. There is no guarantee that our clients will visit our clinics again after their treatment with us. Although we see a stable growth in our business in medical hair care services, we cannot guarantee that our customers for medical hair care services will increase or we will continue to attract new clients for our hair transplant services or other services. If for any reasons, including failure to keep up with various demands and preferences of clients and potential clients and provision of services unsatisfactory to our clients, we may be unable to attract new clients for our hair transplant services and the growth of our medical hair care services may not grow as expected. In the event that we are unable to maintain similar level of number of new clients, our business, results of operations, financial condition and prospects may be materially and adversely affected.

If we fail to implement our expansion plan and growth strategies as planned, our business and prospects could be materially and adversely affected. In addition, the integration process of the newly established clinics may take longer than expected.

We operate the largest and most widely distributed hair transplant clinic chain in China. We grew rapidly during the Track Record Period. The number of our hair transplant clinics increased from 30 by the end of 2018 to 37 by the end of 2019, continued to increase to 48 by the end of 2020 and further increased to 52 by June 30, 2021. We plan to strategically expand our operations to lower-tier cities, in order to serve the unmet needs of our customers. See “Business — Our Strategies — Nationwide

RISK FACTORS

Footprint in Major Metropolitan Centers With Great Growth Potential” for details. However, we cannot assure you that our expansion plan will be successfully implemented without delay or at all. Our ability to successfully implement our expansion plan is subject to a number of risks, including our ability to obtain the requisite permits, licenses and approvals for our clinics and our ability to timely recruit sufficient qualified staff for our newly-established clinics. Any failure or delay in implementing any part of our expansion plan may result in insufficient capacity to support our growth and market expansion, which in turn could materially and adversely affect our business, financial condition and results of operations. Moreover, our expansion plan requires significant capital investment, and the actual costs may exceed our original estimates, which could materially and adversely affect the realization of expected return on our investment. In addition, it typically requires a period of time for newly-established clinics to achieve a utilization rate comparable to our mature-stage clinics, due to factors such as time needed to build client awareness in the local community and to integrate such newly-established clinics into our existing infrastructure. In addition, we may take time to ramp up the sales in such clinics. Such newly-established clinics may even operate at a loss, which could adversely affect our operating results.

Our ability to stay attuned of the market trends or latest technological advancement in the hair-related healthcare industry may affect our business operations.

We operate in an industry with rapidly changing consumer needs and preferences which challenge us to continuously keep up with the latest developments and trends in the hair-related healthcare industry and respond to the changing requests and preferences of our customers. In order to keep up with the latest developments and trends in the hair-related healthcare industry, we need to (i) upgrade our existing medical hair equipment, services and products from time to time; (ii) diversify the services we provided and source new services and products; and (iii) enhance our sales and marketing efficiency and optimize our marketing strategies. If we fail to anticipate and adjust ourselves based on the market trends or fail to introduce latest technologies in the hair-related healthcare industry, we may not be able to provide high-quality services in satisfying customers’ needs. We may lose our existing customers and be unable to attract new customers, which could have a material adverse impact on our business performance, results of operations, financial condition and prospects.

Failure to enhance our sales and marketing efficiency could harm our ability to increase the sales of our services and products and achieve broader market reception.

We rely on our brand image and reputation in marketing and selling our services. As there are an increasing number of potential customers who may seek services based on our reputation and brand in the hair-related healthcare service industry, we will need to constantly manage our reputation and brand image and further enhance consumer education through promotions, advertisements and online marketing activities. We also plan to enhance customer education through sales and marketing activities. During the Track Record Period, our selling and marketing expenses represented the largest components of our revenue, and accounted for 49.6%, 53.1%, 47.6% and 54.9% of our total revenue in 2018, 2019, 2020 and the six months ended June 30, 2021, respectively. Our ability to increase customer base and achieve broader market reception of our services and products will depend to a significant extent on our ability to enhance our sales and marketing efficiency. We expect to enhance our sales and marketing efficiency to cover broader geographical areas in the future. However, there is no guarantee that we will be successful in attracting and maintaining our customers, and our ability to control selling and marketing expenses may significantly affect our profitability. Even if we are successful in expanding our customer base, if these efforts paid to analyze their needs and market our services and products to them would divert our limited resources away from existing customers, our ability to attract and maintain our

RISK FACTORS

current customers would be negatively impacted, which might cause a loss of our current customer base and adversely affect our business operation and financial results.

We have significantly increased the size and capabilities of our organization since our inception, and we may experience difficulties in managing our growth.

We are the leading medical group in China specialized in providing hair-related healthcare services in terms of total revenue for 2020. We achieved fast growth during the Track Record Period, and as our development and commercialization plans and strategies evolve, we may need to add a significant number of experienced managerial, operational, sales, marketing, financial and other personnel. Our recent growth and any future growth will impose significant added responsibilities on members of management, including:

- retaining, recruiting, integrating, maintaining and motivating a sufficient number of qualified and experienced employees in particular, our professional medical staff, including physicians, nurses, and other medical professionals;
- managing our internal development efforts effectively;
- developing and enhancing our services and products, and improving our operating infrastructure;
- increasing innovation to spur business growth and operation efficiency; and
- improving our operational, financial and management controls, reporting systems and procedures.

Our future financial performance will depend, in part, on our ability to effectively manage our recent growth and any future growth, and our management may also have to devote a substantial amount of time to managing these growth activities. Our failure to do so could materially adversely affect our business, financial condition, results of operations and prospects.

We depend on the continued service of our senior management team and other key employees, and our business, financial condition and results of operations will suffer greatly if we lose their services.

We have been, and will continue to be, heavily dependent on the continued services of our senior management team and other key employees, some of whom have been with us since our inception. In particular, we rely on the expertise, experience and leadership of our founder and chief executive officer, Mr. ZHANG, who has led us to stay ahead in China's hair-related healthcare industry. We also rely on a number of key members of our senior management team, such as our assistant president and chief of operations, Mr. XU Yang, our director of finance, Ms. HAN Zhimei, our president of medical department, Mr. LI Xiaolong, and our director of sales and marketing, Mr. HUANG Donghong. Competition for competent candidates in the industry is intense and the pool of competent candidates is limited. If we lose the services of our key personnel, we may not be able to locate suitable or qualified replacements in a timely manner or at all and may incur additional expenses to recruit and train new personnel. Consequently, our business could be disrupted, the implementation of our business strategies could be delayed, and our financial condition and results of operations could be adversely affected. In addition, if

RISK FACTORS

any member of our senior management team or key employees joins a competitor or forms a competing business, we may lose know-how, customers and key professionals and staff. Each of our key employees including all physicians has entered into a confidentiality and non-compete agreement with us. We cannot assure you, however, the extent to which any of these agreements will be enforceable under the applicable laws.

Any substantial increase in rent or non-renewal of lease agreements may affect our business operations.

All of our clinics are currently situated at leased properties, we are particularly susceptible to fluctuations in the property rental market. As of the Latest Practicable Date, we leased 339 properties in the PRC with an aggregate GFA of approximately 194,444.85 sq.m. Among such 339 properties, 133 were operated as offices and clinics, and 206 were used as employee dormitories. Our leases for offices and clinics typically have a term of five years and our leases for dormitories typically have a term of one year, and before the expiry of each of our leases, we have to negotiate the terms of renewal with our respective lessors. There is no assurance that our existing leases would be renewed on similar or favorable terms, in particular with respect to the amount of rent and the term of the lease, or at all. Any substantial increase in the rent of our leased properties may increase our property rental and related expenses, which could materially and adversely affect our profitability. There is also no assurance that our existing leases will not be terminated early by the lessors before the expiry of the relevant term.

In addition, several of our leased properties has title defects, and as advised by our PRC Legal Adviser, our use of these defective leased properties may be affected by third parties' claims or challenges against the lease. For details, see "Business — Properties — Leased Properties — Title Defects."

In the event that we are required to relocate our clinics, there is no assurance that we will be able to identify comparable locations in a timely manner or at all, and that we will secure a lease on comparable terms. We may also incur substantial reinstatement, relocation and renovation costs. Further, the establishment of our hair transplant clinics at new location involves regulatory approvals and reviews by various PRC governmental authorities, and we may need to complete of relevant environmental assessment, construction permits and fire prevention inspection of the new premises by relevant PRC governmental authorities.

There is no long-term agreement between our Group and our suppliers.

During the Track Record Period, our suppliers primarily included providers of advertising services, IT services, pharmaceuticals, surgical consumables and hair care products. Similar to the industry practice, we have not entered, and will not enter into any long-term supply agreement with our suppliers and we cannot assure you that our suppliers will continue to supply to us on commercially reasonable terms. It is also possible that our suppliers may early terminate or refuse to renew the supply agreements with us. If any of our suppliers do not supply our ordered quantities of supplies in a timely manner, we may need to acquire replacements for such supplies from alternate suppliers. We cannot assure you that we will be able to do so in a timely manner and/or at commercially reasonable terms. Any disruption in supply of implants, pharmaceuticals and other medical consumables, or any significant increase of procurement price thereof may adversely affect the capacities of our hair transplant medical clinics in providing services, which may in turn adversely affect our business, results of operations, financial condition and prospects. Moreover, if the prices of supplies increase significantly, we would not

RISK FACTORS

be able to pass on all such increased costs to our customers by simply raising the prices of our services. Any substantial fluctuation in market prices of the supplies required in our services may significantly increase our costs, resulting in reducing, suspending or ceasing provision of certain types of services, thereby reducing our sales and profit.

We have engaged a limited number of suppliers for raw materials, which may render us vulnerable to supply shortages, quality issues and price fluctuations and could materially and adversely affect our business, results of operations, financial condition and prospects.

We have engaged a limited number of suppliers for raw materials and services during the Track Record Period. Any interruptions or changes in the supply of raw materials or services, or our inability to obtain substitute suppliers meeting our quality standards at acceptable prices in a timely manner may impair our ability to meet the demands of our customers, which could have a material adverse effect on our business, results of operations, financial condition and prospects. Moreover, we expect our demand for such raw materials and services increase as we continuously expand our business scale, and we cannot guarantee that our current suppliers have the capacity to meet our increasing demand going forward. On the other hand, we enter into minimum purchase commitments with certain suppliers who are advertising service providers, which may affect our ability to timely adjust the amount of our purchases for their advertising services based on our actual business demands, and may cause us to incur unnecessary advertising costs merely to fulfill such minimum purchase commitments. If demand for our services is less than we expect for reasons beyond our control, such as a slowdown in the global or Chinese economy, we may experience additional excess and obsolete inventories and our profitability may suffer. In the event that our major suppliers terminate their business relationships with us, or fail to provide us with adequate supply to meet our needs, we may not be able to find suitable alternative suppliers within a short period of time. Therefore, if we cannot retain business relationships with our existing suppliers, or if these suppliers increase prices, delay in delivery, provide unqualified equipment or raw materials, or encounter financial, operating or other difficulties, we may experience business disruptions, which could materially and adversely affect our business, financial condition and results of operations. Moreover, prices of certain principal raw materials and services may increase significantly, in which case we may not be able to increase the prices of our services to offset the impacts. Therefore, if our suppliers increase prices of or reduce discounts on the raw materials and we fail to secure replacement for such materials or services at a better price, we may experience a decline of our profits.

We do not have full control over the quality of the medical service equipment, pharmaceuticals and medical consumables we use in providing our services, and we may be subject to product liability claims.

Even though we are selective in choosing our suppliers, we cannot assure you that the medical service equipment, pharmaceuticals and medical consumables we procure from our suppliers during the course of our business operations are safe, free of defects and meeting the relevant quality standards. We depend on our suppliers' quality control procedures. In the event of any quality issues, we could be subject to complaints and product liability claims by our customers. We may not be able to seek indemnification from our suppliers and if we engage in legal proceedings against our suppliers, such proceedings may be time consuming and costly regardless of the outcomes. Any quality issues on our hair transplant equipment, pharmaceuticals and medical consumables may have a material adverse effect on our reputation, brand image, financial performance and lead to negative publicity. Furthermore, we may also need to find alternative suppliers and suitable replacement products, which may result in delay in the provision of our services. If we are unable to find alternative suppliers or suitable replacement products in a timely manner, our business operations may be disrupted.

RISK FACTORS

Failures in properly keeping and maintaining patient records, or in protecting our patients' information from leakage or improper use could expose us, our physicians and other professional medical staff to claims, regulatory actions or litigations.

We are required by applicable laws to properly keep and maintain patient records, and to protect the patients' information from being leaked. We are also subject to, among others, regulations on personal information protection in the PRC which limits the use of personal information of our customers collected by us for such purposes for which they were collected or for a directly related purpose. During our ordinary course of business, we collect certain data of our customers, primarily including name, gender, contact information, basic health information, consultation and treatment records, and other medical records. We collect such information primarily for communications, treatment planning and delivery of our services and products. We have adopted various measures to ensure legal compliance. See “Business — Data Privacy and Protection” for more information. However, the laws and regulations regarding data privacy and protection in China are generally complex and evolving, with uncertainty as to the interpretation and application thereof. For example, on July 10, 2021, the Cyberspace Administration of China published the Measures for Cybersecurity Review (Revised Draft for Comments) (the “**Draft Cybersecurity Review Measures**”), which stipulate that if an operator has collected personal information of over one million users and intends to be listed in a foreign country, it must be subject to the cybersecurity review. Although the number of our customers are far below one million and we believe that our collection and handling of the personal information of our customers do not constitute “data processing activities” or any other activities that may affect national security under the Draft Cybersecurity Review Measures, the application scope of the draft measures remains unclear, and the PRC government authorities may have wide discretion in the interpretation and enforcement of the laws and regulations. If a final version of the Draft Cybersecurity Review Measures is adopted, we may be subject to review when conducting data processing activities, and may face challenges in addressing its requirements and make necessary changes to our internal policies and practices in data processing. Any actual or alleged failure to comply with the evolving data privacy and protection laws and regulations could damage our reputation and negatively affect our business operation and financial position.

In addition, we cannot guarantee that our confidentiality policies and measures can completely prevent our customers' information from leakage or unauthorized use. Our information technology systems could be breached through hacking activities. Medical records in our hair transplant clinics of our customers, if any, are kept manually. Personal information we maintain could be leaked due to any theft, misuse of personal information arising from misconduct or negligence. Any breach of our confidentiality obligations to our customers could expose our Group and/or our physicians and staff to potential liabilities, such as claims, regulatory actions or litigations, or disciplinary actions, which may have a material adverse effect on our brand image and reputation, business, results of operations, financial conditions and prospects.

Acquisition of the businesses of an international brand in a specific jurisdiction may expose us to external risks arising from the businesses of the same brand in other jurisdictions.

During the Track Record Period, we partially acquired the businesses of certain international brands. For example, in 2017, we acquired the mainland China business of *Svenson*, a globally renowned brand originated from London, and there might be other businesses established or to be established under the same brand *Svenson* in Hong Kong and overseas markets. As of the Latest Practicable Date, we had not established any cooperation and/or other contractual relationship with the business of *Svenson* in other regions. In May 2021, we acquired the Hong Kong business of *Nu/Hart Hair*, a renowned hair

RISK FACTORS

transplant service provider originated from the U.S., and there also might be other businesses established or to be established under the same brand *Nu/Hart Hair* in the U.S. and other overseas markets. These businesses are operated by third parties that beyond our control in various other jurisdictions. Since we rely on our brand image and reputation in marketing and selling our services, and there are an increasing number of potential customers who may seek services based on our reputation and brand in the hair-related healthcare service industry, any negative news and media reports related to the businesses of these brands in other jurisdictions may also negatively affect our reputation and even expose us to claims or litigations. Particularly, the medical hair care services we offered in *Svenson Medical Hair Care Centers* have constituted a significant portion of our overall businesses and we plan to further expand our medical hair care services and routine hair care services under the band *Svenson* in the future. If the reputation of the brand were materially damaged by any external risks arising from the businesses in other jurisdictions, we may have to incur extra costs for marketing or even change our branding strategy. If any of the aforesaid happens, our brand image and reputation, business, results of operations, financial conditions and prospects might be adversely affected.

Future acquisitions of businesses, technologies or know-how could materially and adversely affect our business, financial condition and results of operation if we fail to integrate the acquired businesses or technologies successfully into our existing operations or if we discover previously undisclosed liabilities.

To enhance our growth, we may acquire businesses, technologies or know-how that we believe would benefit us in terms of product development, technology advancement or distribution network. For example, in May 2021, we acquired the Hong Kong business of *Nu/Hart Hair* (顯赫植髮), a renowned hair transplant service provider originated from the U.S. Our ability to grow through acquisitions depends upon our ability to identify, negotiate, complete and integrate suitable acquisitions and to obtain any necessary financing. As part of our business strategies, we plan to acquire independent local hair transplant clinics to expedite the concentrated multi-location expansion in key regions. See “Business — Integrate Industry Resources and Promote Multi-Brand Strategy” for details. However, the materialization of our acquisition plan depends on our ability to identify, negotiate, and complete the acquisitions and to obtain necessary financing. Our business growth may be hurdled to some extent as a result of our failure to complete the planned acquisitions. Even if we complete acquisitions, as we have limited experience with significant acquisitions, we may experience:

- difficulties in integrating any acquired companies, technologies, or personnel into our existing business, particularly integrating different quality management, customer service and other business functions;
- delays or failure in realizing the benefits of the acquired company, technologies or know-how;
- diversion of our management’s time and attention from other business concerns;
- higher costs of integration than we anticipated; or
- difficulties in retaining key employees of the acquired business who are necessary to manage these acquisitions.

If we invest in businesses that operate outside China, these risks may increase because of our limited experience in operating overseas.

RISK FACTORS

An acquisition could also materially impair our results of operation by causing us to incur debt or requiring us to amortize acquired intangible assets. We may also discover deficiencies in internal controls, data adequacy and integrity, product quality and regulatory compliance, and product liabilities in businesses we acquire which we did not uncover prior to such acquisition. Therefore, we may become subject to penalties, lawsuits or other liabilities. Any difficulties in the integration of acquired businesses or technologies or unexpected penalties, lawsuits or liabilities in connection with such businesses or technologies could have a material adverse effect on our business, financial condition and results of operations.

Any disruption, malfunction or breakdown of our business management system and network security may interrupt our business operations and materially and adversely affect our business.

Our business operations depend on the satisfactory performance, stability and reliability of our business management system and related software programs, which are critical to our storage of customer records and appointments, management of supplies as well as computation of operational and sales data. However, our business management system may experience disruption, malfunction, breakdown or other performance problems due to reasons such as (i) the licensor terminates the license of the business management system to us; (ii) any unauthorized use of software and allegations regarding infringements of intellectual property rights during our business operation; (iii) increasing pressure on our servers and network capacities as a result of growing customer base and expanding operations; (iv) undetected programming errors, bugs, flaws, corrupted data or other defects; (v) hacking or other attacks on our network infrastructure and system programs; and (vi) floods, fires, extreme temperatures, power loss, telecommunications failures, technical error, computer viruses or similar events. Any disruption, malfunction, breakdown or other performance problems of our business management system may significantly disrupt our business operations and reduce our work efficiency, which may have a negative impact on the quality of our services.

There is no assurance that our business management system will not experience disruption, malfunction, breakdown or other performance problems in the future. There is also no assurance that we will be able to, through the help of our licensor, effectively upgrade our existing systems or develop new systems to support our expanding business operations in a timely manner. Any failure to do so may materially and adversely affect our business, results of operations, financial condition and prospects.

We also receive and maintain certain personal information about our customers when accepting credit cards for payment. If our network security is compromised and such information is stolen or obtained by unauthorized persons or used inappropriately, we may be subject to litigation or other proceedings brought by cardholders and the credit card issuing financial institutions. Any such proceedings could distract our management from running our business and cause us to incur significant unplanned losses and expenses. Consumer perception of our Group and our brands could also be negatively affected by these events, which could further adversely affect our business and results of operations.

RISK FACTORS

There is no assurance that we will be able to successfully enforce the non-competition undertakings contained in the agreements we have entered into with our physicians.

In the PRC, restrictive covenants are enforceable only when the contractual terms restricting a contracting party's activities during or after the termination of his/her agreement are reasonable in all circumstances to protect the legitimate business interests of the other contracting party, i.e. our Group. Despite there are non-competition undertakings contained in the employment agreements we have entered into with our physicians, there is no assurance that they will not, upon termination of their respective agreements with us, engage in business activities that compete, whether directly or indirectly, with our business for a certain period of time. In circumstances where our physicians engage in competing business activities, we cannot assure you that we will be able to successfully enforce such non-competition undertakings under the laws of the PRC. If our physicians engage in competing business activities and we are unable to enforce the relevant non-competition undertakings, our business, results of operations and financial condition may be materially and adversely affected.

Our insurance coverage may be insufficient to cover all risks involved in our business operations.

We have obtained insurance to cover certain potential risks and liabilities. However, we may not be able to acquire any insurance for certain types of risks such as business liability or service disruption insurance for all of our operations in the PRC, and our coverage may not be adequate to compensate for all losses that may occur, particularly with respect to loss of business or operations. For example, we do not maintain business interruption insurance, nor do we maintain key-man life insurance. Any business disruption, litigation, regulatory action, outbreak of epidemic disease or natural disaster could also expose us to substantial costs and diversion of resources. There can be no assurance that our insurance coverage is sufficient to prevent us from any loss or that we will be able to successfully claim our losses under our current insurance policy on a timely basis, or at all. If we incur any loss that is not covered by our insurance policies, or the compensated amount is significantly less than our actual loss, our business, financial condition and results of operations could be materially and adversely affected.

In addition, we do not maintain a medical liability insurance. We are subject to legal proceedings and claims that arise in the ordinary course of business, which primarily include medical disputes brought by our patients against us. Although we believe our comprehensive quality control system can effectively control the safety and quality of the services provided by our medical professionals, there is no assurance that we are able to maintain the occurrence of medical disputes at a manageable level. If we are found to be liable to any material medical incidents and there is no insurance to cover our losses arising therefrom, our business, financial condition and results of operations could be materially and adversely affected.

We may be unable to adequately protect our intellectual property rights and any infringement could materially and adversely affect our business.

We believe that intellectual property rights are critical to our continued success. We have registered or applied for registration of certain trademarks, patents and domain names in the PRC and Hong Kong relating to the names and logos of our clinics. For details, see “Business — Intellectual Property” and “Appendix IV — Statutory and General Information — B. Further Information About the Business of the Company — 2. Our Material Intellectual Property Rights” in this prospectus for details. We endeavor to protect our intellectual property rights but there is no assurance that the measures we have taken to protect our intellectual property rights, including registration of our trademarks, can adequately prevent unauthorized use by third parties or that we will not face any infringement of our

RISK FACTORS

intellectual property rights in the future. Infringement of our intellectual property rights may impair the brand image and discredit our reputation, which may have a material adverse effect on our business, results of operations, financial condition and prospects. If we were to enforce our intellectual property rights through legal proceedings, such proceedings, regardless of the outcome, may be time-consuming and costly and divert our resources and management's attention, which could materially and adversely affect our business, result of operations, financial condition and prospects.

Litigation or third-party claims of intellectual property infringement or challenges to the validity of our patents or other intellectual properties could be expensive, time-consuming and unsuccessful, and may prevent or delay our business development.

We have been, and may continue to be, involved in allegations regarding infringements of intellectual property rights (including the use of computer software, trademarks, copyright and patents), and some of which may be raised by other market players as a way of malicious competition. These allegations, with or without merits, may lead to potential litigations, administrative proceedings, and other disputes. In addition, we may be subject to allegations, litigations or administrative proceedings because of intellectual property infringement committed by our employees or third-party collaborators (for instance, distributors or manufacturers where we purchased our computers or software).

Defending against intellectual property claims arising from allegations, litigations, administrative proceedings and other disputes is time-consuming and costly and can impose a significant burden on our ability to develop, launch and sell our products and services. Such claims, even without merits, may still harm our reputation in the industry. If we are the target of claims by third parties asserting that our potential products or intellectual property infringe upon the rights of others, we may be forced to incur substantial expenses or divert substantial managerial resources from our business. Potential allegations, litigations, administrative proceedings, and other disputes, or any adverse determination therefrom in an intellectual property claim against us, especially in relation to the use of computer software, trademarks, copyright and patents, may adversely affect or even disrupt our operation. For example, such allegations, litigations, administrative proceedings or other disputes, may cause us to stop or delay using certain computer software, which may interrupt our normal operation. Further, an adverse determination in an intellectual property claim to which we may become a party could subject us to significant liabilities, resulting in payments of substantial damages and/or an injunction on us that prevents us from developing relevant potential product candidates or technologies. Further, if a patent infringement claim is brought against us or our collaborators, we or they could be forced to stop or delay research, development, or sales of the service or product that is the subject of the suit.

As of the Latest Practicable Date, we were not involved in any intellectual property infringement actions that would have a material and adverse effect on our business, results of operations and financial condition. In particular, we were not being imposed on any administrative penalties or fines in relation to the use of software which would have a material adverse effect on the operation. However, there is no assurance that our business will not experience disruption or other performance problems in this regard in the future.

RISK FACTORS

We had net current liabilities during the Track Record Period. We cannot assure you that we will not experience net current liabilities in the future, which could expose us to liquidity risks.

During the Track Record Period, we had net current liabilities of RMB52.6 million, RMB102.3 million, RMB67.6 million and RMB31.5 million as of December 31, 2018, 2019 and 2020 and June 30, 2021, respectively. Our net current liability position was primarily attributable to (i) lease liabilities in relation to the properties we leased for our office premises and clinics; (ii) trade and other payables; (iii) contract liabilities in relation to the advanced payments received from customers for services or products that had not yet been provided to the customers; and (iv) borrowings, while our current assets increased at a relatively slower rate during the relevant period. However, there can be no assurance that we will not experience liquidity problems in the future. If we fail to maintain sufficient cash and financing, we may not have sufficient cash flows to fund our business, operations and capital expenditure and our business and financial position will be adversely affected.

The discontinuation of any preferential tax treatment currently available to us could adversely affect our results of operations, cash flow and prospects.

On October 31, 2018, one of our subsidiaries, Yonghe Investment, was qualified as “High and New Technology Enterprises” (“HNTes”) under the relevant PRC laws and regulations, and therefore, was entitled to a preferential income tax rate of 15%. For more details on the preferential tax treatments, Note 12 of Appendix I to this prospectus. In addition, we may enjoy other preferential tax treatments from time to time in relation to the healthcare industry. Our eligibility to receive the preferential tax treatment requires that we continue to qualify for them. The incentives are provided to us at the discretion of the central government or relevant local government authorities, which could determine at any time to eliminate or reduce the preferential tax treatment, generally with prospective effect. Since our receipt of the preferential tax treatment is subject to periodic time lags and changing government practice, as long as we continue to receive these preferential tax treatment, our net income in a particular period may be higher or lower relative to other periods depending on the potential changes in these preferential tax treatment in addition to any business or operational factors that we may otherwise experience. The discontinuation of preferential tax treatment currently available to us could have an adverse effect on our financial condition, results of operations, cash flows and prospects.

We may face risk regarding the obsolescence for our inventories.

Our inventories primarily consist of (i) pharmaceuticals and medical consumables used in our hair transplant services; (ii) medical hair care consumables and (iii) wash and hair care products. As of December 31, 2018, 2019, 2020, and June 30, 2021, our inventories amounted to RMB14.3 million, RMB14.5 million, RMB27.0 million and RMB44.5 million, respectively. During the Track Record Period, we have not identified material inventory items requiring impairment provisioning, as we have maintained an effective inventory management system. We believe that maintaining appropriate levels of inventories helps us meet market demands in a timely manner. We generally purchase supplies based on our estimated demand, and we monitor the expiration dates closely through our logbook and physical inspection to ensure that no expired items will be used or sold. As our business expands, our inventory level may increase and our inventory obsolescence risk may also increase accordingly. Furthermore, any unexpected material fluctuations in the supplies or changes in customers’ preferences may lead to decreased demand and overstocking of supplies and increase the risk of obsolescence.

RISK FACTORS

We may face risk regarding the recoverability of deferred income tax assets.

As of December 31, 2018, 2019, 2020, and June 30, 2021, our deferred income tax assets amounted to RMB12.5 million, RMB20.9 million, RMB29.0 million and RMB32.7 million, which mainly represent temporary differences attributable to unused tax losses, refund liabilities, temporary differences due to leasing and temporary differences due to intercompany transaction. For details on the movements of our deferred income tax assets during the Track Record Period, see Note 27 to Appendix I to this prospectus. Deferred income tax assets are recognized to the extent that it is probable that future taxable profit will be available against which the deductible temporary differences can be utilized. This requires significant judgment on the tax treatments of certain transactions and assessment on the probability that adequate future taxable profits will be available for the deferred income tax assets to be recovered. We cannot guarantee the recoverability or the estimated movement of our deferred income tax assets. If we fail to recover our deferred income tax assets, our future financial condition and results of operations may be adversely affected.

We may incur impairment losses on our intangible assets and goodwill.

We recognize the value of our goodwill, software and trademark as intangible assets. As of December 31, 2018, 2019, 2020, and June 30, 2021, we had intangible assets of RMB1.4 million, RMB3.3 million, RMB3.5 million and RMB34.1 million, respectively. In particular, our intangible assets increased significantly as of June 30, 2021, primarily due to the acquisition of *Nu/Hart Hair*. Goodwill is tested annually for impairment, or more frequently if events or changes in circumstances indicate that they might be impaired. Intangible assets that have an useful life are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. For details on the impairment assessment methods for our intangible assets, see Note 2.8 and 16 to Appendix I to this prospectus. Adverse changes in the future may result in decreases in the value of our intangible assets, which in turn would result in an impairment loss. In addition, we make certain assumptions when assessing the value of our intangible assets, including assumptions on their useful life. There are inherent uncertainties relating to these assumptions. We cannot assure you that our assumptions will prove to be correct. Any such change in our assumptions may require us to re-value our intangible assets, which may in turn result in impairment losses. Significant impairment losses on intangible assets may have a material adverse effect on our financial condition and results of operations and may in turn limit our ability to obtain financing in the future.

The recoverability of our prepayments, deposits and other receivables may affect our business operations.

During the Track Record Period, our prepayments, deposits, and other receivables primarily consisted of (i) prepayments for advertising and information technology service fees to third parties for marketing and promotional related activities; (ii) security deposits for rentals and advertising services; (iii) receivables in relation to rental deposits and other rental related payments yet refunded and (iv) prepaid rental and property management fees. There are uncertainties about the recoverability of our prepayments, deposits and other receivables. As of December 31, 2018, 2019, 2020, and June 30, 2021, we recorded current prepayments, deposits, and other receivables of RMB60.1 million, RMB68.3 million, RMB107.4 million and RMB131.6 million, respectively. However, there is no guarantee that we will be able to proceed with our sales and marketing plan and clinic expansion plan. We conduct assessments on the recoverability of prepayments, deposits and other receivables based on, among others, our historical settlement records, our relationship with relevant counterparties, payment terms, current economic trends and to a certain extent, the larger economic and regulatory environment, which involve

RISK FACTORS

the use of various judgments, assumptions and estimates by our management. However, there is no assurance that our expectations or estimates will be entirely accurate, as we are not in control of all the underlying factors affecting such prepayments, deposits, and other receivables. Therefore, if we are not able to recover the prepayments, deposits, and other receivables as scheduled, our financial position and results of operations may be adversely affected.

We may not be able to fulfil our obligations in respect of contract liabilities.

Our contract liabilities represent our obligations to provide the contracted products and services to customers. Our contract liabilities mainly arise from the advance payment made by customers while the underlying products and services are not yet to be provided. As of December 31, 2018, 2019, 2020 and June 30, 2021, we had contract liabilities of RMB16.9 million, RMB23.4 million, RMB120.4 million and RMB181.8 million, respectively. Our contract liabilities increased significantly over years, which was generally in line with our business growth. In particular, our contract liabilities increased significantly to RMB181.8 million as of June 30, 2021, which was primarily in relation to the medical hair care services we rendered, where we offered hair care services in service components. For further details, see “Financial Information — Discussion of Certain Selected Items From the Consolidated Balance Sheets — Contract Liabilities.”

However, there is no assurance that we will be able to fulfil our obligations in respect of contract liabilities as the completion of our services is subject to various factors, including the normal operation of our clinics, the service capacity of our clinics, the availability of our physicians and other medical staff and the supply of raw materials and consumables from our suppliers. If we are not able to fulfil our obligations with respect to our contract liabilities, the amount of contract liabilities will not be recognized as revenue, and we may have to return the advance payment made by our customers. As a result, our results of operations, liquidity and financial position may be materially and adversely affected.

We may need additional capital, and we may be unable to obtain such capital in a timely manner or on acceptable terms, or at all.

We may require additional capital beyond those generated by the Global Offering from time to time to grow our business, to better serve our customers, develop and enhance our products, and improve our operating infrastructure. Accordingly, we may need to sell additional equity or debt securities or obtain a credit facility. Future issuances of equity or equity-linked securities could significantly dilute our existing shareholders, and any new equity securities we issue could have rights, preferences and privileges superior to those of holders of our ordinary shares. The incurrence of debt financing would result in increased debt service obligations and could result in operating and financing covenants that would restrict our operations or our ability to pay dividends to our shareholders.

Our results of operations, financial conditions, and prospects may be adversely affected by fair value changes and credit risk associated with our financial assets at fair value through profit or loss.

During the Track Record Period, we had certain financial assets at fair value through profit or loss, primarily consisting of wealth management products we purchased by using our free cash. In 2020, we purchased financial assets at fair value through profit or loss of RMB31.1 million and such wealth management products were redeemed in the same period. The fair value of these financial products was determined by discounted cash flow, which was estimated based on expected return, and discounted at a rate that reflects the risk of underlying investments. This requires our management to make estimates

RISK FACTORS

about expected future cash flows, credit risk, volatility and discount rates, and hence they are subject to uncertainty. As a result, such treatment of carrying amounts of our financial assets measured at fair value through profit or loss may cause significant volatility in or materially and adversely affect our period-to-period earnings, financial condition and results of operations.

Failure to comply with anti-corruption and/or anti-commercial bribery laws, rules and regulations could subject us, our physicians, other medical professionals and staff to investigations and administrative or criminal proceedings, which may harm our market reputation and adversely affect the business, financial condition and results of operations.

The remuneration package of our employees includes basic salary, allowance and bonus. Therefore, our staff may be incentivized to adopt inappropriate and excessive sales practices, which may involve advising customers to purchase unnecessary or unsuitable services, in order to boost their sales. Any incidents of inappropriate and excessive sales practices which lead to unnecessary or inadequate services provided to our customers may result in complaints, claims and legal actions to be brought by dissatisfied customers. We therefore face potential penalties for non-compliance. We have adopted policies and procedures designed to ensure that the physicians, other medical professionals and staff in our network reasonably comply with anti-corruption, anti-unfair competition, and anti-commercial bribery laws, rules and regulations. For more details of the relevant laws and regulations, see “Regulatory Overview — Laws and Regulations Regarding Anti-Corruption, Anti-Unfair Competition and Anti-Commercial Bribery.” For more details on our internal control policies and procedures, see “Business — Internal Control and Risk Management — Adoption and Implementation of Internal Control Policies.” However, there is no assurance that our policies and procedures will effectively prevent any non-compliance with relevant anti-corruption, anti-unfair competition, and anti-commercial bribery laws, rules and regulations arising from actions taken by the individual physicians, other medical professionals and staff. If this occurs, we, the physicians, and other medical professionals and staff may be subject to investigations and administrative or criminal proceedings, and our reputation could be significantly harmed by any negative publicity stemming from such incidents, which may materially and adversely affect the business, financial condition and results of operations.

RISKS RELATING TO OUR INDUSTRY

Our business performance may be negatively affected by unfavorable public perception of the overall private healthcare industry, especially the hair-related healthcare industry.

Our existing and potential customers are generally cautious about the risks inherent in hair transplant treatments, and are particularly sensitive to any negative comments, reports or allegations against any medical hair care service providers. From time to time, there are negative news and media reports on the health risks relating to medical hair care services as well as accidents relating to the hair transplant treatment. Any allegations, complaints, or negative news or media reports on any accidents, instances of medical malpractice or professional negligence, unfair selling practices, ineffectiveness of services, or health risks or poor service standard relating to hair-related healthcare industry or hair transplant services may, regardless of merit, lead to a deterioration in market confidence in medical hair care services and a reduction in the overall demand for such services. While such allegations, complaints or negative news or media reports may be unrelated to us, the demand for our medical hair care services may decline and the entire private healthcare industry and its participants, including us, could consequently be exposed to reputational harm, which may materially and adversely affect our business, results of operations, financial condition and prospects.

RISK FACTORS

We may not be able to maintain our revenue and profitability as we operate in a highly competitive industry.

The hair transplant service market and medical hair care service market in the PRC have been competitive due to the abundance of medical institutions. Our major competitors include other private hair transplant institutions, hair transplant departments of public hospitals and aesthetic service providers. Due to continuous technological advancements, the hair-related healthcare industry is defined by rapidly changing market trends. Our customers are constantly looking for innovative and high-performance services at reasonable prices. As a result, we are in constant competition with other hair-related healthcare service providers in aspects such as quality and scope of services, comprehensiveness and diversity of hair-related healthcare service, hair transplant service equipment as well as pricing. In the geographical areas in which we operate, there are other hair-related healthcare service providers, which in many cases provide services comparable to those which we offer and may have greater financial resources to achieve advantageous position in competition with us. New or existing competitors may provide services similar to those we provide, and may further offer broader services, newer or better facilities, with greater convenience or more specialized physicians, or cheaper pricing. If we are unable to attract and maintain customers, or unable to stay competitive or compete successfully with our competitors, we may experience a reduction of market share and significant decrease in the volume of customer visits at our clinics, and our brand image and reputation could be forgotten, which could adversely affect our business, financial condition and results of operations.

Demand for our medical hair care services may not increase as rapidly as we anticipate due to a variety of factors, including weakness in general economic conditions, which would materially and adversely affect our business, results of operations and financial condition.

According to Frost & Sullivan, in China, the population suffering from alopecia was approximately 250.9 million in 2020. On the one hand, according to Frost & Sullivan, the size of the hair-related healthcare market in China reached RMB18.4 billion in 2020, and is projected at RMB138.1 billion in 2030 with a CAGR of 22.3%. However, the future demand of medical hair care services may be difficult to anticipate since it depends on a number of variables, most of which are beyond our control. Consumer spending habits are affected by, among other things, prevailing economic conditions, levels of employment, salaries and wage rates, consumer confidence and consumer perception of economic conditions. A general slowdown in economy of China or other overseas markets or an uncertain economic outlook would adversely affect consumer spending habits which may, among other things, result in a decrease in the number of overall medical hair care services or a reduction in consumer spending on elective or higher value medical hair care services, each of which would have a material adverse effect on our results of operations. The prospect of the hair-related healthcare industry is also uncertain and may develop slower than we expect. The market prospect depends on a number of factors, including, among others, the level of market recognition, competing technologies and the industry's own development. If the demand for medical hair care services fails to increase as rapidly as we anticipate, our business, financial condition, results of operations and prospects may be materially and adversely affected.

RISK FACTORS

RISKS RELATING TO OUR CONTRACTUAL ARRANGEMENTS

If the PRC government deems that the Contractual Arrangements do not comply with PRC regulatory restrictions on foreign investment in the relevant industries, or if these regulations or the interpretation of existing regulations change in the future, we could be subject to severe penalties or be forced to relinquish our interests received through the Contractual Arrangements.

Foreign ownership of certain business in PRC is subject to restrictions under current PRC laws and regulations. For example, foreign investors are not allowed to own 100% of the equity interest in Relevant Businesses. We are an exempted company incorporated in the Cayman Islands, as such, we are classified as a foreign enterprise under PRC laws and regulations. Through our wholly-owned PRC subsidiary, Beijing Haiyouyou, we have entered into a series of Contractual Arrangements with Registered Shareholders, Beijing Xunyi and the VIE Entities. See “Contractual Arrangements” for details. Through our shareholdings and the Contractual Arrangements, our Company acquired effective control over the VIE Entities and Beijing Xunyi, at our Company’s sole discretion, can receive all of the economic interest returns generated by the VIE Entities and Beijing Xunyi.

As advised by our PRC Legal Advisers, save as disclosed in “Contractual Arrangements — Legality of The Contractual Arrangements,” the Contractual Arrangements are legal, valid, enforceable and binding upon the parties thereto under the current laws and regulations. See “Contractual Arrangements — Legality of the Contractual Arrangements” for details. However, our PRC Legal Advisers have also advised us that there are substantial uncertainties regarding the interpretation and application of current or future PRC laws and regulations. The relevant PRC regulatory authorities have broad discretion in determining whether a particular contractual structure violates PRC laws and regulations. Accordingly, there can be no assurance that the PRC government will ultimately take a view that is consistent with the opinion of our PRC Legal Advisers.

On March 15, 2019, the NPC promulgated the Foreign Investment Law of the People’s Republic of China (《中華人民共和國外商投資法》) (the “**FIL**”) which became effective on January 1, 2020. According to the FIL, the “foreign investment” refers to investment activities carried out directly or indirectly by foreign natural persons, enterprises or other organizations (hereinafter referred to as “**Foreign Investors**”). However, the interpretation and application of the FIL remain uncertain. In addition, the FIL stipulates that foreign investment includes “Foreign Investors investing in PRC through many other methods under laws, administrative regulations or provisions prescribed by the State Council.” We cannot assure you that the Contractual Arrangements will not be deemed as a form of foreign investment under laws, regulations or provisions prescribed by the State Council in the future, as a result of which, it will be uncertain whether the Contractual Arrangements will be deemed to be in violation of the foreign investment access requirements and the impact on the Contractual Arrangements. If our ownership structure, Contractual Arrangements and business are found to be in violation of any existing or future PRC laws or regulations, or we fail to obtain or maintain any of the required permits or approvals, the relevant governmental authorities would have broad discretion in dealing with such violations, including:

- levying fines on us;
- confiscating our income or the income of the VIE Entities or Beijing Xunyi;
- revoking our business licenses and/or operating licenses;

RISK FACTORS

- shutting down our clinics;
- discontinuing or placing restrictions or onerous conditions on our operations, requiring us to undergo a costly and disruptive restructuring; and
- taking other regulatory or enforcement actions that could be harmful to our business.

Any of these actions could cause significant disruption to our business operations and severely damage our reputation, which would result in us failing to receive a portion of the economic benefits from VIE Entities, which in turn may materially and adversely affect our business, financial condition and results of operations.

Furthermore, new PRC laws, rules and regulations may be introduced to impose additional requirements that may be applicable to our corporate structure and the Contractual Arrangements. In addition, if any equity interest held by Beijing Haiyouyou in the VIE Entities or Beijing Xunyi is held in the court custody in connection with its litigation, arbitration or other judicial or dispute resolution proceedings, we cannot assure you that the equity interest will be disposed of to us in such proceedings in accordance with the Contractual Arrangements. The occurrence of any of these events could adversely affect our business, financial condition and results of operations.

Our Contractual Arrangements may not be as effective in providing operational control as direct ownership and our VIE Entities, Beijing Xunyi and Registered Shareholders may fail to perform their obligations under our Contractual Arrangements.

We provide business support, technical and consulting services to our VIE Entities and Beijing Xunyi, in which we have no 100% ownership interest and rely on the Contractual Arrangements with the VIE Entities, Beijing Xunyi and the Registered Shareholders to control and operate the Relevant Businesses. Although we have been advised by our PRC Legal Advisers that our Contractual Arrangements constitute valid and binding obligations enforceable against each party of such agreements in accordance with their terms, these Contractual Arrangements may not be as effective in providing us with control over VIE Entities as direct ownership. Direct ownership would allow us, for example, to directly or indirectly exercise our rights as a shareholder to effect changes in the board of directors of the VIE Entities or Beijing Xunyi, which, in turn, could effect changes, subject to any applicable fiduciary obligations, at the management level. If the VIE Entities, Beijing Xunyi and the Registered Shareholders fail to perform its respective obligations under the Contractual Arrangements, we may incur substantial costs and expend substantial resources to enforce our rights. All of these Contractual Arrangements are governed by and interpreted in accordance with PRC laws, and disputes arising from these Contractual Arrangements will be resolved through arbitration or litigation in PRC. However, the legal system in PRC is not as developed as in other jurisdictions, such as the United States. There are very few precedents and little official guidance as to how Contractual Arrangements in the context of a variable interest entity should be interpreted or enforced under PRC laws. There remain significant uncertainties regarding the outcome of arbitration or litigation. These uncertainties could limit our ability to enforce these Contractual Arrangements. The Contractual Arrangements contain provisions to the effect that the arbitral body may award remedies over the shares and/or assets of the VIE Entities and Beijing Xunyi, injunctive relief and/or winding up of these entities. These agreements also contain provisions to the effect that courts of competent jurisdictions are empowered to grant interim remedies in support of the arbitration pending the formation of an arbitral tribunal. However, under PRC laws, these terms may not

RISK FACTORS

be enforceable. Under PRC laws, an arbitral body does not have the power to grant injunctive relief to issue a provisional or final liquidation order. In addition, interim remedies or enforcement order granted by overseas courts such as Hong Kong and the Cayman Islands may not be recognizable or enforceable in the PRC. In the event we are unable to enforce these Contractual Arrangements or we experience significant delays or other obstacles in the process of enforcing these Contractual Arrangements, we may not be able to exert effective full control over the VIE Entities and Beijing Xunyi and may not prevent leakage of equity and values to the Registered Shareholders or obtain the full economic benefits of the same. Our ability to conduct our business may be negatively affected.

Our Contractual Arrangements may result in adverse tax consequences to us.

Under PRC laws and regulations, arrangements and transactions among related parties may be subject to audit or challenge by the PRC tax authorities. We could face material and adverse tax consequences if the PRC tax authorities determine that our Contractual Arrangements were not made on an arm's length basis and adjust our income and expenses for PRC tax purposes by requiring a transfer pricing adjustment. A transfer pricing adjustment could materially and adversely affect us by (i) increasing the tax liabilities of the VIE Entities and Beijing Xunyi without reducing the tax liability of Beijing Haiyouyou; or (ii) limiting the ability of the VIE Entities and Beijing Xunyi to obtain or maintain preferential tax treatments and other financial incentives. In addition, the PRC tax authorities may impose late payment interest. Our profit may be materially reduced if our tax liabilities increase or if it is subject to late payment fees or other penalties.

Beijing Xunyi or the Registered Shareholders may potentially have a conflict of interest with us, and they may breach their contracts with us or cause such contracts to be amended in a manner contrary to our interests.

Our fully control over the VIE Entities and Beijing Xunyi is based upon the Contractual Arrangements with, among others, the Registered Shareholders. These Registered Shareholders may potentially have a conflict of interest with us, and it may breach its agreements with us or if it otherwise acts in bad faith, if it believes the Contractual Arrangements would adversely affect its own interests. We cannot assure you that when conflicts of interest arise between us and Registered Shareholders, Beijing Xunyi will act completely in our interests or that the conflicts of interest will be resolved in our favor. If Beijing Xunyi does not act completely in our interests or the conflicts of interest between us and it are not resolved in our favor, our business and financial condition may be materially and adversely affected.

Currently, we do not have arrangements to address the potential conflicts of interest faced by the Registered Shareholders in their dual capacity as beneficial owners of our Group. We rely on the Registered Shareholders to comply with PRC laws and regulations, which protect contracts and provide that directors and executive officers owe a duty of loyalty to us and require them to avoid conflicts of interest and not to take advantage of their positions for personal gains, and the laws of the Cayman islands, which provide that directors have a duty of care and a duty of loyalty to act honestly in good faith with a view to our best interests. However, the legal frameworks of the PRC and the Cayman Islands do not provide guidance on resolving conflicts in the event of a conflict with another corporate governance regime.

RISK FACTORS

In addition, Registered Shareholders may breach or refuse to renew, or cause Beijing Xunyi to breach or refuse to renew, the Contractual Arrangements with us. If Registered Shareholders or Beijing Xunyi breaches its agreements with us or otherwise have disputes with us, we may have to initiate arbitration or other legal proceedings, which involve significant uncertainty. Such disputes and proceedings may significantly distract our management's attention, adversely affect our ability to fully control VIE Entities and Beijing Xunyi and otherwise result in negative publicity and adversely affect the reputation of our integrated healthcare systems. We cannot assure you that the outcome of any such dispute or proceeding will be in our favor.

Substantial uncertainties exist with respect to the interpretation and implementation of the Foreign Investment Law and how it may impact the viability of our current corporate structure, corporate governance and business operations.

On March 15, 2019, the NPC promulgated the Foreign Investment Law or the FIL, which has become effective on January 1, 2020 and replaced the outgoing laws regulating foreign investment in China, namely, the PRC Equity Joint Venture Law, the PRC Cooperative Joint Venture Law and the Wholly Foreign-owned Enterprise Law, as well their implementation rules and ancillary regulations, or the Outgoing FIE Laws. See “Regulatory Overview — Laws and Regulations Related to Foreign Investment in the PRC.”

Meanwhile, the Implementation Rules to the PRC Foreign Investment Law came into effect as of January 1, 2020, which clarified and elaborated the relevant provisions of the Foreign Investment Law. However, uncertainties still exist in relation to interpretation and implementation of the FIL, especially in regard to, including, among other things, specific rules regulating the organization form of foreign-invested enterprises within the five-year transition period. While FIL does not define contractual arrangements as a form of foreign investment explicitly, it has a catch-all provision under definition of “foreign investment” that includes investments made by foreign investors in the PRC through other means as provided by laws, administrative regulations or the State Council, we cannot assure you that future laws and regulations will not stipulate contractual arrangements as a form of foreign investment. Therefore, there can be no assurance that our control over the VIE Entities and Beijing Xunyi through Contractual Arrangements will not be deemed as foreign investment in the future. In the event that any possible implementing regulations of the FIL, any other future laws, administrative regulations or provisions deem contractual arrangements as a way of foreign investment, or if any of our operations through contractual arrangements is classified in the “restricted” or “prohibited” industry, or “negative list” under the FIL, our Contractual Arrangements may be deemed as invalid and illegal, and we may be required to unwind the Contractual Arrangements and/or dispose of any affected business. Also, if future laws, administrative regulations or provisions mandate further actions to be taken with respect to existing Contractual Arrangements, we may face substantial uncertainties as to whether we can complete such actions in a timely manner, or at all. Furthermore, under the FIL, foreign investors or the foreign investment enterprise should be imposed legal liabilities for failing to report investment information in accordance with the requirements. In addition, the FIL provides that foreign invested enterprises established according to the existing laws regulating foreign investment may maintain their structure and corporate governance within a five-year transition period, which means that we may be required to adjust the structure and corporate governance of certain of our PRC subsidiaries in such transition period. Failure to take timely and appropriate measures to cope with any of these or similar regulatory compliance challenges could materially and adversely affect our current corporate structure, corporate governance, financial condition and business operations.

RISK FACTORS

RISKS RELATING TO DOING BUSINESS IN CHINA

Ongoing regulatory reforms in the PRC are unpredictable. Any adverse change in the PRC regulatory regime could have a material adverse effect on our business.

The PRC's regulatory regime governing the medical healthcare industry may undergo reform. It is uncertain what impact the new regulations and policies would have on our competitiveness, operations and corporate structure. In recent years, the PRC government has gradually reduced regulatory hurdles for establishing and investing in non-public hospitals and medical institutions, in particular by private capital, and encouraged development of hospital management groups. Our business operations and future expansion are largely driven by the PRC's policies, which may change significantly and are beyond our control. There can be no assurance that the PRC government will not impose additional or stricter laws or regulations on healthcare services or foreign investments, or strengthen and tighten supervision and management of medical institutions including hospitals, in particular, non-public hospitals and medical institutions, or implement stricter or more comprehensive regulations on the distribution of pharmaceutical products, medical devices and medical consumables.

Depending on the priorities of the PRC government, the political climate and the regulatory regime with respect to foreign investment control at any given time, and the development of the Chinese healthcare service system, future regulatory changes may affect public hospital reform, limit private or foreign investments in healthcare service industry or implement additional price control on pharmaceutical products or medical services. Any of these events could have a material and adverse impact on our business, financial condition, results of operations, prospects and future growth.

Economic, political and social conditions and government policies in the PRC could affect our business and prospects.

A substantial majority of our revenue is derived from our businesses in the PRC. Accordingly, our financial condition, results of operations and prospects are, to a material extent, subject to economic, political and legal developments in the PRC. The PRC economy differs from the economies of developed countries in many respects, including, among other things, the degree of government involvement, control of investment, level of economic development, growth rate, foreign exchange controls and resource allocation. Although the PRC economy has been transitioning from a planned economy to a more market-oriented economy for about four decades, a substantial portion of productive assets in the PRC is still owned by the PRC government. The PRC government also exercises significant control over the economic growth of the PRC through allocating resources, controlling payments of foreign currency-denominated obligations, setting monetary policy and providing preferential treatment to particular industries or companies. In recent years, the PRC government has implemented measures emphasizing the utilization of market forces in economic reform, the reduction of state ownership of productive assets and the establishment of sound corporate governance practices in business enterprises. Some of these measures benefit the overall PRC economy, but may adversely affect us. For example, our financial condition and results of operations may be adversely affected by government policies on the digital medical service industry in China or changes in tax regulations applicable to us. If the business environment in the PRC deteriorates, our business in the PRC may also be materially and adversely affected.

RISK FACTORS

PRC regulations over loans to and direct investments in PRC entities by offshore holding companies may delay or prevent us from using the proceeds of the Global Offering to make loans or additional capital contributions to our PRC subsidiaries.

Any funds we transfer to our PRC subsidiaries, either as a shareholder loan or as an increase in registered capital, are subject to approval by registration with relevant governmental authorities in China. According to the relevant PRC regulations on foreign-invested enterprises, capital contributions by an offshore holding company to its wholly-owned subsidiary in China shall obtain approvals from or report investment information to MOFCOM or its local counterpart and register with the SAMR or its local counterpart to make capital contributions to the foreign-invested enterprises. In addition, any foreign loan procured by our PRC subsidiaries is required to be registered with SAFE or its local branches, and our PRC subsidiaries may not procure loans exceeding the statutory limits and is required to be registered with the SAFE or its local branches or file with SAFE through its online service platform. We may not obtain these government approvals or complete such registrations on a timely basis, or at all, with respect to future capital contributions or foreign loans by us to our PRC subsidiaries. If we fail to receive such approvals or complete such registration, our ability to use the proceeds of the Global Offering to fund our operations in China may be negatively affected, which in turn could adversely affect our ability to finance and expand our business.

Failure by our Shareholders or beneficial owners who are PRC residents to make required applications and filings pursuant to regulations relating to offshore investment activities by PRC residents may prevent us from distributing dividends and could expose us and our Shareholders who are PRC residents to liability under Chinese laws.

The Circular on Relevant Issues concerning Foreign Exchange Administration of Overseas Investment and Financing and Return Investments Conducted by Domestic Residents through Overseas Special Purpose Vehicles (關於境內居民通過特殊目的公司境外投融資及返程投資外匯管理有關問題的通知) (“SAFE Circular No. 37”), which was promulgated by SAFE and became effective on July 4, 2014, requires a PRC resident (including PRC individuals and PRC corporate entities) (“PRC Resident”) to register with the local SAFE branch before he or she contributes assets or equity interests in an overseas special purpose vehicle (“Offshore SPV”) that is directly established or controlled by the PRC Resident for the purpose of conducting investment or financing. Following the initial registration, the PRC Resident is also required to register with the local SAFE branch for any major change in respect of the Offshore SPV, including, among other things, any major change of a PRC resident shareholder, name or term of operation of the Offshore SPV, or any increase or reduction of the Offshore SPV’s registered capital, share transfer or swap, merger or division. Failure to comply with the registration procedures of SAFE Circular No. 37 may result in penalties and sanctions, including the imposition of restrictions on the ability of the Offshore SPV’s Chinese subsidiary to distribute dividends to its overseas parent. It is unclear how SAFE Circular No. 37 and any future regulation concerning offshore or cross-border transactions will be interpreted, amended or implemented by the relevant government authorities. We cannot predict how these regulations will affect our business operations or future strategies. Any failure by our PRC resident shareholders or beneficial owners to make the registrations or updates with SAFE may subject the relevant PRC resident shareholders or beneficial owners to penalties, restrict our overseas or cross-border investment activities, limit our Chinese subsidiaries’ ability to make distributions or pay dividends, or affect our ownership structure and capital inflow from our offshore subsidiaries. As such, our business, financial condition, results of operations and liquidity as well as our ability to pay dividends or make other distributions to our shareholders may be materially and adversely affected.

RISK FACTORS

Government control of currency conversion and future fluctuations in Renminbi exchange rates could have a material adverse effect on our business, results of operations, financial condition and prospects, and may reduce the value of, and dividends payable on, our Shares in foreign currency terms.

Our revenue and expenses are substantially denominated in Renminbi, which is currently not a freely convertible currency. A portion of the revenue must be converted into other currencies in order to meet our foreign currency obligations. For example, we will need to obtain foreign currency to make payments of declared dividends, if any, on our Shares.

Under China's existing foreign exchange regulations, we are able to make payments of current account items, including paying dividends in foreign currencies without prior approval from SAFE, by complying with certain procedural requirements. However, in the future, China's government may take measures, at its discretion, to restrict access to foreign currencies for capital account and current account transactions under certain circumstances. If such measures are implemented, we may not be able to pay dividends in foreign currencies to holders of our Shares. Foreign exchange transactions under our capital account are subject to significant foreign exchange controls and require the SAFE's approval. These limitations could affect our ability to obtain foreign exchange through offshore financing.

The value of the Renminbi against the Hong Kong dollar and the U.S. dollar and other currencies fluctuates, and is subject to changes resulting from government policies (including those of the PRC government) and depends to a large extent on domestic and international economic and political developments, as well as supply and demand in the local market. With an increased floating range of the Renminbi's value against foreign currencies and a more market-oriented mechanism for determining the mid-point exchange rates, the Renminbi may further appreciate or depreciate significantly in value against the Hong Kong dollar and the U.S. dollar or other foreign currencies in the long-term, depending on the fluctuation of the basket of currencies against which it is currently valued; or it may be permitted to enter into a full float, which may also result in a significant appreciation or depreciation of the Renminbi against the U.S. dollar or other foreign currencies. We cannot assure you that the Renminbi will not experience significant appreciation or depreciation against the U.S. dollar or other foreign currencies in the future.

Our proceeds from the Global Offering will be denominated in Hong Kong dollars. As a result, any appreciation of the Renminbi against the U.S. dollar, the Hong Kong dollar or any other foreign currencies may result in a decrease in the value of our foreign currency-denominated assets and our proceeds from the Global Offering. Conversely, any depreciation of the Renminbi may adversely affect the value of, and any dividends payable on our Shares in foreign currencies. There are limited instruments available for us to reduce our foreign currency risk exposure at reasonable cost in China, and we have not utilized, and may not in the future utilize, any such instrument. Furthermore, currently we are also required to obtain SAFE's approval before converting significant sums of foreign currencies into Renminbi. All of these factors could materially and adversely affect our business, results of operations, financial condition and prospects, and could reduce the value of, and dividends payable on, our Shares in foreign currency terms.

RISK FACTORS

Uncertainties in the legal system and government policies of the PRC may adversely affect our business and limit the legal protection available to you.

Our subsidiaries and operations are located in the PRC and are subject to PRC laws and regulations. The Chinese legal system is a civil law system based on written statutes. Unlike the common law legal system, prior court decisions in a civil law system have little precedential value and can only be used as a reference. Furthermore, The PRC's statutes are subject to the interpretation by the legislative bodies, judicial authorities and enforcement bodies, which increases the uncertainty. Since 1978, when the PRC Government started economic reforms, the PRC has promulgated laws and regulations in relation to economic matters such as foreign investment, corporate organization and governance, commercial transactions, taxation and trade. Many of these laws and regulations are relatively new and subject to frequent changes and uncertainties in implementation and interpretation. There may also be new laws and regulations to cover new economic activities in The PRC. We cannot predict the future developments in the Chinese legal system. For example, the PRC government has formulated policies in the past few years encouraging non-public hospitals to procure professional hospital management services, such as the Notice of the State Council on Forwarding the Opinions of the NDRC, the Department of Health (now known as the NHFPC) and other Departments on Further Encouraging and Guiding Private Capital to Invest in Medical Institutions (國家發改委、衛生部(國家衛生計生委)等部門關於進一步鼓勵和引導社會資本舉辦醫療機構意見的通知). We cannot assure you that these favorable governmental policies will not be revoked, suspended or discontinued in the future or that the laws and regulations of the PRC regulating our business will continue to be interpreted in conformity with these policies. Any favorable regulatory developments or court decisions regarding non-public hospitals' procurement of hospital management services or substantial changes in the interpretation of the laws and regulations relevant to our business model could have a material adverse effect on our business and financial position. These uncertainties in the Chinese legal system may adversely affect our business and limit the legal protection available to you.

You may experience difficulties in effecting service of legal process and enforcing judgments against us and our management.

Substantially all of our assets and all of our Directors are located in the PRC. It may not be possible for investors to effect service of process upon us or those persons in the PRC. The PRC has not entered into treaties or arrangements providing for the recognition and enforcement of judgments made by courts of most other jurisdictions. On July 14, 2006, Hong Kong and the PRC entered into the Arrangement on Reciprocal Recognition and Enforcement of Judgments in Civil and Commercial Matters by the Courts of the Mainland and of the Hong Kong Special Administrative Region Pursuant to Choice of Court Agreements Between Parties Concerned (《最高人民法院關於內地與香港特別行政區法院相互認可和執行當事人協議管轄的民商事案件判決的安排》) (the “**Arrangement**”), pursuant to which a party with an enforceable final court judgment rendered by any designated PRC court or any designated Hong Kong court requiring payment of money in a civil and commercial case according to a written choice of court agreement, may apply for recognition and enforcement of the judgment in the relevant PRC court or Hong Kong court. A written choice of court agreement is defined as any agreement in writing entered into between parties after the effective date of the Arrangement in which a Hong Kong court or a PRC court is expressly designated as the court having sole jurisdiction for the dispute. Therefore, it may not be possible to enforce a judgment rendered by a Hong Kong court in the PRC if the parties in the dispute did not agree to enter into a choice of court agreement in writing. On January 18, 2019, the Supreme People's Court of the PRC and Hong Kong entered into an agreement regarding the scope of judgments which may be enforced between China and Hong Kong (關於內地與香港特別行政區法院相互認可和執行民商案件

RISK FACTORS

判決的安排) (the “**New Arrangement**”). The New Arrangement will broaden the scope of judgments that may be enforced between China and Hong Kong under the Arrangement. Whereas a choice of jurisdiction need to be agreed in writing in the form of an agreement between the parties for the selected jurisdiction to have exclusive jurisdiction over a matter under the Arrangement, the New Arrangement provides that the court where the judgment was sought could apply jurisdiction in accordance with the certain rules without the parties’ agreement. The New Arrangement will replace the Arrangement when the former becomes effective. However, as of the Latest Practicable Date, the New Arrangement has not become effective and no specific date has been determined as its effective date. The Arrangement continues to apply and, as such, it may be difficult or impossible for investors to enforce a Hong Kong court judgment against our assets or our Directors or senior management in China.

On January 9, 2021 MOFCOM promulgated Measures for Blocking Improper Extraterritorial Application of Foreign Laws and Measures (阻斷外國法律與措施不當域外適用辦法) with immediate effect, or Order No. 1, pursuant to which, where a citizen, legal person or other organization of China is prohibited or restricted by foreign legislation and other measures from engaging in normal economic, trade and related activities with a third State (or region) or its citizens, legal persons or other organizations, he or she/it shall truthfully report such matters to MOFCOM within 30 days. Upon assessment and being confirmed that there exists unjustified extra-territorial application of foreign legislation and other measures, MOFCOM shall issue a prohibition order to the effect that, the relevant foreign legislation and other measures are not accepted, executed, or observed, but such a citizen, legal person or other organization of China may apply to MOFCOM for an exemption from compliance with such prohibition order. However, since the Order No. 1 is relatively new, the enforcement of it involves uncertainty in practice.

We face uncertainties with respect to indirect transfers of equity interests in PRC resident enterprises by their non-PRC holding companies.

Pursuant to the Bulletin on Issues of Enterprise Income Tax on Indirect Transfers of Assets by Non-PRC Resident Enterprises (關於非居民企業間接轉讓財產企業所得稅若干問題的公告) (the “**Bulletin 7**”), an “indirect transfer” of PRC taxable assets, including a transfer of equity interests in a PRC resident enterprise, by non-PRC resident enterprises may be re-characterized and treated as a direct transfer of PRC taxable assets, if such arrangement does not have a reasonable commercial purpose and was established for the purpose of avoiding payment of PRC enterprise income tax. As a result, gains derived from such indirect transfer may be subject to PRC enterprise income tax. When determining whether there is a “reasonable commercial purpose” of the transaction arrangement, factors to be taken into consideration include: whether the main value of the equity interest of the relevant offshore enterprise derives from PRC taxable assets; whether the assets of the relevant offshore enterprise mainly consist of direct or indirect investment in China or if its income mainly derives from China; whether the offshore enterprise and its subsidiaries directly or indirectly hold PRC taxable assets have real commercial nature, which is evidenced by their actual function and risk exposure; the duration of shareholders, existence of the business model and organizational structure; the replicability of the transaction by direct transfer of PRC taxable assets; and the tax situation of such indirect transfer and applicable tax treaties or similar arrangements. In respect of an indirect offshore transfer of assets of a PRC establishment, the resulting gain is to be reported on with the enterprise income tax filing of the PRC establishment or place of business being transferred, and would consequently be subject to PRC enterprise income tax at a rate of 25%. Where the underlying transfer relates to equity investments in a PRC resident enterprise, which is not related to a PRC establishment or place of business of a non-resident enterprise, a PRC enterprise income tax of 10% would apply, subject to available

RISK FACTORS

preferential tax treatment under applicable tax treaties or similar arrangements. Late payment of applicable tax will subject the transferor to default interest. Gains derived from the sale of shares by investors through a public stock exchange will not be subject to PRC enterprise income tax pursuant to Bulletin 7 where such shares were acquired in a transaction through a public stock exchange.

There are uncertainties as to the application of Bulletin 7. Bulletin 7 may be determined by the tax authorities to be applicable to sale of the shares of our offshore subsidiaries or investments where PRC taxable assets are involved. We face uncertainties as to the reporting and other implications of certain past and future transactions where PRC taxable assets are involved, such as offshore restructuring, or the sale of the shares in our offshore subsidiaries or investments. Our Company may be subject to filing obligations or taxes if our Company is the transferor in such transactions, and may be subject to withholding obligations if our Company is the transferee in such transactions, under Bulletin 7. For transfers of shares in our Company by investors that are non-PRC resident enterprises, our PRC subsidiary may be requested to assist with the filing under Bulletin 7. As a result, we may be required to expend valuable resources to comply with Bulletin 7 or to request the relevant transferors from whom we purchase taxable assets to comply with these circulars, or to establish that our Company should not be taxed under Bulletin 7, for our previous and future restructuring or disposal of shares of our offshore subsidiaries or investments, which may have a material adverse effect on our financial condition and results of operations.

The PRC tax authorities have the discretion under Bulletin 7 to make adjustments to the taxable capital gains based on the difference between the fair value of the taxable assets transferred and the cost of investment. If the PRC tax authorities make adjustments to the taxable income of the transactions under Bulletin 7, or under Bulletin on Issues Concerning the Withholding of Non-PRC Resident Enterprise Income Tax at Source (關於非居民企業所得稅源泉扣繳有關問題的公告), our income tax costs associated with such potential acquisitions or disposals will increase, which may have an adverse effect on our financial condition and results of operations.

We may be deemed to be a PRC tax resident under the EIT Law, and as a result, our global income could be subject to PRC withholding tax and enterprise income tax.

We are a holding company incorporated under the laws of the Cayman Islands and hold interests in our PRC subsidiaries. Pursuant to the Enterprise Income Tax Law of the PRC (中華人民共和國企業所得稅法) (the “EIT Law”), effective in January 2008, as amended on February 24, 2017 and December 29, 2018, and its implementation rules, dividends payable by a foreign-invested enterprise to its foreign corporate investors who are not deemed a PRC resident enterprise are subject to a 10.0% withholding tax, unless such foreign investor’s jurisdiction of incorporation has a tax treaty with the PRC that provides for a different withholding tax arrangement.

The EIT Law and EIT implementation rules also provide that if an enterprise incorporated outside China has its “de facto management bodies” within China, such enterprise may be deemed a “PRC resident enterprise” for tax purposes and be subject to an enterprise income tax rate of 25.0% on its global incomes. “De facto management body” is defined as the body that has the significant and overall management and control over the business, personnel, accounts and properties of an enterprise. In April 2009, STA promulgated a circular, known as Circular 82, and partially amended by Circular 9 promulgated in January 2014, to clarify the certain criteria for the determination of the “de facto management bodies” for foreign enterprises controlled by PRC enterprises or PRC enterprise groups. Under Circular 82, a foreign enterprise is considered a PRC resident enterprise if all of the following

RISK FACTORS

apply: (1) the senior management and core management departments in charge of daily operations are located mainly within China; (2) decisions relating to the enterprise's financial and human resource matters are made or subject to approval by organizations or personnel in China; (3) the enterprise's primary assets, accounting books and records, company seals, and board and shareholders' meeting minutes are located or maintained in China; and (4) 50.0% or more of voting board members or senior executives of the enterprise habitually reside in China. Further to Circular 82, STA issued a bulletin, known as Bulletin 45, effective in September 2011 and last amended on June 15, 2018 to provide more guidance on the implementation of Circular 82 and clarify the reporting and filing obligations of such "Chinese-controlled offshore incorporated resident enterprises." Bulletin 45 provides for, among other matters, procedures for the determination of resident status and administration of post-determination matters. Although Circular 82 and Bulletin 45 explicitly provide that the above standards apply to enterprises that are registered outside China and controlled by PRC enterprises or PRC enterprise groups, Circular 82 may reflect SAT's criteria for determining the tax residence of foreign enterprises in general.

However, there have been no official implementation rules regarding the determination of the "de facto management bodies" for foreign enterprises not controlled by PRC enterprises (including companies like ourselves). Therefore, it remains unclear how the tax authorities will treat a case such as ours. However, if the PRC authorities were to subsequently determine, or any future regulation provides, that we should be treated as a PRC resident enterprise, we will be subject to the uniform 25.0% enterprise income tax on our global incomes. In addition, although the EIT Law provides that dividend payments between qualified PRC-resident enterprises are exempt from enterprise income tax, due to the relatively short history of the EIT Law, it remains unclear as to the detailed qualification requirements for this exemption and whether dividend payments by our PRC subsidiaries to us will meet such qualification requirements even if we are considered a PRC resident enterprise for tax purposes.

There remains significant uncertainty as to the interpretation and application of applicable PRC tax laws and rules by the PRC tax authorities, and the PRC tax laws, rules and regulations may also change. If there is any change to applicable tax laws and rules and interpretation or application with respect to such laws and rules, the value of your investment in our shares may be materially affected.

Payment of dividends is subject to restrictions under PRC law.

Under PRC law, dividends may be paid only out of distributable profits. Distributable profits is defined as our profits after taxes as determined under PRC GAAP less any recovery of accumulated losses and appropriations to statutory and other reserves that we are required to make. As a result, we may not have sufficient, if any, distributable profits to enable our company to make dividend distributions to its shareholders in the future, including periods for which our company's financial statements indicate that our operations have been profitable. Any distributable profits not distributed in a given year are retained and available for distribution in subsequent years.

Moreover, because the calculation of distributable profits under PRC GAAP is different from the calculation under HKFRS in certain respects, our company may not have distributable profits as determined under PRC GAAP, even if they have profits for that year as determined under HKFRS, or vice-versa. Accordingly, we may not receive sufficient distributions from our PRC subsidiaries. Failure by our operating subsidiaries in the PRC to pay dividends to us could have a negative impact on our cash flow and ability to make dividend distributions to our Shareholders in the future, including those periods in which our financial statements indicate that our operations have been profitable.

RISK FACTORS

RISKS RELATING TO THE GLOBAL OFFERING

There has been no prior public market for our Shares and there can be no assurance that an active market would develop.

Prior to the Global Offering, there has been no public market for our Shares. The initial Offer Price for our Shares was the result of negotiations between us and the Joint Representatives (for themselves and on behalf of the Underwriters) and the Offer Price may differ significantly from the market price for our Shares following the Global Offering. We have applied for listing of and permission to deal in our Shares on the Stock Exchange. There is no assurance that the Global Offering will result in the development of an active, liquid public trading market for our Shares. Factors such as variations in our revenue, earnings and cash flows or any other developments of us may affect the volume and price at which our Shares will be traded. Furthermore, the price and trading volume of our Shares may be volatile. The following factors, among others, may cause the market price of our Shares after the Global Offering to vary significantly from the Offer Price:

- our financial results;
- stability of Hong Kong's economy and financial markets, particularly in light of the recent political unrest in the city;
- unexpected business interruptions resulting from natural disasters or power shortages;
- major changes in our key personnel or senior management;
- changes in laws and regulations in China;
- our inability to compete effectively in the video content market;
- our inability to obtain or maintain regulatory approval for our operations;
- fluctuations in stock market prices and volume;
- changes in analysts' estimates of our financial performance;
- political, economic, financial and social developments in China and Hong Kong and in the global economy; and
- involvement in material litigation.

In addition, shares of other companies listed on the Stock Exchange with operations and assets in China have experienced significant price volatility in the past. As a result, it is possible that our Shares may be subject to changes in price not directly related to our performance and as a result, investors in our Shares may suffer substantial losses.

RISK FACTORS

You will incur immediate and significant dilution and raising additional capital may cause further dilution or restrict our operation.

The Offer Price of the Offer Shares is higher than the net tangible asset value per Share immediately prior to the Global Offering. Therefore, purchasers of the Offer Shares in the Global Offering will experience an immediate dilution in pro forma consolidated net tangible asset value. There can be no assurance that if we were to immediately liquidate after the Global Offering, any assets will be distributed to Shareholders after the creditors' claims. If we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a shareholder. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, limitations on our ability to acquire or license intellectual property rights or declaring dividends, or other operating restrictions.

Future sales or perceived sales of a substantial number of our Shares in the public market following the Global Offering could materially and adversely affect the price of our Shares and our ability to raise additional capital in the future, and may result in dilution of your shareholding.

Prior to the Global Offering, there has not been a public market for our Shares. Future sales or perceived sales by our existing Shareholders of our Shares after the Global Offering could result in a significant decrease in the prevailing market price of our Shares. Only a limited number of the Shares currently outstanding will be available for sale or issuance immediately after the Global Offering due to contractual and regulatory restrictions on disposal and new issuance. Nevertheless, after these restrictions lapse or if they are waived, future sales of significant amounts of our Shares in the public market or the perception that these sales may occur could significantly decrease the prevailing market price of our Shares and our ability to raise equity capital in the future.

We are a Cayman Islands exempted company and, because judicial precedent regarding the rights of shareholders is more limited under the laws of the Cayman Islands than other jurisdictions, you may have difficulties in protecting your shareholder rights.

Our corporate affairs are governed by our Memorandum and Articles and by the Cayman Companies Act and common law of the Cayman Islands. The rights of Shareholders to take legal action against our Directors and us, actions by minority Shareholders and the fiduciary responsibilities of our Directors to us under Cayman Islands law are to a large extent governed by the common law of the Cayman Islands. The common law of the Cayman Islands is derived in part from comparatively limited judicial precedent in the Cayman Islands as well as from English common law, which has persuasive, but not binding, authority on a court in the Cayman Islands. The laws of the Cayman Islands relating to the protection of the interests of minority shareholders differ in some respects from those established under statutes and judicial precedent in existence in the jurisdictions where minority Shareholders may be located. See Appendix III "Summary of the Constitution of the Company and Cayman Islands Company Law." As a result of all of the above, minority Shareholders may enjoy different remedies when compared to the laws of the jurisdiction such shareholders are located in.

RISK FACTORS

The interests of our Controlling Shareholders may conflict with the interests of our Company's public shareholders.

Immediately following the completion of the Global Offering and without taking into account any Shares which may be issued pursuant to the exercise of the Over-allotment Option or Shares which may be issued upon the exercise of options granted under the Share Option Scheme, our Controlling Shareholders will be entitled to exercise voting rights of 68.67% of the total issued share capital of our Company. The interests of our Controlling Shareholders may differ from the interests of our other Shareholders. Our Controlling Shareholders could have significant influence in determining the outcome of any corporate transaction or other matters submitted to our Shareholders for approval. This concentration of ownership, as a result, may discourage, delay or prevent a change in control of our Company, which could deprive our Shareholders of an opportunity to receive a premium for their Shares in a sale of our Company or may reduce the market price of our Shares. In addition, to the extent the interests of our Controlling Shareholders conflict with the interest of our other Shareholders, the interests of our other Shareholders may be disadvantaged or harmed.

As the Offer Price of our Offer Shares is higher than our net tangible book value per share, purchasers of our Shares in the Global Offering may experience immediate dilution upon such purchases.

The Offer Price of our Offer Shares is higher than the net tangible book value per Share immediately prior to the Global Offering. Therefore, purchasers of our Shares in the Global Offering will experience an immediate dilution. Existing Shareholders will receive an increase in the net tangible asset value per share of their shares. If we issue additional Shares in the future, purchasers of our Offer Shares may experience further dilution.

We cannot assure you that we will declare and distribute any amount of dividends in the future.

Our ability to declare future dividends will depend on the availability of dividends, if any, received from our operating subsidiaries. Under applicable laws and the constitutional documents of our operating subsidiaries, the payment of dividends may be subject to certain limitations. The calculation of certain of our operating subsidiaries' profit under applicable accounting standards differs in certain respects from the calculation under HKFRSs. As a result, our operating subsidiaries may not be able to pay a dividend in a given year even if they have profit as determined under HKFRSs. Accordingly, since we derive all of our earnings and cash flows from dividends paid by our operating subsidiaries, we may not have sufficient distributable profit to pay dividends to our Shareholders. In addition, any future dividend declaration and distribution will be at the discretion of our Directors and will depend on our future operations and earnings, capital requirements and surplus, general financial condition, contractual restrictions and other factors that our Directors deem relevant. Any declaration and payment as well as the amount of dividends will also be subject to our Articles of Association and PRC laws, including (where required) the approvals from our Shareholders and our Directors. Our Shareholders at a general meeting must approve any declaration of dividends, which must not exceed the amount recommended by our Board. Moreover, our Directors may from time to time pay such interim dividends as our Board considers to be justified by our profits and overall financial requirements, or special dividends of such amounts and on such dates as they deem appropriate. As a result, we cannot assure you that we will make any dividend payments on our Shares in the future.

RISK FACTORS

We have significant discretion as to how we will use the net proceeds of the Global Offering, and you may not necessarily agree with how we use them.

Our management may spend the net proceeds from the Global Offering in ways with which you may not agree or which do not yield a favorable return to our shareholders. We plan to use the net proceeds from the Global Offering to continue the research and development activities of our product candidates to commercialization, strengthen our research and development capabilities, and to expand our product portfolio, among others. For details, see “Future Plans and Use of Proceeds — Use of Proceeds” in this prospectus. However, our management will have discretion as to the actual application of our net proceeds. You are entrusting your funds to our management, whose judgment you must depend on, for the specific uses we will make of the net proceeds from this Global Offering.

Forward-looking statements contained in this prospectus are subject to risks and uncertainties.

This prospectus contains certain statements and information that are “forward-looking” and uses forward-looking terminology such as “aim”, “anticipate”, “believe”, “continue”, “could”, “expect”, “estimate”, “intend”, “may”, “plan”, “potential”, “predict”, “project”, “propose”, “seek”, “should”, “will”, “would” or similar terms. Those statements include, among other things, the discussion of our growth strategy and expectations concerning future operations, liquidity and capital resources. Investors of our Shares are cautioned that reliance on any forward-looking statements involves risks and uncertainties and that, any or all of those assumptions could prove to be inaccurate and as a result, the forward-looking statements based on those assumptions could also be incorrect. The uncertainties in this regard include, but are not limited to, those identified in this section, many of which are not within our control. In light of these and other uncertainties, the inclusion of forward-looking statements in this prospectus should not be regarded as representations that our plans or objectives will be achieved and investors should not place undue reliance on such forward-looking statements. Our Company does not undertake any obligation to update publicly or release any revisions of any forward-looking statements, whether as a result of new information, future events or otherwise. See “Forward-Looking Statements” in this prospectus for further details.

Certain facts, forecasts and statistics contained in this Prospectus are derived from a third-party report and publicly available official sources and they may not be reliable.

Certain facts, forecasts and other statistics contained in this Prospectus relating to China, the PRC economy and the industry in which we operate have been derived from various official government publications or other third-party reports. We have taken reasonable care in the reproduction or extraction of the official government publications or other third-party reports for the purpose of disclosure in this Prospectus, however, we cannot guarantee the quality or reliability of such source materials. They have not been prepared or independently verified by us, the Underwriters or any of their respective affiliates or advisers and, therefore, we make no representation as to the accuracy of such statistics, which may not be consistent with other information compiled within or outside the PRC. Due to possibly flawed or ineffective collection methods or discrepancies between published information and market practice, such statistics in this Prospectus may be inaccurate or may not be comparable to statistics produced with respect to other economies. Further, there is no assurance that they are stated or compiled on the same basis or with the same degree of accuracy as the case may be in other jurisdictions. In all cases, investors should give consideration as to how much weight or importance they should attach to or place on such facts.

RISK FACTORS

You should read the entire prospectus carefully, and we strongly caution you not to place any reliance on any information contained in press articles or other media regarding us or the Global Offering.

Subsequent to the date of this prospectus but prior to the completion of the Global Offering, there may be press and media coverage regarding us and the Global Offering, which may contain, among other things, certain financial information, projections, valuations and other forward-looking information about us and the Global Offering. We have not authorized the disclosure of any such information in the press or media and do not accept responsibility for the accuracy or completeness of such press articles or other media coverage. We make no representation as to the appropriateness, accuracy, completeness or reliability of any of the projections, valuations or other forward-looking information about us. To the extent such statements are inconsistent with, or conflict with, the information contained in this document, we disclaim responsibility for them. Accordingly, prospective investors are cautioned to make their investment decisions on the basis of the information contained in this document only and should not rely on any other information.

WAIVERS FROM STRICT COMPLIANCE WITH THE LISTING RULES

In preparation for the Global Offering, our Company has sought and has been granted the following waivers from strict compliance with the relevant provisions of the Listing Rules.

WAIVER IN RELATION TO MANAGEMENT PRESENCE IN HONG KONG

Pursuant to Rule 8.12 of the Listing Rules, we must have a sufficient management presence in Hong Kong. This normally means that at least two of our executive Directors must be ordinarily resident in Hong Kong.

Our management, business operations and assets are primarily located outside Hong Kong. The principal management headquarters of our Group are primarily based in mainland PRC. Our Company considers that our Group's management is best able to attend to its functions by being based in the mainland PRC. None of our executive Directors is or will be ordinarily resident in Hong Kong after the Listing of our Company. Our Directors consider that relocation of our executive Directors to Hong Kong will be burdensome and costly for our Company, and it may not be in the best interests of our Company and our Shareholders as a whole to appoint additional executive Directors who are ordinarily resident in Hong Kong. As such, we do not have, and for the foreseeable future will not have, sufficient management presence in Hong Kong for the purpose of satisfying the requirements under Rule 8.12 of the Listing Rules.

Accordingly, we have applied to the Stock Exchange for, and the Stock Exchange has granted us, a waiver from strict compliance with the requirements under Rule 8.12 of the Listing Rules, provided that our Company implements the following arrangements:

- (1) We have appointed two authorized representatives pursuant to Rule 3.05 of the Listing Rules, who will act as our principal channel of communication with the Stock Exchange. The two authorized representatives appointed are Mr. Zhang and Ms. Leung Ching Ching (梁晶晶) (“**Ms. Leung**”). Ms. Leung is situated and based in Hong Kong. Each of our authorized representatives will be available to meet with the Stock Exchange in Hong Kong within a reasonable time frame upon the request of the Stock Exchange and will be readily contactable by telephone, facsimile and email;
- (2) As and when the Stock Exchange wishes to contact our Directors on any matters, each of our authorized representatives has the means to contact all of our Directors (including the independent non-executive Directors) promptly at all times;
- (3) Although our executive Directors are not ordinary residents in Hong Kong, each of our Directors possesses or can apply for valid travel documents to visit Hong Kong and is able to meet with the Stock Exchange within a reasonable period of time, when required;
- (4) We have appointed Somerley Capital Limited as our compliance adviser. Pursuant to Rule 3A.19 of the Listing Rules, our authorized representatives, Directors and senior management will provide promptly such information and assistance as the compliance adviser reasonably require in connection with the performance of the compliance adviser's duties as set forth in Chapter 3A of the Listing Rules, and Somerley Capital Limited will act as an additional channel of communication between the Stock Exchange and us from the Listing Date to the date when our Company distribute our annual report of our financial results for the first full financial year commencing after the Listing Date; and

WAIVERS FROM STRICT COMPLIANCE WITH THE LISTING RULES

- (5) We have provided the Stock Exchange with the contact details of each Director (including their respective mobile phone number, office phone number and e-mail address).

Our Company will inform the Stock Exchange as soon as practicable in respect of any change in the authorized representatives, the Directors and/or the compliance adviser in accordance with the Listing Rules.

WAIVER IN RESPECT OF JOINT COMPANY SECRETARIES

Pursuant to Rules 3.28 and 8.17 of the Listing Rules, the company secretary of an issuer must be an individual who, by virtue of his or her academic or professional qualifications or relevant experience, is, in the opinion of the Stock Exchange, capable of discharging the functions of company secretary.

Our Company had appointed Ms. HAN Zhimei (“**Ms. Han**”) and Ms. Leung as our joint company secretaries. Ms. Leung is a fellow member of The Chartered Governance Institute (formerly known as The Institute of Chartered Secretaries and Administrators) in the United Kingdom and The Hong Kong Chartered Governance Institute (formerly known as The Hong Kong Institute of Chartered Secretaries), and therefore meets the qualification requirements under Note 1 to Rule 3.28 of the Listing Rules and is in compliance with Rule 8.17 of the Listing Rules.

Ms. Han has been responsible for business operations and financial management of our Company since March 2017. She has extensive experience in accounting and corporate finance but presently does not possess any of the qualifications under Rules 3.28 and 8.17 of the Listing Rules. While Ms. Han may not be able to solely fulfill the requirements of the Listing Rules, our Company believes that it would be in the best interests of our Company and the corporate governance of our Company to appoint Ms. Han as our joint company secretary due to her thorough understanding of the internal administration and business operations of our Group.

Accordingly, while Ms. Han does not possess the formal qualifications required of a company secretary under Rule 3.28 of the Listing Rules, we have applied to the Stock Exchange for, and the Stock Exchange has granted, a waiver from strict compliance with the requirements under Rules 3.28 and 8.17 of the Listing Rules such that Ms. Han may be appointed as a joint company secretary of our Company. Pursuant to the Guidance Letter HKEX-GL108-20, the waiver will be for a fixed period of time (“**Waiver Period**”) and on the following conditions:

- (i) the proposed company secretary must be assisted by a person who possesses the qualifications or experience as required under Rule 3.28 (“**Qualified Person**”) and is appointed as a joint company secretary throughout the Waiver Period; and
- (ii) the waiver can be revoked if there are material breaches of the Listing Rules by the issuer.

The waiver is valid for an initial period of three years from the Listing Date, and is granted on the condition that Ms. Leung, as a joint company secretary of our Company, will work closely with, and provide assistance to, Ms. Han in the discharge of her duties as a joint company secretary and in gaining the relevant company secretary experience as required under Rule 3.28 of the Listing Rules and to become familiar with the requirements of the Listing Rules and other applicable Hong Kong laws and regulations. Given Ms. Leung’s professional qualifications and experience, she will be able to explain to

WAIVERS FROM STRICT COMPLIANCE WITH THE LISTING RULES

both Ms. Han and our Company the relevant requirements under the Listing Rules. Ms. Leung will also assist Ms. Han in organizing Board meetings and Shareholders' meetings of our Company as well as other matters of our Company which are incidental to the duties of a company secretary. Ms. Leung is expected to work closely with Ms. Han, and will maintain regular contact with Ms. Han, the Directors and the senior management of our Company. The waiver will be revoked immediately if Ms. Leung ceases to provide assistance to Ms. Han as a joint company secretary for the three-year period after the Listing or where there are material breaches of the Listing Rules by our Company. In addition, Ms. Han will comply with the annual professional training requirement under Rule 3.29 of the Listing Rules and will enhance her knowledge of the Listing Rules during the three-year period from the Listing.

In the course of preparation of the Listing, Ms. Han attended a training session on the respective obligations of the Directors and senior management and our Company under the relevant Hong Kong laws and the Listing Rules provided by our Company's Hong Kong legal adviser, and has been provided with the relevant training materials. Our Company will further ensure that Ms. Han has access to the relevant training and support that would enhance her understanding of the Listing Rules and the duties of a company secretary of an issuer listed on the Stock Exchange, and to receive updates on the latest changes to the applicable Hong Kong laws, regulations and the Listing Rules. Furthermore, both Ms. Leung and Ms. Han will seek and have access to advice from our Company's Hong Kong legal and other professional advisers as and when required.

Our Company has appointed Somerley Capital Limited as the Compliance Adviser upon our Listing pursuant to Rule 3A.19 of the Listing Rules, which will act as our Company's additional channel of communication with the Stock Exchange, and provide professional guidance and advice to our Company and its joint company secretaries as to compliance with the Listing Rules and all other applicable laws and regulations in Hong Kong from the Listing Date to the date when our Company distribute our annual report of our financial results for the first full financial year commencing after the Listing Date.

Prior to the end of the three-year period, the qualifications and experience of Ms. Han and the need for ongoing assistance of Ms. Leung will be further evaluated by our Company. We will liaise with the Stock Exchange to enable it to assess whether Ms. Han, having benefited from the assistance of Ms. Leung for the preceding three years, will have acquired the skills necessary to carry out the duties of company secretary and the "relevant experience" within the meaning of Note 2 to Rule 3.28 of the Listing Rules so that a further waiver will not be necessary.

See "Directors and Senior Management" in this prospectus for further information regarding the qualifications of Ms. Han and Ms. Leung.

NON-EXEMPT CONTINUING CONNECTED TRANSACTIONS

We have entered into, and are expected to continue, certain transactions that will constitute non-exempt continuing connected transactions of our Company under the Listing Rules upon Listing. Accordingly, we have applied to the Stock Exchange for, and the Stock Exchange has granted, waivers from strict compliance with (i) the announcement, (ii) independent Shareholders' approval requirement, (iii) the annual cap requirement and (iv) the requirement of limiting the term of the continuing connected transactions as set out in Chapter 14A of the Listing Rules for such continuing connected transactions. For further details in this respect, see "Continuing Connected Transactions" in this prospectus.

INFORMATION ABOUT THIS PROSPECTUS AND THE GLOBAL OFFERING

DIRECTORS' RESPONSIBILITY FOR THE CONTENTS OF THIS PROSPECTUS

This prospectus, for which our Directors (including any proposed director who is named as such in this prospectus) collectively and individually accept full responsibility, includes particulars given in compliance with the Companies (Winding Up and Miscellaneous Provisions) Ordinance, the Securities and Futures (Stock Market Listing) Rules and the Listing Rules for the purpose of giving information to the public with regard to the Group. Our Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief, the information contained in this prospectus is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement in this prospectus misleading.

UNDERWRITING AND INFORMATION ON THE GLOBAL OFFERING

This prospectus is published solely in connection with the Hong Kong Public Offering, which forms part of the Global Offering. The Global Offering comprises the Hong Kong Public Offering of initially 9,443,000 Offer Shares and the International Offering of initially 84,981,000 Offer Shares (subject to, in each case, reallocation on the basis referred to under the section headed “Structure of the Global Offering” in this prospectus and, in case of the International Offering, to any exercise of the Over-allotment Option).

The listing of our Shares on the Stock Exchange is sponsored by the Joint Sponsors and the Global Offering is managed by the Joint Global Coordinators. The Hong Kong Public Offering is fully underwritten by the Hong Kong Underwriters pursuant to the Hong Kong Underwriting Agreement. The International Underwriting Agreement relating to the International Offering is expected to be entered into on or around Monday, December 6, 2021. Further information regarding the Underwriters and the Underwriting Agreements are set out in the section headed “Underwriting” in this prospectus.

The Hong Kong Offer Shares are offered solely on the basis of the information contained and representations made in this prospectus and on the terms and subject to the conditions set out herein and therein. No person is authorized to give any information in connection with the Global Offering or to make any representation not contained in this prospectus, and any information or representation not contained herein and therein must not be relied upon as having been authorized by the Company, the Joint Sponsors, the Joint Global Coordinators, the Joint Bookrunners, the Joint Lead Managers, the Underwriters, any of their respective directors, officers, employees, partners, agents, employees or advisers or any other party involved in the Global Offering.

Neither the delivery of this prospectus nor any subscription or acquisition made under it shall, under any circumstances, constitute a representation that there has been no change or development reasonably likely to involve a change in our affairs since the date of this prospectus or imply that the information contained in this prospectus is correct as of any date subsequent to the date of this prospectus.

Further information regarding the structure of the Global Offering, including its conditions, are set out in the section headed “Structure of the Global Offering”, and the procedures for applying for our Hong Kong Offer Shares are set out in the section headed “How to Apply for the Hong Kong Offer Shares” in this prospectus.

RESTRICTIONS ON OFFER AND SALE OF THE OFFER SHARES

Each person acquiring the Hong Kong Offer Shares under the Hong Kong Public Offering will be required to, or be deemed by his/her acquisition of the Hong Kong Offer Shares to, confirm that he/she is aware of the restrictions on offers and sales of the Shares described in this prospectus.

No action has been taken to permit a public offering of the Offer Shares in any jurisdiction other than Hong Kong, and no action has been taken to permit the distribution of this prospectus in any jurisdiction other than Hong Kong. Accordingly, without limitation to the following, this prospectus may not be used for the purpose of, and does not constitute, an offer or invitation in any jurisdiction or in any circumstances in which such an offer or invitation is not authorized or to any person to whom it is unlawful to make such an offer or invitation. The distribution of this prospectus and the offering and sales of the Offer Shares in other jurisdictions are subject to restrictions and may not be made except as permitted under the applicable securities laws of such jurisdictions pursuant to registration with or authorization by the relevant securities regulatory authorities or an exemption therefrom. In particular, the Hong Kong Offer Shares have not been publicly offered or sold, directly or indirectly, in the PRC or the United States.

APPLICATION FOR LISTING ON THE STOCK EXCHANGE

We have applied to the Listing Committee for the granting of the listing of, and permission to deal in, the Shares in issue, the Offer Shares to be issued by us pursuant to the Global Offering (including any Shares which may be issued pursuant to the exercise of the Over-allotment Option).

Dealings in the Shares on the Stock Exchange are expected to commence on Monday, December 13, 2021. Save as disclosed in this prospectus, no part of our Shares or loan capital is listed or dealt in on any other stock exchange and no such listing or permission to list is being or proposed to be sought on any other stock exchange as of the date of this prospectus. All the Offer Shares will be registered on the Hong Kong register of members of the Company in order to enable them to be traded on the Stock Exchange.

Under section 44B(1) of the Companies (Winding Up and Miscellaneous Provisions) Ordinance, any allotment made in respect of any application will be invalid if the listing of, and permission to deal in, our Shares on the Stock Exchange is refused before the expiration of three weeks from the date of the closing of the application lists, or such longer period (not exceeding six weeks) as may, within the said three weeks, be notified to the Company by or on behalf of the Stock Exchange.

PROFESSIONAL TAX ADVICE RECOMMENDED

Potential investors in the Global Offering are recommended to consult their professional advisers as to the taxation implications of subscribing for, purchasing, holding or disposal of, and/or dealing in the Offer Shares or exercising rights attached to them. None of us, the Joint Sponsors, the Joint Global Coordinators, the Joint Bookrunners, the Joint Lead Managers, the Underwriters, any of their respective directors, officers, employees, partners, agents, advisers or representatives or any other person or party involved in the Global Offering accepts responsibility for any tax effects on, or liabilities of, any person resulting from the subscription, purchasing, holding, disposition of, or dealing in, the Offer Shares or exercising any rights attached to them.

INFORMATION ABOUT THIS PROSPECTUS AND THE GLOBAL OFFERING

OVER-ALLOTMENT OPTION AND STABILIZATION

Details of the arrangements relating to the Over-allotment Option and stabilization are set out under the sections headed “Underwriting” and “Structure of the Global Offering” in this prospectus.

HONG KONG REGISTER OF MEMBERS AND HONG KONG STAMP DUTY

The Company’s principal register of members will be maintained by its principal share registrar, Campbells Corporate Services Limited, in the Cayman Islands. All of the Offer Shares issued pursuant to the Global Offering will be registered on the Company’s Hong Kong register of members to be maintained in Hong Kong by its Hong Kong Share Registrar, Tricor Investor Services Limited. Dealings in the Shares registered in the Company’s Hong Kong register of members will be subject to Hong Kong stamp duty.

Unless determined otherwise by the Company, dividends payable in Hong Kong dollars in respect of Shares will be paid to the Shareholders listed on the Hong Kong register of members of the Company, by ordinary post, at the Shareholders’ risk, to the registered address of each Shareholder.

SHARES WILL BE ELIGIBLE FOR ADMISSION INTO CCASS

Subject to the granting of the listing of, and permission to deal in, the Shares on the Stock Exchange and compliance with the stock admission requirements of HKSCC, the Shares will be accepted as eligible securities by HKSCC for deposit, clearance and settlement in CCASS with effect from the date of commencement of dealings in the Shares on the Stock Exchange or on any other date as determined by HKSCC. Settlement of transactions between participants of the Stock Exchange is required to take place in CCASS on the second Settlement Day after any trading day. All activities under CCASS are subject to the General Rules of CCASS and CCASS Operational Procedures in effect from time to time. All necessary arrangements have been made enabling the Shares to be admitted into CCASS.

Investors should seek the advice of their stockbrokers or other professional advisers for details of the settlement arrangements as such arrangements may affect their rights and interests.

PROCEDURES FOR APPLICATION FOR HONG KONG OFFER SHARES

The procedures for applying for Hong Kong Offer Shares are set out in the section headed “How to Apply for the Hong Kong Offer Shares” in this prospectus.

STRUCTURE OF THE GLOBAL OFFERING

Details of the structure of the Global Offering, including its conditions, are set out in the section headed “Structure of the Global Offering” in this prospectus.

INFORMATION ABOUT THIS PROSPECTUS AND THE GLOBAL OFFERING

EXCHANGE RATE CONVERSION

Solely for your convenience, this prospectus contains translations among certain amounts denominated in Renminbi, Hong Kong dollars and U.S. dollars. No representation is made that the amounts denominated in one currency could actually be converted into the amounts denominated in another currency at the rates indicated or at all. Unless indicated otherwise, (i) the translations between Renminbi and Hong Kong dollars were made at the rate of RMB6.3952 to US\$1.00, (ii) the translations between U.S. dollars and Hong Kong dollars were made at the rate of HK\$7.7895 to US\$1.00, and (iii) the translation between Hong Kong dollars and Renminbi were made at the rate of HK\$1.00 to RMB0.8210. The RMB to HK\$ and US\$ to RMB exchange rates are quoted by the PBOC for foreign exchange transactions prevailing on November 22, 2021. Any discrepancies in any table between totals and sums of amounts listed therein are due to rounding.

LANGUAGE

If there is any inconsistency between this prospectus and the Chinese translation of this prospectus, this prospectus shall prevail. However, the English names of the PRC nationals, entities, departments, facilities, certificates, titles, laws, regulations and the like are translations of their Chinese names and are included for identification purposes only. If there is any inconsistency, the Chinese name prevails.

ROUNDING

Certain amounts and percentage figures included in this prospectus have been subject to rounding adjustments, or have been rounded to one or two decimal places. Any discrepancies in any table, chart or elsewhere between totals and sums of amounts listed therein are due to rounding.

DIRECTORS AND PARTIES INVOLVED IN THE GLOBAL OFFERING

DIRECTORS

Name	Address	Nationality
<i>Executive Directors</i>		
ZHANG Yu (張玉)	10-3-102, Huarun Gongyuanjiuli, Daxing District, Beijing, PRC	Chinese
ZHANG Hui (張輝)	Room 201, Unit 2, Basement 1 to Floor 2, Building 3, No. 29 Leyuan Road, Daxing District, Beijing, PRC	Chinese
<i>Non-executive Directors</i>		
GENG Jiaqi (耿嘉琦)	Room 405, Floor 29, District 13, Heping Street, Chaoyang District, Beijing, PRC	Chinese
ZHAI Feng (翟鋒)	Room 1201, Building 4, Shiqiao International Trade Apartment, No. 16, East Third Ring Middle Road, Chaoyang District, Beijing, PRC	Chinese

DIRECTORS AND PARTIES INVOLVED IN THE GLOBAL OFFERING

Name	Address	Nationality
<i>Independent Non-executive Directors</i>		
WANG Jiping (王繼萍)	Room 101, Unit 3, Building 13, WeHouse, No. 13 Changqingyuan Nanli District 2, Haidian District, Beijing, PRC	Chinese
CHAN Peng Kuan (陳炳鈞)	Flat B8, 14/F, Viking Garden, 40 Hing Fat Street, North Point, Hong Kong	Chinese (Hong Kong)
LI Xiaopei (李小培)	No.66 Xinji Street, Dazhuang, Si County, Suzhou, Anhui Province, PRC	Chinese

For further information regarding our Directors, see “Directors and Senior Management”.

DIRECTORS AND PARTIES INVOLVED IN THE GLOBAL OFFERING

PARTIES INVOLVED IN THE GLOBAL OFFERING

Joint Sponsors

Morgan Stanley Asia Limited

46/F, International Commerce Centre
1 Austin Road West
Kowloon
Hong Kong

China International Capital Corporation Hong Kong Securities Limited

29/F One International Finance Centre
1 Harbour View Street
Central
Hong Kong

Joint Global Coordinators

Morgan Stanley Asia Limited

46/F, International Commerce Centre
1 Austin Road West
Kowloon
Hong Kong

China International Capital Corporation Hong Kong Securities Limited

29/F One International Finance Centre
1 Harbour View Street
Central
Hong Kong

Joint Bookrunners and Joint Lead Managers

Morgan Stanley Asia Limited

(in relation to the Hong Kong Offering only)
46/F, International Commerce Centre
1 Austin Road West
Kowloon
Hong Kong

Morgan Stanley & Co. International plc

(in relation to the International Offering only)
25 Cabot Square, Canary Wharf
London E14 4QA
United Kingdom

China International Capital Corporation Hong Kong Securities Limited

29/F One International Finance Centre
1 Harbour View Street
Central
Hong Kong

DIRECTORS AND PARTIES INVOLVED IN THE GLOBAL OFFERING

Legal Advisers to the Company

As to Hong Kong and United States laws:

O'Melveny & Myers

31/F, AIA Central

1 Connaught Road Central

Hong Kong

As to PRC law:

Tian Yuan Law Firm

10/F, Tower B, China Pacific Insurance Plaza

28 Fengsheng Lane

Xicheng District

Beijing 100032

China

As to Cayman Islands law:

Campbells

1301, 13/F, York House

The Landmark

15 Queen's Road Central

Hong Kong

Legal Advisers to the Underwriters

As to Hong Kong and United States laws:

Davis Polk & Wardwell

18/F, The Hong Kong Club Building

3A Chater Road

Central

Hong Kong

As to PRC law:

Jingtian & Gongcheng

34/F, Tower 3, China Central Place

77 Jianguo Road

Beijing, PRC

Legal Advisers to CITRON PE Funds II Limited and Panmao Shanghai

As to Hong Kong law

Wilson Sonsini Goodrich & Rosati

Suite 1509, 15/F, Jardine House

1 Connaught Place

Central, Hong Kong

DIRECTORS AND PARTIES INVOLVED IN THE GLOBAL OFFERING

Auditor and Reporting Accountant

PricewaterhouseCoopers

Certified Public Accountants

Registered Public Interest Entity Auditor

22/F, Prince's Building

Central

Hong Kong

Industry Consultant

Frost & Sullivan (Beijing) Inc., Shanghai Branch Co.

2504 Wheelock Square

1717 Nanjing West Road

Shanghai 200040

PRC

Compliance Adviser

Somerley Capital Limited

20/F, China Building

29 Queen's Road Central

Hong Kong

Receiving Bank

Bank of China (Hong Kong) Limited

1 Garden Road

Hong Kong

CORPORATE INFORMATION

Registered office in the Cayman Islands	P.O. Box 2547 Grand Cayman KY1-1104 Cayman Islands
Corporate headquarters	11/F, China Nuclear E&C Building 20 Ganluyuan Nanli Chaoyang District Beijing, PRC
Principal place of business in Hong Kong	Level 54, Hopewell Centre 183 Queen's Road East Hong Kong
Company's website	<u>www.yonghegroup.cn</u> <i>(The contents on this website do not form part of this prospectus)</i>
Joint Company Secretaries	<p>Ms. HAN Zhimei 11/F, China Nuclear E&C Building 20 Ganluyuan Nanli Chaoyang District Beijing, PRC</p> <p>Ms. LEUNG Ching Ching <i>(Fellow of The Hong Kong Chartered Governance Institute (formerly the Hong Kong Institute of Chartered Secretaries) and the Chartered Governance Institute (formerly the Institute of Chartered Secretaries and Administrators) in the United Kingdom)</i> Level 54, Hopewell Centre 183 Queen's Road East Hong Kong</p>
Authorized representatives	<p>Mr. ZHANG 10-3-102, Huarun Gongyuanjiuli, Daxing District, Beijing, PRC</p> <p>Ms. LEUNG Ching Ching Level 54, Hopewell Centre 183 Queen's Road East Hong Kong</p>

CORPORATE INFORMATION

Audit Committee	CHAN Peng Kuan (<i>Chairman</i>) GENG Jiaqi LI Xiaopei
Remuneration Committee	CHAN Peng Kuan (<i>Chairman</i>) ZHANG Yu LI Xiaopei
Nomination Committee	ZHANG Yu (<i>Chairman</i>) CHAN Peng Kuan WANG Jiping
Principal share registrar and transfer office	Campbells Corporate Services Limited Floor 4, Willow House, Cricket Square Grand Cayman KY1-9010 Cayman Islands
Hong Kong Share Registrar	Tricor Investor Services Limited Level 54, Hopewell Centre 183 Queen's Road East Hong Kong
Principal bankers	Ping An Bank, Beijing Branch G/F, Yuan Yang Building 158 Fuxingmennei Avenue Beijing, PRC China Merchants Bank, Beijing Branch 1/F, 156 Fuxingmennei Avenue Xicheng District Beijing, PRC

INDUSTRY OVERVIEW

Certain information and statistics set out in this section have been extracted from various official government publications, market data providers and an Independent Third Party source, Frost & Sullivan. The report (the “Frost & Sullivan Report”) prepared by Frost & Sullivan in June 2021 and cited in this prospectus was commissioned by us. We believe that the sources of this information are appropriate sources for such information and have taken reasonable care in extracting and reproducing such information. We have no reason to believe that such information is false or misleading or that any fact has been omitted that would render such information false or misleading. The information from official government sources has not been independently verified by our Company, the Joint Sponsors, any of their respective directors, employees, agents or advisers or any other person or party involved in the Global Offering, and no representation is given as to its accuracy, fairness and completeness. For a discussion of the risks relating to our industry, see “Risk Factors” in this prospectus.

THE CONSUMER MEDICAL SERVICE MARKET IN CHINA

The consumer medical service refers to discretionary medical services primarily for improving quality of life and not mainly covered by national health insurance. The consumer medical service covers a wide range of services such as hair-related healthcare service, assisted reproductive service, dental service, etc.

Most of the consumer medical service providers in general are private medical institutions. In this market, specialist medical institutions tend to be at the forefront of diagnosis and treatment within specialist disciplines. Among these specialist medical institutions, chain clinic brands generally have higher brand awareness and offer high quality services, therefore business models based on specialist clinic chains have been more widely adopted in the consumer medical service market in China.


With rising household disposable income and growing health awareness, the consumer medical service market has experienced robust growth in the past few years. The market size reached RMB697.9 billion in 2020, rising from RMB392.7 billion in 2016, representing a CAGR of 15.5%. The market is expected to further increase to RMB1,647.0 billion by 2025 and RMB3,311.9 billion by 2030.

THE HAIR-RELATED HEALTHCARE SERVICE MARKET IN CHINA

Overview

Hair-related healthcare service is one type of consumer medical service. As set forth in the table below, the hair-related healthcare service market in China can be divided into the hair transplant service market and medical hair care service market based on whether or not surgery is performed. In 2020, the hair transplant service market and the medical hair care service market accounted for 72.8% and 27.2% of hair-related healthcare service market in China, respectively.

INDUSTRY OVERVIEW



Source: Frost & Sullivan

The hair-related healthcare service market grew significantly since 2016. The market size reached RMB18.4 billion in 2020, rising from RMB7.8 billion in 2016, representing a CAGR of 23.9%. The market is expected to further increase to RMB56.2 billion by 2025 and RMB138.1 billion by 2030, respectively.

THE HAIR TRANSPLANT SERVICE MARKET IN CHINA

Overview

Hair transplant services are relatively safe surgical operations that address the hair-related problems. Hair transplant needs to be performed in professional medical institutions, such as our hair transplant clinics network in China. Hair transplant is a surgical procedure in which hair follicles are extracted from the back occipital area with high quality hair follicles and transplanted to bare and thinning hair areas. Compared with other non-transplant hair health treatments, hair transplant treatment has a significant effect on alopecia, spotted alopecia, and baldness. Considering limited supply of qualified physicians in China and stringent regulatory environment, new entrants will face challenges in the hair transplant service market in China.

Market Size and Penetration Rate

Alopecia is the major hair-related problem presenting a high market demand for treatment. The National Health Commission's survey has shown that China's alopecia population reached 250.9 million in 2020, among which approximately 163.5 million were male and 88.6 million were female. The alopecia population in China is expected to remain in a large size in the next decades and continues to increase to 258.0 million by 2030.


While some topical treatments and even holistic approaches may relieve the symptoms of severe alopecia, hair transplant treatment has a relatively shorter recovery period and more visible treatment results.

In recent years, as affected by a combination of factors, including the increasing disposable income *per capita* of Chinese residents, elevated self-awareness of appearance, and the advances in hair transplants technology, China's hair transplant service market grew rapidly from RMB5.8 billion in 2016 to RMB13.4 billion in 2020 with a CAGR of 23.4%. However, the number of people receiving hair transplant services in China is relatively low compared to the actual number of people suffering from

INDUSTRY OVERVIEW

alopecia in China. In 2020, there were only approximately 516,000 hair transplant procedures performed in China. As a result, the hair transplant penetration rate in China (calculated by dividing the number of recipients of hair transplant procedures by the number of alopecia patients) was only approximately 0.2% in 2020, indicating a huge unmet market demand and great growth potential. Further, with the advent of aesthetic hair transplant, the expansion of hair transplant options, and service innovations, the customer base for hair transplant in China is expected to expand from alopecia patients to a larger group of consumers seeking to enhance appearance through medical treatment, which is projected to drive China's hair transplant service market to RMB75.6 billion in 2030. The following chart sets forth the historical and forecasted market size of hair transplant services in China:

Market Size of Hair Transplant Service in China, 2016-2030E



Source: Expert interview, Frost & Sullivan

Growth Drivers

The following key factors have primarily driven the growth of the hair transplant service market in China:

- *Increasing per capita income of Chinese residents and affordability of hair transplant services.* From 2016 to 2020, the disposable income *per capita* of Chinese residents increased from RMB23,821.0 to RMB32,189.0 with a CAGR of 7.8% and in particular, the disposable income *per capita* of Chinese urban residents reached RMB43,834 in 2020. In contrast, the average price of a hair transplant surgery remained largely stable with a slight increase during the same periods. In 2016, the price of a hair transplant surgery generally ranged from RMB10,000 to 20,000, and in 2020, such price generally ranged from RMB20,000 to RMB30,000. It is expected that the disposable income *per capita* of Chinese residents will further increase to RMB46,902.4 in 2025 with a CAGR of 7.8% from 2020 to 2025, and reach RMB66,090.7 in 2030 with a CAGR of 7.1% from 2025 to 2030. With the increase in disposable income, an increasing number of Chinese consumers are able to afford the out-of-pocket bills relating to hair transplant. Moreover, as a result of the increase in spending power, Chinese consumers are willing to spend more on hair-related healthcare services, including hair transplant.

INDUSTRY OVERVIEW

- *Prevalence of hair-related problems.* A growing number of people of different ages, genders and occupations have been suffering from hair-related problems. Certain severe hair-related problems such as baldness and follicular closure, can only be affectively solved by hair transplants. However, a low hair transplant service market penetration rate of 0.21% indicates significant unmet needs.
- *Increasing investment on consumer education.* As the market expands, there are diversified marketing channels to educate consumers on hair transplants. Consumers will get much easier access to hair transplant knowledge and, as a result, are more likely to accept the hair transplant treatments. It will help the public to accept hair transplant as a reliable solution to address hair-related problems.
- *Development of hair transplant techniques.* Technological refinement drives the market forward. From FUE to microneedle hair transplant technology, the hair transplant technique innovation enables minimal scalp trauma, fast recovery, promising treatment results, high density and natural direction of hair growth after surgery.
- *More multi-site practice medical professionals.* With the implementation of the physician multi-site practice policy which permits physician to practice in multiple sites, more physicians can practice in hair transplant institutions to offer their services, accelerating the professionalism and accessibility of the market.

Future Trends

The hair transplant service market in China is expected to be influenced by the following trends:

- *Rapid growth in the consumer group.* Currently, with the improvement of aesthetic sense and higher expectations and requirements for appearance, both male and female customers in China have raised their attention to hair-related problems such as thinning hair and imperfect hairline. This contributes to the consumer base.
- *Consumer education and brand awareness enhancement.* As hair transplant service is one type of consumer medical service, which requires long-term investment on consumer education. This continuing education ensures rapid growth in market size and penetration rate. With the market expansion, there is an increasing brand recognition and customer stickiness.
- *Penetration in lower-tier cities.* Lower-tier cities and rural areas in China are becoming more urbanized and wealthy, and are increasingly able to afford higher quality hair transplant services. Besides, public medical resources in low-tier cities are limited, most public hospitals even do not offer hair transplant services, this further promotes the development of private hair transplant medical institutions. Therefore, consumers from lower-tier cities have become a key target group of market participants. With the penetration in lower-tier cities by hair transplant service providers, chain hair transplant institutions will gradually invade and even occupy the market of independent local hair transplant institutions.

INDUSTRY OVERVIEW

- *Transparent and standardized service for hair transplant.* As there is an increasing consumer awareness on the hair transplants and the market becomes more mature and regulated, there is a need for more standardized and transparent services.
- *Further market segregation* As the degree of alopecia varies between clients of different genders, ages and regions, the specific hair transplant plan will be adjusted accordingly. With the improvement of customers' aesthetic sense and the higher expectations and requirements for the quality of service, an increasing number of consumers prefer personalized hair transplant than traditional hair transplant treatment. The development of personalized hair transplants is expected to become a new trend.
- *One-stop comprehensive hair management services.* The hair transplant service market shows the trend from hair transplant medical institution to one-stop comprehensive hair management medical institutions, which means that all needs of hair treatment can be met by a one-stop service at one medical institution. This mainly because (i) hair-related problems are complex, which require professional diagnosis and different treatment solutions. Comprehensive hair management medical institutions can satisfy the varied demands from consumers suffering from all hair-related problems, not just alopecia; (ii) to eradicate hair-related problems, it requires a comprehensive therapeutic plan combining various treatment solutions to maintain and reinforce effects; and (iii) in order to achieve optimal treatment results, it is critical to choose the most suitable treatment mix from the wide range of treatment options for hair-related problems, including medicines, professional or medical devices, possible surgeries and hair care products. Only a one-stop comprehensive hair management medical institution can fulfil all requirements.

Entry Barrier

Despite the growth drivers discussed above, significant entry barriers remain in the hair transplant service market in China:

- *Brand reputation.* Even though hair transplant is one of the least risky surgery, patients tend to choose hair transplant service institutions with a strong reputation, as such institutions usually have experienced physicians and robust clinic networks which enable them to provide comprehensive post-treatment services and, most importantly, a proven track record of having performed a significant number of surgeries. It is difficult for new market entrants to establish a good brand reputation and achieve stable patient flow in a short time.
- *Skilled physicians.* As a type of minimally invasive surgery, hair transplant needs to be performed through tiny incisions, the procedure of which requires more precision than traditional surgery. As such, the hair transplant surgery should be performed by qualified physicians with rigorous professional training and long-time practical experience.
- *Medical licenses.* The hair transplant service market in China is subject to strict regulations. All hair transplant service providers shall obtain valid medical licenses. In addition, it has strict and delicate requirements on the medical conditions and the environment of care which can hardly be met by unprofessional institutions.

INDUSTRY OVERVIEW

- *Chain medical service capability.* As hair transplant treatment is mainly an one-off service, customers place great importance on the safety and treatment outcome. Therefore, the chain medical service capability is a strong competitive advantage, which can ensure that all clinics in the network have a consistent high standard of medical quality and operation capability.
- *Comprehensive diagnosis and treatment capability.* As hair-related problems are often caused by multiple factors and can hardly be solved by any single type of treatment method, the comprehensive diagnosis and treatment capability has become critical to the service providers. Moreover, hair transplant service usually needs to be accompanied by effective medical hair care services. It is difficult for late entrants to acquire comprehensive hair management service capabilities in a short time.

Limitations and challenges

The following factors are expected to limit, or bring threats and challenges to, the development of hair transplant industry in China:


- *Stringent regulatory scrutiny.* In order to strengthen the regulation and supervision of the industry, the relevant authorities have established several industry associations, such as the Hair Medicine Branch of the Chinese Association of Plastic and Aesthetics (中國整形美容協會毛髮醫學分會) and the Hair Medicine Branch of the Chinese Association of Integrative Medicine Board of Cosmetic Surgery (中國中西醫結合學會醫學美容專業委員會毛髮分會), to compile unified industry standards and assist the government in regulating and supervising the hair transplant industry. The strengthening regulatory scrutiny is expected to facilitate the healthy and orderly development of the industry, while the market participants who fail to meet the industry standards or comply with the evolving regulatory demands may find it increasingly difficult to compete with others in the industry.
- *Uneven development.* Only a few industry leaders, mostly private hair transplant chains, have the capital resources to expand rapidly and the capabilities to provide quality assurance for their services during their expansion. As a result, such market players have witnessed, and are expected to continue to witness a faster growth rate than others, creating a high barrier for new entrants and causing the market to develop towards an oligopoly structure. Such uneven development of market players may hinder the growth of the entire industry in the long run.
- *Imperfect physician evaluation criteria.* The hair transplant industry is highly dependent on the skill of physicians, which will directly affect the results and effects of the surgery. However, unlike other surgical departments, the evaluation criteria for hair transplant physicians have not yet been consummated, which affords limited control over the service quality and may limit the development of the entire industry.

INDUSTRY OVERVIEW

Market Players and Competitive Landscape

There is a wide range of medical institutions providing hair transplant services in China, including both public hospitals (hair transplant department) and private medical institutions which include chain hair transplant institutions, independent local hair transplant institutions and hair transplant department of aesthetics institutions. Public hospitals in China seldom conduct hair transplant, leaving the huge and fast-growing demand for hair transplants among patients in China unmet. In contrast, private medical institutions, leveraging their rich experience in hair transplant surgeries, are better positioned to fulfill such unmet medical needs, which promises great growth potential. Further, as compared with independent hair transplant institutions, hair transplant chains are more capable of providing quality assurance for their hair transplant services, and will be preferred by potential patients.

The chart below sets forth the market share of these market players in the hair transplant service market in China in 2020.



Source: Expert interview, Frost & Sullivan

Notes:

- (1) Nationwide Private Hair Transplant Chain Institutions refer to our Group, Group A, Group B and Group C as set forth below.
- (2) Other Private Hair Transplant Institutions primarily include independent local hair transplant institutions and other regional hair transplant chain institutions.

INDUSTRY OVERVIEW

In 2018, 2019 and 2020, we accounted for a market share of approximately 9.4%, 10.0% and 10.5%, respectively in China in terms of revenue generated from hair transplant services in the same periods. In addition, in 2020, we ranked first in terms of various key financial and operational indicators among the four top market players, all of which are nationwide private hair transplant chain institutions. Details of our rankings are set forth in the tables below.

Top Market Players in Hair Transplant Market in China by Revenue Generated From Hair Transplant Services in 2020

Rank	Medical Institution	Background	Revenue Generated from Hair Transplant Services <i>(RMB millions)</i>	Market Share
1	Our Group	We are a nationwide private hair transplant chain institution and has been providing hair transplant services in China under the brand name Yonghe since 2010.	1,413	10.5%
2	Group A	A nationwide private hair transplant chain institution founded in 1997 in China.	710	5.3%
3	Group B	A nationwide private hair transplant chain institution founded in 2001 in China.	600	4.5%
4	Group C	A nationwide private hair transplant chain institution founded in 2005 in China.	485	3.6%

Top Market Players in Hair Transplant Market in China by Number of Patients Receiving Hair Transplant Services in 2020

Rank	Medical Institution	Number of Patients Receiving Hair Transplant Services <i>(thousand)</i>	Market Share
1	Our Group	51	9.9%
2	Group B	37	7.2%
3	Group A	30	5.8%
4	Group C	25	4.8%

INDUSTRY OVERVIEW

Top Market Players in Hair Transplant Market in China by Number of In-Network Clinics in 2020

Rank	Medical Institution	Number of In-network Clinics	Market Share ⁽¹⁾
1	Our Group	48	3.7% – 4.8%
2	Group C	32	2.5% – 3.2%
3	Group B	30	2.3% – 3.0%
4	Group A	29	2.2% – 2.9%

Top Market Players in Hair Transplant Market in China by Number of Registered Physicians in 2020

Rank	Medical Institution	Number of Registered Physicians	Market Share ⁽²⁾
1	Our Group	189	17.2% – 21.0%
2	Group B	70	6.4% – 7.8%
3	Group A	60	5.5% – 6.7%
4	Group C	55	5.0% – 6.1%

Notes:

- (1) The respective market share of top market players in terms of the number of in-network clinics is presented in a range based on, among others, the respective market player's revenue and number of patients receiving hair transplant surgeries in 2020, as well as the extensive expert interviews conducted by Frost & Sullivan. A specific number for the total number of hair transplant clinics in China is unavailable, primarily because there is no official statistical caliber for the total number of hair transplant medical institutions nationwide, and a medical institution does not need a special permit or clearly includes "hair transplant" in their names to conduct hair transplant surgeries.
- (2) The respective market share of top market players in terms of the number of registered physicians is presented in a range based on, among others, the respective market player's revenue and number of patients receiving hair transplant surgeries in 2020, as well as the extensive expert interviews conducted by Frost & Sullivan. A specific number for the total number of registered physicians in hair transplant medical institutions in China is unavailable, primarily because a specific number for the total number of hair transplant clinics in China is unavailable for the reasons stated in Note (1) above, and registered physicians do not need a special license to perform hair transplant surgeries in China.

Source: Expert interview, Frost & Sullivan

In 2020, the average number of hair transplant surgeries performed by each physician of our Group, Group A, Group B and Group C (calculated through dividing each of the group's total number of patients receiving hair transplant services in 2020 by the number of their respective registered physicians in the same year as disclosed above) was approximately 270, 500, 529, and 455, respectively.

INDUSTRY OVERVIEW


THE MEDICAL HAIR CARE SERVICE MARKET IN CHINA

Overview

Medical hair care services generally refer to the non-surgical treatments provided by licensed medical institutions to address various scalp and hair problems, such as hair loss, soft hair, itching scalp and oily scalp. Medical hair care service is able to address the diversified needs of a larger patient pool with various scalp and hair problems, including but not limited to hair loss.

In 2020, the overall market size reached RMB5.0 billion, representing a CAGR of 25.4% between 2016 and 2020. However, the penetration rate of medical hair care services in alopecia patients (calculated by dividing the number of recipients of medical hair care procedures by the number of alopecia patients) in China in 2020 was only 1.0%, indicating a great growth potential with an improved patient education efforts. Furthermore, in addition to alopecia patients, medical hair care service is able to address the diversified needs of a larger patient pool with various other scalp and hair problems. Attributable to the enlarging patient pool, as well as other features of medical hair care services as disclosed in detail below, it is believed that the medical hair care service market in China is still in its infancy and is expected to grow at a CAGR of 29.8% from 2020 to 2025 and reach RMB62.5 billion by 2030. The following chart sets forth the historical and forecasted market size of medical hair care services in China.

Market Size of Medical Hair Care Services in China, 2016-2030E



Source: Expert interview, Frost & Sullivan

Features

The medical hair care service market has the following features:

- *High repurchase rate and customer stickiness.* The customers tend to choose the brand that they previously consumed and trusted for medical hair care services, since the services are medical-related and usually need periodic treatment to achieve and maintain the treatment effects. Medical hair care service providers with brand reputation or professional service will be trusted and preferred by clients in the long run. This high repurchase rate contributes to consumer stickiness.

INDUSTRY OVERVIEW

- *Large potential patient pool.* Medical hair care service is able to satisfy treatment needs of patients at various hair loss stages and attend to both female and male patients of different ages. As a result, medical hair care services are expected to be fit for and accepted by a large size of potential patient pool.
- *Significant supplement to hair transplant service market.* Medical hair care service plays a key role in the hair transplant services. The medical hair care services provide an important pre- and post-operative supplement to hair transplant services as well as a long-term maintenance solution for patients suffering varying degree of hair-related problems.

Growth Drivers

The following key factors have primarily driven the growth of the medical hair care service market in China:

- *Non-surgical and more affordable.* For those patients with hair-related problems at early stage, they can seek medical hair care treatment. Medical hair care treatment is non-surgical and more affordable for those patients, which is easy decision-making for potential patients.
- *Effective treatments compared with non-medical hair restoration solutions.* Medical hair care services are provided by medical professionals and the treatments include pharmaceuticals and medical procedures using professional medical devices, which are more reliable and effective as compared with non-medical hair restoration solutions.
- *Growing demand.* A growing number of people have been suffering from a series of hair-related problems at various stages such as folliculitis and shedding hair. Medical hair care treatment is a convenient and affordable treatment option to address the diversified needs of a larger patient pool with various scalp and hair problems, including but not limited to hair loss. However, even assuming that the medical hair care service merely targets alopecia patients, the penetration rate of medical hair care services (calculated by dividing the number of recipients of medical hair care procedures by the number of alopecia patients) in China in 2020 was only 1.0%, indicating a great growth potential with an improved patient education efforts.

Future Trends

The medical hair care service market in China is expected to be influenced by the following trends:

- *Increasing market share.* The current size of the medical hair care service market is relatively small compared to hair transplant service market. However, it shows significant growth rate. The medical hair care service market is projected to account for 32.9% and 45.3% of China's total hair-related healthcare service market by 2025 and 2030. Considering its huge customer base, large room for chain expansion, as well as customers' need for periodic treatment, the medical health care service is expected to become the main growth driver of the hair-related healthcare service market in the future.

INDUSTRY OVERVIEW

- *Growing importance of multi-disciplinary treatment.* Due to the complexity of hair-related disease, multi-discipline treatment, which requires combination among various disciplines such as dermatology and endocrinology, enables a more systematic and comprehensive medical hair care treatment plan for patients.
- *Rise of private medical institutions.* Public hospitals are unable to fully meet the rapid growth in demand for medical hair care services, especially in low-tier cities. This creates market opportunities for private medical institutions which may operate with more flexibility and can offer more personalized care to patients. As such, private medical institutions are expected to continue to capture future growth opportunities in this underserved market.
- *One-stop.* Comprehensive hair management institutions are pursuing to provide the full cycle of care from hair-related disease screening and diagnosis to hair transplant treatment, to post-treatment rehabilitation, and to medical hair care, which we expect will further enlarge the medical hair care service market in China.

Limitations and challenges

The following factors are expected to limit, or bring threats and challenges to, the development of medical hair care industry in China:

- *Excessive marketing.* Medical hair care service market in China is still in its infancy and many new entrants and small market players in the industry tend to exaggerate the effectiveness of medical hair care products and solutions, which, if not properly controlled, may negatively affect consumers' attitude towards the entire industry in the long run.
- *Insufficient regulation.* As of the Latest Practicable Date, there was no applicable laws and regulations in China specifically regulating the medical hair care service industry, and no industry associations had been established to supervise the market players as well, which may affect the healthy development of the industry.
- *High degree of substitutability.* Currently many medical hair care products and services available in the China market are similar and interchangeable. Market players who fail to assure service quality and continue to offer innovative services and products may find it difficult to differentiate themselves from others, and might be immersed in a "price war" as a result, which is expected to have a negative impact on the overall development of the industry.

Market Players and Competitive Landscape

The medical hair care service market is a fragmented market. There is a wide range of medical institutions providing medical hair care services in China, including both public medical institutions and private medical institutions.

INDUSTRY OVERVIEW

As shown in the table below, in terms of revenue generated from medical hair care services and number of in-network clinics providing medical hair care services in 2020, our Group ranked first among all medical institutions with a market share of approximately 4.3%.

Top Market Players in Medical Hair Care Market in China by Revenue Generated From Medical Hair Care Services in 2020

Rank	Medical Institution	Revenue Generated from Medical Hair Care Services (RMB millions)	Market Share
1	Our Group	213	4.3%
2	Group B	180	3.6%
3	Group A	150	3.0%
4	Group C	85	1.7%

Top Market Players in Medical Hair care Market in China by Number of In-Network Clinics in 2020

Rank	Medical Institution	Number of In-network Clinics
1	Our Group	48
2	Group C	32
3	Group B	30
4	Group A	29

Source: Expert interview, Frost & Sullivan

THE FROST & SULLIVAN REPORT

In connection with the Global Offering, we commissioned Frost & Sullivan, an Independent Third Party, to prepare a report on China's hair transplant service and medical hair care service markets. We have agreed to pay a total of RMB600,000 in fees to prepare the Frost & Sullivan Report. Frost & Sullivan is a market research and consulting company that provides market research on various industries, including healthcare. In preparing the report, Frost & Sullivan collected and reviewed publicly available data such as government-derived information, annual reports and industry association statistics, and market data collected by conducting interviews with key industry experts and leading industry participants. Frost & Sullivan has exercised due care in collecting and reviewing the information so collected.

Except as otherwise noted, all data and forecasts in this section come from the Frost & Sullivan Report. Our Directors confirm that, to the best of their knowledge, after taking reasonable care, there has been no adverse change in market information since the date of the Frost & Sullivan Report, which may qualify, contradict or impact the information disclosed in this section.

REGULATIONS ON THE REFORM OF HEALTHCARE INSTITUTIONS

Opinions on Deepening the Reform of the Medical and Healthcare System

The Opinions of the Central Committee of the Communist Party of China and the State Council on Deepening the Reform of the Medical and Healthcare System (中共中央、國務院關於深化醫藥衛生體制改革的意見) promulgated on March 17, 2009 encourage social capital to invest in the healthcare institutions (including investments by the foreign investors), and promote the development of private healthcare institutions and the reform of public healthcare institutions (including those established by state-owned enterprises) through social capital investment.

Notice on Further Encouraging and Guiding the Establishment of Medical Institutions by Social Capital

The Notice of the General Office of the State Council on Forwarding the Opinions of the National Development and Reform Commission, the Ministry of Health and Other Ministries on Further Encouraging and Guiding the Establishment of Medical Institutions by Social Capital (國務院辦公廳轉發發展改革委衛生部等部門關於進一步鼓勵和引導社會資本舉辦醫療機構意見的通知), which was promulgated by the General Office of the State Council on November 26, 2010, stipulates that the PRC government encourages and supports investments by private investors in healthcare institutions of various types. Private investors are permitted to apply to establish for-profit or not-for-profit healthcare institutions. Private healthcare institutions are encouraged to engage or authorise domestic or overseas healthcare institutions with professional experience to participate in the management of hospitals to improve their efficiencies.

Several Opinions on Promoting the Development of Healthcare Service Industry

The Several Opinions on Promoting the Development of Healthcare Service Industry (國務院關於促進健康服務業發展的若干意見), which was promulgated by the State Council on September 28, 2013, encourage the private sector to invest in the healthcare service industry by various means including new establishment and participation in restructuring and propose the idea of the relaxation of the requirements for Sino-foreign equity joint or cooperative joint healthcare institutions and gradually expand eligibility in the pilot program for wholly foreign-invested healthcare institutions.

Several Opinions on Accelerating the Development of Medical Institutions with Social Capital

The Several Opinions on Accelerating the Development of Medical Institutions with Social Capital (關於加快發展社會辦醫的若干意見), which was promulgated on December 30, 2013 by the National Health and Family Planning Commission (the “**NHFPC**”) and the State Administration of Traditional Chinese Medicine (the “**SATCM**”), stipulate the policies that support the development of private-invested healthcare institutions, including but not limited to the (i) gradual relaxation of investment in healthcare institutions by foreign capital; (ii) relaxation of requirements for service sectors, allowing social capital’s investment in the areas which are not explicitly prohibited; and (iii) acceleration of the approval procedures regarding the establishment and operation of private hospitals.

Notice on Printing and Distributing the Outline of the National Medical and Healthcare Service System Plan (2015-2020)

The Notice on Printing and Distributing the Outline of the National Medical and Healthcare Service System Plan (2015-2020) (關於印發全國醫療衛生服務體系規劃綱要(2015-2020年)的通知), which was promulgated by the General Office of the State Council on March 6, 2015, stipulates that private medical institutions are significant and integral parts of the medical and healthcare service system as well as an effective approach to fulfilling people's multi-level and diversified medical and healthcare service needs. Private medical institutions may provide high-end services to fulfil extra needs which are beyond basic needs. The pilot scheme of establishment of medical institutions solely invested by qualified overseas capitals shall be expanded step by step. The restrictions on service scope shall also be reduced and the social capitals shall be allowed to invest in areas not explicitly prohibited by the laws and regulations.

Several Policies and Measures Regarding the Promotion of Accelerating the Development of the Medical Institutions Invested by Social Capital

Several Policies and Measures Regarding the Promotion of Accelerating the Development of the Medical Institutions Invested by Social Capital (關於促進社會辦醫加快發展若干政策措施的通知), which was promulgated by the General Office of the State Council on June 11, 2015 and came into effect on the same day, stipulate (i) the elimination and cancellation of unreasonable preceding items for examination and approval and the reduction in the time required for making such examination and approval; (ii) the reasonable control of the number and scale of the public medical institutions and the exploration of the space for development of the medical institutions invested by social capital; and (iii) the support for the listing and financing of such eligible and qualified for-profit medical institutions invested by social capital.

Notice on Printing Guiding Principles for the Allocation Planning of Medical Institutions (2016-2020)

The Notice on Printing Guiding Principles for the Allocation Planning of Medical Institutions (2016-2020) (國家衛生計生委關於印發醫療機構設置規劃指導原則(2016-2020年)的通知), which was promulgated by the NHFPC on July 21, 2016, encourages the establishment of medical institutions by social capital and stipulates (i) the acceleration of the scale and high-level development of medical institutions with social capital, and the involvement of medical institutions with social capital in relevant planning to reserve space for the allocation of resources such as beds and large medical equipment according to a certain proportion, and (ii) the cancellation of limitations on the amount and location of medical institutions with social capital in accordance with total amount and structure of planning.

REGULATIONS ON THE ADMINISTRATION AND CLASSIFICATION OF HEALTHCARE INSTITUTIONS

Administrative Measures on Medical Institutions and its Implementation Measures

The Administrative Measures on Medical Institutions (醫療機構管理條例), which was promulgated on February 26, 1994 by the State Council and came into effect on 1 September 1994 and amended on February 6, 2016, and the Implementation Measures of the Administrative Measures on Medical Institutions (醫療機構管理條例實施細則), promulgated by the Ministry of Health of the PRC (“MOH”) on August 29, 1994 and came into effect on September 1, 1994 and last amended on February 21, 2017 by NHFPC, stipulate that any entity or individual that intends to establish a healthcare institution must comply with the relevant application and approval procedures and register with the relevant healthcare administrative authorities to obtain a Medical Institution Practicing License (醫療機構執業許可證).

If the medical institution has no bed or less than 100 beds, the entity or individual shall apply to the health administrative department under the people’s government at the county level in the place where the medical institution is about to be located; and if the medical institution has 100 beds or more or is a specialized hospital, the entity or individual shall apply according to the provisions of the health administrative department under the government at the provincial level.

Pursuant to the Basic Standards for Medical Institutions (醫療機構基本標準) promulgated by the Ministry of Health of the PRC (now known as National Health Commission of the PRC) on September 2, 1994 and amended on June 12, 2017, hospitals in China are generally ranked into three classes, i.e., Class I, II and III, with Class III being the highest class. For different classes, there are requirements of different degrees for the allocation of, among others, facilities, equipment and human resources. For example, Class I hospital needs meet certain standards in respect of a minimum of 20 registered beds, a minimum of three licensed physicians and five nurses, and the set-up of certain required equipment, clinical and medical technology departments, internal system and operating procedures.

Administrative Measures for the Examination of Medical Institutions (for Trial Implementation)

The Administrative Measures for the Examination of Medical Institutions (For Trial Implementation) (醫療機構校驗管理辦法(試行)) (the “**Administrative Measures for Examination**”), which was promulgated by the MOH and came into effect on June 15, 2009, stipulate that a healthcare institution’s Medical Institution Practicing License (醫療機構執業許可證) is subject to periodic examinations and verifications by the registration authorities, and will be cancelled if such healthcare institution fails to pass the examination.

Opinions on Implementing Classification Administration of Urban Medical Institutions

The Opinions on Implementing Classification Administration of Urban Medical Institutions (關於城鎮醫療機構分類管理的實施意見), jointly promulgated by the MOH, SATCM, Ministry of Finance (the “**MOF**”) and National Development and Reform Commission (the “**NDRC**”) on July 18, 2000 and came into effect on September 1, 2000, provide that not-for-profit and for-profit healthcare institutions shall be classified based on their business objectives, service purposes and implementation of divergent financial, taxation, pricing and accounting policies.

REGULATORY OVERVIEW

Law on the Promotion of Basic Medical Care, Hygiene and Health

Pursuant to the Law on the Promotion of Basic Medical Care, Hygiene and Health (基本醫療衛生與健康促進法), which was released by the SCNPC on December 28, 2019 and will come into effect on June 1, 2020, lawful registration and classified management for not-for-profit and for-profit medical institutions shall be implemented. Government-run medical institution shall not set up non-independent legal person medical institution with other organizations, or cooperate with social capital to establish for-profit medical institutions. It also provides that the government will take measures to encourage and guide social resources to set up medical institution, and such institution will enjoy similar benefits as government-run institution, in certain areas including basic medical insurance coverage, research and teaching, access to specific medical technologies, and title assessment of medical staff, etc.

Administrative Measures for the Clinical Application of Medical Technologies

According to the Administrative Measures for the Clinical Application of Medical Technologies (醫療技術臨床應用管理辦法), which was promulgated by the National Health Commission on August 13, 2018 and took effect on November 1, 2018, a negative management system is established for the clinical application of medical technologies. More specifically, those listed on the negative list to be promulgated are deemed to be prohibited medical technologies and the clinical application of which is prohibited; certain medical technologies that are beyond the negative list but possess certain prescribed characteristics are subject to strict record-filing management by the relevant health administrative department which require self-assessment of the medical technologies in question and submission of certain prescribed materials; and those medical technologies that are not categorized as prohibited or restricted medical technologies may be subject to clinical application by medical institutions according to their own functions, objectives, technical capabilities and so on and shall be strictly managed by the medical institutions themselves.

REGULATIONS ON THE AESTHETIC MEDICAL SERVICES

Administrative Measures for Aesthetic Medical Services

The Administrative Measures for Aesthetic Medical Services (醫療美容服務管理辦法), which was promulgated by the NHFPC on January 22, 2002, came into effect on May 1, 2002 and amended on February 13, 2009 and January 19, 2016, stipulates that aesthetic medical item shall be classified as first-level subject, aesthetic surgery, aesthetic dentistry, aesthetic dermatology and aesthetic Chinese medicine shall be classified as secondary subject. Medical practitioners of aesthetic medical services shall obtain the qualification license of aesthetic medical attending in-charge physician or provide aesthetic medical clinical services under supervision of licensed attending in-charge physician. Aesthetic medical attending in-charge physicians and personnel providing aesthetic medical nursing services shall meet relevant requirements. Provincial level health authorities may make additional requirements upon qualification review of aesthetic medical attending in-charge physician.

Classification Catalog of Aesthetic Medical Item

The Classification Catalog of Aesthetic Medical Item (醫療美容項目分級管理目錄), which was promulgated by the NHFPC on December 11, 2009 and came into effect on the same date, classifies aesthetic medical services into four categories: (i) aesthetic surgery items; (ii) aesthetic dentistry items; (iii) aesthetic dermatological items and (iv) aesthetic Chinese medicine items. Provincial-level

REGULATORY OVERVIEW

counterparts of the NHFPC may adjust the catalog based on local circumstances. As for aesthetic surgery items, the aesthetic surgery items are divided into four grades in accordance with the difficulty and complexity of the surgery, the possibility of medical malpractice and the level of surgery risk. Surgeries which involve uncomplicated operation process, less technical difficulty and risk shall be classified as grade 1. Surgeries which involve general complexity of operation process, certain technical difficulty and risk, as well as requiring the use of epidural space block anesthesia and intravenous anesthesia, shall be classified as grade 2. Surgeries involving relatively high complexity of operation process, relatively huge technical difficulties and risk, as well as requiring the preoperative blood preparation and tracheal intubation for general anesthesia, shall be classified as grade 3. If highly complicated operation process needed and huge technical difficulty and high risk involved, the surgeries shall be classified as grade 4.

Basic Standard for Aesthetic Medical Institution and Aesthetic Medical Department (For Trial Implementation)

The Basic Standard for Aesthetic Medical Institution and Aesthetic Medical Department (For Trial Implementation) (美容醫療機構、醫療美容科(室)基本標準(試行)), which was promulgated by the NHFPC on April 16, 2002 and came into effect on the same date, specifies basic standards that aesthetic medical hospitals, aesthetic medical out-patient departments, aesthetic medical clinics and aesthetic medical departments should meet, such as the number of beds, clinical departments and medical personnel. For each aesthetic medical clinic, it shall have at least two beds, and for each department in the clinic, it shall have at least one attending physician and at least one nurse.

Circular on Further Strengthening Comprehensive Regulatory Enforcement in the Medical Beauty Industry

On April 3, 2020, the SAMR, the National Health Commission of the PRC (the “NHC”), National Medical Products Administration of the PRC (the “NMPA”), Office of the Central Cyberspace Affairs Commission (the “CCAC”), among others, jointly promulgated the Circular on Further Strengthening Comprehensive Regulatory Enforcement in the Medical Beauty Industry (關於進一步加強醫療美容綜合監管執法工作的通知), which stipulate that medical beauty services shall be implemented by the attending physician (主診醫師) or the practicing physician under the guidance of the attending physician in accordance with the registered medical beauty service items in the medical institutions that set up medical beauty related subjects. No organization or individual shall carry out medical beauty services without meeting the legal conditions. Medical beauty institutions shall purchase drugs and medical devices in enterprises with production and operation qualifications. Medical beauty advertisements belong to medical advertisements, and non-medical institutions shall not publish medical advertisements.

Special Rectification Work Plan for Cracking Down on Illegal Medical Beauty Services

On May 28, 2021, the SAMR, SATCM, NHC, NMPA, CCAC, among others, jointly promulgated the Special Rectification Work Plan for Cracking Down on Illegal Medical Beauty Services (關於印發打擊非法醫療美容服務專項整治工作方案的通知), which stipulate that in order to further safeguard the legitimate rights and interests of consumers and protect people’s health and life safety, the SAMR, SATCM, NHC, NMPA, CCAC, among others, are scheduled to carry out special rectification work against illegal medical and beauty services nationwide from June to December 2021. The work tasks mainly include: (i) severely crack down on illegal activities related to medical beauty, (ii) strictly standardize the behavior of medical beauty service, (iii) severely crack down on the illegal manufacture, sale of drugs and medical devices, and (iv) seriously investigate and prosecute illegal advertising and internet information.

REGULATORY OVERVIEW

REGULATIONS ON THE SUPERVISION OVER PHARMACEUTICALS AND MEDICAL EQUIPMENT IN HEALTHCARE INSTITUTIONS

Measures for the Supervision and Administration of Pharmaceuticals in Medical Institutions (for Trial Implementation)

The Measures for the Supervision and Administration of Pharmaceuticals in Medical Institutions (for Trial Implementation) (醫療機構藥品監督管理辦法(試行)), promulgated by China Food and Drug Administration (the “CFDA”) and came into effect on October 11, 2011, stipulate that medical institutions must purchase pharmaceuticals from enterprises qualified for the production or distribution of pharmaceuticals and comply with certain standards in respect of the storage, dispensation and use of such pharmaceuticals. Pharmaceutical preparation dispensed by a healthcare institution must only be used by and for that healthcare institution. Healthcare institutions are prohibited from selling prescription pharmaceuticals to the public by such means as post, online transaction and open-shelf selection.

Prescription Management

According to the Administrative Measures for Prescriptions (處方管理辦法), which was promulgated by the MOH on February 14, 2007 and came into effect on May 1, 2007, a registered medical practitioner is entitled to issue prescriptions at his registered practice location. The Measures for the Classification and Administration of Prescription Pharmaceuticals and Non-prescription Pharmaceuticals (For Trial Implementation) (處方藥與非處方藥分類管理辦法(試行)), which were promulgated by CFDA on June 18, 1999 and came into effect on January 1, 2000, set forth different systems for the control of prescription and non-prescription drugs. Medical institutions can decide or recommend to use non-prescription drugs on the basis of medical necessity.

LAWS AND REGULATIONS ON MEDICAL PERSONNEL OF HEALTHCARE INSTITUTIONS

Law on Medical Practitioners of the PRC

The Law on Medical Practitioners of the PRC (中華人民共和國執業醫師法), which was promulgated by the Standing Committee of the National People’s Congress (the “SCNPC”) on June 26, 1998 and came into effect on May 1, 1999 and last amended on August 27, 2009, provides that physicians in the PRC must obtain qualification licenses for their medical profession. Qualified physicians and qualified assistant physicians must register with the relevant public health administrative authorities at or above the county level. After registration, physicians may be engaged in relevant medical treatment, disease-prevention or healthcare business in their registered institution within the registered practicing categories and practicing scope. On February 28, 2017, the NHFPC promulgated the Administrative Measures for the Registration of Medical Practitioners (醫師執業註冊管理辦法) (the “**Medical Practitioners Registration Measures**”), which became effective on April 1, 2017, further stipulates that medical practitioners shall obtain the Practicing Certificate to practise upon registration, and provide in detail the requirements and procedures for the registration as well as the modifications to be made to such registration upon occurrence of certain prescribed circumstances.

REGULATORY OVERVIEW

Several Opinions on Accelerating the Development of Medical Institutions with Social Capital and Several Opinions on Promoting and Standardising Multi-Institution Practice of Medical Practitioners

Several Opinions on Accelerating the Development of Medical Institutions with Social Capital (關於加快發展社會辦醫的若干意見), jointly promulgated by the NHFPC and the SATCM on December 30, 2013, specifically stipulates that multi-institution practices of medical practitioners shall be permitted and relevant authorities should permit the orderly movements of the medical personnel among medical institutions of various sponsorships. The Notice on Printing and Distributing Several Opinions on Promoting and Standardising Multi-Institution Practice of Medical Practitioners (關於印發推進和規範醫師多點執業的若干意見的通知), jointly issued by the NHFPC, the NDRC, the Ministry of Human Resources and Social Security, the SATCM and the China Insurance Regulatory Commission on November 5, 2014, stipulates that the clinical, dental and traditional Chinese medicine practitioners are allowed to practise in multiple places. According to the Medical Practitioners Registration Measures, for any other institution in which the medical practitioner intends to practise, such medical practitioner shall apply to the health administrative authority for up the practice of such institution for separate recordation in which the name of such institution shall be indicated.

Regulations on Nurses

The Regulations on Nurses (護士條例), promulgated by the State Council on January 31, 2008 and came into effect on May 12, 2008 and amended on March 27, 2020, provide that a nurse must obtain a Nurse's Practicing Certificate (護士執業證書) which is valid for five years in order to practise. The number of practicing nurses on duty at a healthcare institution shall not be less than the standard number as prescribed by the public health administrative authority of the State Council.

Administrative Measures for the Registration of Practising Nurses

Pursuant to the Administrative Measures for the Registration of Practising Nurses (護士執業註冊管理辦法) promulgated by the NHFPC on May 6, 2008 and latest amended on January 8, 2021, nurses must register and obtain the Nurse Practising Certificate (護士執業證書) before they practise nursing at the registered practising place. Those who have not obtained the Nurse Practising Certificate are not allowed to engage in nursing activities regulated by medical treatment standards.

LAWS AND REGULATIONS REGARDING ANTI-CORRUPTION, ANTI-UNFAIR COMPETITION AND ANTI-COMMERCIAL BRIBERY

The governmental departments of the PRC have formulated the relevant laws and regulations for standardizing the anti-corruption and anti-commercial bribery in medical treatment and health industry. In accordance with the *Code of Conduct for Practitioners in Healthcare Institutions* (醫療機構從業人員行為規範), which was promulgated jointly by the NHFPC, the CFDA and the State Administration of Traditional Chinese Medicine on June 26, 2012, the practitioners in healthcare institutions shall perform their duties honestly, be self-disciplined, and shall abide by medical ethics.

The Anti-Unfair Competition Law of the PRC (中華人民共和國反不正當競爭法) passed by the SCNPC provides certain measures to prevent unfair competition and protect market order, which includes, among others, prohibiting improper prize sale, dumping to crowd out market competitors. Pursuant to which, the business operator shall not bribe any staff of the counterparty, any entity or personnel that entrusted by the counterparty, or influence the entity or personnel of the counterparty

REGULATORY OVERVIEW

using its power, for business opportunity or competitive edge. The regulatory authority may confiscate the income and impose a fine of more than RMB100,000 and less than RMB3 million depending on the seriousness, and revoke the business license in serious case. On May 8, 2019, nine national authorities, including the National Health Commission of the PRC, State Administration for Market Regulation, MOFCOM, and the National Healthcare Security Administration, jointly issued the *Key Points on Correcting the Malpractices in Purchase and Sale of Medicine and Medical Service in 2019* (2019年糾正醫藥購銷領域和醫療服務中不正之風工作要點), stipulates, among others, that the inspection of invoice issued by medical institution shall be strengthened and severely punish the illegal activities such as commercial bribery to protect the market order.

LAWS AND REGULATIONS ON MEDICAL MALPRACTICE

PRC Civil Code

Pursuant to the PRC Civil Code (中華人民共和國民法典) which was promulgated by the National People's Congress (the "NPC") on May 28, 2020 and became effective on January 1, 2021, if a patient suffers damage in the course of diagnosis and treatment and the medical institution or its medical personnel are at fault, the medical institution shall bear the liability for compensation.

Regulations on Handling Medical Malpractice

The Regulations on Handling Medical Malpractice (醫療事故處理條例), which was promulgated by the State Council on April 4, 2002 and came into effect on September 1, 2002, provides a legal framework and detailed provisions regarding the prevention, technical identification, disposition, supervision, compensation and penalties of medical malpractice. For the purpose of the regulation, medical malpractice refers to an accident involving personal injury to patients caused by medical institutions or medical personnel due to malpractice as a result of violation of the laws, administrative regulations or departmental rules on medical and health administration, or of standards or procedures of medical treatment.

REGULATIONS ON PROTECTION OF CONSUMERS

On March 15, 2014, the SCNPC promulgated the Law of the People's Republic of China on the Protection of Rights and Interests of Consumers (中華人民共和國消費者權益保護法), which specifies the consumer rights, obligations of business operators, protection of legitimate consumer rights and interests by the state, legal liability of business operators, etc. Particularly, business operators providing goods or services by way of advance payment shall provide goods or services pursuant to the agreement. Where the goods or services are not provided pursuant to the agreement, the business operator shall perform the agreement as required by the consumer or refund the advance payment and bear the interest on advance payment and reasonable expenses incurred by the consumer.

The Guidance for the Conduct of Consumer Prepaid Service Transaction Contracts in Beijing (Trial Implementation) (北京市消費類預付費服務交易合同行為指引(試行)), which was promulgated by the Beijing Administration for Industry and Commerce on September 1, 2011, provides more specific provisions. Pursuant to this guidance, before collecting the prepaid fee, the business operator shall, according to the characteristics of the transaction, agree with the consumer in writing or inform the consumer of the following contents: service location, service time, service mode, use authority, price standard, preferential conditions, service standard, use of commodity brand, validity period or times, replacement of loss, refund transfer, liability for breach of contract, etc. Business operators shall not

REGULATORY OVERVIEW

make ambiguous lifelong service commitments. The term of validity of the contract agreed between the business operator and the consumer shall be commensurate with the amount of prepaid expenses and the service life of the business site. A consumer who has not used the prepaid fee to receive services within 7 days after the delivery of the prepaid fee has the right to terminate the contract unconditionally, the business operator shall return all the prepaid expenses at one time. If a consumer accepts the free experience or trial service provided by the operator within 7 days after paying the prepaid fee, it will not affect the consumer's exercise of the unconditional right to terminate the contract.

REGULATIONS ON MEDICAL ADVERTISING IN THE PRC

Advertisement Law of the PRC

The Advertisement Law of the PRC (中華人民共和國廣告法) (the “**Advertisement Law**”), which was promulgated by the SCNPC on October 27, 1994 and latest amended on April 29, 2021, provides that advertisements shall not contain false statements nor be deceitful or misleading to consumers. Advertisements legally required to receive censorship, including those that are relating to medical, pharmaceuticals and medical devices, shall be examined by relevant authorities in accordance with relevant rules before being published, and the advertisements shall not be distributed without going through examination. Medical advertisements shall not contain: (i) any assertion or guarantee for efficacy or safety, (ii) any statement on cure rate or effective rate, (iii) comparison with other medical institutions, (iv) use of advertisement endorsers to make endorsements or testimonials; or (v) other items as prohibited by laws and administrative regulations.

Interim Measures for the Administration of Internet Advertisement

The Interim Measures for the Administration of Internet Advertisement (互聯網廣告管理暫行辦法), which was promulgated by the State Administration of Industry and Commerce (the “**SAIC**”) on July 4, 2016 and came into effect on September 1, 2016, provides that internet advertisements shall be identifiable and clearly identified as an “advertisement” so that consumers will identify it is as such. Paid search advertisements shall be clearly distinguished from natural search results. It is prohibited to publish advertisements for prescription drugs and tobaccos via the Internet. No advertisement of any medical treatment, medicines, foods for special medical purpose, medical apparatuses, pesticides, veterinary medicines, dietary supplement or other special commodities or services which are subject to review by advertisement examination authorities as stipulated by laws and regulations shall be released unless it has passed such examination.

Medical Advertisement

The Administrative Measures on Medical Advertisement (醫療廣告管理辦法), jointly promulgated by the SAIC and the MOH on September 27, 1993, took effect on December 1, 1993, amended on November 10, 2006 and came into effect on January 1, 2007, requires that medical advertisements shall be reviewed by relevant health authorities and obtain a Medical Advertisement Examination Certificate (醫療廣告審查證明) before they may be released by a healthcare institution. Medical Advertisement Examination Certificate has an effective term of one year. If the certificate holder needs to continue to publish the medical advertisement after the expiration of the period, it shall apply for examination again. The following circumstances are prohibited in a medical advertisement:

1. Involving medical technology, diagnosis and treatment methods, disease names or drugs.
2. Guaranteeing or implying cure rate.

REGULATORY OVERVIEW

3. Publicize cure rate, effective rate or other diagnosis and treatment effects.
4. Containing obscene, superstitious or absurd contents.
5. Belittling others.
6. Using the name or image of patients, health technicians, medical education and scientific research institutions and personnel, as well as other social associations and organizations as proof.
7. Using the name or image of the People's Liberation Army or the armed police force.
8. Other Circumstances prohibited by laws and administrative regulation.

Pursuant to the Special Rectification Work Plan for Cracking Down on Illegal Medical Beauty Services, medical beauty advertisements belong to medical advertisements, and non-medical institutions shall not publish medical advertisements. Medical beauty institutions shall obtain the Medical Advertisement Examination Certificate before publishing medical advertisements, in strict accordance with the Advertisement Law and the Administrative Measures on Medical Advertisement. Without examination and approval in accordance with the laws and regulations, it is strictly forbidden to publish medical advertisements or false information in the form of news, medical information service topics (columns), health science popularization, etc.

The Enforcement Guidance for the Medical Cosmetology Advertising (醫療美容廣告執法指南) (the “**Enforcement Guidance**”), which was promulgated by the SAMR on November 1, 2021 and came into effect on the same day, stipulates that the market regulatory departments shall rectify the chaos of all kinds of medical beauty advertisements in accordance with the laws and regulations, strive to solve the problems of great harmfulness and concentrated public response, and crack down on the following situations:

1. go against the good social fashion and create “appearance anxiety”. Improperly associate poor appearance with negative evaluation factors such as “imbecility”, “laziness” and “poverty”, or improperly associate good appearance with positive evaluation factors such as “high quality”, “diligence” and “success”.
2. to advertise drugs and medical devices that have not been approved or registered by the drug administrative department in violation of the laws and regulations related to drugs, medical devices and advertisements.
3. to publicize contents such as diagnosis and treatment subjects and service items that have not been approved or registered by the administrative department of health.
4. to publicize the effect of diagnosis or make a guaranteed commitment to the safety and efficacy of diagnosis.

REGULATORY OVERVIEW

5. to use the name or image of industries association or other associations or organizations to prove it; to use the name or image of the patient to compare the effects before and after diagnosis or to prove it.
6. to make use of advertising spokesmen to recommend and certify medical beauty. The so-called “recommendation officer” and “experience officer” that appear in the medical beauty advertisement, who make the recommendation certificate for the medical beauty in their own name or image, should be recognized as advertising spokesmen.
7. to publish medical beauty advertisements in disguised form in the form of introducing health, health-preserving knowledge, exclusive interviews with people, news reports, etc.
8. to publicize the function of treating diseases to food, health food, disinfection products and cosmetics or claiming to have health care functions for foods other than health food.
9. other acts that seriously infringe upon the rights and interests of the masses in violation of advertising laws and regulations.

REGULATIONS ON ENVIRONMENTAL PROTECTION AND FIRE PREVENTION RELATED TO HEALTHCARE INSTITUTIONS

Administrative Measures for Pollutant Discharge Licensing

Administrative Measures for Pollutant Discharge Licensing (for Trial Implementation) (排污許可管理辦法(試行)), which was promulgated by the Ministry of Environmental Protection on January 10, 2018, and amended on August 22, 2019, stipulate that the enterprises, public institutions and other production operators (the “**pollutant discharge entities**”) included in the catalog of classified management of pollutant discharge licenses for stationary pollution sources shall apply for and obtain a pollutant discharge permit as per the prescribed time limit; and those are not included in the catalog are not required to do so for the time of being.

Pursuant to the Classified Management Catalog of Pollutant Discharge Permits for Stationary Sources of Pollution (2019 Edition) (固定污染源排污許可分類管理名錄(2019年版)), which was promulgated by the Ministry of Ecology and Environment on December 20, 2019 and became effective on the same day, a pollutant discharge entity subject to registration management is not required to apply for a pollutant discharge permit. It shall fill in the pollutant discharge registration form on the management information platform of state pollutant discharge permits, and register with its basic information, pollutant discharge route, pollutant discharge standards implemented, pollution prevention, control measures adopted and other information.

Regulations on the Management of Medical Waste and its Implementation Measures

The Regulations on the Management of Medical Waste (醫療廢物管理條例), promulgated by the State Council on June 16, 2003 and came into effect on the same day and further amended and came into effect on January 8, 2011, and the Implementation Measures for the Management of Medical Waste of Medical and Health Institutions (醫療衛生機構醫療廢物管理辦法), promulgated by the MOH on October 15, 2003 and came into effect on the same day, stipulate that healthcare institutions must

REGULATORY OVERVIEW

categorise the medical waste in accordance with the Classified Catalogue of Medical Waste (醫療廢物分類目錄) for management purpose and timely deliver medical waste to a medical waste disposal entity approved by the environmental protection administrative department at or above the county level for centralized disposal. Our emission of medical waste and pollutants are in compliance with these rules and regulations in all material respects. For details, see “Business — Environmental Sustainability and Social Responsibility — Environmental Protection” in this prospectus.

Regulations on Urban Drainage and Sewage Treatment

Enterprises that engage in the activities of industry, construction, catering, and medical treatment, etc. that discharges sewage into urban drainage facilities shall apply to the relevant competent urban drainage department for collecting the permit for discharging sewage into drainage pipelines under relevant laws and regulations, including the Regulations on Urban Drainage and Sewage Disposal (城鎮排水與污水處理條例), which was promulgated on October 2, 2013 and came into force on January 1, 2014, and the Measures for the Administration of Permits for the Discharge of Urban Sewage into the Drainage Network (城鎮污水排入排水管網許可管理辦法), which was promulgated on January 22, 2015 and came into force on March 1, 2015. Drainage entities covered by urban drainage facilities shall discharge sewage into urban drainage facilities in accordance with the relevant provisions of the state. Where a drainage entity needs to discharge sewage into urban drainage facilities, it shall apply for a drainage license in accordance with the provisions of these Measures. The drainage entity that has not obtained the drainage license shall not discharge sewage into urban drainage facilities.

Law on Prevention and Control of Water Pollution of the PRC

Pursuant to the Law on Prevention and Control of Water Pollution of the PRC (中華人民共和國水污染防治法) promulgated by the SCNPC on May 11, 1984 and became effective on November 1, 1984, amended on May 15, 1996 and came into effective on the same day, amended on February 28, 2008 and became effective on June 1, 2008, last amended on June 27, 2017 and became effective on January 1, 2018, the production and operation units must discharge water pollutants in accordance with national and local standards. If the amount of discharged water pollutants exceeds the national or local standards, the production and operation units will be imposed a fine equivalent to an amount between RMB100,000 and RMB1,000,000. In addition, the environmental protection authority is empowered to order the relevant production and operation units to restrict their production, or stop production for rectification, and in serious circumstances, the case will be reported to the competent government with approval authority to impose an order to suspend or shut-down its operation.

Environmental Impact Appraisal

According to the Administration Rules on Environmental Protection of Construction Projects (建設項目環境保護管理條例), which was promulgated by the State Council on November 29, 1998, amended on July 16, 2017 and became effective on October 1, 2017, depending on the impact of the construction project on the environment, a construction employer shall submit an environmental impact report or an environmental impact statement, or file a registration form. As to a construction project, for which an environmental impact report or the environmental impact statement is required, the construction employer shall, before the commencement of construction, submit the environmental impact report or the environmental impact statement to the relevant authority at the environmental protection administrative department for approval. If the environmental impact assessment documents of the construction project have not been examined or approved upon examination by the approval authority in accordance with the law, the construction employer shall not commence the construction.

REGULATORY OVERVIEW

According to the Environmental Impact Appraisal Law of PRC (中華人民共和國環境影響評價法), which was promulgated by the SCNPC on October 28, 2002, amended on July 2, 2016 and December 29, 2018, for any construction projects that have an impact on the environment, an entity is required to produce either a report, or a statement, or a registration form of such environmental impacts depending on the seriousness of effect that may be exerted on the environment.

Fire Prevention Design and Acceptance

The Fire Prevention Law of the PRC (中華人民共和國消防法) (the “**Fire Prevention Law**”) was adopted on April 29, 1998 and latest amended on April 29, 2021. According to the Fire Prevention Law, for special construction projects stipulated by the housing and urban-rural development authority of the State Council, the developer shall submit the fire safety design documents to the housing and urban-rural development authority for examination, while for construction projects other than those stipulated as special development projects, the developer shall, at the time of applying for the construction permit or approval for work commencement report, provide the fire safety design drawings and technical materials which satisfy the construction needs. According to the Regulations on the Supervision and Administration of Fire Prevention in Construction projects (建設工程消防監督管理規定), which was promulgated by the Ministry of Public Security of the PRC on July 17, 2012 and terminated on June 1, 2020, an examination system for fire prevention design and acceptance only applies to the densely populated places and the special construction projects, and for other projects, a record-filing of fire prevention design and acceptance and spot check system would be applied. According to Interim Regulations on Administration of Examination and Acceptance of Fire Control Design of Construction Projects (建設工程消防設計審查驗收管理暫行規定), which was promulgated by the Ministry of Housing and Urban-Rural Development on April 1, 2020 and came into effect on June 1, 2020, an examination system for fire prevention design and acceptance only applies to special construction projects, and for other projects, a record-filing and spot check system would be applied. A construction project with one of the following situations shall be deemed as a special construction project: an outpatient building of a hospital with a total floor area of more than 2,500 square meters, or the ward building of a hospital or sanatorium with a total floor area of more than 1,000 square meters, etc.

LAWS AND REGULATIONS RELATED TO INTELLECTUAL PROPERTY RIGHTS

Trademark

Pursuant to the Trademark Law of the PRC (中華人民共和國商標法) which became effective on March 1, 1983, and was last amended on April 23, 2019 and took effect on November 1, 2019, and the Regulation for the Implementation of Trademark Law of the PRC (中華人民共和國商標法實施條例) which became effective on September 15, 2002 and was amended on April 29, 2014 and took effect on May 1, 2014, the Trademark Office of the administrative department for industry and commerce under the State Council is responsible for the registration and administration of trademarks in the PRC. A trademark registrant enjoys an exclusive right to the trademark. A trademark registrant may, by entering into a trademark licensing contract, license another party to use its registered trademark. Where another party is licensed to use a registered trademark, the licensor shall report the license to the Trademark Office for recordation, and the Trademark Office shall publish the same. An unrecorded license may not be used as a defence against a third party in good faith.

REGULATORY OVERVIEW

Patents

According to the Patent Law of the PRC (中華人民共和國專利法), promulgated by the SCNPC and came into effect on June 1, 2021 and the Implementing Rules of the Patent Law of the PRC (中華人民共和國專利法實施細則), promulgated by the China Patent Bureau Council on January 19, 1985, and last amended on January 9, 2010 by State Council and came into effect on February 1, 2010, the term “invention-creations” refers to inventions, utility models and designs. The duration of a patent right for inventions shall be 20 years, the duration of a patent right for utility models shall be 10 years and the duration of a patent right for design shall be 15 years, all commencing from the filing date. In the event that a dispute arises due to a patent being exploited without the prior authorization of the patentee, that is to say an infringement upon the patent right of the patentee.

Domain Names

In accordance with the Measures for the Administration of Internet Domain Names (互聯網域名管理辦法) which was issued by the Ministry of Industry and Information Technology of the PRC on August 24, 2017 and came into effect on November 1, 2017, the Ministry of Industry and Information Technology of the PRC is responsible for supervision and administration of domain name services in the PRC. Communication administrative bureaus at provincial levels shall conduct supervision and administration of the domain name services within their respective administrative jurisdictions. Domain name registration services shall, in principle, be subject to the principle of “first apply, first register”. A domain name registrar shall, in the process of providing domain name registration services, ask the applicant for which the registration is made to provide authentic, accurate and complete identity information on the holder of the domain name and other domain name registration related information.

LAWS AND REGULATIONS RELATED TO FOREIGN INVESTMENT IN THE PRC

Company Law of the PRC

The Company Law of the PRC (中華人民共和國公司法) (the “**Company Law**”), which was promulgated by the SCNPC on December 29, 1993 and came into effect on July 1, 1994, last amended on October 26, 2018, provides that companies established in the PRC may take form of company of limited liability or company limited by shares. Each company has the status of a legal person and owns its assets itself. Assets of a company may be used in full for the company’s liability. The Company Law applies to foreign-invested companies unless relevant laws provide otherwise.

Laws and Regulations in Relation to Sino-Foreign Joint Ventures

The Law on Sino-Foreign Equity Joint Ventures (中華人民共和國中外合資經營企業法) (the “**EJV Law**”) was promulgated and implemented on July 8, 1979. It was subsequently amended on April 4, 1990, March 15, 2001 and September 3, 2016. The Implementation Rules for the Law on Sino-Foreign Equity Joint Ventures of the PRC (中華人民共和國中外合資經營企業法實施條例) (the “**EJV Rules**”) were promulgated by the State Council on September 20, 1983, and last amended on March 2, 2019. The EJV Law and its implementation rules state the establishment and approval procedures, requirements on registered capital, restrictions on foreign exchange, accounting practices, taxation, labour requirements and other issues applicable to Sino-foreign equity joint ventures. On January 1, 2020, the EJV Law was terminated and replaced by the Foreign Investment Law of the PRC (中華人民共和國外商投資法), and the EJV Rules was terminated and replaced by Implementing Regulations of the Foreign Investment Law of the PRC (中華人民共和國外商投資法實施條例).

The Provisional Measures for the Filing Administration of Establishment and Changes of Foreign-Invested Enterprises

The Provisional Measures for the Filing Administration of Establishment and Changes of Foreign-Invested Enterprises (2018 Revision) (外商投資企業設立及變更備案管理暫行辦法 (2018年修正)), which was promulgated by the MOFCOM on June 29, 2018 and implemented on June 30, 2018, set out the prescribed procedures for the establishment and modifications of foreign-invested enterprises which are not subject to the special management measures on admission as stipulated by the PRC to be filed for records with the delegated commerce authorities and specify the procedures and requirements for such filing in detail. Foreign invested enterprises and their investors shall provide information for filing and completing the declaration form for filing application truthfully, accurately and completely according to such provisional measures without any false records, misleading statements or material omission.

On January 1, 2020, the Provisional Measures for the Filing Administration of Establishment and Changes of Foreign-Invested Enterprises (2018 Revision) was terminated and replaced by the Measures on Reporting of Foreign Investment Information (外商投資信息報告辦法).

The Measures for the Reporting of Foreign Investment Information

The Measures for the Reporting of Foreign Investment Information (外商投資信息報告辦法), which was promulgated by the MOFCOM and the State Administration for Market Regulation (“SAMR”) on December 30, 2019 and came into effect on January 1, 2020, stipulates that a foreign investor who establishes a foreign-invested enterprise within China shall submit an initial report through the enterprise registration system when undergoing formation registration of the foreign-funded enterprise, a foreign investor that acquires a domestic non-foreign-invested enterprise by equity merger shall submit an initial report through the enterprise registration system when undergoing modification registration of the acquired enterprise.

Interim Provisions on Investment Made by Foreign-Invested Enterprises in China

The Interim Provisions on Investment Made by Foreign-Invested Enterprises in China (關於外商投資企業境內投資的暫行規定), jointly promulgated by the Ministry of Foreign Trade and Economic Cooperation of the PRC and the SAIC on July 25, 2000 and amended on October 28, 2015, stipulates that a foreign-invested enterprise (the “FIE”) are not permitted to invest in any sector prohibited to foreign investment. Where the FIE makes investment in a restricted sector, the FIE must file an application with the provincial commercial department of the place where the investee company is located. The relevant company registration authority will, in accordance with the relevant provisions of the Company Law and the Regulations on the Administration of Company Registration of the PRC (中華人民共和國公司登記管理條例), decide whether or not to approve the registration. If the registration is approved, a Business License will be issued with the designation “Invested by a Foreign-Invested Enterprise”. The FIE is required to report the establishment of the investee company within 30 days of the date of its establishment to the original examination and approval authority for record-filing.

DOMESTIC REGULATIONS ON ESTABLISHMENT OF FOREIGN INVESTED HOSPITALS

The Catalogue for the Guidance of Foreign Investment Industries and The Special Administrative Measures (Negative List) for the Access of Foreign Investment

The Catalogue for the Guidance of Foreign Investment Industries (外商投資產業指導目錄) (the “**Catalogue**”), which regulates conducting foreign investment in the PRC, was first issued in 1995 and amended from time to time. The Catalogue promulgated by the MOFCOM and the NDRC on June 28, 2017 and became effective on July 28, 2017 (the “**2017 Catalogue**”), contains specific provisions guiding market access of foreign capital and stipulates in detail the areas of entry pertaining to the categories of encouraged foreign investment industries, restricted foreign investment industries and prohibited foreign investment industries. The latter two categories are included in the negative list, which was first introduced into the 2017 Catalogue, and listed, in a unified manner, the special administrative measures for the entry of foreign investment.

The Special Administrative Measures (Negative List) for the Access of Foreign Investment (2018) (外商投資准入特別管理措施(負面清單)(2018年版)) (the “**2018 Negative List**”), jointly promulgated by the NDRC and MOFCOM on June 28, 2018, and came into effect on July 28, 2018, stipulate that foreign investors may not invest in prohibited foreign investment industries as provided by the 2018 Negative List, and a foreign investment permission must be obtained prior to investing in other areas that are listed on but not prohibited by the 2018 Negative List. The Catalogue of Industries in which Foreign Investment is Encouraged (2019 Revision) (鼓勵外商投資產業目錄(2019年版)), the 2019 Catalogue, and the Special Administrative Measures (Negative List) for the Access of Foreign Investment (2019) (外商投資准入特別管理措施(負面清單)(2019年版)), the 2019 Negative List, which were issued on June 30, 2019 and came into effect on July 30, 2019, have replaced the 2017 Catalogue and the 2018 Negative List and further reduced restrictions on the foreign investment. According to the 2019 Negative List, medical institutions are limited to equity joint ventures and cooperative joint ventures. The Special Administrative Measures (Negative List) for the Access of Foreign Investment (2020 Revision) (外商投資准入特別管理措施(負面清單)(2020年版)) (the 2020 Negative List), which were issued on June 23, 2020 and came into effect on July 23, 2020, has replaced the 2017 Catalogue, the 2018 Negative List and the 2019 Negative List and further reduced restrictions on the foreign investment. According to the 2020 Negative List, medical institutions are limited to the form of joint ventures.

Interim Administrative Measures on Sino-Foreign Equity Medical Institutions and Sino-Foreign Cooperative Medical Institutions

The Interim Administrative Measures on Sino-Foreign Equity Medical Institutions and Sino-Foreign Cooperative Medical Institutions (中外合資、合作醫療機構管理暫行辦法), which was promulgated by MOH and the Ministry of Foreign Trade and Economic Cooperation on May 15, 2000 and came into effect on July 1, 2000, allow foreign investors to partner with Chinese entities to establish a medical institution in China by means of equity joint venture or cooperative joint venture. Establishment of equity joint venture or cooperative joint venture shall meet certain requirements, including the total investment sum shall not be less than RMB20 million and the equity percentage of the Chinese partner in the joint venture shall not be less than 30%. Establishment of equity joint venture or cooperative medical institutions shall be subject to approval by relevant authorities.

Regulations on Mergers and Acquisitions of Domestic Companies by Foreign Investors

The Provisions on Mergers and Acquisitions of Domestic Enterprises by Foreign Investors (關於外國投資者併購境內企業的規定), jointly promulgated by the MOFCOM, State-owned Asset Supervision and Administration Commission of the State Council, STA, SAIC, CSRC and the SAFE on August 8,

REGULATORY OVERVIEW

2006, came into effect on September 8, 2006 and subsequently amended by the MOFCOM on June 22, 2009, require the domestic companies, enterprises or natural persons, when merging or acquiring domestic companies associated with them in the name of the companies in foreign countries legally established or controlled by them, shall report to the Ministry of Commerce for approval.

REGULATIONS ON THE MANAGEMENT OF LEASE HOUSING

Administrative Measures on Leasing of Commodity Housing

Pursuant to (i) the Law on Administration of Urban Real Estate of the PRC (中華人民共和國城市房地產管理法), promulgated by the SCNPC on July 5, 1994 and was amended on August 27, 2009 and August 26, 2019 and took effect on January 1, 2020, and (ii) the Administrative Measures on Leasing of Commodity Housing (商品房屋租賃管理辦法), promulgated by the Ministry of Housing and Urban-Rural Development on December 1, 2010 and came into effect on February 1, 2011, when leasing premises, the lessor and lessee are required to enter into a written lease contract, containing such provisions as the leasing term, use of the premises, rental and repair liabilities, and other rights and obligations of both parties. Both lessor and the lessee shall complete property leasing registration and filing formalities within 30 days from the execution of the property lease contract with the real estate administration department where the leased property is located. If the lessor and lessee fail to go through the registration and filing procedures, both lessor and lessee may be subject to fines.

LAWS AND REGULATIONS RELATED TO LABOUR PROTECTION

According to the (i) Labour Law of the PRC (中華人民共和國勞動法) effected on January 1, 1995 and last amended on December 29, 2018, (ii) the Labour Contract Law of the PRC (中華人民共和國勞動合同法) effected on January 1, 2008 and amended on December 28, 2012 and took effect on July 1, 2013, and (iii) the Regulations on the Implementation of the Labour Contract Law of the PRC (中華人民共和國勞動合同法實施條例) issued and became effective on September 18, 2008, an employer must enter into a written labour contract with any employees and the wage or salary must not be lower than the local minimum wage or salary. In addition, an employer must establish a system related to occupation health and safety, provide job training for employees to avoid occupational hazards and protect the rights of employees. When an employer recruits any employees, such employer must inform the employees of the work content, work conditions, work place, occupational hazards, safety conditions and labour compensations.

According to (i) the Social Insurance Law of the PRC (中華人民共和國社會保險法), which was implemented on July 1, 2011 and amended on December 29, 2018, (ii) the Provisional Regulations on Collection and Payment of Social Insurance Premiums (社會保險費徵繳暫行條例), issued and effected on January 22, 1999 and revised on March 24, 2019, (iii) the Provisional Measures on Maternity Insurance of Enterprise Employees (企業職工生育保險試行辦法), issued on December 14, 1994 and effected January 1, 1995, (iv) the Regulations on Unemployment Insurance (失業保險條例), issued and effective on January 22, 1999, and (v) the Regulations on Work Related Injuries Insurance (工傷保險條例), effected on January 1, 2004 and amended on December 20, 2010 and took effect on January 1, 2011, an employer must make contributions to a number of social security funds for its employees, including the basic pension insurance, basic medical insurance, maternity insurance, unemployment insurance and work-related injury insurance. According to the Regulations on Management of Housing Provident Fund (住房公積金管理條例), effected on April 3, 1999 and last amended on March 24, 2019, an employer must open a housing fund account with the department responsible for the management of housing fund for its employees and make contributions to such housing fund.

LAWS AND REGULATIONS RELATED TO TAXATION

Enterprise Income Tax

According to (i) the Enterprise Income Tax Law of the PRC (中華人民共和國企業所得稅法) (the “**PRC EIT Law**”), which was promulgated by the National People’s Congress on March 16, 2007 and came into effect on January 1, 2008, and further amended on February 24, 2017 and December 29, 2018, and (ii) the Implementation Regulations on the Enterprise Income Tax Law of the PRC (中華人民共和國企業所得稅法實施條例) (the “**EIT Rules**”), which was promulgated by the State Council on December 6, 2007 and came into effect on January 1, 2008 and revised on April 23, 2019, the tax rate for both domestic-funded enterprises and foreign-invested enterprises is 25%. Under the PRC EIT Law and PRC EIT Rules, enterprises are classified as either “resident enterprises” or “non-resident enterprises”. Enterprises established outside the PRC whose “de facto management bodies” are located in the PRC are considered “resident enterprises” and subject to the uniform 25% PRC EIT rate for their global income. According to the PRC EIT Rules, a “de facto management body” refers to a managing body that exercises, in substance, overall management and control over the manufacture and business, personnel, accounting and assets of an enterprise. Dividends, bonuses and other equity investment proceeds distributed between qualified resident enterprises shall be tax-free income.

The PRC EIT Law provides that a non-resident enterprise refers to an entity established under foreign law whose “de facto management bodies” are not within the PRC but which have an establishment or place of business in the PRC, or which do not have an establishment or place of business in the PRC but have income sourced within the PRC. PRC EIT Rules provide that after January 1, 2008, an income tax rate of 10% will normally be applicable to dividends declared to non-resident enterprise investors which do not have an establishment or place of business in the PRC, or which have such establishment or place of business but the relevant income is not effectively connected with such establishment or place of business, to the extent such dividends are derived from source within the PRC. Pursuant to the Notice on the Several Issues of the Implementation of Dividend Clauses in Tax Treaty (國家稅務總局關於執行稅收協定股息條款有關問題的通知), which was promulgated by the SAT and came into effect on February 20, 2009, the income tax on the dividends may be reduced pursuant to a tax treaty between the PRC and the jurisdiction in which the non-resident enterprise investors is located if the non-resident enterprise investor is determined by the competent PRC tax authority to have satisfied relevant conditions and requirements.

The Announcement on Several Issues Concerning the Enterprise Income Tax on Indirect Transfer of Assets by Non-Resident Enterprises (關於非居民企業間接轉讓財產企業所得稅若干問題的公告) (the “**SAT Circular 7**”) was issued by the SAT on February 3, 2015 and last amended on December 29, 2017, provides comprehensive guidelines heightening the PRC tax authorities’ scrutiny on, indirect transfers by a non-resident enterprise of assets, including assets of organisations and premises in PRC, immovable property in the PRC, equity investments in PRC resident enterprises. On October 17, 2017, the SAT issued the Announcement on Issues Relating to Withholding at Source of Income Tax of Non-resident Enterprises (關於非居民企業所得稅源泉扣繳有關問題的公告), which took effect on December 1, 2017 and amended on June 15, 2018, the balance after deducting the equity net value from the equity transfer income shall be the taxable income amount for equity transfer income.

REGULATORY OVERVIEW

Under the SAT Circular 7 and the Law of the People's Republic of China on the Administration of Tax Collection (中華人民共和國稅收徵收管理法), which was promulgated by the SCNPC on September 4, 1992 and last amended on April 24, 2015, in the case of an indirect transfer, entities or individuals obligated to pay the transfer price to the transferor shall act as withholding agents. If they fail to make withholding or withhold the full amount of tax payable, the transferor of equity shall declare and pay tax to the relevant tax authorities within seven days from the occurrence of tax payment obligation.

Tax Treaties

According to the Treaty on the Avoidance of Double Taxation and Tax Evasion between Mainland and Hong Kong (內地和香港特別行政區關於對所得避免雙重徵稅和防止偷漏稅的安排) (the “**Tax Treaty**”) entered into between Mainland China and HKSAR on August 21, 2006, if the non-PRC parent company of a PRC enterprise is a Hong Kong resident which beneficially owns 25% or more interest in the PRC enterprise, the 10% withholding tax rate applicable under the EIT Law may be lowered to 5% for dividends once approvals have been obtained from the relevant tax authorities.

Pursuant to the Notice on the Several Issues of the Implementation of Dividend Clauses in Tax Treaty (國家稅務總局關於執行稅收協定股息條款有關問題的通知), which was promulgated by the SAT and came into effect on February 20, 2009, the non-resident taxpayer or the withholding agent is required to obtain and keep sufficient documentary evidence proving that the recipient of the dividends meets the relevant requirements for enjoying a lower withholding tax rate under a tax treaty. Pursuant to the Administrative Measures for Tax Treaty Treatment for Non-resident Taxpayers (非居民納稅人享受稅收協定待遇管理辦法), which was promulgated by the SAT on August 27, 2015 and amended on June 15, 2018, and further replaced by the Administrative Measures on Non-resident Taxpayers Enjoying Treaty Benefits (國家稅務總局關於發佈《非居民納稅人享受協定待遇管理辦法》的公告), which took effect on January 1, 2020, any nonresident taxpayer satisfying the conditions for enjoying the tax treaty treatment may be entitled to the tax treaty treatment on its own when filing a tax return or making a withholding declaration through a withholding agent, subject to the subsequent administration by the tax authorities.

The Announcement of the State Administration of Taxation on Issues Relating to “Beneficial Owner” in Tax Treaties (國家稅務總局關於稅收協定中“受益所有人”有關問題的公告) issued by the SAT on February 3, 2018 and came into effect on April 1, 2018, provides that the “beneficial owner” shall mean a person who has the ownership and control over the income and the rights and property from which the income is derived. When an individual who is a resident of the treaty counterparty derive dividend income from the PRC, the individual may be determined as a “beneficial owner”.

Value-Added Tax

The Interim Provisions on Value-added Tax of the PRC (中華人民共和國增值稅暫行條例), which was promulgated by the State Council on December 13, 1993, came into effect on January 1, 1994, and last amended on November 19, 2017, and the Implementing Rules of the Interim Provisions on Value-added Tax of the PRC (中華人民共和國增值稅暫行條例實施細則), promulgated by the MOF and became effective on December 25, 1993, and last amended on October 28, 2011 and took effect on November 1, 2011, set out that all taxpayers selling goods or providing processing, repairing or replacement services and importing goods in the PRC shall pay a value-added tax. The tax rate for taxpayers engaging in the sales of goods, labour services, tangible movables lease services or the importation of goods shall be 17% unless otherwise stipulated.

REGULATORY OVERVIEW

According to the Trial Scheme for the Conversion of Business Tax to Value-added Tax (營業稅改徵增值稅試點方案), which was promulgated by the MOF and the SAT on November 16, 2011, the government launched gradual taxation reforms starting from January 1, 2012, whereby it collected value-added tax in lieu of business tax on a trial basis in regions and industries showing strong economic performance, such as transportation and certain modern service industries.

Furthermore, according to the Notice of the Ministry of Finance and the State Administration of Taxation on Overall Implementation of the Pilot Program of Replacing Business Tax with Value-added Tax (財政部、國家稅務總局關於全面推開營業稅改徵增值稅試點的通知), all business tax payers in consumer service industry shall pay value-added tax in lieu of business tax from May 1, 2016 and the medical service provided by the medical institution could be the exempted from value-added tax.

REGULATIONS RELATED TO M&A

According to the Provisions on the Merger or Acquisition of Domestic Enterprises by Foreign Investors (關於外國投資者並購境內企業的規定) (the “**M&A Rules**”), which was jointly issued by the MOFCOM, the State-owned Assets Supervision and Administration Commission of the State Council, the STA, the SAIC, the CSRC and the SAFE, on August 8, 2006, came into effect on September 8, 2006 and subsequently amended by the MOFCOM on June 22, 2009, among other things, (i) the purchase of an equity interest or subscription to the increase in the registered capital of non-foreign-invested enterprises, (ii) the establishment of foreign-invested enterprises to purchase and operate the assets of non-foreign-invested enterprises, or (iii) the purchase of the assets of non-foreign-invested enterprises and the use of such assets to establish foreign-invested enterprises to operate such assets, in each case, by foreign investors shall be subject to the M&A Rules. Particularly, application shall be made for examination and approval of the acquisition of any company in China affiliating to a domestic company, enterprise or natural person, which is made in the name of an oversea company established or controlled by such domestic company, enterprise or natural person.

LAWS AND REGULATIONS OVER FOREIGN EXCHANGE

The Regulations on the Control of Foreign Exchange of the PRC (中華人民共和國外匯管理條例), which was promulgated by the State Council on January 29, 1996, became effective on April 1, 1996 and was last amended on August 5, 2008, set out that foreign exchange receipts of domestic institutions or individuals may be remitted back to the PRC or deposited abroad and that SAFE shall specify the conditions relating to the requirements, time periods and other aspects of such remittance and deposits in accordance with the international receipts, payments status and requirements of foreign exchange administration. Domestic institutions or individuals that make direct investments abroad or are engaged in the distribution or sale of valuable securities or derivative products overseas shall register according to SAFE regulations. Such institutions or individuals subject to prior approval or record-filing with other competent authority shall complete the required approval or record-filing prior to foreign exchange registration. The exchange rate for RMB follows a managed floating exchange rate system based on market demand and supply.

The Regulations on the Administration of the Settlement, Sale and Payment of Foreign Exchange (結匯、售匯及付匯管理規定), which was promulgated by the People's Bank of China on June 20, 1996 and came into effect on July 1, 1996, provides that foreign exchange earnings under the current account of FIEs may be retained to the fullest extent specified by the relevant foreign exchange bureau. Any portion in excess of such amount shall be sold to a designated foreign exchange bank or through a foreign exchange swap centre.

REGULATORY OVERVIEW

On March 30, 2015, the SAFE promulgated the Notice on Reforming the Mode of Management of Settlement of Foreign Exchange Capital of Foreign-Funded Enterprises (關於改革外商投資企業外匯資本金結匯管理方式的通知) (the “**Circular 19**”), which came into effect on June 1, 2015. According to Circular 19, the foreign exchange capital of FIEs shall be subject to the discretionary foreign exchange settlement (the “**Discretional Foreign Exchange Settlement**”) and its proportion is temporarily determined as 100%. Furthermore, Circular 19 stipulates that the use of capital by FIEs shall follow the principles of authenticity and self-use within the business scope of enterprises. The capital of an FIE and capital in RMB obtained by the FIE from foreign exchange settlement shall not be used for certain purposes as prescribed in the Circular 19. On June 9, 2016, the SAFE promulgated the Circular on Reforming and Regulating Policies on the Management of the Settlement of Foreign Exchange of Capital Accounts (關於改革和規範資本項目結匯管理政策的通知) (the “**SAFE Circular 16**”). The SAFE Circular 16 unifies policies on discretionary settlement of foreign exchange receipts under capital accounts of domestic institutions.

Circular of the State Administration of Foreign Exchange on Issues concerning Foreign Exchange Administration over the Overseas Investment and Financing and Round-trip Investment by Domestic Residents via Special Purpose Vehicles (國家外匯管理局關於境內居民通過特殊目的公司境外投融資及返程投資外匯管理有關問題的通知), which was issued and effected on July 4, 2014, provides that domestic residents shall register with the SAFE and its local branches in connection with their direct establishment or indirect control of an offshore entity, for the purpose of overseas investment and financing, with assets or equity interests of onshore companies or offshore assets or interests held by the domestic residents, before contributing the onshore or offshore legal assets or interests to the offshore entity. Following the initial registration, any change of basic information such as individual shareholder, name and term of operation or upon capital increase or deduction, share transfer or swap, merger or division and other significant change, shall report to the SAFE for foreign exchange alteration of the registration formality for offshore investment in time.

The Notice on Further Simplifying and Improving Foreign Exchange Administration Policies in Respect of Direct Investment (關於進一步簡化和改進直接投資外匯管理政策的通知), which was issued on February 13, 2015, effected on June 1, 2015 and partially abolished in December 30, 2019, provides that PRC residents may register with qualified banks instead of SAFE in connection with their establishment or control of an offshore entity established for the purpose of overseas investment or financing. The SAFE and its branches shall implement indirect supervision over foreign exchange registration of direct investment via the banks.

LAWS AND REGULATIONS RELATED TO DIVIDEND DISTRIBUTION

The principal regulation governing distribution of dividends of foreign-invested enterprises is PRC Company Law (中華人民共和國公司法). Under PRC Company Law, wholly foreign-owned enterprises in China may pay dividends only out of their accumulated after-tax profits, if any, determined in accordance with PRC accounting standards and regulations. In addition, wholly foreign-owned enterprises in China are required to allocate at least 10% of their respective accumulated profits each year, if any, to fund statutory reserve funds, unless the statutory reserve funds have reached 50% of the registered capital of the enterprises. Wholly foreign-owned enterprises may allocate a portion of their after tax profits based on PRC accounting standards to fund their discretionary reserve funds after they have drawn statutory reserve funds from the after-tax profits, these reserve funds are not distributable as cash dividends.

LAWS AND REGULATIONS RELATED TO INTERNET INFORMATION SECURITY AND PRIVACY PROTECTION

On November 7, 2016, the SCNPC promulgated the Cybersecurity Law of the PRC (中華人民共和國網絡安全法), which became effective on June 1, 2017, requires network operators to perform certain functions related to cyber security protection and strengthen the network information management. For instance, under the Cybersecurity Law, network operators of key information infrastructure generally shall, during their operations in the PRC, store the personal information and important data collected and produced within the territory of the PRC. When collecting and using personal information, in accordance with the Cybersecurity Law, network operators shall abide by the “lawful, justifiable and necessary” principles. The network operator shall collect and use personal information by announcing rules for collection and use, expressly notify the purpose, methods and scope of such collection and use, and obtain the consent of the person whose personal information is to be collected. The network operator shall neither collect the personal information unrelated to the services they provide, nor collect or use personal information in violation of the provisions of laws and administrative regulations or the agreements with such persons and shall process the personal information they store in accordance with the provisions of laws and administrative regulations and agreements reached with such persons. Network operator shall not disclose, tamper with, or destroy personal information that it has collected, or disclose such information to others without prior consent of the person whose personal information has been collected, unless such information has been processed to prevent specific person from being identified and such information from being restored. Each individual is entitled to require a network operator to delete his or her personal information if he or she finds that collection and use of such information by such operator violate the laws, administrative regulations, or the agreement by and between such operator and such individual; and is entitled to require any network operator to make corrections if he or she finds errors in such information collected and stored by such operator. Such operator shall take measures to delete the information or correct the error. Any individual or organization may neither acquire personal information by stealing or through other illegal ways, nor illegally sell or provide personal information to others.

On June 10, 2021, the SCNPC issued the Data Security Law of the PRC (中華人民共和國數據安全法) (the “**Data Security Law**”), which became effective on September 1, 2021. The Data Security Law protects the rights and interests of individuals and organizations relating to data, encourages the lawful, reasonable and effective use of data, guarantees the orderly and free flow of data in accordance with the law, and promotes the development of the digital economy with data as a key element, which provides that China shall establish a data classification and grading protection system and data security review system, under which data processing activities that affect or may affect national security shall be reviewed for national security. A decision on security review made in accordance with the law shall be final. Processors of data shall establish a sound data security management system throughout the whole process, organize data security education and training, and take corresponding technical measures and other necessary measures to ensure data security, in accordance with the provisions of laws and regulations. To carry out data processing activities by making use of the Internet or any other information network, the aforesaid obligations for data security protection shall be performed on the basis of the graded protection system for cyber security. Processors of data shall clearly specify responsible personnel and management departments for data security and fully implement data security protection responsibilities. Processing data activities shall strengthen risk monitoring, and where processors discover risks such as data security flaws and vulnerabilities, immediately adopt remedial measures; when data security incidents occur, processors shall immediately take solutions, notify the users as required and report the matter to the relevant competent authorities. Any organization or individual

REGULATORY OVERVIEW

collecting data shall adopt lawful and proper methods and shall not steal data or obtain the data by other illegal means. Relevant authorities will establish the measures for the cross-border transfer of import data. If any company violates the Data Security Law of the PRC to provide important data outside China, such company may be punished by administration sanctions, including penalties, fines, and/or may suspension of relevant business or revocation of the business license. As a processor of data, the Company shall implement the relevant data security management system and protection obligations in the entire process of the business operations and new product development and be in compliance with higher requirements on data security protection from multiple perspectives under the Data Security Law of the PRC and require partners to abide by the requirements accordingly.

On July 30, 2021, the State Council Promulgated the Regulations on Security Protection of Critical Information Infrastructure (關鍵信息基礎設施安全保護條例) (the “**CII Regulation**”), which became effective on September 1, 2021. According to the CII regulation, a critical information infrastructure, or CII, refers to an important network facility or information system in important industries and fields such as public communication and information services, energy, transportation, water conservancy, finance, public services, e-government, national defense technology industry, etc., and CII also refers to other important network facility and information system that may seriously endanger national security, national economy and the people’s livelihood, and public interests in the event of damage, loss of function, or data leakage. The competent departments and supervision and management departments of the aforementioned important industries and fields are the departments responsible for the CII security protection work. They will be responsible for organizing the identification of CII in this industry or field in accordance with the identification rules, promptly notify the CII operators of the identification results, and notify the public security department of the State Council.

On July 6, 2021, the General Office of the Communist Party of China Central Committee and the General Office of the State Council also jointly issue the Opinions on Strictly Combating Illegal Securities Activities in Accordance with the Law (關於依法從嚴打擊證券違法活動的意見) (the “**Combating Illegal Securities Activities Measures**”), which stressed on “improving laws and regulations on data security, cross-border data flow and management of confidential information, speeding up the revisions to regulations on strengthening the confidentiality and document management of securities issuance and listing outside the mainland of the PRC (境外上市) to increase the accountability of entities listed outside the mainland of the PRC to information security, and enhancing standardized management of mechanism and procedure for cross-border data transfer, enhancing the cooperation of cross-border audit supervision”.

On July 10, 2021, the Office of the Central Cyberspace Affairs Commission (“**CAC**”), jointly with the relevant authorities, published the Draft Cybersecurity Review Measures, which stipulate that if an operator has collected personal information of over one million users and intends to be listed in a foreign country, it must be subject to the cybersecurity review.

REGULATORY OVERVIEW

On November 14, 2021, the CAC, jointly with the relevant authorities, published the Administrative Regulations on Internet Data Security (Draft for Comment) (“**Draft Internet Data Security Regulations**”). Pursuant to the Draft Internet Data Security Regulations, data processors who carry out the following activities shall apply for a cybersecurity review in accordance with relevant regulations:

1. the merger, reorganization or division of internet platform operators who have gathered a large number of data resources related to national security, economic development and public interest, which affects or may affect national security;
2. the proposed listing in a foreign country of data processor who processes personal information of over one million people;
3. the proposed listing in Hong Kong of data processor which affects or may affect national security; and
4. other data processing activities that affect or may affect national security.

As advised by our PRC Legal Adviser, we believe that the above-mentioned regulatory changes will not have a material adverse effect on our business operations on the following basis:

1. The Combating Illegal Securities Activities Measures stress on strengthening standardized management of mechanism and procedure for the cross-border data transfer. Our relevant operating data are stored in servers located in the PRC and does not involve cross-border data transmission.
2. We have formulated strict policies such as Information Management Policies, Data Privacy Protection Policies and Data Analysis Management Policies to govern the collection, handling, storage, retrieval, and access of our customer’s personal data and medical records. See “Business — Data Privacy and Protection.” As of the Latest Practicable Date, we have not received any fines or other penalties in relation to cybersecurity or data protection.
3. The Combating Illegal Securities Activities Measures emphasize strengthening the supervision of China concept stocks (中概股), however, as of the Latest Practicable Date, no specific rules or regulations has been formally adopted. The supervision scope and measures remain unclear.
4. As a medical group specialized in providing hair-related healthcare services, we only collect limited data of our customers primarily for communications, treatments planning and delivery of our services and products. Our directors believe that our proposed listing in Hong Kong will not affect national security. In view of the above and considering the nature of our business and scope of our collection and usage of data, our PRC Legal Adviser is of the view that the risk of us being required to undertake a cybersecurity review is low.

REGULATORY OVERVIEW

However, our PRC Legal Adviser also advised that since the Draft Cybersecurity Review Measures and the Draft Internet Data Security Regulations have not been formally promulgated and no specific rules and regulations have been adopted under the Combating Illegal Securities Activities Measures, there remains substantial uncertainties regarding the enactment timetable, interpretation, and application. Accordingly, if a final version of the Draft Cybersecurity Review Measures and the Draft Internet Data Security Regulations are adopted, we may be subject to review when conducting data processing activities. We (including our Contractual Arrangements) may also be subject to more severe supervision once the specific rules or regulation are adopted under the Combating Illegal Securities Activities Measures. we will actively monitor policy changes, consult our PRC Legal Adviser regularly, and review and update our internal measures and standards on cybersecurity from time to time to ensure strict compliance with all applicable laws and regulations.

HISTORY, DEVELOPMENT AND CORPORATE STRUCTURE

OVERVIEW

Mr. Zhang, our founder, started hair transplant business in Beijing since 2005. Mr. Zhang recognized the growth potential of the hair transplant business in China and embarked upon establishing independent hair transplant brand. In 2010, Mr. Zhang first established hair transplant business with the brand name Yonghe (“雍禾”). After years of dedication and commitment, we have developed our hair transplant business to a market leading position. As of the Latest Practicable Date, we operated 53 clinics in 52 cities nationwide.

In preparation for the Listing, our Group underwent the Reorganization to streamline our shareholding structure. Our Company was incorporated as an exempted company with limited liability in the Cayman Islands on September 17, 2020 and is the holding Company of our Group. For details of our corporate restructuring, see “— Reorganization” in this section.

BUSINESS MILESTONES

The following table sets forth certain key business development milestones of our Group:

Year	Milestones
2005	Mr. Zhang started hair transplant business in Beijing
2010	Mr. Zhang first established hair transplant business with the brand name Yonghe (“雍禾”) <p>We formulated China’s first hair transplant industry standard which was being reported by CCTV and became the first transplant service provider in China that had obtained the ISO certification</p>
2013	We started to map out a nationwide business coverage and dedicated to own and operate all chain hospitals by ourselves
2014	We pioneered in entering into five service quality assurance agreements with each patient before hair transplant surgeries to enhance patient experience <p>We started to live-stream the whole hair transplant procedures to promote the transparency of the industry</p>
2017	CYH and Panmao Shanghai invested in our Group and became our Controlling Shareholders <p>We introduced high-end service team, named “Yongxiang (雍享)”, to provide personalized hair transplant services</p> <p>We have 22 clinics in operation at the end of the period</p>

HISTORY, DEVELOPMENT AND CORPORATE STRUCTURE

Year	Milestones
2018	<p>We initiated a charity project “Yonghe Caring for Hair Loss Program” (雍禾脫髮愛計劃)</p> <p>We were approved as national high-tech enterprise</p> <p>We have 30 clinics in operation at the end of the period</p>
2019	We have 37 clinics in operation at the end of the period
2020	<p>We strategically cooperated with Ping An Property & Casualty to launch hair transplant insurance, the first insurance product in industry</p> <p>We have 48 clinics in operation at the end of the period</p>
2021	We have 53 clinics in total as of the Latest Practicable Date

CORPORATE DEVELOPMENT

The following sets forth the major corporate history and shareholding changes of our Group.

Beijing Haiyouyou

Our business operations in China were primarily conducted through our principal subsidiary, Beijing Haiyouyou. The following sets forth the major corporate history and shareholding changes of Beijing Haiyouyou.

1. Incorporation of Beijing Haiyouyou in 2015

Beijing Haiyouyou was established by Mr. LAN Feng and Mr. MA Liwei, both are Independent Third Parties, in the PRC on September 2, 2015 with an initial registered capital of RMB10,000,000. The Shareholding structure of Beijing Haiyouyou upon its incorporation was as set forth below:

Name of Shareholders	Share Capital (RMB)	Shareholding Percentage
Mr. LAN Feng (蘭楓)	9,900,000	99%
Mr. MA Liwei (馬立偉)	100,000	1%
Total	10,000,000	100%

2. *Acquisition by Beijing Xunyi in 2016*

On December 13, 2016, Beijing Xunyi acquired 100% of equity interests in Beijing Haiyouyou from Mr. LAN Feng and Mr. MA Liwei at a nominal consideration. The consideration of the equity transfer was determined based on arm's length negotiations among the parties taking into consideration the dormant status of Beijing Haiyouyou at the time of acquisition. The equity transfer was properly and legally completed on December 14, 2016. Upon completion of the equity transfer, Beijing Haiyouyou was wholly owned by Beijing Xunyi.

Beijing Xunyi is a company incorporated in the PRC on November 16, 2016 with a registered capital of RMB100,000. At the time of its establishment, Beijing Xunyi was owned by Mr. ZHANG Hui, brother of Mr. Zhang, as to 85% and by Mr. Zhang as to 15%. Pursuant to a capital contribution transfer agreement on June 28, 2018 between Mr. Zhang and Mr. ZHANG Hui, and as of the Latest Practicable Date, Beijing Xunyi is owned by Mr. Zhang as to 85% and by Mr. ZHANG Hui as to 15%.

3. *Capital Increase and Share transfers in 2017*

In June 2017, Beijing Xunyi, CYH, Panxin Shanghai, Xizang Yonghe and Beijing Haiyouyou entered into a share capital increase and subscription agreement, pursuant to which, (i) CYH subscribed for 6.625% of the enlarged share capital of Beijing Haiyouyou at a consideration of RMB33,125,000; (ii) Panxin Shanghai subscribed for 6.625% of the enlarged share capital of Beijing Haiyouyou at a consideration of RMB33,125,000; (iii) Xizang Yonghe subscribed for 1.75% of the enlarged share capital of Beijing Haiyouyou at a consideration of RMB8,750,000. The share capital increase was properly and legally completed on July 27, 2017. The consideration for the above share subscription was determined at arm's length negotiation between the parties with reference to the earnings and growth prospect of Beijing Haiyouyou. Upon completion of the capital increase, the registered share capital of Beijing Haiyouyou increased from RMB10,000,000 to RMB11,764,706, and Beijing Haiyouyou was owned by Beijing Xunyi, CYH, Panxin Shanghai and Xizang Yonghe (西藏永禾) as to 85%, 6.625%, 6.625% and 1.75%, respectively.

For detailed information of CYH, see "Substantial Shareholders" in this prospectus. The general partner of Panxin Shanghai is Shanghai Panxin Mezzanine Investment Management Company Limited (上海磐信夾層投資管理有限公司) ("**Shanghai Panxin Mezzanine Investment Management**"), a company incorporated in the PRC with limited liability on July 12, 2011 and wholly-owned by CITIC Private Equity Funds Management Co., Ltd. (中信產業投資基金管理有限公司) ("**CITIC PE**"). For detailed information of CITIC PE, see "Substantial Shareholders" in this prospectus. Xizang Yonghe is a limited partnership incorporated in the PRC on December 30, 2016. The general partner of Xizang Yonghe was Xizang Ruizhe Investment Management Company Limited (西藏瑞哲投資管理有限公司), which is wholly owned by Shanghai Panxin Mezzanine Investment Management.

In August 2017, Beijing Xunyi entered into a share transfer agreement with Wulian Yuhui Network Technology Partnership (Limited Partnership) (五蓮玉輝網絡科技合夥企業(有限合夥)) ("**Wulian Yuhui**"), a limited partnership established and controlled by Mr. Zhang, pursuant to which, Beijing Xunyi transferred 45% of the shareholding in Beijing Haiyouyou to Wulian Yuhui at nil consideration. On the same date, Panxin Shanghai entered into a share transfer agreement with Panmao Shanghai, pursuant to which Panxin Shanghai transferred its entire shareholding in Beijing Haiyouyou to Panmao Shanghai at nil consideration. The general partner of Panmao Shanghai is Shanghai Pannuo

HISTORY, DEVELOPMENT AND CORPORATE STRUCTURE

Corporate Management Service Company Limited (上海磐諾企業管理服務有限公司) which is wholly-owned by CITIC PE. The share transfers were properly and legally completed on September 22, 2017. Upon completion of the share transfers, Beijing Haiyouyou was owned by Beijing Xunyi, Wulian Yuhui, CYH, Panmao Shanghai and Xizang Yonghe as to 40%, 45%, 6.625%, 6.625% and 1.75%, respectively.

On October 25, 2017, Wulian Yuhui, CYH, Panmao Shanghai and Xizang Yonghe entered into a share transfer agreement, pursuant to which, Wulian Yuhui (i) transferred 19.875% of the shareholding in Beijing Haiyouyou to CYH at a consideration of RMB109,312,500, (ii) transferred 19.875% of the shareholding in Beijing Haiyouyou to Panmao Shanghai at a consideration of RMB109,312,500, (iii) transferred 5.25% of the shareholding in Beijing Haiyouyou to Xizang Yonghe at a consideration of RMB28,875,000. The share transfers were properly and legally completed on October 30, 2017. The consideration for the above share transfers was determined at arm's length negotiation between the parties with reference to the earnings and growth prospect of Beijing Haiyouyou. The Shareholding structure of Beijing Haiyouyou upon completion of the above share transfers was as set forth below:


Name of Shareholders	Share Capital	Shareholding Percentage
	(RMB)	
Beijing Xunyi (北京迅翼)	4,705,882	40%
CYH	3,117,647	26.5%
Panmao Shanghai (磐茂上海)	3,117,647	26.5%
Xizang Yonghe (西藏永禾)	823,530	7%
Total	11,764,706	100%

4. Share Transfers in 2020

Xizang Yonghe changed its name to Yonghe Yuhui (永禾玉輝) on January 10, 2020. In June 2020, Yonghe Yuhui and Hu&Yan Healthcare Investment Limited (“**Hu&Yan**”) entered into a share transfer agreement, pursuant to which, Yonghe Yuhui transferred 5.349% of the shareholding in Beijing Haiyouyou to Hu&Yan at a consideration of RMB31,625,000. The share transfers was properly and legally completed on July 10, 2020. The consideration for the share transfer was determined at arm's length negotiation between the parties with reference to earning and growth prospects of Beijing Haiyouyou. Upon completion of the share transfers, Beijing Haiyouyou was owned by Beijing Xunyi, CYH, Panmao Shanghai, Hu&Yan and Yonghe Yuhui as to 40%, 26.5%, 26.5%, 5.349% and 1.651%, respectively. Hu&Yan is a company incorporated in Hong Kong and wholly-owned by Mr. HU Tenghe, an employee of Citron PE Investment (Hong Kong) Limited and an Independent Third Party.

HISTORY, DEVELOPMENT AND CORPORATE STRUCTURE

A simplified shareholding structure of Beijing Haiyouyou upon completion of the above shareholding changes is set out as below:



See “— Reorganization” in this section for the shareholding changes of Beijing Haiyouyou in preparation for the Listing.

Yonghe Investment

Yonghe Investment was established in the PRC on September 30, 2015 with an initial registered capital of RMB2,000,000. Upon its establishment, Yonghe Investment was owned as to 85% by Mr. Zhang and 15% by Mr. ZHANG Hui. All of our hair transplant medical institutions in mainland China were wholly-owned by Yonghe Investment before Reorganization.

On October 3, 2017, Mr. Zhang and Mr. ZHANG Hui transferred their entire equity interest in Yonghe Investment to Beijing Haiyouyou at nil consideration. On June 5, 2018, the registered capital of Yonghe Investment was increased to RMB10,000,000 by contribution of RMB8,000,000 by Beijing Haiyouyou and such registered capital was fully paid up on June 15, 2018.


In preparation for the Contractual Arrangement, Beijing Xunyi contributed RMB4,285,714.3 to the registered share capital of Yonghe Investment. Upon completion of the share subscription, Yonghe Investment was owned by Beijing Haiyouyou and Beijing Xunyi as to 70% and 30%, respectively. See “— Reorganization — Onshore Reorganization — Step 1. Onshore Shareholding Adjustments” in this section for details.

HISTORY, DEVELOPMENT AND CORPORATE STRUCTURE

REORGANIZATION

Shareholding Structure before Reorganization

The following chart sets forth our Group's simplified corporate and shareholding structure immediately prior to the commencement of the Reorganization.



Onshore Reorganizations

To ensure that the Contractual Arrangements are narrowly tailored in accordance with the requirements of the Stock Exchange and to streamline our corporate structure, our Group underwent the following onshore reorganization.

Step 1. Onshore Shareholding Adjustments

Transfer of equity interests in certain entities by Yonghe Investment to Beijing Haiyouyou

Yonghe Investment transferred its entire equity interests in the entities which does not engage in restricted or prohibited foreign investment business pursuant to the applicable PRC laws and regulations to Beijing Haiyouyou or its wholly owned subsidiaries. Specifically, Yonghe Investment transferred (i) the 100% equity interests it owned in Beijing Maoduoduo to Beijing Yunyihui on October 22, 2020, for a consideration of RMB5 million, being the registered share capital of Beijing Maoduoduo; (ii) the 100% equity interests it owned in Beijing Yunmao to Yonghe Research Laboratory on November 3, 2020, for a consideration of RMB5 million, being the registered share capital of Beijing Yunmao; (iii) the 100% equity interests it owned in Yonghe Research Laboratory to Beijing Haiyouyou on December 7, 2020, for a consideration of RMB500,000, being the registered share capital of Yonghe Research Laboratory; (iv) the 100% equity interests it owned in Jinan Yongxin Medical Technology Company Limited (濟南雍信醫療科技有限公司) to Yonghe Research Laboratory on March 12, 2021, for a nil consideration; and (v) the 100% equity interests it owned in Chengdu Yonghe to Beijing Haiyouyou on November 17, 2020 for a consideration of RMB500,000, being the registered share capital of Chengdu Yonghe.

HISTORY, DEVELOPMENT AND CORPORATE STRUCTURE

Share Capital Increase in Yonghe Investment and Chengdu Yonghe by Beijing Xunyi

Before the share capital increase, Yonghe Investment was wholly-owned by Beijing Haiyouyou. On November 27, 2020, Beijing Xunyi contributed RMB4,285,714.3 to Yonghe Investment, resulting in the increase in the registered capital of Yonghe Investment to RMB14,285,714.3. Immediately after such capital contribution, Yonghe Investment was held as to 70% by Beijing Haiyouyou and as to 30% by Beijing Xunyi. The consideration for such capital contribution was fully paid up on June 10, 2021.


Before the share capital increase, Chengdu Yonghe was wholly-owned by Beijing Haiyouyou. On November 30, 2020, Beijing Xunyi contributed RMB55,556 to Chengdu Yonghe, resulting in the increase in the registered capital of Chengdu Yonghe to RMB555,556. Immediately after such capital contribution, Chengdu Yonghe was held as to 90% by Beijing Haiyouyou and as to 10% by Beijing Xunyi. The consideration for such capital contribution was fully paid up on June 10, 2021.

Step 2. Contractual Arrangements

On January 6, 2021, Beijing Haiyouyou, Yonghe Investment (together with all the medical institutions it owned), Chengdu Yonghe, Beijing Xunyi, Mr. Zhang and Mr. ZHANG Hui entered into various agreements constituting the Contractual Arrangements, pursuant to which substantially all economic benefits arising from the business of our medical institutions are transferred to Beijing Haiyouyou to the extent permitted under PRC laws and regulations by means of the service fees payable to Beijing Haiyouyou. Contractual Arrangement will be reproduced in relation to new Medical Institutions established after the date of the above mentioned agreements. See “Contractual Arrangements” in this prospectus for further details of the Contractual Arrangements.

HISTORY, DEVELOPMENT AND CORPORATE STRUCTURE

Upon completion of the above shareholding adjustments, the onshore shareholding structure of our Group is as below:



Notes:

1. Mr. Zhang and Mr. Zhang Hui are the Registered Shareholders.
2. “→” denotes direct legal and beneficial ownership in the equity interest.
3. “↔” denotes contractual relationship.
4. “---” denotes the entities that are subject to the Contractual Arrangements.

Offshore Reorganizations

Step 1. Incorporation of Our Holding Structure

Incorporation of our Company

Our Company was incorporated in the Cayman Islands on September 17, 2020 as an exempted company with limited liability as the holding company of our Group. The initial authorized share capital of our Company was US\$50,000 divided into 5,000,000,000 Shares with a par value of US\$0.00001 each. Upon incorporation, one Share of par value US\$0.00001 was allotted and issued to Sertus Nominees (Cayman) Limited, and was subsequently transferred to ZhangYu Hair Service Holdings Limited, a special purpose vehicle incorporated in the BVI and wholly owned by Mr. Zhang.

HISTORY, DEVELOPMENT AND CORPORATE STRUCTURE

Share Subscription by Shareholders of Beijing Haiyouyou

On September 17, 2020, ultimate beneficial owners of Beijing Xunyi and Yonghe Yuhui, who are individual persons, through their respective special purpose vehicles incorporated in the BVI subscribed Shares in our Company in proportion to their ultimate shareholdings in Beijing Haiyouyou respectively. On January 29, 2021, Panmao Shanghai through Yonghe Hair Service Holdings Limited (“**Yonghe Hair Service**”), its special purpose vehicle incorporated in BVI, CYH and Hu&Yan subscribed Shares in our Company in proportion to their shareholdings in Beijing Haiyouyou respectively. Details of the Share subscriptions to the relevant Shareholders are summarized below:

<u>Name of Shareholder</u>	<u>Beneficial Owner</u>	<u>Number of Shares Subscribed</u>	<u>Consideration Paid</u>
ZhangYu Hair Service Holdings Limited (“ ZhangYu Hair Service ”)	ZHANG Yu (張玉)	34,000,000	par value of the Shares
ZhangHui Hair Service Holdings Limited (“ ZhangHui Hair Service ”)	ZHANG Hui (張輝)	6,000,000	par value of the Shares
NieLei Hair Service Holdings Limited (“ NieLei Hair Service ”)	NIE Lei (聶磊)	1,090,000	par value of the Shares
JiaQi Hair Service Holdings Limited (“ JiaQi Hair Service ”)	GENG Jiaqi (耿嘉琦)	190,000	par value of the Shares
SiQi Hair Service Holdings Limited (“ SiQi Hair Service ”)	DUAN Siqi (段斯琪)	190,000	par value of the Shares
TanXu Hair Service Holdings Limited (“ TanXu Hair Service ”)	TAN Xu (譚旭)	90,000	par value of the Shares
LinFeng Hair Service Holdings Limited (“ LinFeng Hair Service ”)	SONG Linfeng (宋林峰)	90,000	par value of the Shares
Yonghe Hair Service	Panmao Shanghai	26,500,000	RMB70,235,414.5
CYH	CYH	26,500,000	Equity interests in Beijing Haiyouyou through share exchange
Hu&Yan ^(note)	HU Tenghe (胡騰鶴)	5,350,000	Equity interests in Beijing Haiyouyou through share exchange
Total		100,000,000	

Note: Hu&Yan transferred its entire shareholdings in our Company at nil consideration to Ever Horizon Developments Limited (“**Ever Horizon**”), a special purpose vehicle incorporated in the BVI and is also wholly owned by HU Tenghe on February 1, 2021.

HISTORY, DEVELOPMENT AND CORPORATE STRUCTURE

The consideration for the subscribed Shares were determined after arm's length negotiations between the parties. The cash considerations for the above share subscriptions was fully settled on June 4, 2021, and the shares exchanges were completed on May 10, 2021.

Incorporation of the BVI Subsidiary

Yonghe Management Consulting Co., Ltd. (“**Yonghe Management Consulting**”) was incorporated in the BVI on September 25, 2020 and is wholly-owned by our Company.

Incorporation of the Hong Kong Subsidiary

Yonghe Medical Holdings Limited (“**Yonghe Medical Holdings**”) was incorporated in Hong Kong on October 9, 2020 with limited liability and is wholly-owned by Yonghe Management Consulting.

Step 2. Share Transfer to Mr. Zhang and Employee Incentive Scheme

In order to incentivize our founder and key employees, the then Shareholders (other than Mr. Zhang and Mr. ZHANG Hui) agreed to transfer a total of 8% of the then issued Shares to Mr. Zhang and our employee incentive platform, Zhirui Technology Holdings Limited. On April 23, 2021, the then Shareholders (other than Mr. Zhang and Mr. ZHANG Hui) of our Company (the “**Transferors**”) transferred in total of 5,000,000 and 3,000,000 Shares (representing 5% and 3% of the then issued Shares in our Company, respectively) to Yunuo Technology Holdings Limited and Zhirui Technology Holdings Limited, at a consideration of RMB69,427,083 and RMB41,656,250, respectively. The Shares transferred was in proportion to the Transferors’ respective shareholding in our Company.

Details of the Share transfers to Yunuo Technology Holdings Limited are summarized below:

Transferor	NieLei Hair Service	JiaQi Hair Service	SiQi Hair Service	TanXu Hair Service	LinFeng Hair Service	Ever Horizon	Yonghe Hair Service	CYH
Shares transferred	90,834	15,833	15,833	7,500	7,500	445,834	2,208,333	2,208,333
Approximate share percentage in the Company	0.08%	0.02%	0.02%	0.01%	0.01%	0.44%	2.21%	2.21%
Consideration (RMB)	1,261,268	219,848	219,848	104,141	104,141	6,190,591	30,663,624	30,663,624
Transferee	Yunuo Technology Holdings Limited							
Completion date	April 23, 2021							

HISTORY, DEVELOPMENT AND CORPORATE STRUCTURE

Details of the Share transfers to Zhirui Technology Holdings Limited are summarized below:

Transferor	NieLei Hair Service	JiaQi Hair Service	SiQi Hair Service	TanXu Hair Service	LinFeng Hair Service	Ever Horizon	Yonghe Hair Service	CYH
Shares transferred	54,500	9,500	9,500	4,500	4,500	267,500	1,325,000	1,325,000
Approximate share percentage in the Company	0.0545%	0.0095%	0.0095%	0.0045%	0.0045%	0.2675%	1.325%	1.325%
Consideration (RMB)	756,756	131,911	131,911	62,484	62,484	3,714,350	18,398,177	18,398,177
Transferee	Zhirui Technology Holdings Limited							
Completion date	April 23, 2021							

Yunuo Technology Holdings Limited is incorporated in the British Virgin Islands on January 15, 2021 and is wholly owned by Mr. Zhang. Zhirui Technology Holdings Limited is our employee incentive platform. For detailed information of Zhirui Technology Holdings Limited, see “— Employee Incentive Scheme” in this section.

The considerations for the above Share transfers were determined after arm’s length negotiations between the parties with reference to the valuation of our Group at the time of share subscriptions by our key employees in the employee incentive platform and was fully settled on May 25, 2021. The consideration for the Share transfer to Zhirui Technology Holdings Limited was self-funded by the key employees who had subscribed shares in the employee incentive platform.

Step 3. Family Trust Arrangement

On March 25, 2021, Mr. Zhang and Mr. ZHANG Hui established their respective family trust and transferred their equity interests in our Company held through ZhangYu Hair Service Holdings Limited and ZhangHui Hair Service Holdings Limited to their respective family trusts on April 22, 2021. For detailed information of the family trust arrangement, see “— Establishment of Family Trusts” in this section.

Step 4. Share Issuance to ZY Family Trust

To further incentivise our founder, on April 26, 2021, we issued 6,382,979 Shares to ZY Investment Capital Ltd, representing approximately 6.0% of the Shares of the Company in issue upon completion of the Share issuance. For detailed information of the new Share issuance, see “— Share Issuance to The ZY Trust” in this section.

HISTORY, DEVELOPMENT AND CORPORATE STRUCTURE

Step 5. Acquisition of Onshore Shareholdings

On May 10, 2021, Beijing Xunyi, Panmao Shanghai, CYH, Hu&Yan and Yonghe Yuhui, being the then shareholders of Beijing Haiyouyou, entered into a share transfer agreement with Yonghe Medical Holdings, our Hong Kong subsidiary, pursuant to which Yonghe Medical Holdings acquired the entire equity interests in Beijing Haiyouyou from each of Beijing Xunyi, Panmao Shanghai, CYH, Hu&Yan and Yonghe Yuhui. The details of the acquisition is set out below. The cash consideration has been fully settled on June 3, 2021.

Transferor	Percentage of equity interest acquired by Yonghe Medical Holdings	Consideration paid
Beijing Xunyi	40%	RMB106,015,720 or equivalent USD
Panmao Shanghai	26.5%	RMB70,235,414.5 or equivalent USD
CYH	26.5%	26,500,000 Shares of our Company
Hu&Yan	5.349%	5,350,000 Shares of our Company
Yonghe Yuhui	1.651%	RMB4,375,798.8 or equivalent USD

Shareholding Structure after Reorganization

For our Group's corporate and shareholding structure immediately after the Reorganization, see “— Our Corporate Structure — Corporate Structure Before the Global Offering” in this section.

ESTABLISHMENT OF FAMILY TRUSTS

On March 25, 2021, Mr. Zhang, as the settlor, established The ZY Trust with Trident Trust Company (Singapore) Pte Limited as the trustee. On April 22, 2021, Mr. Zhang transferred the entire equity interest in our Company held by ZhangYu Hair Service Holdings Limited by way of gift to Trident Trust Company (Singapore) Pte Limited as trustee indirectly holds Shares on trust through ZY Investment Capital Ltd for the benefits of Mr. Zhang and certain of his family members.

On March 25, 2021, Mr. ZHANG Hui, as the settlor, established The ZH Trust with Trident Trust Company (Singapore) Pte Limited as the trustee. On April 22, 2021, Mr. ZHANG Hui transferred the entire equity interest in our Company held by ZhangHui Hair Service Holdings Limited by way of gift to Trident Trust Company (Singapore) Pte Limited as trustee indirectly holds Shares on trust through ZH Investment Capital Ltd for the benefits of Mr. ZHANG Hui and certain of his family members.

HISTORY, DEVELOPMENT AND CORPORATE STRUCTURE

SHARE ISSUANCE TO THE ZY TRUST

To further incentivize our founder, on April 26, 2021, our Company entered into a share subscription and purchase agreement, pursuant to which we issued 6,382,979 Shares, representing approximately 6.0% of the Shares of the Company in issue upon completion of the Share issuance, to ZY Investment Capital Ltd at a consideration of RMB88,630,000 or equivalent US dollars. The consideration was determined with reference to the post-money valuation of our Group of approximately RMB1.477 billion. The transaction was properly and legally completed on May 17, 2021.

ACQUISITION OF NU/HART HAIR SOLUTIONS LIMITED

Nu/Hart Hair Solutions Limited was established in Hong Kong and is wholly owned by Zhuhai Xinsiyu Management Service Co., Ltd. (珠海市新絲域管理服務有限公司) (“Xinsiyu”), a company incorporated in the PRC with limited liability. In order to expand the Company’s international business presence, we through our wholly-owned subsidiary Yuhui Management Holdings Limited, entered into a sale and purchase agreement with Xinsiyu, pursuant to which we purchased the entire issued share capital of Nu/Hart Hair Solutions Limited at a consideration of RMB30 million or equivalent US dollar. The consideration was based on arm’s length negotiation between the Company and Xinsiyu. The acquisition was duly completed on May 31, 2021. Xinsiyu is a company incorporated in the PRC and is wholly-owned by Zhuhai Siyu Industrial Development Company Limited (珠海市絲域實業發展有限公司), which is in turn owned by Shenzhen Zhongxiu Xinsheng Investment Center (Limited Partners) (深圳中秀信升投資中心(有限合夥)), a limited partnership managed by CITIC PE.

PUBLIC FLOAT

Upon completion of the Global Offering (assuming that Over-allotment Option is not exercised), the shares held by our core connected persons will not count towards the public float.

The approximately 31.07% Shares held by ZY Investment and 3.85% Shares held by Yunuo Technology Holdings Limited, both of which are controlled by Mr. Zhang, our executive Director and Controlling Shareholder, will not count towards the public float. In addition, the approximately 4.62% Shares held by ZH Investment, which is controlled by Mr. Zhang Hui, our executive Director, will not count towards the public float. And the approximately 0.13% Shares held by JiaQi Hair Service, which is controlled by Mr. Geng Jiaqi, our non-executive Director, will not count towards the public float. Further, the approximately 17.67% Shares held by CYH and the approximately 17.67% Shares held by Yonghe Hair Service respectively, will not count towards the public float.

Save as disclosed above, to the best of our Directors’ knowledge, all other shareholders of our Company are not core connected persons of our Company. As a result, our other existing Shareholders will aggregately hold a total of approximately 6.85% of the Shares (upon completion of the Global Offering without taking into account the Shares which may be allotted and issued under the Over-allotment Option) which will count towards the public float. Assuming the Offer Shares are allotted and issued to public shareholders, over 25% of our Company’s total issued Shares will be held by the public upon completion of the Global Offering in accordance with 8.08(1)(a) of the Listing Rules.

HISTORY, DEVELOPMENT AND CORPORATE STRUCTURE

EMPLOYEE INCENTIVE SCHEME

In recognition of the contributions of our employees and to incentivize them to further promote our development, Zhirui Technology Holdings Limited (鄧睿科技控股有限公司) (“**Zhirui**”) was incorporated in the BVI as a limited company on January 15, 2021 as an employee incentive platform for our employees.

Zhirui is wholly-owned by Shanghai Zhixin Technology Partnership (Limited Partnership) (上海鄧歆科技合夥企業(有限合夥)) (“**Zhixin**”), a limited partnership incorporated in the PRC on January 13, 2021 with Shanghai Zhizhen Technology Company Limited (上海鄧蓁科技有限公司) (“**Zhizhen**”), a company incorporated in the PRC with Ms. HAN Zhimei (韓志梅) as the sole director and shareholder, as its general partner and Shanghai Zhiyou Technology Partnership (Limited Partnership) (上海鄧宥科技合夥企業(有限合夥)) (“**Zhiyou**”), Shanghai Zhimin Technology Partnership (Limited Partnership) (上海鄧旻科技合夥企業(有限合夥)) (“**Zhimin**”), Shanghai Zhixun Technology Partnership (Limited Partnership) (上海鄧勳科技合夥企業(有限合夥)) (“**Zhixun**”) as its limited partners owned as to 30.01%, 36.68% and 33.28%, respectively. The general partner of Zhiyou, Zhimin and Zhixun is Zhizhen. The limited partners of Zhiyou, Zhimin and Zhixun include Mr. ZHANG Hui (張輝), Ms. HAN Zhimei (韓志梅), Mr. XU Yang (徐洋), Mr. LI Xiaolong (李小龍) and Mr. HUANG Donghong (黃東紅), being our senior management, and 112 employees of our Group, as of the Latest Practicable Date. On April 23, 2021, the Transferors transferred 3,000,000 Ordinary Shares to Zhirui, representing 2.82% of the total issued share capital of our Company as of the Latest Practicable Date. For details of the share transfer, see “— Step 2. Share Transfer to Mr. Zhang and Employee Incentive Scheme” in this section.

PRC LEGAL COMPLIANCE

Corporate Structure and Reorganization

Our Reorganization has been legally and properly completed and settled. Our PRC Legal Adviser has confirmed that all regulatory approvals and permits necessary for our Reorganization had been obtained in accordance with the PRC laws and regulations.

M&A Rules

Pursuant to the Regulations on Mergers and Acquisitions of Domestic Companies by Foreign Investors (關於外國投資者併購境內企業的規定) (the “**M&A Rules**”), which were jointly promulgated by the MOFCOM, the State-owned Assets Supervision and Administration Commission of the State Council, the STA, the SAIC, the CSRC and the SAFE on August 8, 2006, came into effect on September 8, 2006 and subsequently amended on June 22, 2009, a foreign investor is required to obtain necessary approvals when it (i) acquires the equity of a domestic enterprise so as to convert the domestic enterprise into a foreign invested enterprise; (ii) subscribes the increased capital of a domestic enterprise so as to convert the domestic enterprise into a foreign-invested enterprise; (iii) establishes a foreign-invested enterprise through which it purchases the assets of a domestic enterprise and operates these assets; or (iv) purchases the assets of a domestic enterprise, and then invests such assets to establish a foreign-invested enterprise. According to the Article 11 of the M&A Rules, where a domestic enterprise, or a domestic natural person, through an overseas company established or controlled by it/him/her, acquires a domestic enterprise which is related to or connected with it/him/her, approval from the MOFCOM is required.

HISTORY, DEVELOPMENT AND CORPORATE STRUCTURE

Given that (i) CYH, a non-domestic company, is not connected with our Group when it acquired equity interests of Beijing Haiyouyou in July 2017 and October 2017 and such acquisitions were completed in compliance with applicable PRC laws and regulations; (ii) Beijing Haiyouyou was a sino-foreign joint venture when its 100% equity interests was acquired by Yonghe Medical Holdings in May 2021, our PRC Legal Adviser is of the opinion that the onshore reorganization of the Reorganization is not subject to approval from the MOFCOM and the CSRC under the M&A Rules. However, there is uncertainty as to how the M&A Rules will be interpreted or implemented, and whether the relevant PRC government authorities, including CSRC, will reach the same conclusion as our PRC Legal Adviser.

SAFE Circular 37


SAFE promulgated the Circular on Relevant Issues Concerning Foreign Exchange Control on Domestic Residents' Offshore Investment and Financing and Roundtrip Investment through Special Purpose Vehicles (關於境內居民通過特殊目的公司境外投融資及返程投資外匯管理有關問題的通知) (the “**SAFE Circular 37**”) on July 14, 2014, which replaced the former circular commonly known as “SAFE Circular 75” promulgated by SAFE on October 21, 2005. SAFE Circular 37 requires PRC resident to register with local branches of SAFE in connection with their direct establishment or indirect control of an offshore entity, for the purpose of overseas investment and financing, with such PRC residents' legally owned assets or equity interests in domestic enterprises or offshore assets or interests, referred to in SAFE Circular 37 as a “special purpose vehicle”. SAFE Circular 37 further requires amendment to the registration in the event of any significant changes with respect to the special purpose vehicle, such as increase or decrease of capital contributed by PRC individuals, share transfer or swap, merger, division or other material event. In the event that a PRC shareholder holding interests in a special purpose vehicle fails to fulfill the required SAFE registration, the PRC subsidiaries of that special purpose vehicle may be prohibited from making profit distributions to the offshore parent and from carrying out subsequent cross-border foreign exchange activities, and the special purpose vehicle maybe restricted in its ability to contribute additional capital into its PRC subsidiary. Furthermore, failure to comply with the SAFE registration requirements described above could result in liability under PRC law for evasion of foreign exchange controls.

On February 13, 2015, SAFE released the Notice on Further Simplifying the Improving Policies for the Foreign Exchange Administration of Direct Investment (國家外匯管理局關於進一步簡化和改進直接投資外匯管理政策的通知) (the “**SAFE Circular 13**”), which became effective from June 1, 2015. According to SAFE Circular 13, local banks shall examine and handle foreign exchange registration for overseas direct investment, including the initial foreign exchange registration and amendment registration under SAFE Circular 37. However, there exists uncertainties with respect to its interpretation and implementation by governmental authorities and banks.

As advised by our PRC Legal Adviser, each of Mr. Zhang, Mr. Zhang Hui, Mr. Nie Lei, Mr. Geng Jiaqi, Ms. Duan Siqi, Mr. Tan Xu and Mr. Song Linfeng has completed the registration for their respective investments in our Company under SAFE Circular 37 and SAFE Circular 13 on October 10, 2020.

OUR CORPORATE STRUCTURE

Corporate Structure Before the Global Offering



HISTORY, DEVELOPMENT AND CORPORATE STRUCTURE

Notes:

1. Yonghe Hair Service is wholly-owned by Panmao Shanghai, the general partner of which is Shanghai Pannuo, which is in turn wholly-owned by CITIC PE. CITIC PE is owned as to 35% by CITIC Securities Company Limited, a company listed on both the Stock Exchange and the Shanghai Stock Exchange. As of the Latest Practicable Date, Panmao Shanghai has 46 limited partners with no limited partner holding more than 12.4% interest.
2. CYH is wholly owned by CYH Cosmetic Medical Investment Limited, which is owned to approximately 86.3% by CPEChina Fund II and 13.7% by CPEChina Fund IIA. The general partner of CPEChina Fund II and CPEChina Fund IIA is Citron PE Associates II. Citron PE Associates II is an exempted limited partnership registered under the laws of the Cayman Islands whose general partner is Citron PE Funds II. Citron PE Funds II is wholly owned by Citron PE Holdings Limited, formerly known as CITICPE Holdings Limited, which is held as to 35% by CLSA Global Investments Management Limited. CLSA Global Investments Management Limited is wholly owned by CLSA, B.V., which is wholly owned by CITIC Securities International Company Limited, which in turn is wholly owned by CITIC Securities Company Limited. As of the Latest Practicable Date, CPEChina Fund II has 19 limited partners with no limited partner holding more than 17.83% interest, while CPEChina Fund IIA has 3 limited partners, including Maxi Joy Investments Ltd. (holding 56.3% interest and ultimately owned by Bank of China Limited, a company listed on both the Stock Exchange and the Shanghai Stock Exchange), The Norinchukin Bank (holding 16.9% interest and a Japanese cooperative bank headquartered in Tokyo, Japan) and Citron PE Limited (holding 26.8% interest and wholly owned by Citron PE Holdings Limited).
3. ZY Investment Capital Ltd is wholly-owned by ZY Ventures Ltd, which is in turn wholly-owned by Frandor Limited. Frandor Limited is the nominee shareholder of The ZY Trust and is wholly-owned by Trident Trust Company (Singapore) Pte Limited, which is the trustee of The ZY Trust established by Mr. Zhang (as the settlor) and Trident Trust Company (Singapore) Pte Limited (as the trustee) on March 25, 2021.
4. Yunuo Technology Holdings Limited (上海予諾科技控股有限公司) is wholly owned by Shanghai Yuxin Technology Partnership (Limited Partnership) (上海予信科技合夥企業(有限合夥)), the limited partner of which is Mr. Yu Zhang and the general partner of which is Shanghai Yuhe Technology Company Limited (上海予赫科技有限公司), which is in turn wholly-owned by Mr. Yu Zhang.
5. ZH Investment Capital Ltd is wholly-owned by ZH Ventures Ltd, which is in turn wholly-owned by Frandor Limited. Frandor Limited is the nominee shareholder of The ZH Trust and is wholly-owned by Trident Trust Company (Singapore) Pte Limited, which is the trustee of The ZH Trust established by Mr. ZHANG Hui (as the settlor) and Trident Trust Company (Singapore) Pte Limited (as the trustee) on March 25, 2021.
6. Mr. HU Tenghe is an employee of Citron PE Investment (Hong Kong) Limited, which is an affiliate of Citron PE Funds II. Mr. NIE Lei, Mr. GENG Jiaqi and Ms. DUAN Siqi are employees of Beijing Panmao Investment Management Co., Ltd. (北京磐茂投資管理有限公司), which is the fund manager of Panmao Shanghai. Mr. TAN Xu was a former employee of Panxin Shanghai and Mr. SONG Linfeng was a former employee of Panmao Shanghai. Save that Mr. GENG Jiaqi is a non-executive Director, Ms. DUAN Siqi was a past Director of the Company, the other abovementioned individuals are all Independent Third Parties.
7. Zhirui is wholly-owned by Zhixin. The limited partner of Zhixin is Zhizhen and its general partners are Zhiyou, Zhimin and Zhixun. See “— Employee Incentive Scheme” for details.
8. Svenson Beijing was established in the PRC on November 5, 2003 with an initial registered capital of US\$35,000 and is primarily engaged in offering hair care products and anti-hair loss treatment solutions. At the time of its establishment, Svenson Beijing was a wholly foreign-owned company owned by Svenson Hair Centre Limited (史雲遜護髮有限公司), a company incorporated in Hong Kong and an Independent Third Party. On January 22, 2014, Svenson Beijing was acquired by Hainan Beauty Farm Management Service Limited (海南美麗田園管理服務有限公司) (“**Hainan Beauty Farm**”), a company controlled by CITIC PE and in which our non-executive Directors Mr. ZHAI Feng and Mr. GENG Jiaqi are directors. Beijing Haiyouyou acquired Svenson Beijing from Hainan Beauty Farm in December 2017 at a consideration of RMB10 million.

HISTORY, DEVELOPMENT AND CORPORATE STRUCTURE

9. As of the Latest Practicable Date, we have 67 Medical Institutions (including 52 clinics in operation and 15 clinics not in operation) in mainland China. Set out below is a list of our Medical Institutions as of the Latest Practicable Date:


No.	Medical Institutions
(1).	Chengdu Wuhou Yonghe Jimei Medical Beauty Clinic Co., Ltd. (成都武侯雍禾既美醫療美容診所有限公司) (“ Chengdu Yonghe ”)
(2).	Beijing Yonghe Meidu Clinic Co., Ltd. (北京雍禾美度門診部有限公司) (“ Beijing Yonghe ”)
(3).	Wenzhou Yonghe Medical Beauty Clinic Co., Ltd. (溫州雍禾醫療美容門診部有限公司) (“ Wenzhou Yonghe ”)
(4).	Fuzhou Yonghe Medical Beauty Clinic Co., Ltd. (福州雍禾醫療美容門診部有限公司) (“ Fuzhou Yonghe ”)
(5).	Guangzhou Yonghe Medical Beauty Clinic Co., Ltd. (廣州雍禾醫療美容門診部有限公司) (“ Guangzhou Yonghe ”)
(6).	Hangzhou Yonghe Meidu Medical Beauty Clinic Co., Ltd. (杭州雍禾美度醫療美容診所有限公司) (“ Hangzhou Yonghe Meidu ”)
(7).	Hangzhou Niufei Medical Beauty Clinic Co., Ltd. (杭州紐飛絲醫療美容診所有限公司) (“ Hangzhou Niufei ”) (formerly known as Hangzhou Yonghe Jimei Medical Beauty Co., Ltd. (杭州雍禾既美醫療美容診所有限公司))
(8).	Kunming Yonghe Jimei Medical Beauty Co., Ltd. (昆明雍禾既美醫療美容有限公司) (“ Kunming Yonghe ”)
(9).	Nanjing Yonghe Jimei Medical Beauty Clinic Co., Ltd. (南京雍禾既美醫療美容診所有限公司) (“ Nanjing Yonghe ”)
(10).	Nanning Yonghe Medical Beauty Co., Ltd. (南寧雍禾醫療美容有限公司) (“ Nanning Yonghe ”) Medical Beauty Surgery Clinic of Nanning Yonghe Medical Beauty Co., Ltd. (南寧雍禾醫療美容有限公司醫療美容外科診所) (“ Nanning Yonghe Clinic ”)
(11).	Xiamen Siming Yonghe Meidu Plastic Surgery Clinic Co., Ltd. (廈門思明雍禾美度整形外科門診部有限公司) (“ Xiamen Yonghe ”)
(12).	Shanghai Yonghe Aimu Clinic Co., Ltd. (上海雍禾愛慕門診部有限公司) (“ Shanghai Yonghe ”)
(13).	Shenzhen Yonghe Jimei Medical Beauty Clinic (深圳雍禾既美醫療美容門診部) (“ Shenzhen Yonghe ”)
(14).	Shenyang Heping Yonghe Medical Beauty Clinic Co., Ltd. (瀋陽和平雍禾醫療美容診所有限公司) (“ Shenyang Yonghe ”)
(15).	Shijiazhuang Yonghe Medical Services Co., Ltd. (石家莊雍禾醫療服務有限公司) (“ Shijiazhuang Yonghe ”) Qiaoxi Medical Beauty Clinic of Shijiazhuang Yonghe Medical Services Co., Ltd. (石家莊雍禾醫療服務有限公司橋西醫療美容診所) (“ Shijiazhuang Yonghe Qiaoxi Clinic ”)
(16).	Taiyuan Xiaodian Yonghe Medical Beauty Clinic Co., Ltd. (太原市小店區雍禾醫療美容診所有限公司) (“ Taiyuan Yonghe ”)
(17).	Tianjin Hexi Yonghe Meidu Medical Beauty Co., Ltd. (天津河西區雍禾美度醫療美容有限公司) (“ Tianjin Yonghe ”)
(18).	Wuhan Yonghe Meidu Medical Beauty Clinic Co., Ltd. (武漢雍禾美度醫療美容門診部有限公司) (“ Wuhan Yonghe ”)
(19).	Xi'an Yonghe Medical Beauty Co., Ltd. (西安雍禾醫療美容有限公司) (“ Xi'an Yonghe ”)
(20).	Changsha Yonghe Meidu Medical Beauty Co., Ltd. (長沙雍禾美度醫療美容有限公司) (“ Changsha Yonghe Meidu ”)
(21).	Zhengzhou Yonghe Meidu Medical Beauty Clinic Co., Ltd. (鄭州雍禾美度醫療美容診所有限公司) (“ Zhengzhou Yonghe ”)
(22).	Qingdao Yonghe Medical Beauty Clinic Co., Ltd. (青島雍禾醫療美容診所有限公司) (“ Qingdao Yonghe ”) Shinan Medical Beauty Clinic of Qingdao Yonghe Medical Beauty Clinic Co., Ltd. (青島雍禾醫療美容診所有限公司市南醫療美容診所) (“ Qingdao Yonghe South Clinic ”)
(23).	Urumqi Yonghe Medical Beauty Clinic Co., Ltd. (烏魯木齊雍禾醫療美容診所有限公司) (“ Urumqi Yonghe ”)
(24).	Guiyang Yonghe Medical Beauty Co., Ltd. (貴陽雍禾醫療美容有限公司) (“ Guiyang Yonghe ”)
(25).	Chongqing Yonghe Medical Beauty Clinic Co., Ltd. (重慶雍禾醫療美容診所有限公司) (“ Chongqing Yonghe ”)
(26).	Ningbo Yinzhou Yonghe Medical Beauty Clinic Co., Ltd. (寧波鄞州雍禾醫療美容診所有限公司) (“ Ningbo Yonghe ”)
(27).	Hefei Yonghe Plastic Surgery Clinic Co., Ltd. (合肥雍禾整形外科門診部有限公司) (“ Hefei Yonghe ”)
(28).	Dongguan Dongcheng Yonghe Medical Beauty Clinic Co., Ltd. (東莞東城雍禾醫療美容門診部有限公司) (“ Dongguan Yonghe ”)
(29).	Quanzhou Yonghe Plastic Surgery Clinic Co., Ltd. (泉州雍禾整形外科門診部有限公司) (“ Quanzhou Yonghe ”)
(30).	Dalian Yonghe Medical Beauty Clinic Co., Ltd. (大連雍禾醫療美容診所有限公司) (“ Dalian Yonghe ”)
(31).	Harbin Yonghe Medical Beauty Clinic Co., Ltd. (哈爾濱雍禾醫療美容門診部有限公司) (“ Harbin Yonghe ”)
(32).	Wuxi Yonghe Medical Beauty Clinic Co., Ltd. (無錫雍禾醫療美容門診部有限公司) (“ Wuxi Yonghe ”)
(33).	Kunshan Yonghe Medical Beauty Clinic Co., Ltd. (昆山雍禾醫療美容診所有限公司) (“ Kunshan Yonghe ”)
(34).	Nantong Yongxin Medical Beauty Clinic Co., Ltd. (南通雍信醫療美容診所有限公司) (“ Nantong Yonghe ”)
(35).	Zhuhai Yonghe Medical Beauty Clinic Co., Ltd. (珠海雍禾醫療美容診所有限公司) (“ Zhuhai Yonghe ”)

HISTORY, DEVELOPMENT AND CORPORATE STRUCTURE

No.	Medical Institutions
(36).	Lanzhou Yonghe Medical Beauty Clinic Co., Ltd. (蘭州雍禾醫療美容診所有限公司) (“ Lanzhou Yonghe ”) Chengguan Medical Beauty Clinic of Lanzhou Yonghe Medical Beauty Clinic Co., Ltd. (蘭州雍禾醫療美容診所有限公司城關醫療美容診所) (“ Lanzhou Yonghe Chengguan Clinic ”)
(37).	Xuzhou Yonghe Medical Beauty Co., Ltd. (徐州雍禾醫療美容有限公司) (“ Xuzhou Yonghe ”)
(38).	Jiaxing Yonghe Medical Beauty Clinic Co., Ltd. (嘉興雍禾醫療美容門診部有限公司) (“ Jiaxing Yonghe ”)
(39).	Suzhou Yonghe Medical Beauty Clinic Co., Ltd. (蘇州雍禾醫療美容診所有限公司) (“ Suzhou Yonghe ”)
(40).	Jinan Yonghe Medical Beauty Clinic Co., Ltd. (濟南雍禾醫療美容診所有限公司) (“ Jinan Yonghe ”) Licheng Medical Beauty Clinic of Jinan Yonghe Medical Beauty Clinic Co., Ltd. (濟南雍禾醫療美容診所有限公司曆城醫療美容診所) (“ Jinan Yonghe Licheng Clinic ”)
(41).	Nanchang Yonghe Medical Beauty Clinic Co., Ltd. (南昌雍禾醫療美容診所有限公司) (“ Nanchang Yonghe ”)
(42).	Taizhou Yonghe Medical Beauty Co., Ltd. (台州雍禾醫療美容有限公司) (“ Taizhou Yonghe ”)
(43).	Xi'an Beilin Yonghe Jimei Medical Beauty Clinic Co., Ltd. (西安碑林雍禾既美醫療美容診所有限公司) (“ Xi'an Beilin Yonghe ”) First Branch Company of Xi'an Beilin Yonghe Jimei Medical Beauty Clinic Co., Ltd. (西安碑林雍禾既美醫療美容診所有限公司第一分公司) (“ Xi'an Beilin Yonghe First Branch ”)
(44).	Huizhou Yonghe Medical Beauty Clinic Co., Ltd. (惠州雍禾醫療美容診所有限公司) (“ Huizhou Yonghe ”)
(45).	Foshan Yonghe Plastic Surgery Clinic Co., Ltd. (佛山雍禾整形外科門診有限公司) (“ Foshan Yonghe ”)
(46).	Zhongshan Yonghe Medical Beauty Clinic Co., Ltd. (中山雍禾醫療美容門診部有限公司) (“ Zhongshan Yonghe ”)
(47).	Changzhou Yonghe Medical Beauty Clinic Co., Ltd. (常州雍禾醫療美容診所有限公司) (“ Changzhou Yonghe ”)
(48).	Zhanjiang Yonghe Medical Beauty Co., Ltd. (湛江雍禾醫療美容有限公司) (“ Zhanjiang Yonghe ”)
(49).	Luoyang Yonghe Medical Beauty Clinic Co., Ltd. (洛陽雍禾醫療美容診所有限公司) (“ Luoyang Yonghe ”)
(50).	Foshan Yonghe Meidu Medical Beauty Co., Ltd. (佛山雍禾美度醫療美容有限公司) (“ Foshan Yonghe Meidu ”) Shunde Daliang Medical Beauty Clinic of Foshan Yonghe Meidu Medical Beauty Co., Ltd. (佛山雍禾美度醫療美容有限公司順德大良醫療美容診所) (“ Foshan Yonghe Meidu Shunde Clinic ”)
(51).	Jinhua Yonghe Medical Beauty Clinic Co., Ltd. (金華雍禾醫療美容診所有限公司) (“ Jinhua Yonghe ”)
(52).	Changsha Yonghe Jimei Medical Beauty Co., Ltd. (長沙雍禾既美醫療美容有限公司) (“ Changsha Yonghe Jimei ”)
(53).	Beijing Niufeisi Medical Beauty Clinic Co., Ltd. (北京紐飛絲醫療美容診所有限公司) (“ Beijing Niufeisi ”) (formerly known as Beijing Yongxiang Medical Beauty Clinic Co., Ltd. (北京雍享醫療美容診所有限公司))
(54).	Beijing Yonghe Hospital Co., Ltd. (北京雍禾醫院有限公司) (“ Beijing Yonghe Hospital ”)
(55).	Haikou Yonghe Beauty Plastic Surgery Clinic Co., Ltd. (海口雍禾美容整形外科診所有限公司) (“ Haikou Yonghe ”)
(56).	Yancheng Yonghe Medical Beauty Co., Ltd. (鹽城雍禾醫療美容有限公司) (“ Yancheng Yonghe ”)
(57).	Shanghai Yonghe Hospital Co., Ltd. (上海雍禾醫院有限公司) (“ Shanghai Yonghe Hospital ”)
(58).	Urumqi Yonghe Meidu Medical Beauty Co., Ltd. (烏魯木齊雍禾美度醫療美容有限公司) (“ Urumqi Yonghe Meidu ”)
(59).	Yangzhou Yonghe Medical Beauty Clinic Co., Ltd. (揚州雍禾醫療美容診所有限公司) (“ Yangzhou Yonghe ”)
(60).	Yiwu Yonghe Jimei Medical Beauty Clinic Co., Ltd. (義烏雍禾既美醫療美容診所有限公司) (“ Yiwu Yonghe ”)
(61).	Zhangzhou Yonghe Medical Beauty Co., Ltd. (漳州雍禾醫療美容有限公司) (“ Zhangzhou Yonghe ”)
(62).	Shantou Yonghe Medical Beauty Clinic Co., Ltd. (汕頭市雍禾醫療美容診所有限公司) (“ Shantou Yonghe ”)
(63).	Guiyang Yonghe Jimei Medical Beauty Clinic Co., Ltd. (貴陽雍禾既美醫療美容診所有限公司) (“ Guiyang Yonghe Jimei ”)
(64).	Guangzhou Svenson Clinic Co., Ltd. (廣州史雲遜診所有限公司) (“ Guangzhou Svenson ”)
(65).	Shenzhen Niufeisi Medical Beauty Clinic (深圳紐飛絲醫療美容診所) (“ Shenzhen Niufeisi ”)
(66).	Shenzhen Svenson Clinic (深圳史雲遜診所) (“ Shenzhen Svenson ”)
(67).	Yantai Yonghe Medical Beauty Clinic Co., Ltd. (煙臺雍禾醫療美容診所有限公司) (“ Yantai Yonghe ”)

Corporate Structure Immediately Following the Global Offering

The diagram illustrates the corporate and shareholding structure of our Group immediately following the completion the Global Offering (assuming the Over-allotment Option is not exercised).



Note: Please refer to the notes to “Corporate Structure Before the Global Offering” in this section.

OVERVIEW

We are the leading medical group in China specialized in providing hair-related healthcare services in terms of total revenue for 2020. We offer one-stop hair-related healthcare services covering hair transplant, medical hair care, and routine hair restoration and other ancillary services. According to Frost & Sullivan, we are the largest player in China's hair transplant service market with a market share of 10.5% and medical hair care service market with a market share of 4.3%, in terms of total revenue derived from the relevant services in 2020. Among all hair-related healthcare service providers in China, we ranked first in terms of the number of registered physicians at the end of 2020, the number of clinics in operation at the end of 2020, and the number of hair transplant patients for 2020, according to Frost & Sullivan. We adopt a standardized and scalable business model to operate a hair transplant chain consisting of mostly self-operated clinics. As of the Latest Practicable Date, we operated 53 clinics in 52 cities nationwide, making us the largest and most extensive hair transplant clinic chain in China, according to Frost & Sullivan. During the Track Record Period, we opened 29 new clinics in mainland China and acquired one clinic in Hong Kong, achieving the fastest growth among all hair transplant clinic chains in China, and further widening our lead over the runners-up.

Through decades of dedication and commitment to China's hair-related healthcare industry, we have made *Yonghe Hair Transplant* (雍禾植髮) a well-known and highly trusted brand among its peers, and have promoted many major developments and advancements in the industry. We have gone through three stages of development:

- from 2005 to 2009, we gradually built up our in-house team of medical professionals, and accumulated expertise and know-how in providing quality hair transplant services;
- from 2010 to 2017, sticking with the principal of integrity, safety, and transparency, we standardized our medical service procedures, and rapidly expanded our clinic network nationwide. In 2010, we became the first ISO-certified hair transplant service provider in China, and by the end of 2017, we had successfully opened 22 hair transplant clinics across China. In 2017, we obtained investment from CITIC PE, who helped us enhance our corporate governance and further expand our business. In 2017, we acquired the mainland China business of *Svenson*, a globally renowned brand originated from London that had over six decades of experience in offering hair restoration products and services, and also obtained the ownership of all its trademarks registered in the PRC through the acquisition. After reviewing transfer agreements and registered certificates of the relevant trademarks, our PRC Legal Adviser is of the view that we have obtained the relevant trademarks to conduct the business under the brand name of *Svenson* in the PRC because (i) the relevant trademark transfer agreements are effective and legally-binding under the applicable PRC laws and regulations, and (ii) we are the lawfully registered owner of the relevant trademarks. To integrate *Svenson*'s business into ours, we keep the trademarks and most of the original staff and products of the acquired business, while closing certain under-performed stores following the acquisition;

- from 2018 onwards, leveraging our strong medical service capabilities and *Svenson's* extensive experience in hair restoration, we strategically took inroads into the medical hair care service sector and successfully established a *Svenson Medical Hair Care Center* (史雲遜醫學健髮中心) in each of our clinics in mainland China under a “shop-in-shop” model. We also expanded our footprint outside the mainland China in May 2021 by acquiring the Hong Kong business of *Nu/Hart Hair* (顯赫植髮), a renowned hair transplant service provider originated from the U.S. For the six months ended June 30, 2021, each of the revenue and profit contribution of the acquired business of *Nu/Hart Hair* to our Group was less than 0.1%. In the future, we plan to use the Hong Kong business of *Nu/Hart Hair* as a starting point to further expand our businesses in the Great Bay Area. In addition, through our cooperation with prestigious universities such as Sun Yat-sen University, we are blazing a trail toward collaborative research and development with academia and showing the way forward for the hair-related healthcare service industry. We believe that by breaking those new grounds, we are enhancing our core competitiveness and further strengthening our leading position in the industry.

We have been persistently specializing in the hair-related healthcare service market. Driven by the soaring prevalence of hair problems in China, the increasing disposable income *per capita* of Chinese residents and elevated self-awareness of appearance, China's hair-related healthcare service market is expanding rapidly. According to Frost & Sullivan, the size of the hair-related healthcare service market in China reached RMB18.4 billion in 2020, and is projected to grow to RMB138.1 billion in 2030 with a CAGR of 22.3%. China's hair-related healthcare service market consists of two main parts — the hair transplant service market and the medical hair care service market. Hair transplant is a surgical treatment for hair loss, i.e., alopecia. According to Frost & Sullivan, approximately 250.9 million people suffered from alopecia in China in 2020. Medical hair care integrates various non-surgical treatment methods, such as medical devices and medications, and is able to address the diversified needs of a larger patient pool with various scalp and hair problems. According to Frost & Sullivan, China's hair transplant service market reached RMB13.4 billion in 2020, and is projected to grow to RMB75.6 billion in 2030 with a CAGR of 18.9%. China's medical hair care service market is still at an early stage of development with a market size of only RMB5.0 billion in 2020, but is believed to harbor huge growth potential and is expected to grow to RMB62.5 billion in 2030 at a CAGR of 28.7%. We are the largest service provider in each of hair transplant service market and the medical hair care service market in China by revenue derived from the relevant services in 2020, according to Frost & Sullivan. With our industry-leading prowess in medical examination and diagnosis, and continuing innovation in product and service offerings, we believe we are well-positioned to capture the huge growth potential of China's hair-related healthcare service market.

Our in-house professional medical staff is at the core of our hair-related healthcare services. Leveraging our standardized and proven physician training system, as of the Latest Practicable Date, we had built a professional medical team consisting of 1,233 members, including 246 registered physicians and 919 nurses. By standardizing our diagnostic and therapeutic service system, we are able to provide consistent, high-quality medical services and achieve rapid expansion of clinics without compromising the quality of service.

Leveraging our standardized and highly scalable business model, we have achieved industry-leading operational capabilities, enabling us to effectively control costs, boost operational efficiency and improve profitability. During the Track Record Period, our gross profit margin remained largely stable, while our administrative expenses as a percentage of our total revenue continued to decrease.

We have built a one-stop shop for medical hair care services to meet the medical demands of different patients. We continue to improve our diagnostic, therapeutic, and research and development capabilities by collaborating with experts from Class IIIA hospitals and renowned academic institutions. In addition, to continuously improve medical service to patients, to stay ahead of the technological curve and to propel business development, we have always been actively promoting and adopting new technologies in our business, including data usage and analysis, intelligent services and online services. We believe that such strengths have reinforced our industry-leading position and will sustain our growth momentum into the future.

We experienced significant growth during the Track Record Period. Our total revenue increased by 31.1% from RMB934.3 million in 2018 to RMB1.22 billion in 2019, and grew by another 33.8% to RMB1.64 billion in 2020. For the six months ended June 30, 2021, our revenue amounted to RMB1.05 billion, representing an increase of 75.1% as compared to the corresponding period in 2020. While our revenue was generated mainly from rendering hair transplant services, revenue from medical hair care services grew rapidly over the same period. We recorded a net profit of RMB53.5 million in 2018, RMB35.6 million in 2019, RMB163.3 million in 2020 and RMB40.4 million for the six months ended June 30, 2021. The total number of patients receiving our treatments increased by 41.7% from 35,177 in 2018 to 49,851 in 2019, and further increased by 82.7% to 91,069 in 2020. In the six months ended June 30, 2021, the total number of patients receiving our treatments reached 68,112. Our clinics' average initial breakeven period is approximately three months and their average cash investment payback period is approximately 14 months, better than the average for private medical institutions in China, according to Frost & Sullivan.

OUR COMPETITIVE STRENGTHS

We believe the following strengths have contributed to our success and differentiated us from our competitors:

China's Largest Hair Transplant Service Provider

We are the largest hair transplant service provider in China. According to Frost & Sullivan, we ranked first in China's hair transplant industry by various key financial and operational indicators, including:

- *Revenue.* We are number one in the industry by total revenue derived from hair transplant in 2020, which amounted to RMB1.4 billion, greater than the next two runners-up combined.
- *Physician headcount.* We are number one in the industry by the number of registered physicians. As of the Latest Practicable Date, we had a total of 246 registered physicians, which again beats the next two runners-up combined.

- *Number of hair transplant clinics.* As of the Latest Practicable Date, we had 53 hair transplant clinics nationwide in 52 cities, putting us ahead of all our competitors.
- *Number of hair transplant patients.* In 2020, we had a total of 50,694 patients receiving our hair transplant surgeries, more than anyone else in the industry.

According to Frost & Sullivan, approximately 250.9 million people suffered from alopecia in China in 2020. In recent years, by a combination of factors, including the increasing disposable income *per capita* of Chinese residents, elevated self-awareness of appearance, and the advances in hair transplants technology, China's hair transplant service market grew rapidly from RMB5.8 billion in 2016 to RMB13.4 billion in 2020 with a CAGR of 23.4%, according to Frost & Sullivan. Yet, that market is far from saturated, with the hair transplant penetration rate (calculated by dividing the number of recipients of hair transplant procedures by the number of alopecia patients) being only approximately 0.2% in 2020. Further, with the advent of aesthetic hair transplant, the expansion of hair transplant options, and service innovations, the customer base for hair transplant in China is expected to expand from alopecia patients to a larger group of consumers seeking to enhance appearance through medical treatment, which is projected to drive China's hair transplant service market to RMB75.6 billion in 2030. According to Frost & Sullivan, public hospitals in China seldom conduct hair transplant, leaving the huge and fast-growing demand for hair transplants among patients in China unmet. In contrast, private hair transplant clinics, leveraging their rich experience in hair transplant surgeries, are better positioned to fulfil such unmet medical needs, which promises great growth potential. In addition, the growing market also brings a growing demand for quality medical care. Market players operating large hair transplant clinic chains are more capable of providing quality assurance for their hair transplant services as compared with small hair transplant service providers, and will be preferred by potential patients.

During the Track Record Period, we grew faster than the overall hair transplant service market in China, thanks to our quality service and industry-leading operational capabilities. Specifically, revenue generated from our hair transplant business increased at a CAGR of 24.1% from 2018 to 2020, while China's hair transplant service market grew at a CAGR of only 16.7% over the same period, putting us at the top of the industry. As a market leader, we are well positioned to capitalize on the upside potential of China's hair transplant service market, and to maintain continuous, rapid growth in the future.

Nationwide Footprint in Major Metropolitan Centers With Great Growth Potential

We operate the largest and most extensive hair transplant clinic chain in China. We grew rapidly during the Track Record Period. The number of our hair transplant clinics increased from 30 by the end of 2018 to 37 by the end of 2019, continued to increase to 48 by the end of 2020, and further increased to 52 by June 30, 2021. As of the Latest Practicable Date, we operated 53 clinics in 52 cities nationwide, including in Hong Kong and in four tier-one cities, 15 new tier-one cities, 25 tier-two cities and seven lower-tier cities in mainland China. We plan to strategically expand our operations to more lower-tier cities, in order to serve the unmet needs of our customers.

Following our inception, we firstly made our mark in tier-one cities with large populations and high *per capita* income, where we grew rapidly and became a top market player. In provinces with huge hair transplant demands and high *per capita* income, including Guangdong, Zhejiang, Jiangsu, Fujian and Shandong, we are striving to achieve our full regional concentration strategy by opening clinics in more cities within the relevant provinces. According to Frost & Sullivan, we ranked first with a market share

over 10% in each of the five provinces. We typically enter a province by setting up our clinics in the provincial capital first. By leveraging our existing infrastructure, operational experience, and brand recognition in the cities with our presence, we are able to efficiently expand into other cities within the same province. For example, in Guangdong province, after we opened our first clinic in Guangzhou in 2013, we gradually expanded into eight other cities, and became the largest hair transplant chain in Guangdong province.

Meanwhile, we are speeding up our pace to expand to China's tier-two and lower-tier cities as we believe that the growing demands in these cities will drive the next wave of growth of the country's hair transplant industry. As of the Latest Practicable Date, we had extended our footprint in 25 tier-two cities and seven lower-tier cities. In addition to geographic expansion, we are building four comprehensive medical hair care service hospitals in Beijing, Shanghai, Guangzhou, and Shenzhen to serve more patients with varied hair problems. Our comprehensive medical hair care service hospitals will hire physicians from Class IIIA hospitals to diagnose and treat various hair-related diseases. We will also set up multiple hair-related specialty departments in addition to the hair transplant department, such as alopecia department, re-examination department, international department, and feminine beauty department.

Benefiting from our broad geographical reach, our hair transplant business has experienced rapid growth during the Track Record Period. The total number of our hair transplant patients increased from 35,177 in 2018 to 43,087 in 2019, and further increased to 50,694 in 2020. In the six months ended June 30, 2021, the total number of our hair transplant patients reached 29,480. Our revenue from hair transplant increased from RMB0.9 billion in 2018 to RMB1.2 billion in 2019, and increased further to RMB1.4 billion in 2020. For the six months ended June 30, 2021, our revenue from hair transplant amounted to RMB789.5 million, representing an increase of 39.2% as compared to the corresponding period in 2020. We believe our extensive business network discussed above will bring us closer to a broader patient base and create substantial synergy. That synergy will spark interregional sharing and allocation of medical resources, and result in services of consistently high quality and convenience to patients across the country. For example, the senior experts of our hair transplant clinics regularly tour around different regions to share their expertise, and patients who received treatment at one hair transplant clinic are entitled to our diagnostic and treatment services in our other clinics. We believe that this will ultimately translate into patient loyalty and accrue goodwill to our brand. iiMedia Research, a leading industry data mining and analysis agency and an independent third party, released the "Top Eight China Hair Transplant Chain Brands of 2019" (2019年中國植髮連鎖機構品牌排行榜TOP 8) following a comprehensive survey of China's hair transplant chain brands by using big data analysis models and taking into account several factors, including brand value, market recognition, online sensation, media buzz index, and the Internet Word-of-Mouth index. Our brand "Yonghe Hair Transplant" topped that rank.

Industry-Leading Operational and Medical Service Capabilities

We possess industry-leading operational capabilities, enabling us to effectively control our costs and enhance our operational efficiency and profitability. Our operational capabilities benefit from our huge economy of scale. Leveraging our scale, we are able to secure favorable terms from suppliers, improve operational and advertising efficiency, and invest more resources in research and infrastructure, while achieving efficient intragroup resource sharing and improving overall operational efficiency. During the Track Record Period, we experienced substantial growth while our administrative, selling and marketing expenses as a percentage of our total revenues remained largely stable, and even dropped slightly from 2019 to 2020.

We have a highly scalable business model that not only enables rapid geographical expansion, but promotes efficient enrichment of our service offerings and service modes as well. In terms of clinic construction and upgrade, thanks to our efficient organizational capabilities and the support from our headquarters for construction, equipment procurement, and talent recruitment, it generally takes us no more than eight months to complete the opening of a new clinic of around 2,500 sq.m. In addition, our clinics' average initial breakeven period is three months and average cash payback period is 14 months, lower than the average level of China's private medical institutions, according to Frost & Sullivan. In terms of the expansion of our medical service offerings and service modes, backed by a highly experienced and capable professional medical staff, we are able to diversify our service offerings, to adapt to the ever-evolving market conditions and patient needs without significant cost increases. For example, on top of traditional hair transplant, we have added several other hair transplant procedures, such as hairline lowering, eyebrow transplant, and sideburn transplant, with which we have effectively captured a larger group of consumers, particularly female consumers. In addition, leveraging our uniquely large and experienced medical staff, we developed a multilevel service system to meet the diverse medical needs of patients with different purchasing powers. Specifically, we offer hair transplant services at three levels of physician experience and skills, including (1) basic-level service for patients undergoing our standard hair transplant procedures; (2) premium-level service for patients undergoing the upgraded and customized hair transplant procedures performed by our deans, chief or deputy chief physicians; and (3) top-of-the-line "Yongxiang (雍享)" service for patients undergoing the personalized hair transplant procedures performed by industry-renowned hair transplant experts. During the Track Record Period, patient spending on "Yongxiang" service increased year by year, demonstrating our success in developing a high-end clientele.

Furthermore, we had strong medical service capabilities. Through highly standardized service procedure, we ensure that our patients can receive high-quality medical service in any of the clinics in our network. We are convicted that outstanding hair transplant depends on professional physicians. We have assembled a sizable staff of medical professionals through highly selective recruitment, and uniform and comprehensive on-the-job training. In addition, we put in place a customer service system, which provides 24-hour consultation services to patients. For ever-greater patient satisfaction with our medical services, we have been constantly developing our medical technology. As of the Latest Practicable Date, we held eight patents for medical technology inventions, which have been applied to further improve surgical safety and efficacy. Furthermore, to improve the patients' clinical experience and satisfaction, we offer innovative medical technology services, such as hair transplant without shaving, pain-less surgery, and intraoperative comfort care. We continue to research and develop the field of medical hair care services. For we collaborate with Sun Yat-sen University to research, and have achieved preliminary results in, solutions for allogeneic hair follicle transplant rejection, the development of novel small molecule drugs for preventing anxiety-induced alopecia, multifunctional hair transplant surgical bed, and mild foam shampoo.

One-Stop-Shop Hair-Related Healthcare Service System Rooted in Tenacious Innovation in Product and Service Offerings

By persistent trial and innovation, we have successfully built a one-stop shop system for hair-related healthcare service that centers on the diagnosis of medical hair conditions, and integrates various treatments, including surgeries, medical devices, and medications. Starting with testing, we continuously build on our ability to diagnose various hair-related conditions, and have developed our own hair detector which accurately measures hair length and diameter, analyzes severity of hair loss, and assists physicians in diagnosis and treatment planning. We also invite renowned physicians from Class

IIIA hospitals to train and visit our clinics regularly, to the extent permitted by laws and regulations. Our industry-leading capabilities of testing, diagnosis, and treatment of hair-related conditions give us a unique advantage: For each patient visiting our clinics, we are able to provide a comprehensive diagnosis report, detailing the cause of hair loss and the nature and type of hair conditions. We then offer, based on scalp and hair follicle status analysis, a professional and holistic one-stop-shop treatment solution, which may include hair transplant surgeries, medical hair care services, and wigs.

We are constantly pushing the boundaries of our business, and creating, delivering, and capturing value in the medical hair care service sector. In December 2017, we acquired the mainland China business of *Svenson*. Thereafter, leveraging our strong medical service capabilities and *Svenson*'s extensive experience in offering hair restoration products and services, we opened a *Svenson Medical Hair Care Center* (史雲遜醫學健髮中心) in each hair transplant clinic in mainland China under a "shop-in-shop" model to provide medical hair care services. Medical hair care service is able to address the substantial unmet demands of patients for non-surgical, effective and affordable medical solutions on various scalp and hair problems, including but not limited to hair loss, soft hair, itching scalp and oily scalp. It is also able to satisfy treatment needs of patients at various hair loss stages and attend to both female and male patients of different ages. Further, patients receiving medical hair care services generally need to undergo treatments several times for an extended period to achieve optimal results. According to Frost & Sullivan, we are a first mover in the industry and were the largest market participant in China in 2020 by revenue from medical hair care services. The medical hair care service market in China is still in its infancy, valued at RMB5.0 billion in 2020, but since medical hair care services are expected to address the diversified needs of a larger size of potential patient pool, the market is expected to grow significantly to RMB62.5 billion in 2030 at a CAGR of 28.7%. In view of our advantages accumulated by specializing in China's hair transplant industry, we are confident that our extensive experience and industry know-how will propel our rapid penetration into the medical hair care service market and help realize the great growth potential of the market.

Our one-stop-shop hair-related healthcare system has enhanced our capabilities to meet the needs of different patients and made possible our stable growth during the Track Record Period. We started to generate revenue from our medical hair care services in 2019. Alongside the rapid growth of our hair transplant business, revenue from our medical hair care services increased significantly from RMB15.06 million in 2019 to RMB213.21 million in 2020. For the six months ended June 30, 2021, our revenue from medical hair care services amounted to RMB254.2 million, higher than the amount for the entire year in 2020. The repurchase rate of our medical hair care services was 15.6% in 2019 and increased to 28.9% in 2020. Though affected by the outbreak of COVID-19 in 2020, our total revenue increased nonetheless by 33.8% from 2019 to 2020. According to Frost & Sullivan, the average revenue of China's medical hair transplant businesses decreased by approximately 15% over the same period.

Industry-Leading Technology

We adopt industry-leading technology to enhance patient experience, enlarge our patient base, increase our operating efficiency and reduce costs, which is reflected in the following aspects:

- *Data Usage and Analyses.* We have set up an advanced business management system to track, record, and present operational data from our clinics nationwide. According to Frost & Sullivan, we are the first and as of the Latest Practicable Date, the only hair transplant clinic chain in China that realized the real-time presentation and analysis of various key operating metrics, such as the number of patients, the volume of hair transplant surgery, and the volume of follicular transplant. On the one hand, real-time data presentation enhances the transparency of our healthcare services, thereby improving our patients' treatment experience. On the other hand, by analyzing the data collected from operations, we are able to quickly and accurately identify and meet our patients' demands, effectively manage customer profiles, and develop models for predicting patient needs, making prognoses, advising diagnostic and therapeutic procedures, and implementing targeted advertising.
- *Intelligent Services.* We have developed and launched a set of intelligent consultation service software for graphic, telephonic, and video consultation services. That software helps conduct initial screening and triage of patients online, uploads medical records in real time, facilitates perioperative patient management, and provides patients with convenient online consultation and postoperative services. Our service software automatically provides customized services to different types of patients in need of different treatments, *e.g.*, automatically attending to patients at various preoperative stages, and anticipating and satisfying patients' needs at various postoperative stages. Using artificial intelligence algorithms for customer service, we provide automated and intelligent real-time responses to customers' online inquiries. In addition, we are actively launching smart devices, such as follicular detectors, to save our labor costs. Our follicular detector embodies advanced technologies, such as intelligent image recognition and big data algorithms, which can provide patients with accurate medical test reports, including scalp environment analysis, sebum test analysis, hair follicle health analysis, hair density analysis, hair diameter analysis, diagnostic results, and medical advice, thus greatly enhancing patient consultation experience and the professional quality of service.
- *Online Services.* We are actively promoting online medical services, and have put together a dedicated online medical staff. Our online medical service system allows real-time upload of medical documents, such as the patient's medical records, thereby bringing convenient and professional online consultation and postoperative review services to patients. We use Internet platforms to provide online medical services. For example, we developed a hair management mini-program on WeChat to give patients convenient access to introductions of hair transplant procedures, credential of our physicians, pricing information, recent discount policies, and so on. As of the Latest Practicable Date, our WeChat service platform, Hair Manager, had over 811,000 registered users.

We believe our technology-oriented operation represents a unique advantage that differentiates us from other hair-related healthcare service providers, enables continuous improvements of patient experience, attracts more patients, and reinforces patient loyalty, which will further stimulate brand development and solidify our market dominance.

Visionary and Seasoned Management and Strong Shareholder Support

Our success is attributable to our visionary and dedicated management with extensive industry experience. Our founder and chief executive officer, Mr. ZHANG, started hair transplant business in 2005, and has been specializing in the hair transplant industry for 16 years, accumulating a wealth of first-hand experience in the industry. He understands the needs of Chinese patients, and has a profound and unique insight into the pain points and development potential of China's hair-related healthcare service industry. Mr. Zhang is a pioneer and leader in the hair transplant industry, and is committed to providing the most advanced hair transplant solutions for Chinese hair-loss patients. He has introduced advanced technology from abroad, and continues to promote technological innovation and the orderly development of the entire industry. Mr. Zhang led the formulation of our major development strategies in the past, such as clinic expansion strategies, talent recruitment plans in the hair field, and the development of our one-stop-shop service system. Leveraging his foresight of the industry, innovative operational philosophy, and excellent management skills, Mr. Zhang has led us to stay ahead in China's hair-related healthcare service industry.

Our senior management has extensive industry experience and complimentary backgrounds and expertise. Our assistant president and chief operating officer, Mr. XU Yang, has over 18 years of experience in the operations and management for medical service provider chains and Internet companies. He worked for several well-known Internet technology companies, including Baidu Online Network Technology (Beijing) Co., Ltd. (百度在線網絡技術(北京)有限公司), and also worked for Beijing Evercare Medical Technology Group Co., Ltd. (北京伊美爾醫療科技集團股份公司), a renowned plastic surgery chain. In particular, Mr. Xu has rich experience introducing new technology to businesses. Our director of finance, Ms. HAN Zhimei, has over 23 years of experience in corporate financial management and the finance industry, especially in the financial management of medical clinic chains, such as Ciming Health Checkup Management Group Co., Ltd. (慈銘健康體檢管理集團有限公司). Ms. Han has been overseeing the continuously improvements of the group's financial and internal control systems throughout the chained network. Our president of medical services, Mr. LI Xiaolong, has over 10 years of management experience in the medical services sector. He held senior management positions in the People's Liberation Army No. 309 Hospital (解放軍第309醫院), the Health Bureau of the People's Liberation Army General Staff Department (中國人民解放軍總參謀部衛生局). He has a deep understanding of cutting-edge technologies and patient needs, and has led the development of our core diagnostic and therapeutic capabilities. Our director of sales and marketing, Mr. HUANG Donghong, has nearly ten years of experience in marketing, and has been leading our ongoing brand development. For their biographical details, see "Directors and Senior Management" in this prospectus.

In addition to our management team, we also benefit tremendously from the strong support of our Shareholders, who have been working closely with our committed management team to develop and implement our strategies. Our Controlling Shareholder CITIC PE has extensive experience in managing and growing companies in the consumer medical industry, and provided us with invaluable guidance for our value creation strategy and sustainable growth. Leveraging CITIC PE's strong bargaining power backed by the extensive portfolios where it has controlling interest, we are able to obtain more favorable terms when negotiating with our suppliers and other business partners. We also benefit from CITIC PE's broad network of industry experts, talents and enterprises which bring about synergistic business opportunities while maintaining full independence. For example, CITIC PE introduced acquisition targets such as the mainland China business of *Svenson* and the greater China business of *Nu/Hart Hair* to expedite our business expansion. See "History, Development and Corporate Structure" in this prospectus for more details.

OUR STRATEGIES

Our mission is to become a world-leading one-stop shop for hair-related healthcare services. We plan to implement the following strategies to achieve that goal:

Continue Our Network Expansion and Upgrade, and Strengthen Talent Development and Recruitment

We will further expand our geographical coverage by penetrating into lower-tier cities. We will continue to follow and improve the standard operating procedure, increase our penetration rate in cities where we have established operational presence, and further expand to lower-tier cities in China. We aim to reach nearly one hundred hair transplant clinics across the country within the next few years. We will push for the transformation of our hair transplant clinics to comprehensive medical hair care service hospitals. We have started to transform our well-established clinics in tier-one cities to comprehensive medical hair care service hospitals, and plan to upgrade, in due course, our clinics in more provincial capitals to comprehensive hair hospitals, thereby getting us closer to a leading comprehensive hair diagnostic and therapeutic service system as planned. We plan to apply a portion of the net proceeds from the Global Offering for such purposes. See “Future Plans and Use of Proceeds — Use of Proceeds” in this prospectus for details.

We believe professional talents are at the core of the hair-related healthcare service industry, and we plan to focus on establishing a sound talent recruitment, retention and training program to support our continuous expansion. We will continue to bring in physicians who are experts in hair disease diagnosis and treatment from public hospitals to conduct consultation (坐診) and train our staff. We plan to attract more professional talents by collaborating with universities and Class IIIA hospitals. We will attract high-caliber talents by offering competitive pay and career development policies, thus enhancing our operations and management capabilities. In addition, we will further optimize internal staff training by, for instance, starting a dedicated department staffed with specialists, in order to provide a continuous supply of professional talents to the company.

Promote Further Innovations in Product and Service Offerings to Expand the One-Stop-Shop System for Hair-Related Healthcare Service

We will continue to promote product and service innovations with a focus on enhancing patient experience and comfort. We will keep up with the ever-evolving clinical needs of patients and continue to upgrade our treatment solutions. We plan to further optimize our hair transplant procedures such as widow’s peak (美人尖) transplant, hairline lowering, eyebrow transplant, to address the personalized and aesthetic treatment demands of our patients, particularly female patients.

We will continue the research and development of surgical instruments and medical hair care devices through both our own research and development activities and joint efforts with our cooperative partners. For example, to enhance patient comfort as well as the safety and transparency of our treatment, we are developing various instruments and devices such as treatment couch, intelligent shadowless lamp and follicle segregation table. We are also dedicated to providing personal and customized postoperative services and products to our patients. Based on our observation and analysis of the demands of patients at postoperative stages, we are developing several ancillary products such as wigs and functional pillows that are specially designed to enhance patient experience at the recovery stage. We plan to apply a portion of the net proceeds from the Global Offering for such purposes. See “Future Plans and Use of Proceeds — Use of Proceeds” in this prospectus for details.

In addition, we strive for new heights in technology research and development relating to hair disease diagnosis and treatment. We plan to cooperate with more universities and Class IIIA hospitals to research on cutting-edge technologies, such as our collaboration with Sun Yat-sen University in researching follicular regeneration technology. We believe such academic development and cooperation will lead to the next breakthrough in the hair-related healthcare industry and our investment in these cutting-edge research areas will pay off with tremendous growth potential.

Continue to Adopt New Technologies

We will carry on our push for more data usage and analyses, intelligent services and online services, optimize patient experience, enhance operational efficiency, and reduce management costs without compromising the quality of medical service. On intelligent services, we will continue to invest in technology infrastructure and software capabilities to upgrade our service system. In particular, we intend to develop a flexible and scalable information technology system to streamline our one-stop services, covering consultation and examination, diagnosis and treatment, and post-treatment services. We plan to introduce or develop in-house high-tech intelligent equipment or instruments, such as automated follicle detectors and robotic manipulators for follicle transplant, to improve the accuracy of hair diagnosis and hair transplant procedures, while reducing the reliance on manual labor.

On data usage and analysis, we will improve the collection and real-time presentation of more medical data at each clinic or hospital across the country, for greater transparency of our diagnosis and treatment services. We will also put patient service data (after duly desensitization, if needed) to use to guide and inform the development of our hair disease diagnosis and treatment system.

On online services, we will continue to build online hospital services, enhance our online diagnostic and treatment capabilities, enrich our online service offerings, and present and apply the data collected online to patients in real time in a more systematic and visualized way, so as to further enhance patients' consultation experience. We will also rely on the Internet to improve management. For example, we will further the standardization of services and supervise local branches from the headquarters via real-time videos and unified online systems. We plan to apply a portion of the net proceeds from the Global Offering for the aforesaid adoption of new technologies. See "Future Plans and Use of Proceeds — Use of Proceeds" in this prospectus for details. As advised by our PRC Legal Adviser, since the online services we provide to our patients and other online users do not fall within the scope of value-added telecommunication services as stipulated in the applicable PRC laws and regulations, currently we are not subject to any license requirements and/or foreign ownership restrictions for providing such online services. For the details of the licensing and regulatory requirements of the online services we plan to offer in the future, see "— Our Information Technology — Online Services" in this section.

Integrate Industry Resources and Promote Multi-Brand Strategy

We have adopted and will further promote a multi-brand strategy to cater for the different needs of patients. In addition to our established brand *Yonghe Hair Transplant*, we will further promote our services under marks like *Svenson Medical Hair Care*, so as to present a full-spectrum of service offerings to patients. We are also developing a new hair transplant brand targeting female patients. We believe our multi-brand development approach will strengthen our presence in the industry and create substantial synergies to support our future growth.

BUSINESS

We plan to acquire independent local hair transplant clinics to expedite the concentrated multi-location expansion in key regions. We will focus on major economically developed regions in China with high population density, such as South China and East China, to accelerate our rise to the top in those regions. We will consider a variety of factors when selecting acquisition targets, such as the target's diagnostic and treatment capabilities, local brand goodwill, and the medical staff. We plan to apply a portion of the net proceeds from the Global Offering for such acquisitions. See "Future Plans and Use of Proceeds — Use of Proceeds" in this prospectus for details. We currently have no specific target in negotiations. We plan also to open experience demonstration centers (示範體驗中心) and improve our experiential services nationwide to raise brand awareness.

We will effectively integrate our achievements and deepen our cooperation with companies in the supply chain, and innovate the mode of cooperation with businesses upstream and downstream in the supply chain, *e.g.*, strengthening cooperation with medical device and pharmaceutical companies by signing business cooperation framework agreements and equity investment, so as to achieve greater synergy and raise our brand awareness. We plan to fund such cooperation and investment with our internal capital resources. We currently have no material collaboration or investment proposal in negotiations.

OUR BUSINESS

We are the leading medical group in China specialized in providing hair-related healthcare services in terms of total revenue for 2020. During the Track Record Period, we focused on providing hair transplant services while constantly expanding the boundaries of our business. Since 2019, we started to provide medical hair care services by establishing a *Svenson Medical Hair Care Centers* (史雲遜醫學健髮中心) in each of our hair transplant clinics in mainland China under a "shop-in-shop" model. Our *Svenson Medical Hair Care Centers* provide patients with non-surgical, effective and affordable medical solutions on various scalp and hair problems, including but not limited to hair loss, soft hair, itching scalp and oily scalp. In addition to hair transplant and medical hair care, we also generate a small portion of revenue from providing routine hair restoration products and services through non-medical institutions. The following table sets forth the components of our revenue by business line for the period indicated.

	Year Ended December 31,						Six Months Ended June 30,			
	2018		2019		2020		2020		2021	
	<i>RMB'000</i>	%	<i>RMB'000</i>	%	<i>RMB'000</i>	%	<i>RMB'000</i>	%	<i>RMB'000</i>	%
Hair transplant services	918,014	98.3	1,197,775	97.8	1,412,744	86.2	567,225	94.3	789,522	75.0
Medical hair care services	–	–	15,060	1.2	213,214	13.0	30,687	5.1	254,189	24.1
Others ⁽¹⁾	16,312	1.7	11,642	1.0	12,339	0.8	3,651	0.6	9,689	0.9
Total	934,326	100.0	1,224,477	100.0	1,638,297	100.0	601,563	100.0	1,053,400	100.0

Note:

- (1) Others mainly include revenue from *Svenson Hair Care Centers* (史雲遜健髮中心) we acquired in December 2017. These *Svenson Hair Care Centers* are not medical institutions and primarily engaged in providing routine hair restoration products (such as anti-hair loss shampoo and head massager) and services (such as scalp cleaning and massaging) without using medicines or medical devices.


BUSINESS

Ancillary to our provision of medical services, we from time to time sell drugs (including prescription drugs and over-the-counter drugs) to our patients. The prescription drugs primarily include drugs for the treatment of hair loss such as Finasteride Tablets (非那雄胺片) and anesthetics and anti-infection drugs commonly used in hair transplant surgeries such as Lidocaine Hydrochloride (鹽酸利多卡因) and Gentamicin Injections (慶大黴素注射液). The over-the-counter drugs primarily include drugs commonly used to prevent post-operative infections and relieve pains such as Bactroban (百多邦) and Ibuprofen (布洛芬). The fees for these drugs are included in, and typically account for a very small portion, our relevant (i.e., hair transplant or medical hair care) service fees. All of the drugs we provide to our patients are approved for marketing by the National Medical Products Administration of the PRC or its local counterparts. We only provide drugs to our hair transplant or medical hair care patients when providing our medical services, and do not sell any drugs to the general public. The drugs will only be provided to our patients if approved by our licensed physicians, each of whom holds a Practicing Certificate of Physician (執業醫師證). As advised by our PRC Legal Adviser, physicians holding the Practicing Certificates of Physician are qualified to prescribe drugs at their practicing medical institutions, and our clinics do not need special permits or licenses such as Pharmaceutical Trade Licenses (藥品經營許可證) other than the Medical Institution Practicing Licenses already held by our clinics, in order to sell drugs to our patients when providing medical services.

Benefiting from the organic synergies between our hair transplant services and medical hair care services, our patient base was rapidly growing during the Track Record Period. Our total number of patients receiving our treatments increased by 41.7% from 35,177 in 2018 to 49,851 in 2019, and further increased by 82.7% to 91,069 in 2020. In the six months ended June 30, 2021, the total number of patients receiving our treatments reached 68,112.

Our Medical Services

We offer one-stop hair-related healthcare services to patients visiting our clinics. Our typical service process consists of consultation and examination, diagnosis and treatment planning, treatment and post-treatment services. The chart below provides an overview of the typical process of our one-stop hair-related healthcare services.



Consultation and Examination

After a patient visits us for the first time and completes registration, we perform a professional hair and scalp microscopy with our self-developed hair follicle detector to examine the patient's hair and scalp conditions. To obtain a more comprehensive, reliable and accurate diagnosis and to understand the possible causes of hair loss, we will further conduct Dihydrotestosterone test for male patients to assess the risk of androgenic baldness, and hair loss hormone test for female patients to assess their Adrenal Androgens and Serum Ferritin.

Diagnosis and Treatment Planning

During the diagnosis and treatment planning stage, our physicians form a professional opinion of the patient's examination report. They explain in detail to patients the possible causes of hair loss and analyze their scalp condition, hair condition and severity of hair loss. Taking into consideration the demand of patients, appropriate treatment method is then decided by the physician for patients. We recommend medical hair care treatment for patients with early stages of hair problems, and hair transplant treatment for patients with thinning hair or bare follicular closure.

Treatment

Hair Transplant

Hair transplant is a surgical procedure in which hair follicles are extracted from the back occipital area with high quality hair follicles and transplanted to bare and thinning hair areas. In China, hair transplant is classified as Grade I surgery under the *Classification Catalog of Aesthetic Medical Item* (《醫療美容項目分級管理目錄》), indicating that hair transplant is normally safe and carries lower risks than other types of surgeries.

We are the largest hair transplant service provider in China. Backed by a team of highly experienced and capable medical professionals, we are able to offer a broad range of hair transplant services to meet the diverse needs of our patients. In addition to traditional hair transplant services, our services include aesthetic hair transplant such as hairline lowering, eyebrow transplant, and sideburn transplant, as well as bespoke service for female clients suited to their aesthetic aspirations provided by a dedicated surgical team. The surgical procedures and underlying hair transplant techniques involved in different types of hair transplant are generally the same. With the growing awareness around physical appearance in society, our diversified service offerings will effectively help us capture a larger group of consumers.

We are dedicated to providing professional and high-quality hair transplant services to patients. We have adopted a comprehensive set of standard operational procedures aiming to consistently deliver safe, high quality hair transplant services to our patients. For example, in addition to requiring each of our hair transplant surgeries to be performed by licensed physicians and supervised by physicians holding the Aesthetic Medical Attending Physician qualification, we also require all key steps of the hair transplant surgeries (such as anesthesia, follicular extraction, and incision of bald areas) to be performed by physicians personally. Moreover, the performance of hair transplant surgeries by our newly recruited physicians must be under one-on-one supervision of senior physicians for at least one month. When evaluating the performance of our physicians, “productivity” has never been the most important key performance indicator (KPI) considered by our management team; instead, our management team focuses more on KPIs such as procedure success rate, patient feedback, and time devoted to training and guiding junior physicians. In fact, as opposed to driving our physicians to perform as much as procedures as possible, we would proactively manage the workload of our physicians, to ensure that our physicians are not over-burned, and can devote sufficient time and pay close attention to each of their patients. We believe that such efforts will ultimately translate into patient loyalty and accrue goodwill to our brand, and benefit our long-term growth. For more details, see “— Quality Assurance” and “— Our Professional Team” in this section.

We have also strategically established a multilevel service system to address the diverse needs of our patients. As of the Latest Practicable Data, we offered three levels of hair transplant services distinguished by the experience and skills of our physicians, including (1) basic-level service for patients undergoing our standard hair transplant procedures; (2) premium-level service for patients undergoing the upgraded and customized hair transplant procedures performed by our deans, chief or deputy chief physicians; and (3) top-of-the-line “Yongxiang (雍享)” service for patients undergoing the personalized hair transplant procedures performed by industry-renowned hair transplant experts. We typically charge a patient RMB20,000 to RMB30,000 for receiving basic-level services, RMB30,000 to RMB50,000 for receiving premium-level services, and over RMB100,000 for receiving “Yongxiang” services. We determine the prices for different service levels by taking into account a number of factors such as patient demand, treatment complexity, market conditions, the pricing policies of our competitors and operating costs. For details, see “— Pricing and Payment” in this section.

BUSINESS

Our number of hair transplant patients grew rapidly during the Track Record Period as a result of our expanded service offerings and improved service quality. The table below illustrates the key operating data of our hair transplant services.

	Year Ended December 31,			Six Months Ended June 30, 2021
	2018	2019	2020	
Number of patients receiving hair transplant services	35,177	43,087	50,694	29,480
Average spending per patient (RMB)	26,097	27,799	27,868	26,782
Three Levels of Services				
Number of patients that accepted basic-level services	35,037	42,235	48,575	27,254
Number of patients that accepted premium-level services	–	512	1,827	2,088
Number of patients that accepted “Yongxiang” services	140	340	292	138

Medical Hair Care

Medical hair care integrates various non-surgical treatment methods, such as medical devices and medications to provide hair transplant patients with preoperative and postoperative medical services, and to satisfy the various needs of patients who are not in need of, or unfit for, hair transplant. Unlike the hair transplant market, the medical hair care service market is characterized primarily by repeat sales to the same patients. According to Frost & Sullivan, the medical hair care service market in China is still at its infancy with great growth potential.

We are one of the first movers in China’s medical hair care industry and were the largest market participant in China in 2020 by revenue from medical hair care services. Since 2019, we have provided medical hair care treatments through *Svenson Medical Hair Care Centers* (史雲遜醫學健髮中心) in our hair transplant clinics under a “shop-in-shop” model. As of the Latest Practicable Date, we had established a *Svenson Medical Hair Care Center* in each of our 52 hair transplant clinics in mainland China.

At our *Svenson Medical Hair Care Centers*, our registered physicians will provide patients with professional advice and holistic treatments, combining procedures such as lasers and light therapy that use medical devices, and pharmaceuticals representing the leading hair science. We may also give nutritional advice, and recommend lifestyle changes to improve the health of the hair and scalp.

BUSINESS

The table below illustrates the key operating data of our medical hair care services.

	Year Ended December 31,			Six Months Ended June 30,
	2018	2019	2020	2021
Number of patients receiving medical hair care services	–	8,564	59,122	52,633
– Number of patients purchasing prepaid packages	–	2,996	41,830	42,827
– Number of patients not fully utilizing their prepaid packages	–	1,332	17,296	33,879
Average spending per medical hair care patients (<i>RMB</i>)	–	1,759	3,606	4,829
Repurchase Rate* (%)	–	15.6	28.9	22.2

Note:

- * Calculated by the number of patients purchasing our medical hair care services more than once, divided by the total number of patients receiving our medical hair care services during the period.

Many of our medical hair care therapies are delivered in the form of treatment courses, where patients will receive several treatments in a period to obtain optimal treatment results. We provide prepaid packages for these patients. Our prepaid packages normally do not bear an expiry date while the majority of our patients will fully utilize the prepaid packages within two years. Whenever our patients with prepaid packages request for refund and regardless of their reasons, we generally refund them in full if their prepaid packages are unutilized, and if the packages are partly utilized, we will refund them the remaining amounts corresponding to the unutilized services. Despite of our relaxed refund policy, less than 0.5% of the patients who had purchased prepaid packages requested for refund during the Track Record Period. Our medical hair care service staff are compensated by fixed salaries and performance-based bonuses based on their ability to meet or exceed the applicable key performance indices set by the management such as attendance rate and patient feedbacks, which may vary from time to time according to business needs. We make commission payments to our medical professionals based on their length of service and total number of patients served during a period, and to our service managers based on prepaid packages sold and repurchases of our patients. We do not make any direct commission payments to our medical professionals for selling prepaid packages. We believe these policies will properly incentivize our staff, and duly protect the interests of our customers and guarantee the quality of our services at the same time. We designed our prepaid packages with references to the Guidelines for Consumer Prepaid Service Transaction Contracts (北京市消費類預付費服務交易合同行為指引) promulgated by the Beijing AMR, as well as other applicable best practice guidelines issued by the relevant consumer protection bodies. We have also adopted several internal policies to avoid unscrupulous sales practices. See “— Environmental Sustainability and Social Responsibility — Social Responsibility” for more details.

BUSINESS

We are dedicated to establishing long-term relationships with our medical hair care customers. In 2019, the first year we commenced our medical hair care businesses, the repurchase rate of our medical hair care services reached 15.6%. As a result of our efforts in diversifying service offerings and enhancing patient experience, such repurchase rate increased significantly to 28.9% in 2020. Our provision of prepaid packages had, to some extent, affected such repurchase rate during the Track Record Period. As illustrated in the table above, a substantial portion of our medical hair care customers who had purchased the prepaid packages did not fully utilize the services thereunder during the relevant periods. The number of patients purchasing our prepaid packages increased significantly from 2,996 in 2019 to 41,830 in 2020, and reached 42,827 in the first half of 2021, indicating an increasing customer recognition on our services. We expect to strengthen customer loyalty and further improve the repurchase rate of our medical hair care services by continuously improving our service quality.

Post-Treatment Services

After hair transplant surgery, we have a professional post-treatment service team to provide post-surgery consultation and care services to patients. For example, within seven days after surgery, we offer gauze removal, hair washing and blood scab cleaning; within eight days to three months, we provide photodynamic and post-surgery restoration care; within four months to twelve months, we provide recovery examination and other services. In addition to in-hospital review, we also offer remote review services to patients, who can complete post-surgery review, post-surgery recovery, post-surgery medication and other relevant guidance without leaving home.

OUR CLINIC NETWORK

We own and operate the largest and most widely distributed hair transplant clinic chain in China, according to Frost & Sullivan. As of the Latest Practicable Date, we had 53 hair transplant clinics nationwide, 52 of which were self-operated and one was acquired from third parties. We experienced rapid expansion in recent years. The following table sets out the number of our clinics in operation during the Track Record Period:

	Year Ended December 31,			Six Months Ended June 30, 2021
	2018	2019	2020	
Number of clinics in operation at the beginning of the period	22	30	37	48
Number of new clinics opened during the period	8	7	11	3
Number of clinics acquired during the period	–	–	–	1
Number of clinics in operation at the end of the period	30	37	48	52

BUSINESS

During the Track Record Period and up to the Latest Practicable Date, we upgraded some of our clinics, and in a number of instances, such upgrades were completed by relocating old clinics to new locations in the same cities. We made such relocation and upgrades in order to enhance patient experience, and/or to rectify the non-compliances concerning the buildings where the old clinics were located in. Procedurally, such relocations involved the cessation of operation and closure of the old clinics, and the opening of new clinics, but since (i) the old clinics and the new clinics were located in the same cities, (ii) the old clinics and the new clinics were operated and managed by the same teams, and (iii) our business operations in the relevant cities had never experienced any material disruption or cessation as a result of such relocations, we regarded the old clinics and the new clinics as the same clinics. In order to rectify certain non-compliance incidents, we relocated, or plan to relocate four of our clinics in Shanghai, Xi'an, Urumqi and Changsha, respectively. See “— Licenses, Permits, Approvals and Compliance” for more information.

Geographic Locations

As of the Latest Practicable Date, our 53 hair transplant clinics covered 52 cities in 26 provinces, autonomous regions and centrally-administered municipalities across mainland China and in Hong Kong. We typically enter a province by setting up our clinics in the provincial capital first. During the Track Record Period, we primarily focused on establishing our market presence in regions with huge hair transplant demands and high *per capita* income. We are striving to achieve regional concentration strategy by opening clinics in more cities in such regions. The following table sets forth the breakdown of the number of our clinics in operation by geographical regions during the Track Record Period:

	As of December 31,			As of June 30,
	2018	2019	2020	2021
Eastern China ⁽¹⁾	10	15	21	23
Southern China ⁽²⁾	4	5	10	10
Northern China ⁽³⁾	4	4	4	4
Southwestern China ⁽⁴⁾	4	4	4	4
Central China ⁽⁵⁾	3	3	3	4
Northwestern China ⁽⁶⁾	2	3	3	3
Northeastern China ⁽⁷⁾	3	3	3	3
Hong Kong ⁽⁸⁾	—	—	—	1
Total	30	37	48	52

Notes:

- (1) Including Shanghai, Zhejiang, Jiangsu, Fujian, Jiangxi, An'hui and Shandong.
- (2) Including Guangdong and Guangxi.
- (3) Including Beijing, Tianjin, Hebei and Shanxi.
- (4) Including Sichuan, Guizhou, Yunnan and Chongqing.
- (5) Including Henan, Hubei and Hunan.
- (6) Including Shaanxi, Gansu and Xinjiang.
- (7) Including Heilongjiang and Liaoning.
- (8) Including one acquired clinic, *Nu/Hart Hair*, in Hong Kong.

BUSINESS

Following our inception, we firstly established our presence in tier-one cities with large populations and high *per capita* income, where we grew rapidly and became a top market player. As of the Latest Practicable Date, we had extended our footprint in four tier-one cities, 15 new tier-one cities, 25 tier-two cities and seven lower-tier cities and in Hong Kong. As of the Latest Practicable Date, we had only one hair transplant clinic in one city except Hangzhou, where we had two clinics. We are also speeding up our pace to expand to China's tier-two and lower-tier cities. The following table sets forth the breakdown of the number of our clinics in operation by city tiers during the Track Record Period:

	As of December 31,			As of June 30, 2021
	2018	2019	2020	
Tier-One Cities	4	4	4	4
New Tier-One Cities	13	13	16	16
Tier-Two Cities	12	18	24	25
Lower-Tier Cities	1	2	4	6
Hong Kong	—	—	—	1
Total	30	37	48	52

The following maps set forth the relevant information of our clinic network as of the Latest Practicable Date.



BUSINESS

Development Stages

Our clinics can be categorized into three groups based on their respective opening date, including mature-stage clinics (i.e., clinics that have been established for more than three years), developing-stage clinics (i.e., clinics that have been established for one to three years), and newly-established clinics (i.e., clinics that have been established for less than one year). For acquired clinics, we regard the date when their financial position and results of operations are consolidated into our Group as their respective opening date. During the Track Record Period, we only acquired one clinic in May 2021. As of the Latest Practicable Date, we had 30 mature-stage clinics, 17 developing-stage clinics and six newly-established clinics (including the acquired clinic). The following table sets forth the breakdown of the number and revenue of our clinics by development stage for the periods indicated:

	Year Ended December 31,						As off/for the Six Months Ended June 30, 2021	
	2018		2019		2020			
	<i>RMB'000</i>		<i>RMB'000</i>		<i>RMB'000</i>		<i>RMB'000</i>	
Mature-stage clinics	10	555,038	16	831,989	22	1,196,970	24	722,954
Developing-stage clinics	12	300,766	14	338,917	15	328,511	17	234,541
Newly-established clinics	8	62,210	7	41,929	11	100,477	11	86,216
– Acquired clinics	–	–	–	–	–	–	1	754
Total	30	918,014	37	1,212,835	48	1,625,958	52	1,043,711

Initial Breakeven Period and Cash Investment Payback Period

The initial breakeven period represents the period from the opening of a clinic to the time when it records monthly net profit for the first time. The cash investment payback period for a clinic represents the time it takes for the accumulated operating cash flow attributable to us from the relevant clinic to recover the initial investment. The average initial breakeven period of all of our self-operated clinics in operation as of the Latest Practicable Date was approximately three months, and their average cash investment payback period was approximately 14 months.

BUSINESS

Service Capacity of our Clinics

We evaluate the service capacity of a clinic primarily based on the number of hair transplant surgeries can be performed therein. Service capacity and utilization rate affects our results of operations and, to some extent, indicates our growth potential. The table below sets forth the service capacity and utilization rate of our clinics by development stages for the periods indicated:

	For the Year Ended December 31,						For the Six Months Ended June 30,	
	2018		2019		2020		2021	
	Maximum Service Capacity ⁽¹⁾	Utilization Rate ⁽²⁾	Maximum Service Capacity	Utilization Rate	Maximum Service Capacity	Utilization Rate	Maximum Service Capacity	Utilization Rate
		(%)		(%)		(%)		(%)
Mature-stage clinics	26,096	80.9%	44,332	66.3%	65,280	56.2%	36,452	55.6%
Developing-stage clinics	21,500	53.4%	31,248	38.4%	30,256	36.0%	17,324	38.5%
Newly-established clinics ⁽³⁾	7,140	36.1%	8,548	20.0%	12,666	24.5%	12,142	20.8%
Total	54,736	64.3%	84,128	51.2%	108,202	46.9%	65,918	44.7%

Notes:

- (1) Represents the maximum number of surgeries can be performed theoretically in such clinics during a given period. Considering that a hair transplant surgery generally takes three to seven hours to complete, one surgery room can assume up to two hair transplant surgeries in theory every day. The maximum service capacity of our clinics is calculated as the average number of surgery rooms in use of the clinics multiplied by two (the daily maximum number of surgeries per room) and the number of working days in the relevant year or period.
- (2) Represents the actual number of surgeries performed during the given period as a percentage of the maximum service capacity of such clinics in the relevant period.
- (3) Excludes the clinic in Hong Kong acquired by us in May 2021 for the purpose of this table.

Our provision of medical hair care services is generally not limited by the service capacity disclosed above, while it might be affected by various other factors such as the service area of our clinics and the availability of medical devices and equipment. To improve service capacity and enhance patient experience, we selectively upgrade our clinics from time to time to cover larger service areas. See “—Expansion and Acquisitions” in this section for details of our plan to upgrade existing clinics.

Expansion and Acquisitions

As part of our growth strategy, we intend to continue expanding our clinic network to strengthen our presence in our target markets. We plan to apply a portion of the net proceeds from the Global Offering for such purposes. See “Future Plans and Use of Proceeds — Use of Proceeds” in this prospectus for details.

BUSINESS

Expansion

Leveraging our successful track record and highly scalable business model, we intend to continuously establish new clinics across China. We currently plan to establish approximately 50 new hair transplant clinics primarily in China's tier-two and lower-tier cities. The following table sets forth the details of our plans for the establishment of new clinics in the next two years:

Location	Current Status	Estimated GFA (sq.m.)	Expected Year of Opening
Jiangsu	Under renovation	2,420	2021
Fujian	Under renovation	2,390	2022
Guangdong	Under renovation	2,089	2022
Shandong	Under planning	2,000	2021
Guangdong	Under planning	2,000	2022
Guangxi	Under planning	2,000	2022
Guizhou	Under planning	2,000	2022
Inner Mongolia	Under planning	2,000	2022
Hebei	Under planning	2,000	2022
Hebei	Under planning	2,000	2022
Henan	Under planning	2,000	2022
Henan	Under planning	2,000	2022
Shandong	Under planning	1,674	2022
Shandong	Under planning	2,000	2022
Zhejiang	Under planning	2,000	2022
Zhejiang	Under planning	2,000	2022

The opening of a new clinic generally involves a number of steps, primarily including:

- *strategic planning and market research.* At this stage our management will determine the cities where we plan to open new clinics based on the review of market data as well as the evaluation of our internal resources available;
- *site selection and lease negotiation.* at this stage our business development personnel will make site visit to the target cities, select the location of our new clinic base on the site selection criteria as disclosed below, and negotiate and enter into lease with the relevant property owners;
- *design.* At this stage, we will design our clinics following the applicable PRC laws and regulations, and file our design plans with the local health commission for approval;
- *construction and decoration of premises.* Upon the approval of our design plans by the competent authorities, we will engage third party contractors to conduct construction and decoration for our new premises; and
- *inspection and commencement of operations.* Upon completing of the construction, the relevant local authorities will conduct an inspection over our premises in respect of fire

BUSINESS

safety, environmental compliance and others. We may commence the operations after all regulatory approval processes and necessary inspections have been completed.

In addition to the above procedures, the opening of a new clinic may also involve the recruitment of necessary personnel and the acquisition of equipment and supplies. According to our experience during the Track Record Period, the entire process generally takes around no more than eight months to complete. We consider location a critical factor in determining a clinic's long-term success. We carefully consider potential markets and conduct a systematic evaluation of each potential new clinic site. Our site selection criteria primarily include:

- GDP *per capita* and population density of the local community;
- presence of activity centers, such as offices, shopping complexes and residential areas that generate guest traffic;
- accessibility by public transportation, traffic conditions and parking space;
- number and nature of competitors in the commercial district; and
- rental costs, lease economics and estimated return on investment.

We also plan to upgrade two of our clinics to provide a better customer experience and customer satisfaction. The following table sets forth the details of our plans for the upgrade of our existing clinics in the next two years:

<u>Name of Existing Clinics</u>	<u>Current Status</u>	<u>Estimated GFA (sq.m.)</u>	<u>Expected Time of Opening</u>
Guiyang Yonghe	Under planning	3,805	2021
Beijing Yonghe	Under renovation	9,616	2022

In addition, to serve more patients with varied hair problems, we are building four comprehensive medical hair care service hospitals in Beijing, Shanghai, Guangzhou, and Shenzhen, including two hospitals to be newly established in Beijing and Shanghai (i.e., Beijing Yonghe Hospital and Shanghai Yonghe Hospital), and two hospitals to be transformed from existing clinics in Guangzhou and Shenzhen (i.e., Guangzhou Yonghe and Shenzhen Yonghe). Our comprehensive medical hair care service hospitals plan to hire physicians from Class IIIA hospitals to diagnose and treat various hair-related diseases. We will also set up multiple hair-related specialty departments in addition to the hair transplant department, such as alopecia department, re-examination department, international department, and feminine beauty department.

Hospitals in China are ranked into three classes, i.e., Class I, II and III, with Class III being the highest class. We currently intend to apply for the Class I hospital certifications for our comprehensive medical hair care service hospitals. According to the applicable PRC laws and regulations, a Class I hospital needs meet certain standards in respect of facilities, equipment and human resources, such as a minimum of 20 registered beds, a minimum of three licensed physicians and five nurses, and the set-up of certain required clinical departments and medical technology departments. The relevant health commission at provincial level will be responsible for issuing the Class I hospital certifications. For details, see “Regulatory Overview — Regulations on the Administration and Classification of Healthcare Institutions” in this prospectus.

Acquisitions

When appropriate opportunities arise, we will also consider acquiring clinics in new markets with a sizable population and a relatively high demand for hair transplant services. We believe our previous operating experience will aid us in identifying potential acquisition opportunities and successfully integrating newly acquired clinics’ operations into our existing infrastructure. We systematically review and screen potential clinic targets. We evaluate clinic targets based on a number of criteria, including:

- the target’s compatibility with our growth strategies;
- potentials to achieve synergies with our existing clinics;
- potential returns and estimated future value;
- the target’s current operations and capacity taking into consideration its medical professionals and facilities, required licenses and permits for operations; and
- estimated cost to integrate the acquired business into our operations, ongoing operating expenses and capital requirements.

In May 2021, we expanded our footprint outside the mainland China by acquiring the Hong Kong business of *Nu/Hart Hair* (顯赫植髮), a renowned hair transplant service provider originated from the U.S. As of the Latest Practicable Date, we had not entered into any letters of intent or agreements with respect to acquisitions or had identified any definite acquisition targets. For more details of this acquisition, see “History, Development and Corporate Structure — Acquisition of Nu/Hart Hair Solutions Limited” in this prospectus.

To execute our business strategies, we plan to acquire independent local hair transplant clinics to expedite the concentrated multi-location expansion in key regions. We will focus on major economically developed regions in China with high population density, such as South China and East China, to accelerate our rise to the top in those regions. We will consider a variety of factors when selecting acquisition targets, such as the target’s diagnostic and treatment capabilities, local brand goodwill, and the medical staff. According to Frost & Sullivan, independent local hair transplant institutions are a significant group of market participants in China’s hair transplant service market and there are several suitable acquisition targets available in the market. See “Industry Overview — The Hair Transplant Service Market in China — Market Players and Competitive Landscape” for details. We currently have no specific target in negotiations.

BUSINESS

OUR TOP TEN CLINICS

We did not have any loss-making clinics in terms of gross profit during the Track Record Period. The table below sets forth the revenue and gross profit of our top ten clinics (in terms of total revenue contribution during the Track Record Period) for the periods indicated:

Clinic ⁽¹⁾	Year Ended December 31,										Six Months Ended June 30,					
	2018				2019				2020				2021			
	Revenue		Gross Profit		Revenue		Gross Profit		Revenue		Gross Profit		Revenue		Gross Profit	
	<i>RMB'000</i>	<i>% of total</i>	<i>RMB'000</i>	<i>% of total</i>	<i>RMB'000</i>	<i>% of total</i>	<i>RMB'000</i>	<i>% of total</i>	<i>RMB'000</i>	<i>% of total</i>	<i>RMB'000</i>	<i>% of total</i>	<i>RMB'000</i>	<i>% of total</i>	<i>RMB'000</i>	<i>% of total</i>
Beijing Yonghe	142,302	15.2%	116,509	16.6%	145,731	11.9%	110,224	12.4%	140,316 ⁽²⁾	8.6%	105,606	8.6%	76,700	7.3%	57,778	7.5%
Guangzhou Yonghe	73,697	7.9%	52,687	7.5%	100,338	8.2%	74,470	8.4%	105,787	6.5%	77,864	6.4%	60,708	5.8%	43,629	5.6%
Shenzhen Yonghe	59,969	6.4%	45,063	6.4%	89,090	7.3%	64,874	7.3%	104,184	6.4%	80,015	6.5%	66,167	6.3%	50,800	6.6%
Chengdu Yonghe	46,782	5.0%	35,187	5.0%	53,584	4.4%	39,938	4.5%	80,212	4.9%	63,872	5.2%	37,609	3.6%	30,301	3.9%
Shanghai Yonghe	53,410	5.7%	43,214	6.2%	61,715	5.0%	50,012	5.6%	77,494	4.7%	64,309	5.3%	44,101	4.2%	34,112	4.4%
Nanjing Yonghe	27,155	2.9%	19,355	2.8%	48,279	3.9%	34,242	3.9%	59,482	3.6%	43,050	3.5%	31,670	3.0%	22,974	3.0%
Hangzhou Niufeisi	44,291	4.7%	34,850	5.0%	47,093	3.8%	31,972	3.6%	57,820	3.5%	43,097	3.5%	26,218	2.5%	18,339	2.4%
Wuhan Yonghe	58,151	6.2%	44,197	6.3%	60,524	4.9%	44,978	5.1%	53,260	3.3%	39,372	3.2%	32,690	3.1%	25,228	3.3%
Zhengzhou Yonghe	36,495	3.9%	28,580	4.1%	39,208	3.2%	29,873	3.4%	50,170	3.1%	39,233	3.2%	33,575	3.2%	26,275	3.4%
Xi'an Beilin Yonghe	30,112	3.2%	24,179	3.4%	40,133	3.3%	32,760	3.7%	54,731	3.3%	44,051	3.6%	35,913	3.4%	27,664	3.6%
Total	572,364	61.3%	443,821	63.2%	685,695	56.0%	513,343	57.7%	783,456	47.8%	600,469	49.2%	445,351	42.3%	337,100	43.5%

Notes:

- (1) Represents the name of the clinics in operation in the relevant cities as of the Latest Practicable Date.
- (2) The revenue of Beijing Yonghe declined in 2020 as compared to 2019 primarily due to the impact of the COVID-19. We restricted in-store traffic of Beijing Yonghe as requested by the relevant governmental authorities in Beijing for around one and half months from February to March in 2020. Beijing Yonghe had rapidly resumed its operation since April 2020, and the total revenue of Beijing Yonghe for the second half of 2020 increased by approximately 10.5% as compared to the corresponding period in 2019.

BUSINESS

The table below summarizes the key operating data of our top ten clinics:

Clinic	Year of Establishment	GFA	Number of Hair Transplant Patients/ Surgeries				Number of Medical Professionals as of June 30, 2021
			2018	2019	2020	Six Months Ended June 30, 2021	
		(sq.m.)					
Beijing Yonghe	2013	4,012	4,847	4,631	3,792	1,765	67
Guangzhou Yonghe	2013	6,174	2,779	3,273	3,233	1,679	66
Shenzhen Yonghe	2015	5,225	2,598	3,330	3,210	1,700	53
Chengdu Yonghe	2012	3,220	1,975	2,097	2,599	1,132	38
Shanghai Yonghe	2015	1,786	2,022	2,095	2,323	1,209	45
Nanjing Yonghe	2015	2,906	1,091	1,567	1,840	902	30
Hangzhou Yonghe Meidu	2017	3,202	1,756	1,696	1,709	676	25
Wuhan Yonghe	2011	2,463	2,280	2,244	1,607	959	30
Zhengzhou Yonghe	2016	1,756	1,420	1,617	1,669	966	30
Xi'an Beilin Yonghe	2016	3,140	1,088	1,480	1,928	1,241	32

BUSINESS

The following images show our clinics we currently operate.



ORGANIZATIONAL STRUCTURE

Our internal organization consists of three components, namely our headquarters, regional groups and clinics. Our organizational structure enables us to implement uniform standards across our nationwide clinic network.

Headquarters

Our headquarters effectively maintains control over critical aspects of our Group, including medical safety, legal compliances, brand and marketing strategies, procurement, information technology, finance and clinic expansion management. We believe that these aspects of our operations require standardized management to ensure the quality of our medical service and efficiency of our resources allocation. Moreover, we believe that standardized operations in these aspects facilitate our scalable expansion.

Regional Groups

As of the Latest Practicable Date, our clinic network consisted of eight regional groups, which were responsible for directly supervising the clinics within their respective regions. Our regional managers are responsible for quality assurance, operational management, resource allocation and cost control of the clinics within their respective regions. They also supervise and support the individual clinics to ensure their strict adherence to our uniform operational standards and the realization of synergies that will spark sharing and allocation of medical resources within the region. For example, the deans of our clinics within a region regularly tour around different cities to share their expertise.

Clinics

The day-to-day operations of our clinics are managed by clinic managers and clinic medical directors. Our clinic managers are responsible for inspecting the daily operations and financial performance of our clinics. Our clinic medical directors supervise the overall medical service performance and medical quality.

QUALITY ASSURANCE

Our management priority is to offer superior hair transplant and medical hair care services. To this end, we have adopted comprehensive and stringent quality assurance and control measures throughout our business process, which cover, among others, the following areas:

Medical Service Quality Assurance

Although hair transplant is a relative safe surgery, we have established a strict quality control framework to ensure the safety and quality of the medical services provided by our clinics. Our clinic medical directors are responsible for controlling the quality of our medical services.

We have implemented surgical safety guidelines and manuals for the performance of surgical procedures and the use of treatment devices in areas such as obtaining consent from customers, requirements for devices, explaining to customers possible reactions during the use of treatment devices, conducting pre- and post-surgery checks on customers, and emergency response. According to our guidelines, our physicians should provide the most appropriate treatment plan for the patients after diagnosis to ensure the safety and effectiveness of the treatment.

Our comprehensive quality control system primarily includes:

- the implementation of a highly standardized service procedure with clear division of duties to ensure that our patients can receive high-quality medical service in any of the clinics in our network. For example, we have implemented the *Medical Service Procedure Guidelines* detailing the contents and standards for each step of our service processes from patient consultation and examination to post-treatment services;
- the adoption of unified technical guidance for all of our medical professionals to comply with in each hair transplant surgery. For example, we have adopted the *Unified Operational Manual* setting out detailed technical and operational requirements in hair transplant surgeries, such as the correct position of extracting follicular unit, the proper density and volume of follicular transplant, and the proper anesthetic dosing. In particular, during the hair transplant surgery, we use the local infiltration method to inject a low concentration of anesthetic agent into the tissues in the area that requires anesthesia, and the loss-of-sensation produced by such method will be restricted to a superficial, localized area in the body. Our patients generally remain conscious and are able to freely communicate with our medical professionals during the entire surgery. We generally use a 2% lidocaine solution as the anesthetic agent at a dose not exceeding the maximum toxic dose of the day, which is in line with the requirements set out in the Hair Transplantation Standard issued by the Chinese Association of Plastics and Aesthetics (中國整形美容協會). We also complied the *Contraindications for Hair Transplant and Treatment Guidance* to screen out patients who are unsuitable for hair transplant and further ensure the safety of our hair transplant surgeries; and
- the implementation of a series of internal management rules to discipline the behavior of our medical professionals. To this end, we have implemented the *Basics for Keeping Medical Record*, *Medical Accidents Prevention and Treatment Guidance*, the *Emergency Reporting and Handling Guidance*, the *Eight Medical Behaviors Unallowed in Office* (《醫療行為“八不准”制度》) and various other rules.

In addition, we regularly conduct review of the performance of our physicians and other medical professionals. Our medical professionals are properly trained when joining us and accept on-the-job training regularly. For details, see “— Our Professional Team” in this section. We also invite physicians who are experts in hair disease diagnosis and treatment from public hospitals to conduct consultation and train our staff from time to time. These physicians will not directly deliver diagnostic and treatment services to our patients at our clinics. As advised by our PRC Legal Adviser, the physicians from other hospitals conducting consultation and training activities at our clinics does not violate any applicable PRC laws and regulations. During the Track Record Period and up to the Latest Practicable Date, we were not involved in any regulatory actions or claims for damages as a result of such consultation and training activities. As further advised by our PRC Legal Adviser, as the holders of the Medical Institution Practicing licenses, our clinics are responsible for liabilities arising from regulatory actions or claims for damages as result of the services provided by our medical professionals. During the Track Record Period and up to the Latest Practicable Date, we were not involved in any material regulatory actions or claims in this regard. We are subject to legal proceedings and claims that arise in the ordinary course of business, which primarily include medical disputes brought by our patients against us. For details, see “— Licenses, Permits, Approvals and Compliance” in this section.

We believe our comprehensive quality control system disclosed above has effectively controlled the safety and quality of the services provided by our medical professionals, and in turn controlled the occurrence of our medical disputes at a manageable level. Therefore, we do not maintain any form of medical liability insurance. Thanks to our strict quality control framework, we are able to achieve and maintain outstanding treatment results for our patients. To further enhance patient experience, we trailblazed a new cooperation model with a third party insurance company to provide guarantee on our treatment results to our hair transplant patients. For details, see “— Insurance” in this section.

Medical Device and Consumables Quality Assurance

We place great importance on the medical devices and medical consumables that are introduced into our clinics to ensure that they are reliable and capable of providing the desired results to our customers. To this end, we have developed policies and procedures for the assessment and evaluation of medical devices and medical consumables. We have developed supplier management rules and supplier qualification management process to ensure that our suppliers provide qualified medical supplies. For more details, see “— Procurement and Inventory Management” in this section.

OUR PROFESSIONAL TEAM

The qualification and expertise of physicians and other medical professionals practicing at our clinics are vital to the quality of services provided by our clinics and our competitiveness. We believe our professional team is at the core of our medical hair care services. We maintain high standards in selecting experienced medical professionals and provide competitive compensation packages.

The professional team at our clinics comprises physicians, nurses and other medical professionals. As of December 31, 2020 and June 30, 2021, we had a sizable team of 189 and 226 registered physicians, respectively, larger than the combined number of the second and the third market players, according to Frost & Sullivan. The number of physicians and nurses at our clinics far exceed the minimum standards set forth in the *Basic Standard for Aesthetic Medical Institution and Aesthetic Medical Department (For Trial Implementation)* (《美容醫療機構、醫療美容科(室)基本標準(試行)》), which requires each department of aesthetic medical clinic to have at least one physician and one nurse. For details of the regulatory requirements, see “Regulatory Overview — Regulations on the Aesthetic Medical Services” in this prospectus. All of the 246 registered physicians as of the Latest Practicable Date were our full-time employees, while 14 out of the 246 physicians were also practicing at other medical institutions when they were off-duty at our Group. As advised by the PRC Legal Adviser, the multi-institution practice of physicians are allowed and encouraged under the applicable laws and regulations, provided that they complete the required application and registration procedures. For details, see “Regulatory Overview — Laws and Regulations on Medical Personnel of Healthcare Institutions — Several Opinions on Accelerating the Development of Medical Institutions with Social Capital and Several Opinions on Promoting and Standardising Multi-Institution Practice of Medical Practitioners.” The aforesaid physicians have completed all the required approval and registration procedures, and we believe their multi-Institution practicing would not affect their services at our Group.

BUSINESS

The following table sets forth a breakdown of our professional team members at our clinics at the end of the periods indicated:

	As of December 31, 2020	As of June 30, 2021
Professional Team		
Physicians	189	226
– Medical Aesthetic Attending Physician	38	64
– Other Physicians	151	162
Nurses	901	920
Other medical professionals	44	54
– Pharmacists	2	2
– Phlebotomists	42	52
Total	1,134	1,200

Our physicians, nurses and other medical professionals are required to be registered in accordance with the relevant healthcare administrative authorities in the PRC. We closely monitor the qualification registration and licensing records to ensure that all physicians practicing at our in-network clinics comply with all applicable requirements under PRC laws and regulations.

We believe our experienced and stable medical professionals are key to our success. As of June 30, 2021, physicians practicing at our in-network clinics had an average of five years of industry experience, nurses practicing at our in-network clinics had an average of three years of industry experience, longer than the average years of working experiences of the medical professionals of our competitors, according to Frost & Sullivan.

We have maintained a relatively stable medical professional team during the Track Record Period even though the number of our physicians experienced significant growth in the past three years. As of the end of 2018, 2019, 2020 and the six months ended June 30, 2021, we had 92, 111, 189 and 226 physicians, respectively. The turnover rate of our physicians was 4.4%, 4.4%, 4.8% and 3.2% in 2018, 2019, 2020 and the six months ended June 30, 2021, respectively, which was much lower than the typical physician turnover rate at similar hair transplant clinics in China, according to Frost & Sullivan.

Although we attach significant value to the contribution of our physicians, we believe that we do not have any undue reliance on our key physicians. In 2018, 2019, 2020 and the six months ended June 30, 2021, revenue contributed by our top ten physicians accounted for 26.8%, 21.3%, 16.8%, and 13.7% of our total revenue from hair transplant services, respectively, and revenue contributed by the top physician merely accounted for 3.4%, 3.0%, 2.2% and 1.7% of our total revenue from hair transplant services in the same periods. Our employment contracts with such physicians generally have a term of five years, provide for a notice period of 30 days for resignation, and contain non-compete clauses restricting them from engaging in business activities that compete with our business for two years upon termination of their employment. Each of our top ten physicians has been practicing for years and has rich

experience in performing hair transplant surgeries. As of June 30, 2021, our top ten physicians for each of the years/period comprising the Track Record Period had an average of over nine years of practicing experience. Their time of service at our Group ranges from four to twelve years, and as of the Latest Practicable Date, all of such physicians remained in service at our Group.

In 2018, 2019, 2020 and the six months ended June 30, 2021, the total remuneration (including share-based compensation) for our top ten physicians amounted to approximately RMB5.0 million, RMB12.3 million, RMB12.9 million and RMB4.9 million, respectively. Such remuneration increased significantly from 2018 to 2019, primarily because in 2019, we started to adopt a performance-based pay scheme in addition to fixed salaries, in order to incentivize our hair transplant physicians, and to boost our overall business performance. The effective implementation of the performance-based pay scheme from 2019 had enabled us to properly reward and incentivize our physicians, particularly the top performers, based on their respective contribution to our business growth. According to Frost & Sullivan, the salary level of physicians in the hair transplant industry in China depends on a lot of factors. Some of such factors attribute to the institutions where the physicians work for (e.g., the location, reputation, and financial performance of the hair transplant institutions, the pay schemes adopted by the hair transplant institutions, etc.), and some of such factors attribute to the physicians themselves (e.g., the fame of the physicians, etc.). Based on the market research conducted by Frost & Sullivan, during the Track Record Period, the average annual salaries of hair transplant physicians in China were generally within the range of RMB0.3 million to RMB0.4 million in 2018, RMB0.4 million to RMB0.5 million in 2019, and RMB0.4 million to RMB0.5 million in 2020, but for certain “famous hair transplant physicians” in China who are well-known in the industry, highly-regarded by their peers, and whose services are sought-after by the patients, their annual salaries were generally within the range of RMB0.4 million to RMB0.7 million in 2018, RMB0.6 million to RMB1.5 million in 2019, and RMB0.8 million to RMB2.0 million in 2020. As confirmed by Frost & Sullivan, the fame of hair transplant physicians in turn depends on a number of factors, such as the number of years of their practice experience, their education background, their professional skills and capabilities, the positions and titles they hold in industry associations/academic institutions, etc. Although the length of practicing experience is a key factor in determining the fame of a physician, there are a number of hair transplant physicians in China who became famous because of their high quality services, superb treatment effect, and kind attitude towards the patients, among other factors, despite their relatively short practicing experience. Based on the market research conducted by Frost & Sullivan, we had been able to attract and retain a large number of “famous hair transplant physicians” in the industry, and all of our top ten physicians for each of the years/period comprising the Track Record Period were “famous hair transplant physicians” who are well-known among, and whose services are frequently sought-after by, the patients. The remuneration packages (including their compositions) we provide to these physicians are competitive in the industry, and meanwhile were generally in line with the market norm during the Track Record Period, according to Frost & Sullivan.

We generally recruit registered physicians with relevant practice experience. We conduct eligibility searches on the candidates to be recruited to ensure they have the required working experience and qualifications for the new positions. We also plan to cooperate with China’s most renowned medical schools and prestigious medical institutions to build up our talent pipeline. We believe that we provide our medical professionals with competitive compensation packages, continued medical education opportunities, nice working environment and career development. Our physicians are compensated by fixed salaries and performance-based bonuses based on their ability to meet or exceed the applicable key performance indices set by the management such as number of hair transplant surgeries performed by the physicians, attendance and patient feedbacks, which may vary from time to time according to business needs.

We provide structured training and education programs to enable our medical professionals to consistently deliver high quality services. For example, each of our newly recruited physicians is required to undergo a systemic training that lasts for four to six months, including, among others, a clinical practice training under the one-on-one supervision of our deans for at least one month. After the training period, we will assess the physician's professional capabilities by testing their theoretical knowledge and practical skills. We also provide comprehensive on-the-job training for our medical professionals regularly. For example, we keep active dialogues and exchanges of information with well-respected medical institutions in China, and invite leading experts or well-known specialists on a regular basis to share with us their clinical experiences and latest developments in the industry.

We also place significant emphasis on other employee trainings and development. We invest in training programs for our employees with the purpose of upgrading their knowledge on the latest development of the hair transplant and medical hair care industry. Our employees receive mandatory training on relevant policies, standards, protocols and procedures from time to time and are required to strictly follow them in daily operations.

OUR INFORMATION TECHNOLOGY

We seek to be a pioneer in the application of latest technologies in China's hair transplant industry, while focusing on enhancing customer experience and increasing operating revenue. Some of our efforts to enhance customer experience are listed below.

Data Usage and Analyses

We have set up an advanced business management system to track, record, and present operational data from our clinics nationwide. According to Frost & Sullivan, we are the first and as of the Latest Practicable Date, the only hair transplant clinic chain in China that realized the real-time presentation and analysis of various key operating metrics, such as the number of patients, the volume of hair transplant surgery, and the volume of follicular transplant. On the one hand, real-time data presentation enhances the transparency of our healthcare services, thereby improving our patients' treatment experience. On the other hand, by analyzing the data collected from operations, we are able to quickly and accurately identify and meet our patients' demands, effectively manage customer profiles, and develop models for predicting the needs of patients, making prognoses, advising diagnostic and therapeutic procedures, and implementing targeted advertising.

Intelligent Services


We have launched a set of intelligent consultation service software for graphic, telephonic, and video consultation services. That software helps conduct initial screening and triage of patients online, uploads medical records in real time, facilitates perioperative patient management, and provides patients with convenient online consultation and postoperative services. Our service software provides customized services to different types of patients in need of different treatments, e.g., automatically attending to patients at various preoperative stages, and anticipating and satisfying patients' needs at various postoperative stages. Using artificial intelligence algorithms for customer service, we provide automated and intelligent real-time responses to customers' online inquiries.

In addition, we are actively applying smart devices, such as follicular detectors, to save our labor costs. Our follicular detector embodies advanced technologies, such as intelligent image recognition and big data algorithms, which can provide patients with accurate medical test reports, including scalp environment analysis, sebum test analysis, hair follicle health analysis, hair density analysis, hair diameter analysis, diagnostic results, and medical advice, thus greatly enhancing patient consultation experience and the professional quality of service.

Online Services

We are actively promoting online medical services, and have put together a dedicated online medical staff. Our online medical service system allows real-time upload of medical documents, such as the patient's medical records, thereby bringing convenient and professional online consultation and postoperative review services to patients. We use Internet platforms to provide online medical services. For example, we developed a hair management mini-program on WeChat to give patients convenient access to introductions of hair transplant procedures, credential of our physicians, pricing information, recent discount policies, and so on. As of the Latest Practicable Date, our WeChat service platform, Hair Manager, had over 811,000 registered users. As advised by our PRC Legal Adviser, since the online services we provide to our patients and other online users do not fall within the scope of value-added telecommunication services as stipulated in the applicable PRC laws and regulations, we are not subject to any license requirements and/or foreign ownership restrictions for providing such online services.

The pictures below illustrate our data usage and analyses system, smart follicular detector and our WeChat service platform.



As one of our business strategies, we plan to expand our online hospital services in the future, which primarily include the sales of pharmaceuticals and medical devices online and the provision of medical diagnostic and treatment services online, and we plan to provide such online services through online platforms operated by third parties. As advised by our PRC Legal Adviser, in addition to the Medical Institution Practicing License and the Business License, we are required to obtain the License for Drug Information Services over the Internet (互聯網藥品信息服務許可證) in order to sell pharmaceuticals through online platforms operated by third parties and the Registration Certificate for Operating Medical Devices (醫療器械經營備案憑證) in order to sell medical devices through online

BUSINESS

platforms operated by third parties, and to add “online diagnosis and treatment (互聯網診療)” into the business scope contained in our Medical Institution Practicing License, according to the applicable laws and regulation in China. As of the Latest Practicable Date, the operating entity of our online services, Beijing Yonghe, had obtained the License for Drug Information Services over the Internet and the Registration Certificate for Operating Class II Medical Devices, and had successfully added “online diagnosis and treatment” to the business scope contained in its Medical Institution Practicing License. We might be subject to additional regulatory requirements with the expansion of our online services, and we will strictly comply with the applicable rules and regulations to conduct online services in the future. However, the laws and regulations regarding online services in China are generally complex and evolving, with uncertainty as to the interpretation and application thereof. If our online services are subject to any additional licensing or registration requirements in the future, we may have to incur significant expenses to obtain the necessary licenses and/or registration certificates, and if we fail to meet the relevant regulatory requirements, we may need to shrink, or even cease, our online services, which may adversely affect our business, financial condition, results of operations and prospects. For details, see “Risk Factors — Risks Relating to Our Business — Any lack of requisite approvals, licenses, permits, registrations or filings applicable to our business may have a material and adverse impact on our business, financial condition and results of operations”.

OUR DEVICES AND EQUIPMENT

Our clinics are equipped with advanced devices and equipment to provide our patients with accurate diagnoses and treatment while minimizing pain and time of treatment procedures. The table below sets forth details of our major medical devices and equipment:

Equipment/Device	Type	Principal Use	Average Remaining Useful Live
<i>For hair transplant services</i>			
PK-7000	Medical Device	follicular unit extraction	four to five years
Shadowless Floor Standing Surgical Lamp (YCLED500L)	Medical Device	surgical lighting	three to five years
Shadowless Ceiling Mounted Surgical Lamp (YCLED700/500)	Medical Device	surgical lighting	two years
<i>For medical hair care services</i>			
SKIN Management Device (SKIN管理儀)	Hair Restoration Device	cleans scalp to enhance the absorption of hair care products	four years
Photodynamic Instrument (光動力儀)	Hair Restoration Device	promotes wound healing and reduces scalp inflammation	four years

In addition, to facilitate fast post-surgery recovery and enhance medical hair care treatment results, we also provide various portable medical devices such as head massager (頭部按摩器), laser hair care

helmet (激光健發頭盔) and multi-functional hair comb (多功能健發梳) to our patients for use at home. We plan to continuously improve and upgrade our facilities and equipment to provide better services to our patients, which improvement and upgrade will be partially funded with proceeds from the Global Offering. For details, see “Future Plans and Use of Proceeds — Use of Proceeds” in this prospectus.

PRICING AND PAYMENT

Pricing policies are determined by our headquarters based on cost and market positioning. Our headquarters has adopted a uniform pricing guideline. We generally apply the same prices for our services across all clinics in our network. In line with industry practice, the local clinics from time to time offer discounts to customers for certain services they provide, as part of their marketing strategies. Managers of the local clinics have the discretion to determine the appropriate discount level for the relevant services, so long as the discount rate is no higher than 12% (calculated based on the standard prices setting forth on the price guideline). Subject to our headquarters’ prior approval, the local clinics can offer the patients discounts rates higher than 12%, but such discount rates generally would be no higher than 20%. During the Track Record Period, we recorded our revenue based on the actual prices we charged (i.e., after taking into consideration the discounts offered, if any), and did not record the exact amounts of the discounts offered by the clinics. For details of our revenue recognition, see “Financial Information — Significant Accounting Policies and Critical Judgments and Estimates — Significant Accounting Policies — Revenue Recognition.”

Our internal pricing policy provides reference price points of various treatment options across our operations in the PRC. We set this price taking into account certain factors, such as experience of physicians, customer needs and operating costs.

With respect to medical hair care services, we generally offer services by providing treatment program packages that are designed to address the sophisticated needs of customers, allowing the customers to receive appropriate comprehensive medical hair care services. We set this price taking into account certain factors, such as market condition, customer needs, complexity of the treatment, pricing policies of competitors and operating costs.

We generally review our prices annually according to our internal pricing policy. Our headquarters and regional managers strictly control and monitor clinical prices to ensure they have followed our pricing policies. We also closely monitor the pricing of our competitors in the same regions to evaluate our pricing.

CASH MANAGEMENT

We accept cash, credit cards, WeChat Pay, Alipay and other online payment at our clinics, as non-cash payments become increasingly common. As a result, cash payments as a percentage total payments from our guests was low during the Track Record Period, and for the year ended December 31, 2020, the percentage was approximately 1.8%.

To avoid misappropriation and embezzlement of cash, we have deployed a financial management system provided by a third party at each of our clinics. Clinic financial managers are responsible for ensuring that cash received during the day matches the sales records and is timely transferred to bank accounts. We also monitor the accuracy of sales through business and operation systems installed at our clinics.

During the Track Record Period, we had not encountered any incident of cash misappropriation or embezzlement that had a material adverse impact on our business, results of operations or financial condition.

OUR CUSTOMERS

During the Track Record Period, substantially all of our customers base consisted of individual customers, and none of these individual customers accounted for more than 5% of our total revenue. We have not entered into any long-term agreements with our individual customers. We generally do not extend any credit periods to our customers.

To the best knowledge and belief of our Directors, our five largest customers during the Track Record Period were Independent Third Parties. None of our Directors or their close associates or any of our Shareholders (who, to the best knowledge of our Directors, beneficially own more than 5% of our share capital) had any interest in any of our five largest customers during the Track Record Period.

OUR SUPPLIERS

During the Track Record Period, our suppliers primarily included providers of advertising services, IT services, and pharmaceuticals, surgical consumables and hair care products. We have maintained a list of suppliers approved by our senior management team.

Our headquarters is in charge of our overall procurement strategy. Pharmaceuticals, surgical consumables, hair care products and other products are centrally procured by the headquarters. Most procurements have gone through a tender or price comparison process except for a few local procurements in a small scale. For any given type of raw materials or supplies, we typically have multiple suppliers in order to obtain competitive prices from suppliers, maintain sourcing stability and avoid over-reliance risk. During the Track Record Period, we did not experience any interruption in our supplies, early termination of supply agreements, or failure to secure sufficient supplies that had any material adverse impact on our business or results of operations. Our suppliers generally offer us a credit term of 30 to 90 days. We typically settle trade payable obligations with respect to our suppliers through bank transfers. Our procurement agreements with our suppliers generally do not contain any minimum purchase commitment. During the Track Record Period, we made minimum purchase commitments to only two suppliers, including an advertising service provider (supplier A in the tables below) who provides online advertising and marketing services to us, and a raw material supplier who provides routine hair care products to us. During the Track Record Period and up to the Latest Practicable Date, we had entered into four framework agreements with supplier A, which contained a minimum purchase amount of RMB120.0 million (for the contract period from March 2018 to March 2019), RMB142.0 million (for the contract period from March 2019 to March 2020), RMB50.0 million (for the contract period from April 2020 to April 2021) and RMB100.0 million (for the contract period from February 2021 to January 2022), respectively. For the three expired agreements, we had fulfilled our minimum purchase commitments during the relevant contract periods, and the agreement that is still in effect provides that if our total purchase amount during the contract period falls below 80% of the minimum purchase commitments, the supplier may deduct the shortfall from the deposits we paid to the supplier and if the deposits are insufficient, we shall pay for the remaining outstanding amount in cash. As of the Latest Practicable Date, we were not aware of any obstacles that would affect our ability to fulfill our commitments thereunder. For other salient terms of the agreements we entered into with our advertising service providers, see “— Marketing” in this section. The agreement we entered into with the raw material supplier had an initial term of five years, subject to an annual minimum purchase commitment of the British pound of approximately £0.8 million, £0.9 million, £1.1 million, £1.3 million and £1.6 million, respectively, from the first to the fifth year. If we fail to fulfill the commitment, the parties will renegotiate the terms and conditions thereunder on an arm’s length basis. We entered into the agreement in January 2021 and as of the Latest Practicable Date, we were not aware of any obstacles that would affect our ability to fulfill our commitments for the first year thereunder.

BUSINESS

For each of 2018, 2019, 2020 and the six months ended June 30, 2021, purchases from our five largest suppliers amounted to RMB186.4 million, RMB280.6 million, RMB278.7 million and RMB217.4 million, respectively, representing approximately 23%, 25%, 20% and 23%, respectively, of our total purchases for the respective periods. For each of 2018, 2019, 2020 and the six months ended June 30, 2021, purchases from our largest supplier amounted to RMB119.2 million, RMB168.9 million, RMB114.9 million and RMB71.3 million, respectively, representing approximately 15%, 15%, 8% and 7%, respectively, of our total purchases for the respective periods.

The tables below set forth the basic information of our top five suppliers during the Track Record Period.

<u>Supplier</u>	<u>Product or Service Supplied For 2018</u>	<u>Purchase Amount</u>	<u>Percentage of Total Purchases</u>
<i>(RMB in thousands, except percentages)</i>			
Supplier A	Search engine related advertisements	119,162	15%
Supplier B	Display advertisements in subway stations	19,047	2%
Supplier C	Display advertisements in subway stations	16,803	2%
Supplier D	Labour outsourcing services	16,601	2%
Supplier E	IT services	14,832	2%

<u>Supplier</u>	<u>Product or Service Supplied For 2019</u>	<u>Purchase Amount</u>	<u>Percentage of Total Purchases</u>
<i>(RMB in thousands, except percentages)</i>			
Supplier A	Search engine related advertisements	168,859	15%
Supplier E	IT services	39,372	4%
Supplier F	Promotion services through a social network platform	32,073	3%
Supplier G	Promotion services through an online community	25,448	2%
Supplier H	Display advertisements in elevators	14,819	1%

<u>Supplier</u>	<u>Product or Service Supplied For 2020</u>	<u>Purchase Amount</u>	<u>Percentage of Total Purchases</u>
<i>(RMB in thousands, except percentages)</i>			
Supplier I	Promotion services through an online community	114,862	8%
Supplier A	Search engine related advertisements	80,746	6%
Supplier F	Promotion services through a social network platform	29,002	2%
Supplier J	Display advertisements in elevators	28,428	2%
Supplier K	Promotion services through an online community	25,632	2%

BUSINESS

<u>Supplier</u>	<u>Product or Service Supplied For the Six Months Ended June 30, 2021</u>	<u>Purchase Amount</u>	<u>Percentage of Total Purchases</u>
<i>(RMB in thousands, except percentages)</i>			
Supplier I	Promotion services through an online community	71,264	7%
Supplier A	Search engine related advertisements	48,165	5%
Supplier L	Promotion service through online communities	40,484	4%
Supplier F	Promotion services through a social network platform	30,176	3%
Supplier K	Promotion services through an online community	27,327	3%

All of our top five suppliers during the Track Record Period were Independent Third Parties. None of our Directors, their associates or any of our current Shareholders (who, to the knowledge of our Directors, own more than 5% of our share capital) has any interest in any of our top five largest suppliers required to be disclosed under the Listing Rules.

MARKETING

We believe that ultimately, our reputation has been, and will continue to be, built upon our service quality, and that the most effective marketing channel is the spontaneous word-of-mouth referral by our satisfied customers. Based on a survey conducted by Frost & Sullivan among over 1,100 patients who received our services, 29.7% of the surveyed patients first learned about us through recommendations from their friends or family members, and 88.5% of the surveyed patients indicated that they will recommend us to their friends and family members who are in need of hair transplant services.

In the meantime, we recognize the importance of long-term investment in brand building and consumer education. Therefore, in line with other players in the consumer medical service industry, particularly the hair-related healthcare industry, we made significant investments in promoting customer awareness of our brand and our services, and expect to continue to do so in the near future.

We have designed a comprehensive marketing strategy, and utilize a combination of online and offline channels to promote our brand and our services, using various forms of advertisements.

- Brand advertising. We place display advertisements in cooperation with large online channels in China such as Tencent and Bytedance, in order to reach a broad potential customer base and to raise our brand awareness. For many key cities with large population and huge needs for hair transplant and medical hair care services, we also place display advertisements in offline sites with high customer traffic volume, such as subway stations, large office buildings, shopping complexes and cinemas. We also seek to embrace the latest trends in social-based marketing by sponsoring the livestreaming of popular sports games and a number of TV shows.
- Performance-based advertising. We cooperate with many leading online channels in China and place different types of performance-based advertisements. For example, we cooperated with Baidu and conduct search engine-based promotion. We also collaborate with large social network sites and online communities such as Weibo, Bilibili, and Tik Tok, and aim to design more targeted and focused marketing strategies to effectively reach and attract our potential customers from such sites.
- Offline customer education. In addition, our professional medical staff and sales and marketing staff would from time to time visit large enterprises in the region (for example, large internet companies such as Bytedance and iQiyi, and large enterprise in the finance industry). They would hold seminars, share hair care related knowledge, introduce the benefits of our services, and answer questions from the employees of those large enterprises.

The advertising channels employed by us primarily include online and offline channels. With respect to online advertising, we will typically enter into a service agreement with the relevant online channels to provide for, among others, service term, service content and payment method. During the agreed service term, each time when we place an online advertising order, we shall provide the advertisements to be published along with other detailed requests such as the form, time and target area to be published to the relevant online channels. We are generally required to make prepayments for such orders and the relevant online channels typically make settlements with us monthly based on the actual orders placed by us during the period. Our costs of online advertising are primarily calculated based on three metrics, including cost per time (CPM), cost per click (CPC) and cost per mille (CPM). With respect to offline advertising, we typically engage advertising agencies to design advertisements based on the materials provided by us and display the advertisements at specific sites such as subway stations, office buildings, shopping complexes and cinemas per our requests. The offline advertising service agreement typically bears a fixed amount for an advertising campaign and requires us to make payments in installments.

In addition, we actively assumed social responsibilities by initiating the “Yonghe Caring for Hair Loss Program” (雍禾脫髮愛計劃) charity project, in which we performed hair transplant services for free for patients suffering from hair loss caused by burns, scalds and other accidents, with an aim to help them improve their appearances and regain their confidence. Moreover, in 2020, during the COVID-19 outbreak in Wuhan, we again set an example for our industry by quickly responding to the situation and donating money and other resources to the Wuhan Charity Federation. Although we do not consider our such efforts to be marketing activities, we believe that such efforts have further enhanced our brand reputation and awareness.

RESEARCH AND DEVELOPMENT

Research and development (“**R&D**”) is critical to the sustainable growth of our business operations. We are focused on market-driven R&D. Our R&D team is primarily responsible for the innovation of medical technology and the implementation of data-based, intelligence-based and internet-based development strategy of our company.

All of our product R&D is geared towards satisfying customer needs. Our R&D team works closely with our operations and marketing teams to effectively drive our R&D results to fruition. For example, we set R&D goals and carry out product design to address customer needs and suggestions at the early project approval stage of R&D projects, with an emphasis on patient experience and service quality. Our marketing and operations teams are deeply involved in the R&D process and business models are constantly innovated and upgraded.

Medical technology is an important part of our R&D. Our collaboration with external R&D partners is an important part of our R&D strategy. We pay close attention to academic development and exchange, and continuously seek breakthroughs in hair transplant technology by utilizing the most advanced theories obtained from external collaboration. We have entered into long-term collaboration arrangement with Sun Yat-sen University in the studies for follicular regeneration technologies. For example, we entered into a technology development agreement with Sun Yat-sen University in September 2020. Based on the agreement, we entrusted Sun Yat-sen University to develop small molecule drugs with an effect to promote follicular regeneration. We agreed to pay a total of RMB6.0 million by installments for the technology development under the agreement. The term of the agreement is three years. Either party has the right to apply for patent registration for the intellectual properties developed under the agreement. All the interests arising from the patent, once registered, shall be allocated between our Company and Sun Yat-sen University at percentage of 60% and 40%, respectively. This improves the level of research and development technologies relating to hair disease diagnosis and treatment, and participates in the formulation of diagnosis and treatment standards for hair diseases. We believe that such academic development and exchange will lead to the next breakthrough in the hair transplant industry. Our investment in these cutting-edge research areas will pay off with tremendous growth potential.

Our directors believe that we are committed to R&D of high quality technology that allows us to anticipate consumer preferences and meets customer needs. As of the Latest Practicable Date, we hold 24 invention patents for innovation and technology in China. We have spent RMB7.8 million, RMB8.9 million, RMB11.8 million and RMB6.2 million in R&D in 2018, 2019, 2020 and six months ended June 30, 2021, respectively. We have not capitalized our R&D expenditure during the Track Record Period.

BUSINESS

AWARDS AND RECOGNITIONS

As a testimony to our achievements and the quality of our service, hair transplant and hair care experience, we have received various awards and recognitions. The table below sets forth our major awards and recognitions we received during the Track Record Period.

<u>Year</u>	<u>Recipient</u>	<u>Accreditation/Award</u>	<u>Accreditation Organization</u>
2014	Our Company	Gongyibao Charitable Clinic (慈善公益寶愛心醫院)	Hubei Charity Federation (湖北省慈善總會)
2017	Our Company	Demonstration unit of quality, service, and integrity commitment (質量、服務、誠信承諾示範單位)	Publicity Service Center of Hebei Administration for Industry and Commerce (河北省工商行政管理局 宣傳服務中心)
2018	Our Company	Excellent Demonstration Unit for Quality and Trustworthiness (重質守信優秀示範單位)	Shanxi Market Daobao (山西市場導報)
2020	Our Company	People's Corporate Social Responsibility Award (人民企業社會責任獎)	People.cn (人民網)

PROCUREMENT AND INVENTORY MANAGEMENT

Procurement

We have implemented procurement policies. Our headquarters makes centralized procurement according to the budget and the demand of the clinics. Most of the procurements have gone through a tender or price comparison process. The procurement department at the headquarters requests quotations from several suppliers and enters into procurement agreements after negotiating with the suppliers on commercial terms such as price and quantity, and some supplies are subject to a tender process. Our legal department keeps the original copy of the procurement agreements for record.

We have established a return and replacement management system and return defective or expired products to suppliers in accordance with market practice. During the Track Record Period, we have not encountered quality problems or received defective products that could have a material adverse effect on our business, financial condition or operations.

We purchase drugs, medical devices, medical consumables and other supplies from qualified suppliers based on their ability to supply, quality, pricing and service. We require suppliers to hold licenses and permits necessary for their business operation, such as business license and pharmaceutical product trading license. Our procurement department is responsible for reviewing the qualifications of suppliers, periodically reviewing and evaluating the performance of each supplier and checking their qualifications to ensure compliance of the products that we have purchased, and updating our list of suppliers. During the Track Record Period, we have not experienced supply shortages that could have a material or adverse effect on our business, financial condition or results of operations.

Inventory Management

Our supplies are delivered by suppliers in accordance with purchase orders and placed in warehouses that meet storage standards based on their categories after they are inspected and accepted by warehouse management personnel. We use a fully functional supply chain management system for inbound and outbound logistics and inventory management. Such system can accurately display the inventory and related inbound and outbound records and reduce storage costs and risks of expired inventory. We fully comply with the storage requirements and laws and regulations related to medical and non-medical commodities during the storage period.

The inventory of hair transplant clinics mainly includes medical consumables, hair care products, drugs and office supplies and amounted to RMB14.3 million, RMB14.5 million, RMB27.0 million and RMB44.5 million as of December 31, 2018, 2019 and 2020 and June 30, 2021, respectively. We strictly monitor our commodities in inventory, conduct regular physical inventory counts and establish a monthly-based inventory cycle to meet the demand of our clinics. We closely monitor the shelf life of all commodities, and once any commodity expires or medical device reaches the end of its service life, we safely dispose of the commodity or device in accordance with applicable laws and regulations. We have not experienced any significant inventory write-offs during the Track Record Period.

CLIENT FEEDBACK AND COMPLAINT HANDLING

We value patient feedback and complaints as an important basis for improving our services. We take each patient's feedback seriously and have a standardised feedback mechanism to ensure that it is dealt with in a timely and effective manner. We have several channels for receiving client feedback, such as proactive post-treatment satisfaction surveys and published complaint hotlines.

We have established a policy to reach out to all of our clients and inquire about their current conditions and their views with respect to our treatment provided, services received at our clinic, the effect of our services, and the areas that we can improve. During the Track Record Period, over 98% of the clients who provided their feedback expressed that they were generally satisfied with our services.

As of the Latest Practicable Date, we had a team of around 100 professionals who were responsible for client satisfaction. A team is designated to deal with any complaints raised by customers, who will respond positively and provide explanations and reassurances after promptly checking with the clinics. In conjunction with the clinic manager, we will investigate the case in question and analyse it after resolving the client's concerns. Depending on the circumstances, we may offer a refund to the client.

BUSINESS

The table below summarizes the complaint rate and nature of unfavorable feedback we received for the periods indicated. As of the Latest Practicable Date, all of the unfavorable client feedbacks listed below had been properly addressed and satisfactorily resolved.

Nature of unfavorable feedbacks from clients	Year ended December 31,			Six Months Ended June 30,
	2018	2019	2020	2021
Complaints regarding treatment results ⁽¹⁾	0.05%	0.03%	0.03%	0.02%
Complaints regarding our services ⁽²⁾	0.10%	0.04%	0.04%	0.01%
Complaint rate of other unfavourable feedbacks ⁽³⁾	0.03%	0.02%	0.02%	0.01%

Notes:

- (1) Calculated by the number of clients who complained that the treatment results were not up to their expectation divided by the total number of clients who had provided feedbacks.
- (2) Calculated by the number of clients who complained they were unsatisfied with our services divided by the total number of clients who had provided feedbacks.
- (3) Calculated by the number of clients who had other unfavorable feedbacks divided by the total number of clients who had provided feedbacks.

The total refunds we made to our hair transplant patients in 2018, 2019, 2020 and the six months ended June 30, 2021 amounted to approximately RMB3.0 million, RMB4.0 million, RMB5.2 million and RMB3.2 million, respectively, representing approximately 0.33%, 0.34%, 0.38% and 0.40% of our total revenue from hair transplant services for the same periods, respectively. Our Directors estimate variable considerations to be included in the transaction price for the refund to customers in respect of unsatisfactory services rendered. The refunds we made during the Track Record Period were in line with the corresponding variable considerations estimated by our Directors. We update our assessment of expected refund on a regular basis and adjust refund liabilities accordingly. Based on the expected refund and from prudent perspectives, we recognized refund liabilities of approximately RMB3.9 million, RMB5.0 million, RMB7.6 million and RMB11.3 million, as of the end of 2018, 2019, 2020 and June 30, 2021, respectively. For details, see Note 4(a) “Estimation of variable consideration for refund to customers” to the Accountant’s Report in Appendix I to this prospectus. During the Track Record Period, for our medical hair care services, we did not made any material refunds to patients in respect of unsatisfactory services rendered. We may, from time to time, refund the patients for their unutilized prepaid packages. Since the services not yet rendered were recorded as contract liabilities, such refunds would not affect our revenue for the relevant periods. For details, see “Financial Information — Discussion of Certain Selected Items From the Consolidated Balance Sheets — Contract Liabilities” in this prospectus.

Our Directors further confirm that during the Track Record Period and up to the Latest Practicable Date, we did not experience any material medical incident involving fatalities or severe bodily injuries of our patients, nor did we receive any complaints or unfavorable feedback which had a material impact on our business and operation.

MARKET AND COMPETITION

The hair transplant service market and medical hair care service market in the PRC have been competitive due to the abundance of medical institutions. According to Frost & Sullivan, we were the largest hair-related healthcare service provider in China in 2020 with a leading market share of approximately 10.5% and 4.3% in the hair transplant service market and the medical hair care service market, respectively. Our major competitors include other private hair transplant institutions, hair transplant departments of public hospitals and aesthetic services providers.

We believe our principal competitive advantages are our national coverage and footprint, brand reputation, operational and medical service capabilities, one-stop-shop hair-related healthcare service system, technology, strong management team and shareholder support. For more details of our market position and the competitive landscape of the markets, see “Industry Overview” in this prospectus.

INSURANCE

In January 2021, we introduced our hair transplant insurance service, which enhances our service coverage for hair transplant patients. We entered into a cooperation agreement with Ping An Property & Casualty Insurance Company of China, Ltd., Liaoning Branch (“**Ping An Property & Casualty**”) in December 2020 for the relevant insurance arrangements, salient terms of which are summarized below:

Insurer:	Ping An Property & Casualty
Policy holder and Insuree:	Yonghe Investment
Insured Person:	Each of the patients receiving our ordinary hair transplant surgeries (excluding revision surgeries)
Name of the Insurance Plan:	Yonghe & Ping An Hair Transplant Insurance (雍禾&平安植髮險)
Insurance Plan:	If the insured person’s hair follicle survival rate falls below 95% within one year after receiving our hair transplant surgery, the insurer shall pay the patient up to RMB20,000 per claim
Policy Term:	One year
Insurance Premium and Payment:	RMB99.0 per insured person. The insuree shall pay the insurer no less than RMB990,000 per year at the time when the insurer firstly issues the insurance policy, and when the number of insured person expects to exceed 10,000, the insuree shall settle the increased insurance premium monthly based on the number of hair transplant appointments made by our patients to maintain the insurance policy

BUSINESS

As confirmed by Frost & Sullivan, Yonghe & Ping An Hair Transplant Insurance was the first hair transplant insurance plan in the China market. We believe that such arrangements can provide patients who are dissatisfied with the treatment results a way to receive compensation other than through bringing claims against us, thereby alleviating their dissatisfaction and reducing our exposure to potential liabilities arising from disputes over treatment results. In addition, the introduction of such insurance plan to our business operations also demonstrates our confidence and capability to consistently provide quality medical services to our patients.

As of the Latest Practicable Date, we did not maintain a medical liability insurance. According to our PRC Legal Adviser, there is no statutory requirement for our clinics to maintain such insurance coverage, and according to Frost & Sullivan Report, it is not a common industry practice for private hair transplant institutions to maintain medical liability insurance. Considering the relatively low risks of hair transplant surgeries and our comprehensive quality control system, we believe we are able to maintain the occurrence of our medical disputes at a manageable level. However, we cannot assure that we will have sufficient insurance coverage for all liabilities, losses or damages that may arise in our business operations. For more information, see “Risk Factors — Risks Relating to Our Business — Our insurance coverage may be insufficient to cover all risks involved in our business operation” in this prospectus.

During the Track Record Period and up to the Latest Practicable Date, we had not made or been required to make any insurance claims that are material in nature.

EMPLOYEES

We believe our success depends critically on our ability to attract, develop and retain our employees. We are committed to retaining renowned and influential physicians to maintain our hair transplant services’ high quality consistently. As of the Latest Practicable Date, we had a total of 4,374 full-time employees, among which 514 employees work in our headquarters.

The following table sets forth a breakdown of our full-time employees by function as of the Latest Practicable Date. For a detailed breakdown of our professionals at our clinics, see “— Our Professional Team” in this section.

	As of the Latest Practicable Date
Professionals Team	1,233
Management	63
Customer Service and Service Consultants	1,353
Marketing Staff	716
Administrative and others	1,009
Total	4,374

Each of the clinics in our network directly recruits their employees and generally enters into employment contracts with them. Recruiting is conducted through offline recruitment channels such as professional recruitment websites, internal referrals and campus recruitment.

BUSINESS

Our employees typically enter into standard employment contracts with us. Remuneration packages for our employees may comprise one or more of the following elements: base salary, performance-based bonus and discretionary bonus. We set performance targets for our employees based on their positions and departments and periodically review their performance. The results of such reviews are used in their salary determinations, bonus awards and promotion appraisals. We offer various employee benefit plans, including housing provident funds, pension, medical, maternity, work-related injuries and unemployment benefits in accordance with applicable laws and regulations.

During the Track Record Period, we also engage labor outsourcing service providers, with whom we have entered into labor outsourcing agreements for provision of housekeeping and security staff. Pursuant to such agreements, these labor outsourcing service providers should outsource to us suitable staff as requested, and we should pay the outsource service fees to the labor outsourcing service providers. The responsibility and liability of wages, social insurance and housing provident fund contributions of staff are borne by the labor outsourcing service providers and not by our Group according to such agreements.

We did not experience significant staff turnover during the Track Record Period or any disruption to our business operations due to labor disputes. As of the Latest Practicable Date, we had complied with all statutory social insurance and housing fund obligations applicable to us under PRC laws and regulations in all material aspects and were not subject to any fines or administrative actions due to non-compliance with any relevant regulations.

LICENSES, PERMITS, APPROVALS AND COMPLIANCE

Our Directors, as advised by our PRC Legal Adviser, confirm that as of the Latest Practicable Date, we had complied with all relevant PRC laws and regulations in all material respects and have obtained all material licenses, approvals and permits that we are required to obtain from relevant regulatory authorities for our operations in China, except as disclosed below.

The following table sets out a list of material licenses, permits and certificates relating to our operations, which include the Business License (營業執照), the Medical Institution Practicing license (醫療機構執業許可證) the Fire Safety Approval (消防手續) and the Water Discharge License (排水許可證) for each of our 52 clinics in operation in mainland China as of the Latest Practicable Date.

	<u>Holding Entity</u>	<u>License/Permit/Certificate</u>	<u>Issuing Authority</u>	<u>Expiry Date</u>
1.	Beijing Yonghe	Business License	Chaoyang District Bureau of Market Supervision and Administration of Beijing Municipality	2033.1.4
		Medical Institution Practicing License	Chaoyang District Commission of Health and Family Planning of Beijing Municipality	2021.12.31
		Fire Safety Approval	Beijing Chaoyang District Public Security Fire Detachment	Long term
		Water Discharge License ⁽¹⁾	Beijing Water Authority	2025.9.1

BUSINESS

	Holding Entity	License/Permit/Certificate	Issuing Authority	Expiry Date
2.	Wenzhou Yonghe	Business License	Lucheng District Bureau of Market Supervision and Administration of Wenzhou Municipality	Long term
		Medical Institution Practicing License	Lucheng District Health Bureau of Wenzhou Municipality	2024.10.22
		Fire Safety Approval	Wenzhou Lucheng District Housing and Urban-Rural Development Bureau	Long term
		Water Discharge License	Wenzhou Lucheng District Comprehensive Administrative Law Enforcement Bureau	2025.11.5
3.	Chengdu Yonghe	Business License	Wuhou District Administrative Examination and Approval Bureau of Chengdu Municipality	Long term
		Medical Institution Practicing License	Wuhou District Administrative Examination and Approval Bureau of Chengdu Municipality	2022.12.24
		Fire Safety Approval	Chengdu Wuhou District Public Security Fire Brigade	Long term
		Water Discharge License ⁽²⁾	N/A	N/A
4.	Fuzhou Yonghe	Business License	Jin'an District Market Supervision Administration of Fuzhou Municipality	2069.4.22
		Medical Institution Practicing License	Jin'an District Health bureau of Fuzhou Municipality	2023.1.12
		Fire Safety Approval	Fuzhou Jin'an District Urban-Rural Construction Bureau	Long term
		Water Discharge License ⁽¹⁾	Fuzhou Urban-Rural Construction Bureau	Long term
5.	Guangzhou Yonghe	Business License	Tianhe District Administrative Examination and Approval Bureau of Guangzhou Municipality	Long term
		Medical Institution Practicing License	Tianhe District Health Bureau of Guangzhou Municipality	2022.11.22
		Fire Safety Approval	Real Estate Leasing Management Office of Guangdong Military Region	Long term
		Water Discharge License ⁽²⁾	N/A	N/A
6.	Hangzhou Niufeisi	Business License	Xiacheng District Market Supervision Administration of Hangzhou Municipality	Long term
		Medical Institution Practicing License	Xiacheng District Health Bureau of Hangzhou Municipality	2023.12.8
		Fire Safety Approval	Hangzhou Public Security Fire Bureau	Long term
		Water Discharge License	Hangzhou City Management Bureau	2026.3.24
7.	Nanning Yonghe Clinic	Business License	Qingxiu District ASEAN Market supervision and management Institute of Nanning Municipality	Long term
		Medical Institution Practicing License	Nanning Administrative Examination and Approval Bureau	2024.3.25
		Fire Safety Approval	Nanning Public Security Fire Brigade	Long term
		Water Discharge License ⁽¹⁾	Nanning Administrative Examination and Approval Bureau	2023.6.12

BUSINESS

	Holding Entity	License/Permit/Certificate	Issuing Authority	Expiry Date
8.	Xuzhou Yonghe	Business License	Yunlong District Administrative Examination and Approval Bureau of Xuzhou Municipality	Long term
		Medical Institution Practicing License	Yunlong District Health Committee of Xuzhou Municipality	2024.12.29
		Fire Safety Approval	Xuzhou Housing and Urban-Rural Development Bureau	Long term
		Water Discharge License	Xuzhou Water Authority	2025.12.30
9.	Jiaxing Yonghe	Business License	Nanhu District Administrative Examination and Approval Bureau of Jiaxing Municipality	Long term
		Medical Institution Practicing License	Nanhu District Administrative Examination and Approval Bureau of Jiaxing Municipality	2025.2.19
		Fire Safety Approval	Jiaxing Nanhu District Housing and Urban-Rural Development Bureau	Long term
		Water Discharge License ⁽¹⁾	Jiaxing Nanhu District Administrative Examination and Approval Bureau	2026.7.6
10.	Suzhou Yonghe	Business License	Gusu District Administrative Examination and Approval Bureau of Suzhou Municipality	Long term
		Medical Institution Practicing License	Gusu District Civil Affairs and Health Bureau of Suzhou Municipality	2025.5.20
		Fire Safety Approval	Not yet obtained	N/A
		Water Discharge License	Suzhou Water Authority	2026.7.21
11.	Nanchang Yonghe	Business License	Administrative Examination and Approval Bureau of Nanchang Municipality	Long term
		Medical Institution Practicing License	Administrative Examination and Approval Bureau of Nanchang Municipality	2025.2.19
		Fire Safety Approval	Nanchang Honggutan District Housing and Urban-Rural Development Bureau	Long term
		Water Discharge License	Nanchang Honggutan New District Urban Management and Environmental Protection Bureau	2026.3.16
12.	Taizhou Yonghe	Business License	Jiaojiang District Market Supervision Administration of Taizhou Municipality	Long term
		Medical Institution Practicing License	Jiaojiang District Health Bureau of Taizhou Municipality	2024.11.17
		Fire Safety Approval	Taizhou Housing and Urban-Rural Development Bureau	Long term
		Water Discharge License	Taizhou Jiaojiang District Urban Administration Bureau	2026.3.21
13.	Huizhou Yonghe	Business License	Huicheng District Market Supervision Administration of Huizhou Municipality	Long term
		Medical Institution Practicing License	Huicheng District Health Bureau of Huizhou Municipality	2025.8.2
		Fire Safety Approval	Huizhou Huicheng District Housing and Urban-Rural Development Bureau	Long term
		Water Discharge License ⁽²⁾	N/A	N/A

BUSINESS

	<u>Holding Entity</u>	<u>License/Permit/Certificate</u>	<u>Issuing Authority</u>	<u>Expiry Date</u>
14.	Xi'an Beilin Yonghe	Business License	Beilin District Administrative Examination and Approval Bureau of Xi'an Municipality	Long term
		Medical Institution Practicing License	Beilin District Health Bureau of Xi 'an Municipality	2025.8.19
		Fire Safety Approval	Xi'an Beilin District Housing and Urban Construction Bureau	Long term
		Water Discharge License ⁽²⁾	N/A	N/A
15.	Zhengzhou Yonghe	Business License	Jinshui District Market Supervision Administration of Zhengzhou Municipality	Long term
		Medical Institution Practicing License	Jinshui District Health Bureau of Zhengzhou Municipality	2026.6.12
		Fire Safety Approval	Zhengzhou Jinshui District Public Security Fire Brigade	Long term
		Water Discharge License	Zhengzhou Urban Administration Bureau	2026.3.23
16.	Qingdao Yonghe South Clinic	Business License	Shinan District Market Supervision Administration of Qingdao Municipality	Long term
		Medical Institution Practicing License	Shinan District Health and Family Planning Bureau of Qingdao Municipality	2023.10.24
		Fire Safety Approval	Qingdao Public Security Fire Detachment City South District Brigade	Long term
		Water Discharge License	Qingdao Administrative Examination and Approval Service Bureau	2025.12.6
17.	Urumqi Yonghe Meidu	Business License	Tianshan District market supervision and Administration Bureau of Urumqi	Long term
		Medical Institution Practicing License	Tianshan District Health Committee	2026.6.30
		Fire Safety Approval	Urumqi Construction Bureau	Long term
		Water Discharge License	Tianshan District Water Affairs Bureau of Urumqi	2026.7.15
18.	Guiyang Yonghe	Business License	Nanming District Market supervision Administration of Guiyang Municipality	2047.9.1
		Medical Institution Practicing License	Nanming District Health and Family Planning Bureau of Guiyang Municipality	2025.06.12
		Fire Safety Approval	Guiyang Public Security Fire Detachment Nanming District Brigade	Long term
		Water Discharge License	Guiyang Nanming District Urban Administration Bureau	2025.12.7
19.	Chongqing Yonghe	Business License	Yuzhong District Market Supervision Administration of Chongqing Municipality	Long term
		Medical Institution Practicing License	Yuzhong District Health and Family Planning Commission of Chongqing Municipality	2023.02.04
		Fire Safety Approval	Chongqing Yuzhong District Public Security Fire Brigade	Long term
		Water Discharge License ⁽²⁾	N/A	N/A

BUSINESS

	<u>Holding Entity</u>	<u>License/Permit/Certificate</u>	<u>Issuing Authority</u>	<u>Expiry Date</u>
20.	Shenyang Yonghe	Business License	Heping District Market Supervision Administration of Shenyang Municipality	Long term
		Medical Institution Practicing License	Heping District Administrative Examination and Approval Service Bureau of Shenyang Municipality	2023.2.6
		Fire Safety Approval	Shenyang Heping District Public Security Fire Brigade	Long term
		Water Discharge License	Shenyang Heping District Administrative Examination and Approval Bureau	2026.5.13
21.	Shijiazhuang Yonghe Qiaoxi Clinic	Business License	Shijiazhuang Qiaoxi District Administrative Examination and Approval Bureau	Long term
		Medical Institution Practicing License	Shijiazhuang Administrative Examination and Approval Bureau	2024.3.31
		Fire Safety Approval	Shijiazhuang Qiaoxi District Public Security Fire Brigade	Long term
		Water Discharge License ⁽²⁾	N/A	N/A
22.	Taiyuan Yonghe	Business License	Xiaodian District Administrative Examination and Approval Service Administration of Taiyuan Municipality	2037.3.22
		Medical Institution Practicing License	Xiaodian District Administrative Examination and Approval Service Administration of Taiyuan Municipality	2025.3.29
		Fire Safety Approval	Not yet obtained	N/A
		Water Discharge License	Taiyuan Administrative Examination and Approval Service Administration	2026.4.22
23.	Tianjin Yonghe	Business License	Hexi District Market Supervision Administration of Tianjin Municipality	2066.11.9
		Medical Institution Practicing License	Hexi District Administrative Examination and Approval Bureau of Tianjin Municipality	2022.8.27
		Fire Safety Approval	Tianjin Hexi District Public Security Fire Brigade	Long term
		Water Discharge License	Tianjin Water Affairs Bureau	2025.11.29
24.	Wuhan Yonghe	Business License	Administrative Examination and Approval Bureau of Jiangnan District, Wuhan city	2067.7.24
		Medical Institution Practicing License	Administrative Examination and Approval Bureau of Jiangnan District, Wuhan city	2023.4.11
		Fire Safety Approval	Fire Brigade of Jiangnan District Branch of Wuhan Public Security Bureau	Long term
		Water Discharge License	Wuhan Jiangnan District Administrative Examination and Approval Bureau	2026.3.22

BUSINESS

	<u>Holding Entity</u>	<u>License/Permit/Certificate</u>	<u>Issuing Authority</u>	<u>Expiry Date</u>
25.	Jinhua Yonghe	Business License	Jindong District Market supervision administration of Jinhua Municipality	Long term
		Medical Institution Practicing License	Jindong District Health Bureau of Jinhua Municipality	2026.3.10
		Fire Safety Approval	Jinhua Jindong District Housing and Urban Rural Development Bureau	Long term
		Water Discharge License	Jinhua Jindong District Housing and Urban Rural Development Bureau	2026.3.21
26.	Changsha Yonghe Jimei	Business License	Tianxin District Market Supervision Administration of Changsha Municipality	2070.7.14
		Medical Institution Practicing License	Tianxin District Health Bureau of Changsha Municipality	2024.1.27
		Fire Safety Approval	Changsha Tianxin District Housing and Urban Rural Development Bureau	Long term
		Water Discharge License	Changsha Tianxin District Housing and Urban Rural Development Bureau	2026.3.26
27.	Yancheng Yonghe Yannan Clinic	Business License	Market Supervision administration of Yannan Hi-tech Industrial Development Zone of Jiangsu Province	Long term
		Medical Institution Practicing License	Yancheng Municipal Health Commission	2026.1.13
		Fire Safety Approval	Housing and Construction Bureau of Yannan High Tech Industrial Development Zone of Jiangsu Province	Long term
		Water Discharge License	Yancheng Housing and Urban Rural Development Bureau	2025.8.6
28.	Ningbo Yonghe	Business License	Yinzhou District Market Supervision Administration of Ningbo Municipality	Long term
		Medical Institution Practicing License	Yinzhou District Health Bureau of Ningbo Municipality	2024.6.30
		Fire Safety Approval	Yinzhou District Brigade of Ningbo Public Security Fire Brigade	Long term
		Water Discharge License	Ningbo Yinzhou District Water Resources Bureau	2026.1.11
29.	Dongguan Yonghe	Business License	Dongguan Market Supervision And Administration Bureau	Long term
		Medical Institution Practicing License	Dongguan Municipal Health Bureau	2026.9.22
		Fire Safety Approval	Dongcheng Brigade of Dongguan Public Security Fire Bureau	Long term
		Water Discharge License	Dongguan Ecological Environment Bureau	2026.4.25
30.	Hefei Yonghe	Business License	Hefei High-tech Development Zone Market Supervision Administration	Long term
		Medical Institution Practicing License	Hefei Municipal Health and Family Planning Commission	2023.10.19
		Fire Safety Approval	Public Security Fire Brigade of Hefei High Tech Industrial Development Zone	Long term
		Water Discharge License ⁽²⁾	N/A	N/A

BUSINESS

	Holding Entity	License/Permit/Certificate	Issuing Authority	Expiry Date
31.	Quanzhou Yonghe	Business License	Quanzhou Administration for Industry and Commerce Fengze branch	Long term
		Medical Institution Practicing License	Quanzhou Fengze District Health and Family Planning Bureau	2024.8.8
		Fire Safety Approval	Not yet obtained	N/A
		Water Discharge License	Quanzhou City Urban Administration Bureau	2026.5.25
32.	Dalian Yonghe	Business License	Xigang District Market Supervision Administration of Dalian Municipality	2048.5.21
		Medical Institution Practicing License	Xigang District Health and Family Planning Bureau of Dalian Municipality	2023.11.4
		Fire Safety Approval	Dalian Xigang Public Security Fire Brigade	Long term
		Water Discharge License	Dalian Xigang District Urban Management Comprehensive Administrative Law Enforcement Bureau	2026.8.16
33.	Kunshan Yonghe	Business License	Kunshan Market Supervision and Administration Bureau	2068.5.28
		Medical Institution Practicing License	Kunshan Health Commission	2024.1.21
		Fire Safety Approval	Kunshan Public Security Fire Brigade	Long term
		Water Discharge License	Kunshan Water Affairs Bureau	2025.12.29
34.	Harbin Yonghe	Business License	Nangang District Market Supervision administration of Harbin City	Long term
		Medical Institution Practicing License	Nangang District Health and Family Planning Bureau of Harbin City	2023.10.22
		Fire Safety Approval	Online filing acceptance system	Long term
		Water Discharge License	Harbin Nangang District Housing and Urban-Rural Development Bureau	2026.4.6
35.	Lanzhou Yonghe Chengguan Clinic	Business License	Lanzhou City Administration for Industry and Commerce Chengguan Branch	Long term
		Medical Institution Practicing License	Chengguan District Health Bureau of Lanzhou City	2022.5.4
		Fire Safety Approval	Lanzhou Chengguan District Housing and Urban-Rural Development Bureau	Long term
		Water Discharge License	Not yet obtained	N/A
36.	Wuxi Yonghe	Business License	Liangxi District Administrative Examination and Approval Bureau of Wuxi City	Long term
		Medical Institution Practicing License	Liangxi District Health Committee of Wuxi City	2024.4.9
		Fire Safety Approval	Wuxi Liangxi district housing and Urban Rural Development Bureau	Long term
		Water Discharge License ⁽¹⁾	Wuxi Municipal and Garden Bureau	2026.6.9

BUSINESS

	<u>Holding Entity</u>	<u>License/Permit/Certificate</u>	<u>Issuing Authority</u>	<u>Expiry Date</u>
37.	Nantong Yonghe	Business License	Nantong Administrative Examination and Approval Bureau	Long term
		Medical Institution Practicing License	Chongzhou District Health and Family Planning Commission of Nantong City	2024.6.30
		Fire Safety Approval	Nantong Public Security Fire Brigade	Long term
		Water Discharge License	Nantong Municipal and Garden Bureau	2025.12.10
38.	Foshan Yonghe	Business License	Chancheng District Market Supervision Administration of Foshan City	Long term
		Medical Institution Practicing License	Chancheng District Health Bureau of Foshan City	2025.9.11
		Fire Safety Approval	Foshan Chancheng District Bureau of Housing, Urban Rural Development and Water Conservancy	Long term
		Water Discharge License ⁽²⁾	N/A	N/A
39.	Zhuhai Yonghe	Business License	Xiangzhou District Market Supervision Administration of Zhuhai City	Long term
		Medical Institution Practicing License	Health bureau of Xiangzhou District, Zhuhai city	2024.9.19
		Fire Safety Approval	Zhuhai Municipal Bureau of housing and urban-rural development	Long term
		Water Discharge License	Zhuhai Xiangzhou District Urban Management and Comprehensive Law Enforcement Bureau	2026.4.12
40.	Jinan Yonghe Licheng Clinic	Business License	Administrative Examination and Approval Service Bureau of Licheng District, Jinan	Long term
		Medical Institution Practicing License	Administrative Examination and Approval Service Bureau of Licheng District, Jinan	2025.3.16
		Fire Safety Approval	Jinan Licheng District Fire Rescue Brigade	Long term
		Water Discharge License	Licheng District Urban-Rural Water Bureau of Jinan	2026.4.14
41.	Zhongshan Yonghe	Business License	Zhongshan Market Supervision and Administration Bureau	Long term
		Medical Institution Practicing License	Zhongshan Health Bureau	2025.10.8
		Fire Safety Approval	Zhongshan Municipal Bureau of Housing and Urban-Rural Development	Long term
		Water Discharge License	Zhongshan Water Affairs Bureau	2026.7.4
42.	Changzhou Yonghe	Business License	Changzhou National High-tech Industry Development Zone (New North District) Administrative Examination and Approval Bureau	Long term
		Medical Institution Practicing License	Changzhou National High-tech Industry Development Zone (New North District) Administrative Examination and Approval Bureau	2025.10.19
		Fire Safety Approval	Housing and Urban Rural Development Bureau of Changzhou National High tech Industrial Development Zone	Long term
		Water Discharge License ⁽¹⁾	Changzhou Urban Rural Development Bureau	2022.8.14

BUSINESS

	<u>Holding Entity</u>	<u>License/Permit/Certificate</u>	<u>Issuing Authority</u>	<u>Expiry Date</u>
43.	Zhanjiang Yonghe	Business License	Market Supervision Administration of Zhanjiang Economic and Technological Development Zone	Long term
		Medical Institution Practicing License	Zhanjiang Development Zone Administration of Population and Social Affairs	2025.9.24
		Fire Safety Approval	Housing, Planning and Construction Bureau of Zhanjiang Economic and technological Development Zone	Long term
		Water Discharge License	Zhanjiang Municipal Bureau of Housing and Urban-Rural Development	2026.2.24
44.	Foshan Yonghe Meidu Shunde Clinic	Business License	Shunde District Market Supervision Administration of Foshan City	Long term
		Medical Institution Practicing License	Shunde District Health Bureau of Foshan City	2025.11.22
		Fire Safety Approval	Foshan Shunde District Housing Urban-Rural Construction and Water Conservancy Bureau	Long term
		Water Discharge License	Foshan Shunde District Housing Urban-Rural Construction and Water Conservancy Bureau	2024.4.21
45.	Luoyang Yonghe	Business License	Luolong District Market Supervision Administration of Luoyang City	Long term
		Medical Institution Practicing License	Luolong District Health Committee of Luoyang City	2026.2.6
		Fire Safety Approval	Luoyang Housing and Urban-Rural Development Bureau	Long term
		Water Discharge License	Luoyang City Urban Administration Bureau	2026.3.18
46.	Shanghai Yonghe	Business License	Huangpu District Market Supervision Administration of Shanghai Municipality	2022.1.31
		Medical Institution Practicing License	Huangpu District Health and Family Planning Commission of Shanghai Municipality	2022.7.23
		Fire Safety Approval	Not yet obtained	N/A
		Water Discharge License	Not yet obtained	N/A
47.	Xiamen Yonghe	Business License	Siming District Market Supervision Administration of Xiamen City	2066.11.30
		Medical Institution Practicing License	Siming District Health Bureau of Xiamen City	2023.2.2
		Fire Safety Approval	Siming District Brigade of Xiamen Public Security Fire Detachment	Long term
		Water Discharge License	Xiamen Siming District Environmental Protection Bureau	2026.1.2
48.	Shenzhen Yonghe	Business License	Market Supervision Administration of Shenzhen Municipality	Long term
		Medical Institution Practicing License	Futian District Health and Family Planning Bureau of Shenzhen Municipality	2023.11.29
		Fire Safety Approval	Futian District Brigade of Shenzhen Public Security Fire Detachment	Long term
		Water Discharge License	Futian District Water Bureau of Shenzhen	2025.12.21

BUSINESS

	<u>Holding Entity</u>	<u>License/Permit/Certificate</u>	<u>Issuing Authority</u>	<u>Expiry Date</u>
49.	Nanjing Yonghe	Business License	Qinhuai District Market Supervision administration of Nanjing city	Long term
		Medical Institution Practicing License	Qinhuai District Health and Family Planning Bureau of Nanjing City	2023.7.19
		Fire Safety Approval	Qinhuai District Brigade of Nanjing Public Security Fire Brigade	Long term
		Water Discharge License	Nanjing Qinhuai District administrative examination and approval Bureau	2025.11.29
50.	Hangzhou Yonghe Meidu	Business License	Gongshu District Market supervision administration of Hangzhou City	Long term
		Medical Institution Practicing License	Health and Family Planning Bureau of Gongshu District, Hangzhou	2023.10.23
		Fire Safety Approval	Gongshu District Brigade of Hangzhou Public Security Fire Detachment	Long term
		Water Discharge License	Hangzhou Municipal Urban Administration Bureau	2026.2.1
51.	Kunming Yonghe	Business License	Wuhua District Market Supervision Administration of Kunming City	2038.7.3
		Medical Institution Practicing License	Wuhua District Health and Family Planning Bureau of Kunming City	2024.3.14
		Fire Safety Approval	Wuhua District Housing and Urban-Rural Development Bureau of Kunming	Long term
		Water Discharge License	Wuhua District Housing and Urban-Rural Development Bureau of Kunming	2026.6.24
52.	Haikou Yonghe	Business License	Hainan Provincial Market Supervision Administration	Long term
		Medical Institution Practicing	Haikou Meilan District Health Committee	2026.6.14
		Fire Safety Approval	Bureau of Housing and Urban-Rural Development of Meilan District, Haikou	Long term
		Water Discharge License	Meilan District Water Bureau of Haikou	2026.7.7

Notes:

- (1) As confirmed by the competent authority, the property owner (instead of our clinic) shall apply for the water discharge license for the whole building in which our clinic is located, and the property owner had already obtained the water discharge license.
- (2) As confirmed by the competent authority, the property owner (instead of our clinic) shall apply for the water discharge license for the whole building in which our clinic is located, but the property owner had not yet obtained the water discharge license.

We intend to apply for renewal of the above material licenses prior to their respective expiry dates. The successful renewal of our existing licenses, permits and certificates will be subject to our fulfilment of relevant requirements. As of the Latest Practicable Date, our Directors were not aware of any reason that would cause or lead to the non-renewal of such licenses, permits and certificates. As advised by our PRC Legal Adviser, as of the Latest Practicable Date, there was no legal impediment for us to renew these licenses, permits and certificates as long as we comply with the relevant legal requirements.

Non-Compliances

During the Track Record Period and up to the Latest Practicable Date, we experienced certain non-compliance incidents, including failure to obtain, or to promptly update, certain licenses and permits necessary for the operation of some of our clinics, and non-compliances relating to the Advertisement Law of the PRC. The details of which are set forth in the table below:

Nature of the Non-Compliances	Reasons For the Non-Compliances	Legal Consequences, Maximum Potential Penalty/Liabilities, and Potential Operational and Financial Impacts	Remedial/Rectification Actions Taken and Internal Control Measures
Began trial operation for some of our clinics prior to obtaining, or promptly updating, the Medical Institution Practicing Licenses (醫療機構執業許可證)			
In 2018 and 2019, ten of our clinics began their trial operation after obtaining their business licenses (營業執照), but prior to obtaining, or promptly updating, the Medical Institution Practicing Licenses (醫療機構執業許可證).	<p>(i) With respect to nine of such clinics, the non-compliance incidents were resulting from inadvertent oversight by the local management teams of the relevant clinics previously in charge of supervising the compliance status of such clinics, who mistakenly believed that since hair transplant clinics are not expressly listed as medical institutions under applicable laws and regulations and the clinics can start trial operation so long as they have obtained the business licenses.</p> <p>(ii) With respect to one of such clinics, it started its trial operation in November 2012, after obtaining its Business License and the Medical Institution Practicing License. However, its original Medical Institution Practicing License expired in November 2017, and the local management team of the clinic forgot to timely renew such license in time due to an inadvertent oversight.</p> <p>The foregoing oversight was not a result of any willful misconduct by our Directors or any of our employees, but did reflect insufficiencies in our internal control measures adopted at the time, which insufficiencies contributed to our failure to prevent and to timely detect such non-compliances. We took prompt remedial and/or rectification measures as soon as we identified such non-compliances, and had fully resolved such non-compliances without suffering any material negative impact in relation thereto. We had also adopted enhanced internal control measures in this regard to prevent the recurrence of similar non-compliances. Please refer to the fourth column for more information.</p>	<p>According to our PRC Legal Adviser, pursuant to the Regulations on the Management of Medical Institutions (醫療機構管理條例) promulgated by the State Council, if a clinic began operation prior to obtaining, or promptly updating, the Medical Institution Practicing Licenses, the maximum penalty is (i) confiscation of the illegal income (i.e., those generated prior to obtaining the Medical Institution Practicing License or during the period the licenses were expired and not updated); (ii) confiscation of the relevant medicines and medical devices used; and (iii) an administrative penalty of up to RMB10,000.</p> <p>During the Track Record Period, we were penalized for four of such clinics, and incurred penalties or confiscation of income in an aggregated amount of approximately RMB0.33 million. All of the penalties or confiscation of income had been fully settled, and our PRC Legal Adviser is of the view that the risk that we be penalized again for the same matter is remote.</p>	<p>With respect to the nine clinics set forth in (i) the second column, all of them had obtained the Medical Institution Practicing Licenses within the same year that they began their trial operation. In fact, substantially all of them obtained the Medical Institution Practicing Licenses within a few weeks, or even days, after they began their trial operation.</p> <p>With respect to the clinic set forth in (ii) in the second column, it successfully renewed the Medical Institution Practicing License in July 2018, promptly after we identified the oversight in June 2018.</p> <p>To prevent similar incidents from occurring again, we have adopted the following internal control measures:</p> <ul style="list-style-type: none"> • We adopted more stringent requirements and procedures for new clinic openings, especially in the area of obtaining all the necessary licenses and permits in compliance with the applicable laws and regulations; • We have updated our licenses and permits management policy to monitor and manage the license application and renewal processes for our clinics;

BUSINESS

Nature of the Non-Compliances	Reasons For the Non-Compliances	Legal Consequences, Maximum Potential Penalty/Liabilities, and Potential Operational and Financial Impacts	Remedial/Rectification Actions Taken and Internal Control Measures
		<p>With respect to the six clinics that we did not receive administrative penalties, all the relevant non-compliances occurred, and were fully rectified, over two years ago as of the Latest Practicable Date. As advised by our PRC Legal Adviser, pursuant to the Administrative Penalty Law of the PRC (中華人民共和國行政處罰法), for non-compliances that had been rectified for over two years and were not penalized, the competent authorities shall not impose any penalties for such historical non-compliances. Therefore, our PRC Legal Adviser is of the view that the risk that the we be penalized for such historical non-compliances is remote.</p> <p>Our Directors believe that such penalties, even in the aggregate, did not and would not have any material adverse effect on our business operation and financial position.</p>	<ul style="list-style-type: none"> • We have provided, and will continue to provide, various training programs to all of our employees about the applicable laws and regulations in relation to the operation of our clinics, with particular focuses on the necessary licenses and permits that we need to obtain prior to operating the clinics; • We have established a regulatory compliance committee at the Group level, which is headed by Mr. Zhang, our founder and chief executive officer, and comprised seven Directors and/or senior officers of our Group, including Mr. XU Yang, our operation director, Ms. HAN Zhimei, our finance director, and Mr. ZHANG Hui, our Procurement director, among others. We require our regulatory compliance committee to closely monitors the compliance status of our headquarters as well as the local clinics, to keep the records of their reviewing and monitoring processes, and to report to our Board of Directors on a monthly basis with respect to its findings.

BUSINESS

Nature of the Non-Compliances	Reasons For the Non-Compliances	Legal Consequences, Maximum Potential Penalty/Liabilities, and Potential Operational and Financial Impacts	Remedial/Rectification Actions Taken and Internal Control Measures
Failure to complete the necessary fire safety procedures with respect to some of our clinics			
As of the end of the Track Record Period, we had not obtained the required fire safety approvals for a total of twelve clinics.	<p>Among these twelve clinics, there were:</p> <p>(i) one clinic in Shanghai for which we were not able to complete the required fire safety approvals despite of exercising reasonable best efforts seeking to obtain such approvals, because of practical difficulties outside of our control, i.e., the owner of the entire property where our clinic is located did not complete the required fire safety procedures, and the relevant local authority will not issue the fire safety approvals to us on a standalone basis;</p> <p>(ii) two clinics in Urumqi and Xi'an for which we had ceased operation as of August 1, 2021 and August 6, 2021, respectively, and it was impracticable for us to obtain the fire safety approvals for closed clinics; and</p> <p>(iii) nine clinics for which we had submitted or were in the process of completing the applications for the required fire safety approvals, but had not obtained the relevant approvals despite of exercising reasonable best efforts, as of the end of the Track Record Period. As of the Latest Practicable Date, we had submitted the applications for the required fire safety approvals for all these clinics, and had completed the relevant fire safety approvals for six of them. Please refer to the fourth column for more details of the latest status of our rectification efforts with respect to these clinics.</p>	<p>With respect to the one clinic set forth in (i) in the previous column, we, together with our PRC Legal Adviser, made inquiries with the local competent authorities, and the relevant local competent authorities confirmed that we are allowed to continue the operation of the clinic and they would not impose any administrative penalties on us because of such non-compliance incident. In 2018, 2019, 2020 and the six months ended June 30, 2021, the revenue contributed by this clinic amounted to RMB53.4 million, RMB61.7 million, RMB77.5 million and RMB44.1 million, respectively. The gross profit for this clinic amounted to RMB43.2 million, RMB50.0 million, RMB64.3 million and RMB34.1 million, respectively, for the same periods. As set out in the next column, we plan to relocate the clinic to another location in the same city, and to close the non-compliant clinic, in December 2021. The new clinic is currently under renovation and would be larger than the old clinic, and we expect to generate more revenue from the new clinic. We do not expect to incur significant costs as a result of such relocation.</p>	<p>With respect to the one clinic set forth in (i) in the second column, we currently plan to relocate the clinic to another location in the same city, and to close the non-compliant clinic, in December 2021. We did not close such clinic earlier because we had been using our commercially reasonable efforts to push the property owner to complete the required fire safety procedures for the entire building. After receiving confirmation from the property owner that they do not expect to complete the necessary procedures for the entire building any time soon, and receiving confirmation from the relevant competent authorities that they will not issue the fire safety approvals to us on a standalone basis, and also considering the difficulties in obtaining the required fire safety approval for this clinic as set forth below, we decided to close this clinic. It generally takes around a quarter for us to complete the deregistration and closure procedures.</p>

BUSINESS

Nature of the Non-Compliances	Reasons For the Non-Compliances	Legal Consequences, Maximum Potential Penalty/Liabilities, and Potential Operational and Financial Impacts	Remedial/Rectification Actions Taken and Internal Control Measures
	<p>We became aware of such non-compliance incidents during our company-wide compliance reviews. We commenced our operation at the twelve clinics prior to obtaining the required fire safety approvals primarily due to the evolving and varied requirements and practices on the relevant fire safety procedures adopted by the local governmental authorities of different cities in China where our clinics are located, which resulted in misunderstanding of the applicable local requirements and practices by certain of our employees at the local clinics who were previously in charge of completing the relevant fire safety procedures.</p> <p>The foregoing oversight was not a result of any willful misconduct by our Directors or any of our employees, but did reflect insufficiencies in our internal control measures adopted at the time, which insufficiencies contributed to our failure to prevent and to timely detect such non-compliances. We took prompt remedial and/or rectification measures as soon as we identified such non-compliances, and had made significant progresses resolving such non-compliances. However, despite our reasonable best efforts, as of the Latest Practicable Date, there were still a small number of such non-compliances remain unresolved, for reasons outside of our control. We had nevertheless adopted enhanced internal control measures in this regard to prevent the recurrence of similar non-compliances. Please refer to the fourth column for more information.</p>	<p>With respect to the two clinics set forth in (ii) in the previous column, as advised by our PRC Legal Adviser, our maximum exposure for the non-compliances is a penalty in an amount of up to RMB0.31 million. In 2018, 2019, 2020 and the six months ended June 30, 2021, the aggregate revenue contributed by these two clinics amounted to RMB45.5 million, RMB65.5 million, RMB54.2 million and RMB18.2 million, respectively. The gross profit for these two clinics amounted to RMB34.8 million, RMB51.9 million, RMB44.3 million and RMB14.7 million, respectively, for the same periods. As set out in the next column, we had relocated these two clinics as of the Latest Practicable Date. The new clinics are larger than the old clinics, and we expect to generate more revenue from the new clinics. We did not incur significant costs as a result of such relocation.</p>	<p>With respect to the two clinics set forth in (ii) in the second column, we had ceased their operation, and have relocated the clinics to other locations in the same cities, as of the Latest Practicable Date.</p> <p>With respect to the nine clinics set forth in (iii) in the second column, we are in the process of completing the necessary procedures as soon as possible. During the period between the end of the Track Record Period and the Latest Practicable Date, we had obtained the required fire safety approvals for six additional clinics. We currently expect to obtain the required fire safety approvals for two of the three remaining clinics in February 2022 and the last one in March 2022. As advised by our PRC Legal Adviser, there is no material legal impediment for us to obtain the required approvals and licenses for the remaining clinics as long as we comply with the relevant legal requirements.</p> <p>With respect to each of these three remaining clinics (in fact, also with respect to one other clinic that we had already completed the necessary fire safety procedures as of the Latest Practicable Date and with respect to the clinic set forth in (i) in the second column), we engaged a third party fire safety consultant to conduct fire safety inspections on it (collectively, the “Fire Safety Consultants”). Each of the Fire Safety Consultants we engaged is a professional fire safety inspection institution holding the relevant qualifications and having a dedicated inspection team consisting of certified fire safety specialists. The Fire</p>

BUSINESS

Nature of the Non-Compliances	Reasons For the Non-Compliances	Legal Consequences, Maximum Potential Penalty/Liabilities, and Potential Operational and Financial Impacts	Remedial/Rectification Actions Taken and Internal Control Measures
			<p>Safety Consultants conducted comprehensive review and inspection on our clinics through on-site inspection, surveys and document review. The aspects inspected by the Fire Safety Consultants included, among others, (i) the compliance of our fire protection system with applicable regulations and industry standards, (ii) the adequacy and reliability of the fire safety equipment and systems installed in our clinics (including fire alarm systems, fire extinguishing systems, smoke removal systems, lighting systems, water supply, power supply, etc.), (iii) the adequacy and reliability of the emergency evacuation equipment in the premises where our clinics are located, and (iv) the fire protection and heat insulation capabilities of the construction materials we used in our clinics. Each of our clinics passed the relevant inspection. Upon completion of their respective inspection, each of the Fire Safety Consultants issued a fire safety inspection report, and was of the view that the relevant clinic inspected by it has installed fire protection systems and adopted fire safety procedures in compliance with applicable laws and regulations and industry standards, and the relevant fire safety equipment and systems installed were adequate and reliable.</p>

BUSINESS

Nature of the Non-Compliances	Reasons For the Non-Compliances	Legal Consequences, Maximum Potential Penalty/Liabilities, and Potential Operational and Financial Impacts	Remedial/Rectification Actions Taken and Internal Control Measures
		<p>With respect to the nine clinics set forth in (iii) in the previous column, we had either obtained written confirmations from, or made inquiries with, the relevant local competent authorities, for eight of them. As advised by our PRC Legal Adviser, based on, among others, the relevant confirmations and inquiry results, the risk that the relevant local competent authorities imposing any material administrative penalties on us, or requiring the relevant clinics to suspend or terminate their business operations is remote. In 2018, 2019 and 2020, aggregate revenue contributed by these eight clinics amounted to RMB27 million, RMB76 million and RMB200 million, respectively.</p> <p>With respect to the remaining one clinic, as advised by our PRC Legal Adviser, our maximum exposure for the non-compliance is (a) a penalty in an amount of up to RMB5,000, and (b) closure of the clinic. In 2018, 2019 and 2020, the revenue contributed by this clinic amounted to RMB4 million, RMB17 million and RMB26 million, respectively. If we were required by the competent authorities to close such non-compliant clinic, we may suffer revenue loss as a result of such closure, may need to terminate the lease for the existing clinic and incur contractual penalties, and may forfeit our deposit and certain portion of the paid rents.</p>	<p>Despite our failure to complete in time the necessary fire safety procedures during the Track Record Period, we nonetheless placed significant importance on in-store fire safety, with a goal to mitigate our risk exposure to potential fire safety accidents and public safety concerns. To this end, we had taken a series of internal control measures, which include (i) engaging professional fire protection engineers to identify risks and design safeguards that aid in preventing, controlling and mitigating the effects of fires when building new clinics, (ii) devising a fire safety plan with guidance on the use of building and decoration materials and electrical appliances, standard operation procedures in case of fire alarm and proper evacuation plan, (iii) installing the necessary fire safety equipment as required by applicable PRC laws and regulations, including fire extinguishers, smoke detectors and automatic water spray, and (iv) applying fire resistant construction and decoration materials, installing proper evacuation route indication signs and where applicable, proper emergency exits. Due to such internal control measures on fire safety, we passed the subsequent regular and/or random fire safety inspections by the relevant governmental authorities that all of our clinics are subject to, without being imposed on any material administrative penalties or fines, during the Track Record Period and up to the Latest Practicable Date.</p>

BUSINESS

Nature of the Non-Compliances	Reasons For the Non-Compliances	Legal Consequences, Maximum Potential Penalty/Liabilities, and Potential Operational and Financial Impacts	Remedial/Rectification Actions Taken and Internal Control Measures
		<p>As advised by our PRC Legal Adviser, each of the authorities we obtained written confirmations from or made inquiries with is a competent authority, according to the <i>Fire Prevention Law of the PRC</i> (中華人民共和國消防法), the <i>Interim Regulations on Administration of Examination and Acceptance of Fire Control Design of Construction Projects</i> (建設工程消防設計審查驗收管理暫行規定), and the information set forth on the official websites of such authorities.</p> <p>Our Directors believe that such non-compliance incidents would not have a material adverse effect on our business, results of operations or financial condition or the Global Offering, on the grounds that: (i) we had not been subject to any material administrative penalties during the Track Record Period and up to the Latest Practicable Date because of such non-compliances, (ii) the maximum potential penalty of approximately RMB0.31 million accounted for less than 0.02% of our revenue in 2020; and (iii) we have enhanced our internal control measures and procedures to prevent the reoccurrence of such non-compliance incidents.</p>	<p>Furthermore, we have enhanced our internal control measures and procedures with respect to fire safety to manage associated risks and prevent the reoccurrence of such non-compliance incidents. Set forth below are key efforts we have made with respect to fire safety, in addition to those measures discussed in “— Began trial operation for some of our clinics prior to obtaining the Medical Institution Practicing Licenses (醫療機構執業許可證)” above:</p> <ul style="list-style-type: none"> • <i>Fire safety policies.</i> We have established our in-store fire safety management policies, which unify the fire safety practice at every clinic throughout our network. Our heightened in-store fire safety management policies provide detailed guidance on the use and maintenance of fire safety facilities. According to the heightened in-store fire safety management policies, every clinic shall make plans for fire safety work and conduct fire safety inspection on a regular basis. • <i>Employee trainings.</i> We provide regular trainings on fire safety to our in-store staff and other employees, which cover key aspects of our daily operations. We also organize fire drills on a regular basis to increase our employees’ fire safety awareness.

BUSINESS

Nature of the Non-Compliances	Reasons For the Non-Compliances	Legal Consequences, Maximum Potential Penalty/Liabilities, and Potential Operational and Financial Impacts	Remedial/Rectification Actions Taken and Internal Control Measures
			<ul style="list-style-type: none"> • <i>Management of licenses and certificates.</i> We have devised our license and certificate management policies, which govern the applications for the required as-built acceptance check on fire prevention or fire safety filing or the fire safety inspections, as the case may be, among other things. The license and certificate management policies explicitly require every new clinic to be opened only after the required fire safety approvals have been detained. • <i>Designated personnel.</i> According to our license and certificate management policies, we designate dedicated personnel to manage licenses and certificates required for our business operation, who are responsible for managing the use of licenses and certificates, monitoring their status and renewing those near to expire in a timely manner.

BUSINESS

Nature of the Non-Compliances	Reasons For the Non-Compliances	Legal Consequences, Maximum Potential Penalty/Liabilities, and Potential Operational and Financial Impacts	Remedial/Rectification Actions Taken and Internal Control Measures
Failure to obtain the water discharge licenses with respect to some of our clinics			
As of the end of the Track Record Period, we were not able to obtain the water discharge licenses that we are required to obtain from relevant regulatory authorities for a total of seven clinics.	<p>Among these seven clinics, there were:</p> <ul style="list-style-type: none"> (i) one clinic in Shanghai for which we were not able to obtain the required water discharge licenses despite of exercising reasonable best efforts seeking to obtain such licenses, because of practical difficulties outside of our control, i.e., the building where our clinic is located was constructed years ago and cannot install the relevant water discharge facilities in line with current laws and regulations; (ii) two clinics in Xi'an and Changsha for which we had ceased operation as of the Latest Practicable Date, and it is impracticable for us to obtain the required water discharge licenses for closed clinics; and (iii) four clinics for which we had submitted or were in the process of completing the applications for the required water discharge licenses, but had not obtained the relevant licenses despite of exercising reasonable best efforts, as of the end of the Track Record Period. As of the Latest Practicable Date, we had submitted the applications for the required water discharge licenses for all these clinics, and had obtained the water discharge licenses for three of them. Please refer to the fourth column for more details of the latest status of our rectification efforts with respect to these clinics. 	<p>As advised by our PRC Legal Adviser, with respect to the one clinic set forth in (i) in the previous column, our maximum exposure for the non-compliance is a penalty in an amount of up to RMB0.5 million. In 2018, 2019, 2020 and the six months ended June 30, 2021, the revenue contributed by this clinic amounted to RMB53.4 million, RMB61.7 million, RMB77.5 million and RMB44.1 million, respectively. The gross profit for this clinic amounted to RMB43.2 million, RMB50.0 million, RMB64.3 million and RMB34.1 million, respectively, for the same periods. As set out in the next column, we plan to relocate the clinic to another location in the same city, and to close the non-compliant clinic, in December 2021. The new clinic is currently under renovation and would be larger than the old clinic, and we expect to generate more revenue from the new clinic. We do not expect to incur significant costs as a result of such relocation.</p> <p>As advised by our PRC Legal Adviser, with respect to each of the two clinics set forth in (ii) in the previous column, our maximum exposure for the non-compliance is a penalty in an amount of up to RMB0.5 million. In 2018, 2019, 2020 and the six months ended June 30, 2021, the aggregate revenue contributed by these two clinics amounted to RMB55.6 million, RMB66.9 million, RMB74.2 million and RMB11.1 million, respectively. The gross profit for these two clinics amounted to RMB43.3 million, RMB53.0 million, RMB61.9 million and RMB8.4 million, respectively, for the same periods.</p>	<p>With respect to the one clinic set forth in (i) in the second column, we currently plan to relocate the clinic to another location in the same city, and to close the non-compliant clinic in December 2021. We did not close such clinic earlier because we had been using our commercially reasonable efforts to push the property owner to install the relevant water discharge facilities in line with current laws and regulations. After receiving confirmation from the property owner that the building was constructed years ago and cannot install the relevant water discharge facilities, and considering the difficulties in completing the necessary fire safety procedures for this clinic as set forth above, we decided to close this clinic. It generally takes around a quarter for us to complete the deregistration and closure procedures.</p> <p>With respect to the two clinics set forth in (ii) in the second column, we had ceased their operation, and have relocated the clinics to other locations in the same cities as of the Latest Practicable Date.</p>

BUSINESS

Nature of the Non-Compliances	Reasons For the Non-Compliances	Legal Consequences, Maximum Potential Penalty/Liabilities, and Potential Operational and Financial Impacts	Remedial/Rectification Actions Taken and Internal Control Measures
Failure to obtain the water discharge licenses with respect to some of our clinics			
	<p>We became aware of such non-compliance incidents during our company-wide compliance reviews. We commenced our operation at the seven clinics before we obtain the required water discharge licenses primarily due to the evolving and varied requirements and practices on applying and issuing the water discharge licenses adopted by the local governmental authorities of different cities in China where our clinics are located, which resulted in misunderstanding of the applicable local requirements and practices by certain of our employees at the local clinics who were previously in charge of obtaining the required water discharge licenses.</p> <p>The foregoing non-compliances were not a result of any willful misconduct by our Directors or any of our employees, but did reflect insufficiencies in our internal control measures adopted at the time, which insufficiencies contributed to our failure to prevent and to timely detect such non-compliances. We took prompt remedial and/or rectification measures as soon as we identified such non-compliances, and had made significant progresses resolving such non-compliances. However, despite our reasonable best efforts, as of the Latest Practicable Date, there were still a small number of such non-compliances remain unresolved, for reasons outside of our control. We had nevertheless adopted enhanced internal control measures in this regard to prevent the recurrence of similar non-compliances. Please refer to the fourth column for more information.</p>	<p>With respect to the four clinics set forth in (iii) in the previous column, we had either obtained written confirmations from, or made inquiries with, the relevant local competent authorities, for all of them.</p> <p>As advised by our PRC Legal Adviser, based on, among others, the relevant confirmations and inquiry results, the risk that the relevant local competent authorities imposing any material administrative penalties on us is remote. In 2018, 2019 and 2020, the aggregate revenue contributed by these four clinics amounted to RMB3 million, RMB16 million and RMB48 million, respectively. As advised by our PRC Legal Adviser, each of the authorities we obtained written confirmations from or made inquiries with is a competent authority, according to the <i>Measures for the Administration of Permits for the Discharge of Urban Sewage into the Drainage Network</i> (城镇污水排入排水管网许可管理办法) and the information set forth on the official websites of such authorities.</p>	<p>With respect to the four clinics set forth in (iii) in the second column, we are in the process of completing the necessary procedures as soon as possible. During the period between the end of the Track Record Period and the Latest Practicable Date, we had obtained the required water discharge licenses for three additional clinics. We currently expect to obtain the required water discharge licenses for the remaining one clinic in March 2022, and in any event no later than by the end of the first quarter of 2022. As advised by our PRC Legal Adviser, there is no material legal impediment for us to obtain the required approvals and licenses for the remaining clinic as long as we comply with the relevant legal requirements.</p> <p>Furthermore, we have enhanced our internal control measures and procedures with respect to water discharge to manage associated risks and prevent the reoccurrence of such non-compliance incidents. Set forth below are key efforts we have made with respect to water discharge licenses, in addition to those measures discussed in “— Began trial operation for some of our clinics prior to obtaining the Medical Institution Practicing Licenses (醫療機構執業許可證)” above:</p> <ul style="list-style-type: none"> • <i>Employee trainings.</i> We provide regular trainings on water discharge to our in-store staff and other employees, which cover key aspects of our daily operations. We also organize legal trainings on a regular basis to enhance our employees’ compliance awareness.

BUSINESS

Nature of the Non-Compliances	Reasons For the Non-Compliances	Legal Consequences, Maximum Potential Penalty/Liabilities, and Potential Operational and Financial Impacts	Remedial/Rectification Actions Taken and Internal Control Measures
		<p>Our Directors believe that such non-compliance incidents would not have a material adverse effect on our business, results of operations or financial condition or the Global Offering, on the grounds that: (i) we had not been subject to any material administrative penalties during the Track Record Period and up to the Latest Practicable Date because of such non-compliances, (ii) the maximum potential penalty of RMB1.0 million accounted for less than 0.06% of our revenue in 2020; and (iii) we have enhanced our internal control measures and procedures to prevent the reoccurrence of such non-compliance incidents.</p>	<ul style="list-style-type: none"> • <i>Management of licenses and certificates.</i> We have devised our license and certificate management policies, which govern the applications for the required water discharge licenses. The license and certificate management policies explicitly require every new clinic to be opened only after the required water discharge license is obtained. • <i>Designated personnel.</i> According to our license and certificate management policies, we designate dedicated personnel to manage the licenses and certificates required for our business operation, who are responsible for managing the use of the licenses and certificates, monitoring their status and renewing those near to expire in a timely manner.

BUSINESS

Nature of the Non-Compliances	Reasons For the Non-Compliances	Legal Consequences, Maximum Potential Penalty/Liabilities, and Potential Operational and Financial Impacts	Remedial/Rectification Actions Taken and Internal Control Measures
Non-Compliances relating to the Advertisement Law of the PRC and/or the Administrative Measures of Medical Advertisements			
<p>During the Track Record Period, we experienced a number of isolated non-compliance incidents relating to our failure to comply with <i>the Advertisement Law of the PRC</i> (中華人民共和國廣告法) and/or the <i>Administrative Measures of Medical Advertisements</i> (醫療廣告管理辦法).</p>	<p>Similar to other companies in the consumer healthcare industry, and the hair-related healthcare industry in particular, we rely heavily on promotions, advertisements and online marketing activities to educate the potential customers of our services, and to promote our brand and services. However, medical advertising and promotions are heavily and strictly regulated in the PRC. The applicable laws and regulations were subject to frequent changes, and the interpretation of applicable laws and regulations by local governmental authorities vary greatly, which resulted in misunderstanding of the applicable local requirements and practices by certain of our employees previously in charge of our compliance work in this regard. As a result, we experienced a number of isolated non-compliance incidents.</p> <p>Specifically, (i) our Beijing headquarters was fined twice in 2018, primarily for (a) posting advertisements containing false, misleading information, or overly extreme, (b) posting advertisements containing images of real patients, and (c) posting advertisements prior to completing the necessary governmental review process, and paid penalties in an amount of RMB800,000 and approximately RMB1.8 million, respectively.</p>	<p>As advised by our PRC Legal Adviser, according to the Administrative Measures of Medical Advertisements, with respect to unspecified non-compliances with the applicable advertisement laws, the penalty amount for each violation shall generally be between RMB10,000 to RMB30,000.</p> <p>With respect to certain specified non-compliances, such as the incidents of our Beijing headquarters set forth in (i)(a) in the previous column, the penalty amounts were calculated based on the following formula: for immaterial violations, the penalty amount shall be between 1-3 times of the expenses actually incurred for the relevant non-compliant advertisement; but if the expenses incurred was not readily determinable or were obviously low, the penalty amount shall be between RMB200,000 to RMB1 million; for repeated violations (more than three times in two years) or material violations, the penalty amount shall be between 5-10 times of the expenses actually incurred for the relevant non-compliant advertisement; but if the expenses incurred was not readily determinable or were obviously low, the penalty amount shall be between RMB1 million to RMB2 million. In addition, for material violations, the competent authorities can revoke the business license, the medical institution practicing license, and/or the medical advertisement examination certificate, and can refuse the renewal applications for the advertisement examination certificates for a period of one year.</p>	<p>We ceased publishing the relevant advertisements, removed those already published to the extent practicable, and duly settled the fines immediately after receiving the notices from the competent authorities.</p> <p>We have adopted the following internal control measures to prevent future occurrence of such non-compliance:</p> <ul style="list-style-type: none"> • <i>Training.</i> We have engaged PRC legal advisers to conduct legal compliance training periodically to our employees, including the management teams of our local clinics as well as members of our marketing teams, to increase their awareness of the relevant PRC laws and regulations, including the newly enacted Enforcement Guidance; • <i>Policy.</i> We have formulated and distributed to our employees an internal control policy with respect to the contents of medical advertisements, as well as the relevant procedures of the government review ; and • <i>Review and monitor.</i> We designate our legal department team to review and monitor the status of medical advertisements published by us and require all medical advertisements to be reviewed and approved by our legal department before publishing. We also require our legal department to keep the records of their reviewing and monitoring processes.

BUSINESS

Nature of the Non-Compliances	Reasons For the Non-Compliances	Legal Consequences, Maximum Potential Penalty/Liabilities, and Potential Operational and Financial Impacts	Remedial/Rectification Actions Taken and Internal Control Measures
	<p>(ii) our Kunming subsidiary was fined once in 2018 primarily for (a) posting advertisements containing false or misleading information, and (b) posting advertisements prior to completing the necessary governmental review process, and paid penalties in an amount of RMB200,000.</p> <p>(iii) our Shanghai subsidiary was fined (a) once in 2019 for posting advertisements without including the governmental review record number, posting advertisements containing images of real patients, and posting online advertisements without highlighting the “close” button and without ensuring the viewers can close the advertisement window with a single click; and (b) once in 2021 for posting advertisements containing images of real patients and the success rate of our treatment services, and paid penalties in an amount of RMB40,000 and RMB150,000, respectively.</p> <p>Other than the foregoing, in 2018, 2019, 2020 and during the period between December 31, 2020 to the Latest Practicable Date, we experienced four, three, seven and four incidents of non-compliances with the Advertisement Law of the PRC and/or the Administrative Measures of Medical Advertisements, respectively, and a total of 13 subsidiaries were involved, but each of such remaining non-compliance incidents was a minor violation involving penalties of no higher than RMB30,000.</p>	<p>With relevant to the non-compliance incidents of our Beijing headquarters set forth in (i)(b) and (i)(c), and the non-compliance incidents of our Shanghai subsidiary set forth in (iii) in the previous column, the penalty amounts were calculated based on the following formula: for immaterial violations, the penalty amount shall be between 1-3 times of the expenses actually incurred for the relevant non-compliant advertisement; but if the expenses incurred was not readily determinable or were obviously low, the penalty amount shall be between RMB100,000 to RMB200,000; for material violations, the penalty amount shall be between 3-5 times of the expenses actually incurred for the relevant non-compliant advertisement; but if the expenses incurred was not readily determinable or were obviously low, the penalty amount shall be between RMB200,000 to RMB1 million. In addition, for material violations, the competent authorities can revoke the business license, and/or the medical advertisement examination certificate, and can refuse the renewal applications for the advertisement examination certificates for a period of one year.</p>	

BUSINESS

Nature of the Non-Compliances	Reasons For the Non-Compliances	Legal Consequences, Maximum Potential Penalty/Liabilities, and Potential Operational and Financial Impacts	Remedial/Rectification Actions Taken and Internal Control Measures
	<p>The foregoing non-compliances were not a result of any willful misconduct by our Directors or any of our employees. Such non-compliances occurred primarily because there were a number of ambiguities in the applicable regulations, and there were certain inconsistencies in the interpretation and/or application of the regulations by local government authorities. Our Directors are of the view that the enactment of the Enforcement Guidance, which explicitly stipulates what types of activities are illegal and clearly streamlines the interpretation and application standards, would actually help our Group in ensuring our ongoing compliance with the applicable regulations, and would significantly reduce the uncertainties faced by us in this regard. See “Summary — Recent Developments and No Material Adverse Change” for more information about the newly enacted Enforcement Guidance. We have also adopted enhanced internal control measures in this regard to prevent similar non-compliances from recurring. Please refer to the fourth column for more information.</p>	<p>With respect to the non-compliance incidents of our Kunming subsidiary set forth in (ii) in the previous column, the penalty amounts were calculated based on the following formula: the penalty amount shall be between 3-5 times of the expenses actually incurred for the relevant non-compliant advertisement; but if the expenses incurred was not readily determinable or were obviously low, the penalty amount shall be between RMB200,000 to RMB1 million; for repeated violations (more than three times in two years) or material violations, the penalty amount shall be between 5-10 times of the expenses actually incurred for the relevant non-compliant advertisement; but if the expenses incurred was not readily determinable or were obviously low, the penalty amount shall be between RMB1 million to RMB2 million. In addition, but if the expenses incurred was not readily determinable or were obviously low, the penalty amount shall be between RMB200,000 to RMB1 million. In addition, for material violations, the competent authorities can revoke the business license, the medical institution practicing license, and/or the medical advertisement examination certificate, and can refuse the renewal applications for the advertisement examination certificates for a period of one year.</p>	

BUSINESS

Nature of the Non-Compliances	Reasons For the Non-Compliances	Legal Consequences, Maximum Potential Penalty/Liabilities, and Potential Operational and Financial Impacts	Remedial/Rectification Actions Taken and Internal Control Measures
		<p>Based on, among others, the administrative penalty notices received from the competent authorities, the amounts we actually incurred for the relevant advertisements, the penalty amounts we actually paid, and the fact that the competent authorities never revoked the business license, the medical institution practicing license, or the medical advertisement examination certificate of our Beijing headquarters, and granted the subsequent renewal applications made by our Beijing headquarters for the advertisement examination certificates, our PRC Legal Adviser is of the view that the relevant non-compliances of our Beijing headquarters were immaterial violations as specified under the applicable advertisement laws, and the risk of revocation of our medical advertisement examination certificate by the competent authorities is remote.</p>	

BUSINESS

Nature of the Non-Compliances	Reasons For the Non-Compliances	Legal Consequences, Maximum Potential Penalty/Liabilities, and Potential Operational and Financial Impacts	Remedial/Rectification Actions Taken and Internal Control Measures
		<p>Our PRC Legal Adviser also confirmed that the abovementioned penalties are all historical penalties and we have already settled the penalties imposed by relevant authorities. Our Directors believe that such non-compliance would not have a material and adverse effect on our business and results of operations, considering that: (1) the fines imposed by the competent authorities accounted for less than 0.3% of our total revenue in 2018; (2) we had duly settled the fines imposed by the relevant authorities and rectified the non-compliance incidents as requested by the relevant authorities; (3) all of our clinics successfully obtained or renewed, as applicable, the medical advertisement examination certificates, and did not experience any material impediment during the certificate application/renewal process because of the historical non-compliance, and (4) as advised by our PRC Legal Adviser, considering that we had fully settled the fines and rectified the non-compliance incidents as requested by the relevant authorities, the risk that the relevant government authorities imposing additional fines or penalties on us for the same matters is remote.</p>	

BUSINESS

Nature of the Non-Compliances	Reasons For the Non-Compliances	Legal Consequences, Maximum Potential Penalty/Liabilities, and Potential Operational and Financial Impacts	Remedial/Rectification Actions Taken and Internal Control Measures
Potential title defects in relation to some of our leased properties			
<p>As of the Latest Practicable Date, the actual usage of five leased properties (with an aggregate GFA of approximately 16,083.5 square meters, representing approximately 8.27% of our total leased GFA) was inconsistent with the usage set out in their respective title certificates or relevant authorization documents.</p>	<p>The potential title defects exist because the approved usage of the properties were for research, industrial, kindergarten, municipal public construction, and/or military, respectively, but the lessors leased the properties to us and we used those properties for offices or clinics. Such inconsistencies in the approved usage and the actual usage did not result in any discount on the rents we contracted to pay, and did not negatively affect the safety conditions of the properties we leased, based on our market studies and using experience.</p> <p>The foregoing non-compliances were not a result of any willful misconduct by our Directors or any of our employees, but did reflect insufficiencies in our internal control measures adopted at the time, which insufficiencies contributed to our failure to prevent and to timely detect such non-compliances. We took prompt remedial and/or rectification measures as soon as we identified such non-compliances, and had exercised our reasonable best efforts to request, convince, and facilitate the relevant lessors and/or other responsible parties to correct such non-compliances. However, as of the Latest Practicable Date, the non-compliances were still not fully resolved because of reasons outside of our control. We have adopted enhanced internal control measures in this regard to prevent similar non-compliances from recurring. Please refer to the fourth column for more information.</p>	<p>As advised by our PRC Legal Adviser, it is primarily the lessors' responsibility to ensure the actual usage is consistent with the approved usage, and to the extent necessary, to complete the relevant "change of registration" procedures with the competent authorities to register the changed usage; we as the tenant will not be subject to any administrative punishment or penalties because of the lessors' failure to complete such procedures, but our use of these leased properties may be affected by third party claims or challenges against the lease. If the lessors do not have the requisite rights to lease these defective leased properties to us for our intended usage, the relevant lease agreements may be deemed invalid, and as a result we may be required to vacate these defective leased properties.</p>	<p>We have enhanced our internal control measures in connection with property rentals. We require all of our lessors to provide the valid title certificates and other necessary documentation before we enter into lease agreements with them. Before entering into any new lease agreements, we will carefully review the relevant documents provided by the lessors, to ensure that we will not inadvertently lease any property with title defects. All the lease agreements as well as the relevant documents provided by the lessors need to be approved by our legal department, who will report to our Compliance Committee periodically. We also provide trainings to members of our legal department as well as employees at our local clinics to familiarize them with the legal requirements in relation to property rentals.</p>

BUSINESS

Nature of the Non-Compliances	Reasons For the Non-Compliances	Legal Consequences, Maximum Potential Penalty/Liabilities, and Potential Operational and Financial Impacts	Remedial/Rectification Actions Taken and Internal Control Measures
		<p>Based on our market research, there are plenty of other properties close to these properties, at substantially the same rental prices. We believe that if necessary, we would be able to relocate our offices and clinics to different sites relatively easily, and the relocation could be completed within three to six months. We expect that our relocation costs for each of the five defective properties would be up to approximately RMB0.3 million. Even if we are required to vacate any such properties, we expect that that transition period would be sufficient for us to open new clinics/offices before closing the old ones, so we do not expect our operation would be materially and negatively affect and do not expect to suffer any significant loss of revenue because of such relocation. In addition, as advised by our PRC Legal Adviser, in the event that we are unable to continue using these defective leased properties, according to the lease agreements, we as the tenant will not need to continue to pay the rents.</p> <p>During the Track Record Period and up to the Latest Practicable Date, we had not encountered any safety issues or disputes with respect to these defective leased properties.</p>	

BUSINESS

Nature of the Non-Compliances	Reasons For the Non-Compliances	Legal Consequences, Maximum Potential Penalty/Liabilities, and Potential Operational and Financial Impacts	Remedial/Rectification Actions Taken and Internal Control Measures
		<p>Our Directors believe that these title defects described above will not, individually or in the aggregate, materially affect our business and results of operation, on the grounds that: (i) during the Track Record Period and up to the Latest Practicable Date, to the best knowledge of our Directors, our leases with respect to these defective leased properties had never been challenged by any third parties, (ii) these defective leased properties are geographically dispersed across China under the jurisdiction of different local governmental authorities, so we believe it is unlikely that we would be subject to claims of rights from various third parties or required by the governmental authorities to relocate with respect to a significant number of these defective leased properties at the same time, (iii) we maintain a pool of site candidates for our clinics, offices and employee dormitories, and believe we would be able to relocate to different sites relatively easily should we be required to do so, and (iv) we have enhanced our internal control measures and procedures to prevent the leasing of properties with title defects.</p>	

BUSINESS

Nature of the Non-Compliances	Reasons For the Non-Compliances	Legal Consequences, Maximum Potential Penalty/Liabilities, and Potential Operational and Financial Impacts	Remedial/Rectification Actions Taken and Internal Control Measures
Failure to complete the lease registration for some of our lease agreements			
<p>As of the Latest Practicable Date, with respect to 111 out of our 339 leased properties (with an aggregate GFA of approximately 84,444 square meters, representing approximately 43.43% of our total leased GFA), the relevant lease agreements we entered into have not been registered with the relevant PRC governmental authorities as required by applicable laws.</p>	<p>We were not able to complete the lease registration because our lessors failed to provide the necessary documents for us to register the leases in spite of our multiple requests. The non-registration of the leases did not result in any discount on the rents we contracted to pay, and did not negatively affect the safety conditions of the properties we leased, based on our market studies and using experience.</p> <p>The foregoing non-compliances were not a result of any willful misconduct by our Directors or any of our employees, but did reflect insufficiencies in our internal control measures adopted at the time, which insufficiencies contributed to our failure to prevent and to timely detect such non-compliances. We took prompt remedial and/or rectification measures as soon as we identified such non-compliances, and had exercised our reasonable best efforts to request, convince, and facilitate the relevant lessors and/or other responsible parties to correct such non-compliances. However, as of the Latest Practicable Date, the non-compliances were still not fully resolved because of reasons outside of our control. We have adopted enhanced internal control measures in this regard to prevent similar non-compliances from recurring. Please refer to the fourth column for more information.</p>	<p>As advised by our PRC Legal Adviser, according to the <i>PRC Civil Code</i>, failure to complete the registration and filing of lease agreements will not affect the validity of the lease agreements. However, the relevant PRC authorities may impose a fine on us ranging from RMB1,000 to RMB10,000 for each unregistered lease.</p> <p>Our Directors believe that the non-registrations of leases described above will not, individually or in the aggregate, materially affect our business and results of operation, on the grounds that: (i) no penalty had been imposed on us for our failure to register and file the relevant lease agreements during the Track Record Period and up to the Latest Practicable Date, (ii) the maximum potential penalty for the non-registration of the leases will be approximately RMB1.11 million, so even if we were penalized by the competent authorities, it would not materially and adversely affect our business or financial position, (iii) as advised by our PRC Legal Adviser, if the lease registration can be completed in accordance with the relevant laws and regulations within a reasonable time from the date of application or the prescribed time limit ordered by the competent governmental authorities, the risk of governmental authorities imposing a penalty on us with respect to these leased properties is remote, and (iv) we have enhanced our internal control measures and procedures to prevent the re-occurrence of such incidents.</p>	<p>We are using our commercially reasonable efforts to register all the relevant leases.</p> <p>We have enhanced our internal control measures in connection with property rentals. We require all of our lessors to provide the necessary documentation before we enter into lease agreements with them, and to cooperate with us in completing the registration of the lease agreements. Designated staff from our legal department will conduct self-inspections from time to time on whether the lease agreements are properly registered, and if they identify any non-registered lease agreement, they will require the responsible employees at our local clinics to follow-up on the registration status. The designated staff from our legal department are required to keep records of the lease registration status, and to report to our Compliance Committee periodically about their findings. We also provide trainings to members of our legal department as well as employees at our local clinics to familiarize them with the legal requirements in relation to property rentals.</p>

BUSINESS

Nature of the Non-Compliances	Reasons For the Non-Compliances	Legal Consequences, Maximum Potential Penalty/Liabilities, and Potential Operational and Financial Impacts	Remedial/Rectification Actions Taken and Internal Control Measures
Performance of hair transplant surgeries without the supervision of physicians holding the Aesthetic Medical Attending Physician (醫療美容主診醫師) qualification			
<p>During the Track Record Period, we identified three isolated incidents where physicians at our clinics performed hair transplant surgeries for patients without the supervision of physicians possessing the Aesthetic Medical Attending Physician qualification.</p>	<p>We have a large team of medical professionals. In each of our clinics, we have physicians (each holding a Practicing Certificate of Physician (執業醫師證)), and resident physician (holding the Aesthetic Medical Attending Physician qualification) as required. As advised by our PRC Legal Adviser, the qualification of Aesthetic Medical Attending Physician is an ancillary qualification to the Practicing Certificate of Physician (執業醫師證).</p> <p>We have designed a set of standard procedures to ensure that the resident physicians holding the Aesthetic Medical Attending Physician qualification will be present when we provide aesthetic medical services to our customers. However, during the Track Record Period and up to the Latest Practicable Date, we identified three isolated incidents where hair transplant surgeries were performed by physicians holding only the Practicing Certificates of Physician, without the supervision of any physician holding the Aesthetic Medical Attending Physician qualification. Based on the results of our self-inspection, such incidents occurred because certain of our employees at the relevant local clinics did not strictly follow our standard procedures, and the physician holding the Aesthetic Medical Attending Physician qualification were not present at the relevant clinics when the surgeries were conducted, due to personal reasons.</p>	<p>As advised by our PRC Legal Adviser, the <i>Classification Catalog of Aesthetic Medical Items</i> (醫療美容項目分級管理目錄) classified aesthetic medical services into four categories based on the risks involved in the relevant procedures, and hair transplant surgeries are classified as Grade 1, the grade with the lowest risks. The <i>Rules of Aesthetic Medical Services Management</i> (醫療美容服務管理辦法) require aesthetic medical services be conducted by, or under the supervision of, physician holding the Aesthetic Medical Attending Physician qualification, but did not specify the penalty for violation of such requirements. According to our PRC Legal Adviser, based on precedent cases, the maximum penalty for each violation would be a fine of approximately RMB50,000.</p> <p>During the Track Record Period and up to the Latest Practicable Date, two of our clinics, namely Kunshan and Nanchang clinics, were penalized for the three incidents identified of performing hair transplant surgeries for patients without the supervision of physicians possessing the Aesthetic Medical Attending Physician qualification. The Kunshan clinic and the Nanchang clinic paid a penalty in an amount of RMB9,000 and RMB10,000, respectively.</p>	<p>We have further enhanced our internal control measures to ensure that the resident physicians holding the Aesthetic Medical Attending Physician qualification will be present when we provide aesthetic medical services to our customers. We established a Medical Quality Control Committee led by Mr. LI Xiaolong, our general medical service director, and comprised ten senior medical staff and 15 medical quality experts. The medical service quality control committee further updated the practice guidelines that all the physicians at our local clinics need to follow. Pursuant to the updated practice guidelines, whenever a surgery is performed at our clinic, the handling physician, as well as the resident physician holding the Aesthetic Medical Attending Physician qualification, are required to sign on the patient's medical record form. If for whatever reason, the resident physicians holding the Aesthetic Medical Attending Physician qualification is not present in any given day, the clinics are strictly prohibited from conducting surgeries on that day. Members of our Medical Quality Control Committee will from time to time conduct inspections on our local clinics and examine the medical records of the patients, to ensure strict compliance with such requirements by the physicians. Our Medical Quality Control Committee will report to our Compliance Committee periodically about their findings.</p>

BUSINESS

Nature of the Non-Compliances	Reasons For the Non-Compliances	Legal Consequences, Maximum Potential Penalty/Liabilities, and Potential Operational and Financial Impacts	Remedial/Rectification Actions Taken and Internal Control Measures
	<p>The foregoing non-compliances were not a result of any willful misconduct by our Directors, but did reflect insufficiencies in our internal control measures adopted at the time, which insufficiencies contributed to our failure (i) to strictly enforce our standard operational procedures at our local clinics to each of our employees, and (ii) to prevent and to timely detect such non-compliances. We took prompt remedial and/or rectification measures as soon as we identified such non-compliances, and had penalized the responsible employees at the relevant clinics. We have also adopted enhanced internal control measures in this regard to prevent the recurrence of similar non-compliances. Please refer to the fourth column for more information.</p>	<p>The relevant authorities confirmed that the relevant non-compliances were not material violations. Our PRC Legal Adviser confirmed that we have already settled the penalties. Our Directors believe that such non-compliance would not have a material and adverse effect on our business and results of operations, considering that: (1) the fines imposed by the competent authorities accounted for less than 0.001% of our total revenue in 2020; (2) we had duly settled the fines imposed by the relevant authorities and rectified the non-compliance incidents as requested by the relevant authorities; and (3) as advised by our PRC Legal Adviser, considering that we had fully settled the fines and rectified the non-compliance incidents as requested by the relevant authorities, the risk that the relevant government authorities imposing additional fines or penalties on us for the same matters is remote.</p> <p>In addition, such non-compliances may involve us in medical disputes. For example, as of the Latest Practicable Date, we had two ongoing legal proceedings involving medical disputes brought by our hair transplant patients, and one of them was filed against our Kunshan clinic. Based on the claims made by the plaintiff, we estimate that our maximum exposure in relation to this legal proceeding will not exceed RMB190,000. See “— Legal Proceedings” for more details of the ongoing legal proceedings.</p>	

Our PRC Legal Adviser confirms that except as disclosed above, we have complied with the material laws and regulations applicable to our business during the Track Record Period and up to the Latest Practicable Date in all material respect.

In addition, Mr. Zhang, one of our Controlling Shareholders, had entered into a Deed of Indemnity and had agreed to indemnify our Group at all times from and against any losses, liabilities, damages, costs, expenses and fines suffered by or incurred by the Group arising from any further claims brought by any regulatory authorities or any other third party in connection with the non-compliances as set out above.

LEGAL PROCEEDINGS

During the Track Record Period and up to the Latest Practicable Date, we were not involved in any litigation or arbitration proceedings pending or, to our knowledge, threatened against us or any of our Directors that could have a material and adverse effect on our business, financial condition or results of operations.

We are subject to legal proceedings and claims that arise in the ordinary course of business, which primarily include medical disputes brought by our patients against us. During the Track Record Period and up to the Latest Practicable Date, none of these medical disputes involved fatalities or severe bodily injuries of our patients. Medical disputes arise in our operations were mostly related to patients' dissatisfaction with hair transplant results. Depending on hair type, the density of the follicles, the stage of hair loss and other physical health conditions, the results of our treatment for an individual patient may vary greatly. As part of our risk management and internal control procedures, we have informed our patients of these inherent risks and obtained their consents before conducting relevant treatments or procedures. Most of the medical disputes with our patients were settled through direct negotiations. However, they may choose to seek claims against us through legal proceedings if initial negotiation to reach a settlement fails. During the Track Record Period, we did not experience any material medical disputes that could cause a material adverse effect on our business, financial condition or results of operations. For the year 2018, 2019, 2020, and the six months ended June 30, 2021, the aggregate amount of monetary compensation paid to our patients by us were approximately RMB0.4 million, RMB0.3 million, RMB2,353 and nil, respectively.

As of the Latest Practicable Date, we had two ongoing legal proceedings involving medical disputes brought by our hair transplant patients. One was filed against our clinic in Shenzhen, Guangdong province (the “**Shenzhen Case**”), and the other one was filed against our clinic in Kunshan, Jiangsu province (the “**Kunshan Case**”). The Shenzhen Case was filed by a hair transplant customer against Shenzhen Yonghe in April 2020, alleging, among others, that the effects of the hair transplant performed by Shenzhen Yonghe did not meet the proclaimed and guaranteed effects as provided in the service agreements entered into between the parties. The plaintiff claimed the compensation in the total sum of RMB64,029.6. The local district court rendered a decision in December 2020 rejecting all claims by the plaintiff. The plaintiff appealed to the intermediate court in January 2021, and the intermediate court reversed the first trial verdict and remanded for a new trial in July 2021. As of the Latest Practicable Date, the Shenzhen Case was still under consideration by the relevant court. The Kunshan Case was filed by a hair transplant customer against Kunshan Yonghe and Yonghe Investment in April 2021, alleging, among others, (i) unsatisfactory effects of the hair transplant; (ii) refusal of inspection of original medical record; and (iii) the handling physician did not possess relevant qualification of Medical Aesthetic Attending Physician. The plaintiff claimed a return of the service fees and a compensation in an aggregate amount of RMB183,820. As of the Latest Practicable Date, the Kunshan Case was still under consideration by the relevant court. Based on the aggregate amounts claimed by the plaintiffs in the two cases, we estimate that our maximum exposure in relation to the proceedings will not exceed RMB250,000. During the Track Record Period and up to the Latest Practicable Date, none of our medical disputes involved any determination by the relevant authorities that we were liable for medical malpractice.

We believe these medical disputes reflect the inherent risks related to our business and operations. We may continue to face potential legal proceedings and claims in our operations. See “Risk Factors — Risks Relating to Our Business — We are exposed to inherent risks of medical incidents, malpractice,

medical negligence, misconduct claims arising from our operations, and resolving such incidents could result in significant costs and materially and adversely affect our reputation and business”.

ENVIRONMENTAL SUSTAINABILITY AND SOCIAL RESPONSIBILITY

We are committed to building a lasting brand, and we believe our long-term success rests on our ability to make positive impacts on the environment and society. Corporate social responsibility is a core part of our business philosophy and will be pivotal to creating sustainable value for our Shareholders. Accordingly, our Board of Directors has adopted a comprehensive policy on environmental, social and corporate governance responsibilities (the “**ESG Policy**”) in accordance with the Listing Rules, which sets forth our corporate social responsibility objectives and provides guidance on practicing corporate social responsibility in our daily operations.

Under our ESG Policy, we aim to build a sustainable community with our employees, customers and business partners by supporting local initiatives that aim to create effective and lasting benefits to the local community through various initiatives that may include corporate philanthropy, establishing community partnerships, and mobilizing our employees to participate in volunteer work.

During the Track Record Period, we have taken the following environmental sustainability and social responsibility initiatives:

Environmental Protection

We are subject to various laws and regulations in the PRC in relation to environmental matters and the disposal of medical waste, which includes medical sanitation, reduction of occupational hazards in clinics, prevention of medical accidents, disease control, disposal of medical waste and discharge of wastewater and pollutants. For further details, see “Regulatory Overview” in this prospectus.

We are committed to complying with applicable PRC regulatory requirements, preventing and reducing various hazards and risks associated with our operations, and ensuring the health and safety of the patients and employees of our clinics and surrounding communities. Our operations do not involve heavy use of harmful or hazardous materials, so in practice, the amount of medical waste, wastewater and pollutants our clinics actually discharge are far below the permitted level.

We generate various medical wastes and substances, such as used disposable medical supplies and devices including needles, cotton pads and other wound dressings and waste blood, from various procedures during our provision of hair transplant services and medical hair care services to our clients. In compliance with the relevant environmental laws and regulations, we have adopted stringent internal control measures to ensure the proper disposal and processing of medical wastes and substances. For example, we have adopted the *Medical Wastes Management Policies* to set our detailed requirements and procedures for disposing and processing medical wastes, including classifying medical wastes according to the relevant PRC laws and regulations and engaging qualified third parties to collect medical wastes from our clinics. We have also adopted the *Response Plan for Medical Wastes Leakage Accidents* to prepare our staff for the potential emergency situations. We have contracted with qualified waste management companies for the collection and processing of our medical wastes and wastewater, and timely paid wastewater processing fees as part of our water bills to the relevant authorities during the Track Record Period and up to the Latest Practicable Date.

To ensure the proper implementation of our policies on environmental protection, we will conduct inspections over each of our clinics regularly and provide trainings to our staff from time to time to update them with the relevant internal standards and procedures, as well as the relevant environmental laws and regulations, to ensure their compliance with the same. We have also adopted policies regarding the efficient use of water and electricity to reduce the waste of resources.

We believe that we are not susceptible to climate change, and we have not experienced extreme weather in the areas where we conduct our operations. As of the Latest Practicable Date, we had not experienced any material impact on our business operations or financial performance as a result of climate change or extreme weather conditions.

For 2018, 2019, 2020 and the six months ended June 30, 2021, our total costs of compliance with applicable environmental laws and regulations were RMB0.25 million, RMB0.54 million, RMB0.77 million and RMB0.43 million.

During the Track Record Period and up to the Latest Practicable Date, we had not been subject to any fines, penalties or other legal actions by any government agencies resulting from any material non-compliance with any environmental protection laws. We believe that we are in compliance in all material respects with applicable environmental regulations in the PRC. In the future, we expect that the annual cost of compliance with health, safety and environmental protection rules and regulations may increase in line with the growth and expansion of our business.

Social Responsibility

We view corporate social responsibility as part of our core growth philosophy that will be pivotal to our ability to create sustainable value for our Shareholders by embracing diversity and public interests. For example, we actively assumed social responsibilities by initiating the “Yonghe Caring for Hair Loss Program” (雍禾脫髮愛計劃) charity project, in which we performed hair transplant services for free for patients suffering from hair loss caused by burns, scalds and other accidents, with an aim to help them improve their appearances and regain their confidence. Moreover, in 2020, during the COVID-19 outbreak in Wuhan, we again set an example for our industry by quickly responding to the situation and donating money and other resources to the Wuhan Charity Federation.

We stick to integrity, safety, and transparency for providing medical services, which is enforced through a variety of means, such as entering into service quality assurance agreements with patients, and live-streaming surgical operations. We require our physicians to thoroughly inform our patients of the risks and possible side effects prior to the performance of any treatment procedures. Further, in order to avoid unscrupulous sales practices, we have established a series of control measures such as preventing our staff from overselling and adopting reasonable refund policies. We do not provide sales on credit or any kind of loans to our clients in respect of the service fees in order to avoid the sale of excessive and unnecessary medical procedures to clients. We provide trainings to our sales and marketing team from time to time in relation to proper sales practices. We have also established systematic and efficient client feedback management system and client complaints management system to handle any clients’ feedback and complaints in relation to our services. For details, see “— Client Feedback and Complaint Handling” in this section.

We will also focus on embracing diversity within our organization and equal and respectful treatment of all of our employees in their hiring, training, wellness, and professional and personal development. We recognize and embrace the benefits of having a diverse Board of Directors to enhance the quality of its performance. To this end, we have adopted a board diversity policy that requires all board appointments to be based on meritocracy and candidates to be considered against objective criteria. While maximizing equal career opportunities for everyone, we will also promote work-life balance and create a happy culture in our workplace for all of our employees.

We value the importance of maintaining a safe, healthy and efficient work environment for all of our employees. We have implemented various internal occupational health and safety procedures to maintain a safe work environment, including adopting protective measures at our facilities, maintaining the hygiene of surgery rooms and offices, inspecting our equipment and devices regularly to identify and address safety hazards, and providing regular training to our employees on safety awareness. During the outbreak of COVID-19, we have endeavored to provide a safe work environment by implementing company-wide self-protection policies for employees, including providing protective masks and sanitization to our employees. During the Track Record Period, we did not experience any material accidents involving personal injury or property damage and we were not subject to any material claims, lawsuits, penalties or disciplinary actions as a result of any material accidents.

Metrics and Targets

Through devising our ESG Policy, we have established a set of key performance indicators (KPIs) in relation to environmental protection to restrain and guide our business operation. Historically, consistent with the industry norm, we mainly tracked the KPIs for medical waste disposal, water usage and power usage of our in-network clinics. In setting targets for each KPIs, we have taken into account their respective historical levels during the Track Record Period, and have considered our planned business expansion in a thorough and prudent manner with a view to balancing business growth and environmental protection to achieve sustainable development. Set forth below are our major KPIs during the Track Record Period and our targets for such KPIs in the next three years.

- *Medical waste disposal.* During the Track Record Period substantially all of our medical wastes were generated from hair transplant surgeries. The medical wastes disposed by our clinics totaled approximately 82.3 tons, 151.4 tons, 178.7 tons and 95.9 tons, respectively, in 2018, 2019, 2020 and the six months ended June 30, 2021, which was in line with the increase in the volume of hair transplant surgeries performed by our clinics. Based on historical levels and the estimated increase in the volume of hair transplant surgeries to be performed by our clinics as a result of our planned business expansion, we expect that the total medical wastes disposed by our clinics will range from 200 tons to 400 tons per annum in the next three years. We have adopted stringent internal control measures to ensure the proper disposal and processing of medical wastes. We will continue to engage qualified waste management companies to collect and process our medical wastes. We expect that the fees paid by us for medical waste collection and processing will increase as a result of our business growth, while the relevant expenses are expected to remain as a small portion of our total operating expenses and will not significantly affect our financial position in the foreseeable future.

BUSINESS

- *Water usage.* During the Track Record Period, the water usage of our clinics totaled approximately 38,481 tons, 65,551 tons, 77,693 tons and 47,555 tons, respectively, in 2018, 2019, 2020 and the six months ended June 30, 2021, which was in line with the increase in the number of patients receiving treatments at our clinics. Based on historical levels and the estimated increase in the number of patients, we expect that our total water usage will range from 100,000 tons to 220,000 tons per annum in the next three years. We have devised a plan on managing and controlling water usage per head, and adopted policies regarding the efficient use of water to reduce waste. We expect that our water bills will increase as a result of our business growth, while the relevant expenses are expected to remain as a small portion of our total operating expenses and will not significantly affect our financial position in the foreseeable future.
- *Power usage.* During the Track Record Period, the power usage of our clinics totaled approximately 4.0 million kWh, 6.1 million kWh, 7.9 million kWh and 5.1 million kWh, respectively, in 2018, 2019, 2020 and the six months ended June 30, 2021, which was in line with the increase of the total operating area of our clinics. Based on historical levels and the planned operating area of our clinics to be established or upgraded, we expect that our total power usage will range from 15.0 million kWh to 25.0 million kWh per annum in the next three years. We have devised a plan on managing and controlling power usage per square meter, and adopted policies regarding the efficient use of electricity to reduce waste. We expect that our electricity bills will increase as a result of our business growth, while the relevant expenses are expected to remain as a small portion of our total operating expenses and will not significantly affect our financial position in the foreseeable future.

Our Board of Directors has the collective and overall responsibility for establishing, adopting and reviewing the ESG vision, policy and target of our Group, and evaluating, determining and addressing our ESG-related risks at least once a year. Our Board of Directors may assess or engage independent third party(ies) to evaluate the ESG risks and review our existing strategy, target and internal controls. Necessary improvement will then be implemented to mitigate the risks. As advised by our PRC Legal Adviser, there were no breaches or violations of the PRC environmental laws and regulations applicable to our business operations during the Track Record Period that would have a material and adverse impact on our business, or results of operation taken as a whole. In addition, we had not been subject to any material claim or penalty in relation to health, safety, social and environmental protection, or been involved in any significant work place accident or fatality. During the Track Record Period, our total expenses for implementing our ESG Policy and for compliance with the relevant rules and regulations were insignificant and we expect such expenses to remain at relatively low levels in the foreseeable future.

INTELLECTUAL PROPERTY

We believe that intellectual property rights are critical to our continued success. We primarily rely on the applicable laws and regulations on trademarks, patents, trade secrets, and confidentiality agreements to protect our intellectual property rights. We have registered or applied for registration of certain trademarks, patents and domain names in the PRC and Hong Kong relating to the names and logos of our clinics. As of the Latest Practicable Date, we had (i) 186 trademarks registered in the PRC, two trademarks registered in Hong Kong, one trademark registered in Macau and 69 pending trademark applications in the PRC; (ii) 24 patents registered in the PRC and six pending patent applications in the PRC; (iii) 17 computer softwares registered in the PRC; and (iv) 130 registered domain names in the PRC. As we direct more resources towards research and development, we will continue to patent new techniques, technologies and other innovations.

BUSINESS

As of the Latest Practicable Date, our material registered patents were set out in tables below:

Registered Patents

No.	Patient No.	Description	Patent type	Place of Registration	Registered owner	Application date
1.	ZL201930685346.3	Operating room communication trolley	Design	PRC	Yonghe Investment	December 9, 2019
2.	ZL201930685445.1	Hair testing machine	Design	PRC	Yonghe Investment	December 9, 2019
3.	ZL201930555554.1	Hair testing machine	Design	PRC	Yonghe Investment	October 12, 2019
4.	ZL201921693956.9	A testing device	Utility model	PRC	Yonghe Investment	October 10, 2019
5.	ZL201820622564.2	Hair transplant punch and hair transplant surgery equipment	Utility model	PRC	Yonghe Investment	April 27, 2018
6.	ZL201730131657.6	Hair follicles extract needles	Design	PRC	Yonghe Investment	April 19, 2017
7.	ZL201720102689.8	A hair follicles extract needle	Utility model	PRC	Yonghe Investment	February 2, 2017
8.	ZL202130288308.1	Postoperative effect imaging contraster	Design	PRC	Yonghe Investment	May 14, 2021

During the Track Record Period and up to the Latest Practicable Date, there was no material infringement of third-party intellectual property rights by our Group. As of the Latest Practicable Date, we were not aware of any material infringement or dispute regarding our intellectual property rights. We believe that we have taken reasonable measures to prevent infringement of our intellectual property rights. For more details, see “Appendix IV — Statutory and General Information — B. Further Information About the Business of the Company — 2. Our Material Intellectual Property Rights.”

DATA PRIVACY AND PROTECTION

During our ordinary course of business, we collect an extensive volume of data of our customers, primarily including name, gender, contact information, basic health information, consultation and treatment records, and other medical records. We collect such information primarily for communications, treatment planning and delivery of our services and products. We retain the ownership of such information and data, and generally store such personal information and data on our physical servers for the minimum time necessary for the purpose of their processing, ranging from years to permanent preservation, which, as advised by our PRC Legal Adviser, is in accordance with the applicable laws and regulations in all material respects.

We have formulated strict policies such as *Information Management Policies*, *Data Privacy Protection Policies* and *Data Analysis Management Policies* to govern the collection, handling, storage, retrieval, and access of our customer's personal data and medical records. Our clinics use secured information technology systems to manage our clients' personal information and medical records. Access to such systems is subject to clearance control and authorization. We take safety precautions in online data storage and processing. We utilize hypertext transfer protocol secure ("HTTPS") to secure the communications over our network and file encryption technology that prevents unauthorized view or modification. Our information technology network is configured with multiple layers of protection to secure our databases and servers. We have also implemented a variety of protocols and procedures, such as regular system checks, password policy, server access logging, network access authentication, user authorization review and approval and data back-up, as well as data recovery test, to safeguard our data assets and prevent unauthorized access to our network.

In addition, to protect patient data against unauthorized physical access, files that include such data are stored in lockable cabinets, which can only be accessed by designated personnel of our clinics. For medical records of our clients that are kept manually, we have designated personnel at our clinics responsible for the safekeeping of such medical records.

Furthermore, we enter into confidentiality agreements with our employees who have access to any aforementioned privacy information. The confidentiality agreements provide that, among others, these employees are legally obligated not to misuse the confidential information while in office, to surrender all confidential information in possession while resigning, and to retain their confidential obligations after they leave office. We also implement a series of measures to ensure our employees' compliance with our data security measures. For instance, we require new hires to receive onboarding training on data security and employees to receive on-the-job training regularly to reinforce relevant data security policies. Employees shall acknowledge to us that they understand and will follow our data security policies.

During the Track Record Period, we did not experience any breach of confidential client information or any other client information-related incidents which could cause a material adverse effect on our business, financial condition or results of operations.

PROPERTIES

We do not own any property but instead lease certain properties in China in connection with our business operations. These properties are used for non-property activities as defined under Rule 5.01(2) of the Listing Rules. They mainly include premises for our clinics, offices and employee dormitories.

According to Section 6(2) of the Companies Ordinance (Exemption of Companies and Prospectuses from Compliance with Provisions) Notice (Cap. 32L of the Laws of Hong Kong) and Chapter 5 of the Listing Rules, this document is exempted from compliance with the requirements of Section 342(1)(b) of the Third Schedule to the Companies (Winding Up and Miscellaneous Provisions) Ordinance, which require a valuation report with respect to all of our interests in land and buildings, for the reason that, as of December 31, 2020, we had no property interest with a carrying amount of 15% or more of our total assets.

Leased Properties

As of the Latest Practicable Date, we leased 339 properties in the PRC with an aggregate GFA of approximately 194,444.85 sq.m. Among such 339 properties, 133 were operated as offices and clinics, and 206 were used as employee dormitories.

Title Defects

As of the Latest Practicable Date, the actual usage of five leased properties (with an aggregate GFA of approximately 16,083.5 square meters, representing approximately 8.27% of our total leased GFA) was inconsistent with the usage set out in their title certificates or relevant authorization documents. See “— Licenses, Permits, Approvals and Compliance — Non-Compliances” for more details about such potential title defects.

Lease Registration

As of the Latest Practicable Date, with respect to 111 out of our 339 leased properties (with an aggregate GFA of approximately 84,444 square meters, representing approximately 43.43% of our total leased GFA), the relevant lease agreements we entered into have not been registered with the relevant PRC governmental authorities as required by applicable laws. Our lessors’ failure to provide the necessary documents for us to register the leases does not result in any reduction in rent. See “— Licenses, Permits, Approvals and Compliance — Non-Compliances” for more details about the failure to complete the lease registration.

INTERNAL CONTROL AND RISK MANAGEMENT

Our internal control and risk management measures are designed to meet our specific business needs and minimize our risk exposure. We have adopted different internal guidelines, policies and procedures to monitor and reduce the impact of risks relevant to our business, improve our corporate governance and ensure compliance with the applicable laws and regulations. Our Board is responsible for establishing our internal control and risk management measures and reviewing their effectiveness.

Adoption and Implementation of Internal Control Policies

In preparation for the Listing, we have engaged an independent internal control consultant (the “**Internal Control Consultant**”) to perform a review of our internal controls over financial reporting in 2020. The work scope of the Internal Control Consultant covers operational, financial reporting and anti-bribery compliance-related controls. We had improved our internal control system by adopting and implementing a series of new internal control policies. Going forward, we will continue to regularly review and improve these internal control policies, measures and procedures.

Following the advice from the Internal Control Consultant, we have adopted and implemented a series of new internal control policies as well as measures and procedures designed to provide further assurance on effective and efficient operations, reliable financial reporting and compliance with applicable laws and regulations. Going forward, we will continue to regularly review and improve these internal control policies, measures and procedures. To further enhance our corporate governance practices and the effectiveness of our internal control procedures, we have adopted the following steps and measures:

- (i) With respect to medical disputes, we require all our departments and staff to follow our internal procedures on handling medical disputes. Any material incident which has caused or may cause injury or any other serious consequences shall immediately be reported to senior managements in the headquarters, which shall investigate the incidents. Our dean is responsible for preserving relevant evidence and offering our clients and/or their families an explanation, and try to solve the disputes amicably;
- (ii) With respect to anti-corruption, we have specific policies and procedures in place. Our management and audit committee oversees the design and implementation of anti-corruption policies and procedures. Related policies are set forth in the employee handbook and code of conduct. We have a zero tolerance policy towards accepting any form of bribes by physicians, staff and clinic management. We have also established a whistleblower program, dedicated hotline and email address to receive named or anonymous reports of corruption charges and stringent investigation protocols. Any employee found in breach of the relevant anti-corruption policies faces termination of employment. Our employees undergo anti-corruption training on an annual basis and we maintain relevant training records;
- (iii) With respect to patient and staff safety, we have implemented safety measures at our clinics to ensure compliance with applicable regulatory requirements and minimize injury risk to employees. We have a proper system in place for recording and handling accidents. We have designated personnel responsible for handling work accidents and injuries and maintaining health and work safety compliance records;
- (iv) With respect to medical advertising, we have promulgated medical advertising related guideline, which sets forth the relevant requirements on the content and management of medical advertisements, and require the relevant departments to comply with the guidelines. We require our marketing department to update and publish the guidelines and interpret the procedures and closely follow any changes in the regulatory requirements on medical advertising-related laws. Besides, we organize periodic trainings on a monthly basis to our employees regarding compliance with the Advertisement Law of the PRC, the Measures for

the Administration of Medical Advertisement, as well as the newly enacted Enforcement Guidance. In addition, our senior managements in the headquarters performs regular reviews on the design and implementation of the relevant internal controls;

- (v) With respect to our title defects of leased properties during the Track Record Period, starting in 2021, we have required all of our lessors to provide the necessary documentation and valid title certificates before we enter into lease agreements with them and we will not enter into lease agreements for properties with title defects. Moreover, we have more stringently required our lessors to register our lease agreements with the relevant housing administrative authorities; and
- (vi) With respect to certain non-compliance incidents we experienced during the Track Record Period and up to the Latest Practicable Date, including failure to obtain certain licenses and permits necessary for the operation of some of our clinics, and non-compliances relating to the Advertisement Law of the PRC, we have adopted enhanced internal control measures to prevent the future occurrence of such non-compliances, see “— Licenses, Permits, Approvals and Compliance” in this section for details.

Enhanced Internal Control Measures

In accordance with the applicable PRC and Hong Kong laws and regulations, we have implemented measures intending to establish and maintain our internal control system, including monitoring operational processes, establishing risk management policies, and compliance with applicable laws and regulations. In particular:

- (i) In order to ensure our business operates fully in compliance with applicable regulatory requirements and to prevent non-compliance incidents such as failure to complete necessary fire safety procedures, failure to obtain water discharge licenses, failure to comply with Advertisement Law of the PRC, lease properties with title defects, failure to complete lease registration for lease agreements, we established regulatory compliance committee (“**Regulatory Compliance Committee**”) to oversee our Group’s overall regulatory compliance works and formulate the Group’s regulatory compliance management strategies.

The Regulatory Compliance Committee comprises seven members, namely Mr. ZHANG (our chief executive officer), Ms. HAN Zhimei (our finance director), Mr. XU Yang (our operating director), Mr. HUANG Donghong (our marketing director), Mr. ZHANG Hui (our procurement director) and our general counsel. For further details of Mr. ZHANG, Ms. HAN Zhimei, Mr. XU Yang, Mr. HUANG Donghong and Mr. ZHANG Hui, see “Directors and Senior Management — Directors” and “Directors and Senior Management — Senior Management” in this prospectus.

The primary duties of the Regulatory Compliance Committee are to ensure compliance with regulatory matters as well as the adequacy and effectiveness of regulatory compliance procedures and system of the Company. The members of the Regulatory Compliance Committee, individually or as a whole, have unrestricted access to advice given by professional advisers of our Group. The roles of the Regulatory Compliance Committee include, but not limited to, the following:

- formulate major policies and implementation plans for the Group's regulatory compliance management;
- review and monitor the overall goals and basic policies of the Group's regulatory compliance management;
- monitor the regulatory compliance status of the Group, review material non-compliance incidents (including but not limited to the non-compliance incidents listed above) of the Group and formulate corresponding solutions; and
- supervise the implementation of rectification measures for non-compliance (including but not limited to the non-compliance incidents listed above), supervise and evaluate the compliance management works of the company's compliance management inspection team ("**Compliance Management Inspection Team**").

The Regulatory Compliance Committee will be assisted by the Compliance Management Inspection Team to monitor, manage and supervise the non-compliance status of the Group. The Compliance Management Inspection Team comprises staff from the Company's legal and compliance department and audit department. The roles and responsibilities of the Compliance Management Inspection Team include, but not limited to, the following:

- continuously monitor the compliance management of the Company's business operation, especially focusing on (i) the completeness of the licenses and approvals required for opening new clinics, including fire safety procedures and water discharge licenses, (ii) compliance management of medical qualifications of physicians and nurses at the Company's clinics, (iii) compliance management of licenses for construction works at new clinics, (iv) compliance management for property leasing and leasing agreement registration, and (v) compliance management of marketing advertisements;
- on a regular basis, randomly check and track the completion of the rectification status of the Group's non-compliance incidents at each clinic. The Compliance Management Inspection Team has the power to request the cooperation of the relevant departments at our headquarters as well as each of our local clinics, to award and incentivize those employees who made significant contributions in our non-compliance rectification process, and to design disciplinary and/or punishment measures for those employees who perform poorly in this regard;
- report to the Regulatory Compliance Committee quarterly on the Group's penalties for non-compliance matters, and the rectification status of the previously identified non-compliance matters, and put forward compliance management recommendations;

- make amendment suggestion to terms of department rules of various departments of the Company from the perspective of compliance management; and
 - perform other tasks arranged and required by the Regulatory Compliance Committee.
- (ii) In order to improve our medical activity quality and prevent the non-compliances incidents in relation to medical activities from happening, we established medical quality control committee (“**Medical Quality Control Committee**”) at the headquarter level to enhance the Group’s management of medical service quality and improve the Group’s medical technology.

The Medical Quality Control Committee comprises 10 members from our Group’s senior medical staff, including Mr. LI Xiaolong (our general medical service director), medical service director, medical quality director, national head nurse, infection control director, medical policy director, two medial quality control heads, medical assistant and senior customer service manager, and 15 medical quality experts who are experienced medical practitioners.

The responsibilities of the Medical Quality Control Committee at the headquarter level include, but not limited to, the following:

- supervise and manage the medical activities quality and medical technology quality, formulate annual work plan for management of medical activities quality and medical technology quality;
- organize and assess the Group’s medical quality management system, comprehensively assess the Group’s medical quality, and propose feasible plans to improve the quality of medical activity and medical technology;
- held meetings every half-yearly, discuss and evaluate issues detected in the medical quality management process, so as to improve the medical quality of the Group;
- formulate and improve the medical quality management system and the continuous improvement plan, and standardize the surgical quality standards, doctors and nurses’ technical operating procedures and writing of medical documents;
- handle the complaints, errors, adverse events, negligence and accidents in medical care and medical technology works;
- publish medical quality management policy, and provide trainings to medical staff to improve their medical quality and medical safety awareness; and
- conduct regular inspection in nationwide clinics, using information technology to evaluate each and every hair transplant surgery.

The Medical Quality Control Committee will be assisted by medical quality control team (“**Medical Quality Control Team**”) in each clinic of the Company. The Medical Quality Control Team in each clinic comprises deans, head nurse and attending physician of such clinic. The roles and responsibilities of the Medical Quality Control Team in each clinic include, but not limited to, the following:

- promote the implementation of the standards for medical activities, medical care and medical quality and conduct monthly self-inspection;
 - promote the implementation of the surgery quality standards, technical operation standards and medical documents writing standards; and
 - formulate the medical quality management annual plan in each clinic and report to the Medical Quality Control Committee.
- (iii) we have compiled, with the assistance of our PRC Legal Adviser, a checklist of the relevant licenses and permits that would be required in order for us to commence operation of a new clinic, including primarily the medical institution practicing license, the business license, the construction permit, and the relevant approvals and inspections in connection with fire safety, water discharge and environment protection. Our in-house legal and compliance department will update this list from time to time based on our experience with local authorities and also advice given by our PRC Legal Adviser. Our Regulatory Compliance Committee and legal and compliance department will monitor the application process of the licenses and approvals/permits against the check list referred to above;
- (iv) we will conduct rigorous due diligence as to the ownership certificate and other necessary licenses, permits and approvals of the landlords before we sign leases for our new clinics. Our legal and compliance department requires that the certificates or proofs of the ownership of the properties must be reviewed for new lease agreements. If the lessor is not the owner of the property, the authorization of the sublease by the owner to the lessor must be obtained. Furthermore, the legal and compliance department will review the certificates or proofs of the ownership of the properties and the authorization of the sublease;
- (v) with respect to non-compliance incidents in relation to fire safety, in addition to requiring completion of fire safety procedures before opening the new clinic as mentioned in above, we have also established our fire safety management policies, which unify the fire safety practice at every clinic throughout our network. According to our fire safety management policies, every clinic shall make plans for fire safety work and conduct fire safety inspection on a regular basis. We provide regular trainings on fire safety to our employees, which cover key aspects of daily operations of our clinics;
- (vi) we have compiled, with the recommendation of our Internal Control Consultant and our PRC Legal Adviser, a code of conduct and practicing guidance for our management and medical staff at headquarter level and clinic level. According to the code of conduct for management and medical staff, we require our management and medical staff to perform their works with high level of integrity and ethical standards, follow the standards of medical industry, familiarise themselves with the laws and regulations in relation to our business operations, including any market trends or new legislation that may affect the Company’s business operation;

BUSINESS

- (vii) we had arranged our executive Directors and senior management, as well as the local management teams of our clinics, to attend training sessions conducted by our PRC Legal Advisers, on applicable PRC laws, rules and regulations in relation to operating medical institutions and the relevant latest development thereof, in order to familiarise and update the relevant personnel on the laws and regulations applicable to our business operation. We will continue to implement various training programs which are relevant to our operations at least semi-annually after Listing, with the help of our in-house legal and compliance department to update our Directors, senior management and employees on the relevant PRC laws and regulations and our internal control policies;
- (viii) we will provide trainings, with the assistance of our legal and compliance department and external legal advisers, on our internal policies with respect to key operational aspects to our Directors, senior management and other key personnel of our Group on a need basis;
- (ix) our Directors have attended training conducted by our Hong Kong legal adviser on the ongoing obligations, duties and responsibilities of directors of publicly listed companies under the Companies Ordinance, the SFO and the Listing Rules and the Directors are fully aware of their duties and responsibilities as directors of a listed company in Hong Kong;
- (x) we have instituted procedures for lines of communication and provided a process by which our employees can identify and report potential non-compliance exposures;
- (xi) we have appointed Somerley Capital Limited as our compliance adviser pursuant to Rule 3A.19 of the Listing Rules to ensure that, among other things, we will be properly guided and advised as to compliance with the Listing Rules and all other applicable laws, rules, codes and guidelines in Hong Kong from the Listing Date to the date when our Company distribute our annual report of our financial results for the first full financial year commencing after the Listing Date; and
- (xii) we have established an audit committee comprising two independent non-executive Directors and one non-executive Director. The audit committee has also adopted its terms of reference which set out its duties and obligations for ensuring compliance with the relevant regulatory requirements. In particular, the audit committee is empowered under its terms of reference to review any arrangement which may raise concerns about possible improprieties in financial reporting, internal control or other matters.

We also engaged our Internal Control Consultant to perform a follow-up review (the “**Follow-up Review**”) on the implementation status of the specific enhanced internal control measures (the “**Specific Internal Control Measures**”) adopted by us, and to make relevant recommendations to us on the areas that need further improvements in order to prevent the recurrence of the non-compliances mentioned above. The Internal Control Consultant considered that the Specific Internal Control Measure have been implemented and did not have any further recommendation in their follow-up review.

Furthermore, in October 2021, we also engaged Protiviti Shanghai Co., Ltd. (甫瀚諮詢(上海)有限公司) (“**Protiviti**”) to perform another review of our internal control measures related to the non-compliances mentioned above (the “**Further Review**”). Based on the results of such Further Review, Protiviti is of the view that the relevant enhanced internal control measures, if implemented continuously, are adequate and effective to reasonably prevent the recurrence of similar non-compliances.

Our Directors and senior officers treated each non-compliance incident seriously, and would adopt rectification measures as well as enhanced internal control measures promptly after identifying any non-compliance incident. Therefore, the foregoing measures were adopted by us on a rolling basis, with certain measures adopted as early as in 2019. After all the foregoing enhanced internal control measures were fully adopted by the end of September 2021, we had not identified any recurrence of the foregoing non-compliance incident (except that with respect to certain lease agreements we newly entered into after September 2021, it would need to take us and/or the relevant lessors some time to complete the necessary lease registration process), nor had we identified any other non-compliance incident which would have a material impact on our business, financial condition and results of operation. Having considered, among others, (i) the nature and reasons for the non-compliance incidents as stated in this paragraph headed “Licenses, Permits, Approvals and Compliance” in this section; (ii) the various confirmations obtained from relevant competent governmental authorities in relation to the non-compliance incidents; (iii) the remedial actions undertaken and the Specific Internal Control Measures adopted by us; (iv) the significant progresses made by us in resolving the non-compliances and preventing their recurrence during the period between the end of the Track Record Period and the Latest Practicable Date; and (v) the Follow-up Review work performed by our Internal Control Consultant as well as the Further Review conducted by Protiviti, our Directors are of the view that our enhanced internal control measures are adequate and effective in preventing the recurrence of non-compliance incidents which could have a material adverse effect on our Group’s business, financial condition and results of operations.

Based on (i) the discussion with the management of our Company about the nature and reasons for the non-compliance incidents, the remedial actions undertaken and the Specific Internal Control Measures adopted by our Group, and the latest status of rectification of the non-compliance incidents as of the Latest Practicable Date stated in this paragraph headed “Licenses, Permits, Approvals and Compliance” in this section; (ii) the discussion with the Internal Control Consultant on the Follow-up Review work performed and the discussion with Protiviti on the Further Review conducted by it; and (iii) our Directors’ view mentioned above, nothing has come to the Joint Sponsors’ attention which would cause them to disagree with our Directors’ view above in relation to our enhanced internal control measures.

Further, having considered,

- (i) the nature and reasons for the non-compliance incidents stated in this paragraph headed “Licenses, Permits, Approvals and Compliance” in this section; (ii) the various confirmations obtained from relevant competent governmental authorities in relation to the non-compliance incidents to the extent available; (iii) the relevant legal advice from our PRC Legal Adviser to the extent available; (iv) the remedial actions we have undertaken in relation to the non-compliance incidents and the significant progresses we made in this regard during the period between the end of the Track Record Period and up to the Latest Practicable Date, as disclosed in the paragraphs headed “Licenses, Permits, Approvals and Compliance” in this section;

BUSINESS

- our Group has adopted and implemented the Specific Internal Control Measures to, among others, prevent the recurrence of the non-compliances;
- since the implementation of the Specific Internal Control Measures and up to the Latest Practicable Date, we have not identified, nor have we been accused of committing, any breach of applicable laws and regulations that will result in a material adverse effect on our Group's business, financial conditions and results of operation;
- the discussion with the Internal Control Consultant on the Follow-up Review work performed, its work results that the Specific Internal Control Measure have been implemented and that the Internal Control Consultant did not have any further recommendation in their the Follow-up Review;
- the discussion with Protiviti on the further review conducted by it, its view that the relevant enhanced internal control measures, if implemented continuously, are adequate and effective to reasonably prevent the recurrence of similar non-compliances;
- our Directors have devoted significant attention and resources on rectifying the non-compliance incidents and preventing their recurrence since they became aware of such non-compliances, have made significant progresses in these regards, and have undertaken to continue to rectify those non-compliances that are not fully rectified as of the Latest Practicable Date, the latest status of rectification of the non-compliance incidents as of the Latest Practicable Date are stated in this paragraph headed "Licenses, Permits, Approvals and Compliance" in this section;
- our Company and our Directors confirmed that the occurrence of the non-compliance incidents stated in this paragraph headed "Licenses, Permits, Approvals and Compliance" in this section was not due to the dishonesty, gross negligence or recklessness of our Directors nor for illegitimate purposes, and that none of the abovementioned non-compliance incidents suggested any dishonesty or fraud that would (i) affect our Directors' ability to fulfil their fiduciary duties in addition to their duties of skill, care and diligence towards our Shareholders; or (ii) raise any issue regarding the integrity of our Directors;
- none of the non-compliance incidents stated in this paragraph headed "Licenses, Permits, Approvals and Compliance" in this section has any material impact on our business operations and financial position;
- the Deed of Indemnity entered into by Mr. Zhang, one of our Controlling Shareholders, in favor of our Group. See "— Licenses, Permits, Approvals and Compliance — Non-Compliances" for details; and
- our Directors confirmed that they are aware of the requirements and obligations as directors of a listed issuer pursuant to the Listing Rules and have undertaken to observe and comply with all the relevant laws, rules and regulations,

BUSINESS

our Directors are of the view that the foregoing demonstrated our Directors' willingness as well as capabilities to operate our business in a compliant manner, and that our Directors are suitable to act as directors of a listed issuer under Rules 3.08 and 3.09 of the Listing Rules and our Company is suitable for listing under Rule 8.04 of the Listing Rules; and considering the foregoing, the Joint Sponsors concur with the Directors' view in relation to their suitability under Rules 3.08 and 3.09 of the Listing Rules and the suitability for listing of our Company under Rule 8.04 of the Listing Rules. Our Directors will continue to use their respective reasonable best efforts to ensure our compliance with all applicable laws and regulations. The audit committee of our Board will closely supervise the ongoing rectification of the non-compliance incidents that had not been fully rectified as of the Latest Practicable Date, ensure the full rectification of such non-compliance incidents in accordance with the estimated timeline as disclosed in this prospectus, and report in the interim reports and annual reports of the Company on the status of rectification of the non-compliance incidents after Listing.

FINANCIAL INFORMATION

The following discussion and analysis should be read in conjunction with the consolidated financial information together with the accompanying notes in the Accountant's Report included in Appendix I to this prospectus. Our historical financial information and the consolidated financial statements of our Group have been prepared in accordance with the HKFRS, which may differ in certain material aspects from generally accepted accounting principles in other jurisdictions. You should read the whole Appendix I and not rely merely on the information contained in this section. Unless the context otherwise requires, historical financial information in this section is described on a consolidated basis.

The discussion and analysis set forth in this section contains forward-looking statements that involve risks and uncertainties. These statements are based on assumptions and analyses made by us in light of our experience and perception of historical trends, current conditions and expected future developments as well as other factors we believe are appropriate under the circumstances. Our actual results may differ significantly from those projected. Factors that could cause or contribute to such differences include, without limitation, those discussed in the sections headed "Risk Factors" and "Business" and elsewhere in this prospectus. Discrepancies between totals and sums of amounts listed in this section in any table or elsewhere in this prospectus may be due to rounding.

OVERVIEW

We are the leading medical group in China specialized in providing hair-related healthcare services in terms of total revenue for 2020. We offer one-stop hair-related healthcare services covering hair transplant, medical hair care, and routine hair restoration and other ancillary services. According to Frost & Sullivan, we are the largest player in China's hair transplant service market with a market share of 10.5% and medical hair care service market with a market share of 4.3%, in terms of total revenue derived from the relevant services in 2020. Among all hair-related healthcare service providers in China, we ranked first in terms of the number of registered physicians at the end of 2020, the number of clinics in operation at the end of 2020, and the number of hair transplant patients for 2020, according to Frost & Sullivan. We adopt a standardized and scalable business model to operate a hair transplant chain consisting of mostly self-operated clinics. As of the Latest Practicable Date, we operated 53 clinics in 52 cities nationwide, making us the largest and most extensive hair transplant clinic chain in China, according to Frost & Sullivan. During the Track Record Period, we opened 29 new clinics in mainland China and acquired one clinic in Hong Kong, achieving the fastest growth among all hair transplant clinic chains in China and further widening our lead over the runners-up.

Driven in part by the rapid expansion of our clinic network, we experienced significant financial growth during the Track Record Period. Our revenue experienced an increase from RMB934.3 million in 2018 to RMB1,224.5 million in 2019 and further to RMB1,638.3 million in 2020. In addition, our revenue increased from RMB601.6 million for the six months ended June 30, 2020 to RMB1,053.4 million for the six months ended June 30, 2021. Our gross profit experienced significant growth from RMB702.1 million in 2018 to RMB889.1 million in 2019 and further to RMB1,221.6 million in 2020. In addition, our gross profit increased from RMB435.6 million for the six months ended June 30, 2020 to RMB775.4 million for the six months ended June 30, 2021. In addition, as a result of our successful operation, we recorded net cash generated from operating activities of RMB194.6 million, RMB182.5 million, RMB501.6 million, and RMB218.3 million in 2018, 2019, 2020, and the six months ended June 30, 2021, respectively.

FINANCIAL INFORMATION

MAJOR FACTORS AFFECTING OUR RESULTS OF OPERATIONS

Our Clinic Network Expansion

During the Track Record Period, we generated most of our revenue from hair transplant services and medical hair care services at our clinics. Our revenue is largely affected by the number of our clinics in operation, and our future revenue growth depends on our ability to open new clinics and expand our clinic network. The following table sets forth the total number of our clinics in operation for the periods indicated:

	Year Ended December 31,			Six Months Ended June 30,
	2018	2019	2020	2021
Number of clinics in operation at the beginning of the period	22	30	37	48
Number of new clinics opened during the period	8	7	11	3
Number of clinics acquired during the period	–	–	–	1
Number of clinics in operation at the end of the period	30	37	48	52

As of the Latest Practicable Date, our 53 hair transplant clinics covered 52 cities nationwide. Our clinics can be categorized into three groups based on their respective opening date, including mature-stage clinics (i.e., clinics that have been established for more than three years), developing-stage clinics (i.e., clinics that have been established for one to three years), and newly-established clinics (i.e., clinics that have been established for less than one year). For acquired clinics, we regard the date when their financial position and results of operations are consolidated into our Group as their respective opening date. During the Track Record Period, we only acquired one clinic in May 2021. As of the Latest Practicable Date, we had 30 mature-stage clinics, 17 developing-stage clinics and six newly-established clinics (including the acquired clinic). The following table sets forth information on revenue generated from our clinics by development stage for the periods indicated:

	Year Ended December 31,			Six Months Ended June 30,	
	2018	2019	2020	2020	2021
	<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>
Mature-stage clinics	555,038	831,989	1,196,970	415,415	722,954
Developing-stage clinics	300,766	338,917	328,511	150,618	234,541
Newly-established clinics	62,210	41,929	100,477	31,879	86,216
– Acquired clinic	–	–	–	–	754
Total	918,014	1,212,835	1,625,958	597,912	1,043,711

FINANCIAL INFORMATION

We will further expand our geographical coverage by penetrating into lower-tier cities. We will continue to follow and improve the standard operating procedure, increase our penetration rate in cities where we have established operational presence, and further expand to lower-tier cities in China. We aim to reach nearly one hundred hair transplant clinics across the country within the next few years. For details of our expansion strategy, see “Business — Our Strategies — Continue Our Network Expansion and Upgrade, and Strengthen Talent Development and Recruitment.”

A newly-established clinic generally achieves normal ramp-up operation in a few months, during which its operating efficiency may be lower than that of mature-stage clinics or developing-stage clinics. We also incur substantial expenses before the commencement of operations, including construction and renovation costs as well as equipment costs, which could have a short-term negative impact on our liquidity and profitability. Based on our previous operating experience, our clinics’ average initial breakeven period is three months and average cash payback period is 14 months. The breakeven periods may be further affected by the specific characteristics of a clinic, such as its size, initial investment and location. Our progress in opening new clinics from period to period may also occur at an uneven rate. As a result, our profitability may fluctuate from period to period.

Growth of the Hair-Related Healthcare Service Market in China

Our financial results are driven primarily by the growing overall demand for hair-related healthcare services. Driven by the soaring prevalence of hair loss in a population that is increasingly beauty-conscious and with a burgeoning *per capita* income at its disposal, China’s related healthcare market is expanding rapidly. According to Frost & Sullivan, the size of hair-related healthcare service market in China reached RMB18.4 billion in 2020, and is projected at RMB138.1 billion in 2030 with a CAGR of 22.3%. China’s hair-related healthcare service market consists of two main parts – the hair transplant service market and the medical hair care service market. According to Frost & Sullivan, the size of the hair transplant service market in China reached RMB13.4 billion in 2020, and is projected at RMB75.6 billion in 2030 with a CAGR of 18.9%. China’s medical hair care service market is still at an early stage, but is believed to harbor huge growth potential and it is expected to reach RMB62.5 billion in 2030 at a CAGR of 28.7%. As a leader in China’s hair transplant industry, we are well-positioned to capture the growth of the China’s hair transplant service market with our industry-leading operation and medical services capabilities. Conversely, a slowdown of the hair transplant market or a slowdown of the hair-related healthcare market in China may adversely affect our results of operations.

FINANCIAL INFORMATION

Ability to Control Our Staff Costs

Our success relies on our ability to attract, recruit and retain a team of skilled medical staff, including physicians and other medical professionals. In addition, we also rely on other employees for selling and marketing, administrative and research and development. Our staff costs constituted the largest component of our cost of sales and services, general and administrative expenses and research and development expenses, and the second largest component of our selling and marketing expenses. In 2018, 2019, 2020, and the six months ended June 30, 2021, our total employee benefits expenses (including those recorded in cost of sales and services, selling and marketing expenses, general and administrative expenses and research and development expenses) accounted for 28.3%, 30.2%, 30.2%, and 31.3%, respectively of our total revenue for the same periods. The number of our employees has been increasing along with the growth of our business, and the increases in the staff costs during the Track Record Period were primarily attributable to such increase in the headcount and increased compensation level in order to recruit and retain medical professionals and other employees. Being able to do this would provide us with a competitive advantage over our competitors. The following table sets out a sensitivity analysis of the effect of the fluctuations of our staff costs during the Track Record Period, assuming no change of any other costs and expenses:

	Year Ended December 31,			Six Months Ended	
	2018	2019	2020	June 30, 2020	2021
Staff costs	Impact on our profit before tax for the year				
(decrease)/increase					
(15)%	39,727	55,543	74,233	29,197	49,503
(10)%	26,485	37,029	49,489	19,465	33,002
(5)%	13,242	18,514	24,744	9,732	16,501
5%	(13,242)	(18,514)	(24,744)	(9,732)	(16,501)
10%	(26,485)	(37,029)	(49,489)	(19,465)	(33,002)
15%	(39,727)	(55,543)	(74,233)	(29,197)	(49,503)

FINANCIAL INFORMATION

We expect that staff costs to continue to be one of our significant costs and expenses going forward, particularly in light of the continued expansion and ramping up of our clinic network. Therefore, any change in staff costs, including salaries and bonuses, social insurance, welfare and other benefits, and other forms of incentives, could affect our results of operations. To save costs and improve our operational efficiency, we also plan to adopt technological solutions to improve the professionalism of our services and reduce reliance on manual labor. For example, we plan to develop automated follicle detectors, to improve the accuracy and automation of hair diagnosis.

Selling and Marketing Expenses

We recognize the importance of long-term investment in brand building and consumer education. Therefore, in line with other players in the consumer medical service industry, particularly the hair-related healthcare industry, we made significant investments in promoting customer awareness of our brand and our services, and expect to continue to do so in the near future. As hair-related healthcare service is one type of consumer medical service, it requires long-term investment on consumer education. And such network-wide consumer education and brand exposure will increase our brand recognition and consumer stickiness. As a result, during the Track Record Period, our selling and marketing expenses represented the largest components of our revenue, and accounted for 49.6%, 53.1%, 47.6%, and 54.9% of our total revenue in 2018, 2019, 2020, and the six months ended June 30, 2021, respectively. We have designed a comprehensive marketing strategy, and utilize a combination of online and offline channels to promote our brand and our services, using various forms of advertisements, including brand advertising and performance-based advertising. For brand advertising, it usually takes time to convert the advertising effects into profitable revenue, but with long-term benefit to our brand reputation and awareness. In addition, due to the marketing strategies for a particular period, there are differences in timing of brand advertising placement. For instance, we strategically focused on brand advertising during the NBA season in the first half of 2021 and targeted NBA audience, which consists of a large percentage of male audience, as our potential customers. During the same period, we started to focus on *Svenson*-related brand awareness and had more promotional activities in this regard. Both of them led to a higher selling and marketing expenses in the first half of 2021. However, in 2020, we focused on brand advertising in the second half of 2020. For example, our brand advertising on subways, elevators and buses was substantially increased during this period. Therefore, the timing of our brand advertising placement had an impact on the fluctuation of our financial results. By contrast, for performance-based advertising, it usually takes a shorter period of time to realize its commercial results.

Selling and marketing expenses have historically been, and are expected to continue to be, a large portion of our overall costs and expenses. Our ability to control selling and marketing expenses may significantly affect our profitability. Going forward, we expect to continuously evaluate and monitor the effectiveness and efficiency of our promotion activities and marketing spending in order to further enhance our brand awareness and attract a broader customer base in a sustainable manner.

FINANCIAL INFORMATION

BASIS OF PRESENTATION

Our historical financial information has been prepared in accordance with Hong Kong Financial Reporting Standards (“**HKFRS**”) issued by the Hong Kong Institute of Certified Public Accountants (“**HKICPA**”). The financial information has been prepared under the historical cost convention, except for certain financial assets, which are carried at fair value. The preparation of historical financial information in conformity with HKFRS requires the use of certain critical accounting estimates, as well as our management’s judgment in applying our accounting policies. See Note 4 to the Accountant’s Report in Appendix I to this prospectus for the areas involving a high degree of judgment or complexity, or areas where assumptions and estimates are significant to the historical financial information. We have applied HKFRS 16 “Leases” consistently during the Track Record Period, which became effective for annual periods beginning on or after January 1, 2018.

SIGNIFICANT ACCOUNTING POLICIES AND CRITICAL JUDGMENTS AND ESTIMATES

Some of our accounting policies require us to apply estimates and assumptions as well as complex judgments relating to accounting items. The estimates and assumptions we use and the judgments we make in applying our accounting policies have a significant impact on our financial position and results of operations. Our management continually evaluates such estimates, assumptions and judgments based on past experiences and other factors, including expectations of future events that are believed to be reasonable under the circumstances. There has not been any material deviation between our management’s estimates or assumptions and actual results, and we have not made any material changes to these estimates or assumptions during the Track Record Period. We do not expect any material changes in these estimates and assumptions in the foreseeable future. Set forth below are discussions of the accounting policies that we believe are of critical importance to us or involve the most significant estimates, assumptions and judgments used in the preparation of our financial statements. Other significant accounting policies, estimates, assumptions and judgments, which are important for understanding our financial condition and results of operations, are set forth in detail in Notes 2 and 4 to the Accountant’s Report in Appendix I to this prospectus.

Significant Accounting Policies

Revenue Recognition

Revenues are recognized when, or as, the control of the goods or services is transferred to the customer. Depending on the terms of the contract and the laws applicable, control of the goods and services may be transferred over time or at a point in time. Control of the goods and services is transferred over time if our performance:

- provides all the benefits received and consumed simultaneously by the customer;
- creates and enhances an asset that the customer controls as we perform; or
- does not create an asset with an alternative use to us and we have an enforceable right to payment for performance completed to date.

FINANCIAL INFORMATION

If control of the goods and services transfers over time, revenue is recognized over the period of the contract by reference to the progress towards complete satisfaction of that performance obligation. Otherwise, revenue is recognized at a point in time when the customer obtains control of the goods and services. The progress towards complete satisfaction of performance obligation is measured based on direct measurements of the value of individual services transferred by us to the customer. If contracts involve the sale of multiple goods, goods followed by related services, or multiple services, the transaction price will be allocated to each performance obligation based on their relative stand-alone selling prices. If the stand-alone selling prices are not directly observable, they are estimated based on expected cost plus a margin, depending on the availability of observable information.

We offer discounts to the customers, and revenue is recognized based on the price specified in the contract, net of the discount. When either party to a contract has performed, we present the contract in the balance sheets as a contract asset or a contract liability, depending on the relationship between the entity's performance and the customer's payment. If a customer pays consideration or we have a right to an amount of consideration that is unconditional, before we transfer a good or service to the customer, we present the contract as a contract liability when the payment is made or the receivable is recorded (whichever is earlier). A contract liability is our obligation to transfer goods or services to a customer for which we have received consideration (or an amount of consideration is due) from the customer.

A receivable is recorded when we have an unconditional right to consideration. A right to consideration is unconditional if only the passage of time is required before payment of that consideration is due. A refund liability is the constructive obligation to refund some or all of the consideration received (or receivable) from the customer and is measured at the amount we ultimately expect it will have to return to the customer. We update its estimates of refund liabilities (and the corresponding change in the transaction price) at the end of each reporting period.

Hair Transplant

For hair transplant services, customers normally receive treatment which contains various treatment components (e.g. pre-surgery medical checking, surgery treatment and post-surgery cleaning) that are all highly relevant and regarded as one performance obligation. Revenue from provision of hair transplantation services recognized at a point in time when the services have been rendered to customers.

We usually receive the payment from customers in advance before the services are rendered. The majority of the customers normally do not ask for a refund of payment and the services not yet rendered are recorded as contract liability. We have estimated the refund in respect of unsatisfactory services rendered based on our past experience with customers and recognized as refund liabilities. The contract liability is recognized as revenue when the related services are rendered. Sales of hair transplant related goods are recognized when an entity has transferred the products to the customer, and the customer has obtained control of the products.

Medical Hair Care

We provide medical hair care services in package which is accounted as multiple elements of services. Revenue from medical hair care services is recognized over the period of the contract by reference to the progress towards complete satisfaction of the performance obligation. The progress towards the complete satisfaction of performance obligation is measured by direct measures of the value of individual service transferred to the customer. Normally, there is no expiry date for the packages while

FINANCIAL INFORMATION

majority of the customers take up all the services in the packages within two years. We do not generate any forfeited income from the service packages. We usually receive the payment from customers in advance before the services are rendered. The majority of the customers normally do not ask for a refund of payment and the services not yet rendered are recorded as contract liability. We have estimated the refund in respect of unsatisfactory services rendered based on our past experience with customers and recognized as refund liabilities. The contract liability is recognized as revenue when the related services are rendered. And no revenue is recognized with respect to prepaid service packages until the services have been rendered to customers. Sales of goods related to medical hair care are recognized when an entity has transferred the products to the customer, and the customer has obtained control of the products.

Other

We also provide routine hair care services in package which is accounted as multiple elements of services. Revenue from routine hair care services is recognized over the period of the contract by reference to the progress towards complete satisfaction of the performance obligation. The progress towards the complete satisfaction of performance obligation is measured by direct measures of the value of individual service transferred to the customer. Normally, there is no expiry date for the packages while majority of the customers take up all the services in the packages within two years. We do not generate any forfeited income from the service packages. We usually receive the payment from customers in advance before the services are rendered. Customers normally do not ask for a refund of payment and the services not yet rendered are recorded as contract liability. The contract liability is recognized as revenue when the related services are rendered. And no revenue is recognized with respect to prepaid service packages until the services have been rendered to customers. Sales of goods related to routine hair care are recognized when an entity has transferred the products to the customer, and the customer has obtained control of the products.

During the Track Record Period, we only recognized revenue when we provided relevant services with respect to prepaid service packages and no unused prepaid package was canceled or expired, and therefore, there was nil forfeiture rate during the same period.

Share-Based Compensation

Share-based compensation benefits are provided to employees, and information relating to these schemes is set out in Note 23 to the Accountant's Report in Appendix I to this prospectus. The fair value of awarded shares granted to employees less amount paid by employees is recognized as an employee benefits expense over the relevant service period, being the vesting period of the shares, and the credit is recognized in equity in the share-based compensation reserve. The fair value of the shares is measured at the grant date. The number of shares expected to vest is estimated based on the non-market vesting conditions. The estimates are revised at the end of each reporting period and adjustments are recognized in profit or loss and the share-based compensation reserve. Where shares are forfeited due to a failure by the employee to satisfy the service conditions, any expenses previously recognized in relation to such shares are reversed effective at the date of the forfeiture.

FINANCIAL INFORMATION

Leases

We lease buildings as lessee. Rental contracts are typically made for fixed periods of 1 to 15 years. Leases are recognized as a right-of-use asset and a corresponding liability at the date at which the leased asset is available for use by us. Contracts may contain both lease and non-lease components. We allocate the consideration in the contract to the lease and non-lease components based on their relative stand-alone prices. Assets and liabilities arising from a lease are initially measured on a present value basis. Lease liabilities include the net present value of the following lease payments (if applicable):

- fixed payments (including in-substance fixed payments), less any lease incentives receivable;
- variable lease payment that are based on an index or a rate, initially measured using the index or rate as at the commencement date;
- amounts expected to be payable by us under residual value guarantees; and
- the exercise price of a purchase option if we are reasonably certain to exercise that option, and payments of penalties for terminating the lease, if the lease term reflects exercising that option.

Lease payments to be made under reasonably certain extension options are also included in the measurement of the liability. The lease payments are discounted using the interest rate implicit in the lease. If that rate cannot be readily determined, which is generally the case for leases in us, the lessee's incremental borrowing rate is used, being the rate that the individual lessee would have to pay to borrow the funds necessary to obtain an asset of similar value to the right-of-use asset in a similar economic environment with similar terms, security and conditions.

To determine the incremental borrowing rate, we:

- where possible, uses recent third-party financing received by the individual lessee as a starting point, adjusted to reflect changes in financing conditions since third party financing was received;
- uses a build-up approach that starts with a risk-free interest rate adjusted for credit risk for leases held by us, which does not have recent third-party financing, and makes adjustments specific to the lease, e.g. term, country, currency and security.

Lease payments are allocated between principal and finance cost. The finance cost is charged to profit or loss over the lease period so as to produce a constant periodic rate of interest on the remaining balance of the liability for each period.

Right-of-use assets are measured at cost comprising the following (if applicable):

- the amount of the initial measurement of lease liability;
- any lease payments made at or before the commencement date less any lease incentives received; and
- any initial direct costs.

FINANCIAL INFORMATION

Right-of-use assets are generally depreciated over the shorter of the asset's useful life and the lease term on a straight-line basis. If we are reasonably certain to exercise a purchase option, the right-of-use asset is depreciated over the underlying asset's useful life.

Payments associated with short-term leases and all leases of low-value assets are recognized on a straight-line basis as an expense in profit or loss. Short-term leases are leases with a lease term of 12 months or less.

A lessee normally recognizes an asset and a lease liability when it enters into most leases under HKFRS 16. We consider the lease as a single transaction in which the asset and liability are integrally linked, so there is no net temporary difference at inception. Subsequently, as differences arise on settlement of the liability and the amortisation of the leased asset, there will be a net temporary difference on which deferred tax is recognized.

Amendment to HKFRS 16 provides a practical expedient for lessees to elect not to apply lease modification accounting for rent concessions arising as a direct consequence of the COVID-19 pandemic. The practical expedient applies only to rent concessions occurring as a direct consequence of the pandemic and only if (i) the change in lease payments results in revised consideration for the lease that is substantially the same as, or less than, the consideration for the lease immediately preceding the change; (ii) any reduction in lease payments affects only payments originally due on or before June 30, 2021; and (iii) there is no substantive change to other terms and conditions of the lease. The amendment is effective for annual periods beginning on or after June 1, 2020 with earlier application permitted and shall be applied retrospectively.

During the year ended December 31, 2020, certain monthly lease payments for the leases of our workspaces have been reduced or waived by the lessors upon reducing the scale of production as a result of the COVID-19 pandemic and there are no other changes to the terms of the leases. We have early adopted the amendment on January 1, 2020 and elected not to apply lease modification accounting for all rent concessions granted by the lessors as a result of the pandemic during the year ended December 31, 2020.

Intangible Assets

We recognized goodwill due to the acquisition of *NU/Hart* on May 31, 2021, and the good will has been allocated to *NU/Hart* for impairment testing. On June 30, 2021, management performed an impairment assessment on the goodwill. The recoverable amounts of the hair transplant business operated by *NU/Hart* have been assessed by an independent valuer and determined based on value-in-use ("VIU") calculation. The calculation used cash flow projections based on financial budgets covering a five-year period approved by management. The following table sets forth each key assumption on which management has based its cash flow projections to undertake impairment testing of goodwill as of June 30, 2021:

Revenue 2021 (% annual growth rate)	6%
Revenue 2022 to 2025 (% annual growth rate)	15%
Revenue 2026 (% annual growth rate)	8%
Terminal growth rate	2%
Pre-tax discount rate	18.3%

FINANCIAL INFORMATION

As of June 30, 2021, the recoverable amount of RMB32 million calculated based on VIU calculation exceeded its carrying value of RMB30 million by RMB2 million. The management has considered and assessed reasonably possible changes for other key assumptions and have not identified any instances that could cause the carrying amount to exceed their recoverable amount.

Management has undertaken sensitivity analysis on the impairment test of goodwill. The following table sets forth all possible changes to the key assumptions of the impairment test and the changes taken in isolation in the VIU calculations that would remove the remaining headroom as of June 30, 2021:

Annual revenue growth rate	-0.12%
Discount rate	+0.24%

The goodwill of approximately RMB25 million represents the excess of the acquisition consideration transferred over the fair value of the net identifiable assets acquired as of the acquisition date May 31, 2021. As of June 30, 2021, the recoverable amount of the CGU in NU/Hart is estimated to exceed the carrying amount of the CGU by approximately RMB2 million. Such recoverable amount of the CGU is determined based on VIU calculations. The calculation requires us to estimate the future cash flow expected to arise from CGU and a suitable discount rate in order to calculate the present value. As at recoverable amount valuation date, it has been only one month since the acquisition date and no significant changes in expected future cash flows generated from the CGU as well as the discount rate, the management expects that the recoverable amount would not increase significantly from the fair value of the net identifiable assets acquired as at the acquisition date. Therefore, the headroom only amounts to RMB2 million.

Our Directors considered there is no reasonably possible change in key parameters would cause the carrying amount of each CGU to exceed its recoverable amount. By reference to the recoverable amount assessed by the independent valuer as of June 30, 2021, our Directors determined that no impairment provision on goodwill for the six months ended June 30, 2021.

Critical Accounting Estimate

Estimation of Variable Consideration for Refund to Customers

We estimate variable considerations to be included in the transaction price for the refund to customers in respect of unsatisfactory services rendered. We have estimated the refund which is based on our past experience with customers. Any significant changes in experience as compared to historical patterns will impact the expected refund estimated by us. We update our assessment of expected refund on a regular basis and the refund liabilities are adjusted accordingly.

FINANCIAL INFORMATION

Recognition of Share-Based Compensation Expenses

An equity-settled share-based compensation plan was granted to the employees. The directors have used discounted cash flow method to determine the total fair value of the underlying shares granted to employees, which is to be expensed over the vesting period. Significant estimate on key assumptions, such as discount rate, risk-free interest rate, expected volatility and discount for lack of marketability, is required to be made by the directors in applying the discounted cash flow method. For details, see Note 23 to the Accountant's Report in Appendix I to this prospectus. As the awards granted in equity-settled share-based compensation plan are conditional on a Qualified Initial Public Offerings ("QIPO"), the directors have estimated the QIPO's probability and QIPO date when they calculated share-based compensation expenses at each reporting period end. Since QIPO condition is considered as vesting condition, we also need to estimate on the basis of the most likely outcome.

Income Taxes

We subject to income taxes in the PRC. Significant judgment is required in determining the provision for income taxes. There are some transactions and calculations for which the ultimate tax determination is uncertain. Where the final tax outcome of these matters is different from the amounts that were initially recorded, such differences will impact the current income tax and deferred income tax provisions in the period in which such determination are made.

Yonghe Investment is qualified as HNTes and is entitled to the preferential income tax rate of 15%. The qualification is valid 3 years, and upon expiry, we are required to submit the application to relevant government authority to certify the high-tech qualification. If we disqualified from the high-tech certification, we cannot enjoy the preferential income tax, and the change in tax rate will affect the current and deferred income taxes in the period in which the change takes place.

Deferred income tax assets relating to tax losses and unused tax credits are recognized as management considers it is probable that future taxable profit will be available against which the tax losses and tax credits can be utilised. Future taxable profit includes the profit from operating results and taxable profits of future periods reversed of taxable temporary differences. Estimates and judgment are required in determining the timing and amount of future taxable profit generated. In case where the actual future taxable profit generated are less than expected, or change in facts and circumstances which result in revision of future taxable profit estimation, a material reversal or further recognition of deferred income tax assets may arise, which will be recognized in the profit or loss in the period in which such a reversal or further recognition takes place.

FINANCIAL INFORMATION

DESCRIPTION OF SELECTED COMPONENTS OF CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

The following table sets forth a summary of our consolidated statements of comprehensive income for the periods indicated:

	Year Ended December 31,						Six Months Ended June 30,			
	2018		2019		2020		2020		2021	
	RMB'000	% of Revenue	RMB'000	% of Revenue	RMB'000	% of Revenue	RMB'000	% of Revenue	RMB'000	% of Revenue
Revenue	934,326	100.0	1,224,477	100.0	1,638,297	100.0	601,563	100.0	1,053,400	100.0
Cost of sales and services	(232,207)	(24.9)	(335,379)	(27.4)	(416,667)	(25.4)	(166,012)	(27.6)	(277,983)	(26.4)
Gross profit	702,119	75.1	889,098	72.6	1,221,630	74.6	435,551	72.4	775,417	73.6
Selling and marketing expenses	(463,681)	(49.6)	(650,262)	(53.1)	(779,611)	(47.6)	(246,631)	(41.0)	(577,947)	(54.9)
General and administrative expenses	(93,952)	(10.1)	(129,962)	(10.6)	(162,022)	(9.9)	(69,443)	(11.5)	(91,142)	(8.7)
Research and development expenses	(7,807)	(0.8)	(8,869)	(0.7)	(11,815)	(0.7)	(5,456)	(0.9)	(6,151)	(0.6)
Net impairment losses on financial assets	(1,633)	(0.2)	(34)	–	(487)	–	(279)	–	(376)	–
Other income	933	0.1	1,443	0.1	6,304	0.4	1,354	0.2	2,133	0.2
Other gains and losses, net	(7,021)	(0.8)	(3,373)	(0.3)	(7,738)	(0.5)	(5,766)	(1.0)	7,211	0.7
Operating profit	128,958	13.8	98,041	8.0	266,261	16.3	109,330	18.2	109,145	10.4
Finance costs – net	(17,669)	(1.9)	(26,518)	(2.2)	(35,347)	(2.2)	(15,789)	(2.6)	(20,270)	(1.9)
Profit before income tax	111,289	11.9	71,523	5.8	230,914	14.1	93,541	15.5	88,875	8.4
Income tax expense	(57,789)	(6.2)	(35,899)	(2.9)	(67,582)	(4.1)	(28,082)	(4.7)	(48,434)	(4.6)
Profit for the year/period	53,500	5.7	35,624	2.9	163,332	10.0	65,459	10.9	40,441	3.8
Other comprehensive income										
<i>Items that may be subsequently reclassified to profit or loss</i>										
– Currency translation differences	–	–	–	–	–	–	–	–	710	0.1
<i>Items that will not be reclassified to profit or loss</i>										
– Currency translation differences	–	–	–	–	–	–	–	–	(1,657)	(0.2)
Total comprehensive income for the year/period	53,500	5.7	35,624	2.9	163,332	10.0	65,459	10.9	39,494	3.7
Profit and total comprehensive income for the year/period attributable to:										
Owners of the Company	53,500	5.7	35,624	2.9	163,332	10.0	65,459	10.9	39,494	3.7

FINANCIAL INFORMATION

Revenue

Revenue by Business Line

Our revenue is generated from providing (i) hair transplant services, including traditional hair transplant and aesthetic hair transplant such as hairline lowering, eyebrow transplant, and sideburn transplant; (ii) medical hair care services, which mainly include the medical hair care treatment we offered in *Svenson Medical Hair Care Center* (史雲遜醫學健髮中心) in each of our clinics in mainland China; and (iii) others, which mainly include services provided and goods sold by stand-alone *Svenson* stores. For details, see “Business — Our Business.” The table below sets forth a breakdown of our revenue by business line for the periods indicated:

	Year Ended December 31,						Six Months Ended June 30,			
	2018		2019		2020		2020		2021	
	RMB'000	%	RMB'000	%	RMB'000	%	RMB'000	%	RMB'000	%
Hair transplant services	918,014	98.3	1,197,775	97.8	1,412,744	86.2	567,225	94.3	789,522	75.0
Medical hair care services	–	–	15,060	1.2	213,214	13.0	30,687	5.1	254,189	24.1
Others ⁽¹⁾	16,312	1.7	11,642	1.0	12,339	0.8	3,651	0.6	9,689	0.9
Total	934,326	100.0	1,224,477	100.0	1,638,297	100.0	601,563	100.0	1,053,400	100.0

Note:

- (1) mainly include revenue from *Svenson Hair Care Centers* (史雲遜健髮中心) we acquired in December 2017. These *Svenson Hair Care Centers* are not medical institutions and primarily engaged in providing routine hair restoration products (such as anti-hair loss shampoo and head massager) and services (such as scalp cleaning and massaging) without using medicines or medical devices.

Revenue by Development Stage

Our clinics can be categorized into three groups based on their respective opening date. As of the Latest Practicable Date, we had 30 mature-stage clinics, 17 developing-stage clinics, and six newly-established clinics (including one acquired clinic). The table below sets forth a breakdown of our revenue by development stage for the periods indicated:

	Year Ended December 31,						Six Months Ended June 30,			
	2018		2019		2020		2020		2021	
	RMB'000	%	RMB'000	%	RMB'000	%	RMB'000	%	RMB'000	%
Mature-stage clinics	555,038	59.4	831,989	67.9	1,196,970	73.1	415,415	69.1	722,954	68.6
Developing-stage clinics	300,766	32.2	338,917	27.7	328,511	20.1	150,618	25.0	234,541	22.3
Newly-established clinics	62,210	6.7	41,929	3.4	100,477	6.1	31,879	5.3	86,216	8.2
– Acquired clinic	–	–	–	–	–	–	–	–	754	–
Others ⁽¹⁾	16,312	1.7	11,642	1.0	12,339	0.7	3,651	0.6	9,689	0.9
Total	934,326	100.0	1,224,477	100.0	1,638,297	100.0	601,563	100.0	1,053,400	100.0

Note:

- (1) mainly include revenue from *Svenson Hair Care Centers* (史雲遜健髮中心) we acquired in December 2017. These *Svenson Hair Care Centers* are not medical institutions and primarily engaged in providing routine hair restoration products and services without using medicines or medical devices.

FINANCIAL INFORMATION

Revenue by Geographical Regions

The table below sets forth a breakdown of our revenue by geographical regions for the periods indicated:

	Year Ended December 31,						Six Months Ended June 30,			
	2018		2019		2020		2020		2021	
	RMB'000	%	RMB'000	%	RMB'000	%	RMB'000	%	RMB'000	%
Eastern China ⁽¹⁾	259,128	27.7	369,918	30.2	563,896	34.4	196,273	32.6	363,024	34.4
Southern China ⁽²⁾	174,960	18.7	261,075	21.3	348,583	21.3	122,381	20.3	249,233	23.7
Northern China ⁽³⁾	191,221	20.5	208,752	17.0	234,407	14.3	91,744	15.3	128,929	12.2
Southwestern China ⁽⁴⁾	97,950	10.5	121,176	9.9	184,969	11.3	71,100	11.8	100,996	9.6
Central China ⁽⁵⁾	120,146	12.9	126,507	10.3	143,004	8.7	53,190	8.9	96,804	9.2
Northwestern China ⁽⁶⁾	45,463	4.9	72,122	5.9	93,740	5.7	41,480	6.9	67,553	6.4
Northeastern China ⁽⁷⁾	29,146	3.1	53,285	4.4	57,359	3.5	21,744	3.6	36,418	3.5
Hong Kong ⁽⁸⁾	–	–	–	–	–	–	–	–	754	0.1
Others ⁽⁹⁾	16,312	1.7	11,642	1.0	12,339	0.8	3,651	0.6	9,689	0.9
Total	934,326	100.0	1,224,477	100.0	1,638,297	100.0	601,563	100.0	1,053,400	100.0

Notes:

- (1) Including Shanghai, Zhejiang, Jiangsu, Fujian, Jiangxi, An'hui and Shandong.
- (2) Including Guangdong and Guangxi.
- (3) Including Beijing, Tianjin, Hebei and Shanxi.
- (4) Including Sichuan, Guizhou, Yunnan and Chongqing.
- (5) Including Henan, Hubei and Hunan.
- (6) Including Shaanxi, Gansu and Xinjian
- (7) Including Heilongjiang and Liaoning.
- (8) Including one acquired clinic, Nu/Hart Hair, in Hong Kong.
- (9) Including the four Svenson Hair Care Centers that are not medical institutions, three of which are located in Shanghai and the remaining one is located in Beijing.

FINANCIAL INFORMATION

Cost of Sales and Services

Cost of Sales and Services by Nature

Our cost of sales and services primarily consists of (i) staff costs, representing wages, benefits and bonuses for our business operation personnel, such as physicians and other medical staff; (ii) amortization and depreciation charges, which primarily include amortization and depreciation of lease and medical equipment mainly used to provide hair transplant services; (iii) cost of inventories and consumables, primarily including (a) hair care products and (b) sterilization supplies, reagent and pharmaceuticals used in providing hair transplant services; (iv) operation related expenses, which primarily include utilities and maintenance fee; and (v) others expenses, primarily including non-deductible input taxes and surcharges. The following table sets forth a breakdown of our cost of sales and services by nature for the periods indicated:

	Year Ended December 31,						Six Months Ended June 30,			
	2018		2019		2020		2020		2021	
	RMB'000	%	RMB'000	%	RMB'000	%	RMB'000	%	RMB'000	%
Staff costs	105,807	45.6	145,445	43.4	165,946	39.8	64,781	39.0	116,881	42.0
Amortization and depreciation charges	75,423	32.5	114,948	34.3	141,686	34.0	66,190	39.9	86,802	31.2
Cost of inventories and consumables	25,941	11.2	40,405	12.0	63,951	15.3	19,831	11.9	46,307	16.7
Operation related expenses	14,430	6.2	17,212	5.1	21,164	5.1	10,437	6.3	12,387	4.5
Other expenses	10,606	4.5	17,369	5.2	23,920	5.8	4,773	2.9	15,606	5.6
Total	232,207	100.0	335,379	100.0	416,667	100.0	166,012	100.0	277,983	100.0

Cost of Sales and Services by Business Line

The following table sets forth our cost of sales and services by business line for the periods indicated:

	Year Ended December 31,						Six Months Ended June 30,			
	2018		2019		2020		2020		2021	
	RMB'000	%	RMB'000	%	RMB'000	%	RMB'000	%	RMB'000	%
Hair transplant services	214,247	92.3	311,075	92.8	351,600	84.4	149,706	90.2	217,216	78.1
Medical hair care services	–	–	10,244	3.1	55,909	13.4	12,906	7.8	56,372	20.3
Others	17,960	7.7	14,060	4.1	9,158	2.2	3,400	2.0	4,395	1.6
Total	232,207	100.0	335,379	100.0	416,667	100.0	166,012	100.0	277,983	100.0

FINANCIAL INFORMATION

Gross Profit and Gross Profit Margin

Our gross profit represents our revenue less cost of sales and services. In 2018, 2019, 2020 and the six months ended June 30, 2021, our gross profit was RMB702.1 million, RMB889.1 million, RMB1,221.6 million and RMB775.4 million, respectively. Gross profit margin represents our gross profit as a percentage of our revenue. In 2018, 2019, 2020 and the six months ended June 30, 2021, our gross profit margin was 75.2%, 72.6%, 74.6% and 73.6%, respectively. The following table sets forth a breakdown of our gross profit and gross profit margin by business line for the periods indicated:

	Year Ended December 31,						Six Months Ended June 30,			
	2018		2019		2020		2020		2021	
	<i>Gross</i>		<i>Gross</i>		<i>Gross</i>		<i>Gross</i>		<i>Gross</i>	
	<i>Gross</i>	<i>profit</i>	<i>Gross</i>	<i>profit</i>	<i>Gross</i>	<i>profit</i>	<i>Gross</i>	<i>profit</i>	<i>Gross</i>	<i>profit</i>
	<i>profit</i>	<i>margin</i>	<i>profit</i>	<i>margin</i>	<i>profit</i>	<i>margin</i>	<i>profit</i>	<i>margin</i>	<i>profit</i>	<i>margin</i>
	RMB'000	%	RMB'000	%	RMB'000	%	RMB'000	%	RMB'000	%
Hair transplant services	703,767	76.7	886,700	74.0	1,061,144	75.1	417,519	73.6	572,306	72.5
Medical hair care services	–	–	4,816	32.0	157,305	73.8	17,781	57.9	197,817	77.8
Others	(1,648)	(10.1)	(2,418)	(20.8)	3,181	25.8	251	6.9	5,294	54.6
Total gross profit/overall gross profit margin	702,119	75.2	889,098	72.6	1,221,630	74.6	435,551	72.4	775,417	73.6

Our total gross profit is primarily affected by the gross profit of each of the services we offered in each year. We had increased gross profit during the Track Record Period primarily due to the increases in gross profit of our hair transplant services, which represented the largest component of our service offerings. In December 2017, we started to develop our other business offerings and acquired *Svenson China*. Leveraging our strong medical service capabilities and *Svenson China*'s extensive experience in offering hair restoration products and services, we opened a *Svenson Medical Hair Care Center* (史雲遜醫學健髮中心) in each hair transplant clinic in mainland China under a “shop-in-shop” model to provide hair transplant patients with preoperative and postoperative medical services. Thereafter, we started to offer medical hair care services since the late 2019 and recorded relatively low gross profit and gross profit margin in medical hair care services during the initial stage of its operations. Furthermore, we recorded gross losses in other services in 2018 and 2019, primarily because we incurred more costs (for example, the amortization and depreciation charges in relation to rent of new leases and staff costs for hiring relevant employees) as compared to revenue at initial stage of *Svenson Hair Care Centers* (史雲遜健髮中心) and its business integration. In addition, we primarily focused on hair transplant services and started *Svenson*-related integration in late 2019, and therefore, our other services started to record positive gross profit and gross profit margin in 2020 and achieved robust growth in the six months ended June 30, 2021.

FINANCIAL INFORMATION

In addition, our overall gross profit margin is affected by our revenue mix due to the differences among the gross profit margins of our service offerings. During the Track Record Period, we experienced slight variation in our overall gross profit margin and our overall gross profit margin was relatively stable at 75.2%, 72.6%, 74.6%, 72.4% and 73.6% in 2018, 2019, 2020, six months ended June 30, 2020 and 2021, respectively.

- *Hair transplant services:* Our hair transplant services represented the largest component of our service offerings and the gross profit margin of such services was relatively stable at 76.7%, 74.0%, 75.1%, 73.6% and 72.5% in 2018, 2019, 2020, six months ended June 30, 2020 and 2021, respectively. However, our gross profit margin of hair transplant services may fluctuate slightly in certain period, and such fluctuation may lead to the variation of our overall gross profit margin. For instance, our gross profit margin of hair transplant services slightly decreased in 2019 as compared with that of 2018, primarily due to an increase in fix expenses, such as amortization and depreciation charges in relation to rent of new leases and staff costs for hiring employees. Such decrease in hair transplant services gross profit margin was attributable to the decrease in our overall gross profit margin in 2019.
- *Medical hair care services:* Since the late 2019, we started offering medical hair care services and had significant growth in gross margin, from 32.0% in 2019 to 73.8% in 2020 and from 57.9% for the six months ended June 30, 2020 to 77.8% for the six months ended June 30, 2021. We recorded relatively lower gross profit margin in 2019 and the first half of 2020, primarily because the *Svenson Medical Hair Care Center* business was at its initial stage and took time to grow the customer base.
- *Others:* We recorded negative profit margin for other services in 2018 and 2019. Since we acquired *Svenson China* in December 2017, it took time for us to transform the *Svenson* business and integrate such into our exiting service offerings. Since late 2019, we started to develop *Svenson Hair Care Centers* and recorded gross profit margin of 25.8%. In addition, as we continue to develop *Svenson Hair Care Centers*, we enjoyed greater economies of scale and recorded an increased gross profit margin from 6.9% for the six months ended June 30, 2020 to 54.6% for the six months ended June 30, 2021.

Going forward, we plan to further develop our medical hair-care services, continue to develop our *Svenson*-related brand awareness, and aim to provide a full-spectra of our hair-related healthcare service offerings. For details of our results of operations, see “— Results of Operations.”

FINANCIAL INFORMATION

Selling and Marketing Expenses

Our selling and marketing expenses primarily consist of (i) marketing and promotion expenses, which primarily include service fees paid to the third-party marketing service providers to promote our brand and services; (ii) staff costs, representing wages, benefits and bonuses of our in-house sales and marketing team; (iii) travel and transportation expenses incurred by our in-house sales and marketing team; (iv) operation related expenses for sales and marketing team, which primarily include utilities, maintenance and rental payments; and (v) amortization and depreciation. The following table sets forth a breakdown of our selling and marketing expenses for the periods indicated:

	Year Ended December 31,			Six Months Ended June 30,	
	2018	2019	2020	2020	2021
	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
Marketing and promotion expenses					
– Online channels ⁽¹⁾					
– Performance-based advertising ⁽²⁾	154,592	278,410	317,104	96,780	251,099
– Brand advertising ⁽³⁾	23,010	87,056	64,903	20,404	63,684
Subtotal	177,602	365,466	382,007	117,184	314,783
– Offline channels ⁽⁴⁾	150,490	92,673	125,660	31,323	74,653
Staff costs	98,021	142,243	220,623	79,143	153,295
Travel expenses	23,928	24,000	22,675	7,400	15,807
Operation related expenses	8,131	14,985	16,165	5,940	9,596
Amortization and depreciation charges	4,211	9,089	11,074	5,075	6,826
Others	1,298	1,806	1,407	566	2,987
Total	463,681	650,262	779,611	246,631	577,947

Notes:

- (1) Advertisements posted in cooperation with large online channels in China such as Tencent, Baidu, Bytedance, Kuaishou, Weibo, Bilibili, etc.
- (2) For performance-based advertisements, we are obligated to pay only when there are measurable results. The payment amounts were calculated based on the pricing models agreed between us and the advertising agents, with references to the relevant measurable metrics (e.g., cost-per-click (CPC), cost-per-mille (CPM), or cost-per-lead (CPL)). For example, we cooperated with Baidu and conducted search engine-based promotion. In addition, we also posted performance-based advertisements in collaboration with large social network sites and online communities such as Weibo, Bilibili, and TikTok.
- (3) For brand advertisements, we are obligated to pay regardless of the results of such advertisements. The payment amounts were typically fixed amounts agreed between us and the advertising agents. For example, we designed an advertising campaign in cooperation with Tencent, which helped us promote our *Yonghe Hair Transplant* brand when broadcasting NBA games; we also cooperated with Toutiao and posted a number of advertisements to raise the awareness of our *Svenson* brand.
- (4) Advertisements posted in cooperation with offline channels such as subway stations, office buildings, shopping complexes and cinemas.

FINANCIAL INFORMATION

General and Administrative Expenses

Our general and administrative expenses primarily consist of (i) staff costs, representing share-based compensation expenses, wages, benefits and bonuses of our administrative staff; (ii) operation related expenses for our administrative team, which primarily include conference fees, utilities, maintenance fees and rental payments; (iii) professional and consulting service fees incurred in relation to audit services, rental agencies and internet services; (iii) amortization and depreciation charges in relation to our properties and office equipment; and (iv) travelling and entertainment expenses. The following table sets forth a breakdown of our general and administrative expenses for the periods indicated:

	Year Ended December 31,			Six Months Ended June 30,	
	2018	2019	2020	2020	2021
	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
Staff costs	55,012	75,099	99,357	46,212	55,166
Operation related expenses	14,937	18,559	11,835	3,841	6,998
Professional and consulting service fees	2,188	2,232	5,708	4,245	3,168
Amortization and depreciation charges	4,773	5,565	6,216	3,116	3,358
Travel expenses	5,135	5,858	4,677	994	2,730
Listing expenses	–	–	5,027	–	8,601
Others					
– Agency fees ⁽¹⁾	2,867	1,662	5,858	2,803	534
– Bank transaction fees	3,648	4,335	4,943	1,792	3,354
– Human resource service fees ⁽²⁾	1,878	7,768	6,742	279	1,341
– Disability security funds	711	1,954	1,052	155	307
– Non-deductible input taxes and surcharges ⁽³⁾	–	–	6,185	1,858	4,126
– Others ⁽⁴⁾	2,803	6,930	4,422	4,148	1,459
Total	93,952	129,962	162,022	69,443	91,142

Notes:

- (1) primarily include business agency, tax agency, and rental agency service fees. Our agency fees decreased by RMB1.2 million in 2019 as compared with that of 2018, primarily because in 2018, we paid a substantial amount of service fees to (i) a market research agency for conducting market and customer profiling researches; and (ii) a tax agency for assisting us in the application of the “high-tech enterprise” status. Such services were provided on a one-off basis and we did not incur such service fees in 2019. Further, our agency fees increased significantly in 2020, primarily because we paid a significantly increased amount of services fees in 2020 to (i) rental agencies for property rental services in relation to our new clinic openings; and (ii) advertising agencies for conducting reviews for the advertisements we posted to ensure the quality of our advertainments. Such increases were generally in line with our business growth. In addition, our agency fees decreased by RMB2.3 million for the six months ended June 30, 2021 as compared with that of the six months ended June 30, 2020, primarily because we had not incurred any substantial rental agency service fees in the first half of 2021, which was in line with the pace of our new clinic openings.

FINANCIAL INFORMATION

- (2) represent service fees paid to human resource agencies for providing recruitment services and employee training services. Our human resource service fees have steadily increased over the years primarily due to (i) the increased needs for qualified employees to support our business growth; and (ii) the increased needs for employee trainings to ensure our compliance with the applicable laws and regulations, and to maintain our service quality. Our human resource service fees slightly decreased in 2020 as compared with that of 2019, mainly due to the reduced spending in recruitment services and employee training services as a result of the outbreak of the COVID-19 pandemic.
- (3) primarily include input taxes that could not be deducted against output taxes. With respect to a number of our intra-group transactions, the input taxes incurred by our clinics could not be deducted against the corresponding output taxes because the hair transplant business is exempted from VAT. For instance, since 2020, the Group started to provide management services (including human resources and finance) to local clinics in order to standardize our operation and implement centralized quality control. And such taxes for service expenses could not be deducted against the output taxes by each local clinic. As a result, when we consolidated our results of operations, we offset the income and expenses arising from intra-group transactions and recorded non-deductible input taxes and surcharges of RMB6.2 million in 2020 and RMB4.1 million in the six months ended June 30, 2021.
- (4) primarily include logistics costs, property insurance costs, uniform fees, and other working capital related fees.

Research and Development Expenses

Our research and development expenses primarily consist of (i) staff costs, representing wages, benefits and bonuses of our R&D staff; (ii) professional service fees in relation to research and development of new technologies related to hair transplantation; (iii) operation related expenses, including utilities, maintenance fee and rental expenses. The following table sets forth a breakdown of our research and development expenses for the periods indicated:

	Year Ended December 31,			Six Months Ended June 30,	
	2018	2019	2020	2020	2021
	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
Staff costs	6,006	7,502	8,960	4,510	4,680
Professional service fees	115	388	935	33	1,039
Travel expenses	358	104	570	144	31
Operation related expenses	834	486	541	375	271
Depreciation charges	42	103	149	97	81
Other expenses ⁽¹⁾	452	286	660	297	49
Total	7,807	8,869	11,815	5,456	6,151

Note:

- (1) primarily include cost of materials and consumables used for research and development activities.

Net Impairment Loss on Financial Assets

Our net impairment losses on financial assets primarily consist of impairment made for trade and other receivables. In 2018, 2019, 2020 and the six months ended June 30, 2021, we recorded net impairment losses on financial assets of RMB1.6 million, RMB34,000, RMB0.5 million and RMB0.4 million, respectively.

FINANCIAL INFORMATION

Other Income

Our other income consists of (i) government grants, representing short-term working subsidies received from the local governments in connection with the business development, rewards for financial and employment contribution and capital expenditure incurred on certain projects, income-based tax credits, all of which were one-off in nature; and (ii) VAT additional deduction, mainly represents the VAT deduction and tax-free income. The following table sets forth a breakdown of our other income for the periods indicated:

	Year Ended December 31,			Six Months Ended June 30,	
	2018	2019	2020	2020	2021
	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
Government grants	24	505	4,082	601	493
VAT additional deduction	–	938	1,802	629	1,640
Others ⁽¹⁾	909	–	420	124	–
Total	933	1,443	6,304	1,354	2,133

Note:

(1) represented income generated from subleasing office space.

Other Gains and Losses – Net

During the Track Record Period, our other gains primarily comprised (i) compensation received from a landlord in relation to the early-termination of a property lease by such landlord; and (ii) gains on disposal of subsidiaries, namely, Shenzhen Yonghe Meidu Medical Beauty Clinic (“**Shenzhen Yonghe Meidu**”) and Nanning Fangguanrui Cosmetic Clinic (“**Nanning Fangguanrui**”). With respect to (i), we entered into a lease agreement in September 2019 with Wuhan Junheng Property Management Co. Ltd., a property management company, for our newly-established clinic in Shanghai. The property we leased was located at Huangpu district, Shanghai, with a total GFA of approximately 6,628.02 sq.m. In November 2019, the lease agreement was unilaterally terminated by the property management company without just or sufficient cause. According to the lease agreement, the property management company was in breach of the contract and we were eligible to receive the refund (consisting of 2-month advanced rental fees of approximately RMB2.6 million and 3-month rental deposits of approximately RMB3.8 million) as well as compensation due to the landlord’s breach. We recorded compensation of RMB6.4 million after we had received such payments in full in June 2021 through our negotiation. With respect to (ii), we received cash payment of RMB2.4 million from a network platform company based in Beijing for the disposal of Shenzhen Yonghe Meidu, and cash payment of RMB1.1 million from an individual entrepreneur for the disposal of Nanning Fangguanrui. To the best knowledge of our Directors, each of these two purchasers was an independent third party to our Company. We made these disposals because as our business scales in Shenzhen and Nanning developed, our management team determined that the spaces where Shenzhen Yonghe Meidu and Nanning Fangguanrui were located were no longer sufficient to satisfy our increased business scale and the needs of the local patients. Therefore, in order to enhance patient experience, we relocated the clinics in Shenzhen and Nanning to newer, and larger, locations, and disposed of the old

FINANCIAL INFORMATION

clinics after the relocations were completed. Our Directors confirm that the consideration for the disposals were determined after arms' length negotiations between the parties, and during such negotiations, we primarily considered (a) the value of the remaining lease term with respect to such properties; (b) the residual value of the interior decoration and fixtures of such properties (including the air conditioning system, fire safety facilities, and other security facilities); and (c) the various costs that need to be incurred by an independent third party in securing commercial properties with location and gross floor areas similar to that of our old clinics. Prior to the disposal, Shenzhen Yonghe Meidu and Nanning Fangguanrui were profit-making. None of Shenzhen Yonghe Meidu and Nanning Fangguanrui was the subject of any material non-compliant incidents, claims, litigation or legal proceedings (whether actual or threatened) during the Track Record Period and up to the time of disposal. During the same period, our other expenses and losses primarily comprised losses on property, plant and equipment and donation to Wuhan during the COVID-19 epidemic. The following table sets forth a breakdown of our other gains and losses – net for the periods indicated:

	Year Ended December 31,			Six Months Ended June 30,	
	2018	2019	2020	2020	2021
	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
Compensation from the early-termination of a property lease	–	–	–	–	6,431
Gains on disposal of subsidiaries	2,400	1,100	–	–	–
Losses on disposal of property, plant and equipment	(5,704)	(1,849)	(3,984)	(3,597)	(451)
Donation	–	–	(1,000)	(1,000)	–
Compensation expenditure to customers	(394)	(297)	(2)	–	–
Others ⁽¹⁾	(3,323)	(2,327)	(2,752)	(1,169)	1,231
Total	(7,021)	(3,373)	(7,738)	(5,766)	7,211

Note:

- (1) primarily include gains or losses of termination of lease, fixed assets inventory losses, inventory obsolescence and penalty expenses primarily in relation to advertising non-compliance.

FINANCIAL INFORMATION

Finance Costs – Net

During the Track Record Period, our finance income comprised interest income of bank savings. During the same period, our finance costs comprised interest expenses on borrowings and interest on lease liabilities. The following table sets forth a breakdown of our net finance costs for the periods indicated:

	Year Ended December 31,			Six Months Ended June 30,	
	2018	2019	2020	2020	2021
	<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>
Finance income					
Interest income on current deposits	139	210	941	218	2,408
Finance costs					
Interest expenses for lease liabilities	(17,808)	(25,453)	(34,800)	(14,982)	(21,528)
Interest expenses on bank borrowings	–	(1,275)	(1,488)	(1,025)	(1,150)
Finance costs – net	<u>(17,669)</u>	<u>(26,518)</u>	<u>(35,347)</u>	<u>(15,789)</u>	<u>(20,270)</u>

Income Tax Expense

Our principal applicable taxes and tax rates are set forth as follows:

Mainland China

Our income tax expenses consist of current and deferred income taxes payable in the PRC by our subsidiaries. Income tax provision in respect of our operations in the PRC has been calculated at the applicable tax rate on the estimated assessable profits for the year or period, based on existing legislation and interpretations and practices in respect thereof. In addition, certain of our subsidiaries in the PRC are qualified as small and micro enterprises under the relevant tax rules and regulations of the PRC, and accordingly, the part of their taxable income not exceeding RMB3 million are subject to a reduced corporate income tax rate of 20% during the Track Record Period. Other than the above-mentioned subsidiary, our other PRC Operating Entities are subject to standard income tax rate of 25% pursuant to the EIT Law and related regulations.

During the Track Record Period, we incurred income tax expense of RMB57.8 million, RMB35.9 million, RMB67.6 million, RMB28.1 million and RMB48.4 million in 2018, 2019, 2020, and the six months ended June 30, 2020 and 2021, representing an effective tax rate of 51.9%, 50.2%, 29.3%, 30.0% and 54.5%, respectively. Our effective income tax rate is calculated by dividing income tax expense by profit before income tax. Our effective income tax rate during the Track Record Period were above the 25% statutory tax rate, which were mainly due to the increase in tax adjustment on advertising expenses.

FINANCIAL INFORMATION

Pursuant to the EIT Law and related regulations, the pre-tax deduction for advertising expenses is limited to the 15% of the revenue in its current year, and the excess will be carried forward for deduction in the following years. Therefore, according to the EIT law, the taxable income was higher than our profit before income tax, which in turn resulting a higher effective income tax rate. In addition, our effective tax rate decreased significantly from 50.2% in 2019 to 29.3% in 2020, primarily due to the significant increase in our revenue in 2020 corresponding with the increased pre-tax deduction for advertising expenses. Our effective tax rate further increased from 30.0% in 2020 to 54.5% in six months ended June 30, 2021, primarily due to (i) an increase in tax expenses due to the payment of shares transfer of Beijing Haiyouyou during our Reorganization and (ii) a decreased pre-tax deduction for advertising expenses since the advertising expenses for the relevant period were above 15% of the revenue.

Cayman Islands

Our Company is incorporated in the Cayman Islands as an exempted company with limited liability under the Companies Act of the Cayman Islands and, accordingly, is exempted from Cayman Islands income tax.

British Virgin Islands

Under the current laws of the British Virgin Islands, our subsidiaries incorporated in British Virgin Islands are not subject to income tax.

Hong Kong

The subsidiary incorporated in Hong Kong is subject to Hong Kong profits tax at the rate of 16.5% on any estimated assessable profits arising in Hong Kong.

Operating Profit and Profit for the Year

For the years ended December 31, 2018, 2019, 2020 and the six months ended June 30, 2021, our operating profit amounted to RMB129.0 million, RMB98.0 million, RMB266.3 million, and RMB109.1 million, respectively, with an operating margin of 13.8%, 8.0%, 16.3% and 10.4% for the respective period.

As a result of the above, for the years ended December 31, 2018, 2019, 2020 and the six months ended June 30, 2021, our profit for the year amounted to RMB53.5 million, RMB35.6 million, RMB163.3 million and RMB40.4 million, respectively.

FINANCIAL INFORMATION

RESULTS OF OPERATIONS

Six Months Ended June 30, 2021 Compared with Six Months Ended June 30, 2020

Revenue

Our revenue increased from RMB601.6 million for the six months ended June 30, 2020 to RMB1,053.4 million for the six months ended June 30, 2021.

Revenue from Hair Transplant Services

Our revenue from hair transplant services increased from RMB567.2 million for the six months ended June 30, 2020 to RMB789.5 million for the six months ended June 30, 2021 due to the organic growth our existing clinics and the sales ramp up for our newly established clinics. In addition, due to the continued sales and marketing efforts, we have enhanced our brand recognition with strong presence in the hair transplant industry, thus, we have attracted more customers for hair transplant services. The number of hair transplant patients increased by 48.3% from 19,883 for the six months ended June 30, 2020 to 29,480 for the six months ended June 30, 2021.

Revenue from Medical Hair Care Services

Our revenue from medical hair care services increased from RMB30.7 million for the six months ended June 30, 2020 to RMB254.2 million for the six months ended June 30, 2021 due to the continued robust growth of medical hair care services since we started to develop such services in late 2019. Alongside the rapid growth of hair transplant services, it creates a synergistic effect with our hair care services by deriving more customers from the growth of hair transplant services. In particular, we started to focus on *Svenson*-related brand awareness, reflecting (i) an increased number of patients purchased medical hair care services, from 18,067 patients for the six months ended June 30, 2020 to 52,633 patients for the six months ended June 30, 2021 and (ii) an increased average spending per medical hair care patient from RMB1,698 for the six months ended June 30, 2020 to RMB4,829 for the six months ended June 30, 2021. Such significant increase in average spending per medical hair care patient was primarily due to our expanded service offerings, improved hair care formula, and improved service quality. In particular, our medical hair care services were relatively at their initial stage of businesses in the first half of 2020 as compared with that of 2021. Therefore, the significant increase in average spending per medical hair care patient was also in line with our business growth.

Revenue from Other Services

Our revenue from other services increased from RMB3.7 million for the six months ended June 30, 2020 to RMB9.7 million for the six months ended June 30, 2021, primarily due to the organic growth of our *Svenson Hair Care Centers* as we continued to enhance our *Svenson's* image and brand recognition. Alongside the rapid growth of hair transplant services, it creates a synergistic effect with our hair care services by deriving more customers from the growth of hair transplant services. Furthermore, such increase in revenue was also due to the recovery from adverse impact of COVID-19 pandemic. In the first half of 2020, our *Svenson Hair Care Centers* experienced more COVID-19 related restrictions on business due to their locations in shopping malls and office buildings.

FINANCIAL INFORMATION

Cost of Sales and Services

Our cost of sales and services increased from RMB166.0 million for the six months ended June 30, 2020 to RMB278.0 million for the six months ended June 30, 2021 due to (i) an increase in staff costs as a result of salary increases and an increase in our employee headcount to support our business operation; (ii) an increase in cost of inventories and consumables due to the organic growth in all three business lines; and (iii) an increase in amortization and depreciation charges due to our clinic network expansion.

Gross Profit and Gross Profit Margin

Our gross profit increased from RMB435.6 million for the six months ended June 30, 2020 to RMB775.4 million for the six months ended June 30, 2021; our gross profit margin increased from 72.4% for the six months ended June 30, 2020 to 73.6% for the six months ended June 30, 2021.

Hair Transplant Services

Our gross profit from hair transplant services increased from RMB417.5 million for the six months ended June 30, 2020 to RMB572.3 million for the six months ended June 30, 2021, primarily due to the continued business growth of our hair transplant services. In particular, as the number of patients continue to grow, we efficiently manage our costs and expenses, and the economies of large-scale effect gradually appears. Our gross profit margin remained relatively stable at 73.6% and 72.5% for the six months ended June 30, 2020 and 2021, respectively.

Medical Hair Care Services

Our gross profit from medical hair care services increased from RMB17.8 million for the six months ended June 30, 2020 to RMB197.8 million for the six months ended June 30, 2021, respectively. In addition, our gross profit margin increased from 57.9% and 77.8% for the same periods. As the number of total repurchase amounts continue to grow, the organic growth in medical hair care services was attributable to the realization of large-scale effects reflecting the efficiencies and economies in fixed costs, such as staff costs and amortization and depreciation charges.

Other Services

Our gross profit from other services increased from RMB0.3 million for the six months ended June 30, 2020 to RMB5.3 million for the six months ended June 30, 2021; our gross profit margin increased from 6.9% for the six months ended June 30, 2020 to 54.6% for the six months ended June 30, 2021. Such increases were primarily attributable to (i) the organic growth of our *Svenson Hair Center* as we continued to enhance our *Svenson's* image and brand recognition and (ii) recovery from adverse impact of COVID-19 pandemic as our *Svenson Hair Care Centers* experienced more COVID-19 related restrictions on business due to their locations in shopping malls and office buildings.

Selling and Marketing Expenses

Our selling and marketing expenses increased from RMB246.6 million for the six months ended June 30, 2020 to RMB577.9 million for the six months ended June 30, 2021, primarily due to the differences in timing of our brand advertising placement. In 2021, in line with our marketing strategies, we strategically focused on brand advertisements during NBA season in the first half of 2021, and

FINANCIAL INFORMATION

targeted NBA audience, which consists of a large percentage of male audience, as our potential customers. In addition, in the first half of 2021, with the development of our medical hair care and other services, we continued to promote *Svenson*-related brand awareness and had more promotional activities in this regard. However, in 2020, we focused on brand advertising in the second half of 2020. For example, our brand advertising on subways, elevators and buses was substantially increased during this period. Therefore, our selling and marketing increased from six months ended June 30, 2020 to six months ended June 30, 2021.

General and Administrative Expenses

Our general and administrative expenses increased from RMB69.4 million for the six months ended June 30, 2020 to RMB91.1 million for the six months ended June 30, 2021, primarily due to (i) the listing expenses in relation to the Global Offering; (ii) an increase in staff costs due to the salary increases and the increase in our employee headcount for administration in line with our clinic network expansion; and (iii) an increase in operation related expenses due to the recovery of COVID-19.

Research and Development Expenses

Our research and development expenses increased from RMB5.5 million for the six months ended June 30, 2020 to RMB6.2 million for the six months ended June 30, 2021, primarily due to an increase in professional service fees, which was in line with the increase in our research and development activities. For example, we developed certain projects to enhance the success rate of our hair transplant services during this period.

Net Impairment Losses on Financial Assets

Our net impairment losses on financial assets increased from RMB0.3 million for the six months ended June 30, 2020 to RMB0.4 million for the six months ended June 30, 2021.

Other Income

Our other income increased from RMB1.4 million for the six months ended June 30, 2020 to RMB2.1 million for the six months ended June 30, 2021, primarily due to an increase in VAT additional deductions in connection with our increased procurement.

Other Gains and Losses – Net

For the six months ended June 30, 2020, we recorded RMB5.8 million other expenses and losses primarily due to (i) RMB3.6 million in losses on disposal of property, plant and equipment due to the depreciation; and (ii) RMB1.0 million in donation. For the six months ended June 30, 2021, we recorded RMB7.2 million in other gains, primarily due to (i) the compensation from early-termination of a property lease and (ii) other gains in relation to the differences between the carrying amounts of the right-of-use asset and the lease liability.

Finance Costs – Net

Our net finance costs increased from RMB15.8 million for the six months ended June 30, 2020 to RMB20.3 million for the six months ended June 30, 2021, primarily due to an increase in interest expenses for lease liabilities. Such increase in finance costs was partially offset by an increase in interest income on bank deposits.

FINANCIAL INFORMATION

Income Tax Expense

Our income tax expense increased from RMB28.1 million for the six months ended June 30, 2020 to RMB48.4 million for the six months ended June 30, 2021, primarily due to (i) an increase in tax expenses due to the payment of shares transfer of Beijing Haiyouyou during our Reorganization and (ii) a decreased pre-tax deduction for advertising expenses since the advertising expenses for the relevant period were above 15% of the revenue.

Profit for the Period

As a result of the above, our net profit decreased from RMB65.5 million for the six months ended June 30, 2020 to RMB40.4 million for the six months ended June 30, 2021.

Year Ended December 31, 2020 Compared with Year Ended December 31, 2019

Revenue

Our revenue increased from RMB1,224.5 million in 2019 to RMB1,638.3 million in 2020.

Revenue from Hair Transplant Services

Our revenue from hair transplant services increased from RMB1,197.8 million in 2019 to RMB1,412.7 million in 2020, primarily due to an increase in the number of hair transplant patients. The number of hair transplant patients increased by 17.7% from 43,087 in 2019 to 50,694 in 2020, which was in line with our business growth and clinic network expansion and upgrade.

Revenue from Medical Hair Care Services

Our revenue from medical hair care services increased significantly from RMB15.1 million in 2019 to RMB213.2 million in 2020. Such increase was mainly because we started to ramp up medical hair care services since the end of 2019 and offered more hair care related products and services. We opened a *Svenson Medical Hair Care Center* in each of our hair transplant clinics under a “shop-in-shop” model to provide hair transplant patients with preoperative and postoperative medical services. Furthermore, unlike the hair transplant market, the medical hair care service market is characterized primarily by repeat sales to the same patients, which indicates tremendous future growth potentials.

Revenue from Other Services

Our revenue from other services remained relatively stable from RMB11.6 million in 2019 to RMB12.3 million in 2020.

FINANCIAL INFORMATION

Cost of Sales and Services

Our cost of sales and services increased from RMB335.4 million in 2019 to RMB416.7 million in 2020, primarily due to (i) an increase in amortization and depreciation charges due the increases in amortization of property, plant and equipment and depreciation of right-of-use assets, both of which were in line with our clinic network expansion as we established new clinics and upgraded our existing clinics; (ii) an increase in staff costs as a result of salary increases and an increase in our employee headcount to support our business operation and medical hair care service expansion; and (iii) an increase in cost of inventories and consumables which was in line with our business growth.

Gross Profit and Gross Profit Margin

Our gross profit increased from RMB889.1 million in 2019 to RMB1,221.6 million in 2020; our gross profit margin increased from 72.6% in 2019 to 74.6% in 2020.

Hair Transplant Services

Our gross profit from hair transplant services increased from RMB886.7 million in 2019 to RMB1,061.1 million in 2020, primarily due to the business growth of our hair transplant services. In particular, the number of hair transplant patients increased by 17.7% from 43,087 in 2019 to 50,694 in 2020. Our gross profit margin remained relatively stable from 74.0% to 75.1% in 2019 and 2020, respectively.

Medical Hair Care Services

Our gross profit from medical hair care services increased significantly from RMB4.8 million in 2019 to RMB157.3 million in 2020; and our gross profit margin increased from 32.0% in 2019 to 73.8% in 2020. Such increases in gross profit and gross profit margin from 2019 to 2020 were mainly related to our medical hair care business integration. In 2019, our business of the medical hair care services was in its initial operation stage, and therefore, we recorded relatively lower gross profit and gross profit margin. Since the late 2019, we started to ramp up our business in medical hair care sector and formed a scale effect corresponding with the growth of our hair transplant services.

Other Services

We recorded gross loss of RMB2.4 million and gross loss margin of 20.8% in 2019. Due to our continuous development of other services, we recorded gross profit of RMB3.2 million and gross profit margin of 25.8% in 2020.

Selling and Marketing Expenses

Our selling and marketing expenses increased from RMB650.3 million in 2019 to RMB779.6 million in 2020, primarily due to an increase in marketing and promotion expenses, which was in line with our business expansion. In particular, we continue to focus on brand marketing and advertising to enhance our brand recognition. In addition, the increase in selling and marketing expenses was also attributable to the increase in staff costs due to the increase in our sales and marketing employee headcount primarily for medical hair care services. The selling and marketing expenses as percentage of our revenue was decreased from 53.1% in 2019 to 47.6% in 2020, primarily because we optimized our advertising distribution channels in 2020 to improve the efficiency of selling and marketing activities.

FINANCIAL INFORMATION

General and Administrative Expenses

Our general and administrative expenses increased from RMB130.0 million in 2019 to RMB162.0 million in 2020, primarily due to (i) an increase in staff costs as a result of the salary increases and the increase in our employee headcount for administration. In particular, we have established customer service department to improve our customer satisfaction; (ii) an increase in professional service fees due to the increase in rental consulting services (representing the services fees paid to third-parties for clinic site selection and lease recommendations), audit services and technical fees; (iii) an increase in other expenses mainly due to the increase in taxes and surcharges and bank transaction fees in line with our business growth. In addition, we recorded RMB5.0 million in relation to listing expenses in 2020.

Research and Development Expenses

Our research and development expenses increased from RMB8.9 million in 2019 to RMB11.8 million in 2020, primarily due to an increase in staff costs due to the salary increases and the increase in our employee headcount for research and development. In addition, such increase was also due to the increases in other expenses and professional service fees, both of which were related to the increase in our research and development activities. For example, in 2020, we have developed and launched a set of intelligent consultation service. For details, see “Business — Our Competitive Strengths — Industry-Leading Technology.”

Net Impairment Losses on Financial Assets

Our net impairment losses on financial assets increased from RMB34,000 in 2019 to RMB0.5 million in 2020 based on our assessment of the recoverability of certain trade and other receivables.

Other Income

Our other income increased from RMB1.4 million in 2019 to RMB6.3 million in 2020, primarily due to the government grants received in 2020. These government grants were primarily comprised of hiring subsidies and economic subsidies.

Other Gains and Losses – Net

Our net other expenses and losses increased from RMB3.4 million in 2019 to RMB7.7 million in 2020, primarily due to losses on disposal of property, plant and equipment and donation to Wuhan during the COVID-19 epidemic.

Finance Costs – Net

Our net finance costs increased from RMB26.5 million in 2019 to RMB35.3 million in 2020, primarily due to an increase in interest expenses for lease liabilities, and was partially offset by an increase in interest income on bank deposit.

Income Tax Expense

Our income tax expenses increased from RMB35.9 million in 2019 to RMB67.6 million in 2020, primarily due to an increase in our profit before income tax.

FINANCIAL INFORMATION

Profit for the Year

As a result of the above, our net profit increased significantly from RMB35.6 million in 2019 to RMB163.3 million in 2020.

Year Ended December 31, 2019 Compared with Year Ended December 31, 2018

Revenue

Our revenue increased from RMB934.3 million in 2018 to RMB1,224.5 million in 2019.

Revenue from Hair Transplant Services

Our revenue from hair transplant services increased from RMB918.0 million in 2018 to RMB1,197.8 million in 2019. Such growth was supported by the increase in the number of hair transplant patients. The number of hair transplant patients increased from 35,177 in 2018 to 43,087 in 2019, representing significant growth of approximately 22.5%.

Revenue from Medical Hair Care Services

We started to develop our medical hair care services in 2019 and recorded revenue of RMB15.1 million in the same year. We plan to quickly penetrate into the medical hair care market by offering full-cycle medical hair care services. In particular, we started to offer service packages in our clinics to meet the hair-related demands from different customers.

Revenue from Other Services

Our revenue from other services decreased from RMB16.3 million in 2018 to RMB11.6 million in 2019. Such decrease was primarily due to the store integration, as we closed three *Svenson* stores in 2019 and started to establish “*Svenson Medical Hair Care Centers* (史雲遜健髮中心)” in our hair transplant clinics.

Cost of Sales and Services

Our cost of sales and services increased from RMB232.2 million in 2018 to RMB335.4 million in 2019, primarily due to (i) an increase in staff costs as a result of salary increases and an increase in our employee headcount to support our business operation; (ii) an increase in amortization and depreciation charges due to the increase in amortization of property, plant and equipment and depreciation of right-of-use assets both of which were related to our clinic network expansion; and (iii) an increase in cost of inventories and consumables.

Gross Profit and Gross Profit Margin

Our gross profit increased from RMB702.1 million in 2018 to RMB889.1 million in 2019; our gross profit margin decreased from 75.2% in 2018 to 72.6% in 2019. The decrease in gross profit margin was primarily due to the increased amortization and depreciation charges as a result of our clinic network expansion.

FINANCIAL INFORMATION

Hair Transplant Services

Our gross profit from hair transplant services increased from RMB703.8 million in 2018 to RMB886.7 million in 2019, primarily due to the continued business growth of our hair transplant services. The number of hair transplant patients increased from 35,177 in 2018 to 43,087 in 2019, representing significant growth of approximately 22.5%. Our gross profit margin decreased from 76.7% in 2018 to 74.0% in 2019 primarily due to our rapid clinic expansion and upgrade in 2019 as we recorded significant amount of amortization and depreciation charges at their initial stage of operations.

Medical Hair Care Services

We started to generate revenue in medical hair care services under *Svenson Medical Hair Care Centers* and recorded gross profit of RMB4.8 million and gross profit margin of 32.0%.

Other Services

Our gross loss from other services increased from RMB1.6 million to RMB2.4 million, corresponding with the increase of gross loss margin from 10.1% to 20.8% in 2018 and 2019, respectively. The increases in gross loss and gross loss margin were primarily due to our business integration where we closed several *Svenson* stores and began to establish shop-in-shop model.

Selling and Marketing Expenses

Our selling and marketing expenses increased from RMB463.7 million in 2018 to RMB650.3 million in 2019, primarily due to (i) an increase in staff costs due to the increase in our sales and marketing employee headcount in line with our regional marketing strategies to expand our operations to other cities; (ii) an increase in marketing and promotion expenses as we further diversified our advertising channels; and (iii) an increase in operation related expenses, as we expand our sales and marketing team to other cities in China. In particular, besides performance-based advertisements, we started increasing the usage of brand advertising in 2019 to enhance our brand recognition.

General and Administrative Expenses

Our general and administrative expenses increased from RMB94.0 million in 2018 to RMB130.0 million in 2019, primarily due to (i) an increase in staff costs due to the salary increases and the increase in our employee headcount for administration in line with our clinic network expansion and (ii) an increase in other expenses due to the increase in bank transaction fees in line with our business growth.

Research and Development Expenses

Our research and development expenses increased from RMB7.8 million in 2018 to RMB8.9 million in 2019, primarily due to an increase in staff costs as a result of salary increases and the increase in our employee headcount for research and development.

FINANCIAL INFORMATION

Net Impairment Losses on Financial Assets

Our net impairment losses on financial assets decreased from RMB1.6 million in 2018 to RMB34,000 in 2019, based on our assessment of the recoverability of certain trade and other receivables. We recorded relatively higher net impairment losses on financial assets in 2018 mainly due to the movement in loss allowance of certain deposits and other receivables.

Other Income

Our other income increased from RMB0.9 million in 2018 to RMB1.4 million in 2019, primarily due to the VAT additional deduction.

Other Gains and Losses – Net

Our net other expenses and losses decreased from RMB7.0 million in 2018 to RMB3.4 million in 2019, primarily because of (i) a decrease in losses on disposal of property, plant and equipment and (ii) a decrease in penalty, and certain of these losses were one-off expenses.

Finance Costs – Net

Our net finance costs increased from RMB17.7 million in 2018 to RMB26.5 million in 2019, primarily due to an increase in interest expenses for lease liabilities.

Income Tax Expense

Our income tax expense decreased from RMB57.8 million in 2018 to RMB35.9 million in 2019, due to a decrease in our profit before income tax.

Profit for the Year

As a result of the above, our profit for the year decreased from RMB53.5 million in 2018 to RMB35.6 million in 2019.

FINANCIAL INFORMATION

DISCUSSION OF CERTAIN SELECTED ITEMS FROM THE CONSOLIDATED BALANCE SHEETS

The table below sets forth selected information from our consolidated Balance Sheets as of the dates indicated:

	As of December 31,			As of June 30,
	2018	2019	2020	2021
	<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>
ASSETS				
Non-current assets				
Property, plant and equipment	168,158	231,136	309,437	380,720
Right-of-use assets	398,862	494,985	810,653	761,324
Intangible assets	1,398	3,307	3,547	34,148
Deferred income tax assets	12,517	20,853	29,012	32,735
Prepayments, deposits and other receivables	863	2,499	4,095	2,216
Total non-current assets	<u>581,798</u>	<u>752,780</u>	<u>1,156,744</u>	<u>1,211,143</u>
Current assets				
Inventories	14,255	14,486	26,996	44,496
Trade receivables	9,805	5,859	10,330	6,929
Prepayments, deposits and other receivables	60,111	68,299	107,430	131,626
Restricted cash	–	–	–	149,500
Cash and cash equivalents	68,476	89,789	292,856	453,100
Total current assets	<u>152,647</u>	<u>178,433</u>	<u>437,612</u>	<u>785,651</u>
Total assets	<u>734,445</u>	<u>931,213</u>	<u>1,594,356</u>	<u>1,996,794</u>
EQUITY				
Equity attributable to owners of the Company				
Share capital	–	–	–	7
Other reserves	150,365	150,365	153,971	241,798
Retained earnings	53,131	88,755	252,087	292,528
Total equity	<u>203,496</u>	<u>239,120</u>	<u>406,058</u>	<u>534,333</u>

FINANCIAL INFORMATION

	As of December 31,			As of June 30,
	2018	2019	2020	2021
	RMB'000	RMB'000	RMB'000	RMB'000
LIABILITIES				
Non-current liabilities				
Lease liabilities	324,932	411,172	682,879	644,381
Deferred income tax liabilities	794	193	219	964
Total non-current liabilities	325,726	411,365	683,098	645,345
Current liabilities				
Borrowings	–	44,827	25,870	214,395
Trade and other payables	62,469	77,098	138,232	212,006
Contract liabilities	16,892	23,354	120,423	181,792
Income tax liabilities	50,481	38,581	73,624	50,944
Lease liabilities	75,381	96,868	147,051	157,979
Total current liabilities	205,223	280,728	505,200	817,116
Total liabilities	530,949	692,093	1,188,298	1,462,461
Net current liabilities	52,576	102,295	67,588	31,465

Property, Plant and Equipment

Our property, plant and equipment primarily consist of medical treatment and safety infrastructure and leasehold improvement, medical equipment, office fixtures and motor vehicles. Our property, plant and equipment increased from RMB168.2 million as of December 31, 2018 to RMB231.1 million as of December 31, 2019 to RMB309.4 million as of December 31, 2020 and further to RMB380.7 million as of June 30, 2021, primarily due to the increase in medical treatment and safety infrastructure and leasehold improvement as a result of our clinic network expansion and upgrade.

Right-of-use Assets

Our right-of-use assets are primarily related to our leased premises used in our operations. Our right-of-use assets increased from RMB398.9 million as of December 31, 2018 to RMB495.0 million as of December 31, 2019 and further to RMB810.7 million as of December 31, 2020, primarily because we leased more premises as hair transplant clinics and offices in 2019 and 2020. Our right-of-use assets decreased from RMB810.7 million as of December 31, 2020 to RMB761.3 million as of June 30, 2021, primarily due the certain lease expiration during this period.

FINANCIAL INFORMATION

Inventories

Our inventories primarily consist of (i) pharmaceuticals and medical consumables used in our hair transplant services; (ii) medical hair care consumables represented the consumables used in providing hair care services; and (iii) wash and hair care products that customers can purchase and use at home. We had inventories of RMB14.3 million, RMB14.5 million, RMB27.0 million, and RMB44.5 million as of December 31, 2018, 2019, 2020, and June 30, 2021, respectively. The following table sets forth our inventories as of the date indicated:

	As of December 31,			As of June 30,
	2018	2019	2020	2021
	RMB'000	RMB'000	RMB'000	RMB'000
Pharmaceuticals and medical consumables	9,618	7,355	11,305	13,788
Medical hair care consumables	729	956	8,621	14,493
Wash and hair care products	2,731	4,422	3,876	10,546
Others ⁽¹⁾	1,177	1,753	3,194	5,669
<i>Less: allowance for impairment of inventories</i>	—	—	—	—
Total	14,255	14,486	26,996	44,496

Note:

(1) primarily include stationery and office supplies.

Our inventories remained relatively stable from RMB14.3 million as of December 31, 2018 to RMB14.5 million as of December 31, 2019. In particular, our inventories of pharmaceuticals and medical consumables decreased from RMB9.6 million as of December 31, 2018 to RMB7.4 million as of December 31, 2019, primarily because we implemented a set of more stringent inventory control measures and more refined supply chain management system in 2019. Our inventories for wash and hair care products increased from RMB2.7 million as of December 31, 2018 to RMB4.4 million as of December 31, 2019, primarily due to the business development of our medical hair care services and other services. As of December 31, 2020, our inventories increased to RMB27.0 million primarily due to (i) an increase in medical hair care consumables in line with the increased procurements to support the growth of medical hair care services and (ii) an increase in pharmaceuticals and medical consumables as we strategically procured more pharmaceuticals and medical consumables in anticipation of the impact of the COVID-19 pandemic. As of June 30, 2021, our inventories increased to RMB44.5 million, primarily due to the increases in wash and hair care products and medical hair care consumables, both of which were in line with our business growth. In particular, we procured more wash and hair care products in 2021 as we switched an existing domestic supplier to an overseas supplier for better price and product iteration. In anticipation of the transportation and custom clearance, we strategically increased our inventories.

FINANCIAL INFORMATION

The following table sets forth the number of our inventory turnover days for the periods indicated:

	Year Ended December 31,			Six Months Ended June 30,
	2018	2019	2020	2021
Inventory turnover days ⁽¹⁾	15.5	15.6	18.2	23.1

Note:

- (1) *inventory turnover days was calculated based on the average of opening and closing inventory balance for the relevant year/period, divided by the cost of sales for the same year/period, and multiplied by 365 days for 2018, 2019 and 2020 and 180 days for the six months ended June 30, 2021.*

Our inventory turnover days remained stable of 15.5 days and 15.6 days as of December 31, 2018 and 2019, respectively. Our inventory turnover days increased from 15.6 days as of December 31, 2019 to 18.2 days as of December 31, 2020, which was primarily due to an increase in procurement of inventories and consumables in line with our business expansion. In addition, in anticipation of the impact of the COVID-19 pandemic, we strategically procured more pharmaceuticals and medical consumables to control the potential shortage of consumables. Our inventory turnover days further increased to 23.1 as of June 30, 2021, primarily due to the increase in procurement in line with our business growth. In particular, we procured more wash and hair products due to the switch of an supplier.

As of October 31, 2021, approximately RMB30.1 million, or 67.7%, of our inventories as of June 30, 2021 had been delivered or consumed.

Trade Receivables

During the Track Record Period, our trade receivables comprised the payment made by customers but not yet received from financial institution or third-party payment platforms. The following table sets forth the details of our trade receivables as of the dates indicated:

	As of December 31,			As of June 30,
	2018	2019	2020	2021
	RMB'000	RMB'000	RMB'000	RMB'000
Trade receivables				
Trade receivables from contracts with customers	9,871	5,887	10,409	6,982
<i>Less: allowance for impairment of trade receivables</i>	(66)	(28)	(79)	(53)
Subtotal	9,805	5,859	10,330	6,929

FINANCIAL INFORMATION

Our trade receivables fluctuated during the Track Record Period and was substantially affected by the volume of the surgeries on the last day of the year. Due to the public holiday schedule in 2018 and 2020, we had more customers on the last day of 2018 and 2020, and recorded relatively large amount of trade receivables.

The following table sets forth the number of our trade receivables turnover days for the periods indicated:

	Year Ended December 31,			Six Months Ended June 30,
	2018	2019	2020	2021
Trade receivables turnover days ⁽¹⁾	3.4	2.3	1.8	1.5

Note:

- (1) trade receivables turnover days was calculated based on the average of opening and closing balance of trade receivables less allowance for impairment for the relevant year/period, divided by the revenue for the same year/period and multiplied by 365 days for 2018, 2019 and 2020 and 180 days for the six months ended June 30, 2021.

In 2018, 2019, 2020, and the six months ended June 30, 2021, our trade receivables turnover days decreased from 3.4 days to 2.3 days and to 1.8 days and further to 1.5 days primarily due to the volume of the surgeries on the last day of the year or period. Generally, our customers are required to make payments prior to or at the time of providing services with no credit term. For third-party payment platforms, we grant credit terms on an individual basis with credit period within 15 days. We have established a credit control department to minimize our credit risk and maintain control over our outstanding receivables. Our management regularly review the settlement situations of customers with relatively long credit periods. The following table sets forth an aging analysis of our trade receivables as of the dates indicated presented based on invoice date:

	As of December 31,			As of June 30,
	2018	2019	2020	2021
	<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>
– Up to 3 months	9,871	5,861	10,403	6,982
– 3 to 6 months	–	12	6	–
– 6 months to 1 year	–	14	–	–
<i>Less: allowance for impairment of inventories</i>	<i>(66)</i>	<i>(28)</i>	<i>(79)</i>	<i>(53)</i>
Total	9,805	5,859	10,330	6,929

As of October 31, 2021, approximately RMB69.1 million, or 99.8%, of our trade receivables as of June 30, 2021 had been settled.

FINANCIAL INFORMATION

Prepayments, Deposits and Other Receivables

During the Track Record Period, our prepayments, deposits, and other receivables primarily consisted of (i) prepayments for advertising and information technology service fees to third parties for marketing and promotional related activities; (ii) security deposits for rentals and advertising services; (iii) receivables in relation to rental deposits and other rental related payments yet refunded and (iv) prepaid rental and property management fees. The following table sets forth the details of our prepayments, deposits, and other receivables as of the dates indicated:

	As of December 31,			As of June 30,
	2018	2019	2020	2021
	RMB'000	RMB'000	RMB'000	RMB'000
Prepayments				
Advertising and information technology service fees	19,416	22,826	37,454	27,321
Prepaid rental and property management fees	6,602	2,982	5,342	13,559
Professional and agency service fees	5,654	1,038	2,315	5,939
Capitalization of listing expenses	—	—	—	2,339
Purchase of inventory	1,179	2,366	4,441	13,629
Others ⁽¹⁾	1,100	2,087	2,473	1,620
<i>Subtotal</i>	<i>33,951</i>	<i>31,299</i>	<i>52,025</i>	<i>64,407</i>
Deductible input VAT	652	574	3,367	7,279
Other receivables				
Deposits	22,468	28,828	43,606	54,954
Cash advance to employees	1,120	590	479	2,698
Amount due from related party	36	110	133	—
Considerations of disposal subsidiaries	1,800	150	—	—
Others				
– Receivables in relation to early-termination of a property lease ⁽²⁾	—	6,431	6,431	—
– Social insurance plans and housing provident funds withholding ⁽³⁾	905	1,336	2,296	3,338
– Petty cash in relation to customer services ⁽⁴⁾	29	31	—	557
– Others ⁽⁵⁾	1,120	992	1,571	1,273
<i>Less: provision for impairment of other receivables⁽⁶⁾</i>	<i>(1,970)</i>	<i>(2,042)</i>	<i>(2,478)</i>	<i>(2,880)</i>
<i>Subtotal</i>	<i>25,508</i>	<i>36,426</i>	<i>52,038</i>	<i>59,940</i>
Total	60,111	68,299	107,430	131,626

Notes:

(1) primarily included prepaid utilities and energy fees.

FINANCIAL INFORMATION

- (2) represented the receivables from a landlord due to the early termination of a property lease. Such amount was fully settled in June 2021. For details, see “— Description of Selected Components of Consolidated Statements of Comprehensive Income — Other Gains and Losses – Net” in this section.
- (3) represented the advance payments we made on behalf of our employees to contribute their housing provident funds and social securities. The recognition of such receivables was due to the different timeline between certain employees’ monthly payroll and monthly deadline for contributions of housing provident funds and the social securities. In general, such advances will be deducted and subsequently settled by employees’ wages in the next month.
- (4) represented the petty cash used for customer services such as purchasing drinking water or snacks for customers.
- (5) primarily represented the incidental or one-time receivables in relation to business operation.
- (6) we make periodic assessments and individual assessments on the recoverability based on the historical settlement records and past experience. The expected credit losses also incorporate forward-looking information. For details, see Note 19(c) to the Accountant’s Report in Appendix I to this prospectus.

Our prepayments, deposits, and other receivables increased from RMB60.1 million as of December 31, 2018 to RMB68.3 million as of December 31, 2019 primarily due to (i) an increase in deposits as a result of our clinic network expansion; (ii) an increase in receivables in relation to rental deposits and other rental related payments yet refunded. Such receivables were fully settled in June 2021; and (iii) an increase in advertising and information technology services fees due to our increased demands for advertising and information related services. Such increase was partially offset by decreases in professional and agency service fees and repaid rental and property management fees for the same period.

Our prepayments, deposits, and other receivables further increased from RMB68.3 million as of December 31, 2019 to RMB107.4 million as of December 31, 2020, primarily due to (i) an increase in advertising and information technology services fees as a result of our increased demands for advertising and information related services and (ii) an increase in deposits as a result of our clinic network expansion and deposits for certain sales and marketing services.

Our prepayments, deposits, and other receivables further increased from RMB107.4 million as of December 31, 2020 to RMB131.6 million as of June 30, 2021, primarily due to (i) an increase in purchase of inventory due to the increased procurement for wash and hair products from an overseas supplier and the growth of our wig business; (ii) an increase in deposits as a result of deposits for sales and marketing activities and deposits for lease in relation to business growth and clinic expansion.

FINANCIAL INFORMATION

Restricted Cash

During the Track Record Period, we had restricted cash of RMB149.5 million as of June 30, 2021, consisted of restricted deposits held at the relevant lenders as security corresponding to certain of our bank borrowings that were repayable within one year. Such restricted cash were pledged as collateral for our foreign currency borrowings of the USD equivalent of RMB120.2 million. Such foreign currency borrowings were used to pay the consideration for the shares transfer of Beijing Haiyouyou during our Reorganization. For details, see Note 24(b) to the Accountant's Report in Appendix I to this prospectus.

Cash and Cash Equivalents

Our cash and cash equivalents primarily consisted of bank deposits and cash on hand. The following table sets forth a breakdown of our cash and cash equivalents as of the dates indicated:

	As of December 31,			As of June 30,
	2018	2019	2020	2021
	RMB'000	RMB'000	RMB'000	RMB'000
Bank deposits	68,260	89,705	292,763	452,898
Cash on hand	216	84	93	202
Total	68,476	89,789	292,856	453,100

Our cash and cash equivalents increased from RMB68.5 million as of December 31, 2018 to RMB89.8 million as of December 31, 2019, which was primarily attributable to the increase in net cash generated from operating activities. Our cash and cash equivalents further increased significantly from RMB89.8 million as of December 31, 2019 to RMB292.9 million as of December 31, 2020. Such increase was primarily attributable to a combination of the increase in business expansion and the advance payments made by customers in relation to hair care services. Our cash and cash equivalents increased from RMB292.9 million as of December 31, 2020 to RMB453.1 million as of June 30, 2021, which was primarily attributable to (i) an increase in net cash generated from operating activities; (ii) an increase in capital; and (iii) an increase in bank borrowings.

FINANCIAL INFORMATION

Trade and Other Payables

Our trade payables primarily consist of payments we owed to third parties in relation to renovation of our offices and hair transplant clinics, rental expenses and promotion expenses payable to third-party marketing service providers. Our other payables primarily consisted of (i) accrued employee benefits representing salaries and bonuses to be paid to our employees; (ii) refund liabilities for sales returns and quality assurance; (iii) accrued expenses in relation to daily operation; and (iv) tax payables. The following table sets forth the details of our trade and other payables as of the dates indicated:

	As of December 31,			As of June 30,
	2018	2019	2020	2021
	RMB'000	RMB'000	RMB'000	RMB'000
Trade payable	16,574	22,545	44,676	66,645
Accrued employee benefits	26,856	32,226	71,077	74,962
Refund liabilities	3,935	5,024	7,581	11,253
Accrued expenses	4,738	2,283	4,219	6,074
Tax payable	4,039	5,928	3,555	19,809
Security deposit	3,079	3,178	3,135	4,467
Amount due to related party	785	749	30	25,886
Others ⁽¹⁾	2,463	5,165	3,959	2,910
Total	62,469	77,098	138,232	212,006

Note: represented tax transaction payables and security insurance withholding payables

Our trade and other payables increased from RMB62.5 million as of December 31, 2018 to RMB77.1 million as of December 31, 2019, which was primarily attributable to (i) an increase in trade payable in relation to renovation of our offices and (ii) an increase in accrued employee benefits due to an increase in the number of our employees. Our trade and other payables further increased to RMB138.2 million as of December 31, 2020, which was primarily attributable to (i) an increase in trade payable in relation to renovation of our offices and promotion expenses payable to third-party marketing service providers and (ii) an increase in accrued employee benefits due to an increase in the number of our employees, partially offset by a decrease in tax payable. Our trade and other payables further increased to RMB212.0 million as of June 30, 2021, which was primarily attributable to (i) an increase in amounts due to related parties in relation to the acquisition of Nu/Hart Hair; (ii) an increase in tax payables as certain of our medical hair care services were eligible for preferential tax treatments in 2020 due to the COVID-19, but such tax treatments were ceased in 2021 and (iii) an increase in trade payable as a result of the increased purchase of marketing services in line with our business growth and better payment terms granted by certain of our suppliers.

FINANCIAL INFORMATION

The following table sets forth an aging analysis of our trade payables as of the dates indicated based on the invoice date:

	As of December 31,			As of June 30,
	2018	2019	2020	2021
	RMB'000	RMB'000	RMB'000	RMB'000
Up to 3 months	14,649	16,579	37,948	57,512
– 3 to 6 months	1,322	4,796	3,851	3,654
– 6 months to 1 year	400	845	2,344	4,307
– 1 to 2 years	138	260	408	1,172
– Over 2 years	65	65	125	–
Total	16,574	22,545	44,676	66,645

The following table sets forth the number of our trade payables turnover days for the periods indicated:

	Year Ended December 31,			Six Months Ended June 30,
	2018	2019	2020	2021
Trade payables turnover days ⁽¹⁾	26.7	21.3	29.4	36.0

Note:

(1) trade payables turnover days was calculated based on the average of opening and closing balance of trade payables for the relevant year/period, divided by the cost of sales for the same year/period, and multiplied by 365 days for 2018, 2019 and 2020 and 180 days for the six months ended June 30, 2021.

Our trade payables turnover days were 26.7 days, 21.3 days, 29.4 days, and 36.0 days in 2018, 2019, 2020, and the six months ended June 30, 2021, respectively. Our trade payables turnover days decreased from 26.7 days in 2018 to 21.3 days in 2019, primarily due to the settlement of trade payables with certain suppliers. Our trade payables turnover days increased from 21.3 days in 2019 to 29.4 days in 2020. Such increase was primarily due to the increased bargaining power as we negotiated relatively longer credit periods with our suppliers during this period. Our trade payables turnover days increased from 29.4 days in 2020 to 36.0 days for the six months ended June 30, 2021 as a result of the increased purchase of marketing services and better payment terms granted by certain of our suppliers.

As of October 31, 2021, approximately RMB51.5 million, or 77.3%, of our trade payables as of June 30, 2021 had been settled.

FINANCIAL INFORMATION

Contract Liabilities

Our contract liabilities primarily represent advanced payments received from customers for services or products that had not yet been provided to the customers. Our contract liabilities increased from RMB16.9 million as of December 31, 2018 to RMB23.4 million as of December 31, 2019, which was generally in line with our business growth. In particular, our contract liabilities increased significantly to RMB120.4 million as of December 31, 2020, which was primarily in relation to the medical hair care services we rendered, where we offered hair care services in service components. The following table sets forth a breakdown of our contract liabilities as of the dates indicated:

	As of December 31,			As of June 30,
	2018	2019	2020	2021
	RMB'000	RMB'000	RMB'000	RMB'000
Contract liabilities				
– Hair transplant services	6,223	8,375	11,196	11,850
– Medical hair care services	–	4,054	97,706	159,749
– Other	10,669	10,925	11,521	10,193
Total	16,892	23,354	120,423	181,792

The following table sets forth the revenue recognized during the Track Record Period relating to carried-forward contract liabilities:

	Year Ended December 31,			Six Months Ended June 30,	
	2018	2019	2020	2020	2021
	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
				(unaudited)	
Hair transplant services	2,221	3,083	3,075	2,711	3,935
Medical hair care services	–	–	3,285	2,563	64,902
Other	3,976	4,880	3,179	1,211	2,434
Total	6,197	7,963	9,539	6,485	71,271

As of October 31, 2021, approximately RMB105.4 million, or 58.0%, of our contract liabilities as of June 30, 2021 had been recognized as revenue.

LIQUIDITY AND CAPITAL RESOURCES

Overview

Our principal use of cash during the Track Record Period was for working capital purposes. Our main source of liquidity has been generated from cash flow from operation. Going forward, we believe

FINANCIAL INFORMATION

that our liquidity requirements will be satisfied with a combination of cash flows generated from our operating activities, bank facilities and net proceeds from the Global Offering. As of June 30, 2021, we had cash and cash equivalents of RMB453.1 million.

Taking into account the financial resources available to us, including cash flow from operating activities and the estimated net proceeds from the Global Offering, our Directors are of the view that we have sufficient working capital to meet our present requirements and for the next 12 months from the date of this prospectus.

As of the Latest Practicable Date, we had unutilized banking facilities of RMB15.8 million.

Cash Flows

The following table sets forth our consolidated statements of cash flows for the periods indicated:

	Year Ended December 31,			Six Months Ended June 30,	
	2018	2019	2020	2020	2021
	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
Cash generated from operations before movements in working capital	218,011	228,529	437,159	191,197	215,732
Changes in working capital	(5,181)	10,477	104,144	22,622	74,918
Cash generated from operations	212,830	239,006	541,303	213,819	290,650
Interests received on bank deposits	139	210	941	218	2,408
Income tax paid	(18,402)	(56,736)	(40,673)	(40,146)	(74,744)
Net cash flows generated from operating activities	194,567	182,480	501,571	173,891	218,314
Net cash flows used in investing activities	(102,789)	(105,352)	(142,388)	(44,802)	(97,174)
Net cash flows (used in)/from financing activities	(69,689)	(55,815)	(156,116)	(83,877)	38,341
Net increase in cash and cash equivalents	22,089	21,313	203,067	45,212	159,481
Cash and cash equivalents at beginning of the year	46,387	68,476	89,789	89,789	292,856
Exchange gains on cash and cash equivalents	—	—	—	—	763
Cash and cash equivalents at end of the year	68,476	89,789	292,856	135,001	453,100

FINANCIAL INFORMATION

Net Cash Flows Generated from Operating Activities

For the six months ended June 30, 2021, our net cash generated from operating activities was RMB218.3 million, which was primarily attributable to our profit before income tax of RMB88.9 million, adjusted for non-cash and non-operating items. Positive adjustments for non-cash and non-operating items primarily included depreciation and amortization of RMB97.1 million, net finance costs of RMB20.3 million and listing expenses of RMB8.6 million. The amount was then further adjusted positively by changes in working capital, primarily including an increase in contract liabilities of RMB61.1 million and an increase in trade and other payables of RMB47.6 million, partially offset by an increase in inventories of RMB17.5 million and an increase in trade and other receivables of RMB16.4 million. The amount was then adjusted negatively by income tax paid of RMB74.7 million.

In 2020, our net cash generated from operating activities was RMB501.6 million, which was primarily attributable to our profit before income tax of RMB230.9 million, adjusted for non-cash and non-operating items. Positive adjustments for non-cash and non-operating items primarily included depreciation and amortization of RMB159.1 million, losses on disposal of property, plant and equipment of RMB4.0 million, and net finance costs of RMB35.3 million. The amount was then further adjusted positively by changes in working capital, primarily including an increase in contract liabilities of RMB97.1 million, and an increase in trade and other payables of RMB65.4 million, partially offset by an increase in trade and other receivables of RMB45.8 million and an increase in inventories of RMB12.5 million. The amount was then adjusted negatively by income tax paid of RMB40.7 million.

In 2019, our net cash generated from operating activities was RMB182.5 million, which was primarily attributable to our profit before income tax of RMB71.5 million, adjusted for non-cash and non-operating items. Positive adjustments for non-cash and non-operating items primarily included depreciation and amortization of RMB129.7 million and net finance costs of RMB26.5 million. The amount was then further adjusted positively by changes in working capital, primarily including an increase in trade and other payables of RMB11.8 million and an increase in contract liabilities of RMB6.5 million, partially offset by an increase in trade and other receivables of RMB7.6 million. The amount was then adjusted negatively by income tax paid of RMB56.7 million.

In 2018, our net cash generated from operating activities was RMB194.6 million, which was primarily attributable to our profit before income tax of RMB111.3 million, adjusted for non-cash and non-operating items. Positive adjustments for non-cash and non-operating items primarily included depreciation and amortization of RMB84.4 million. The amount was then adjusted negatively by changes in working capital, primarily including an increase in inventories of RMB8.8 million and a decrease in trade and other payables of RMB5.0 million, partially offset by a decrease in trade and other receivable of RMB8.6 million. The amount was then adjusted negatively by income tax paid of RMB18.4 million.

FINANCIAL INFORMATION

Net Cash Flows Used in Investing Activities

For the six months ended June 30, 2021, our net cash used in investing activities was RMB97.2 million, primarily as a result of (i) purchases of property, plant and equipment of RMB92.5 million; (ii) payment for acquisition of subsidiary of RMB3.8 million and (iii) purchase of intangible assets of RMB1.0 million.

In 2020, our net cash used in investing activities was RMB142.4 million, primarily as a result of purchases of property, plant and equipment of RMB142.2 million.

In 2019, our net cash used in investing activities was RMB105.4 million, primarily as a result of (i) purchases of property, plant and equipment of RMB105.8 million and (ii) purchase of intangible assets of RMB2.3 million, and partially offset by proceeds from disposals of subsidiaries of RMB2.8 million.

In 2018, our net cash used in investing activities was RMB102.8 million, primarily as a result of purchases of property, plant and equipment of RMB135.4 million, and purchase of intangible assets of RMB1.3 million, and partially offset by disposal of financial assets at fair value through profit or loss of RMB30.3 million, and proceeds from disposals of subsidiaries of RMB3.3 million.

Net Cash Flows Used in Financing Activities

For the six months ended June 30, 2021, our net cash generated from financing activities was RMB38.3 million, primarily as a result of proceeds from borrowings of RMB232.7 million and capital contribution from shareholder of RMB88.7 million, and partially offset by restricted cash of guarantee for borrowings of RMB149.5 million, payment of lease liabilities of RMB77.6 million, repayment of borrowings of RMB45.9 million and payments of listing expenses of RMB9.0 million.

In 2020, our net cash used in financing activities was RMB156.1 million, primarily as a result of payment of lease liabilities of RMB132.3 million, repayment of borrowings of RMB47.8 million and interest paid of RMB1.5 million, and partially offset by proceeds from borrowings of RMB28.9 million.

In 2019, our net cash used in financing activities was RMB55.8 million, primarily as a result of payment of lease liabilities of RMB99.4 million and interest paid of RMB1.3 million, and partially offset by proceeds from borrowings of RMB44.8 million.

In 2018, our net cash used in financing activities was RMB69.7 million, primarily as a result of payment of lease liabilities of RMB69.7 million.

FINANCIAL INFORMATION

Net Current Assets/Liabilities

	As of December 31,			As of June 30,	As of October 31,
	2018	2019	2020	2021	
	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000 (unaudited)
Current assets:					
Inventories	14,255	14,486	26,996	44,496	51,540
Trade receivables	9,805	5,859	10,330	6,929	26,042
Prepayments, deposits and other receivables	60,111	68,299	107,430	131,626	158,447
Restricted cash	–	–	–	149,500	149,500
Cash and cash equivalents	68,476	89,789	292,856	453,100	422,266
Total current assets	152,647	178,433	437,612	785,651	807,795
Total assets	734,445	931,213	1,594,356	1,996,794	2,149,010
Current liabilities:					
Borrowings	–	44,827	25,870	214,395	193,104
Trade and other payables	62,469	77,098	138,232	212,006	218,739
Contract liabilities	16,892	23,354	120,423	181,792	181,454
Income tax liabilities	50,481	38,581	73,624	50,944	70,170
Lease liabilities	75,381	96,868	147,051	157,979	177,930
Total current liabilities	205,223	280,728	505,200	817,116	841,397
Total liabilities	530,949	692,093	1,188,298	1,462,461	1,562,446
Net current liabilities	52,576	102,295	67,588	31,465	33,602

INDEBTEDNESS

Our indebtedness mainly included bank borrowings, amounts due to related parties and lease liabilities during the Track Record Period. Except as disclosed in the table below, we did not have any material mortgages, charges, debentures, loan capital, debt securities, loans, bank overdrafts or other similar indebtedness, finance lease or hire purchase commitments, liabilities under acceptances (other than normal trade bills), acceptance credits, which are either guaranteed, unguaranteed, secured or unsecured, or guarantees or other contingent liabilities as of October 31, 2021. After due and careful consideration, our Directors confirm that there had been no material adverse change in our indebtedness since October 31, 2021 and up to the Latest Practicable Date.

FINANCIAL INFORMATION

The following table sets forth a breakdown of our indebtedness as of the dates indicated:

	As of December 31,			As of June 30,	As of October 31,
	2018	2019	2020	2021	
	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000 (unaudited)
Current					
Bank borrowings:					
unsecured	–	44,827	25,870	94,173	74,173
Bank borrowings:					
secured	–	–	–	120,222	118,931
Amounts due to related					
parties (non-trade)	785	749	30	25,886	25,863
Lease liabilities	75,381	96,868	147,051	157,979	177,930
Non-current					
Lease liabilities	324,932	411,172	682,879	644,381	720,123
Total	<u>401,098</u>	<u>553,616</u>	<u>855,830</u>	<u>1,042,641</u>	<u>1,117,020</u>

Borrowings

Our bank loans and other borrowings during the Track Record Period were primarily used to supplement our working capital. During the Track Record Period, our bank loans bore interest at a rate equivalent to 1.79% to 6.5% per year. Certain of our bank loans were guaranteed by related parties and the guarantee from the related parties had been released in June 2021. For further details of these pledges, see Note 24 to the Accountant's Report in Appendix I to this prospectus.

Our Directors confirm that we have not defaulted in the repayment of the bank loans and other borrowings during the Track Record Period. Our Directors have confirmed that, as of the Latest Practicable Date, there was no material covenant on any of our outstanding debt and there was no breach of any covenants during the Track Record Period and up to the Latest Practicable Date. During the Track Record Period and up to the Latest Practicable Date, to the best knowledge of our Directors, we did not experience any difficulty in obtaining bank loans. As at the date of this Prospectus, we did not have any plan for material external debt financing. Given our credit history and our current credit status, we believe that we will not encounter any major difficulties in obtaining additional bank borrowings in the future.

Amounts due to Related Parties

As of December 31, 2018, 2019, 2020, June 30, 2021 and October 31, 2021, we had amounts due to related parties (non-trade) of RMB0.8 million, RMB0.7 million, RMB30,000, RMB25.9 million and RMB25.9 million, respectively. Save for the outstanding balance with Xinsiyu in relation to the acquisition of Nu/Hart Hair, we plan to settle the outstanding balances with other related parties, which were non-trade in nature, before Listing. The outstanding balance with Xinsiyu is expected to be settled upon Listing using proceeds from the Global Offering. See “Future Plans and Use of Proceeds — Use of Proceeds” for further details.

FINANCIAL INFORMATION

Lease Liabilities

The following table sets forth our lease liabilities as of the dates indicated:

	As of December 31,			As of	As of
	2018	2019	2020	June 30,	October 31,
	RMB'000	RMB'000	RMB'000	2021	RMB'000
					(unaudited)
Current	75,381	96,868	147,051	157,979	177,930
Non-current	324,932	411,172	682,879	644,381	720,123
Total	<u>400,313</u>	<u>508,040</u>	<u>829,930</u>	<u>802,360</u>	<u>898,053</u>

Our lease liabilities amounted to RMB400.3 million, RMB508.0 million, RMB829.9 million, RMB802.4 million, and RMB898.1 million as of December 31, 2018, 2019, 2020, June 30, 2021 and October 31, 2021, respectively, which were primarily in relation to the properties we leased for our office premises and hair transplant medical clinics. We recognize a lease liability with respect to all leases, except for short-term leases and leases of low value assets.

CAPITAL EXPENDITURES

We regularly incur capital expenditures to expand our operations, upgrade our facilities and increase our operating efficiency. Our capital expenditures represented payment for purchases of property, plant and equipment and payments for intangible assets during the Track Record Period. The following table sets forth our capital expenditures for the periods indicated:

	Year Ended December 31,			Six Months Ended
	2018	2019	2020	June 30,
	RMB'000	RMB'000	RMB'000	2021
				RMB'000
Payments for property, plant and equipment	135,424	105,808	142,204	92,462
Payments for intangible assets	<u>1,270</u>	<u>2,300</u>	<u>643</u>	<u>992</u>
Total	<u>136,694</u>	<u>108,108</u>	<u>142,847</u>	<u>93,454</u>

For the years ending December 31, 2021 and 2022, our planned capital expenditure is expected to be RMB335 million and RMB188 million, respectively, primarily relating to the purchase of equipment and payment of intangible assets. We plan to finance our future capital expenditures through cash generated from our operations, bank borrowings and proceeds from the Global Offering. Our actual capital expenditures may differ from the amounts set forth above due to various factors, including our future cash flows, results of operations and financial and market condition.

FINANCIAL INFORMATION

CONTRACTUAL OBLIGATIONS

Capital Commitments

As of December 31, 2018, 2019, 2020, and June 30, 2021, we had capital commitments of RMB12.1 million, RMB13.3 million, RMB73.5 million, and RMB26.0 million, respectively, primarily in connection with our medical treatment and safety infrastructure and leasehold improvement. In particular, due our clinic expansions, we recorded an increased amount of capital commitments resulted from medical treatment and safety infrastructure and leasehold improvement. The following table sets forth our capital commitments as of the date indicated:

	As of December 31,			As of June 30,
	2018	2019	2020	2021
	<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>
Medical treatment and safety infrastructure and leasehold improvement	11,672	13,099	72,346	25,863
Property, plant and equipment	2	151	1,112	125
Intangible assets	470	—	—	—
Total	12,144	13,250	73,458	25,988

Lease Commitments

We entered into short-term leases primarily for employee dormitories. As of December 31, 2018, 2019, 2020 and June 30, 2021, the outstanding lease commitment relating to these premises was RMB8.1 million, RMB8.2 million, RMB3.8 million and RMB5.8 million, respectively.

CONTINGENT LIABILITIES

As of December 31, 2018, 2019, 2020, and June 30, 2021, we did not have any material contingent liabilities. We confirm that as of the Latest Practicable Date, there had been no material changes or arrangements to our contingent liabilities.

OFF-BALANCE SHEET COMMITMENTS AND ARRANGEMENTS

As of the Latest Practicable Date, we had not entered into any off-balance sheet transactions.

FINANCIAL INFORMATION

KEY FINANCIAL RATIOS

The table below sets forth the key financial ratios for the periods or as of the dates indicated:

	As of/For the Year Ended December 31,			As of/ For the Six Months Ended June 30,
	2018	2019	2020	2021
Return on average equity ⁽¹⁾	30.3%	16.1%	50.6%	17.2% ⁽⁷⁾
Return on average assets ⁽²⁾	8.5%	4.3%	12.9%	4.5% ⁽⁷⁾
Current ratio ⁽³⁾	0.74	0.64	0.87	0.96
Quick ratio ⁽⁴⁾	0.67	0.58	0.81	0.91
Gearing ratio ⁽⁵⁾	N/M ⁽⁶⁾	0.19	0.06	0.40

Notes:

- (1) Equals profit for the year/period divided by average balance of total equity attributable to owners of the Company at the beginning and the end of that year/period and multiplied by 100%.
- (2) Equals profit for the year/period divided by average balance of total assets at the beginning and the end of that year/period and multiplied by 100%.
- (3) Equals current assets divided by current liabilities as of the same date.
- (4) Equals current assets less inventories and divided by current liabilities as of the same date.
- (5) Equals bank loans and other borrowings divided by total equity as of the same date.
- (6) As of December 31, 2018, the Group had no bank loans or other borrowings, so the gearing ratio as of that date is not meaningful.
- (7) Calculated based on annualized basis.

Our return on average equity decreased from 30.3% as of December 31, 2018 to 16.1% as of December 31, 2019 primarily due to (i) a decrease in our profit from the year of 2018 to the year of 2019; and (ii) an increase in total equity resulting from the growth of retained earnings. Our return on average equity increased from 16.1% as of December 31, 2019 to 50.6% as of December 31, 2020 primarily due to an increase in our profit from the year of 2019 to the year of 2020. Our return on average equity decreased from 50.6% for 2020 to 17.2% for the six months ended June 30, 2021, primarily due to (i) a decrease in profit and (ii) an increase in total equity accumulation of profit during the relevant period.

Our return on average assets decreased from 8.5% in 2018 to 4.3% in 2019 primarily due to (i) a decrease in net profit; (ii) increases in total assets from right-of-use assets and property, plant and equipment, both of which were in line with our business expansion. Our return on average assets increased from 4.3% in 2019 to 12.9% in 2020, primarily due to the increase in our profit for the year of 2019 to the year of 2020. Our return on average assets decreased from 12.9% in 2020 to 4.5% for the six months ended June 30, 2021, primarily due to (i) an increase in total assets as a result of the increases in cash and cash equivalents and restricted cash and (ii) a decrease in profit for the period due to the increase in selling and marketing expenses.

FINANCIAL INFORMATION

Our current ratio decreased from 0.74 as of December 31, 2018 to 0.64 as of December 31, 2019, mainly attributable to the increase in our total current liabilities primarily due to new bank borrowings and an increase in lease liabilities, while our current assets increased at a relatively slower rate. Our current ratio increased from 0.64 as of December 31, 2019 to 0.87 as of December 31, 2020, mainly attributable to the increase in our total current assets primarily due to a significant increase in cash and cash equivalents and trade and other receivables. Our current ratio increased from 0.87 as of December 31, 2020 to 0.96 as of June 30, 2021, primarily due to an increase in current assets which was primarily attributable to the increases cash and cash equivalents, restricted cash and inventories, and our current liabilities increased at a relatively slower rate.

Our quick ratio decreased from 0.67 as of December 31, 2018 to 0.58 as of December 31, 2019, mainly attributable to the increase in our total current liabilities primarily due to new bank borrowings and an increase in lease liabilities, while our current assets increased at a relatively slower rate. Our quick ratio increased from 0.58 as of December 31, 2019 to 0.81 as of December 31, 2020, mainly attributable to the increase in our total current assets primarily due to a significant increase in cash and cash equivalents and trade and other receivables, and was partially offset by the increase in inventories for the same year. Our quick ratio increased from 0.81 as of December 31, 2020 to 0.91 as of June 30, 2021, primarily due to an increase in quick assets which was primarily attributable to the increases cash and cash equivalents and restricted cash, and our current liabilities increased at a relatively slower rate.

Our gearing ratio as of December 31, 2018 was not meaningful as we did not have any bank loans or other borrowings. Our gearing ratio decreased from 0.19 as of December 31, 2019 to 0.06 as of December 31, 2020 primarily due to the increase in total equity as a result of the increase in cash and cash equivalents. Our gearing ratio increased from 0.06 as of December 31, 2020 to 0.40 as of June 30, 2021, primarily due to an increase in borrowings.

RELATED PARTY TRANSACTIONS

Transaction with Related Parties

During the Track Record Period, we had entered into certain related party transactions, details of which are set out in Note 31 to the Accountant's Report in Appendix I to this prospectus. Our related party transactions mainly represent bank borrowings guarantees provided by a related party. The table below sets forth significant transactions between us and our related parties during the Track Record Period.

	As of December 31,			As of June 30,
	2018	2019	2020	2021
	RMB'000	RMB'000	RMB'000	RMB'000
Acquisition of a subsidiary	—	—	—	30,000
Services purchasing	133	—	—	—

FINANCIAL INFORMATION

Outstanding Balances with Related Parties

The table below sets forth outstanding balances with related parties during the Track Record Period.

	As of December 31,			As of June 30,
	2018	2019	2020	2021
	RMB'000	RMB'000	RMB'000	RMB'000
Amounts due from related parties (non-trade)	36	110	133	—
Amounts due to related parties (non-trade)	785	749	30	25,886

Our Directors confirm that all material related party transactions during the Track Record Period were conducted on an arm's length basis, and would not distort our results of operations over the Track Record Period or make our historical results over the Track Record Period not reflective of our expectations for our future performance. Save for the outstanding balance with Xinsiyu in relation to the acquisition of Nu/Hart Hair, which was non-trade in nature, we plan to settle the outstanding balances with other related parties, which were non-trade in nature, before Listing. The outstanding balance with Xinsiyu is expected to be settled upon Listing using proceeds from the Global Offering. See "Future Plans and Use of Proceeds — Use of Proceeds" for further details.

MARKET RISK DISCLOSURE

We are exposed to a variety of financial risks and market risk, including foreign currency risk, cash flow and fair value interest rate risk, credit risk and liquidity risk. Our overall risk management program focuses on the unpredictability of financial markets and seeks to minimize potential adverse effects on our Group's financial performance. For more details, see Note 3.1 to the Accountant's Report in Appendix I to this prospectus. As of the Latest Practicable Date, we did not hedge or consider necessary to hedge any of these risks.

Foreign Currency Risk

The functional currency of the majority of our entities is Renminbi, and most of our transactions are based and settled in Renminbi. Foreign currencies are used to settle our revenue and borrowings out of mainland China. Renminbi is not freely convertible into other foreign currencies and conversion of Renminbi into foreign currencies is subject to rules and regulations of foreign exchange control promulgated by the China's government. Our management monitors foreign exchange exposure and will consider appropriate hedging measures in the future should the need arises.

FINANCIAL INFORMATION

Cash Flow and Fair Value Interest Rate Risk

Our income and operating cash flows are substantially independent of changes in market interest rates and we have no significant interest-bearing assets except for cash and cash equivalents, details of which have been disclosed in Note 28 to the Accountant's Report in Appendix I to this prospectus. Our directors do not anticipate there is any significant impact to interest-bearing assets resulted from the changes in interest rates, because the interest rates of these assets are not expected to change significantly.

Credit Risk

We are exposed to credit risk primarily in relation to our cash and cash equivalents as well as trade receivables and other financial assets at amortized cost. The carrying amount of each class of the above financial assets represents our Group's maximum exposure to credit risk in relation to the corresponding class of financial assets.

We expect that there is no significant credit risk associated with cash and cash equivalents, because they are mainly placed with state-owned or reputable financial institutions in the PRC. There has been no recent history of default in relation to these financial institutions. Management does not expect that there will be any significant losses from non-performance by these counterparties.

The expected loss rates are based on the historical credit losses and adjusted to reflect current and forward-looking information on macroeconomic factors affecting the ability of the customers to settle the receivables. We have identified economic policies, macroeconomic conditions, industry risks, probabilities of default and expected operating performance of the debtors in which it sells its services to be the most relevant factors, and accordingly adjusts the historical loss rates based on expected changes in these factors.

For other financial assets at amortized cost, our management makes periodic assessments as well as individual assessment on the recoverability based on historical settlement records, experience and forward-looking information on macroeconomic factors affecting the ability of the customers to settle the receivables. The Directors believe that there is no material credit risk inherent in our Group's outstanding balance of other financial assets at amortized cost. For more details, see Note 3.1 to the Accountant's Report in Appendix I to this prospectus.

Liquidity Risk

We aim to maintain sufficient cash and cash equivalents. Due to the dynamic nature of the underlying businesses, we regularly monitor our liquidity risk and maintain flexibility in funding by maintaining adequate cash and cash equivalents. For more details, see Note 3.1 to the Accountant's Report in Appendix I to this prospectus.

FINANCIAL INFORMATION

DIVIDENDS

During the Track Record Period, our Company did not pay or declare any dividend. We paid out a cash dividend of RMB70 million, being approximately RMB0.1645 per Share (after the Share Split), utilizing our existing cash at hand at the time to our existing Shareholders on November 25, 2021. The Dividend was approved by our Board and Shareholders on November 12, 2021. We believe that the distribution of the Dividend will not have a material impact on the sufficiency of our working capital after the Listing and we will be able to maintain sufficient funds to meet our working capital requirements and debt obligations. Our historical declarations of dividends may not reflect our future declarations of dividends.

Currently, we do not have a formal dividend policy or a fixed dividend payout ratio. Our Board may declare dividends in the future after taking into account our results of operations, financial condition, cash requirements and availability and other factors as it may deem relevant at such time. Any declaration and payment as well as the amount of dividends will be subject to our constitutional documents and the Companies Act. In addition, our Directors may from time to time pay such interim dividends as our Board considers to be justified by our profits and overall financial requirements, or special dividends of such amounts and on such dates as they deem appropriate. No dividend shall be declared or payable except out of our profits, retained earnings or share premium, subject to a solvency test being satisfied.

Future dividend payments will also depend upon the availability of dividends received from our subsidiaries in China. PRC laws require that dividends be paid only out of net profits calculated according to PRC accounting principles, which differ in many aspects from generally accepted accounting principles in other jurisdictions, including HKFRS. PRC laws also require enterprises incorporated in the PRC to set aside at least 10% of their after-tax profits based on the relevant accounting standards set out by the PRC regulatory authorities at the end of each year to fund certain statutory reserves until the statutory reserves reach and remain at or above 50% of the relevant PRC entity's registered capital. Distributions from our subsidiaries may also be restricted if they incur debt or losses, or in accordance with any restrictive covenants in bank credit facilities or other agreements that we or our subsidiaries may enter into in the future.

DISTRIBUTABLE RESERVES

As of June 30, 2021, we did not have any distributable reserves.

LISTING EXPENSES

Listing expenses to be borne by us are estimated to be approximately RMB111.0 million (HK\$135.2 million) (at the Offer Price of HK\$15.80 per Share and assuming the Over-allotment Option is not exercised) among which (i) underwriting-related expenses, including underwriting commission and other expenses are approximately RMB55.1 million (HK\$67.1 million) and (ii) non-underwriting-related expenses are approximately RMB55.9 million (HK\$68.1 million), comprising (a) fees and expenses of legal advisors and Reporting Accountants of approximately RMB32.7 million (HK\$39.9 million) and (b) other fees and expenses of approximately RMB23.2 million (HK\$28.2 million). We incurred approximately RMB16.0 million (HK\$19.5 million) of listing expenses during the Track Record Period, among which approximately RMB13.6 million (HK\$16.6 million) was recorded as expenses and approximately RMB2.4 million (HK\$2.9 million) was recorded as prepayment.

FINANCIAL INFORMATION

We estimate that additional listing expenses of approximately RMB95.0 million (HK\$115.7 million) (including underwriting commissions of approximately RMB48.7 million (HK\$59.3 million), assuming the Over-allotment Option is not exercised and based on the Offer Price of HK\$15.80 per Offer Share) will be incurred by our Company, approximately RMB39.1 million (HK\$47.6 million) of which is expected to be charged to profit or loss, and approximately RMB55.9 million (HK\$68.1 million) of which is expected to be capitalized. Our listing expenses as a percentage of gross proceeds is 9.06%, assuming an Offer Price of HK\$15.80 per Share, assuming that the Over-allotment Option is not exercised. The listing expenses above are the latest practicable estimate for reference only, and the actual amount may differ from this estimate.

UNAUDITED PRO FORMA STATEMENT OF ADJUSTED NET TANGIBLE ASSETS

The following unaudited pro forma statement of adjusted net tangible assets of our Group prepared in accordance with Rule 4.29 of the Listing Rules is for illustrative purposes only, and is set out below to illustrate the effect of the Global Offering on the consolidated net tangible assets of our Group attributable to the owners of our Company as of June 30, 2021 as if the Global Offering had taken place on June 30, 2021 assuming the over-allotment is not exercised.

The unaudited pro forma statement of adjusted net tangible assets has been prepared for illustrative purpose only and, because of its hypothetical nature, it may not give a true picture of the consolidated net tangible assets of our Group had the Global Offering been completed as of June 30, 2021 or as of any future dates.

	Unadjusted audited consolidated net tangible assets of our Group attributable to the owners of our Company as of June 30, 2021	Estimated net proceeds from the Global Offering	Unaudited pro forma adjusted consolidated net tangible assets attributable to the owners of our Company as of June 30, 2021	Unaudited pro forma adjusted consolidated net tangible assets per Share as of June 30, 2021	
	<i>RMB'000</i> <i>(Note 1)</i>	<i>RMB'000</i> <i>(Note 2)</i>	<i>RMB'000</i>	<i>RMB</i> <i>(Note 3)</i>	<i>HK\$</i> <i>(Note 4)</i>
Based on an Offer Price of HK\$15.80 per Share	500,185	1,113,829	1,614,014	3.10	3.78

FINANCIAL INFORMATION

Notes:

- (1) The unadjusted audited consolidated net tangible assets of our Group attributable to owners of our Company as of June 30, 2021 is extracted from the Accountant's Report as set out in Appendix I to this prospectus, which is based on the audited consolidated net assets of our Group attributable to owners of our Company as of June 30, 2021 of RMB534,333,000 with an adjustment for the intangible assets attributable to owners of our Company as of June 30, 2021 of RMB34,148,000.
- (2) The estimated net proceeds from the Global Offering are based on 94,424,000 Shares at the indicative Offer Price of HK\$15.80 per share, after deduction of the estimated underwriting fees and other related expenses payable by our Company and takes no account of any shares which may be issued upon the exercise of the Over-allotment Option.
- (3) The unaudited pro forma adjusted consolidated net tangible assets per Share is arrived at after the adjustments referred to in the preceding paragraphs and on the basis that 519,955,916 Shares were in issue immediately upon completion of the Share Split and the Global Offering, which is assumed to be on June 30, 2021 for the purpose of the pro forma financial information, and takes no account of any Shares which may be issued upon exercise of the Over-allotment Option.
- (4) For the purpose of this unaudited pro forma adjusted net tangible assets, the amounts stated in Renminbi are converted into Hong Kong dollars at the rate of HK\$1.00 to RMB0.8210. No representation is made that Renminbi has been, could have been or may be converted to Hong Kong dollars, or vice versa, at that rate.
- (5) No adjustment has been made to reflect any trading result or other transactions of our Group entered into subsequent to June 30, 2021.
- (6) The unaudited pro forma adjusted consolidated net tangible assets of the Group have not taken into account the cash dividend of RMB70,000,000 approved by the Board and Shareholders on November 12, 2021. The unaudited pro forma adjusted consolidated net tangible assets per Share would have been HK\$3.62 (equivalent to RMB2.97) per Share based on the indicative Offer Price of HK\$15.80, after taking into account the declaration and payment of the cash dividend.

NO MATERIAL ADVERSE CHANGE

Our Directors confirm that up to the date of this prospectus, other than as disclosed under the "Recent Developments and No Material Adverse Change" in the "Summary" section in this prospectus, there had been no material adverse change in our financial, operational or prospects since June 30, 2021, being the latest balance sheet date of our consolidated financial statements as set out in the Accountant's Report in Appendix I to this prospectus.

DISCLOSURE UNDER RULES 13.13 TO 13.19 OF THE LISTING RULES

Our Directors have confirmed that, as of the Latest Practicable Date, there was no circumstance that would give rise to a disclosure requirement under Rules 13.13 to 13.19 of the Listing Rules.

CONTRACTUAL ARRANGEMENTS

BACKGROUND OF THE CONTRACTUAL ARRANGEMENTS

PRC Laws and Regulations Relating to Foreign Ownership Restriction

The Special Administrative Measures for the Access of Foreign Investment (Negative List) (2020) (外商投資准入特別管理措施(負面清單)(2020年版)) (the “**Negative List**”) promulgated jointly by the MOFCOM and the NDRC, the Negative List stipulates industries in which foreign investments is restricted and prohibited. According to the Negative List, foreign investment is restricted in operating of medical institutions, and therefore may not be held 100% by foreign investors. Our Group engages in providing hair transplant services and medical hair care services (the “**Relevant Businesses**”), which involve the operating of medical institutions, and therefore falls into the scope of the “restricted” category of the Negative List. As such, we do not own 100% equity interest in the VIE Entities.

According to the Provisional Measures for the Administration on Sino-Foreign Equity and Cooperative Medical Institutions (中外合資合作醫療機構管理暫行辦法), operation of “medical institutions” falls within the “restricted category” and foreign investors are not allowed to hold more than 70% equity interest in a “medical institution”. These investor qualification requirements and establishment criteria may be relaxed where the foreign-invested medical institution is to be established in Central and Western China or areas inhabited by more elderly, ethnic-minorities and poorer demographics. Further, according to the Administrative Measures on Sino-Foreign Equity and Cooperative Medical Institutions in the Sichuan Province (《四川省中外合資、合作醫療機構管理辦法》), the equity ratio or interests attributable to joint venture of foreign investor in the Sino-foreign cooperative medical institutes shall not be more than 90%.

With respect to the foreign investment restriction on medical services and medical institutions, the respective PRC legal advisers of our Company and of the Joint Sponsors conducted verbal consultations with officers of the National Health Commission of the PRC (“**NHC**”) and the Beijing MOFCOM. The officers of NHC and Beijing MOFCOM confirmed that (i) generally foreign investors are not allowed to hold, either directly or indirectly, more than 70% equity interest in a medical institution, other than in Sichuan Province the local policy is that foreign investors are not allowed to hold more than 90% equity interest in a medical institution. Our PRC legal adviser are of the view that the NHC and Beijing MOFCOM are the competent authorities to give such confirmation in respect of foreign investments. Based on the information in the official websites of such authorities regarding their respective functions as well as the officer's introduction of their responsibilities and confirmation provided during the interview, the PRC legal adviser of the Company is of the view that the officers of NHC and Beijing MOFCOM who provided the regulatory confirmations are competent persons to give such confirmations.

Based on the interview above, our PRC Legal Advisers is of the opinion that, the Company, as a foreign entity, shall not hold, either directly or indirectly, more than (i) 90% equity interest in the Company's hair transplant institutions located in Sichuan province; and (ii) 70% equity interest in the Company's hair transplant institutions located in other provinces other than Sichuan (collectively, the “**Foreign Ownership Restriction**”).

The Contractual Arrangements are narrowly tailored to address solely the Foreign Ownership Restriction as set forth in the above paragraph. The Contractual Arrangements are also narrowly tailored to achieve the business purposes of the Company and to minimize the potential conflict with relevant PRC laws and regulations. The Company will not incur additional income tax and business tax after the entering into of the Contractual Arrangements.

Circumstances in which we will unwind the Contractual Arrangements


As regards the Contractual Arrangements, if and when MOFCOM and/or other relevant governmental departments promulgate any measures for the administration of foreign-invested

CONTRACTUAL ARRANGEMENTS

enterprises engaging in operating medical institution business or such entities invested by foreign investors, depending on the limit of the percentage equity interest permitted to be held by foreign investors (if any), we will partially unwind the Contractual Arrangements and hold (directly or indirectly) equity interest in the VIE Entities up to the percentage limit prescribed by such measures; and if there is no prescribed limit of the percentage equity interest permitted to be held by foreign investors and that our Company would be allowed to directly hold 100% of the equity interests in the VIE Entities, we will fully unwind the Contractual Arrangements and directly hold the entire equity interest in the VIE Entities.

OUR CONTRACTUAL ARRANGEMENTS

The Contractual Arrangements apply to the 30% and 10% equity interests in Yonghe Investment and Chengdu Yonghe, respectively. Yonghe Investment is the holding company of our Medical Institutions (other than Chengdu Yonghe). The following simplified diagram illustrates the flow of economic benefits from our VIE Entities to our Group as stipulated under the Contractual Arrangements:



Notes:

1. Mr. Zhang and Mr. ZHANG Hui are the Registered Shareholders.
2. “—>” denotes direct legal and beneficial ownership in the equity interest.
3. “<--->” denotes contractual relationship.
4. “----” denotes the entities that are subject to the Contractual Arrangements.

CONTRACTUAL ARRANGEMENTS

SUMMARY OF THE MATERIAL TERMS OF THE CONTRACTUAL ARRANGEMENTS

A description of each of the specific agreements that comprise the Contractual Arrangements is set out below.

(1) Exclusive Operation Services Agreement

The Registered Shareholders, Beijing Xunyi, Yonghe Investment and the VIE Entities have entered into exclusive operation services agreements with Beijing Haiyouyou on January 6, 2021, April 8, 2021, August 17, 2021, September 30, 2021, October 12, 2021 and October 20, 2021, (the “**Exclusive Operation Services Agreement**”), pursuant to which, the VIE Entities, Registered Shareholders and Beijing Xunyi agreed to engage Beijing Haiyouyou as their exclusive provider of technical support, consulting services and other services in exchange for a service fee.

Under the Exclusive Operation Services Agreement, the services to be provided include but are not limited to (i) business, financing and investment, (ii) medical technology related consultation, medical resources sharing and medical professionals training, (iii) human resources management, (iv) market research, (v) strategies for marketing and business expansion, (vi) supplier and inventory management, (vii) operation and marketing strategy formulation and monitoring, (viii) medical service quality control, (ix) internal management and (x) other services relating to management and operation of medical institutions. Beijing Haiyouyou has proprietary rights to all the intellectual properties developed or created by itself from the performance of these services. During the term of the Exclusive Operation Service Agreement, Beijing Haiyouyou may use the intellectual property rights owned by Beijing Xunyi and the VIE Entities free of charge and without any conditions. Beijing Xunyi and the VIE Entities may also use the intellectual property work created by Beijing Haiyouyou from the services performed by Beijing Haiyouyou in accordance with the Exclusive Operation Service Agreement.

Under the Exclusive Operation Services Agreement, the service fee shall be an amount equal to the distributable net profit of the VIE Entities of a given audited financial year, after deducting losses from the previous financial years (if any) and any statutory provident fund (if applicable). Apart from the service fees, Beijing Xunyi and the VIE Entities shall reimburse all reasonable costs, reimbursed payments and out-of-pocket expenses incurred by Beijing Haiyouyou in connection with the performance of the Exclusive Operation Services Agreement and provision of services.

In addition, absent of a prior written consent of Beijing Haiyouyou, during the term of the Exclusive Operation Services Agreement, the Registered Shareholders, Beijing Xunyi and the VIE Entities shall not directly or indirectly accept the same or any similar services provided by any third party and shall not establish similar corporation relationships with any third party. Beijing Haiyouyou has the right to appoint any third party to provide any or all of the services, or to fulfill its obligations under the Exclusive Operation Services Agreement.

The Exclusive Operation Services Agreement shall become effective from January 6, 2021, and shall remain valid for three years and shall, subject to compliance with the Listing Rules, be automatically renewed for three years each time when its term ends, unless being terminated in accordance with the terms therein.

CONTRACTUAL ARRANGEMENTS

According to the Exclusive Operation Services Agreement, unless otherwise required by applicable PRC laws and regulations, none of the parties to the agreement (except Beijing Haiyouyou) is entitled to unilaterally terminate the agreement. Furthermore, pursuant to the Exclusive Operation Services Agreement, it may only be terminated in the event that (i) continued performance of the obligations of the agreements will result in violation of or non-compliance with the applicable PRC laws and regulations, the Listing Rules or the requirements of the Stock Exchange, (ii) Beijing Haiyouyou or its designated person directly holds all the equity interests in Beijing Xunyi, and all of the Registered Shareholders' equity interests in Beijing Xunyi or all of the assets of Beijing Xunyi attributable to the Registered Shareholders are transferred to Beijing Haiyouyou pursuant to applicable PRC laws and regulations, or (iii) Beijing Haiyouyou unilaterally terminates the agreement.

(2) Exclusive Purchase Option Agreements

On January 6, 2021, April 8, 2021, August 17, 2021, September 30, 2021, October 12, 2021 and October 20, 2021, Beijing Haiyouyou, the Registered Shareholders, Beijing Xunyi, Yonghe Investment and the VIE Entities entered into exclusive purchase option agreements (the “**Exclusive Purchase Option Agreements**”).

Pursuant to the Exclusive Purchase Option Agreements, (i) each of the Registered Shareholders irrevocably and unconditionally grants an exclusive option to Beijing Haiyouyou which entitles Beijing Haiyouyou to elect to purchase at any time, when permitted by the then applicable PRC laws, all or any part of the equity interest in Beijing Xunyi itself or through its designated person(s), (ii) Beijing Xunyi irrevocably and unconditionally grants an exclusive option to Beijing Haiyouyou which entitles Beijing Haiyouyou to elect to purchase at any time, when permitted by the then applicable PRC laws, all or part of the assets of Beijing Xunyi itself or through its designated person(s), (iii) Beijing Xunyi irrevocably and unconditionally grants an exclusive option to Beijing Haiyouyou which entitles Beijing Haiyouyou to elect to purchase at any time, when permitted by the then applicable PRC laws, all or any part of the equity interests held by Beijing Xunyi in the VIE Entities from Beijing Xunyi itself or through its designated person(s), (iv) Yonghe Investment irrevocably and unconditionally grants an exclusive option to Beijing Haiyouyou which entitles Beijing Haiyouyou to elect to purchase at any time, when permitted by the then applicable PRC laws, all or any part of the equity interests of the Medical Institutions (other than Chengdu Yonghe) held by Yonghe Investment, and (iv) VIE Entities irrevocably and unconditionally grant an exclusive option to Beijing Haiyouyou which entitles Beijing Haiyouyou to elect to purchase at any time, when permitted by the then applicable PRC laws, all or part of the assets of the VIE Entities from the VIE Entities themselves or through their designated person(s). Beijing Haiyouyou may appoint designated person(s) in its sole discretion when exercising its option. The transfer price of the relevant equity interests and assets shall be the minimum purchase price permitted under PRC law, and each of the Registered Shareholders, Beijing Xunyi and the VIE Entities will undertake that he/it will, subject to applicable PRC laws, return in full the consideration received in relation to such transfer of equity interests or assets to Beijing Haiyouyou and/or its designated person(s) within ten (10) business days.

The Registered Shareholders and BeijingXunyi undertake to develop the business of the VIE Entities and not to take any action which may affect their asset value, goodwill and effectiveness of business licenses. Furthermore, in the absence of prior written consent of Beijing Haiyouyou, the Registered Shareholders and BeijingXunyi shall not (i) transfer or otherwise dispose of any option under the Exclusive Purchase Option Agreements, or create any encumbrances thereon; and the VIE Entities shall not assist in transferring or otherwise disposing of any option under the Exclusive Purchase Option Agreements, or creating any encumbrances thereon; and (ii) directly or indirectly (by itself or through the entrustment of any other natural person or legal person entity) carry out, own or acquire any business compete with or likely compete with the business of Beijing Haiyouyou or our Group.

CONTRACTUAL ARRANGEMENTS

In addition, the Registered Shareholders, BeijingXunyi and the VIE Entities undertake that, upon Beijing Haiyouyou issuing the notice to exercise the option in accordance with the Exclusive Purchase Option Agreements, they will implement necessary actions to affect the transfer and relinquish any pre-emptive right, if any. Each of the parties to the Exclusive Purchase Option Agreements confirms and agrees that (i) in the event of a dissolution or liquidation of Beijing Xunyi and the VIE Entities (as applicable) under the PRC laws, all the residual assets which are attributable to the Registered Shareholders and Beijing Xunyi (as applicable) shall be transferred to Beijing Haiyouyou or its designated person(s) at the minimum purchase price permitted under PRC law, and each of the Registered Shareholders, Beijing Xunyi and the VIE Entities undertakes that they will, subject to applicable PRC laws, return in full the consideration received in relation to such transfer to Beijing Haiyouyou or its designated person(s), (ii) in the event of bankruptcy, reorganization or merger of Beijing Xunyi, death or incapacity of the Registered Shareholders or any other event which causes changes to the Registered Shareholders' shareholding in Beijing Xunyi and Beijing Xunyi's shareholding in the VIE Entities, (a) the successor of the Registered Shareholders' equity interest in Beijing Xunyi and the successor of Beijing Xunyi's equity interest in the VIE Entities shall be bound by the Contractual Arrangements, and (b) any disposal of shareholding in Beijing Xunyi and the VIE Entities shall be governed by the Contractual Arrangements unless Beijing Haiyouyou consents otherwise in writing.

Exclusive Purchase Option Agreements shall become effective from January 6, 2021. Each of the Exclusive Purchase Option Agreements has an indefinite term and a termination provision which stipulates that unless otherwise required by applicable PRC laws and regulations, none of the parties to the agreements (except Beijing Haiyouyou) is entitled to unilaterally terminate the agreements.

Each of the Exclusive Purchase Option Agreements may only be terminated in the event that (i) continued performance of the obligations of the agreement will result in violation of or non-compliance with the applicable laws and regulations, the Listing Rules or the requirements of the Stock Exchange, (ii) Beijing Haiyouyou or its designated person directly holds all the equity interests in Beijing Xunyi, and all of the Registered Shareholders' equity interests in Beijing Xunyi or all of the assets of Beijing Xunyi attributable to the Registered Shareholders are transferred to Beijing Haiyouyou pursuant to applicable PRC laws and regulations, (iii) Beijing Haiyouyou or its designated person directly holds all the equity interests in Beijing Xunyi and all of Beijing Xunyi's equity interests in the VIE Entities or all of the assets of the VIE Entities are transferred to Beijing Haiyouyou pursuant to applicable PRC laws and regulations or (iv) Beijing Haiyouyou unilaterally terminates the agreements.

(3) Shareholders' Rights Entrustment Agreements

On January 6, 2021, April 8, 2021, August 17, 2021, September 30, 2021, October 12, 2021 and October 20, 2021, Beijing Haiyouyou, the Registered Shareholders, Beijing Xunyi, Yonghe Investment and the VIE Entities entered into the shareholders' rights entrustment agreements (the **"Shareholders' Rights Entrustment Agreements"**).

Pursuant to the Shareholders' Rights Entrustment Agreements, (i) the Registered Shareholders irrevocably agree to authorize Beijing Haiyouyou (and its successors or liquidators) or a natural person designated by Beijing Haiyouyou to exercise all of its rights and powers as a shareholder of Beijing Xunyi, including the rights to vote at a shareholders' meeting, sign minutes, and file documents with the relevant companies registry, (ii) Beijing Xunyi irrevocably agrees to authorize Beijing Haiyouyou (and its successors or liquidators) or a natural person designated by Beijing Haiyouyou to exercise all of its rights and powers as a shareholder of Yonghe Investment and Chengdu Yonghe (as applicable), including

CONTRACTUAL ARRANGEMENTS

the rights to vote at a shareholders' meeting, sign minutes, and file documents with the relevant companies registry, and (iii) Yonghe Investment irrevocably agrees to authorize Beijing Haiyouyou (and its successors or liquidators) or a natural person designated by Beijing Haiyouyou to exercise all of its rights and powers as a shareholder of each of the Medical Institutions (other than Chengdu Yonghe) held by it, including the rights to vote at a shareholders' meeting, sign minutes, and file documents with the relevant companies registry. Pursuant to the Shareholders' Rights Entrustment Agreements, the power of attorney granted in favor of the Company and actions it takes in relation to the Contractual Arrangement will only be decided by officers or Directors who are not the Registered Shareholders. As Beijing Haiyouyou is a subsidiary of the Company, the terms of the Shareholders' Rights Entrustment Agreements will give the Company control over all corporate decisions of the VIE Entities and 100% equity interests of Beijing Xunyi.

Shareholders' Rights Entrustment Agreements shall become effective from January 6, 2021. Each of the Shareholders' Rights Entrustment Agreements has an indefinite term and a termination provision which stipulates that unless otherwise required by applicable PRC laws and regulations, none of the parties to the agreement (except Beijing Haiyouyou) is entitled to unilaterally terminate it.

Each of the Shareholders' Rights Entrustment Agreements may only be terminated in the event that (i) continued performance of the obligations of the agreement will result in violation of or non-compliance with the applicable laws and regulations, the Listing Rules or the requirements of the Stock Exchange, (ii) Beijing Haiyouyou or its designated person directly holds all the equity interests in Beijing Xunyi, and all of the Registered Shareholders' equity interests in Beijing Xunyi or all of the assets of Beijing Xunyi are transferred to Beijing Haiyouyou pursuant to applicable PRC laws and regulations, (iii) Beijing Haiyouyou or its designated person directly holds all the equity interests in VIE Entities and all of the Beijing Xunyi's equity interests in VIE Entities or all of the assets of VIE Entities attributable to Beijing Xunyi are transferred to Beijing Haiyouyou pursuant to applicable PRC laws and regulations; or (iv) Beijing Haiyouyou unilaterally terminates the agreement.

(4) Equity Pledge Agreements

On January 6, 2021, Beijing Xunyi, the Registered Shareholders, Beijing Haiyouyou, Yonghe Investment and Chengdu Yonghe entered into equity pledge agreements (the “**Equity Pledge Agreements**”). Pursuant to the Equity Pledge Agreements, (i) the Registered Shareholders agree to pledge all of their respective equity interests in Beijing Xunyi, and (ii) Beijing Xunyi agrees to pledge all of its equity interests in Yonghe Investment and Chengdu Yonghe to Beijing Haiyouyou to secure performance of all their obligations and the obligations of the Registered Shareholders, Beijing Xunyi, Yonghe Investment and Medical Institutions (where applicable) under the Exclusive Operation Services Agreement, the Exclusive Purchase Option Agreements, the Shareholders' Rights Entrustment Agreements and the Equity Pledge Agreements underlying the Contractual Arrangements.

If Yonghe Investment, Chengdu Yonghe and Beijing Xunyi declare any dividend during the term of the pledge, Beijing Haiyouyou is entitled to receive all dividends or other income arising from the pledged equity interests, if any. In case of any breach of obligations by any of Beijing Xunyi, the Registered Shareholders and Yonghe Investment, Chengdu Yonghe, Beijing Haiyouyou, upon issuing a written notice to the Registered Shareholders or Beijing Xunyi, will be entitled to all remedies available in the Contractual Arrangements including but not limited to disposing of the pledged equity interests.

CONTRACTUAL ARRANGEMENTS

In addition, pursuant to the Equity Pledge Agreements, the Registered Shareholders and Beijing Xunyi undertake to Beijing Haiyouyou, among other things, not to transfer their pledged equity interests and not to create or allow any pledge or encumbrance thereon that may affect the rights and interest of Beijing Haiyouyou without its prior written consent. Beijing Xunyi, Yonghe Investment and Chengdu Yonghe undertake to Beijing Haiyouyou, among other things, not to consent to any transfer the pledged equity interests or to create or allow any pledge or encumbrance thereon without Beijing Haiyouyou's prior written consent.

The pledges in respect of Beijing Xunyi, Yonghe Investment and Chengdu Yonghe takes effect upon the completion of registration with the relevant Administration for Market Regulations and we have registered the equity pledges contemplated under the Equity Pledge Agreements with the relevant PRC legal authority pursuant to PRC laws and regulations.

Equity Pledge Agreements became effective from January 6, 2021. Each of the Equity Pledge Agreements has an indefinite term and a termination provision which stipulates that unless otherwise required by applicable PRC laws and regulations, none of the parties to the agreement (except Beijing Haiyouyou) is entitled to unilaterally terminate it.

Each of the Equity Pledge Agreements may only be terminated in the event that (i) continued performance of the obligations of the agreement will result in violation of or non-compliance with the applicable laws and regulations, the Listing Rules or the requirements of the Stock Exchange, (ii) Beijing Haiyouyou or its designated person directly holds all the equity interests in Beijing Xunyi, and all of the Registered Shareholders' equity interests in Beijing Xunyi or all of the assets of Beijing Xunyi are transferred to Beijing Haiyouyou pursuant to applicable PRC laws and regulations, (iii) Beijing Haiyouyou or its designated person directly holds all the equity interests in Yonghe Investment and Chengdu Yonghe or all of the assets of Yonghe Investment and Chengdu Yonghe attributable to Beijing Xunyi are transferred to Beijing Haiyouyou pursuant to applicable PRC laws and regulations or (iv) Beijing Haiyouyou unilaterally terminates the agreement.

(5) Spouse Undertakings

The spouses of each of the Registered Shareholders has signed an undertaking (the “**Spouse Undertakings**”) to the effect that each of the spouses has no right to or control over such interests of the respective persons and will not have any claim on such interests.

Our PRC Legal Advisers are of the view that (i) the above arrangements provide protection to our Group even in the event of death or divorce of the Registered Shareholders, and (ii) the death or divorce of the Registered Shareholders would not affect the validity of the Contractual Arrangements, and Beijing Haiyouyou or our Company can still enforce their right under the Contractual Arrangements against the Registered Shareholders and their successors.

Common terms of the Contractual Arrangements

Dispute Resolution

Each of the agreements under the Contractual Arrangements contains a dispute resolution provision. Pursuant to such provision, in the event of any dispute arising from the performance of or relating to the Contractual Arrangements, any party has the right to submit the relevant dispute to the Beijing Arbitration Commission for arbitration, in accordance with the then effective arbitration rules.

CONTRACTUAL ARRANGEMENTS

The language used during arbitration shall be Chinese. The arbitration award shall be final and binding on all parties. The dispute resolution provisions also provide that the arbitral tribunal may award remedies over the shares or assets of the Registered Shareholders, Beijing Xunyi and the VIE Entities or injunctive relief (e.g. limiting the conduct of business, limiting or restricting transfer or sale of shares or assets) or order the winding up of Beijing Xunyi and the VIE Entities; any party may apply to the courts of Hong Kong, the Cayman Islands (being the place of incorporation of our Company), the PRC and the places where the principal assets of Beijing Haiyouyou or Beijing Xunyi or our VIE Entities are located for interim remedies or injunctive relief.

However, our PRC Legal Advisers have advised that the above provisions may not be enforceable under the PRC laws. For instance, the arbitral tribunal has no power to grant such injunctive relief, nor will it be able to order the winding up of Beijing Xunyi and the VIE Entities pursuant to the current PRC laws. In addition, interim remedies or enforcement order granted by overseas courts such as Hong Kong and the Cayman Islands may not be recognizable or enforceable in the PRC.

As a result of the above, in the event that Beijing Xunyi, the VIE Entities or the Registered Shareholders breach any terms of the Contractual Arrangements, we may not be able to obtain sufficient remedies in a timely manner, and our ability to exert fully effective control over Beijing Xunyi and conduct our business could be materially and adversely affected. See “Risk Factors — Risks Relating to Our Contractual Arrangements” in this prospectus for further details.

Succession

As advised by our PRC Legal Advisers, the provisions set out in the Contractual Arrangements are also binding on any successor(s) of the Registered Shareholders as if such successors were a signing party to the Contractual Arrangements. As such, any breach by the successors would be deemed to be a breach of the Contractual Arrangements. Under the PRC Civil Code, the statutory successors include the spouse, children, parents, brothers, sisters, paternal grandparents and maternal grandparents. In the case of a breach, Beijing Haiyouyou can enforce its rights against the successors. Pursuant to the Contractual Arrangements, in the event of changes in the shareholding of Beijing Xunyi, any successor(s) of Beijing Xunyi shall assume any and all rights and obligations of Beijing Xunyi under the Contractual Arrangements as if such successor were a signing party to the relevant contract.

Conflicts of Interests

Each of Registered Shareholders and Beijing Xunyi undertake that, during the period that the Contractual Arrangements remain effective, they shall not take or omit to take any action which may lead to a conflict of interest with Beijing Haiyouyou or its direct or indirect shareholders. If there is any conflict of interest, Beijing Haiyouyou shall have the right to decide in its sole discretion on how to deal with such conflict of interest in accordance with the applicable PRC laws. Registered Shareholders and Beijing Xunyi will unconditionally follow the instructions of Beijing Haiyouyou to take any action to eliminate such conflict of interest.

CONTRACTUAL ARRANGEMENTS

Loss Sharing

Under the relevant PRC laws and regulations, none of our Company or Beijing Haiyouyou is legally required to share the losses of, or provide financial support to Beijing Xunyi and the VIE Entities. Further, Beijing Xunyi and the VIE Entities are limited liability companies and shall be solely liable for its own debts and losses with assets and properties owned by them. In addition, given that our Group conducts a substantial portion of its business operations in the PRC through Beijing Xunyi and the VIE Entities, which hold the requisite PRC operational licenses and approvals, and that its financial position and results of operations are consolidated into our Group's financial statements under the applicable accounting principles, our Company's business, financial position and results of operations would be adversely affected if Beijing Xunyi and the VIE Entities suffer losses.

Liquidation

Pursuant to the Equity Interest Pledge Agreements, in the event of a mandatory liquidation required by the PRC laws, the shareholders of Beijing Xunyi and the VIE Entities shall, upon the request of Beijing Haiyouyou, give the proceeds they received from liquidation as a gift to Beijing Haiyouyou or its designee(s) to the extent permitted by the PRC laws.

Accordingly, in the event a winding up of Beijing Xunyi and the VIE Entities, Beijing Haiyouyou is entitled to liquidation proceeds of Beijing Xunyi and the VIE Entities based on the Contractual Arrangements for the benefit of our Company's creditors and shareholders.

Insurance

Our Company does not maintain an insurance policy to cover the risks relating to the Contractual Arrangements.

Our Confirmation

As of the Latest Practicable Date, we had not encountered any interference or encumbrance from any PRC governing bodies in operating our businesses through Beijing Xunyi and the VIE Entities under the Contractual Arrangements.

Legality of the Contractual Arrangements

As advised by our PRC Legal Advisers, NHC and Beijing MOFCOM as the competent authorities for foreign investment administration of the Company, are of the view that the Company, as a foreign entity, shall not hold more than 90% and 70% shares in any medical institution in Chengdu Yonghe and Yonghe Investment, respectively.

Our PRC Legal Advisers conducted an interview with officers of Beijing MOFCOM and NHC in respect of the proposed Contractual Arrangements entitling the Company to control the other 10% equity interest in Chengdu Yonghe and the other 30% equity interest in Yonghe Investment. According to the officers interviewed, (i) no approval from the authority is required for the execution of the Contractual Arrangements; (ii) the execution of the Contractual Arrangements does not fall into the current supervision of NHC and Beijing MOFCOM concerning foreign investment activities; and (iii) the Contractual Arrangements does not violate any prohibitive or restrictive provisions with respect to under

CONTRACTUAL ARRANGEMENTS

current PRC law. Our PRC Legal Advisers are of the view that NHC and Beijing MOFCOM are the competent authorities to give such confirmation in respect of foreign investments.

Based on the above, our PRC Legal Adviser is of the opinion that:

- each of the agreements under the Contractual Arrangements, taken individually and collectively, constitutes legal, valid and binding obligations of the parties thereto except that (a) the Beijing Arbitration Commission has no power to grant injunctive relief, nor will it be able to order the winding up of the VIE Entities pursuant to the current PRC laws and regulations; and (b) interim remedies or enforcement orders granted by overseas courts such as the courts of Hong Kong and the Cayman Islands may not be recognized or enforceable in the PRC;
- no approval or authorization from the PRC governmental authorities are required for entering into and the performance of the Contractual Arrangements except that each of the equity pledges under Equity Pledge Agreements is subject to registration requirements with the relevant Administration for Market Regulations and the exercising of the exclusive options by Beijing Haiyouyou, according to the Exclusive Purchase Option Agreements, shall be subject to the then effective PRC laws and regulations and relevant approval procedures (if applicable).

Furthermore, the PRC Civil Code (中華人民共和國民法典) came into effect on January 1, 2021 and the PRC Contract Law and the General Principles of the PRC Civil Law were repealed simultaneously. The PRC Civil Code stipulates certain circumstances which will lead to the invalidation of civil juristic acts, including but not limited to a civil juristic act performed by a person having no capacity for civil conducts, a civil juristic act performed by the actor and the counterparty based on false expression of intention, a civil juristic act violates the mandatory provisions of laws and administrative regulations, a civil juristic act violates of public order and morals, etc. The provisions on the validity of civil juristic acts also apply to the validity of contracts. Our PRC Legal Adviser is of the view that the Contractual Arrangements would not fall within the above circumstances which will lead such arrangements as invalid civil juristic act under the PRC Civil Code.

We have been advised by our PRC Legal Advisers, however, that there are substantial uncertainties regarding the interpretation and application of current and future PRC laws and regulations. Accordingly, there can be no assurance that the PRC regulatory authorities will not take a view that is contrary to or otherwise different from the above opinion of our PRC Legal Advisers. We have been further advised by our PRC Legal Advisers that if the PRC government finds that the Contractual Arrangements do not comply with PRC government restrictions on foreign investment in the Relevant Businesses, we could be subject to severe penalties, which could include:

- (a) revoking the business and operating licenses of Beijing Haiyouyou, Yonghe Investment and our VIE Entities;
- (b) restricting or prohibiting the Contractual Arrangements among Beijing Haiyouyou, Yonghe Investment and our VIE Entities;

CONTRACTUAL ARRANGEMENTS

- (c) imposing fines or other requirements with which our Company, Beijing Haiyouyou, Yonghe Investment and our VIE Entities may find difficult or impossible to comply; and
- (d) requiring us, Beijing Haiyouyou, Yonghe Investment and our VIE Entity to restructure the relevant ownership structure or operations.

The imposition of any of these penalties could have a material adverse effect on our ability to conduct our business. See “Risk Factors — Risks Relating to Our Contractual Arrangements.” for detailed information.

Development in the PRC Legislation on Foreign Investment

Background of the FIL

On March 15, 2019, the NPC promulgated the Foreign Investment Law of the People’s Republic of China (《中華人民共和國外商投資法》) (the “**FIL**”) and replaced effective on January 1, 2020. After the FIL comes into effect, the FIL replaced the law on Sino-Foreign Equity Joint Ventures (《中外合資經營企業法》), the law on Sino-Foreign Contractual Joint Ventures (《中外合作經營企業法》) and the law on Foreign-Capital Enterprises (《外資企業法》) and became the legal foundation for foreign Investment in the PRC. The FIL stipulates three forms of foreign investment, but does not explicitly stipulate the contractual arrangements as a form of foreign investment.

The Potential Impact of the FIL on the Contractual Arrangements

Conducting operations through contractual arrangements has been adopted by many PRC-based companies, and has been adopted by our Company in the form of the Contractual Arrangements, to establish control of our VIE Entities, through which we operate our business in the PRC. As advised by our PRC Legal Advisers, since Contractual Arrangements are not specified as foreign investment under the FIL, the Implementation Regulations on the FIL and if future laws, regulations and provisions prescribed by the State Council do not incorporate contractual arrangements as a form of foreign investment, then the possibility that the legal effectiveness of the Contractual Arrangements become materially adversely affected due to violation of the entry requirements under the FIL is relatively low.

Notwithstanding the above, the FIL stipulates that foreign investment includes “Foreign Investors invest in China through many other methods under laws, administrative regulations or provisions prescribed by the State Council”. There are possibilities that future laws, administrative regulations or provisions prescribed by the State Council the NPC promulgated may regard Contractual Arrangements as a form of foreign investment, at which time it will be uncertain whether the Contractual Arrangements will be deemed to be in violation of the foreign investment access requirements and how the above-mentioned Contractual Arrangements will be handled. Therefore, there is no guarantee that the Contractual Arrangements and the business of the VIE Entities will not be materially and adversely affected in the future due to changes in PRC laws and regulations. In the event that such measures are not complied with, the Stock Exchange may take enforcement actions against us which may have a material adverse effect on the trading of our Shares. See “Risk Factors — Risks Relating to Our Contractual Arrangements”.

CONTRACTUAL ARRANGEMENTS

Compliance with the Contractual Arrangements

Our Group will adopt the following measures to ensure the effective operation of our Group with the implementation and compliance of the Contractual Arrangements:

- (a) major issues arising from the implementation and compliance with the Contractual Arrangements or any regulatory enquiries from government authorities will be submitted to our Board, if necessary, for review and discussion on an occurrence basis;
- (b) our Board will review the overall performance of and compliance with the Contractual Arrangements at least once a year;
- (c) our Company will disclose the overall performance and compliance with the Contractual Arrangements in its annual reports and interim reports to update our Shareholders and potential investors; and
- (d) our Company will engage external legal advisers or other professional advisers, if necessary, to assist the Board to review the implementation of the Contractual Arrangements and the legal compliance of Beijing Haiyouyou, Beijing Xunyi and the VIE Entities to deal with specific issues or matters arising from the Contractual Arrangements.

In addition, notwithstanding that the Registered Shareholders, Mr. Zhang and Mr. Zhang Hui, are our Directors, our Company believes that our Directors are able to perform their roles in our Group independently and our Group is capable of managing its business independently after the Listing under the following measures:

- (a) the decision-making mechanism of our Board as set out in the Articles of Association includes provisions to avoid conflict of interest by providing, amongst other things, that in the event of conflict of interest in such contract or arrangement which is material, a Director shall declare the nature of his or her interest at the earliest meeting of our Board at which it is practicable for him or her to do so, and if he or she is to be regarded as having material interest in any contracts or arrangements, such Director shall abstain from voting and not be counted in the quorum;
- (b) each of our Directors is aware of his or her fiduciary duties as a Director which requires, amongst other things, that he or she acts for the benefits and in the best interests of our Group;
- (c) our Company will appoint three independent non-executive Directors, comprising more than one-third of the Board, to provide a balance of the number of interested and independent Directors with a view to promoting the interests of our Company and the Shareholders as a whole; and
- (d) our Group will disclose in its announcements, circulars and annual and interim reports in accordance with the requirements under the Listing Rules regarding decisions on matters reviewed by our Board (including independent non-executive Directors) relating to any business or interest of each Director and his associates that competes or may compete with the business of our Group and any other conflicts of interest which any such person has or may have with our Group.

CONTRACTUAL ARRANGEMENTS

Accounting Aspects of the Contractual Arrangements

Under the Exclusive Operation Services Agreements, it was agreed that, in consideration of the services provided by Beijing Haiyouyou, Beijing Xunyi will pay service fees to Beijing Haiyouyou. The annual service fees payable are determined with the services provided. The amount and payment deadline will be determined by Beijing Haiyouyou and Beijing Xunyi through arms' length negotiations after considering (i) the complexity and difficulty of the services provided by Beijing Haiyouyou, (ii) the title of and time consumed by employees of Beijing Haiyouyou providing the services, (iii) the contents and value of the services provided by Beijing Haiyouyou, (iv) the market price of the same type of services, (v) the operation conditions of the Registered Shareholders and Beijing Xunyi, and (vi) the essential cost, expenses, taxes and statutory reserve or retaining funds. Accordingly, through the Exclusive Operation Services Agreement, Beijing Haiyouyou has the ability, at its sole discretion, to extract substantially (i) 30% of the economic benefit of Yonghe Investment derived from the 67 medical institutions, respectively, and (ii) 10% of the economic benefit of Chengdu Yonghe.

In addition, under the Exclusive Operation Services Agreements, Beijing Haiyouyou has absolute contractual control over the distribution of dividends or any other amounts to the equity holders of Beijing Xunyi and the VIE Entities as Beijing Haiyouyou's prior written consent is required before any distribution can be made. In the event that Beijing Xunyi and the Registered Shareholders receive any profit distribution or dividend from the VIE Entities, Beijing Xunyi and the Registered Shareholders must immediately pay or transfer all of such amount (subject to the relevant tax payment being made under the relevant laws and regulations) to the Company.

As a result of the aforementioned Contractual Arrangements, our Company has obtained control of the VIE Entities through Beijing Haiyouyou and, at our Company's sole discretion, can receive substantially all of the economic interest returns generated by the VIE Entities.

SHARE CAPITAL

AUTHORIZED AND ISSUED SHARE CAPITAL

The following is a description of the authorized and issued share capital of our Company in issue and to be issued as fully paid prior to and immediately following the completion of the Global Offering:

		Aggregate par value (US\$)
<i>Authorized share capital</i>		
20,000,000,000	Shares of par value of US\$0.0000025 each as at the Latest Practicable Date	50,000.00
<i>Issued and to be issued, fully paid or credited as fully paid immediately upon completion of the Global Offering</i>		
425,531,916	Shares in issue as at the date of this prospectus	1,063.82979
94,424,000	Shares to be issued under the Global Offering	236.0600
<u>519,955,916</u>	Total	<u>1,299.88979</u>

ASSUMPTION

The above table assumes that the Global Offering becomes unconditional and the Shares are issued pursuant to the Global Offering. The above table does not take into account any Shares which may be allotted and issued pursuant to the exercise of the Over-allotment Option or any Shares which may be issued or repurchased by our Company pursuant to the general mandates granted to our Directors to issue or repurchase Shares as described below.

RANKING

The Offer Shares are ordinary shares in the share capital of our Company and will rank equally in all respects with all Shares in issue or to be issued as set forth in the above table, and will qualify and rank in full for all dividends or other distributions declared, made or paid after the date of this prospectus.

CIRCUMSTANCES UNDER WHICH GENERAL MEETINGS ARE REQUIRED

Our Company will have only one class of Shares upon completion of the Global Offering, namely ordinary shares, and each ranks pari passu with the other Shares. Pursuant to the Companies Act and the terms of the Memorandum of Association and Articles of Association, our Company may from time to time by ordinary resolution of shareholders (i) increase its capital; (ii) consolidate and divide its capital into shares of larger amount; (iii) divide its shares into several classes; (iv) subdivide its shares into shares of smaller amount; and (v) cancel any shares which have not been taken. In addition, our Company may subject to the provisions of the Companies Act reduce its share capital or capital redemption reserve

SHARE CAPITAL

by its shareholders passing a special resolution. For details, see “Summary of the Constitution of the Company and Cayman Islands Company Law” in Appendix III to this prospectus.

GENERAL MANDATE TO ISSUE SHARES

Subject to the Global Offering becoming unconditional, our Directors have been granted a general unconditional mandate to allot, issue and deal with Shares and to make or grant offers, agreements or options which might require such Shares to be allotted and issued or dealt with at any time subject to the requirement that the aggregate nominal value of the Shares so allotted and issued or agreed conditionally or unconditionally to be allotted and issued, shall not exceed the sum of:

- (a) 20% of the aggregate nominal value of the share capital of the Company in issue immediately following completion of the Global Offering; and
- (b) the nominal amount of our share capital repurchased by the Company (if any) pursuant to the repurchase mandate (as mentioned below).

This mandate does not cover Shares to be allotted, issued, or dealt with under a rights issue or scrip dividend scheme or similar arrangements or a specific authority granted by our Shareholders or upon the exercise of the Over-allotment Option.

This mandate to issue Shares will remain in effect until:

- (i) at the conclusion of our next annual general meeting; or
- (ii) the expiration of the period within which the next annual general meeting of our Company is required to be held under any applicable laws or the Articles of Association; or
- (iii) it is varied or revoked by an ordinary resolution of our Shareholders at a general meeting,

whichever is the earliest.

For further details of this general mandate, see “Appendix IV — Statutory and General Information — A. Further Information about Our Group — 4. Resolutions of the Shareholders of the Company Passed on November 24, 2021” in this prospectus.

GENERAL MANDATE TO REPURCHASE SHARES

Subject to the Global Offering becoming unconditional, our Directors have been granted a general unconditional mandate to exercise all the powers of our Company to repurchase Shares with an aggregate nominal value of not more than 10% of the aggregate nominal value of our share capital in issue immediately following the Global Offering (excluding any Shares which may be allotted and issued pursuant to the exercise of the Over-allotment Option).

SHARE CAPITAL

This mandate relates to repurchases made on the Stock Exchange, or on any other stock exchange which the Shares may be listed (and which is recognized by the SFC and the Stock Exchange for this purpose), and made in accordance with all applicable laws and regulations and the requirements of the Listing Rules. A summary of the relevant Listing Rules is set out in the section headed “Statutory and General Information — Repurchase of Our Shares”.

This general mandate to repurchase Shares will remain in effect until:

- (a) at the conclusion of our next annual general meeting; or
- (b) the expiration of the period within which the next annual general meeting of our Company is required to be held under any applicable laws or the Articles of Association; or
- (c) it is varied or revoked by an ordinary resolution of our Shareholders at a general meeting, whichever is the earliest.

For further details of this general mandate, see “Appendix IV — Statutory and General Information — A. Further Information about Our Group — 4. Resolutions of the Shareholders of the Company Passed on November 24, 2021” in this prospectus.

RELATIONSHIP WITH OUR CONTROLLING SHAREHOLDERS

OUR CONTROLLING SHAREHOLDERS

Immediately upon completion of the Global Offering (assuming the Over-allotment Option is not exercised), our Company will be held as to approximately 34.91% by Mr. Zhang through ZY Investment Capital Ltd and Yunuo Technology Holdings Limited. ZY Investment Capital Ltd is wholly-owned by ZY Ventures Ltd, which is in turn wholly-owned by Frandor Limited. Frandor Limited is wholly-owned by Trident Trust Company (Singapore) Pte. Limited, which is the trustee of The ZY Trust, a discretionary trust established by Mr. Zhang as the settlor.

Yonghe Hair Service and CYH has been forming agreed-upon decisions amongst themselves before general meetings of the Company were convened and casting the same voting decisions at general meetings of the Company. As such, immediately upon completion of the Global Offering (assuming the Over-allotment Option is not exercised), the exercise of the 35.34% voting rights in our Company will be jointly controlled by Yonghe Hair Service and CYH.

Yonghe Hair Service is wholly-owned by Panmao Shanghai the general partner of which is Shanghai Pannuo, which is in turn wholly-owned by CITIC Private Equity Funds Management Co., Ltd. CITIC Private Equity Funds Management Co., Ltd is owned as to 35% by CITIC Securities Company Limited, a company listed on both the Stock Exchange and the Shanghai Stock Exchange. CYH is wholly-owned by CYH Cosmetic Medical Investment Limited, which in turn is owned as to approximately 86.3% by CPEChina Fund II and 13.7% by CPEChina Fund IIA. The general partner of CPEChina Fund II and CPEChina Fund IIA is Citron PE Associates II. Citron PE Associates II is an exempted limited partnership registered under the laws of the Cayman Islands whose general partner is Citron PE Funds II, a company is wholly-owned by Citron PE Holdings Limited, which is held as to 35% by CLSA Global Investments Management Limited. Each of Panmao Shanghai, CPEChina Fund II and CPEChina Fund IIA is an investment holding entity principally engaged in private equity investment.

Therefore, for the purpose of this prospectus, (i) Mr. Zhang, ZY Investment Capital Ltd, ZY Ventures Ltd, (ii) Yonghe Hair Service, Panmao Shanghai, Shanghai Pannuo, CITIC Private Equity Funds Management Co., Ltd., CYH, CYH Cosmetic Medical Investment Limited, CPEChina Fund II, CPEChina Fund IIA, Citron PE Associates II, Citron PE Funds II, Citron PE Holdings Limited are our Controlling Shareholders. Frandor Limited is a nominee shareholder holding shares of ZY Ventures Ltd on behalf of The ZY Trust and is wholly-owned by Trident Trust Company (Singapore) Ptd. Limited. Trident Trust Company (Singapore) Pte. Limited as a professional trustee and Frandor Limited as a nominee shareholder are not entitled to exercise or control the exercise of any voting powers at general meeting of the Company and therefore are not regarded as our Controlling Shareholder.

DELINEATION OF BUSINESS

As of the Latest Practicable Date, our Controlling Shareholders confirm that they did not have an interest in a business, apart from the business of our Group, which competes or is likely to compete, directly or indirectly, with our business, that requires disclosure under Rule 8.10 of the Listing Rules.

RELATIONSHIP WITH OUR CONTROLLING SHAREHOLDERS

INDEPENDENCE FROM OUR CONTROLLING SHAREHOLDERS

The Controlling Shareholders confirm that as of the Latest Practicable Date, they did not have any interest in a business, apart from the business of our Group, which competes or is likely to compete, directly or indirectly, with our business, and requires disclosure under Rule 8.10 of the Listing Rules.

Having considered the following factors, our Directors are satisfied that we are capable of carrying on our business independently of our Controlling Shareholder and their close associates after the Listing.

Management Independence

The Board comprises two executive Directors, two non-executive Directors and three independent non-executive Directors. Each of our Directors is aware of his or her fiduciary duties as a Director which require, among others, that he or she must act for the benefit of and in the best interests of our Company and not allow any conflict between his or her duties as a Director and his personal interests. Further, we believe our independent non-executive Directors will bring independent judgment to the decision-making process of our Board. See “— Corporate Governance Measures” for further details.

Based on the above, our Directors are satisfied that our Board as a whole together with our senior management team is able to perform the managerial role in our Group independently.

Operational Independence

Although our Controlling Shareholders will retain a controlling interest in us after Listing, we have full rights to make all decisions on, and to carry out, our own business operations independently. Our Company, through our subsidiaries, holds the licenses and qualifications necessary to carry on our current business, and has sufficient capital, facilities, technology and employees to operate the business independently from our Controlling Shareholder. We have access to third parties independently from and not connected to our Controlling Shareholder for sources of suppliers and customers.

Based on the above, our Directors are satisfied that we will be able to function and operate independently from our Controlling Shareholders and their close associates.

Financial Independence

We have established our own finance department with a team of financial staff, who are responsible for financial control, accounting, reporting, group credit and internal control functions of our Company, independent from our Controlling Shareholders. We can make financial decisions independently and our Controlling Shareholders do not intervene with our use of funds. We have also established an independent audit system, a standardized financial and accounting system and a complete financial management system. In addition, we have been and are capable of obtaining financing from third parties without relying on any guarantee or security provided by our Controlling Shareholders or their respective associates. During the Track Record Period and as of the Latest Practicable Date, there were no loans, advances and balances due to and from the Controlling Shareholders.

Based on the above, our Directors are of the view that they and our senior management are capable of carrying on our business independently of, and do not place undue reliance on our Controlling Shareholders and their close associates after the Listing.

RELATIONSHIP WITH OUR CONTROLLING SHAREHOLDERS

CORPORATE GOVERNANCE MEASURES

Our Directors recognize the importance of good corporate governance in protecting our Shareholders' interests. We have adopted the following measures to safeguard good corporate governance standards and to avoid potential conflict of interests between our Group and our Controlling Shareholders:

- (a) under the Articles of Association, where a Shareholders' meeting is to be held for considering proposed transactions in which any of our Controlling Shareholder or any of their associates has a material interest, the Controlling Shareholders or their associates will not vote on the relevant resolutions;
- (b) our Company has established internal control mechanisms to identify connected transactions. Upon the Listing, if our Company enters into connected transactions with our Controlling Shareholders or any of their associates, our Company will comply with the applicable Listing Rules;
- (c) the independent non-executive Directors will review, on an annual basis, whether there are any conflicts of interests between our Group and our Controlling Shareholder (the "**Annual Review**") and provide impartial and professional advice to protect the interests of our minority Shareholders;
- (d) our Controlling Shareholder will undertake to provide all information necessary, including all relevant financial, operational and market information and any other necessary information as required by the independent non-executive Directors for the Annual Review;
- (e) our Company will disclose decisions on matters reviewed by the independent non-executive Directors either in its annual reports or by way of announcements as required by the Listing Rules;
- (f) where our Directors reasonably request the advice of independent professionals, such as financial advisers, the appointment of such independent professionals will be made at our Company's expenses; and
- (g) we have appointed Somerley Capital Limited as our compliance adviser to provide advice and guidance to us in respect of compliance with the applicable laws and regulations in Hong Kong, as well as the Listing Rules, including various requirements relating to corporate governance from the Listing Date to the date when our Company distribute our annual report of our financial results for the first full financial year commencing after the Listing Date.

Based on the above, our Directors are satisfied that sufficient corporate governance measures have been put in place to manage conflicts of interest that may arise between our Group and our Controlling Shareholders, and to protect our minority Shareholders' interests after the Listing.

CONTINUING CONNECTED TRANSACTIONS

OVERVIEW

Prior to the Listing, our Group has entered into certain transactions with parties who will, upon the Listing, become connected persons (as defined in the Listing Rules) of our Company. Details of the non-exempt continuing connected transaction of our Company following the Listing are set out below.

NON-EXEMPT CONTINUING CONNECTED TRANSACTIONS — CONTRACTUAL ARRANGEMENTS

Background for the Contractual Arrangements

As disclosed in the section headed “Contractual Arrangements” of this prospectus, due to regulatory restrictions on foreign ownership in the PRC, we are restricted from directly owning 100% equity interest in the Medical Institutions. Therefore, in order for our Group to effectively control and enjoy the entire economic benefit of the Medical Institutions, a series of Contractual Arrangements have been entered into among Beijing Haiyouyou, the VIE Entities, Beijing Xunyi, and the Registered Shareholders. The Contractual Arrangements enable us to (i) receive substantially all of the economic benefits of the VIE Entities and Beijing Xunyi; (ii) exercise effective full control over the VIE Entities and Beijing Xunyi; and (iii) hold an exclusive option to purchase all or part of the equity interests in the VIE Entities and/or Beijing Xunyi when and to the extent permitted by PRC law.

Principal Terms of the Transactions

The Contractual Arrangements consist of five types of agreements: (a) the Exclusive Operation Services Agreement; (b) the Exclusive Purchase Option Agreements; (c) the Shareholders’ Rights Entrustment Agreements; (d) the Equity Pledge Agreements; and (e) the Spouse Undertakings (all as defined in the section headed “Contractual Arrangements” in this prospectus) (the “**Contractual Arrangements Agreements**”). See “Contractual Arrangements” in this prospectus for detailed terms of the Contractual Arrangements.

Listing Rules Implications

The transactions contemplated under the Contractual Arrangements constitute continuing connected transactions of our Company under the Listing Rules upon Listing as certain parties to the Contractual Arrangements, namely Mr. Zhang, Mr. ZHANG Hui and Beijing Xunyi, are connected persons of the Group. Mr. Zhang is one of our Controlling Shareholders and Directors, Mr. ZHANG Hui is one of our Directors, therefore Mr. Zhang and Mr. ZHANG Hui are connected persons of our Company. Beijing Xunyi is owned by Mr. Zhang and Mr. ZHANG Hui as to 85% and 15% respectively, and therefore is an associate of Mr. Zhang and a connected person of our Company.

Reasons for the Continuing Connected Transactions and Waiver Application

Our Directors (including the independent non-executive Directors) are of the view that the Contractual Arrangements and the transactions contemplated therein are fundamental to our Group’s legal structure and business, that such transactions have been and will be entered into in the ordinary and usual course of business of our Group, are on normal commercial terms and are fair and reasonable and in the interests of our Company and the Shareholders as a whole. In addition, given the Contractual Arrangements were entered into prior to the Global Offering and are disclosed in this prospectus, and

CONTINUING CONNECTED TRANSACTIONS

potential investors of our Company will participate in the Global Offering on the basis of such disclosure. Accordingly, notwithstanding that the transactions contemplated under the Contractual Arrangements technically constitute continuing connected transactions under Chapter 14A of the Listing Rules, the Directors consider that, given that our Group is placed in a special situation in relation to the connected transactions rules under the Contractual Arrangements, it would be unduly burdensome and impracticable, and would add unnecessary administrative costs to our Company, if such transactions are subject to strict compliance with the requirements set out under Chapter 14A of the Listing Rules.

WAIVER FROM THE STOCK EXCHANGE

In relation to the Contractual Arrangements, we have applied to the Stock Exchange for, and the Stock Exchange has granted, a waiver from strict compliance with (i) the announcement, circular and independent shareholders' approval requirements under Chapter 14A of the Listing Rules in respect of the transactions contemplated under the Contractual Arrangements pursuant to Rule 14A.105 of the Listing Rules, (ii) the requirement of setting an annual cap for the transactions under the Contractual Arrangements under Rule 14A.53 of the Listing Rules, and (iii) the requirement of limiting the term of the Contractual Arrangements to three years or less under Rule 14A.52 of the Listing Rules, for so long as the Shares are Listed on the Stock Exchange subject however to the following conditions:

- (a) **No change without independent non-executive Directors' approval.** No change to the Contractual Arrangements (including with respect to any fees payable to Beijing Haiyouyou thereunder) will be made without the approval of our independent non-executive Directors.
- (b) **No change without independent Shareholders' approval.** Save as described in "(d) Renewal and reproduction" below, no change to the agreements constituting the Contractual Arrangements will be made without the approval of our Company's independent Shareholders. Once independent Shareholders' approval of any change has been obtained, no further announcement, circular or approval of the independent Shareholders will be required under Chapter 14A of the Listing Rules unless and until further changes are proposed. The periodic reporting requirement regarding the Contractual Arrangements in the annual reports of our Company (as set out in "(e) Ongoing reporting and approvals" below) will however continue to be applicable.
- (c) **Economic benefits flexibility.** The Contractual Arrangements shall continue to enable our Group to receive the entire economic benefits derived by the VIE Entities and Beijing Xunyi through (i) our Group's option (if and when so allowed under the applicable PRC laws) to acquire all or part of the entire equity interests in Beijing Xunyi and/or Yonghe Investment and Chengdu Yonghe for nil consideration or the minimum amount of consideration permitted by applicable PRC laws and regulations, (ii) the business structure under which the entire profit generated by the VIE Entities and Beijing Xunyi is retained by our Group, such that no annual cap shall be set on the amount of service fees payable to Beijing Haiyouyou by Beijing Xunyi under the Exclusive Consultation and Service Agreement, and (iii) the Group's right to control the management and operation of, in substance, all of the voting rights of the VIE Entities and Beijing Xunyi.

CONTINUING CONNECTED TRANSACTIONS

- (d) **Renewal and reproduction.** On the basis that the Contractual Arrangements provide an acceptable framework for the relationship between our Company and its subsidiaries in which our Company has direct shareholding, on the one hand, and Beijing Xunyi, on the other hand, that framework may be renewed and/or reproduced upon the expiry of the existing arrangements or in relation to any existing or new foreign invested enterprise or operating company (including branch company) engaging in the same business as that of our Group which the Group might wish to establish when justified by business expediency, without obtaining the approval of the Shareholders, on substantially the same terms and conditions as the existing Contractual Arrangements. The directors, chief executive or Substantial Shareholders of any existing or new foreign invested enterprise or operating company (including branch company) engaging in the same business as that of our Group which our Group may establish will, upon renewal and/or reproduction of the Contractual Arrangements, however be treated as connected persons of our Company and transactions between these connected persons and our Company other than those under similar contractual arrangements shall comply with Chapter 14A of the Listing Rules. This condition is subject to relevant PRC laws, regulations and approvals.
- (e) **Ongoing reporting and approvals.** Our Group will disclose details relating to the Contractual Arrangements on an on-going basis as follows:
- (i) The Contractual Arrangements in place during each financial period will be disclosed in our Company's annual report and accounts in accordance with the relevant provisions of the Listing Rules.
 - (ii) Our independent non-executive Directors will review the Contractual Arrangements annually and confirm in our Company's annual report and accounts for the relevant year that (i) the transactions carried out during such year have been entered into in accordance with the relevant provisions of the Contractual Arrangements, (ii) no dividends or other distributions have been made by Yonghe Investment or Chengdu Yonghe to Beijing Xunyi or by Beijing Xunyi to the Registered Shareholders which are not otherwise subsequently assigned or transferred to our Group, and (iii) any new contracts entered into, renewed or reproduced between our Group and Beijing Xunyi during the relevant financial period under paragraph (iii) above are fair and reasonable, or advantageous to our Shareholders, so far as our Group is concerned and in the interests of our Company and our Shareholders as a whole.
 - (iii) Our Company's auditor will carry out review procedures annually on the transactions carried out pursuant to the Contractual Arrangements and will provide a letter to our Directors with a copy to the Stock Exchange confirming that the transactions have received the approval of our Directors, have been entered into in accordance with the relevant Contractual Arrangements and that no dividends or other distributions have been made by Yonghe Investment or Chengdu Yonghe to Beijing Xunyi or by Beijing Xunyi to the Registered Shareholders which are not otherwise subsequently assigned or transferred to our Group.

CONTINUING CONNECTED TRANSACTIONS

- (iv) For the purpose of Chapter 14A of the Listing Rules, and in particular the definition of “connected person”, the VIE Entities and Beijing Xunyi will be treated as our Company’s wholly-owned subsidiary, and at the same time, the directors, chief executive officers or substantial shareholders of the VIE Entities and Beijing Xunyi (where applicable) and their respective associates will be treated as connected persons of our Company (excluding for this purpose, the VIE Entities), and transactions between these connected persons and our Group (including for this purpose, the VIE Entities), other than those under the Contractual Arrangements, will be subject to requirements under Chapter 14A of the Listing Rules.
- (v) Beijing Xunyi will undertake that, for so long as the Shares are listed on the Stock Exchange, Beijing Xunyi will provide our Group’s management and our Company’s auditors full access to its relevant records for the purpose of our Company’s auditors’ review of the connected transactions.

CONFIRMATION FROM OUR DIRECTORS

Our Directors (including the independent non-executive Directors) are of the view that the Contractual Arrangements and the transactions contemplated therein are fundamental to our Group’s legal structure and business, that such transactions have been and will be entered into in the ordinary and usual course of business of our Group, are on normal commercial terms and are fair and reasonable and in the interests of our Company and the Shareholders as a whole, and with respect to the term of the Contractual Arrangements Agreements which is of a duration of longer than three years, taking into consideration the reasons for entering into the Contractual Arrangements with details set out in this section above, it is reasonable for these agreements to be for a duration of more than three years and it is normal business practice for agreements of this type to be of such duration. Accordingly, notwithstanding that the transactions contemplated under the Contractual Arrangements technically constitute continuing connected transactions under Chapter 14A of the Listing Rules, the Directors consider that, given that our Group is placed in a special situation in relation to the connected transactions rules under the Contractual Arrangements, it would be unduly burdensome and impracticable, and would add unnecessary administrative costs to our Company if such transactions are subject to strict compliance with the requirements set out under Chapter 14A of the Listing Rules.

CONFIRMATION FROM THE JOINT SPONSORS

Based on the documentation provided by the Company and the Joint Sponsor’s participation in the due diligence and discussion with the management of the Company and the PRC Legal Adviser, the Joint Sponsors are of the view that the Contractual Arrangements are fundamental to our Group’s legal structure and business operations and that the Contractual Arrangements have been entered into in the ordinary and usual course of business, on normal commercial terms and are fair and reasonable and are in the interests of the Shareholders as a whole.

The Joint Sponsors are of the view that with respect to the term of those Contractual Arrangements Agreements which is of a duration of longer than three years, taking into consideration the reasons for entering into the Contractual Arrangements with details set out in this section above, it is reasonable for these agreements to be for a duration of more than three years and it is normal business practice for agreements of this type to be of such duration.

THE CORNERSTONE PLACING

We have entered into cornerstone investment agreements (each a “**Cornerstone Investment Agreement**”, and together the “**Cornerstone Investment Agreements**”) with the cornerstone investors set out below (each a “**Cornerstone Investor**”, and together the “**Cornerstone Investors**”), pursuant to which the Cornerstone Investors have agreed to, subject to certain conditions, subscribe at the Offer Price for such number of Offer Shares (rounded down to the nearest whole board lot of 500 Shares) that may be purchased for an aggregate amount of US\$97 million (or approximately HK\$755.58 million) (the “**Cornerstone Placing**”).

The total number of Offer Shares to be subscribed by the Cornerstone Investors at the Offer Price of HK\$15.8 would be 47,821,000 Offer Shares, representing approximately 50.64% of the Offer Shares pursuant to the Global Offering and approximately 9.20% of our total issued share capital immediately upon completion of the Global Offering (assuming the Over-allotment Option is not exercised).

Our Company is of the view that, leveraging on the Cornerstone Investors’ investment experience, in particular in the healthcare sector, the Cornerstone Placing will help to raise the profile of our Company and to signify that such investors have confidence in our business and prospect. Our Company became acquainted with each of the Cornerstone Investors through introduction by the Joint Global Coordinators in the Global Offering.

The Cornerstone Placing will form part of the International Offering and the Cornerstone Investors will not subscribe for any Offer Shares under the Global Offering (other than pursuant to the Cornerstone Investment Agreements). The Offer Shares to be subscribed by the Cornerstone Investors will rank *pari passu* in all respect with the fully paid Shares in issue and to be listed on the Stock Exchange, and will be counted towards the public float of the Company. None of the Cornerstone Investors will become a substantial shareholder of our Company, the Cornerstone Investors or their close associates will not, by virtue of their cornerstone investments, have any Board representation in our Company. Other than a guaranteed allocation of the relevant Offer Shares at the Offer Price, the Cornerstone Investors do not have any preferential rights in the Cornerstone Investment Agreements compared with other public Shareholders.

To the best knowledge of our Company, (i) each of the Cornerstone Investors is an Independent Third Party; (ii) none of the Cornerstone Investors is accustomed to take instructions from our Company, its subsidiaries, the Directors, chief executive, Controlling Shareholders, substantial Shareholders, existing Shareholders or any of their respective close associates in relation to the acquisition, disposal, voting, or other disposition of Shares registered in its name or otherwise held by it; and (iii) none of the subscription of the relevant Offer Shares by any of the Cornerstone Investors is financed by our Company, its subsidiaries, the Directors, chief executive, Controlling Shareholders, substantial Shareholders, existing Shareholders or any of their respective close associates. Each of the Cornerstone Investors has confirmed that all necessary approvals have been obtained with respect to the Cornerstone Placing and that no specific approval from its shareholders is required for the relevant cornerstone investment as each of them has general authority to invest.

CORNERSTONE INVESTORS

As confirmed by each of the Cornerstone Investors, their subscription under the Cornerstone Placing would be financed by their own internal resources or funds under their discretionary management. There are no side arrangements or agreements between our Company and the Cornerstone Investors or any benefit, direct or indirect, conferred on the Cornerstone Investors by virtue of or in relation to the Cornerstone Placing, other than a guaranteed allocation of the relevant Offer Shares at the Offer Price.

The total number of Offer Shares to be subscribed by the Cornerstone Investors pursuant to the Cornerstone Placing may be affected by reallocation of the Offer Shares between the International Offering and the Hong Kong Public Offering in the event of over-subscription under the Hong Kong Public Offering as described in the section headed “Structure of the Global Offering — The Hong Kong Public Offering — Reallocation and Clawback”. In the event of over-subscription under the Hong Kong Public Offering, the amount allocated to each Cornerstone Investor will be scaled back on a *pro rata* basis. In the event that 50% of the total number of Offer Shares initially made available under the Global Offering is reallocated to the Hong Kong Public Offering, the amount of Offer Shares allocated to the Cornerstone Investors will be adjusted in proportion to their original subscription amount and represent, in aggregate, approximately 50% of the total number of Offer Shares initially available under the Global Offering. Assuming that the Over-allotment Option is fully exercised, the Offer Shares allocated to the Cornerstone Investors, in aggregate, will represent approximately 43.48% of the total number of Offer Shares (as enlarged by the exercise of the Over-allotment Option).

Details of the actual number of Offer Shares to be allocated to the Cornerstone Investors will be disclosed in the allotment results announcement of our Company to be published on or around December 10, 2021.

The Joint Global Coordinators may defer the delivery of a portion of the Offer Shares some Cornerstone Investors have subscribed for to a date later than the Listing Date under the Cornerstone Investment Agreements. The delay delivery arrangement was in place to facilitate the over-allocation in the International Offering. For details of the Over-allotment Option and the stabilization action by the Stabilizing Manager, please refer to the sections headed “Structure of the Global Offering — Over-allotment Option” and “Structure of the Global Offering — Stabilization” in this prospectus, respectively. Each Cornerstone Investor has agreed that it shall pay the relevant Offer Shares on or before the dealings in the Shares on the Stock Exchange commences. There will be no delayed settlement of payment by the Cornerstone Investors.

CORNERSTONE INVESTORS

THE CORNERSTONE INVESTORS

Based on the Offer Price of HK\$15.80, the tables below sets forth details of the Cornerstone Placing:

Cornerstone Investor	Total investment Amount	Number of Offer Shares to be acquired ^(note)	Assuming the Over-allotment Option is not exercised		Assuming the Over-allotment Option is fully exercised	
			Approximate % of the Offer Shares	Approximate % of ownership	Approximate % of the Offer Shares	Approximate % of ownership
	<i>(US\$ in million)</i>					
NCC Fund						
(as defined below)	20	9,860,000	10.44%	1.90%	9.08%	1.85%
Lake Bleu Prime (as defined below)	10	4,930,000	5.22%	0.95%	4.54%	0.92%
Hudson Bay (as defined below)	10	4,930,000	5.22%	0.95%	4.54%	0.92%
LAV Star Funds (as defined below)	10	4,930,000	5.22%	0.95%	4.54%	0.92%
E Fund						
(as defined below)	10	4,930,000	5.22%	0.95%	4.54%	0.92%
WT (as defined below)	10	4,930,000	5.22%	0.95%	4.54%	0.92%
Enreal and Forreal Funds						
(as defined below)	10	4,930,000	5.22%	0.95%	4.54%	0.92%
IvyRock						
(as defined below)	7	3,451,000	3.65%	0.66%	3.18%	0.65%
Athos Capital						
(as defined below)	5	2,465,000	2.61%	0.47%	2.27%	0.46%
York Asian Opportunities						
(as defined below)	5	2,465,000	2.61%	0.47%	2.27%	0.46%
Total	97	47,821,000	50.64%	9.20%	44.04%	8.95%

Note:

(1) Subject to rounding down to the nearest whole board lot of 500 Shares.

The information about our Cornerstone Investors set forth below has been provided by our Cornerstone Investors in connection with the Cornerstone Placing.

NCC China A-Share Master Fund

NCC China A-share Master Fund (“**NCC Fund**”) was established in Cayman Islands in 2014. It is managed by Neo-Criterion Capital Singapore Pte. Ltd. (“**NCC Capital**”). As at the end of October 2021, NCC Fund has 31 shareholders, among which only one shareholder, National University of Singapore, holds more than 10% interest. The order placer for NCC Fund’s investment is Neo-Criterion Capital Limited, which is the investment advisor of NCC Capital. NCC Capital is an asset management company focusing on the secondary market investment opportunities in China. It is headquartered in Singapore. As of June 30, 2021, the total asset under management was approximately USD2.9 billion. Its clients are mainly established institutional investors, including public pension plan, sovereign fund, endowment fund, etc. NCC Capital adopts a proprietary, robust in-depth research and investment approach to identify companies that are able to deliver alpha and generate absolute return on a sustainable basis.

NCC Capital is regulated by the Monetary Authority of Singapore under the Capital Markets Services license for fund management and a Registered Investment Adviser with the U.S. Securities and Exchange Commission.

Lake Bleu Prime Healthcare Master Fund Limited

Lake Bleu Prime Healthcare Master Fund Limited (“**Lake Bleu Prime**”) is managed by Lake Bleu Capital (Hong Kong) Limited. Lake Bleu Prime is a long-bias public equity fund focusing in Asia/Greater China healthcare. The fund primarily invests in public equities. The fund invests across the entire healthcare value chain, in pharmaceuticals, biotech, medical devices, distribution, hospitals and mobile health. Recently, Lake Bleu Prime acts as a cornerstone investor for Joinn Laboratories (HKSE Stock Code: 6127), Suzhou Bascare Medical (HKSE Stock Code: 2170), New Horizon Health (HKSE Stock Code: 6606), JD Health International Inc. (HKSE Stock Code: 6618), Microport Cardioflow Medtech Corporation (HKSE Stock Code: 2160), Akeso, Inc. (HKSE Stock Code: 9926), Pharmaron Beijing Co., Ltd. (HKSE Stock Code: 3759), Remegen Co., Ltd. (HKSE Stock Code: 9995), Hygeia Healthcare Holdings Co., Limited (HKSE Stock Code: 6078), and Kangji Medical Holdings Limited (HKSE Stock Code: 9997). The fund assets under management (“**AUM**”) is not less than US\$1.8 billion as of June 2021. Lake Bleu Prime has more than 10 passive investors. As a healthcare specialist, Lake Bleu Prime is keen to help the portfolio companies on value-added activities and has successfully helped many companies on this front. Lake Bleu Capital (Hong Kong) limited is also licensed by the SFC to carry out Type 9 regulated activities.

Hudson Bay Master Fund Ltd

Hudson Bay Master Fund Ltd (“**Hudson Bay**”) is a Cayman Islands limited company managed by Hudson Bay Capital Management LP (“**HBC**”), a multi-billion-dollar asset management firm operating in New York and London. The only shareholders of Hudson Bay Master Fund Ltd are Hudson Bay Fund LP and Hudson Bay International Fund Ltd. There is no single investor owns more than 20% interest in any of Hudson Bay Fund LP and Hudson Bay International Fund Ltd. With over 100 employees, HBC has been managing assets on behalf of outside investors since 2006. The firm invests across multiple strategies by utilizing rigorous fundamental analysis and seeks to identify value and growth opportunities that are uncorrelated to each other and market indices. HBC promotes an integrated team culture emphasizing collaboration and cross-pollination of ideas across sectors and strategies. HBC’s dedicated investment team seeks to achieve outstanding performance by investing in companies that are poised for growth or are undervalued while maintaining a focus on risk management.

LAV Star Limited and LAV Star Opportunities Limited

LAV Star Limited is wholly-owned by LAV Fund VI, L.P. and LAV Star Opportunities Limited (together with LAV Star Limited, the “**LAV Star Funds**”) is wholly-owned by LAV Fund VI Opportunities, L.P. Both LAV Fund VI L.P. and LAV Fund VI Opportunities, L.P. are Cayman exempted limited partnerships and none of the limited partners in any of LAV Funds VI L.P. and LAV Fund VI Opportunities, L.P. holds more than 30% interest. The general partner of LAV Fund VI, L.P. and LAV Fund VI Opportunities, L.P. are LAV GP VI, L.P. and LAV GP VI Opportunities, L.P., respectively. The general partner of LAV GP VI, L.P. and LAV GP VI Opportunities, L.P. are LAV Corporate VI GP, Ltd. and LAV Corporate VI GP Opportunities, Ltd., respectively. Both LAV Fund VI L.P. and LAV Fund VI Opportunities, L.P. are the investment arm of Lilly Asia Ventures (the “**LAV**”). LAV is an Asia-based life science investment firm with portfolios covering all major sectors of the biomedical and healthcare industry including biopharmaceuticals, medical devices, diagnostics and healthcare services. LAV is managed by a team of professionals with substantial biomedical domain expertise, as well as extensive investing experiences.

Yi Fang Da Hadar Investment Limited

Yi Fang Da Hadar Investment Limited (“**E Fund**”) is an investment company incorporated in the British Virgin Islands. It is the investment vehicle controlled and held by E Fund Management (Hong Kong) Co., Limited (“**E Fund HK**”). E Fund HK was incorporated in Hong Kong in August 2008. E Fund HK is licensed for Type 1 (Dealing in Securities), Type 4 (Advising on Securities) and Type 9 (Asset Management) regulated activities by the SFC. E Fund HK serves as the global investment and business platform for its parent company, E Fund Management Co., Limited (“**E Fund Group**”). As E Fund Group’s only window company overseas, E Fund HK strategically connects China and the overseas market. E Fund HK capitalizes the investment and research capabilities of E Fund Group and its competitive advantage in the overseas market to provide comprehensive quality service to its clients. As of September 30, 2020, E Fund Group had over RMB1.8 trillion under management. The shareholders of E Fund Group include (1) Guangdong Finance Trust Co., Ltd. (廣東粵財信託有限公司), (2) GF Securities Co., Ltd. (廣發證券股份有限公司), which is listed on the Hong Kong Stock Exchange (HKSE Stock Code: 1776) and the Shenzhen Stock Exchange (Stock Code: 776.SZ), and (3) Infore Holding Group Co., Ltd (盈峰控股集團有限公司), each holding 22.65% in E Fund Group. Approval of the shareholders of GF Securities Co., Ltd. (廣發證券股份有限公司), the Hong Kong Stock Exchange or the Shenzhen Stock Exchange is not required for the subscription for the Offer Shares pursuant to the relevant Cornerstone Investment Agreement.

WT Asset Management Limited

WT Asset Management Limited (“**WT**”) is a company incorporated in Hong Kong with limited liability and licensed by the SFC to carry on Type 9 (Asset Management) regulated activity. WT is beneficially owned as to 100% by Mr. Tongshu Wang (王通書), who is an Independent Third Party. WT has agreed to procure WT China Fund Limited and/or WT China Focus Fund (the “**WT Funds**”), funds that WT has discretionary investment management power over, to subscribe for such number of the Shares. The WT Funds are managed by WT as investment manager. The WT Funds pursue to achieve absolute return and long-term capital appreciation by investing primarily in the listed securities of companies which have great exposure or material impact by the Greater China region (which includes the PRC, Hong Kong, Macau and Taiwan). Investors of the WT Funds include but are not limited to pension funds, sovereign wealth funds, fund of funds, family offices and other sophisticated institutional investors. As of June 30, 2021, the total AUM of the WT Funds is approximately US\$4.01 billion.

Enreal China Master Fund and Forreal China Value Fund

Enreal China Master Fund is an investment fund focused on investing in technology-driven opportunities in China. The fund will invest in the Hong Kong/mainland China equity market as well as ADRs, and mainly covers sectors including TMT, Advanced Manufacturing, Consumer and Healthcare etc. The fund currently invested in cash or cash equivalent instruments and listed equities.

Forreal China Value Fund is a parallel fund of Enreal China Master Fund focused on investing in technology-driven opportunities in China. The fund will invest in the Hong Kong/mainland China equity market as well as ADRs, and mainly covers sectors including TMT, Advanced Manufacturing, Consumer and Healthcare etc. The two funds will generally invest and divest concurrently on substantially similar terms. The fund currently invested in cash or cash equivalent instruments and listed equities both Enreal China Master Fund and Forreal China Value Fund (together, “**Enreal and Forreal Funds**”) are Cayman Islands exempted companies. Enreal and Forreal Funds have 8 shareholders who are passive financial investors, with no individual shareholder has more than 25% interest in any of them. Enreal Management Limited, a BVI company, is the investment manager of Enreal China Master Fund and holds all of its management shares; Forreal Management Limited, a BVI company, is the investment manager of Forreal China Value Fund and holds all of its management shares. Enreal Management Limited and Forreal Management Limited are ultimately controlled by Miss. Jiang Yi (江怡).

IvyRock Asset Management (HK) Limited

IvyRock Asset Management (HK) Limited 常春藤資產管理(香港)有限公司 (“**IvyRock**”) is incorporated with limited liability in Hong Kong in 2009 and licensed by the SFC to carry out Type 9 (Asset Management) regulated activity in 2014. The ultimate beneficial owner of IvyRock is Mr. Yong HUANG (黃勇). IvyRock as an investment manager of certain commingled funds and institutional separate managed accounts has agreed to subscribe for such number of the Offer Shares through certain funds that IvyRock has discretionary investment management power, namely, Ivyrock China Focus Master Fund, IvyRock China Equity Master Fund and ABS Direct Equity Fund LLC, Asia Series 6 (together, the “**IvyRock Funds**”). IvyRock Funds have 80 shareholders who are passive financial investors, with no shareholder has more than 15% interest in any of them.

The IvyRock Funds pursue to achieve long-term capital appreciation by investing primarily in the listed securities of companies which have great exposure to the greater china region with a fundamentals-driven approach.

Athos Capital Limited

Athos Capital Limited (“**Athos Capital**”) serves as the investment manager of Athos Asia Event Driven Master Fund. Athos Asia Event Driven Master Fund is an exempted company incorporated with limited liability in the Cayman Islands, it has over 30 investors with no single investor holds more than 30 interest in it. Athos Capital Manages Assets of over US\$1 billion on behalf of a global institutional investor base, including sovereign wealth funds, university endowments, foundations and family offices. Founded in 2011, Athos Capital pursues a variety of investment strategies with a view to providing superior and sustainable long term returns for its clients. Athos Capital is wholly-owned by Mr. Matthew Love Moskey and Mr. Friedrich Bela Schulte-Hillen, who also serve as the two responsible officers of Athos Capital.

York Asian Opportunities Investments Master Fund, LP

York Asian Opportunities Investments Master Fund, LP (“**York Asian Opportunities**”) is a limited partnership formed under the laws of the Cayman Islands and operating as a private investment fund. MY.Alpha Management HK Advisors Limited serves as the investment manager to York Asian Opportunities. York Asian Opportunities has a total of 166 limited partners, with no limited partner has more than 10% interest. The investors of York Asian Opportunities include, among others, pensions, endowments, foundations and fund of funds. York Asian Opportunities is a global event-driven fund that focuses on a wide range of strategies that collectively seek to generate attractive returns with low correlation to traditional markets. York Asian Opportunities’ longstanding equity capital markets-focused strategies include investments in disruptive events and technologies with the potential to transform traditional industries.

CLOSING CONDITIONS

The obligation of each of the Cornerstone Investors to acquire the Offer Shares under the respective Cornerstone Investment Agreement is subject to, among other things, the following closing conditions:

- (i) the Hong Kong Underwriting Agreement and the International Underwriting Agreement being entered into and having become effective and unconditional (in accordance with their respective original terms or as subsequently waived or varied by agreement of the parties thereto) by no later than the time and date as specified in the Hong Kong Underwriting Agreement and the International Underwriting Agreement;
- (ii) neither the Hong Kong Underwriting Agreement nor the International Underwriting Agreement having been terminated;
- (iii) the Listing Committee having granted the approval for the listing of, and permission to deal in, the Shares (including the Shares under the Cornerstone Placing) as well as other applicable waivers and approvals and such approval, permission or waiver having not been revoked prior to the commencement of dealings in the Shares on the Stock Exchange;
- (iv) no laws shall have been enacted or promulgated which prohibits the consummation of the transactions contemplated in Hong Kong Public Offering, the International Offering or the Cornerstone Investment Agreements, and there shall be no orders or injunctions from a court of competent jurisdiction in effect precluding or prohibiting consummation of such transactions; and
- (v) the respective representations, warranties, acknowledgements, undertakings and confirmations of the Cornerstone Investor under the Cornerstone Investment Agreements are and will be (as of the closing of the Cornerstone Investment Agreements) accurate and true in all respects and not misleading and that there is no material breach of the Cornerstone Investment Agreement on the part of the Cornerstone Investor.

CORNERSTONE INVESTORS

RESTRICTIONS ON THE CORNERSTONE INVESTOR

Each of the Cornerstone Investors has agreed that it will not, whether directly or indirectly, at any time during the period of six months from the Listing Date (the “**Lock-up Period**”), dispose of any of the Offer Shares they have purchased pursuant to the relevant Cornerstone Investment Agreements, save for certain limited circumstances, such as transfers to any of its wholly-owned subsidiaries who will be bound by the same obligations of such Cornerstone Investor, including the Lock-up Period restriction.

SUBSTANTIAL SHAREHOLDERS

So far as our Directors are aware, immediately following the completion of the Global Offering and without taking into account any Shares which may be issued pursuant to the exercise of the Over-allotment Option, the following persons will have an interest or short position in the Shares or the underlying Shares which would fall to be disclosed to us and the Stock Exchange under the provisions of Divisions 2 and 3 of Part XV of the SFO, or who is, directly or indirectly, interested in 10% or more of the issued voting shares of our Company:

Name	Capacity/nature of interest⁽¹⁾	Number of Shares held as of the Latest Practicable Date	Approximate percentage of shareholding in the total issued share capital of our Company as of the Latest Practicable Date	Number of Shares held immediately following completion of the Global Offering	Approximate percentage of shareholding in the total issued share capital of our Company immediately following completion of the Global Offering
ZY Investment Capital Ltd ⁽²⁾	Beneficial owner	161,531,916	37.96%	161,531,916	31.07%
ZY Ventures Ltd ⁽²⁾	Interest in controlled corporation	161,531,916	37.96%	161,531,916	31.07%
Yunuo Technology Holdings Limited ⁽³⁾	Beneficial owner	20,000,000	4.70%	20,000,000	3.85%
Shanghai Yuxin Technology Partnership (Limited Partnership) ⁽³⁾	Interest in controlled corporation	20,000,000	4.70%	20,000,000	3.85%
Shanghai Yuhe Technology Company Limited ⁽³⁾	Interest in controlled corporation	20,000,000	4.70%	20,000,000	3.85%
Mr. Zhang ⁽²⁾⁽³⁾	Interest in controlled corporation	181,531,916	42.66%	181,531,916	34.91%
Yonghe Hair Service ⁽⁴⁾	Beneficial owner	91,866,668	21.59%	91,866,668	17.67%
	Interest jointly held with another person	91,866,668	21.59%	91,866,668	17.67%
Panmao Shanghai ⁽⁴⁾	Interest in controlled corporation	183,733,336	43.18%	183,733,336	35.34%

SUBSTANTIAL SHAREHOLDERS

Name	Capacity/nature of interest ⁽¹⁾	Number of Shares held as of the Latest Practicable Date	Approximate percentage of shareholding in the total issued share capital of our Company as of the Latest Practicable Date	Number of Shares held immediately following completion of the Global Offering	Approximate percentage of shareholding in the total issued share capital of our Company immediately following completion of the Global Offering
Shanghai Pannuo ⁽⁴⁾	Interest in controlled corporation	183,733,336	43.18%	183,733,336	35.34%
CITIC Private Equity Funds Management Co., Ltd. ⁽⁴⁾ (中信產業投資基金管理有限公司)	Interest in controlled corporation	183,733,336	43.18%	183,733,336	35.34%
CYH ⁽⁵⁾	Beneficial owner	91,866,668	21.59%	91,866,668	17.67%
	Interest jointly held with another person	91,866,668	21.59%	91,866,668	17.67%
CYH Cosmetic Medical Investment Limited ⁽⁵⁾	Interest in controlled corporation	183,733,336	43.18%	183,733,336	35.34%
CPEChina Fund II ⁽⁵⁾	Interest in controlled corporation; interest jointly held with another person	183,733,336	43.18%	183,733,336	35.34%
CPEChina Fund IIA ⁽⁵⁾	Interest in controlled corporation; interest jointly held with another person	183,733,336	43.18%	183,733,336	35.34%
Citron PE Associates II ⁽⁵⁾	Interest in controlled corporation	183,733,336	43.18%	183,733,336	35.34%
Citron PE Funds II ⁽⁵⁾	Interest in controlled corporation	183,733,336	43.18%	183,733,336	35.34%

SUBSTANTIAL SHAREHOLDERS

Name	Capacity/nature of interest ⁽¹⁾	Number of Shares held as of the Latest Practicable Date	Approximate percentage of shareholding in the total issued share capital of our Company as of the Latest Practicable Date	Number of Shares held immediately following completion of the Global Offering	Approximate percentage of shareholding in the total issued share capital of our Company immediately following completion of the Global Offering
Citron PE Holdings Limited ⁽⁵⁾	Interest in controlled corporation	183,733,336	43.18%	183,733,336	35.34%
CLSA Global Investments Management Limited ⁽⁵⁾	Interest in controlled corporation	183,733,336	43.18%	183,733,336	35.34%
CLSA, B.V. ⁽⁵⁾	Interest in controlled corporation	183,733,336	43.18%	183,733,336	35.34%
CITIC Securities International Company Limited ⁽⁵⁾	Interest in controlled corporation	183,733,336	43.18%	183,733,336	35.34%
CITIC Securities Company Limited (中信證券股份有限公司) ⁽⁴⁾⁽⁵⁾	Interest in controlled corporation	183,733,336	43.18%	183,733,336	35.34%
ZH Investment Capital Ltd ⁽⁶⁾	Beneficial owner	24,000,000	5.64	24,000,000	4.62%
ZH Ventures Ltd ⁽⁶⁾	Interest in controlled corporation	24,000,000	5.64	24,000,000	4.62%
ZHANG Hui ⁽⁶⁾	Interest in controlled corporation	24,000,000	5.64	24,000,000	4.62%
Frاندor Limited ⁽²⁾⁽⁶⁾⁽⁷⁾	Interest in controlled corporation	185,531,916	43.6	185,531,916	35.69%
Trident Trust Company (Singapore) Pte Limited ⁽²⁾⁽⁶⁾⁽⁷⁾	Trustee	185,531,916	43.6	185,531,916	35.69%

SUBSTANTIAL SHAREHOLDERS

Notes:

1. All interests stated are long positions.
2. ZY Investment Capital Ltd is wholly-owned by ZY Ventures Ltd, which is in turn wholly-owned by Frandor Limited. Frandor Limited is a nominee shareholder holding shares of ZY Ventures Ltd on behalf of The ZY Trust and is wholly-owned by Trident Trust Company (Singapore) Pte Limited, which is the trustee of The ZY Trust established by Mr. Zhang (as the settlor) and Trident Trust Company (Singapore) Pte Limited (as the trustee) on March 25, 2021.
3. Yunuo Technology Holdings Limited (上海予諾科技控股有限公司) is wholly owned by Shanghai Yuxin Technology Partnership (Limited Partnership) (上海予信科技合夥企業(有限合夥)), the general partner of which is Shanghai Yuhe Technology Company Limited (上海予赫科技有限公司), which is in turn wholly-owned by Mr. Zhang. As such, Mr. Zhang is deemed to be interested in the 40,382,979 Shares held by ZY Investment Capital Ltd and the 5,000,000 Shares held by Yunuo Technology Holdings Limited under the SFO.
4. Yonghe Hair Service is wholly-owned by Panmao Shanghai, the general partner of which is Shanghai Pannuo, which is in turn wholly-owned by CITIC Private Equity Funds Management Co., Ltd. CITIC Private Equity Funds Management Co., Ltd is owned as to 35% by CITIC Securities Company Limited, a company listed on both the Stock Exchange and the Shanghai Stock Exchange.
5. CYH is wholly-owned by CYH Cosmetic Medical Investment Limited, which is owned to approximately 86.3% by CPEChina Fund II and 13.7% by CPEChina Fund IIA. CYH Cosmetic Medical Investment Limited is jointly controlled by CPEChina Fund II and CPEChina Fund IIA. CPEChina Fund II and CPEChina Fund IIA are two exempted limited partnerships registered under the laws of the Cayman Islands. The general partner of CPEChina Fund II and CPEChina Fund IIA is Citron PE Associates II. Citron PE Associates II is an exempted limited partnership registered under the laws of the Cayman Islands whose general partner is Citron PE Funds II. Citron PE Funds II is wholly owned by Citron PE Holdings Limited, which is held as to 35% by CLSA Global Investments Management Limited. CLSA Global Investments Management Limited is wholly owned by CLSA, B.V., which is wholly owned by CITIC Securities International Company Limited, which in turn is wholly owned by CITIC Securities Company Limited.
6. ZH Investment Capital Ltd is wholly-owned by ZH Ventures Ltd, which is in turn wholly-owned by Frandor Limited. Frandor Limited is a nominee shareholder holding shares of ZH Ventures Ltd on behalf of The ZH Trust and is wholly-owned by Trident Trust Company (Singapore) Pte Limited, which is the trustee of The ZH Trust established by Mr. ZHANG Hui (as the settlor) and Trident Trust Company (Singapore) Pte Limited (as the trustee) on March 25, 2021. As such, Mr. ZHANG Hui is deemed to be interested in the 24,000,000 Shares held by ZH Investment Capital Ltd under the SFO.
7. Frandor Limited is a nominee shareholder holdings shares of ZY Ventures Ltd and ZH Ventures Ltd on behalf of The ZY Trust and The ZH Trust, respectively. It is wholly-owned by Trident Trust Company (Singapore) Pte Limited, the trustee of The ZY Trust and The ZH Trust. Accordingly, each of Frandor Limited and Trident Trust Company (Singapore) Pte Limited is deemed to be interested in the 185,531,916 Shares by virtue of the SFO.

Except as disclosed above, our Directors are not aware of any other person who will, immediately following the completion of the Global Offering (assuming the Over-allotment Option is not exercised), have any interest and/or short positions in the Shares or underlying Shares of our Company which would fall to be disclosed to us pursuant to the provisions of Divisions 2 and 3 of Part XV of the SFO, or, who are, directly or indirectly, interested in 10% or more of the nominal value of any class of our share capital carrying rights to vote in all circumstances at general meetings of our Company or any other member of our Group.

DIRECTORS AND SENIOR MANAGEMENT

BOARD OF DIRECTORS

Our Board consists of seven Directors, of whom two are executive Directors, two are non-executive Directors and three are independent non-executive Directors. Our Board is responsible and has general powers for the management and conduct of our business. The table below sets out certain information in respect of the members of the Board.

Name	Position	Age	Date of appointment as Director	Date of joining our Group	Role and responsibility	Relationship with other Directors and senior management
ZHANG Yu (張玉)	Chairman of the Board, Executive Director and chief executive officer	36	September 17, 2020	July 2010	Overall strategic planning, business direction, operational management and marketing	Elder brother of Mr. ZHANG Hui
ZHANG Hui (張輝)	Executive Director and procurement director	34	September 17, 2020	May 2011	Overall procurement management and business development	Younger brother of Mr. ZHANG
ZHAI Feng (翟鋒)	Non-executive Director	53	September 17, 2020	July 2017	Provide advice on strategic development	None
GENG Jiaqi (耿嘉琦)	Non-executive Director	50	September 17, 2020	July 2017	Provide advice on strategic development	None
WANG Jiping (王繼萍)	Independent non-executive Director	60	June 1, 2021	June 2021	Provide independent advice and judgment to our Board	None
CHAN Peng Kuan (陳炳鈞)	Independent non-executive Director	58	June 1, 2021	June 2021	Provide independent advice and judgment to our Board	None
LI Xiaopei (李小培)	Independent non-executive Director	35	June 1, 2021	June 2021	Provide independent advice and judgment to our Board	None

DIRECTORS AND SENIOR MANAGEMENT

DIRECTORS

Executive Directors

Mr. ZHANG Yu (張玉) (“Mr. Zhang”), aged 36, is our founder, executive Director, chairman of the Board and the chief executive officer. He was appointed as a Director on September 17, 2020 and re-designated as the an executive director on June 1, 2021. He founded the Group in July 2010 and has been the chief executive officer of the Group since July 2010. Mr. Zhang is in charge of the overall strategic planning, business direction and operational management of the Group.

Mr. Zhang has been dedicated to medical haircare service industry for over 16 years, and thus has a deep understanding of the needs of our customers from his years of frontline experience. Mr. Zhang ventured into the hair transplant sector in March 2005 when he joined Beijing Churong Fuyun Medical Beauty Clinic (北京楚蓉福運醫療美容診所) and resigned in November 2007. After that, he founded our Group and started his own hair transplant business with the brand name of Yonghe (雍禾) in 2010. Mr. Zhang is a pioneer in advocating and being relentlessly committed to the development of hair transplant service by introducing and subsequently upgrading the most advanced hair transplant solutions to Chinese patients. Mr. Zhang has led the formulation of our strategic development decisions, established and developed our medical profession team. As such, our Group has gained a significant first mover advantage and grown successfully in China. Leveraging his forward-looking industry vision, we have further expand our business lines to cover the diagnosis and treatment of various hair-related diseases, hair transplant, medical and routine hair care, wig research and production and various other hair-related product and service offerings. Under his leadership, we have developed a management style reflective of the values and characteristics of the “Yonghe” brand and obtained many prestigious accreditations and recognitions.

Mr. Zhang graduated from Sixian Dazhuang Middle School (泗縣大莊初級中學) in June 2001. Mr. Zhang is the deputy head of the hair medicine and scalp health management group of skin professional committee of the Chinese Non-government Medical Institutions Association (中國非公立醫療機構協會皮膚專業委員會毛髮醫學與頭皮健康管理學組) since September 2018.

Mr. ZHANG Hui (張輝), aged 34, was appointed as a Director on September 17, 2020 and re-designated as the an executive Director on June 1, 2021. He has been the procurement director of the Group since May 2011. Mr. Zhang Hui is in charge of the overall procurement management and business development of the Group.

He accumulated over 10 years of experience in medical haircare service industry within our Group. Since joining our Group, Mr. Zhang Hui developed and optimized our Group’s strategies and process relating to supply chain management and business development. His strong support towards high-quality and just-in-time management concept of the procurement process contributed to and been instrumental to the steady expansion of our Group. Mr. Zhang Hui has actively promoted our business development, and further fortified our leading position in this industry in China.

Mr. Zhang Hui graduated from Beijing Language and Culture University (北京語言大學網絡教育學院), the PRC, through long-distance education, with an associate degree in economic management in January 2019.

DIRECTORS AND SENIOR MANAGEMENT

Mr. ZHAI Feng (翟鋒), aged 53, was appointed as a Director on September 17, 2020 and re-designated as a non-executive Director on June 1, 2021. Mr. Zhai is responsible for providing advice on strategic development of our Group. Mr. Zhai has been serving as managing director at Beijing Panmao Investment Management Co., Ltd. (北京磐茂投資管理有限公司) since January 2019, a company specializing in asset management, where he is primarily responsible for post-investment management and operation related matters of the invested companies.

Mr. Zhai has over 30 years of experience in investment and management industry. Mr. Zhai was a managing director at Shanghai Panxin Mezzanine Investment Management Company Limited (上海磐信夾層投資管理有限公司) from January 2013 to December 2018. From July 1991 to November 2012, Mr. Zhai worked at Procter & Gamble (China) Sales Co. Ltd. (寶潔(中國)有限公司) with his last position as a president of sales in Greater China. Mr. Zhai has served as director of Shaanxi Tourism Culture Industry Holding Co. Ltd. (陝西旅遊文化產業股份有限公司) (“**Shaanxi Tourism**”) (stock code: 870432), and CIIC Guanaitong (Shanghai) Technology Co., Ltd. (中智關愛通(上海)科技股份有限公司) (stock code: 871282), both listed on the National Equities Exchange and Quotations Co., Ltd., since December 2015 and November 2016, respectively. From October 2014 to July 2019, he served as director of Weihai Guangwei Composites Co., Ltd. (威海光威複合材料股份有限公司), which is listed on the Shenzhen Stock Exchange (stock code: 300699). From December 2017 to November 2019, he served as director of Beijing Hualian Department Store Co., Ltd (北京華聯商厦股份有限公司), which is listed on the Shenzhen Stock Exchange (stock code: 000882).

Mr. Zhai obtained his bachelor’s degree in environmental engineering from Tongji University (同濟大學), the PRC, in July 1991.

Mr. Zhai was a director of Shaanxi Tourism Cultural Industry Development Co. Ltd (陝西旅遊文化產業發展股份有限公司), a company established in the PRC which was deregistered on June 30, 2016 as a result of merger by absorption by Shaanxi Tourism. He was also a director of Horgos Chinatoporeddit, a company established in the PRC and was deregistered on December 3, 2018. Mr. Zhai was a director of Panxin Rongtai (Shanghai) Asset Management Co., Ltd. (磐信鎔泰(上海)資產管理有限公司), a company established in the PRC and was deregistered on January 29, 2019. Mr. Zhai confirmed that each of the above companies was solvent prior to its deregistration and was deregistered as it had not commenced business since establishment or had ceased to conduct business. He further confirmed that, as of the Latest Practicable Date, no claims have been made against him and he was not aware of any threatened or potential claims made against him and there are no outstanding claims and/or liabilities as a result of the deregistration of each of the above companies.

Mr. GENG Jiaqi (耿嘉琦), aged 50, was appointed as a Director on September 17, 2020 and re-designated as a non-executive Director on June 1, 2021. Mr. Geng is responsible for provide advice on strategic development of the Group.

Mr. Geng has over 13 years of experience in investment and management industry. Mr. Geng has been an investment director of Beijing Panmao Investment Management Co., Ltd. (北京磐茂投資管理有限公司) since October 2020. Mr. Geng was an investment director of Tianjin Panmao Enterprise Management Limited Liability Partnership (天津磐茂企業管理合夥企業(有限合夥)) from January 2019 to September 2020. From May 2015 to December 2018, he was an investment director of Shanghai Panxin Equity Investment Management Limited (上海磐信股權投資管理有限公司). He was a director of Wangfujing Group Co., Ltd., a company listed on Shanghai Stock Exchange (stock code: 600859), from December 2016 to December 2019. Mr. Geng was a senior investment manager of Beijing Hony Future Investment Advisor Ltd. (北京弘毅遠方投資顧問有限公司) from September 2008 to March 2010.

DIRECTORS AND SENIOR MANAGEMENT

Mr. Geng obtained his bachelor's degree in accounting & finance and business administration & management from Oxford Brookes University, the United Kingdom, in July 1996 and his master's degree in business administration from State University of New Jersey, the U.S., in January 2001.

Independent Non-executive Directors

Ms. WANG Jiping (王繼萍), aged 60, was appointed as an independent non-executive Director on June 1, 2021 and is responsible for providing independent advice and judgment to our Board.

Ms. Wang has over 18 years of experience in hair transplant surgery industry. Ms. Wang was the head of Hair Transplant Center of the Fourth Medical Centre, Chinese PLA General Hospital (解放軍總醫院第四醫學中心) from February 2008 to December 2020. She worked in Plastic Surgery Hospital of Peking Union Medical College (北京協和醫學院整形外科醫院) from November 1997 to February 2008, and was subsequently promoted as the director of Hair Transplant Center from 2003 to 2008 and the director of Outpatient Department from 2003 to 2006.

Ms. Wang obtained her bachelor's degree in medicine from Shandong Medical College (山東醫學院) (now known as Shandong University School of Medicine (山東大學醫學院)) in August 1984. She was awarded the practice certificate for medical practitioners issued by the Ministry of Health of the PRC in May 1999. She was certified as a chief physician in plastic surgery by the Ministry of Health of the PRC in July 2007.

She was awarded the second prize of National Science and Technology Progress Award (國家科學技術進步獎) for "A series of technological innovations and applications for the repair of soft tissue damage and functional reconstruction in war trauma (burns) (戰創(燒)傷軟組織毀損修復與功能重建系列技術創新與應用)" issued by the State Council of the PRC.

Mr. CHAN Peng Kuan (陳炳鈞), aged 58, was appointed as an independent non-executive Director on June 1, 2021 and is responsible for providing independent advice and judgment to our Board.

Mr. Chan has more than 20 years of experience in finance and banking. Mr. Chan has been the independent non-executive director of Yincheng International Holding Co., Ltd., a company listed on the Stock Exchange (stock code: 1902), since February 2019. He was the chief financial officer of Elegance Optical International Holdings Limited, a company listed on the Stock Exchange (stock code: 907), from October 2017 to May 2019. He served as the chief operating officer of CITIC Merchant Co., Limited (中信國通投資管理有限公司) from January 2012 to September 2017. Prior to that, Mr. Chan was the Head of Asia CIG and Cleantech of Piper Jaffray Asia Limited from February 2011 to November 2011. From March 2005 to January 2011, Mr. Chan also worked at BNP Paribas Capital (Asia Pacific) Limited with his last position as a managing director of Corporate Finance — Greater China Coverage department.

DIRECTORS AND SENIOR MANAGEMENT

From August 2000 to December 2004, Mr. Chan served as an executive director of Sanyuan Group Limited (三元集團有限公司) (“**Sanyuan Group**”), a company delisted from the Stock Exchange in December 2009 (stock code: 0140).

Mr. Chan obtained his bachelor’s degree in commerce from University of Canterbury in New Zealand in May 1989. He received his master’s degree in applied finance from Macquarie University in Australia in November 1998. Mr. Chan has been a member of the Hong Kong Institute of Certified Public Accountants (previously known as Hong Kong Society of Accountants) since July 1993. He obtained his professional qualification as a Chartered Accountant in November 1992 from the Chartered Accountants Australia and New Zealand (previously known as the Institute of Chartered Accountants of New Zealand).

Mr. Chan was a director of the following companies, which were involuntarily wound up:

<u>Name of Company</u>	<u>Place of incorporation</u>	<u>Principal business activity immediately before being voluntarily wound up or struck off</u>	<u>Voluntarily wound up or being struck off</u>
Pacific Engineering Limited	Hong Kong	a company principally engaged in the trading of the sea sand	Involuntarily wound up on 11 May 2006 due to winding up order
Infinity Properties Limited	Hong Kong	a property holding company	Involuntarily wound up on 31 January 2007 due to winding up order
Propland Limited	Hong Kong	a property holding company	involuntarily wound up on 6 October 2006 due to winding up order
V & O Company Limited	Hong Kong	a property holding company	Involuntarily wound up on 6 October 2006 due to winding up order

Mr. Chan was appointed on 31 August 2000 as a director of each of Pacific Engineering Limited, Infinity Properties Limited, Propland Limited and V&O Company Limited (collectively, the “**Relevant Companies**”), all of which were incorporated in Hong Kong and wholly-owned subsidiaries of Sanyuan Group.

There was no wrongful act on the part of Mr. Chan leading to the winding up of the Relevant Companies.

DIRECTORS AND SENIOR MANAGEMENT

Mr. Chan has confirmed that, (i) he was not involved in the daily operations of the Relevant Companies at any time; and (ii) during the course of the liquidation of the Relevant Companies, there was no allegation of fraud or other impropriety, judgment debt or disqualification order made against him.

Mr. LI Xiaopei (李小培), aged 35, was appointed as an independent non-executive Director on June 1, 2021 and is responsible for providing independent advice and judgment to our Board.

Mr. Li has over 10 years of experience in organic and polymer chemistry industry. He is currently served as a technical adviser at Tianjin Changyuan Medical Technology Company Limited (天津長元醫藥科技有限公司) since June 2020. From April 2020 to March 2021, he was a research assistant of Institute for Chemical Research, Kyoto University. He worked in Beijing Boyalife Weiming Union Stem Cell Technology Company Limited (北京博雅未名聯合幹細胞科技有限公司) from January 2014 to May 2014. From February 2011 to November 2011, he worked in WuXi AppTec (Tianjin) Co., Ltd. (天津藥明康德新藥開發有限公司).

Mr. Li received a bachelor degree in materials chemistry from Huaibei Normal University (淮北師範大學), the PRC, in June 2009 and a master degree in polymer chemistry from Kyoto University, Japan, in March 2018. He was awarded a scholarship from China Scholarship Council to attend Kyoto University and subsequently received a PhD degree in polymer chemistry from Kyoto University, Japan, in March 2021.

Other Disclosure Pursuant to Rule 13.51(2) of the Listing Rules

Save as disclosed above and in this prospectus, each of our Directors confirms with respect to himself or herself that he or she (1) did not hold other long positions or short positions in the Shares, underlying Shares, debentures of our Company or any associated corporation (within the meaning of Part XV of the SFO) as of the Latest Practicable Date; (2) had no other relationship with any Directors, senior management or substantial shareholders of our Company as of the Latest Practicable Date; (3) did not hold any other directorships in the three years prior to the Latest Practicable Date in any public companies of which the securities are listed on any securities market in Hong Kong and/or overseas; and (4) there are no other matters concerning our Director's appointment that need to be brought to the attention of our Shareholders and the Stock Exchange or shall be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Listing Rules.

DIRECTORS AND SENIOR MANAGEMENT

SENIOR MANAGEMENT

Our senior management is responsible for the day-to-day management of our business. Mr. Zhang and Mr. Zhang Hui are each a Director of our Group and also a member of our senior management team. See their biographies in the part headed “— Directors” above. The table below sets out certain information in respect of the senior management, in addition to our Directors, of the Group.

Name	Position	Age	Date of appointment	Date of joining our Group	Role and responsibility	Relationship with other Directors and senior management
ZHANG Yu (張玉)	Chief executive officer	35	July 2010	July 2010	Overall strategic planning, business direction and operational management	Elder brother of Mr. ZHANG Hui
XU Yang (徐洋)	Operation director and assistant to the chief executive officer	42	September 2, 2019	September 2019	Responsible for daily operations and administrative matters of our Group	None
HAN Zhimei (韓志梅)	Finance director	44	March 20, 2017	March 2017	Responsible for financing, accounting, budget control, internal control, financial management of the Group	None
ZHANG Hui (張輝)	Procurement director	34	May 2011	May 2011	Overall procurement management and business development of our Group	Younger brother of Mr. ZHANG
LI Xiaolong (李小龍)	General medical service director	56	June 28, 2020	June 2020	Responsible for medical quality control and procedure standardization of our Group	None
HUANG Donghong (黃東紅)	Marketing director	35	May 8, 2020	May 2012	Responsible for overall branding, sales and marketing management of our Group	None

DIRECTORS AND SENIOR MANAGEMENT

Mr. XU Yang (徐洋), aged 42, has been the operation director and assistant to the chief executive officer since September 2, 2019. Mr. Xu is responsible for daily operations and administrative matters of our Group.

Mr. Xu has around 10 years of experience in management industry. Mr. Xu was a product manager of Baidu Online Network Technology (Beijing) Co., Ltd. (百度在線網絡技術(北京)有限公司) from June 2016 to March 2018. He was a president of a hospital owned by Beijing Evercare Medical Technology Group Co., Ltd. (北京伊美爾醫療科技集團股份公司) from November 2011 to December 2014.

Mr. Xu obtained his bachelor's degree in economic information management from Shandong institute of business and technology (山東工商學院) (formerly known as China Coal Economic Institute (中國煤炭經濟學院)) in July 2002 and his master's degree in business management from Nankai University (南開大學) in July 2009.

Ms. HAN Zhimei (韓志梅), aged 44, has been the finance director since March 20, 2017 and is responsible for financing, accounting, budget control, internal control, financial management of the Group.

Ms. Han has over 23 years of experience in accounting and corporate finance. Prior to joining our Group, from March 2016 to March 2017, she served as the finance director of KR Space (Beijing) Information Technology Co., Ltd., (氦空間(北京)信息技術有限公司). From February 2014 to September 2015, Ms. Han served as general manager of finance center of CiMing Health Management Group Co., Ltd. (慈銘健康管理集團股份有限公司). From May 2012 to February 2014, she served as finance director in Beijing Yangguangwo Cultural Development Co., Ltd. (北京陽光喔文化發展有限公司). Ms. Han was the accounting director of finance center of CiMing Health Management Group Co., Ltd. (慈銘健康管理集團股份有限公司) from August 2011 to May 2012. She was the vice director of finance department of Beijing Tianyou Education Consulting Co., Ltd. (北京天有教育諮詢有限公司) from October 2008 to July 2011. Earlier, Ms. Han served as a finance manager of China Real Estate Development North America Investment Group Co., Ltd. (中房北美投資集團有限公司) (formerly known as China Real Estate Hongdu Investment Group Co., Ltd. (中房鴻都投資集團有限公司)) from July 1997 to April 2008.

Ms. Han obtained her bachelor degree in accounting from Beijing Institute of Light Industry (北京輕工業學院) (now known as Beijing Technology and Business University (北京工商大學)), the PRC, in July 1998. She obtained intermediate accounting professional and technical qualification certificate issued by the Ministry of Finance in September 2003.

Mr. LI Xiaolong (李小龍), aged 56, has been the general medical service director since June 28, 2020. Mr. Li is responsible for medical quality control and procedure standardization of our Group.

Mr. Li has over 10 years of experience in medical service industry. From March 2015 to March 2018, he was the vice president of The People's Liberation Army No.309 Hospital (解放軍第309醫院). He served as a vice director of Health Administration of Management Assurance Department of The People's Liberation Army General Staff Apartment (解放軍總參謀部管理保障部衛生局) from March 2011 to June 2013.

DIRECTORS AND SENIOR MANAGEMENT

Mr. Li obtained his bachelor's degree in clinical medicine from Army Medical University (陸軍軍醫大學) (formerly known as No. 3 Army Medical University (第三軍醫大學)) in July 1987 and his master's degree in business management from Tiangong University (天津工業大學) in January 2010. He also holds a master of business management degree jointly awarded by Concordia University in the U.S. and Guanghua School of Management, Pecking University in July 2009. He was awarded the practice certificate for medical practitioners issued by Health Administration of The People's Liberation Army General Staff Apartment (解放軍總參謀部衛生局) in May 2011. He was awarded a chief physician professional qualification issued by The People's Liberation Army General Staff Apartment (解放軍總參謀部) in December 2015.

Mr. HUANG Donghong (黃東紅), aged 35, has been the marketing director since May 8, 2020. Mr. Huang is responsible for overall branding, sales and marketing management of our Group.

Mr. Huang has over 9 years of experience in sales and marketing industry. He has been with us since his graduation from Communication University of China in 2012. Mr. Huang has held various positions in the Group, including regional marketing manager.

Mr. Huang obtained his bachelor's degree in arts from Gannan Normal College (贛南師範學院) (now known as Gannan Normal University (贛南師範大學)), the PRC, in June 2009 and his master's degree in arts from Communication University of China (中國傳媒大學), the PRC, in June 2012.

JOINT COMPANY SECRETARIES

Ms. HAN Zhimei (韓志梅), aged 44, was appointed as a joint company secretary of our Company on June 1, 2021. Ms. Han is also a member of senior management of our Company. See “— Senior Management” in this section for her biographical details.

Ms. Leung Ching Ching (梁晶晶), is a senior manager of Corporate Services of Tricor Services Limited, a global professional services provider specializing in integrated business, corporate and investor services. She has over 15 years of experience in the corporate secretarial field. She is a Chartered Secretary and a fellow of both The Hong Kong Chartered Governance Institute (formerly The Hong Kong Institute of Chartered Secretaries) and The Chartered Governance Institute (formerly The Institute of Chartered Secretaries and Administrators). Ms. Leung received a bachelor degree of social science and a master degree of arts in professional accounting and information system.

Ms. Leung has been a joint company secretary of China Huirong Financial Holdings Limited (中國匯融金融控股有限公司), a company listed on the Stock Exchange with stock code 1290, since October 2013, a company secretary of C&D International Investment Group Limited (建發國際投資集團有限公司), a company listed on the Stock Exchange with stock code 1908, since November 2017, a company secretary of Fosun Tourism Group (復星旅遊文化集團), a company listed on the Stock Exchange with stock code 1992, since June 2019, a joint company secretary of Shanghai Henlius Biotech, Inc. (上海復宏漢霖生物技術股份有限公司), a company listed on the Stock Exchange with stock code 2696, since September 2019, and a company secretary of C&D Property Management Group Co., Ltd (建發物業管理集團有限公司), a company listed on the Stock Exchange with stock code 2156, since December 2020.

DIRECTORS AND SENIOR MANAGEMENT

COMPLIANCE ADVISER

We have appointed Somerley Capital Limited as our compliance adviser pursuant to Rule 3A.19 of the Listing Rules. Pursuant to Rule 3A.23 of the Listing Rules, the compliance adviser will advise us on the following circumstances:

- before the publication of any announcements, circulars or financial reports required by regulatory authorities or applicable laws in Hong Kong;
- where a transaction, which might be a notifiable or connected transaction under Chapters 14 and 14A of the Listing Rules is contemplated, including share issues and share repurchases;
- where we propose to use the proceeds of the Global Offering in a manner different from that detailed in this prospectus or where our business activities, developments or results deviate from any forecast, estimate or other information in this prospectus; and
- where the Stock Exchange makes an inquiry of us regarding unusual price movement and trading volume or other issues under Rule 13.10 of the Listing Rules.

The terms of the appointment shall commence on the Listing Date and end on the date which we distribute our annual report of our financial results for first full the financial year commencing after the Listing Date and such appointment may be subjected to extension by mutual agreement.

BOARD COMMITTEES

We have established the following committees in our Board in accordance with the relevant PRC laws and regulation, the Articles and the Listing Rules: an audit committee, a remuneration and appraisal committee and a nomination committee. The committees operate in accordance with the terms of reference established by our Board.

Audit Committee

Our Company has established an audit committee (effective from the Listing Date) with written terms of reference in compliance with Rule 3.21 of the Listing Rules and paragraph C.3 and paragraph D.3 of the Corporate Governance Code as set out in Appendix 14 to the Listing Rules (the “**Corporate Governance Code**”). The audit committee consists of two independent non-executive Directors being Mr. Chan, Mr. Li and one non-executive Directors being Mr. Geng. The chairman of the audit committee is Mr. Chan. Mr. Chan holds the appropriate professional qualifications as required under Rules 3.10(2) and 3.21 of the Listing Rules. The primary duties of the audit committee include, but are not limited to, the following:

- monitoring and evaluating the work of the external auditor;
- supervising the implementation of our internal audit system;
- reviewing and commenting on our financial reports and related disclosures; and
- other duties conferred by the Board.

DIRECTORS AND SENIOR MANAGEMENT

Remuneration and Appraisal Committee

Our Company has established a remuneration and appraisal committee (effective from the Listing Date) with written terms of reference in compliance with Rule 3.25 of the Listing Rules and paragraph B.1 of the Corporate Governance Code. The remuneration and appraisal committee consists of two independent non-executive Directors being Mr. Chan and Mr. Li, and one Director being Mr. Zhang. The remuneration and appraisal committee is chaired by Mr. Chan. The primary duties of the remuneration and appraisal committee include, but are not limited to, the following:

- making recommendations to our Board on our policy and structure for all remuneration of Directors and senior management and on the establishment of a formal and transparent procedure for developing policy on such remuneration;
- determining the specific remuneration packages of all Directors and senior management;
- reviewing and approving performance-based remuneration by reference to corporate goals and objectives resolved by our Board from time to time;
- reviewing and managing the share incentive scheme(s) of our Company, including determining the scope of the eligible participants and conditions of a grant and auditing the exercise conditions; and
- other duties conferred by the Board.

Nomination Committee

Our Company has established a nomination committee (effective from the Listing Date) with written terms of reference in compliance with paragraph A.5 of the Corporate Governance Code. The nomination committee consists of two independent non-executive Directors being Mr. Chan and Ms. Wang, and one Director being Mr. Zhang. The chairman of the Nomination Committee is Mr. Zhang. The primary functions of the nomination committee include, but are not limited to, the following:

- reviewing the structure, size and composition of our Board;
- assessing the independence of independent non-executive Directors;
- making recommendations to our Board on matters relating to the appointment of Directors; and
- other duties conferred by the Board.

DIRECTORS AND SENIOR MANAGEMENT

CORPORATE GOVERNANCE

Mr. ZHANG is our chairman of the Board and chief executive officer. With extensive experience in the hair health industry and having served in our Company since its establishment, Mr. Zhang is in charge of the overall strategic planning, business direction and operational management of our Group. Our Board considers that vesting the roles of the chairman of the Board and the chief executive officer in the same person is beneficial to the management of our Group. The balance of power and authority is ensured by the operation of our Board, which comprises experienced and diverse individuals. Our Board currently comprises two executive Directors (including Mr. Zhang), two non-executive Directors and three independent non-executive Directors, and therefore has a strong independent element in its composition.

Save as disclosed above, our Company intends to comply with all code provisions under the Corporate Governance Code after the Listing.

Board Diversity

In order to enhance the effectiveness of the Board and to maintain the high standard of corporate governance, we have adopted the board diversity policy which sets out our objectives and approach to achieve and maintain diversity of the Board. Pursuant to this policy, we seek to achieve board diversity through the consideration of a number of factors when selecting the candidates to the Board, including but not limited to gender, skills, age, professional experience, knowledge, cultural and education background, ethnicity and length of service. The ultimate decision of the appointment will be based on merit and the contribution which the selected candidates will bring to the Board.

The Board comprises seven members, including two executive Directors, two non-executive Directors and three independent non-executive Directors. Our Directors have a balanced mix of gender, knowledge, skills, perspectives and experience, including management, organic and polymer chemistry, hair transplant surgery, business development, finance, investment and banking. They obtained professional and academic qualifications including medicine, business administration, accounting & finance, clinical medicine and commerce. Furthermore, the Board possesses members spanning a wide range of ages, from 34 years old to 60 years old. Taking into account our existing business model and specific needs as well as the different background of our Directors, the composition of the Board satisfies our board diversity policy, and the Board and the nomination committee of our Company will assess the Board composition regularly.

Our nomination committee is responsible for reviewing the diversity of the Board. After Listing, our nomination committee will continue to monitor and evaluate the implementation of the board diversity policy from time to time to ensure its continued effectiveness and we will disclose in our corporate governance report about the implementation of the board diversity policy, including any measurable objectives set for implementing the board diversity policy and the progress on achieving these objectives on an annual basis. We will also continue to take steps to promote gender diversity at all levels of our Company, including but without limitation at the Board and senior management levels.

DIRECTORS AND SENIOR MANAGEMENT

COMPENSATION OF DIRECTORS AND MANAGEMENT

Our Directors receive compensation in the form of fees, salaries, discretion bonuses, other allowances and benefits in kind. We determine the salaries of our independent non-executive Directors based on each their responsibilities, qualification, position and seniority.

The aggregate amount of remuneration to our Directors for the three years ended December 31, 2018, 2019, 2020 and the six months ended June 30, 2021 were approximately RMB1.1 million, RMB1.8 million, RMB5.7 million and RMB1.0 million, respectively.

It is estimated that remuneration and benefits in kind (excluding any possible payment of discretionary bonus) equivalent to approximately RMB2.2 million in aggregate will be paid and granted to our Directors by us in respect of the financial year ending December 31, 2021 under arrangements in force at the date of this prospectus.

The aggregate amount of remuneration to our five highest paid individuals (including both employees and Directors) for the three years ended December 31, 2018, 2019, 2020 and the six months ended June 30, 2021 were approximately RMB2.8 million, RMB7.0 million, RMB11.5 million and RMB2.8 million, respectively.

During the Track Record Period, (i) no remuneration was paid to our Directors or the five highest paid individuals as an inducement to join, or upon joining our Group; (ii) no compensation was paid to, or receivable by, our Directors, past Directors or the five highest paid individuals for the loss of office as director of any member of our Group or of any other office in connection with the management of the affairs of any member of our Group; and (iii) none of our Directors waived any emoluments.

For details of our share incentives, see “History, Development and Corporate Structure” and Note 23 “Share-Based Compensation” of the Accountant’s Report set out in Appendix I to this prospectus.

FUTURE PLANS AND USE OF PROCEEDS

FUTURE PLANS

See “Business — Our Strategies” for a detailed description of our future plans.

USE OF PROCEEDS

We estimate that we will receive net proceeds from the Global Offering of approximately HK\$1,356.7 million, after deducting underwriting commissions, fees and estimated expenses payable by us in connection with the Global Offering, and assuming there is no exercise of the Over-allotment Option. In the event that the Over-allotment Option is exercised in full, we estimate that we will receive additional net proceeds of approximately HK\$213.7 million. We intend to use the net proceeds of the Global Offering for the following purposes:

- approximately 42.1%, or HK\$571.2 million, will be used to expand and upgrade existing hair transplant clinics in our network in China. In particular, we intend to allocate the net proceeds in the amounts as set forth below:
 - (i) approximately 24.6%, or HK\$333.7 million, will be used to fund part of our expansion plan in China within the next few years, including (a) establishing approximately 50 new hair transplant clinics primarily in China’s tier-two and lower-tier cities as we believe that the growing demands in these cities will drive the next wave of growth of the country’s hair transplant industry; and (b) establishing approximately 60 stand-alone *Svenson Medical Hair Care Centers* in addition to those opened in our hair transplant clinics under a “shop-in-shop” model. We plan to obtain a Medical Institution Practicing License for each of these stand-alone *Svenson Medical Hair Care Centers*. The number of new medical hair care centers to be opened exceeds that of new hair transplant clinics, primarily because we currently plan to open only one hair transplant clinic in one city, while depending on the relevant medical demands of patients in a city, we may open multiple medical hair care centers in one city to give patients convenient access to our services. In addition, we plan to speed up our expansion in medical hair care sector as we believe that China’s medical hair care service market will harbor huge growth potential in the next few years and such expansion will gain us significant first mover advantages. We expect to incur a total capital expenditure of approximately RMB510.0 million for the establishment of the aforesaid new clinics and medical hair care centers, and to fund the part that exceeds the allocated net proceeds with our internal capital resources;
 - (ii) approximately 17.5%, or HK\$237.4 million, will be used to fund the building of six comprehensive medical hair care service hospitals in China. We plan to set up multiple hair-related specialty departments in such hospitals in addition to the hair transplant department, and our service offerings in such hospitals will be further expanded to the diagnosis and treatment of various hair-related diseases. We are currently building four comprehensive medical hair care service hospitals, including two hospitals to be newly established in Beijing and Shanghai, and two hospitals to be transformed from existing clinics in Guangzhou and Shenzhen. We plan to build two more comprehensive medical hair care service hospitals in provincial capitals in China in the next few years, and are currently in the process of selecting the target cities.

See “Business — Our Clinic Network — Expansion and Acquisitions — Expansion” for details.

FUTURE PLANS AND USE OF PROCEEDS

- approximately 17.5%, or HK\$237.4 million, will be used to fund our innovations in product and service offerings. In particular, we intend to allocate the net proceeds in the amounts as set forth below:
 - (i) approximately 9.7%, or HK\$131.6 million to research and develop surgical instruments and medical hair care services products. For example, to enhance patient comfort as well as the safety and transparency of our treatment, we are developing various instruments and devices with smart features such as smart treatment couch, intelligent shadowless lamp and intelligent follicle segregation table. Such instruments and devices, as compared to the conventional ones we currently use, are expected to have smart functions such as automatic position adaptation, automatic light adjustment, and intelligent calculation of follicle number. We are also developing several ancillary products such as wigs of various types and functional pillows that are specially designed to enhance patient experience at the recovery stage;
 - (ii) approximately 4.9%, or HK\$66.5 million to expand research and development (“R&D”) team. We expect to recruit qualified R&D personnel to drive the continuous development of our products and services, including the promotion and adoption of new technologies in our business.

The following table sets forth the details of our recruitment plan based on our current estimation, which is subject to changes according to our actual needs and market conditions at the relevant time.

Research Area	Positions	Expected Number of New Hires			Expected Average Annual Compensation (RMB)	Primary qualifications
		2021	2022	2023		
Medical device product development	Researchers and engineers	4	3	2	200,000 to 1,500,000	<ul style="list-style-type: none"> • a bachelor’s degree or above in the relevant major • five to seven years of experience in the relevant industry • proficiency in medical device development or design, manufacturing techniques of medical devices, the course of device processing craft, etc.
Intelligent software development	Researchers and engineers	8	3	2	200,000 to 1,500,000	<ul style="list-style-type: none"> • a bachelor’s degree or above in the relevant major • five to seven years of experience in the relevant industry • proficiency in software development, database design and development, AI, etc.

FUTURE PLANS AND USE OF PROCEEDS

Research Area	Positions	Expected Number of			Expected Average Annual Compensation (RMB)	Primary qualifications
		New Hires				
		2021	2022	2023		
Hair care product development	Scientific researchers and medical professionals	8	10	2	200,000 to 1,500,000	<ul style="list-style-type: none">• a bachelor's degree or above in the relevant major• two to three years of experience in the relevant industry• familiar with hair-related medical services and capable of conducting scientific researches
Software development in medical field	Scientific researchers and medical professionals	10	7	3	200,000 to 1,500,000	<ul style="list-style-type: none">• a bachelor's degree or above in the relevant major• two to five years of experience in the relevant industry• mastering basic skills including software development, AI, etc.

(iii) approximately 2.9%, or HK\$39.3 million to upgrade our medical service. We plan to further optimize our hair transplant procedures to address the personalized and aesthetic treatment demands of our patients. We also plan to provide personal and customized postoperative services to our patients.

- approximately 9.7%, or HK\$131.6 million, will be used for investment in research and development to upgrade our service system with cutting-edge technology. We expect to incur significantly higher expenses on research and development initiatives in the next few years than we did during the Track Record Period, primarily because (i) we are in the process of transforming our hair transplant clinics into comprehensive medical hair care service hospitals, which requires a substantial update of our current business systems (such as the accounting system, online service system and data management system) for the management of a more complicated business model; and (ii) we aim to expand our clinic network to at least double our current size within the next few years (including establishing approximately 50 new hair transplant clinics and 60 stand-alone medical hair care centers), which requires the establishment of a robust information technology infrastructure to support an effective and efficient control of our growing business. In particular, we intend to allocate the net proceeds in the amounts as set forth below:

- (i) approximately 4.9%, or HK\$66.5 million to invest in technology infrastructure and software capabilities to upgrade our service system and build online hospital services. We have launched a set of intelligent consultation service software for graphic, telephonic, and video consultation services. With our clinic network expansion and transformation of clinics to hospitals as planned, our current system would no longer be able to satisfy the growing and ever-evolving demands of patients. We plan to cooperate with top information technology companies in China to develop and upgrade the business system for all institutions in our network;

FUTURE PLANS AND USE OF PROCEEDS

- (ii) approximately 2.4%, or HK\$32.6 million to fund more data usage and analyses. We plan to engage professionals to further improve the real-time collection of more medical data at each clinic or hospital in our network for greater transparency of our diagnosis and treatment services. We also plan to put patient service data (after duly desensitization, if needed) to use to guide and inform the development of our hair disease diagnosis and treatment system; and
 - (iii) approximately 2.4%, or HK\$32.6 million to build intelligent hospitals, develop, procure and upgrade hardware equipment. We plan to introduce or develop in-house high-tech intelligent equipment or instruments, such as automated follicle detectors and robotic manipulators for follicle transplant, to improve the accuracy of hair diagnosis and hair transplant procedures, while reducing the reliance on manual labor.
- approximately 23.4%, or HK\$317.5 million, will be used to integrate industry resources to raise brand awareness in China. In particular, we intend to allocate the net proceeds in the amounts as set forth below:
 - (i) approximately 18.5%, or HK\$251.0 million to acquire independent local hair transplant clinics to expedite the concentrated multi-location expansion in key regions. We will focus on major economically developed regions in China with high population density, such as South China and East China, to accelerate our rise to the top in those regions. We will consider a variety of factors when selecting acquisition targets. We will only consider the targets that (i) have a good compliance track record without any material breach of all applicable laws and regulations since their establishments; (ii) have a relatively clear and simple shareholding structure and do not involve in any material litigation or arbitration proceedings; and (iii) hold all necessary permits, licenses and approvals for operating their businesses. In addition, we also consider (i) the targets' location, for example, whether they are situated in the cities in line with our regional concentration strategy and are located where traffic is convenient; (ii) the targets' past performance, for which we will evaluate various operating indicators such as number of patient visits, average spending per patient, client feedback and complaint rate; and (iii) the targets' medical serving capabilities, which are primarily demonstrated by the targets' scale of medical staff, number of surgery rooms and their related utilization rate. As confirmed by Frost & Sullivan, in 2020, independent local hair transplant institutions and other regional hair transplant chain institutions accounted for over 45% of the market share of China's hair transplant service market, and there are over 100 suitable acquisition targets available in the market. We may acquire the targets that satisfy our acquisition criteria from related parties, and we will strictly comply with all the requirements under the Listing Rules and seek for independent Shareholders' approval for such acquisition as appropriate. We currently plan to acquire five local hair transplant clinics that satisfy the aforesaid criteria within the next three years, and may adjust our acquisition plans based on our business needs and market conditions. As of the Latest Practicable Date, we had no specific acquisition plans nor had identified any specific targets. See "Business — Our Clinic Network — Expansion and Acquisitions — Acquisitions" for details;

FUTURE PLANS AND USE OF PROCEEDS

- (ii) approximately 4.9%, or HK\$66.5 million to fund various forms of brand marketing, such as academic exchanges and collaborations. Going forward, we will continue to cooperate with experts from Class IIIA hospitals and renowned academic institutions through various forms such as inviting experts to conduct trainings for our physicians regularly and actively participating in or sponsoring industry conferences to promote communications and enhance our brand recognition.
- approximately 1.6%, or HK\$21.7 million, will be used to settle the outstanding balance of the acquisition considerations payable by us to Xinsiyu, a related party, for our acquisition of Nu/Hart Hair in May 2021. The total consideration for the acquisition is RMB30.0 million. As of June 30, 2021, the outstanding balance amounted to approximately RMB25.9 million, which shall be paid before the end of 2022 according to the sale and purchase agreement. See “Financial Information — Our Clinic Network — Expansion and Acquisitions — Acquisitions” for details.
- approximately 5.7%, or HK\$77.3 million, will be used for our working capital and general corporate purposes.

In the event that the net proceeds from the Global Offering are not sufficient to fund our expansion plan as disclosed above, we plan to utilize our internal capital resources or external financing as we believe appropriate to fund our future expansion.

To the extent that the net proceeds are not immediately applied to the above purposes, we intend to deposit the net proceeds into short-term demand deposits with licensed banks or financial institutions.

UNDERWRITING

HONG KONG UNDERWRITERS

Morgan Stanley Asia Limited

China International Capital Corporation Hong Kong Securities Limited

UNDERWRITING

This prospectus is published solely in connection with the Hong Kong Public Offering. The Hong Kong Public Offering is fully underwritten by the Hong Kong Underwriters on a conditional basis. The International Offering is expected to be fully underwritten by the International Underwriters.

The Global Offering comprises the Hong Kong Public Offering of initially 9,443,000 Hong Kong Offer Shares and the International Offering of initially 84,981,000 International Offering Shares, subject, in each case, to reallocation on the basis as described in the section headed “Structure of the Global Offering” in this prospectus as well as to the Over-allotment Option (in the case of the International Offering).

UNDERWRITING ARRANGEMENTS AND EXPENSES

Hong Kong Public Offering

Hong Kong Underwriting Agreement

Pursuant to the Hong Kong Underwriting Agreement, the Company is offering the Hong Kong Offer Shares for subscription on the terms and conditions set out in this prospectus and the Hong Kong Underwriting Agreement at the Offer Price.

Subject to (a) the Listing Committee granting approval for the listing of, and permission to deal in, the Shares (including any additional Shares that may be issued pursuant to the exercise of the Over-allotment Option) on the Main Board of the Stock Exchange and such approval not having been subsequently revoked prior to the commencement of trading of the Shares on the Stock Exchange and (b) certain other conditions set out in the Hong Kong Underwriting Agreement, the Hong Kong Underwriters have agreed severally but not jointly to procure subscribers for, or themselves to subscribe for, their respective applicable proportions of the Hong Kong Offer Shares being offered which are not taken up under the Hong Kong Public Offering on the terms and conditions set out in this prospectus and the Hong Kong Underwriting Agreement.

The Hong Kong Underwriting Agreement is conditional on, among other things, the International Underwriting Agreement having been executed and becoming unconditional and not having been terminated in accordance with its terms.

UNDERWRITING

Grounds for termination

If any of the events set out below occur at any time prior to 8:00 a.m. on the Listing Date, the Joint Global Coordinators (for themselves and on behalf of the Hong Kong Underwriters) shall be entitled by written notice to the Company to terminate the Hong Kong Underwriting Agreement with immediate effect:

- (i) there shall develop, occur, exist or come into effect:
 - (a) any local, national, regional or international event or circumstance, or series of events, whether in continuation or in the nature of force majeure (including, without limitation, any acts of government, declaration of a national, regional or international emergency or war, calamity, crisis, epidemic, pandemic, large scale outbreak of diseases (including, without limitation, SARS, swine or avian flu, H5N1, H1N1, H7N9, contagious coronavirus (COVID-19) and such related/mutated forms), economic sanctions, strikes, lock-outs, fire, explosion, flooding, earthquake, volcanic eruption, civil commotion, riots, paralysis in government operations, interruption or delay in transportation, tsunamis, public disorder, acts of war, outbreak or escalation of hostilities (whether or not war is declared), acts of God or acts of terrorism) in or affecting the Cayman Islands, the BVI, Hong Kong, the PRC, the United States, the United Kingdom, the European Union or any member thereof, or any other jurisdiction relevant to any business operations of the Group or the Global Offering (collectively, the “**Relevant Jurisdictions**”); or
 - (b) any change, or any development involving a prospective change, or any event or circumstance likely to result in any change or development involving a prospective change, in any local, national, regional or international financial, economic, political, military, industrial, fiscal, regulatory, currency, credit or market conditions (including, without limitation, conditions in the stock and bond markets, money and foreign exchange markets, the interbank markets and credit markets) in or affecting any Relevant Jurisdictions; or
 - (c) any moratorium, suspension or restriction (including, without limitation, any imposition of or requirement for any minimum or maximum price limit or price range) in or on trading in securities generally on the Stock Exchange, the Shanghai Stock Exchange, the Shenzhen Stock Exchange, the New York Stock Exchange, the NASDAQ Global Market or the London Stock Exchange; or
 - (d) any general moratorium on commercial banking activities in the Cayman Islands, Hong Kong (imposed by the Financial Secretary or the Hong Kong Monetary Authority or other competent Authority), the PRC (imposed by the People’s bank of China), New York (imposed at Federal or New York State level or other competent Authority), London, or any other Relevant Jurisdiction, or any disruption in commercial banking or foreign exchange trading or securities settlement or clearance services, procedures or matters in any Relevant Jurisdiction; or

UNDERWRITING

- (e) any new national, central, federal, provincial, state, regional, municipal, local, domestic or foreign laws (including, without limitations, any common law or case law), statutes, ordinances, legal codes, regulations or rules (including, without limitations, any and all regulations, rules, orders, judgments, decrees, rulings, opinions, guidelines, measures, notices or circulars (in each case, whether formally published or not and to the extent mandatory or, if not complied with, the basis for legal, administrative, regulatory or judicial consequences) (“**Laws**”) of any administrative, governmental or regulatory commission, board, body, authority or agency, or any stock exchange, self-regulatory organization or other non-governmental regulatory authority, or any court, tribunal or arbitrator, in each case whether national, central, federal, provincial, state, regional, municipal, local, domestic, foreign or supranational) (“**Authority**”), or any change or any development involving a prospective change or any event or circumstance likely to result in a change or a development involving a prospective change in (or in the interpretation or application by any court or other competent Authority of) existing Laws, in each case, in or affecting any of the Relevant Jurisdictions; or
- (f) the imposition of economic sanctions, in whatever form, directly or indirectly, under any sanction Laws, or regulations in, Hong Kong, the PRC, the United States or any other Relevant Jurisdictions; or
- (g) a change or development involving a prospective change or amendment in or affecting taxes or foreign exchange control, currency exchange rates or foreign investment regulations (including, without limitation, a material devaluation of the Hong Kong dollar or the Renminbi against any foreign currencies, a change in the system under which the value of the Hong Kong dollar is linked to that of the United States dollar or RMB is linked to any foreign currency or currencies), or the implementation of any exchange control, in any of the Relevant Jurisdictions; or
- (h) any litigation, dispute, legal action or claim being threatened or instigated against any Director, Yonghe Hair Service Holdings Limited, Panmao Shanghai, Shanghai Pannuo, CYH, CYH Cosmetic Medical Investment Limited, CPEChina Fund II, CPEChina Fund IIA, Citron PE Associates II, Citron PE Funds II, Citron PE Holdings Limited, Mr. Zhang, ZY Investment Capital Ltd, ZY Ventures Ltd, or member of the Group; or
- (i) a Director or a member of the Group’s senior management as named in this prospectus being charged with an indictable offense or prohibited by operation of Law or otherwise disqualified from taking part in the management or taking directorship of a company; or
- (j) the chairman, the chief executive officer or the chief financial officer of the Company or the executive Directors vacating his or her office; or
- (k) an Authority or a political body or organization in any Relevant Jurisdiction commencing any investigation or other action, or announcing an intention to investigate or take other action, against any Director, Yonghe Hair Service Holdings Limited, Panmao Shanghai, Shanghai Pannuo, CYH, CYH Cosmetic Medical Investment Limited, CPEChina Fund II, CPEChina Fund IIA, Citron PE Associates II, Citron PE Funds II, Citron PE Holdings Limited, Mr. Zhang, ZY Investment Capital Ltd, ZY Ventures Ltd, or member of the Group; or

UNDERWRITING

- (l) a contravention by any member of the Group of the Listing Rules or applicable Laws; or
- (m) a prohibition by an Authority on the Company for whatever reason from offering, allotting, issuing or selling any of the Shares (including the Shares that may be issued or sold pursuant to the exercise of the Over-allotment Option) pursuant to the terms of the Global Offering; or
- (n) non-compliance of this prospectus (or any other documents used in connection with the contemplated offer and sale of the Offer Shares) or any aspect of the Global Offering with the Listing Rules or any other applicable Laws; or
- (o) the issue or requirement to issue by the Company of any supplement or amendment to this prospectus or the Green Application Form (or to any other documents issued or used in connection with the contemplated offer and sale of the Shares) pursuant to the Companies Ordinance or the Companies (Winding Up and Miscellaneous Provisions) Ordinance or the Listing Rules or any requirement or request of the Stock Exchange and/or the SFC; or
- (p) a valid demand by any creditor for repayment or payment of any material indebtedness of any member of the Group or in respect of which any member of the Group is liable prior to its stated maturity; or
- (q) any change or development involving a prospective change in, or a materialization of, any of the risks set out in the section headed “Risk Factors” of this prospectus; or
- (r) any order or petition for the winding up of any member of the Group or any composition or arrangement made by any member of the Group with its creditors or a scheme of arrangement entered into by any member of the Group or any resolution for the winding-up of any member of the Group or the appointment of a provisional liquidator, receiver or manager over all or part of the material assets or undertaking of any member of the Group or anything analogous thereto occurring in respect of any member of the Group,

which, individually or in the aggregate, in the sole and absolute opinion of the Joint Global Coordinators (for themselves and on behalf of the Hong Kong Underwriters): (1) has or will have or may have a material adverse effect on the assets, liabilities, business, general affairs, management, prospects, shareholders’ equity, profits, losses, results of operations, position or condition, financial or otherwise, or performance of the Group as a whole; or (2) has or will have or may have a material adverse effect on the success or marketability of the Global Offering or the level of applications or distribution of the Offer Shares under the Hong Kong Public Offering or the level of interest under the International Offering; or (3) makes or will make or may make it inadvisable or inexpedient or impracticable for the Global Offering to proceed or to market the Global Offering or the delivery or distribution of the Offer Shares on the terms and in the manner contemplated under this prospectus; or (4) has or will have or may have the effect of making any material part of the Hong Kong Underwriting Agreement (including underwriting) incapable of performance in accordance with its terms or preventing or delaying the processing of applications and/or payments pursuant to the Global Offering or pursuant to the underwriting thereof.

UNDERWRITING

- (ii) there has come to the notice of the Joint Global Coordinators or the Joint Sponsors that:
- (a) any statement contained in any of this prospectus, the formal notice, the receiving bank agreement, the registrar agreement, the cornerstone investment agreements, agreement between the Company and the White Form eIPO Service Provider, the preliminary and final offering circular, the post-hearing information proof and/or in any notices, announcements, advertisements, communications or other documents issued or used by or on behalf of the Company in connection with the Hong Kong Public Offering (including any supplement or amendment thereto) (collectively, the “**Offer Related Documents**”) but excluding information relating to the Underwriters) was, when it was issued, or has become, untrue, incorrect, inaccurate, incomplete in any material respects or misleading or deceptive, or that any estimate, forecast, expression of opinion, intention or expectation contained in any of such documents is not fair and honest and based on reasonable grounds or reasonable assumptions;
 - (b) any matter has arisen or has been discovered which would, had it arisen or been discovered immediately before the date of this prospectus, constitute a material omission from, or misstatement in, any of the Offer Related Documents; or
 - (c) any material breach of any of the obligations imposed upon the Company, Yonghe Hair Service Holdings Limited, Panmao Shanghai, Shanghai Pannuo, CYH, CYH Cosmetic Medical Investment Limited, CPEChina Fund II, CPEChina Fund IIA, Citron PE Associates II, Citron PE Funds II, Citron PE Holdings Limited, Mr. Zhang, ZY Investment Capital Ltd, ZY Ventures Ltd under the Hong Kong Underwriting Agreement or the International Underwriting Agreement (including any material breach of, or any event or circumstance rendering untrue or incorrect in any respect, any of the warranties therein); or
 - (d) any event, act or omission which gives or is likely to give rise to any material liability of any of the indemnifying parties pursuant to the Hong Kong Underwriting Agreement; or
 - (e) any adverse change, or any development involving a prospective adverse change, in the assets, liabilities, business, general affairs, management, prospects, shareholders’ equity, profits, losses, results of operations, position or condition, financial or otherwise, or performance of the Group as a whole; or
 - (f) any material adverse change; or
 - (g) that approval by the Listing Committee of the Stock Exchange of the listing of, and permission to deal in, the Shares to be issued or sold (including any additional Shares that may be issued or sold pursuant to the exercise of the Over-allotment Option) under the Global Offering is refused or not granted, other than subject to customary conditions, on or before the Listing Date, or if granted, the approval is subsequently withdrawn, cancelled, qualified (other than by customary conditions), revoked or withheld; or
 - (h) the Company withdraws any of this prospectus or the Green Application Form or the Global Offering; or

UNDERWRITING

- (i) any expert (other than the Joint Sponsors), whose consent is required for the issue of this prospectus with the inclusion of its reports, letters or opinions and references to its name included in the form and context in which it respectively appears, has withdrawn or is subject to withdrawing its consent to being named in this prospectus or to the issue of any of this prospectus or the Green Application Form; or
- (j) that a material portion of the orders placed or confirmed in the bookbuilding process, or of the investment commitments made by any cornerstone investors under agreements signed with such cornerstone investors, have been withdrawn, terminated or cancelled, or any of the cornerstone investment agreements is terminated.

Undertakings to the Stock Exchange pursuant to the Listing Rules

(A) Undertakings by the Company

Pursuant to Rule 10.08 of the Listing Rules, the Company has undertaken to the Stock Exchange that it will not issue any further Shares, or securities convertible into equity securities of the Company (whether or not of a class already listed) or enter into any agreement to such issue within six months from the Listing Date (whether or not such issue of Shares or securities will be completed within six months from the Listing Date), except pursuant to the Global Offering, the Over-allotment Option or for the circumstances permitted under Rule 10.08 of the Listing Rules.

(B) Undertakings by the Controlling Shareholders

Pursuant to Rule 10.07 of the Listing Rules and Guidance Letter GL89-16 published by the Stock Exchange, the Controlling Shareholders have undertaken to the Stock Exchange, the Joint Sponsors and our Company that, save as disclosed in the this prospectus and except pursuant to the Global Offering (including pursuant to the Stock Borrowing Agreement) or the exercise of the Over-allotment Option, he/it will not and will procure that the relevant registered holder(s) (if any) of the Shares in which any of them has a beneficial interests will not:

- (i) at any time in the period commencing on the date by reference to which disclosure of his/its holding of Shares is made in this prospectus and ending on the date which is six months from the Listing Date, dispose of, nor enter into any agreement to dispose of or otherwise create any options, rights, interests or encumbrances in respect of, any of the Shares in respect of which any of them are shown by this prospectus to be the beneficial owner; and
- (ii) at any time in the period of six months from the date on which the period referred to in paragraph (i) above expires, dispose of, nor enter into any agreement to dispose of or otherwise create any options, rights, interests or encumbrances in respect of, any of the Shares to such extent that immediately following such disposal or upon the exercise or enforcement of such options, rights, interests or encumbrances, he/it will, directly or indirectly cease to be controlling shareholders of the Company (as defined in the Listing Rules).

provided that the foregoing shall not prevent the Controlling Shareholders from using securities of the Company beneficially owned by them as security (including a charge or a pledge) in favor of an authorized institution (as defined in the Banking Ordinance (Chapter 155 of the laws of Hong Kong)) for a bona fide commercial loan.

UNDERWRITING

The Controlling Shareholders have undertaken to the Stock Exchange and our Company that, he/it will, within the period commencing from the date by reference to which disclosure of his/its shareholding in the Company is made in this prospectus and ending on the date which is 12 months from the Listing Date immediately inform the Company and the Stock Exchange in writing of:

- (i) any pledge(s) or charge(s) of any Shares or securities of the Company beneficially owned by any of him/it, whether directly or indirectly, in favor of any authorized institution (as defined in the Banking Ordinance (Chapter 155 of the laws of Hong Kong)) for a bona fide commercial loan as permitted under the Listing Rules, and the number of such Shares or securities of the Company so pledged or charged; and
- (ii) any indication(s) received by any of him/it, either verbal or written, from any pledgee or chargee of any Shares or other securities of the Company pledged or charged that any of such Shares or other share capital will be sold, transferred or disposed of.

Undertakings pursuant to the Hong Kong Underwriting Agreement

(A) Undertakings by the Company

Except for the offer and sale of the Offer Shares pursuant to the Global Offering (including pursuant to the Over-allotment Option), during the period commencing on the date of the Hong Kong Underwriting Agreement and ending on, and including, the date that is six months after the Listing Date (the “**First Six-Month Period**”), the Company has undertaken to each of the Joint Global Coordinators, the Joint Bookrunners, the Joint Lead Managers, the Hong Kong Underwriters and the Joint Sponsors not to without the prior written consent of the Joint Sponsors and the Joint Global Coordinators (on behalf of the Hong Kong Underwriters) and unless in compliance with the requirements of the Listing Rules:

- (i) allot, issue, sell, accept subscription for, offer to allot, issue or sell, contract or agree to allot, issue or sell, mortgage, charge, pledge, hypothecate, lend, grant or sell any option, warrant, contract or right to subscribe for or purchase, grant or purchase any option, warrant, contract or right to allot, issue or sell, or otherwise transfer or dispose of or create an encumbrance over, or agree to transfer or dispose of or create an encumbrance over, either directly or indirectly, conditionally or unconditionally, or repurchase, any Shares or other securities of the Company, as applicable, or any interest in any of the foregoing (including, without limitation, any securities convertible into or exchangeable or exercisable for or that represent the right to receive, or any warrants or other rights to purchase, any Shares or other securities of the Company, as applicable or any interest in any of the foregoing), or deposit any Shares or other securities of the Company, as applicable, with a depositary in connection with the issue of depositary receipts; or
- (ii) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership (legal or beneficial) of any Shares or other securities of the Company, as applicable, or any interest in any of the foregoing (including, without limitation, any securities of which are convertible into or exchangeable or exercisable for or that represent the right to receive, or any warrants or other rights to purchase, any Shares or other securities of the Company, as applicable or any interest in any of the foregoing); or

UNDERWRITING

- (iii) enter into any transaction with the same economic effect as any transaction described in paragraphs (i) or (ii) above; or
- (iv) offer to or agree to or announce any intention to effect any transaction specified in paragraphs (i), (ii) or (iii) above, in each case, whether any of the transactions specified in paragraphs (i), (ii) or (iii) above is to be settled by delivery of Shares or other securities of the Company, or in cash or otherwise (whether or not the issue of such Shares or other shares or securities will be completed within the First Six-Month Period).

During the period of six months commencing on the date on which the First Six-Month Period expires (the “**Second Six-Month Period**”), the Company shall not enter into any of the transactions specified in paragraphs (i), (ii) or (iii) above or offer to or agree to or announce any intention to effect any such transaction such that any Controlling Shareholder, directly or indirectly, would cease to be a controlling shareholder (within the meaning defined in the Listing Rules) of the Company. In the event that the Company enters into any of the transactions specified in paragraphs (i), (ii) or (iii) above or offers to or agrees to or announces any intention to effect any such transaction, the Company shall take all reasonable steps to ensure that it will not create a disorderly or false market in the securities of the Company.

(B) Undertakings by the Controlling Shareholders

Each of Yonghe Hair Service Holdings Limited, Panmao Shanghai, Shanghai Pannuo, CYH, CYH Cosmetic Medical Investment Limited, CPEChina Fund II, CPEChina Fund IIA, Citron PE Associates II, Citron PE Funds II, Citron PE Holdings Limited, Mr. Zhang, ZY Investment Capital Ltd and ZY Ventures Ltd (the “**Undertaking Controlling Shareholders**”) has undertaken to each of the Company, the Joint Global Coordinators, the Joint Bookrunners, the Joint Lead Managers, the Hong Kong Underwriters and the Joint Sponsors that, without the prior written consent of the Joint Sponsors and the Joint Global Coordinators (on behalf of the Hong Kong Underwriters) and unless in compliance with the requirements of the Listing Rules:

- (i) he or it will not, at any time during the First Six-Month Period, (a) sell, offer to sell, contract or agree to sell, mortgage, charge, pledge, hypothecate, lend, grant or sell any option, warrant, contract or right to purchase, grant or purchase any option, warrant, contract or right to sell, or otherwise transfer or dispose of or create an encumbrance over, or agree to transfer or dispose of or create an encumbrance over, either directly or indirectly, conditionally or unconditionally, any Shares or other securities of the Company or any interest therein (including any securities convertible into or exchangeable or exercisable for or that represent the right to receive, or any warrants or other rights to purchase, any Shares), or deposit any Shares or other securities of the Company with a depositary in connection with the issue of depositary receipts, or (b) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of any Shares or other securities of the Company or any interest therein (including any securities convertible into or exchangeable or exercisable for or that represent the right to receive, or any warrants or other rights to purchase, any Shares), or (c) enter into any transaction with the same economic effect as any transaction specified in (a) or (b) above, or (d) offer to or agree to or announce any intention to effect any transaction specified in (a), (b) or (c) above, in each case, whether any of the transactions specified in (a), (b) or (c) above is to be settled by delivery of Shares or other securities of the Company or in cash or otherwise (whether or not the issue of such Shares or other securities will be completed within the First Six-Month Period);

UNDERWRITING

- (ii) he or it will not, during the Second Six-Month Period, enter into any of the transactions specified in paragraph (i) (a), (b) or (c) above or offer to or agree to or announce any intention to effect any such transaction if, immediately following any sale, transfer or disposal or upon the exercise or enforcement of any option, right, interest or encumbrance pursuant to such transaction, it will cease to be a “controlling shareholder” (as the term is defined in the Listing Rules) of the Company; and
- (iii) until the expiry of the Second Six-Month period, in the event that it enters into any of the transactions specified in paragraph (i) (a), (b) or (c) above or offer to or agrees to or announce any intention to effect any such transaction, it will take all reasonable steps to ensure that it will use its commercially reasonable effort to avoid creating a disorderly or false market in the securities of the Company.

For the avoidance of doubt, any Share(s) that may be acquired by any of the Undertaking Controlling Shareholders from the secondary market after Listing shall not fall within the remit of paragraph (i) to (iii).

(C) Undertakings by the existing Shareholders

Each of the existing Shareholders of the Company (other than the Controlling Shareholders) (being Yunuo Technology Holdings Limited, ZH Investment Capital Ltd, Ever Horizon Developments Limited, NieLei Hair Service Holdings Limited, JiaQi Hair Service Holdings Limited, Siqi Hair Service Holdings Limited, Tanxu Hair Service Holdings Limited, LinFeng Hair Service Holdings Limited and Zhirui Technology Holdings Limited) and their respective legal owners (the “**Existing Shareholders**”) has entered into a deed of lock-up undertaking (the “**Lock-up Undertakings**”) in favour of the Joint Global Coordinators and the Company imposing certain restrictions on dealings with their respective Shares.

Pursuant to the Lock-up Undertakings, each of the Existing Shareholders undertakes that, inter alia, the Existing Shareholders will not and will procure that no company controlled by it or any nominee or trustee holding in trust for it will, at any time during the period ending on a date which is six months from the Listing Date (the “**Lock-up Period**”):

- (a) offer, pledge, charge, sell, contract or agree to sell, mortgage, charge, pledge, hypothecate, lend, grant or sell any option, warrant, contract or right to purchase, grant, or purchase any option, warrant, contract or right to sell, grant or agree to grant any option, right or warrant to purchase or subscribe for, lend or otherwise transfer or dispose of or create an encumbrance over, either directly or indirectly, conditionally or unconditionally, any Shares or other securities of the Company or any interest in any of the foregoing (including, but not limited to, any securities that are convertible into or exchangeable or exercisable for, or that represent the right to receive, or any warrants or other rights to purchase, any Shares or any interest in any company or entity holding or controlling (directly or indirectly) any Shares or, permit or cause a change in control (as defined in The Codes on Takeovers and Mergers and Share Buy-backs promulgated by the SFC) of any company or entity holding or controlling (directly or indirectly) any Shares or other securities of the Company) beneficially owned by such Shareholder as of the Listing Date (the “**Locked-up Shares**”);

UNDERWRITING

- (b) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of, any Locked-up Shares;
- (c) enter into any transaction with the same economic effect as any transaction described in (a) or (b) above; or
- (d) offer to or contract to or agree to or publicly disclose that such Shareholder will or may enter into any transaction described in (a), (b) or (c) above,

whether any such transaction described in (a), (b) or (c) above is to be settled by delivery of such Shares or other securities of the Company, in cash or otherwise (whether or not the settlement or delivery of such Shares or other securities will be completed within the Lock-up Period). However, the Lock-up Undertakings shall not, among others, prevent the Existing Shareholders from using the Shares beneficially owned by such Existing Shareholder as security (including a charge or a pledge) in favor of an authorized institution (as defined in the Banking Ordinance (Chapter 155 of the Laws of Hong Kong)) for a *bona fide* commercial loan, provided that (i) the Existing Shareholder immediately informs the Company, the Joint Sponsors and the Joint Global Coordinators of such pledge or charge together with the number of Shares so pledged or charged, and (ii) when the Existing Shareholder receives indications, either verbal or written, from the pledgee or chargee of any Shares that any of the pledged or charged Shares will be disposed of, immediately inform the Company, the Joint Sponsors and the Joint Global Coordinators of such indications.

Hong Kong Underwriters' interests in the Company

Save for their respective obligations under the Hong Kong Underwriting Agreement, as of the Latest Practicable Date, none of the Hong Kong Underwriters was interested, legally or beneficially, directly or indirectly, in any Shares or any securities of any member of the Group or had any right or option (whether legally enforceable or not) to subscribe for or purchase, or to nominate persons to subscribe for or purchase, any Shares or any securities of any member of the Group.

Following the completion of the Global Offering, the Hong Kong Underwriters and their affiliated companies may hold a certain portion of the Shares as a result of fulfilling their respective obligations under the Hong Kong Underwriting Agreement.

International Offering

International Underwriting Agreement

In connection with the International Offering, the Company expects to enter into the International Underwriting Agreement with, among others, the International Underwriters. Under the International Underwriting Agreement and subject to the Over-allotment Option, the International Underwriters would, subject to certain conditions set out therein, agree severally but not jointly to procure subscribers for, or themselves to subscribe for, their respective applicable proportions of the International Offering Shares initially being offered pursuant to the International Offering. It is expected that the International Underwriting Agreement may be terminated on similar grounds as the Hong Kong Underwriting Agreement. Potential investors should note that in the event that the International Underwriting Agreement is not entered into, the Global Offering will not proceed. See “Structure of the Global Offering — The International Offering.”

UNDERWRITING

Over-allotment Option

The Company is expected to grant to the International Underwriters the Over-allotment Option, exercisable by the Joint Global Coordinators on behalf of the International Underwriters at any time from the Listing Date until 30 days after the last day for lodging applications under the Hong Kong Public Offering, pursuant to which the Company may be required to issue up to an aggregate of 14,163,500 Shares, representing not more than 15% of the number of Offer Shares initially available under the Global Offering, at the Offer Price, to cover over-allocations in the International Offering, if any. See “Structure of the Global Offering — Over-allotment Option.”

Commissions and Expenses

The Underwriters will receive an underwriting commission of 3.5% of the aggregate Offer Price of all the Offer Shares (including any Offer Shares to be issued pursuant to the exercise of the Over-allotment Option), out of which they will pay any sub-underwriting commissions and other fees.

The Company may pay to each of the Joint Global Coordinators and the Joint Bookrunners a discretionary incentive fee of up to but not exceeding 1.0% of the Offer Price for each Offer Share.

For any unsubscribed Hong Kong Offer Shares reallocated to the International Offering, the underwriting commission will not be paid to the Hong Kong Underwriters but will instead be paid, at the rate applicable to the International Offering, and such commission will be paid to the relevant International Underwriters.

The aggregate underwriting commissions and fees together with the Stock Exchange listing fees, the SFC transaction levy and the Stock Exchange trading fee, legal and other professional fees and printing and all other expenses relating to the Global Offering (collectively, the “**Commissions and Fees**”) are estimated to be approximately HK\$135.2 million (assuming the Over-allotment Option is not exercised).

Indemnity

The Company has agreed to indemnify the Joint Sponsors, the Joint Global Coordinators, the Joint Bookrunners, the Joint Lead Managers and the Hong Kong Underwriters for certain losses which they may suffer or incur, including losses arising from their performance of their obligations under the Hong Kong Underwriting Agreement and any breach by the Company of the Hong Kong Underwriting Agreement.

ACTIVITIES BY SYNDICATE MEMBERS

The underwriters of the Hong Kong Public Offering and the International Offering (together, the “**Syndicate Members**”) and their affiliates may each individually undertake a variety of activities (as further described below) which do not form part of the underwriting or stabilizing process.

The Syndicate Members and their affiliates are diversified financial institutions with relationships in countries around the world. These entities engage in a wide range of commercial and investment banking, brokerage, funds management, trading, hedging, investing and other activities for their own account and for the account of others. In the ordinary course of their various business activities, the

UNDERWRITING

Syndicate Members and their respective affiliates may purchase, sell or hold a broad array of investments and actively trade securities, derivatives, loans, commodities, currencies, credit default swaps and other financial instruments for their own account and for the accounts of their customers. Such investment and trading activities may involve or relate to assets, securities and/or instruments of the Company and/or persons and entities with relationships with the Company and may also include swaps and other financial instruments entered into for hedging purposes in connection with the Group's loans and other debt.

In relation to the Shares, the activities of the Syndicate Members and their affiliates could include acting as agent for buyers and sellers of the Shares, entering into transactions with those buyers and sellers in a principal capacity, including as a lender to initial purchasers of the Shares (which financing may be secured by the Shares) in the Global Offering, proprietary trading in the Shares, and entering into over the counter or listed derivative transactions or listed or unlisted securities transactions (including issuing securities such as derivative warrants listed on a stock exchange) which have as their underlying assets, assets including the Shares. Such transactions may be carried out as bilateral agreements or trades with selected counterparties. Those activities may require hedging activity by those entities involving, directly or indirectly, the buying and selling of the Shares, which may have a negative impact on the trading price of the Shares. All such activities could occur in Hong Kong and elsewhere in the world and may result in the Syndicate Members and their affiliates holding long and/or short positions in the Shares, in baskets of securities or indices including the Shares, in units of funds that may purchase the Shares, or in derivatives related to any of the foregoing.

In relation to issues by Syndicate Members or their affiliates of any listed securities having the Shares as their underlying securities, whether on the Stock Exchange or on any other stock exchange, the rules of the stock exchange may require the issuer of those securities (or one of its affiliates or agents) to act as a market maker or liquidity provider in the security, and this will also result in hedging activity in the Shares in most cases.

All such activities may occur both during and after the end of the stabilizing period described in the section headed "Structure of the Global Offering" in this prospectus. Such activities may affect the market price or value of the Shares, the liquidity or trading volume in the Shares and the volatility of the price of the Shares, and the extent to which this occurs from day to day cannot be estimated.

It should be noted that when engaging in any of these activities, the Syndicate Members will be subject to certain restrictions, including the following:

- (a) the Syndicate Members (other than the Stabilization Manager or any person acting for it) must not, in connection with the distribution of the Offer Shares, effect any transactions (including issuing or entering into any option or other derivative transactions relating to the Offer Shares), whether in the open market or otherwise, with a view to stabilizing or maintaining the market price of any of the Offer Shares at levels other than those which might otherwise prevail in the open market; and
- (b) the Syndicate Members must comply with all applicable laws and regulations, including the market misconduct provisions of the SFO, including the provisions prohibiting insider dealing, false trading, price rigging and stock market manipulation.

Certain of the Syndicate Members or their respective affiliates have provided from time to time, and expect to provide in the future, investment banking and other services to the Company and each of its affiliates for which such Syndicate Members or their respective affiliates have received or will receive customary fees and commissions.

In addition, the Syndicate Members or their respective affiliates may provide financing to investors to finance their subscriptions of Offer Shares in the Global Offering.

STRUCTURE OF THE GLOBAL OFFERING

THE GLOBAL OFFERING

This prospectus is published in connection with the Hong Kong Public Offering as part of the Global Offering. Morgan Stanley Asia Limited and China International Capital Corporation Hong Kong Securities Limited are the Joint Global Coordinators of the Global Offering.

The listing of the Shares on the Stock Exchange is sponsored by the Joint Sponsors. The Joint Sponsors have made an application on behalf of the Company to the Stock Exchange for the listing of, and permission to deal in, the Shares in issue and to be issued as mentioned in this prospectus.

94,424,000 Offer Shares will initially be made available under the Global Offering comprising:

- (a) the Hong Kong Public Offering of initially 9,443,000 Shares (subject to reallocation) in Hong Kong as described in “— The Hong Kong Public Offering” in this section below; and
- (b) the International Offering of initially 84,981,000 Shares (subject to reallocation and the Over-allotment Option) (i) in the United States solely to QIBs in reliance on Rule 144A or another exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and (ii) outside the United States (including to professional and institutional investors within Hong Kong) in offshore transactions in reliance on Regulation S, as described in the sub-section headed “— The International Offering” in this section below.

Investors may either:

- (i) apply for Hong Kong Offer Shares under the Hong Kong Public Offering; or
- (ii) apply for or indicate an interest for International Offering Shares under the International Offering, but may not do both.

The Offer Shares will represent approximately 18.16% of the total Shares in issue immediately following the completion of the Global Offering, assuming the Over-allotment Option is not exercised. If the Over-allotment Option is exercised in full, the Offer Shares (including Shares issued pursuant to the full exercise of the Over-allotment Option) will represent approximately 20.33% of the total Shares in issue immediately following the completion of the Global Offering and the issue of Offer Shares pursuant to the Over-Allotment Option.

References in this prospectus to applications, application monies or the procedure for applications relate solely to the Hong Kong Public Offering.

STRUCTURE OF THE GLOBAL OFFERING

THE HONG KONG PUBLIC OFFERING

Number of Offer Shares initially offered

The Company is initially offering 9,443,000 Shares for subscription by the public in Hong Kong at the Offer Price, representing approximately 10.0% of the total number of Offer Shares initially available under the Global Offering. The number of Offer Shares initially offered under the Hong Kong Public Offering, subject to any reallocation of Offer Shares between the International Offering and the Hong Kong Public Offering, will represent approximately 1.82% of the total Shares in issue immediately following the completion of the Global Offering (assuming the Over-allotment Option is not exercised).

The Hong Kong Public Offering is open to members of the public in Hong Kong as well as to institutional and professional investors in Hong Kong. Professional investors generally include brokers, dealers, companies (including fund managers) whose ordinary business involves dealing in shares and other securities and corporate entities that regularly invest in shares and other securities.

Completion of the Hong Kong Public Offering is subject to the conditions set out in “— Conditions of the Global Offering” in this section.

Allocation

Allocation of Offer Shares to investors under the Hong Kong Public Offering will be based solely on the level of valid applications received under the Hong Kong Public Offering. The basis of allocation may vary, depending on the number of Hong Kong Offer Shares validly applied for by applicants. Such allocation could, where appropriate, consist of balloting, which could mean that some applicants may receive a higher allocation than others who have applied for the same number of Hong Kong Offer Shares, and those applicants who are not successful in the ballot may not receive any Hong Kong Offer Shares.

For allocation purposes only, the total number of Hong Kong Offer Shares available under the Hong Kong Public Offering (after taking into account any reallocation referred to below) will be divided equally (to the nearest board lot) into two pools: pool A and pool B (with any odd lot being allocated to pool A). The Hong Kong Offer Shares in pool A will be allocated on an equitable basis to applicants who have applied for Hong Kong Offer Shares with an aggregate price of HK\$5 million (excluding the brokerage, the SFC transaction levy and the Stock Exchange trading fee payable) or less. The Hong Kong Offer Shares in pool B will be allocated on an equitable basis to applicants who have applied for Hong Kong Offer Shares with an aggregate price of more than HK\$5 million (excluding the brokerage, the SFC transaction levy and the Stock Exchange trading fee payable) and up to the total value in pool B.

Investors should be aware that applications in pool A and applications in pool B may receive different allocation ratios. If any Hong Kong Offer Shares in one (but not both) of the pools are unsubscribed, such unsubscribed Hong Kong Offer Shares will be transferred to the other pool to satisfy demand in that other pool and be allocated accordingly. For the purpose of the immediately preceding paragraph only, the “price” for Hong Kong Offer Shares means the price payable on application therefor (without regard to the Offer Price as finally determined). Applicants can only receive an allocation of Hong Kong Offer Shares from either pool A or pool B and not from both pools. Multiple or suspected multiple applications under the Hong Kong Public Offering and any application for more than 4,721,500 Hong Kong Offer Shares is liable to be rejected.

STRUCTURE OF THE GLOBAL OFFERING

Reallocation and Clawback

The allocation of the Offer Shares between the Hong Kong Public Offering and the International Offering is subject to reallocation. Paragraph 4.2 of Practice Note 18 of the Listing Rules requires a clawback mechanism to be put in place which would have the effect of increasing the number of Offer Shares under the Hong Kong Public Offering to a certain percentage of the total number of Offer Shares offered under the Global Offering if certain prescribed total demand levels are reached.

If the International Offering is fully subscribed or oversubscribed and the number of Offer Shares validly applied for under the Hong Kong Public Offering represents (a) 15 times or more but less than 50 times, (b) 50 times or more but less than 100 times and (c) 100 times or more of the total number of Offer Shares initially available under the Hong Kong Public Offering, then Offer Shares will be reallocated to the Hong Kong Public Offering from the International Offering. As a result of such reallocation, the total number of Offer Shares available under the Hong Kong Public Offering will be increased to 28,327,500 Offer Shares (in the case of (a)), 37,770,000 Offer Shares (in the case of (b)) and 47,212,000 Offer Shares (in the case of (c)), representing approximately 30%, approximately 40% and 50% of the total number of Offer Shares initially available under the Global Offering, respectively (before any exercise of the Over-allotment Option) (the “**PN18 Clawback**”). In each case, the additional Offer Shares reallocated to the Hong Kong Public Offering will be allocated between pool A and pool B and the number of Offer Shares allocated to the International Offering will be correspondingly reduced in such manner as the Joint Global Coordinators deem appropriate.

If the Hong Kong Public Offering is not fully subscribed for, the Joint Global Coordinators have the authority to reallocate all or any unsubscribed Hong Kong Offer Shares to the International Offering, in such proportions as the Joint Global Coordinators deem appropriate. In addition, the Joint Global Coordinators may in their sole discretion reallocate Offer Shares from the International Offering to the Hong Kong Public Offering to satisfy valid applications under the Hong Kong Public Offering. In particular, if (i) the International Offering is not fully subscribed and the Hong Kong Public Offering is fully subscribed or oversubscribed irrespective of the number of times; or (ii) the International Offering is fully subscribed or oversubscribed and the Hong Kong Public Offering is fully subscribed or oversubscribed with the number of Offer Shares validly applied for in the Hong Kong Public Offering representing less than 15 times of the number of Shares initially available for subscription under the Hong Kong Public Offering, the Joint Global Coordinators have the authority to reallocate International Offer Shares originally included in the International Offering to the Hong Kong Public Offering in such number as they deem appropriate, provided that in accordance with Guidance Letter HKEX-GL91-18 issued by the Stock Exchange, the number of International Offer Shares reallocated to the Hong Kong Public Offering should not exceed 9,443,000 Shares, representing approximately 10% of the Offer Shares initially available under the Global Offering, increasing the total number of Offer Shares available under the Hong Kong Public Offering to 18,886,000 Shares, representing approximately 20% of the Offer Shares.

In each case, the additional Offer Shares reallocated to the Hong Kong Public Offering will be allocated between pool A and pool B and the number of Offer Shares allocated to the International Offering will be correspondingly reduced in such manner as the Joint Global Coordinators deem appropriate.

Details of any reallocation of Offer Shares between the Hong Kong Public Offering and the International Offering will be disclosed in the results announcement of the Global Offering, which is expected to be published on Friday, December 10, 2021.

STRUCTURE OF THE GLOBAL OFFERING

Applications

Each applicant under the Hong Kong Public Offering will be required to give an undertaking and confirmation in the application submitted by him that he and any person(s) for whose benefit he is making the application has not applied for or taken up, or indicated an interest for, and will not apply for or take up, or indicate an interest for, any International Offering Shares under the International Offering. Such applicant's application is liable to be rejected if such undertaking and/or confirmation is/are breached and/or untrue (as the case may be) or if he has been or will be placed or allocated International Offering Shares under the International Offering.

Applicants under the Hong Kong Public Offering are required to pay, on application, the Offer Price of HK\$15.80 per Offer Share in addition to the brokerage, the SFC transaction levy and the Stock Exchange trading fee payable on each Offer Share, amounting to a total of HK\$7,979.61 for one board lot of 500 Shares. Further details are set out in the section headed "How to Apply for the Hong Kong Offer Shares" in this prospectus.

THE INTERNATIONAL OFFERING

Number of Offer Shares initially offered

The International Offering will consist of an offering of initially 84,981,000 Shares, representing approximately 90.0% of the total number of Offer Shares initially available under the Global Offering (subject to reallocation and the Over-allotment Option). The number of Offer Shares initially offered under the International Offering, subject to any reallocation of Offer Shares between the International Offering and the Hong Kong Public Offering, will represent approximately 16.34% of the total Shares in issue immediately following the completion of the Global Offering (assuming the Over-allotment Option is not exercised).

Allocation

The International Offering will include selective marketing of Offer Shares to QIBs in the United States as well as institutional and professional investors and other investors anticipated to have a sizeable demand for such Offer Shares in Hong Kong and other jurisdictions outside the United States in reliance on Regulation S. Professional investors generally include brokers, dealers, companies (including fund managers) whose ordinary business involves dealing in shares and other securities and corporate entities that regularly invest in shares and other securities. Allocation of Offer Shares pursuant to the International Offering will be effected in accordance with the "book-building" process described in "— Pricing of the Global Offering" in this section and based on a number of factors, including the level and timing of demand, the total size of the relevant investor's invested assets or equity assets in the relevant sector and whether or not it is expected that the relevant investor is likely to buy further Shares and/or hold or sell its Shares after the Listing. Such allocation is intended to result in a distribution of the Shares on a basis which would lead to the establishment of a solid professional and institutional shareholder base to the benefit of the Group and the Shareholders as a whole.

STRUCTURE OF THE GLOBAL OFFERING

The Joint Global Coordinators (on behalf of the Underwriters) may require any investor who has been offered Offer Shares under the International Offering and who has made an application under the Hong Kong Public Offering to provide sufficient information to the Joint Global Coordinators so as to allow it to identify the relevant applications under the Hong Kong Public Offering and to ensure that they are excluded from any allocation of Offer Shares under the Hong Kong Public Offering.

Reallocation

The total number of Offer Shares to be issued or sold pursuant to the International Offering may change as a result of the clawback arrangement described in “— The Hong Kong Public Offering — Reallocation and Clawback” in this section above, the exercise of the Over-allotment Option in whole or in part and/or any reallocation of unsubscribed Offer Shares originally included in the Hong Kong Public Offering.

OVER-ALLOTMENT OPTION

In connection with the Global Offering, the Company is expected to grant the Over-allotment Option to the International Underwriters, exercisable by the Joint Global Coordinators (on behalf of the International Underwriters).

Pursuant to the Over-allotment Option, the International Underwriters will have the right, exercisable by the Joint Global Coordinators (on behalf of the International Underwriters) at any time from the Listing Date until 30 days after the last day for lodging applications under the Hong Kong Public Offering, to require the Company to issue up to an aggregate of 14,163,500 additional Shares, representing not more than 15% of the total number of Offer Shares initially available under the Global Offering, at the Offer Price under the International Offering to, among other things, cover over-allocations in the International Offering, if any.

If the Over-allotment Option is exercised in full, the additional Offer Shares to be issued pursuant thereto will represent approximately 2.65% of the total Shares in issue immediately following the completion of the Global Offering and the issue of Offer Shares pursuant to the Over-allotment Option. If the Over-allotment Option is exercised, an announcement will be made.

STABILIZATION

Stabilization is a practice used by underwriters in some markets to facilitate the distribution of securities. To stabilize, the underwriters may bid for, or purchase, the securities in the secondary market during a specified period of time, to retard and, if possible, prevent a decline in the initial public market price of the securities below the offer price. Such transactions may be effected in all jurisdictions where it is permissible to do so, in each case in compliance with all applicable laws and regulatory requirements, including those of Hong Kong. In Hong Kong, the price at which stabilization is effected is not permitted to exceed the offer price.

In connection with the Global Offering, the Stabilization Manager (or any person acting for it), on behalf of the Underwriters, may over-allocate or effect transactions with a view to stabilizing or supporting the market price of the Shares at a level higher than that which might otherwise prevail for a limited period after the Listing Date. However, there is no obligation on the Stabilization Manager (or any person acting for it) to conduct any such stabilizing action. Such stabilizing action, if taken, (a) will be

STRUCTURE OF THE GLOBAL OFFERING

conducted at the absolute discretion of the Stabilization Manager (or any person acting for it) and in what the Stabilization Manager reasonably regards as the best interest of the Company, (b) may be discontinued at any time and (c) is required to be brought to an end within 30 days of the last day for lodging applications under the Hong Kong Public Offering. The number of Shares that may be over-allocated will not exceed the number of Shares that may be sold under the Over-allotment Option, being 14,163,500 Shares, which is approximately 15% of the Offer Shares initially available under the Global Offering.

Stabilization action will be entered into in accordance with the laws, rules and regulations in place in Hong Kong. Stabilization action permitted in Hong Kong pursuant to the Securities and Futures (Price Stabilizing) Rules of the SFO includes (a) over-allocating for the purpose of preventing or minimizing any reduction in the market price of the Shares, (b) selling or agreeing to sell the Shares so as to establish a short position in them for the purpose of preventing or minimizing any reduction in the market price of the Shares, (c) purchasing, or agreeing to purchase, the Shares pursuant to the Over-allotment Option in order to close out any position established under paragraph (a) or (b) above, (d) purchasing, or agreeing to purchase, any of the Shares for the sole purpose of preventing or minimizing any reduction in the market price of the Shares, (e) selling or agreeing to sell any Shares in order to liquidate any position established as a result of those purchases, and (f) offering or attempting to do anything as described in paragraph (b), (c), (d) or (e) above.

Specifically, prospective applicants for and investors in the Offer Shares should note that:

- (a) the Stabilization Manager (or any person acting for it) may, in connection with the stabilizing action, maintain a long position in the Shares;
- (b) there is no certainty as to the extent to which and the time or period for which the Stabilization Manager (or any person acting for it) will maintain such a long position;
- (c) liquidation of any such long position by the Stabilization Manager (or any person acting for it) and selling in the open market may have an adverse impact on the market price of the Shares;
- (d) no stabilizing action can be taken to support the price of the Shares for longer than the stabilization period, which will begin on the Listing Date, and is expected to expire on Wednesday, January 5, 2022, being the 30th day after the last day for lodging applications under the Hong Kong Public Offering. After this date, when no further stabilizing action may be taken, demand for the Shares, and therefore the price of the Shares, could fall;
- (e) the price of the Shares cannot be assured to stay at or above the Offer Price either during or after the stabilization period by the taking of any stabilizing action; and
- (f) stabilizing bids or transactions effected in the course of the stabilizing action may be made at any price at or below the Offer Price and can, therefore, be done at a price below the price paid by applicants for, or investors in, the Offer Shares.

STRUCTURE OF THE GLOBAL OFFERING

In order to effect stabilization actions, the Stabilizing Manager will arrange cover of up to an aggregate of 14,163,500 Shares, representing up to approximately 15% of the initial Offer Shares, through borrowing of Shares from the Shareholders and/or delayed delivery arrangements with investors who have been allocated Offer Shares in the International Offering. The delayed delivery arrangements (if specifically agreed by an investor) relate only to the delay in the delivery of the Offer Shares to such investor and the Offer Price for the Offer Shares allocated to such investor will be paid on the Listing Date.

The Company will ensure or procure that an announcement in compliance with the Securities and Futures (Price Stabilizing) Rules of the SFO will be made within seven days of the expiration of the stabilization period.

Over-Allocation

Following any over-allocation of Shares in connection with the Global Offering, the Stabilization Manager (or any person acting for it) may cover such over-allocations by exercising the Over-allotment Option in full or in part, by using Shares purchased by the Stabilization Manager (or any person acting for it) in the secondary market at prices that do not exceed the Offer Price or through stock borrowing arrangements or a combination of these means.

PRICING OF THE GLOBAL OFFERING

The Offer Price will be HK\$15.80 per Offer Share unless otherwise announced, as further explained below, not later than the morning of the last day for lodging applications under the Hong Kong Public Offering.

The International Underwriters will be soliciting from prospective investors indications of interest in acquiring Offer Shares in the International Offering. Prospective professional and institutional investors will be required to specify the number of Offer Shares under the International Offering they would be prepared to acquire either at different prices or at a particular price. This process, known as “book-building,” is expected to continue up to, and to cease on or about, the last day for lodging applications under the Hong Kong Public Offering.

The Joint Global Coordinators (on behalf of the Underwriters) may, where they deem appropriate, based on the level of interest expressed by prospective investors during the book-building process in respect of the International Offering, and with the consent of the Company, reduce the number of Offer Shares offered and/or the Offer Price below that stated in this prospectus at any time on or prior to the morning of the last day for lodging applications under the Hong Kong Public Offering. In such a case, the Company will, as soon as practicable following the decision to make such reduction, and in any event not later than the morning of the last day for lodging applications under the Hong Kong Public Offering, cause to be published on the websites of the Company and the Stock Exchange at www.yonghegroup.cn and www.hkexnews.hk, respectively, notices of the reduction. Upon the issue of such a notice, the revised number of Offer Shares and/or the Offer Price will be final and conclusive. If the number of Offer Shares and/or the Offer Price range is so reduced, all applicants who have already submitted an application will be entitled to withdraw their applications and will need to confirm their applications in accordance with the procedures set out in the supplemental prospectus. Failure to confirm within the prescribed time will lead to the application being lapsed and all unconfirmed applications will not be valid.

STRUCTURE OF THE GLOBAL OFFERING

Before submitting applications for the Hong Kong Offer Shares, applicants should have regard to the possibility that any announcement of a reduction in the number of Offer Shares and/or the Offer Price may not be made until the last day for lodging applications under the Hong Kong Public Offering. Such notice will also include confirmation or revision, as appropriate, of the working capital statement and the Global Offering statistics as currently set out in this prospectus, and any other financial information which may change as a result of any such reduction. In the absence of any such notice so published, the number of Offer Shares and/or the Offer Price will not be reduced.

STOCK BORROWING AGREEMENT

In order to facilitate the settlement of over-allocations, if any, in connection with the Global Offering, the Stabilization Manager, its affiliates, or any person acting for it may choose to borrow up to 14,163,500 Shares (being the maximum number of Shares which may be issued upon exercise of the Over-allotment Option) pursuant to the Stock Borrowing Agreement, or acquire Shares from other sources, including the exercising of the Over-allotment Option.

The same number of Shares so borrowed must be returned to ZY Investment Capital Ltd on or before the third business day following the earlier of (a) the last day for exercising the Over-allotment Option and (b) the day on which the Over-allotment Option is exercised in full.

The stock borrowing arrangements under the Stock Borrowing Agreement will comply with the requirements set out in Listing Rule 10.07(3). No payment will be made to ZY Investment Capital Ltd by the Stabilizing Manager, its affiliates, or any person acting for it, in relation to such Shares borrowing arrangement.

UNDERWRITING

The Hong Kong Public Offering is fully underwritten by the Hong Kong Underwriters under the terms and conditions of the Hong Kong Underwriting Agreement and is subject to, among other things, the Joint Global Coordinators (on behalf of the Underwriters) and the Company agreeing on the Offer Price.

The Company expects to enter into the International Underwriting Agreement relating to the International Offering on or about December 6, 2021.

These underwriting arrangements, including the Underwriting Agreements, are summarized in the section headed “Underwriting” in this prospectus.

CONDITIONS OF THE GLOBAL OFFERING

Acceptance of all applications for Offer Shares will be conditional on, among other things:

- (a) the Listing Committee granting approval for the listing of, and permission to deal in, the Shares in issue and to be issued pursuant to the Global Offering on the Main Board of the Stock Exchange and such approval not subsequently having been withdrawn or revoked prior to the commencement of trading of the Shares on the Stock Exchange;
- (b) the execution and delivery of the International Underwriting Agreement on or about December 6, 2021; and

STRUCTURE OF THE GLOBAL OFFERING

- (c) the obligations of the Hong Kong Underwriters under the Hong Kong Underwriting Agreement and the obligations of the International Underwriters under the International Underwriting Agreement becoming and remaining unconditional and not having been terminated in accordance with the terms of the respective agreements or otherwise,

in each case on or before the dates and times specified in the respective Underwriting Agreements (unless and to the extent such conditions are validly waived on or before such dates and times).

The consummation of each of the Hong Kong Public Offering and the International Offering is conditional upon, among other things, the other offering becoming unconditional and not having been terminated in accordance with its terms.

If the above conditions are not fulfilled or waived prior to the dates and times specified, the Global Offering will lapse and the Stock Exchange will be notified immediately. Notice of the lapse of the Hong Kong Public Offering will be published on the websites of the Company and the Stock Exchange at www.yonghegroup.cn and www.hkexnews.hk, respectively, on the next day following such lapse. In such a situation, all application monies will be returned, without interest, on the terms set out in the section headed “How to Apply for the Hong Kong Offer Shares — 13. Refund of Application Monies” in this prospectus. In the meantime, all application monies will be held in separate bank account(s) with the receiving banks or other bank(s) in Hong Kong licensed under the Banking Ordinance (Chapter 155 of the Laws of Hong Kong).

Share certificates for the Offer Shares will only become valid at 8:00 a.m. on Monday, December 13, 2021, provided that the Global Offering has become unconditional in all respects at or before that time.

DEALINGS IN THE SHARES

Assuming that the Hong Kong Public Offering becomes unconditional at or before 8:00 a.m. in Hong Kong on Monday, December 13, 2021, it is expected that dealings in the Shares on the Stock Exchange will commence at 9:00 a.m. on Monday, December 13, 2021.

The Shares will be traded in board lots of 500 Shares each and the stock code of the Shares will be 2279.

HOW TO APPLY FOR THE HONG KONG OFFER SHARES

IMPORTANT NOTICE TO INVESTORS: FULLY ELECTRONIC APPLICATION PROCESS

We have adopted a fully electronic application process for the Hong Kong Public Offering. We will not provide any printed copies of this prospectus or any printed copies of any application forms for use by the public.

This prospectus is available at the website of the Stock Exchange at www.hkexnews.hk under the “*HKEXnews > New Listings > New Listing Information*” section, and our website at www.yonghegroup.cn. If you require a printed copy of this prospectus, you may download and print from the website addresses above.

The contents of the electronic version of the prospectus are identical to the printed prospectus as registered with the Registrar of Companies in Hong Kong pursuant to Section 342C of the Companies (Winding Up and Miscellaneous Provisions) Ordinance.

Set out below are procedures through which you can apply for the Hong Kong Offer Shares electronically. We will not provide any physical channels to accept any application for the Hong Kong Offer Shares by the public.

If you are an intermediary, broker or agent, please remind your customers, clients or principals, as applicable, that this prospectus is available online at the website addresses above.

1. HOW TO APPLY

We will not provide any printed application forms for use by the public.

To apply for Hong Kong Offer Shares, you may:

- (1) apply online via the **HK eIPO White Form** service in the **IPO App** (which can be downloaded by searching “**IPO App**” in App Store or Google Play or downloaded at www.hkeipo.hk/IPOApp or www.tricorglobal.com/IPOApp) or at www.hkeipo.hk; or
- (2) apply through the **CCASS EIPO** service to electronically cause HKSCC Nominees to apply on your behalf, including by:
 - (i) instructing your broker or custodian who is a CCASS Clearing Participant or a CCASS Custodian Participant to give **electronic application instructions** via CCASS terminals to apply for the Hong Kong Offer Shares on your behalf; or
 - (ii) (if you are an existing CCASS Investor Participant) giving **electronic application instructions** through the CCASS Internet System (<https://ip.ccass.com>) or through the CCASS Phone System by calling +852 2979 7888 (using the procedures in HKSCC’s “An Operating Guide for Investor Participants” in effect from time to time). HKSCC can also input **electronic application instructions** for CCASS Investor Participants through HKSCC’s Customer Service Centre at 1/F, One & Two Exchange Square, 8 Connaught Place, Central, Hong Kong by completing an input request.

HOW TO APPLY FOR THE HONG KONG OFFER SHARES

If you apply through channel (1) above, the Hong Kong Offer Shares successfully applied for will be issued in your own name.

If you apply through channels (2)(i) or (2)(ii) above, the Hong Kong Offer Shares successfully applied for will be issued in the name of HKSCC Nominees and deposited directly into CCASS to be credited to your or a designated CCASS Participant's stock account.

None of you or your joint applicant(s) may make more than one application, except where you are a nominee and provide the required information in your application.

The Company, the Joint Global Coordinators, the **HK eIPO White Form** Service Provider and their respective agents may reject or accept any application in full or in part for any reason at their discretion.

2. WHO CAN APPLY

Eligibility for the Application

You can apply for Hong Kong Offer Shares if you or the person(s) for whose benefit you are applying:

- are 18 years of age or older; and
- are outside the United States, and are not a United States Person (as defined in Regulation S under the U.S. Securities Act).

The number of joint applicants may not exceed four.

If you are a firm, the application must be in the individual members' names.

Unless permitted by the Listing Rules, you cannot apply for any Hong Kong Offer Shares if you are:

- an existing beneficial owner of Shares in the Company and/or any its subsidiaries;
- a Director or chief executive officer of the Company and/or any of its subsidiaries;
- a close associate (as defined in the Listing Rules) of any of the above; or
- have been allocated or have applied for any International Offering Shares or otherwise participate in the International Offering.

Items Required for the Application

If you apply for the Hong Kong Offer Shares online through the **HK eIPO White Form** service, you must:

- (a) have a valid Hong Kong identity card number/passport number (for individual applicant) or Hong Kong business registration number/certificate of incorporation number (for body corporate applicant);
- (b) have a Hong Kong address; and

HOW TO APPLY FOR THE HONG KONG OFFER SHARES

- (c) provide a valid e-mail address and a contact telephone number.

If you are applying for the Hong Kong Offer Shares online by instructing your **broker** or **custodian** who is a CCASS Clearing Participant or a CCASS Custodian Participant to give **electronic application instructions** via CCASS terminals, please contact them for the items required for the application.

3. TERMS AND CONDITIONS OF AN APPLICATION

By applying through the application channels specified in this prospectus, you:

- (i) undertake to execute all relevant documents and instruct and authorize the Company and/or the Joint Global Coordinators (or their agents or nominees), as agents of the Company, to execute any documents for you and to do on your behalf all things necessary to register any Hong Kong Offer Shares allocated to you in your name or in the name of HKSCC Nominees as required by the Articles of Association;
- (ii) agree to comply with the Companies (Winding Up and Miscellaneous Provisions) Ordinance, the Cayman Companies Act and the Articles of Association;
- (iii) confirm that you have read the terms and conditions and application procedures set out in this prospectus and agree to be bound by them;
- (iv) confirm that you have received and read this prospectus and have only relied on the information and representations contained in this prospectus in making your application and will not rely on any other information or representations except those in any supplement to this prospectus;
- (v) confirm that you are aware of the restrictions on the Global Offering in this prospectus;
- (vi) agree that none of the Company, the Joint Global Coordinators, the Underwriters, the **HK eIPO White Form** Service Provider, their respective directors, officers, employees, partners, agents, advisers and any other parties involved in the Global Offering is or will be liable for any information and representations not in this prospectus (and any supplement to it);
- (vii) undertake and confirm that you or the person(s) for whose benefit you have made the application have not applied for or taken up, or indicated an interest for, and will not apply for or take up, or indicate an interest for, any Offer Shares under the International Offering nor participated in the International Offering;
- (viii) agree to disclose to the Company, our Hong Kong Share Registrar, receiving banks, the Joint Global Coordinators, the Underwriters and/or their respective advisers and agents any personal data which they may require about you and the person(s) for whose benefit you have made the application;

HOW TO APPLY FOR THE HONG KONG OFFER SHARES

- (ix) if the laws of any place outside Hong Kong apply to your application, agree and warrant that you have complied with all such laws and none of the Company, the Joint Global Coordinators and the Underwriters nor any of their respective officers or advisers will breach any law outside Hong Kong as a result of the acceptance of your offer to purchase, or any action arising from your rights and obligations under the terms and conditions contained in this prospectus;
- (x) agree that once your application has been accepted, you may not rescind it because of an innocent misrepresentation;
- (xi) agree that your application will be governed by the laws of Hong Kong;
- (xii) represent, warrant and undertake that (i) you understand that the Hong Kong Offer Shares have not been and will not be registered under the U.S. Securities Act; and (ii) you and any person for whose benefit you are applying for the Hong Kong Offer Shares are outside the United States (as defined in Regulation S) or are a person described in paragraph (h)(3) of Rule 902 of Regulation S;
- (xiii) warrant that the information you have provided is true and accurate;
- (xiv) agree to accept the Hong Kong Offer Shares applied for, or any lesser number allocated to you under the application;
- (xv) authorize the Company to place your name(s) or the name of the HKSCC Nominees, on the Company's register of members as the holder(s) of any Hong Kong Offer Shares allocated to you, and the Company and/or its agents to send any Share certificate(s) and/or any e-Auto Refund payment instructions and/or any refund cheque(s) to you or the first-named applicant for joint application by ordinary post at your own risk to the address stated on the application, unless you are eligible to collect the Share certificate(s) and/or refund cheque(s) in person;
- (xvi) declare and represent that this is the only application made and the only application intended by you to be made to benefit you or the person for whose benefit you are applying;
- (xvii) understand that the Company and the Joint Global Coordinators will rely on your declarations and representations in deciding whether or not to make any allotment of any of the Hong Kong Offer Shares to you and that you may be prosecuted for making a false declaration;
- (xviii) (if the application is made for your own benefit) warrant that no other application has been or will be made for your benefit by giving **electronic application instructions** to HKSCC or to the **HK eIPO White Form** Service Provider by you or by any one as your agent or by any other person; and
- (xix) (if you are making the application as an agent for the benefit of another person) warrant that (i) no other application has been or will be made by you as agent for or for the benefit of that person or by that person or by any other person as agent for that person by giving **electronic application instructions** to HKSCC or to the **HK eIPO White Form** Service Provider; and (ii) you have due authority to give **electronic application instructions** on behalf of that other person as their agent.

HOW TO APPLY FOR THE HONG KONG OFFER SHARES

Section 40 of the Hong Kong Companies (Winding Up and Miscellaneous Provisions) Ordinance

For the avoidance of doubt, the Company and all other parties involved in the preparation of this document acknowledge that each applicant and CCASS Participant who gives or causes to give **electronic application instructions** is a person who may be entitled to compensation under Section 40 of the Companies (Winding Up and Miscellaneous Provisions) Ordinance (as applied by Section 342E of the Companies (Winding Up and Miscellaneous Provisions) Ordinance).

4. MINIMUM APPLICATION AMOUNT AND PERMITTED NUMBERS

Your application through the **HK eIPO White Form** service or the **CCASS EIPO** service must be for a minimum of 500 Hong Kong Offer Shares and in one of the numbers set out in the table below. You are required to pay the amount next to the number you select.

No. of Hong Kong Offer Shares applied for	Amount payable on application	No. of Hong Kong Offer Shares applied for	Amount payable on application	No. of Hong Kong Offer Shares applied for	Amount payable on application	No. of Hong Kong Offer Shares applied for	Amount payable on application
	HK\$		HK\$		HK\$		HK\$
500	7,979.61	7,000	111,714.52	50,000	797,960.83	700,000	11,171,451.62
1,000	15,959.22	8,000	127,673.73	60,000	957,553.00	800,000	12,767,373.28
1,500	23,938.83	9,000	143,632.95	70,000	1,117,145.16	900,000	14,363,294.94
2,000	31,918.43	10,000	159,592.17	80,000	1,276,737.33	1,000,000	15,959,216.60
2,500	39,898.05	15,000	239,388.25	90,000	1,436,329.49	2,000,000	31,918,433.20
3,000	47,877.65	20,000	319,184.33	100,000	1,595,921.66	3,000,000	47,877,649.80
3,500	55,857.26	25,000	398,980.42	200,000	3,191,843.32	4,000,000	63,836,866.40
4,000	63,836.87	30,000	478,776.50	300,000	4,787,764.98	4,721,500 ⁽¹⁾	75,351,441.18
4,500	71,816.48	35,000	558,572.58	400,000	6,383,686.64		
5,000	79,796.08	40,000	638,368.66	500,000	7,979,608.30		
6,000	95,755.30	45,000	718,164.75	600,000	9,575,529.96		

(1) Maximum number of Hong Kong Offer Shares you may apply for.

No application for any other number of the Hong Kong Offer Shares will be considered and any such application is liable to be rejected.

5. APPLYING THROUGH THE HK eIPO WHITE FORM SERVICE

General

Applicants who meet the criteria set out in the sub-section headed “— 2. Who Can Apply” in this section, may apply through the **HK eIPO White Form** service for the Offer Shares to be allotted and registered in their own names through the **IPO App** or the designated website at www.hkeipo.hk.

HOW TO APPLY FOR THE HONG KONG OFFER SHARES

Detailed instructions for application through the **HK eIPO White Form** service are in the **IPO App** or on the designated website. If you do not follow the instructions, your application may be rejected and may not be submitted to the Company. If you apply through the **IPO App** or the designated website, you authorize the **HK eIPO White Form** Service Provider to apply on the terms and conditions in this prospectus, as supplemented and amended by the terms and conditions of the **HK eIPO White Form** service.

Time for Submitting Applications under the HK eIPO White Form Service

You may submit your application to the **HK eIPO White Form** Service Provider in the **IPO App** or at www.hkeipo.hk (24 hours daily, except on the last application day) from 9:00 a.m. on Wednesday, December 1, 2021 until 11:30 a.m. on Monday, December 6, 2021 and the latest time for completing full payment of application monies in respect of such applications will be 12:00 noon on Monday, December 6, 2021 or such later time under the “— 10. Effect of Bad Weather and/or Extreme Conditions on the Opening and Closing of the Applications Lists” in this section.

6. APPLYING THROUGH THE CCASS EIPO SERVICE

General

CCASS Participants may give **electronic application instructions** to apply for the Hong Kong Offer Shares and to arrange payment of the money due on application and payment of refunds under their participant agreements with HKSCC and the General Rules of CCASS and the CCASS Operational Procedures.

If you are a **CCASS Investor Participant**, you may give these **electronic application instructions** through the CCASS Internet System (<https://ip.ccass.com>) or through the CCASS Phone System by calling +852 2979 7888 (using the procedures in HKSCC’s “An Operating Guide for Investor Participants” in effect from time to time). HKSCC can also input **electronic application instructions** for CCASS Investor Participants through HKSCC’s Customer Service Center at 1/F, One & Two Exchange Square, 8 Connaught Place, Central, Hong Kong if you complete an input request.

If you are **not a CCASS Investor Participant**, you may instruct your broker or custodian who is a CCASS Clearing Participant or a CCASS Custodian Participant to give **electronic application instructions** via CCASS terminals to apply for the Hong Kong Offer Shares on your behalf.

You will be deemed to have authorized HKSCC and/or HKSCC Nominees to transfer the details of your application to the Company, the Joint Global Coordinators and our Hong Kong Share Registrar.

HOW TO APPLY FOR THE HONG KONG OFFER SHARES

Applying through the CCASS EIPO service

Where you have applied through the **CCASS EIPO** service (either indirectly through a **broker** or **custodian** or directly) and an application is made by HKSCC Nominees on your behalf:

- (i) HKSCC Nominees will only be acting as a nominee for you and is not liable for any breach of the terms and conditions of this prospectus;
- (ii) HKSCC Nominees will do the following things on your behalf:
 - agree that the Hong Kong Offer Shares to be allotted shall be issued in the name of HKSCC Nominees and deposited directly into CCASS for the credit of the CCASS Participant's stock account on your behalf or your CCASS Investor Participant's stock account;
 - agree to accept the Hong Kong Offer Shares applied for or any lesser number allocated;
 - undertake and confirm that you have not applied for or taken up, will not apply for or take up, or indicate an interest for, any Offer Shares under the International Offering;
 - (if the **electronic application instructions** are given for your benefit) declare that only one set of **electronic application instructions** has been given for your benefit;
 - (if you are an agent for another person) declare that you have only given one set of **electronic application instructions** for the other person's benefit and are duly authorized to give those instructions as their agent;
 - confirm that you understand that the Company, the Directors and the Joint Global Coordinators will rely on your declarations and representations in deciding whether or not to make any allotment of any of the Hong Kong Offer Shares to you and that you may be prosecuted if you make a false declaration;
 - authorize the Company to place HKSCC Nominees' name on the Company's register of members as the holder of the Hong Kong Offer Shares allocated to you and to send share certificate(s) and/or refund monies under the arrangements separately agreed between us and HKSCC;
 - confirm that you have read the terms and conditions and application procedures set out in this prospectus and agree to be bound by them;
 - confirm that you have received and/or read a copy of this prospectus and have relied only on the information and representations in this prospectus in causing the application to be made, save as set out in any supplement to this prospectus;

HOW TO APPLY FOR THE HONG KONG OFFER SHARES

- agree that none of the Company, the Joint Global Coordinators, the Underwriters, their respective directors, officers, employees, partners, agents, advisers and any other parties involved in the Global Offering, is or will be liable for any information and representations not contained in this prospectus (and any supplement to it);
- agree to disclose your personal data to the Company, our Hong Kong Share Registrar, receiving banks, the Joint Global Coordinators, the Underwriters and/or its respective advisers and agents;
- agree (without prejudice to any other rights which you may have) that once HKSCC Nominees' application has been accepted, it cannot be rescinded for innocent misrepresentation;
- agree that any application made by HKSCC Nominees on your behalf is irrevocable before the fifth day after the time of the opening of the application lists (excluding any day which is Saturday, Sunday or public holiday in Hong Kong), such agreement to take effect as a collateral contract with us and to become binding when you give the instructions and such collateral contract to be in consideration of the Company agreeing that it will not offer any Hong Kong Offer Shares to any person before the fifth day after the time of the opening of the application lists (excluding any day which is Saturday, Sunday or public holiday in Hong Kong), except by means of one of the procedures referred to in this prospectus. However, HKSCC Nominees may revoke the application before the fifth day after the time of the opening of the application lists (excluding for this purpose any day which is a Saturday, Sunday or public holiday in Hong Kong) if a person responsible for this prospectus under Section 40 of the Companies (Winding Up and Miscellaneous Provisions) Ordinance (as applied by Section 342E of the Companies (Winding Up and Miscellaneous Provisions) Ordinance) gives a public notice under that section which excludes or limits that person's responsibility for this prospectus;
- agree that once HKSCC Nominees' application is accepted, neither that application nor your **electronic application instructions** can be revoked, and that acceptance of that application will be evidenced by the Company's announcement of the Hong Kong Public Offering results;
- agree to the arrangements, undertakings and warranties under the participant agreement between you and HKSCC, read with the General Rules of CCASS and the CCASS Operational Procedures, for the giving **electronic application instructions** to apply for Hong Kong Offer Shares;
- agree with the Company, for itself and for the benefit of each Shareholder (and so that the Company will be deemed by its acceptance in whole or in part of the application by HKSCC Nominees to have agreed, for itself and on behalf of each of the Shareholders, with each CCASS Participant giving **electronic application instructions**) to observe and comply with the Companies (Winding Up and Miscellaneous Provisions) Ordinance and the Articles of Association; and

HOW TO APPLY FOR THE HONG KONG OFFER SHARES

- agree that your application, any acceptance of it and the resulting contract will be governed by the Laws of Hong Kong.

Effect of Applying through the CCASS EIPO Service

By applying through the **CCASS EIPO** service, you (and, if you are joint applicants, each of you jointly and severally) are deemed to have done the following things. Neither HKSCC nor HKSCC Nominees shall be liable to the Company or any other person in respect of the things mentioned below:

- instructed and authorized HKSCC to cause HKSCC Nominees (acting as nominee for the relevant CCASS Participants) to apply for the Hong Kong Offer Shares on your behalf;
- instructed and authorized HKSCC to arrange payment of the Offer Price, brokerage, SFC transaction levy and the Stock Exchange trading fee by debiting your designated bank account and, in the case of a wholly or partially unsuccessful application, refund of the application monies (including brokerage, SFC transaction levy and the Stock Exchange trading fee) by crediting your designated bank account; and
- instructed and authorized HKSCC to cause HKSCC Nominees to do on your behalf all the things stated in this prospectus.

Time for Inputting Electronic Application Instructions⁽¹⁾

CCASS Clearing/Custodian Participants can input **electronic application instructions** at the following times on the following dates:

Wednesday, December 1, 2021	–	9:00 a.m. to 8:30 p.m.
Thursday, December 2, 2021	–	8:00 a.m. to 8:30 p.m.
Friday, December 3, 2021	–	8:00 a.m. to 8:30 p.m.
Monday, December 6, 2021	–	8:00 a.m. to 12:00 noon

CCASS Investor Participants can input **electronic application instructions** from 9:00 a.m. on Wednesday, December 1, 2021 until 12:00 noon on Monday, December 6, 2021 (24 hours daily, except on Monday, December 6, 2021, the last application day).

The latest time for inputting your **electronic application instructions** will be 12:00 noon on Monday, December 6, 2021, the last application day or such later time as described in “— 10. Effect of Bad Weather and/or Extreme Conditions on the Opening and Closing of the Application Lists” in this section.

(1) These times are subject to change as HKSCC may determine from time to time with prior notification to CCASS Clearing/Custodian Participants and/or CCASS Investor Participants.

HOW TO APPLY FOR THE HONG KONG OFFER SHARES

If you are instructing your **broker** or **custodian** who is a CCASS Clearing Participant or a CCASS Custodian Participant to give **electronic application instructions** via CCASS terminals to apply for the Hong Kong Offer Shares on your behalf, you are advised to contact your **broker** or **custodian** for the latest time for giving such instructions which may be different from the latest time as stated above.

Personal Data

The following Personal Information Collection Statement applies to any personal data held by the Company, the Hong Kong Share Registrar, the receiving bankers, the Joint Global Coordinators, the Underwriters and any of their respective advisers and agents about you in the same way as it applies to personal data about applicants other than HKSCC Nominees. By applying through the **CCASS EIPO** service, you agree to all of the terms of the Personal Information Collection Statement below.

Personal Information Collection Statement

This Personal Information Collection Statement informs applicant for, and holder of, the Hong Kong Offer Shares, of the policies and practices of the Company and its Hong Kong Share Registrar in relation to personal data and the Personal Data (Privacy) Ordinance (Chapter 486 of the Laws of Hong Kong).

Reasons for the collection of your personal data

It is necessary for applicants and registered holders of the Hong Kong Offer Shares to supply correct personal data to the Company or its agents and the Hong Kong Share Registrar when applying for the Hong Kong Offer Shares or transferring the Hong Kong Offer Shares into or out of their names or in procuring the services of the Hong Kong Share Registrar.

Failure to supply the requested data may result in your application for the Hong Kong Offer Shares being rejected, or in delay or the inability of the Company or its Hong Kong Share Registrar to effect transfers or otherwise render their services. It may also prevent or delay registration or transfers of the Hong Kong Offer Shares which you have successfully applied for and/or the dispatch of Share certificate(s) to which you are entitled.

It is important that the holders of the Hong Kong Offer Shares inform the Company and the Hong Kong Share Registrar immediately of any inaccuracies in the personal data supplied.

HOW TO APPLY FOR THE HONG KONG OFFER SHARES

Purposes

Your personal data may be used, held, processed, and/or stored (by whatever means) for the following purposes:

- processing your application and refund check, where applicable, verification of compliance with the terms and application procedures set out in this prospectus and announcing results of allocation of the Hong Kong Offer Shares;
- compliance with applicable laws and regulations in Hong Kong and elsewhere;
- registering new issues or transfers into or out of the names of the holders of the Company's Shares including, where applicable, HKSCC Nominees;
- maintaining or updating the Company's Register of Members;
- verifying identities of the holders of the Company's Shares;
- establishing benefit entitlements of holders of the Company's Shares, such as dividends, rights issues, bonus issues, etc.;
- distributing communications from the Company and its subsidiaries;
- compiling statistical information and profiles of the holder of the Company's Shares;
- disclosing relevant information to facilitate claims on entitlements; and
- any other incidental or associated purposes relating to the above and/or to enable the Company and the Hong Kong Share Registrar to discharge their obligations to holders of the Company's Shares and/or regulators and/or any other purposes to which the securities' holders may from time to time agree.

Transfer of personal data

Personal data held by the Company and its Hong Kong Share Registrar relating to the holders of the Hong Kong Offer Shares will be kept confidential but the Company and its Hong Kong Share Registrar may, to the extent necessary for achieving any of the above purposes, disclose, obtain or transfer (whether within or outside Hong Kong) the personal data to, from or with any of the following:

- the Company's appointed agents such as financial advisers, receiving bankers and overseas principal share registrar;
- where applicants for the Hong Kong Offer Shares request a deposit into CCASS, HKSCC or HKSCC Nominees, who will use the personal data for the purposes of operating CCASS;

HOW TO APPLY FOR THE HONG KONG OFFER SHARES

- any agents, contractors or third-party service providers who offer administrative, telecommunications, computer, payment or other services to the Company or the Hong Kong Share Registrar in connection with their respective business operation;
- the Hong Kong Stock Exchange, the SFC and any other statutory regulatory or governmental bodies or otherwise as required by laws, rules or regulations; and
- any persons or institutions with which the holders of the Hong Kong Offer Shares have or propose to have dealings, such as their bankers, solicitors, accountants or stockbrokers etc.

Retention of personal data

The Company and its Hong Kong Share Registrar will keep the personal data of the applicants and holders of the Hong Kong Offer Shares for as long as necessary to fulfil the purposes for which the personal data were collected. Personal data which is no longer required will be destroyed or dealt with in accordance with the Personal Data (Privacy) Ordinance.

Access to and correction of personal data

Holders of the Hong Kong Offer Shares have the right to ascertain whether the Company or the Hong Kong Share Registrar hold their personal data, to obtain a copy of that data, and to correct any data that is inaccurate. The Company and the Hong Kong Share Registrar have the right to charge a reasonable fee for the processing of such requests. All requests for access to data or correction of data should be addressed to the Company, at the Company's registered address disclosed in the section headed "Corporate Information" in this prospectus or as notified from time to time, for the attention of the secretary, or the Company's Hong Kong Share Registrar for the attention of the privacy compliance officer.

7. WARNING FOR ELECTRONIC APPLICATIONS

The subscription of the Hong Kong Offer Shares by the **CCASS EIPO** service (directly or indirectly through your broker or custodian) is only a facility provided to CCASS Participants. Similarly, the application for Hong Kong Offer Shares through the **HK eIPO White Form** service is also only a facility provided by the **HK eIPO White Form** Service Provider to public investors. Such facilities are subject to capacity limitations and potential service interruptions and you are advised not to wait until the last application day in making your electronic applications. The Company, the Directors, the Joint Bookrunners, the Joint Sponsors, the Joint Global Coordinators and the Underwriters take no responsibility for such applications and provide no assurance that any CCASS Participant or person applying through the **HK eIPO White Form** service will be allotted any Hong Kong Offer Shares.

To ensure that CCASS Investor Participants can give their **electronic application instructions**, they are advised not to wait until the last minute to input their instructions to the systems. In the event that CCASS Investor Participants have problems in the connection to CCASS Phone System/CCASS Internet System for submission of **electronic application instructions**, they should go to HKSCC's Customer Service Centre to complete an input request form for **electronic application instructions** before 12:00

HOW TO APPLY FOR THE HONG KONG OFFER SHARES

noon on Monday, December 6, 2021, the last day for applications, or such later time as described in “10. Effect of Bad Weather and/or Extreme Conditions on the Opening and Closing of the Application Lists” below.

8. HOW MANY APPLICATIONS CAN YOU MAKE

No Multiple Applications

Multiple applications for the Hong Kong Offer Shares are not allowed except by nominees. If you are a nominee and apply through the **HK eIPO White Form** service, in the box marked “For Nominees”, you must include an account number or some other identification code for each beneficial owner or, in the case of joint beneficial owners, for each joint beneficial owner when you fill in the application details. If you do not include this information, the application will be treated as being made for your own benefit.

All of your applications will be rejected if more than one application through the **CCASS eIPO** service (directly or indirectly through your **broker** or **custodian**) or through the **HK eIPO White Form** service is made for your benefit (including the part of the application made by HKSCC Nominees acting on **electronic application instructions**), and the number of Hong Kong Offer Shares applied by HKSCC Nominees will be automatically reduced by the number of Hong Kong Offer Shares for which you have given such instructions and/or for which such instructions have been given for your behalf. If you are suspected of submitting more than one application through the **HK eIPO White Form** service or by any other means, all of your applications are liable to be rejected.

If you apply by means of the **HK eIPO White Form** service, once you complete payment in respect of any electronic application instruction given by you or for your benefit through the **HK eIPO White Form** service to make an application for Hong Kong Offer Shares, an actual application shall be deemed to have been made. For the avoidance of doubt, giving an **electronic application instruction** under the **HK eIPO White Form** service more than once and obtaining different application reference numbers without effecting full payment in respect of a particular reference number will not constitute an actual application. However, any **electronic application instructions** to make an application for the Hong Kong Offer Shares given by you or for your benefit to HKSCC will be deemed to be an actual application for the purposes of considering whether multiple applications have been made.

The Hong Kong Share Registrar would record all applications into its system and identify suspected multiple applications with identical names, identification document numbers and reference numbers according to the Best Practice Note on Treatment of Multiple/Suspected Multiple Applications (“**Best Practice Note**”) issued by the Federation of Share Registrars Limited.

With regard to the announcement of results of allocations specified in “— 11. Publication of Results” in this section, the list of identification document number(s) may not be a complete list of successful applicants, only successful applicants whose identification document numbers are provided to HKSCC by CCASS Participants are disclosed. Applicants who applied for the Offer Shares through their brokers can consult their brokers to enquire about their application results.

HOW TO APPLY FOR THE HONG KONG OFFER SHARES

Since applications are subject to personal information collection statements, beneficial owner identification codes displayed are redacted. Applicants with beneficial names only but not identification document numbers are not disclosed due to personal privacy issue.

If an application is made by an unlisted company and:

- the principal business of that company is dealing in securities; and
- you exercise statutory control over that company,

then the application will be treated as being for your benefit.

“**Unlisted company**” means a company with no equity securities listed on the Stock Exchange.

“**Statutory control**” means you:

- control the composition of the board of directors of the company;
- control more than half of the voting power of the company; or
- hold more than half of the issued share capital of the company (not counting any part of it which carries no right to participate beyond a specified amount in a distribution of either profits or capital).

9. HOW MUCH ARE THE HONG KONG OFFER SHARES

You must pay the Offer Price, brokerage, SFC transaction levy and the Stock Exchange trading fee in full upon application for the Hong Kong Offer Shares. This means that for one board lot of 500 Hong Kong Offer Shares, you will pay HK\$7,979.61.

You may submit an application through the **HK eIPO White Form** service or the **CCASS EIPO** service in respect of a minimum of 500 Hong Kong Offer Shares. Each application or **electronic application instruction** in respect of more than 500 Hong Kong Offer Shares must be in one of the numbers set out in the table in “— 4. Minimum Application Amount and Permitted Numbers”, or as otherwise specified in the **IPO App** or on the designated website at www.hkeipo.hk.

If your application is successful, brokerage will be paid to the Exchange Participants, and the SFC transaction levy and the Stock Exchange trading fee are paid to the Stock Exchange (in the case of the SFC transaction levy, collected by the Stock Exchange on behalf of the SFC).

For further details on the Offer Price, see “Structure of the Global Offering — Pricing of the Global Offering” in this prospectus.

HOW TO APPLY FOR THE HONG KONG OFFER SHARES

10. EFFECT OF BAD WEATHER AND/OR EXTREME CONDITIONS ON THE OPENING AND CLOSING OF THE APPLICATION LISTS

The application lists will not open if there is/are:

- a tropical cyclone warning signal number 8 or above;
- a “black” rainstorm warning; and/or
- Extreme Conditions,

in force in Hong Kong at any time between 9:00 a.m. and 12:00 noon on Monday, December 6, 2021. Instead they will open between 11:45 a.m. and 12:00 noon on the next Business Day which does not have either of those warnings in Hong Kong in force at any time between 9:00 a.m. and 12:00 noon.

If the application lists do not open and close on Monday, December 6, 2021 or if there is/are a tropical cyclone warning signal number 8 or above or a “black” rainstorm warning signal and/or Extreme Conditions in force in Hong Kong that may affect the dates mentioned in the section headed “Expected Timetable” in this prospectus, an announcement will be made on our website at www.yonghegroup.cn and the website of the website of the Stock Exchange at www.hkexnews.hk.

11. PUBLICATION OF RESULTS

The Company expects to announce the level of indication of interest in the International Offering, the level of applications in the Hong Kong Public Offering and the basis of allocation of the Hong Kong Offer Shares on Friday, December 10, 2021 on the Company’s website at www.yonghegroup.cn and the website of the Stock Exchange at www.hkexnews.hk.

The results of allocations and the Hong Kong identity card/passport/Hong Kong business registration/certificate of incorporation numbers of successful applicants under the Hong Kong Public Offering will be available at the times and date and in the manner specified below:

- in the announcement to be posted on the Company’s website at www.yonghegroup.cn and the Stock Exchange’s website at www.hkexnews.hk by no later than 9:00 a.m. on Friday, December 10, 2021;
- from the “IPO Results” function in the **IPO App** and the designated results of allocations website at www.tricor.com.hk/ipo/result or www.hkeipo.hk/IPOResult with a “search by ID” function on a 24-hour basis from 8:00 a.m. on Friday, December 10, 2021 to 12:00 midnight on Thursday, December 16, 2021; and
- from the allocation results telephone enquiry line by calling +852 3691 8488 between 9:00 a.m. and 6:00 p.m. on Friday, December 10, 2021 to Wednesday, December 15, 2021 (excluding Saturday, Sunday, and public holiday in Hong Kong).

HOW TO APPLY FOR THE HONG KONG OFFER SHARES

If the Company accepts your offer to purchase (in whole or in part), which it may do by announcing the basis of allocations and/or making available the results of allocations publicly, there will be a binding contract under which you will be required to purchase the Hong Kong Offer Shares if the conditions of the Global Offering are satisfied and the Global Offering is not otherwise terminated. Further details are contained in the section headed “Structure of the Global Offering” in this prospectus.

You will not be entitled to exercise any remedy of rescission for innocent misrepresentation at any time after acceptance of your application. This does not affect any other right you may have.

12. CIRCUMSTANCES IN WHICH YOU WILL NOT BE ALLOCATED HONG KONG OFFER SHARES

You should note the following situations in which the Hong Kong Offer Shares will not be allotted to you:

(i) If your application is revoked:

By applying through the **CCASS EIPO** service or through the **HK eIPO White Form** service, you agree that your application or the application made by HKSCC Nominees on your behalf cannot be revoked on or before the fifth day after the time of the opening of the application lists (excluding for this purpose any day which is Saturday, Sunday or public holiday in Hong Kong). This agreement will take effect as a collateral contract with the Company.

Your application or the application made by HKSCC Nominees on your behalf may only be revoked on or before the fifth day after the time of the opening of the application lists (excluding any days which is a Saturday, Sunday or public holiday in Hong Kong) in the following circumstances:

- (a) if a person responsible for this prospectus under Section 40 of the Companies (Winding Up and Miscellaneous Provisions) Ordinance (as applied by Section 342E of the Companies (Winding Up and Miscellaneous Provisions) Ordinance) gives a public notice under that section on or before the fifth day after the time of the opening of the application lists (excluding any days which is a Saturday, Sunday or public holiday in Hong Kong) which excludes or limits that person’s responsibility for this prospectus; or
- (b) if any supplement to this prospectus is issued, applicants who have already submitted an application will be notified that they are required to confirm their applications. If applicants have been so notified but have not confirmed their applications in accordance with the procedure to be notified, all unconfirmed applications will be deemed revoked.

If your application or the application made by HKSCC Nominees on your behalf has been accepted, it cannot be revoked. For this purpose, acceptance of applications which are not rejected will be constituted by notification in the press of the results of allocation, and where such basis of allocation is subject to certain conditions or provides for allocation by ballot, such acceptance will be subject to the satisfaction of such conditions or results of the ballot respectively.

HOW TO APPLY FOR THE HONG KONG OFFER SHARES

(ii) If the Company or its agents exercise their discretion to reject your application:

The Company, the Joint Global Coordinators, the **HK eIPO White Form** Service Provider and their respective agents and nominees have full discretion to reject or accept any application, or to accept only part of any application, without giving any reasons.

(iii) If the allotment of Hong Kong Offer Shares is void:

The allotment of Hong Kong Offer Shares will be void if the Listing Committee of the Stock Exchange does not grant permission to list the Shares either:

- within three weeks from the closing date of the application lists; or
- within a longer period of up to six weeks if the Listing Committee notifies the Company of that longer period within three weeks of the closing date of the application lists.

(iv) If:

- you make multiple applications or suspected multiple applications;
- you or the person for whose benefit you are applying have applied for or taken up, or indicated an interest for, or have been or will be placed or allocated (including conditionally and/or provisionally) Hong Kong Offer Shares and International Offer Shares;
- your **electronic application instructions** through the **HK eIPO White Form** service are not completed in accordance with the instructions, terms and conditions in the **IPO App** or on the designated website at www.hkeipo.hk;
- your payment is not made correctly;
- the Underwriting Agreements do not become unconditional or are terminated;
- the Company or the Joint Global Coordinators believe that by accepting your application, it or they would violate applicable securities or other laws, rules or regulations; or
- your application is for more than 50% of the Hong Kong Offer Shares initially offered under the Hong Kong Public Offering.

HOW TO APPLY FOR THE HONG KONG OFFER SHARES

13. REFUND OF APPLICATION MONIES

If an application is rejected, not accepted or accepted in part only, or if the conditions of the Hong Kong Public Offering are not fulfilled in accordance with “Structure of the Global Offering — Conditions of the Global Offering” in this prospectus or if any application is revoked, the application monies, or the appropriate portion thereof, together with the related brokerage, SFC transaction levy and the Stock Exchange trading fee, will be refunded, without interest.

Any refund of your application monies will be made on or before Friday, December 10, 2021.

14. DESPATCH/COLLECTION OF SHARE CERTIFICATES AND REFUND MONIES

You will receive one Share certificate for all Hong Kong Offer Shares allotted to you under the Hong Kong Public Offering (except pursuant to applications made through the **CCASS EIPO** service where the Share certificates will be deposited into CCASS as described below).

No temporary document of title will be issued in respect of the Shares. No receipt will be issued for sums paid on application.

Subject to arrangement on dispatch/collection of Share certificates and refund monies as mentioned below, any refund cheques and Share certificates are expected to be posted on or before Friday, December 10, 2021. The right is reserved to retain any Share certificate(s) and any surplus application monies pending clearance of cheque(s) or banker’s cashier’s order(s).

Share certificates will only become valid at 8:00 a.m. Monday, December 13, 2021, provided that the Global Offering has become unconditional and the right of termination described in the section headed “Underwriting” in this prospectus has not been exercised. Investors who trade Shares prior to the receipt of Share certificates or the Share certificates becoming valid do so at their own risk.

Personal Collection

(i) If you apply through the HK eIPO White Form service

If you apply for 1,000,000 Hong Kong Offer Shares or more and your application is wholly or partially successful, you may collect your Share certificate(s) from the Hong Kong Share Registrar, Tricor Investor Services Limited, at Level 54, Hopewell Centre, 183 Queen’s Road East, Hong Kong, from 9:00 a.m. to 1:00 p.m. on Friday, December 10, 2021, or such other date as notified by the Company in the newspapers as the date of despatch/collection of Share certificates/e-Auto Refund payment instructions/refund cheques.

HOW TO APPLY FOR THE HONG KONG OFFER SHARES

If you are an individual who is eligible for personal collection, you must not authorise any other person to collect for you. If you are a corporate applicant which is eligible for personal collection, your authorised representative must bear a letter of authorization from your corporation stamped with your corporation's chop. Both individuals and authorized representatives must produce, at the time of collection, evidence of identity acceptable to the Hong Kong Share Registrar.

If you do not collect your Share certificate(s) personally within the time specified for collection, they will be sent to the address specified in your application instructions by ordinary post at your own risk.

If you apply for less than 1,000,000 Hong Kong Offer Shares, your Share certificate(s) (where applicable) will be sent to the address specified in your application instructions on or before Friday, December 10, 2021 by ordinary post at your own risk.

If you apply and pay the application monies from a single bank account, any refund monies will be despatched to that bank account in the form of e-Auto Refund payment instructions. If you apply and pay the application monies from multiple bank accounts, any refund monies will be despatched to the address as specified in your application instructions in the form of refund cheque(s) in favour of the applicant (or, in the case of joint applications, the first-named applicant) by ordinary post at your own risk.

(ii) If you apply through the CCASS EIPO service

Allocation of Hong Kong Offer Shares

For the purposes of allocating Hong Kong Offer Shares, HKSCC Nominees will not be treated as an applicant. Instead, each CCASS Participant who gives **electronic application instructions** or each person for whose benefit instructions are given will be treated as an applicant.

Deposit of Share Certificates into CCASS and Refund of Application Monies

- If your application is wholly or partially successful, your Share certificate(s) will be issued in the name of HKSCC Nominees and deposited into CCASS for the credit of your designated CCASS Participant's stock account or your CCASS Investor Participant stock account on Friday, December 10, 2021, or, on any other date determined by HKSCC or HKSCC Nominees.
- The Company expects to publish the application results of CCASS Participants (and where the CCASS Participant is a broker or custodian, the Company will include information relating to the relevant beneficial owner), your Hong Kong identity card number/passport number or other identification code (Hong Kong business registration number for corporations) and the basis of allotment of the Hong Kong Public Offering in the manner specified in "11. Publication of Results" above on Friday, December 10, 2021. You should check the announcement published by the Company and report any discrepancies to HKSCC before 5:00 p.m. on Friday, December 10, 2021 or such other date as determined by HKSCC or HKSCC Nominees.

HOW TO APPLY FOR THE HONG KONG OFFER SHARES

- If you have instructed your broker or custodian to give **electronic application instructions** on your behalf, you can also check the number of Hong Kong Offer Shares allotted to you and the amount of refund monies (if any) payable to you with that broker or custodian.
- If you have applied as a CCASS Investor Participant, you can also check the number of Hong Kong Offer Shares allotted to you and the amount of refund monies (if any) payable to you via the CCASS Phone System and the CCASS Internet System (under the procedures contained in HKSCC's "An Operating Guide for Investor Participants" in effect from time to time) on Friday, December 10, 2021. Immediately following the credit of the Hong Kong Offer Shares to your stock account and the credit of refund monies to your bank account, HKSCC will also make available to you an activity statement showing the number of Hong Kong Offer Shares credited to your CCASS Investor Participant stock account and the amount of refund monies (if any) credited to your designated bank account.
- Refund of your application monies (if any) in respect of wholly and partially unsuccessful applications will be credited to your designated bank account or the designated bank account of your broker or custodian on Friday, December 10, 2021.

15. ADMISSION OF THE SHARES INTO CCASS

If the Stock Exchange grants the listing of, and permission to deal in, the Shares and we comply with the stock admission requirements of HKSCC, the Shares will be accepted as eligible securities by HKSCC for deposit, clearance and settlement in CCASS with effect from the date of commencement of dealings in the Shares or any other date HKSCC chooses. Settlement of transactions between Exchange Participants (as defined in the Listing Rules) is required to take place in CCASS on the second Settlement Day after any trading day.

All activities under CCASS are subject to the General Rules of CCASS and CCASS Operational Procedures in effect from time to time.

Investors should seek the advice of their stockbroker or other professional adviser for details of the settlement arrangement as such arrangements may affect their rights and interests.

All necessary arrangements have been made enabling the Shares to be admitted into CCASS.

The following is the text of a report set out on pages I-1 to I-3, received from the Company's reporting accountant, PricewaterhouseCoopers, Certified Public Accountants, Hong Kong, for the purpose of incorporation in this prospectus. It is prepared and addressed to the directors of the Company and to the Joint Sponsors pursuant to the requirements of HKSIR 200 Accountants' Reports on Historical Financial Information in Investment Circulars issued by the Hong Kong Institute of Certified Public Accountants.



羅兵咸永道

ACCOUNTANT'S REPORT ON HISTORICAL FINANCIAL INFORMATION TO THE DIRECTORS OF YONGHE MEDICAL GROUP CO., LTD. AND MORGAN STANLEY ASIA LIMITED AND CHINA INTERNATIONAL CAPITAL CORPORATION HONG KONG SECURITIES LIMITED

Introduction

We report on the historical financial information of Yonghe Medical Group Co., Ltd. (the "Company") and its subsidiaries (together, the "Group") set out on pages I-4 to I-70, which comprises the consolidated balance sheets as at December 31, 2018, 2019 and 2020 and June 30, 2021, the balance sheets of the Company as at December 31, 2020 and June 30, 2021 and the consolidated statements of comprehensive income, the consolidated statements of changes in equity and the consolidated statements of cash flows for each of the years ended December 31, 2018, 2019 and 2020 and the six months ended June 30, 2021 (the "Track Record Period") and a summary of significant accounting policies and other explanatory information (together, the "Historical Financial Information"). The Historical Financial Information set out on pages I-4 to I-70 forms an integral part of this report, which has been prepared for inclusion in the prospectus of the Company dated December 1, 2021 (the "Prospectus") in connection with the initial listing of shares of the Company on the Main Board of The Stock Exchange of Hong Kong Limited.

Directors' responsibility for the Historical Financial Information

The directors of the Company are responsible for the preparation of Historical Financial Information that gives a true and fair view in accordance with the basis of presentation and preparation set out in Notes 1.3 and 2.1 to the Historical Financial Information, and for such internal control as the directors determine is necessary to enable the preparation of Historical Financial Information that is free from material misstatement, whether due to fraud or error.

Reporting accountant's responsibility

Our responsibility is to express an opinion on the Historical Financial Information and to report our opinion to you. We conducted our work in accordance with Hong Kong Standard on Investment Circular Reporting Engagements 200, *Accountants' Reports on Historical Financial Information in Investment Circulars* issued by the Hong Kong Institute of Certified Public Accountants ("HKICPA"). This standard requires that we comply with ethical standards and plan and perform our work to obtain reasonable assurance about whether the Historical Financial Information is free from material misstatement.

*PricewaterhouseCoopers, 22/F Prince's Building, Central, Hong Kong
T: +852 2289 8888, F: +852 2810 9888, www.pwchk.com*

Our work involved performing procedures to obtain evidence about the amounts and disclosures in the Historical Financial Information. The procedures selected depend on the reporting accountant's judgement, including the assessment of risks of material misstatement of the Historical Financial Information, whether due to fraud or error. In making those risk assessments, the reporting accountant considers internal control relevant to the entity's preparation of Historical Financial Information that gives a true and fair view in accordance with the basis of presentation and preparation set out in Notes 1.3 and 2.1 to the Historical Financial Information in order to design procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. Our work also included evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the directors, as well as evaluating the overall presentation of the Historical Financial Information.

We believe that the evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Opinion

In our opinion, the Historical Financial Information gives, for the purposes of the accountant's report, a true and fair view of the financial position of the Company as at December 31, 2020 and June 30, 2021 and the consolidated financial position of the Group as at December 31, 2018, 2019 and 2020 and June 30, 2021 and of its consolidated financial performance and its consolidated cash flows for the Track Record Period in accordance with the basis of presentation and preparation set out in Notes 1.3 and 2.1 to the Historical Financial Information.

Review of stub period comparative financial information

We have reviewed the stub period comparative financial information of the Group which comprises the consolidated statement of comprehensive income, the consolidated statement of changes in equity and the consolidated statement of cash flows for the six months ended June 30, 2020 and other explanatory information (the "Stub Period Comparative Financial Information"). The directors of the Company are responsible for the presentation and preparation of the Stub Period Comparative Financial Information in accordance with the basis of presentation and preparation set forth in Notes 1.3 and 2.1 to the Historical Financial Information. Our responsibility is to express a conclusion on the Stub Period Comparative Financial Information based on our review. We conducted our review in accordance with Hong Kong Standard on Review Engagements 2410, *Review of Interim Financial Information Performed by the Independent Auditor of the Entity* issued by the HKICPA. A review consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Hong Kong Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. Based on our review, nothing has come to our attention that causes us to believe that the Stub Period Comparative Financial Information, for the purposes of the accountant's report, is not prepared, in all material respects, in accordance with the basis of presentation and preparation set forth in Notes 1.3 and 2.1 to the Historical Financial Information.

Report on matters under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Listing Rules”) and the Companies (Winding Up and Miscellaneous Provisions) Ordinance

Adjustments

In preparing the Historical Financial Information, no adjustments to the Underlying Financial Statements as defined on page I-4 have been made.

Dividends

We refer to Note 34 to the Historical Financial Information which states that no dividends have been paid by Yonghe Medical Group Co., Ltd. in respect of the Track Record Period. We refer to Note 35 which contains information about the dividends declared and paid by Yonghe Medical Group Co., Ltd. after the Track Record Period and up to the date of this Prospectus.

No statutory financial statements for the Company

No statutory financial statements have been prepared for the Company since its date of incorporation.

PricewaterhouseCoopers

Certified Public Accountants

Hong Kong

December 1, 2021

I. HISTORICAL FINANCIAL INFORMATION OF THE GROUP**Preparation of Historical Financial Information**

Set out below is the Historical Financial Information which forms an integral part of this accountant's report.

The financial statements of the Group for the years ended December 31, 2018, 2019 and 2020 and the six months ended June 30, 2021 (the "Track Record Period"), on which the Historical Financial Information is based, were audited by PricewaterhouseCoopers in accordance with Hong Kong Standards on Auditing issued by the HKICPA ("the Underlying Financial Statements").

The Historical Financial Information is presented in Renminbi ("RMB") and all values are rounded to the nearest thousand (RMB'000) except when otherwise indicated.

Consolidated Statements of Comprehensive Income

	<i>Note</i>	Year ended December 31,			Six months ended June 30,	
		2018	2019	2020	2020	2021
		<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>
					(Unaudited)	
Revenue from contracts with customers	6	934,326	1,224,477	1,638,297	601,563	1,053,400
Cost of sales and services	9	(232,207)	(335,379)	(416,667)	(166,012)	(277,983)
Gross profit		702,119	889,098	1,221,630	435,551	775,417
Selling and marketing expenses	9	(463,681)	(650,262)	(779,611)	(246,631)	(577,947)
General and administrative expenses	9	(93,952)	(129,962)	(162,022)	(69,443)	(91,142)
Research and development expenses	9	(7,807)	(8,869)	(11,815)	(5,456)	(6,151)
Net impairment losses on financial assets	3.1(c)	(1,633)	(34)	(487)	(279)	(376)
Other income	7	933	1,443	6,304	1,354	2,133
Other gains and losses, net	8	(7,021)	(3,373)	(7,738)	(5,766)	7,211
Operating profit		128,958	98,041	266,261	109,330	109,145
Finance income	11	139	210	941	218	2,408
Finance costs	11	(17,808)	(26,728)	(36,288)	(16,007)	(22,678)
Finance costs – net	11	(17,669)	(26,518)	(35,347)	(15,789)	(20,270)
Profit before income tax		111,289	71,523	230,914	93,541	88,875
Income tax expense	12	(57,789)	(35,899)	(67,582)	(28,082)	(48,434)
Profit for the year/period		53,500	35,624	163,332	65,459	40,441

	<i>Note</i>	Year ended December 31,			Six months ended June 30,	
		2018	2019	2020	2020	2021
		<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>
					(Unaudited)	
Other comprehensive income						
<i>Items that may be subsequently reclassified to profit or loss</i>						
Currency translation differences		–	–	–	–	710
<i>Items that will not be reclassified to profit or loss</i>						
Currency translation differences		–	–	–	–	(1,657)
Total comprehensive income for the year/period		<u>53,500</u>	<u>35,624</u>	<u>163,332</u>	<u>65,459</u>	<u>39,494</u>
Profit and total comprehensive income for the year/period attributable to owners of the Company		<u>53,500</u>	<u>35,624</u>	<u>163,332</u>	<u>65,459</u>	<u>39,494</u>
Earnings per share attributable to owners of the Company						
Basic earnings per share (<i>RMB</i>)	13	0.13	0.09	0.39	0.16	0.10
Diluted earnings per share (<i>RMB</i>)	13	0.13	0.09	0.39	0.16	0.10

Consolidated Balance Sheets

	<i>Note</i>	As at December 31,			As at
		2018	2019	2020	June 30,
		<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>	2021
					<i>RMB'000</i>
Assets					
Non-current assets					
Property, plant and equipment	14	168,158	231,136	309,437	380,720
Right-of-use assets	15	398,862	494,985	810,653	761,324
Intangible assets	16	1,398	3,307	3,547	34,148
Deferred income tax assets	27	12,517	20,853	29,012	32,735
Prepayments, deposits and other receivables	19	863	2,499	4,095	2,216
Total non-current assets		581,798	752,780	1,156,744	1,211,143
Current assets					
Inventories	20	14,255	14,486	26,996	44,496
Trade receivables	18	9,805	5,859	10,330	6,929
Prepayments, deposits and other receivables	19	60,111	68,299	107,430	131,626
Restricted cash	24(b)	–	–	–	149,500
Cash and cash equivalents	21	68,476	89,789	292,856	453,100
Total current assets		152,647	178,433	437,612	785,651
Total assets		734,445	931,213	1,594,356	1,996,794
Equity					
Equity attributable to owners of the Company					
Share capital	22	–	–	–	7
Other reserves	22	150,365	150,365	153,971	241,798
Retained earnings		53,131	88,755	252,087	292,528
Total equity		203,496	239,120	406,058	534,333

		As at December 31,			As at June 30,
	<i>Note</i>	2018	2019	2020	2021
		<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>
Liabilities					
Non-current liabilities					
Lease liabilities	15	324,932	411,172	682,879	644,381
Deferred income tax liabilities	27	794	193	219	964
Total non-current liabilities		325,726	411,365	683,098	645,345
Current liabilities					
Borrowings	24	–	44,827	25,870	214,395
Trade and other payables	25	62,469	77,098	138,232	212,006
Contract liabilities	26	16,892	23,354	120,423	181,792
Current income tax liabilities		50,481	38,581	73,624	50,944
Lease liabilities	15	75,381	96,868	147,051	157,979
Total current liabilities		205,223	280,728	505,200	817,116
Total liabilities		530,949	692,093	1,188,298	1,462,461
Total equity and liabilities		734,445	931,213	1,594,356	1,996,794

Balance Sheets of the Company

	<i>Note</i>	As at December 31, 2020	As at June 30, 2021
		<i>RMB'000</i>	<i>RMB'000</i>
Assets			
Non-current assets			
Investment in subsidiaries	1.2(i)(g)	—	265,039
Total non-current assets		—	265,039
Current assets			
Amount due from subsidiaries		—	113,004
Cash and cash equivalents	21	—	92,355
Total current assets		—	205,359
Total assets		—	470,398
Equity			
Share capital	22(i)	—	7
Other reserves		—	352,282
Accumulated losses		—	(2,113)
Total equity		—	350,176
Liabilities			
Non-current liabilities			
Total non-current liabilities		—	—
Current liabilities			
Borrowing	24	—	120,222
Total current liabilities		—	120,222
Total liabilities		—	120,222
Total equity and liabilities		—	470,398

Consolidated Statements of Changes in Equity

	<i>Note</i>	Attributable to owners of the Company			Total equity <i>RMB'000</i>
		Share capital	Other reserves	Retained earnings	
		<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>	
Balance at January 1, 2018					
(Unaudited)		–	150,365	(369)	149,996
Profit for the year		–	–	53,500	53,500
Total comprehensive income		–	–	53,500	53,500
Balance at December 31, 2018		–	150,365	53,131	203,496
Balance at January 1, 2019		–	150,365	53,131	203,496
Profit for the year		–	–	35,624	35,624
Total comprehensive income		–	–	35,624	35,624
Balance at December 31, 2019		–	150,365	88,755	239,120
Balance at January 1, 2020		–	150,365	88,755	239,120
Profit for the year		–	–	163,332	163,332
Total comprehensive income		–	–	163,332	163,332
Transaction with owners					
Share-based compensation	23	–	3,606	–	3,606
Balance at December 31, 2020		–	153,971	252,087	406,058

	<i>Note</i>	Attributable to owners of the Company			
		Share capital	Other reserves	Retained earnings	Total equity
		<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>
Balance at January 1, 2020		–	150,365	88,755	239,120
Profit for the period		–	–	65,459	65,459
Total comprehensive income		–	–	65,459	65,459
Transaction with owners					
Share-based compensation	23	–	3,513	–	3,513
Balance at June 30, 2020 (Unaudited)		–	153,878	154,214	308,092
Balance at January 1, 2021		–	153,971	252,087	406,058
Profit for the period		–	–	40,441	40,441
Currency translation differences		–	(947)	–	(947)
Total comprehensive (loss)/income		–	(947)	40,441	39,494
Transaction with owners					
Issue of shares	22	7	(7)	–	–
Issue of shares to ZY Investment Capital Ltd.	22	–	88,689	–	88,689
Deemed capital contribution from shareholders in Reorganization	1.2(i)(g)	–	74,052	–	74,052
Deemed distribution to shareholders for shares transfer of Beijing Haiyouyou in Reorganization	1.2(i)(g)	–	(74,052)	–	(74,052)
Share-based compensation	23	–	92	–	92
Balance at June 30, 2021		7	241,798	292,528	534,333

Consolidated Statements of Cash Flows

		Year ended December 31,			Six months ended June 30,	
	<i>Note</i>	2018	2019	2020	2020	2021
		<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>
					(Unaudited)	
Cash flows from operating activities						
Cash generated from operations	28(a)	212,830	239,006	541,303	213,819	290,650
Interest received		139	210	941	218	2,408
Income tax paid		(18,402)	(56,736)	(40,673)	(40,146)	(74,744)
Net cash from operating activities		<u>194,567</u>	<u>182,480</u>	<u>501,571</u>	<u>173,891</u>	<u>218,314</u>
Cash flows from investing activities						
Payments for property, plant and equipment		(135,424)	(105,808)	(142,204)	(44,907)	(92,462)
Payments for intangible assets		(1,270)	(2,300)	(643)	(18)	(992)
Proceeds from disposals of property, plant and equipment		305	6	178	123	82
Proceeds from disposals of subsidiaries		3,267	2,750	150	–	–
Payment for acquisition of a subsidiary, net of cash acquired	30(b)	–	–	–	–	(3,802)
Purchase of financial assets at fair value through profit or loss		–	–	(31,100)	–	–
Disposal of financial assets at fair value through profit or loss		<u>30,333</u>	<u>–</u>	<u>31,231</u>	<u>–</u>	<u>–</u>
Net cash used in investing activities		<u>(102,789)</u>	<u>(105,352)</u>	<u>(142,388)</u>	<u>(44,802)</u>	<u>(97,174)</u>

	<i>Note</i>	Year ended December 31,			Six months ended June 30,	
		2018	2019	2020	2020	2021
		<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>
					(Unaudited)	
Cash flows from financing activities						
Proceeds from borrowings		–	44,827	28,870	25,370	232,685
Repayment of borrowings		–	–	(47,827)	(44,114)	(45,870)
Interest paid		–	(1,275)	(1,488)	(1,025)	(1,150)
Payment of lease liabilities		(69,689)	(99,367)	(132,289)	(64,108)	(77,554)
Payments of listing expenses		–	–	(3,382)	–	(8,959)
Restricted cash as guarantee for borrowings		–	–	–	–	(149,500)
Capital contribution from ZY Investment Capital Ltd.	22(b)	–	–	–	–	88,689
Capital contribution from shareholders in Reorganization	1.2(i)(g)	–	–	–	–	74,052
Payment for consideration for shares transfer of Beijing Haiyouyou in Reorganization	1.2(i)(g)	–	–	–	–	(74,052)
Net cash (used in)/from financing activities		<u>(69,689)</u>	<u>(55,815)</u>	<u>(156,116)</u>	<u>(83,877)</u>	<u>38,341</u>
Net increase in cash and cash equivalents		22,089	21,313	203,067	45,212	159,481
Cash and cash equivalents at beginning of the year/period		46,387	68,476	89,789	89,789	292,856
Exchange gains on cash and cash equivalents		<u>–</u>	<u>–</u>	<u>–</u>	<u>–</u>	<u>763</u>
Cash and cash equivalents at end of the year/period		<u>68,476</u>	<u>89,789</u>	<u>292,856</u>	<u>135,001</u>	<u>453,100</u>

II. NOTES TO THE HISTORICAL FINANCIAL INFORMATION

1. GENERAL INFORMATION, REORGANISATION AND BASIS OF PRESENTATION

1.1 General information

Yonghe Medical Group Co., Ltd. (the “Company”) was incorporated in the Cayman Islands on September 17, 2020 as an exempted company with limited liability under the Companies Act, Cap. 22 (Law 3 of 1961, as consolidated and revised) of the Cayman Islands. The address of the Company’s registered office is P.O. Box 2547, Grand Cayman, KY1-1104, Cayman Islands.

The Company is an investment holding company and its subsidiaries (together, the “Group”) are primarily engaged in the provision of (i) Hair transplant and (ii) Medical hair care services in the People’s Republic of China (the “PRC”) (the “Listing Business”).

This Historical Financial Information is presented in Renminbi (“RMB”) and all amounts are rounded to the nearest thousand of RMB (“RMB’000”), unless otherwise stated.

1.2 Reorganisation

Prior to the incorporation of the Company and the completion of the reorganisation as described below (the “Reorganisation”), the Listing Business was primarily carried out by companies now comprising the Group, including Beijing Haiyouyou Technology Company Limited (“Beijing Haiyouyou”), and its subsidiaries (collectively, the “operating companies”) in the PRC during the years ended December 31, 2018, 2019 and 2020 and the six months ended June 30, 2021 (the “Track Record Period”).

In preparation for the initial listing of the Company’s shares on the Main Board of The Stock Exchange of Hong Kong Limited (the “Listing”), the Reorganisation was undertaken to transfer the Listing Business to the Company principally through the following steps:

(i) *Incorporation of overseas companies*

- (a) On September 17, 2020, the Company was incorporated under the laws of the Cayman Islands as an exempted company with limited liability. The initial authorised share capital of the Company was US\$50,000 divided into 5,000,000,000 shares with a par value of US\$0.00001 each. Upon incorporation, one share with par value US\$0.00001 was allotted and issued to Sertus Nominees (Cayman) Limited, and was subsequently transferred to ZhangYu Hair Service Holdings Limited, a special purpose vehicle incorporated in the British Virgin Islands (“BVI”) and wholly owned by Mr. Zhang Yu.

On September 17, 2020, Mr. Zhang Yu and Mr. Zhang Hui, the shareholders of Beijing Xunyi Technology Development Company Limited (“Beijing Xunyi”) and Mr. Nie Lei, Mr. Geng Jiaqi, Ms. Duan Siqi, Mr. Tan Xu and Mr. Song Linfeng, the partners of Tianjin Yonghe Yuhui Enterprise Management Partnership (Limited Partnership) (“Yonghe Yuhui”), who are individual persons, through their respective special purpose vehicles incorporated in the BVI subscribed shares in the Company in proportion to their ultimate shareholdings in Beijing Haiyouyou respectively. On January 29, 2021, Panmao (Shanghai) Investment Center (Limited Partnership) (“Panmao Shanghai”) through Yonghe Hair Service Holdings Limited, its special purpose vehicle incorporated in BVI, CYH Cosmetic Medical Holdings Limited (“CYH”) and Hu & Yan Healthcare Investment Limited (the “Hu & Yan”) subscribed shares in the Company in proportion to their shareholdings in Beijing Haiyouyou respectively.

- (b) Yonghe Management Consulting Co., Ltd. (“Yonghe BVI”) was incorporated in the BVI on September 25, 2020 by the Company.
- (c) Yonghe Medical Holdings Limited (“Yonghe HK”) was incorporated in Hong Kong on October 9, 2020 with limited liability by Yonghe BVI.
- (d) In order to incentivize Mr. Zhang Yu (the “founder”) and key employees, the then Shareholders (other than Mr. Zhang Yu and Mr. Zhang Hui) agreed to transfer 5% and 3% of the then issued shares to Mr. Zhang Yu and the employee incentive platform, Zhirui Technology Holdings Limited. On April 23, 2021, the then Shareholders (other than Mr. Zhang Yu and Mr. Zhang Hui) of the Company (the “Transferors”) transferred in total 5,000,000 and 3,000,000 shares (representing 5% and 3% of the issued shares in the Company, respectively) to Yunuo Technology Holdings Limited and Zhirui Technology Holdings Limited, at a consideration of RMB69,427,083 and RMB41,656,250, respectively. The shares transferred was in proportion to the Transferors’ respective shareholding in the Company.

Yunuo Technology Holdings Limited is incorporated in the BVI on January 15, 2021 and is wholly owned by Mr. Zhang Yu. Zhirui Technology Holdings Limited is the employee incentive platform. For detailed information of the Transferors, see Note 23.

- (e) On March 25, 2021, Mr. Zhang Yu and Mr. Zhang Hui established their respective family trust and transferred their equity interests in the Company held through ZhangYu Hair Service Holdings Limited and ZhangHui Hair Service Holdings Limited to their respective family trusts.
- (f) To further incentivise the founder, on April 26, 2021, the Company issued 6,382,979 shares to ZY Investment Capital Ltd., representing approximately 6.0% of the shares of the Company in issue upon completion of the share issuance at a consideration of RMB89 million.
- (g) On May 10, 2021, Beijing Xunyi, Panmao Shanghai, CYH, Hu & Yan and Yonghe Yuhui, being the then shareholders of Beijing Haiyouyou, entered into a share transfer agreement with Yonghe HK, the Hong Kong subsidiary, pursuant to which Yonghe HK acquired the entire equity interests in Beijing Haiyouyou from each of Beijing Xunyi, Panmao Shanghai and Yonghe Yuhui through cash payment, CYH and Hu & Yan through share exchange to the Company, at the consideration of RMB265 million. Upon completion of the share transfers, Beijing Haiyouyou was wholly owned by Yonghe HK. The cash consideration of RMB70 million, RMB4 million and RMB106 million has been fully paid to Panmao Shanghai, Yonghe Yuhui and Beijing Xunyi on June 4, 2021. Then the consideration has been contributed to the Company and Beijing Yonghe Medical Investment Management Company Limited (the “Yonghe Investment”, which is wholly owned by Beijing Haiyouyou) by Panmao Shanghai through Yonghe Hair Service Holdings Limited, its special purpose vehicle incorporated in BVI, Yonghe Yuhui and Beijing Xunyi, respectively. The shares exchanges from Beijing Haiyouyou to the Company of CYH and Hu & Yan were completed on May 10, 2021.

(ii) *Transfer of shares of the operating companies*

The Group underwent the following onshore reorganisation:

- (a) Yonghe Investment transferred its entire equity interests in the entities which does not engage in restricted or prohibited foreign investment business pursuant to the applicable PRC laws and regulations to Beijing Haiyouyou or its wholly owned subsidiaries. Specifically, Yonghe Investment transferred (i) the 100% equity interests it owned in Beijing Maoduoduo Skin Clinic Company Limited to Beijing Yunyihui Medical Management Company Limited on October 22, 2020; (ii) the 100% equity interests it owned in Beijing Yunmao Chuangxiang Network Technology Company Limited to Beijing Yonghe Hair Transplant Technique Research Laboratory Company Limited (the “Yonghe Research Laboratory”) on November 3, 2020; (iii) the 100% equity interests it owned in Yonghe Research Laboratory to Beijing Haiyouyou on December 7, 2020; (iv) the 100% equity interests it owned in Jinan Yongxin Medical Technology Company Limited to Yonghe Research Laboratory on March 17, 2021; and (v) the 100% equity interests it owned in Chengdu Wuhou Yonghe Jimei Medical Aesthetic Clinic Company Limited (“Chengdu Yonghe”) to Beijing Haiyouyou on November 17, 2020.
- (b) On November 27, 2020, Beijing Xunyi contributed RMB4,285,714 to Yonghe Investment, resulting in the increase in the registered capital of Yonghe Investment to RMB14,285,714. Immediately after such capital contribution, Yonghe Investment was held as to 70% by Beijing Haiyouyou and 30% by Beijing Xunyi. The consideration for such capital contribution was fully paid up on June 10, 2021.
- (c) On November 30, 2020, Beijing Xunyi contributed RMB555,556 to Chengdu Yonghe, resulting in the increase in the registered capital of Chengdu Yonghe to RMB555,556. Immediately after such capital contribution, Chengdu Yonghe was held as to 90% by Beijing Haiyouyou and 10% by Beijing Xunyi. The consideration for such capital contribution was fully paid up on June 10, 2021.

(iii) VIE arrangements

The Group originally has 70% and 90% equity interest in Yonghe Investment and Chengdu Yonghe (collectively, the “VIE entities”) and is considered to have control over the VIE entities. On January 6, 2021, Beijing Haiyouyou, Yonghe Investment (together with all the medical institutions it owned), Chengdu Yonghe, Beijing Xunyi, Mr. Zhang Yu and Mr. Zhang Hui entered into various agreements constituting the contractual arrangements (the “Contractual Arrangements”) apply to the 30% and 10% equity interests in Yonghe Investment and Chengdu Yonghe, respectively, which enable the Group to:

- (a) receive 30% and 10% of the economic interest returns generated by Yonghe Investment and Chengdu Yonghe, respectively, in consideration for technical support, consulting services and other services provided by Beijing Haiyouyou;
- (b) exercise 30% and 10% equity holders’ rights and power of Yonghe Investment and Chengdu Yonghe, respectively; exercise all of the rights and powers as a shareholder of Beijing Xunyi;
- (c) obtain an irrevocable and exclusive right to purchase all or part of equity interests in the VIE entities from Beijing Xunyi at a minimum purchase price permitted under PRC laws and regulations. The Group may exercise such options at any time until it has acquired all equity interests and/or all assets of the VIE entities;
- (d) obtain an irrevocable and exclusive right to purchase all or part of equity interests in Beijing Xunyi from Mr. Zhang Yu and Mr. Zhang Hui at a minimum purchase price permitted under PRC laws and regulations. The Group may exercise such options at any time until it has acquired all equity interests and/or all assets of Beijing Xunyi;
- (e) obtain a pledge over the respective equity interest in Beijing Xunyi of Mr. Zhang Yu and Mr Zhang Hui and a pledge over the entire equity interest of VIE entities from Beijing Xunyi to secure performance of all the obligations of Mr. Zhang Yu, Mr Zhang Hui and Beijing Xunyi underlying the Contractual Arrangements.

As a result of the Contractual Arrangements, the Group can consolidated 100% interests over the VIE entities without non-controlling interests and Beijing Xunyi.

As a result, the Reorganisation was completed on June 10, 2021.

Upon completion of the Reorganisation and as at the date of this report, the Company had direct or indirect interests in the following principal subsidiaries:

Company Name	date of incorporation/ establishment	Issued and paid-up capital	Attributable equity interest of the Group				Principal activities/ place of operation	Notes	
			As at December 31,			As at June 30, 2021			As at the date of this report
			2018	2019	2020				
Directly held:									
Yonghe Management Consulting Co., Ltd.	The BVI, September 25, 2020, limited liability company	RMB6.81	N/A	N/A	100%	100%	100%	Consulting, the BVI	(1) and (3)
Indirectly held:									
Yonghe Investment (“北京雍禾醫療投資管理有限 公司”)	The PRC, September 30, 2015, limited liability company	RMB14,285,714.30	100%	100%	100%	100%	100%	Hair transplant , The PRC	(1) and (2)
Svenson Hair Centre (Beijing) Company Limited (“史雲遜護髮 (北京) 有限公司”)	The PRC, November 5, 2003, limited liability company	RMB8,751,841.25	100%	100%	100%	100%	100%	Hair care, The PRC	(1) and (3)
Beijing Hafada Hair Increase Technology Company Limited (“北京哈發達增發科技有限 公司”)	The PRC, May 9, 2020, limited liability company	RMB8,000,000.00	N/A	N/A	100%	100%	100%	Wig business, The PRC	(1) and (3)
Beijing Yunyihui Medical Management Company Limited (“北京雲醫匯醫療管理有限 公司”)	The PRC, October 13, 2020, limited liability company	RMB10,000,000.00	N/A	N/A	100%	100%	100%	Hair consulting, The PRC	(1) and (3)
Yonghe Research Laboratory (“北京雍禾植發技術研究院有 限公司”)	The PRC, May 9, 2011, limited liability company	RMB500,000.00	100%	100%	100%	100%	100%	Hair research, The PRC	(1) and (3)

Notes:

- (1) All companies comprising the Group have adopted December 31, as their financial year end date.
- (2) The statutory auditor of Yonghe Investment was BDO China Shu Lun Pan CPA LLP for the years ended December 31, 2018 and 2019, and Beijing Xiwen CPA LLP for the year ended December 31, 2020. No statutory audited financial statements were issued for the six months ended June 30, 2021.
- (3) No statutory audited financial statements were issued for the years ended December 31, 2018, 2019 and 2020 and the six months ended June 30, 2021, as they were newly incorporated or not required to issue audited financial statements under relevant rules and regulations in their respective jurisdiction of incorporation.

1.3 Basis of Presentation

The companies now comprising the Group, engaging in the Listing Business, were under common control of the controlling shareholder, immediately before and after the Reorganization. Accordingly, the Reorganisation is regarded as a business combination under common control, and for the purpose of this report, the Historical Financial Information has been prepared using the principles of merger accounting, as prescribed in Hong Kong Accounting Guideline 5 “Merger Accounting for Common Control Combinations” issued by the Hong Kong Institute of Certified Public Accountants (“HKICPA”).

The Historical Financial Information has been prepared by including the historical financial information of the companies engaged in the Listing Business, under the common control of the controlling shareholder immediately before and after the Reorganisation and now comprising the Group as if the current group structure had been in existence throughout the periods presented, or since the date when the combining companies first came under the common control, whichever is a shorter period.

The net assets of the combining companies were consolidated using the existing book values from the controlling shareholder's perspective. No amount is recognised in consideration for goodwill or excess of acquirer's interest in the net fair value of acquiree's identifiable assets, liabilities and contingent liabilities over cost at the time of business combination under common control, to the extent of the continuation of the controlling party's interest.

For companies acquired from, or disposed to a third party during each of the years ended December 31, 2018, 2019 and 2020 and the six months ended June 30, 2021, they are included in or excluded from the consolidated Historical Financial Information of the Group from the date of acquisition or disposal.

Inter-company transactions, balances and unrealised gains/losses on transactions between group companies are eliminated on consolidation.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

This note provides a list of significant accounting policies adopted in the preparation of the Historical Financial Information. These policies have been consistently applied to all the years presented, unless otherwise stated. The Historical Financial Information is for the Group consisting of the Company and the companies now comprising the Group.

2.1 Basis of preparation

(i) *Compliance with HKFRS*

The Historical Financial Information of the Company has been prepared in accordance with principal accounting policies as set out below which are in accordance with Hong Kong Financial Reporting Standards (“HKFRS”) issued by the HKICPA .

The preparation of Historical Financial Information in conformity with HKFRSs requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the Group's accounting policies. The areas involving a higher degree of judgement or complexity, or areas where assumptions and estimates are significant to the Historical Financial Information are disclosed in Note 4.

(ii) *Historical cost convention*

The Historical Financial Information has been prepared on a historical cost basis, as modified by the revaluation of financial assets at fair value through profit and loss.

(iii) *New and amended standards adopted by the Group*

The HKICPA has issued a number of new and amended HKFRSs. For the purpose of preparing these Historical Financial Information, the Group has adopted all applicable new and amended HKFRSs consistently throughout the Track Record Period except for any new or amended standards and interpretations that are not yet effective and also the early adoption of Amendment to HKFRS 16 COVID-19 Related Rent Concession in 2020 (the impact of which has been detailed in Note 2.25).

(iv) New standards and interpretations not yet adopted

The Group has not early applied the following new and amendments to HKFRSs that have been issued but are not yet effective:

	Effective for annual periods beginning on or after
HKFRS 17 – Insurance Contracts	January 1, 2023
Amendments to HKAS 1 – Classification of Liabilities as Current or Non-current	January 1, 2023
Amendments to HKAS 37 – Onerous Contracts – Cost of Fulfilling a Contract	January 1, 2022
Amendments to HKAS 16 – Property, Plant and Equipment: Proceeds before Intended Use	January 1, 2022
Amendments to HKFRS 3 – Reference to the Conceptual Framework	January 1, 2022
Amendments to HKFRS 10 and HKAS 28 – Sale or Contribution of Assets between an Investor and its Associate or Joint Venture	To be determined
Annual Improvements to HKFRS Standards 2018-2020	January 1, 2022
Amendments to HKAS 12 – Deferred Tax Related to Assets and Liabilities arising from a Single Transaction	January 1, 2023
Amendments to HKAS 1 and HKFRS Practice Statement 2 – Disclosure of Accounting Policies	January 1, 2023
Amendments to HKAS 8 – Disclosure of Accounting Policies	January 1, 2023

The directors of the Company anticipate that the application of the above new standard, amendments and annual improvements will have no material impact on the Group's significant accounting policies and the presentation of its consolidated financial statements.

(v) Going concern

As at December 31, 2018, 2019 and 2020 and as at June 30, 2021, the Group's current liabilities exceeded its current assets by approximately RMB53 million, RMB102 million, RMB68 million and RMB31 million, respectively.

Management of the Company ("management") closely monitors the Group's financial performance and liquidity position. The Group meets its day to day working capital requirements through: (i) the Group have steady operating cash inflow during the Track Record Period; (ii) as at June 30, 2021, the Group had undrawn borrowing facilities amounting to approximately RMB16 million, which can be used to finance its daily operational cash flows. Management had prepared a cash flow projection covering the year ending December 31, 2022. Based on the projection, the Group is expected to remain solvent during the next twelve months from June 30, 2021.

The directors of the Company (the "directors") have reviewed the Group's cash flow projection and have made due and careful enquiry and considered the basis and assumptions of management's projections. The directors are of the opinion that, taking into account the Group's future operational performance and the expected future operating cash inflows, the Group will have sufficient financial resources to support its operations and to meet its financial obligations as and when they fall due in the coming year. Accordingly, the Historical Financial Information have been prepared on a going concern basis.

2.2 Principles of consolidation and equity accounting*(i) Subsidiaries*

Subsidiaries are all entities over which the Group has control. The Group controls an entity where the Group is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power to direct the activities of the entity. Subsidiaries are fully consolidated from the date on which control is transferred to the Group. They are deconsolidated from the date that control ceases.

The acquisition method of accounting is used to account for business combinations by the Group (Note 2.3).

Inter-company transactions, balances and unrealised gains on transactions between group companies are eliminated. Unrealised losses are also eliminated unless the transaction provides evidence of an impairment of the transferred asset. Accounting policies of subsidiaries have been changed where necessary to ensure consistency with the policies adopted by the Group.

Non-controlling interests in the results and equity of subsidiaries are shown separately in the consolidated statements of comprehensive income, statements of changes in equity and balance sheets respectively.

(ii) *Changes in ownership interests*

The Group treats transactions with non-controlling interests that do not result in a loss of control as transactions with equity owners of the Group. A change in ownership interest results in an adjustment between the carrying amounts of the controlling and non-controlling interests to reflect their relative interests in the subsidiary. Any difference between the amount of the adjustment to non-controlling interests and any consideration paid or received is recognised in a separate reserve within equity attributable to owners of the Company.

When the Group ceases to consolidate or equity account for an investment because of a loss of control, or significant influence, any retained interest in the entity is remeasured to its fair value with the change in carrying amount recognised in profit or loss. This fair value becomes the initial carrying amount for the purposes of subsequently accounting for the retained interest as an associate or financial asset. In addition, any amounts previously recognised in other comprehensive income in respect of that entity are accounted for as if the Group had directly disposed of the related assets or liabilities. This may mean that amounts previously recognised in other comprehensive income are reclassified to profit or loss or transferred to another category of equity as specified/ permitted by applicable HKFRSs.

If the ownership interest in an associate is reduced but joint control or significant influence is retained, only a proportionate share of the amounts previously recognised in other comprehensive income are reclassified to profit or loss where appropriate.

2.3 Business combinations

(i) *Business combinations not under common control*

The acquisition method of accounting is used to account for all business combinations, regardless of whether equity instruments or other assets are acquired. The consideration transferred for the acquisition of a subsidiary comprises the:

- fair values of the assets transferred
- liabilities incurred to the former owners of the acquired business
- equity interests issued by the Group
- fair value of any asset or liability resulting from a contingent consideration arrangement, and
- fair value of any pre-existing equity interest in the subsidiary.

Identifiable assets acquired and liabilities and contingent liabilities assumed in a business combination are, with limited exceptions, measured initially at their fair values at the acquisition date. The Group recognises any non-controlling interest in the acquired entity on an acquisition-by-acquisition basis either at fair value or at the non-controlling interest's proportionate share of the acquired entity's net identifiable assets.

Acquisition-related costs are expensed as incurred.

The excess of the consideration transferred, the amount of any non-controlling interest in the acquiree and the acquisition-date fair value of any previous equity interest in the acquiree over the fair value of the identifiable net assets acquired is recorded as goodwill. If the total of consideration transferred, non-controlling interest recognised and previously held interest measured is less than the fair value of the net assets of the subsidiary acquired in the case of a bargain purchase, the difference is recognised directly in profit or loss.

Where settlement of any part of cash consideration is deferred, the amounts payable in the future are discounted to their present value as at the date of exchange. The discount rate used is the entity's incremental borrowing rate, being the

rate at which a similar borrowing could be obtained from an independent financier under comparable terms and conditions. Contingent consideration is classified either as equity or a financial liability. Amounts classified as a financial liability are subsequently remeasured to fair value with changes in fair value recognised in profit or loss.

If the business combination is achieved in stages, the acquisition date carrying value of the acquirer's previously held equity interest in the acquiree is remeasured to fair value at the acquisition date. Any gains or losses arising from such remeasurement are recognised in profit or loss.

(ii) Business combinations under common control

The Historical Financial Information incorporates the financial statement items of the entities or businesses in which the common control combination occurs as if they had been consolidated from the date when the entities or businesses first came under the control of the controlling party.

The net assets of the combining entities or businesses are consolidated using the existing book values from the controlling party's perspective. No amount is recognised in consideration for goodwill or excess of acquirer's interest in the net fair value of acquirer's identifiable assets, liabilities and contingent liabilities over cost at the time of common control combination, to the extent of the continuation of the controlling party's interest.

The consolidated statements of comprehensive income include the results of each of the combining entities or businesses from the earliest date presented or since the date when the combining entities or businesses first came under the common control, where this is a shorter period, regardless of the date of the common control combination.

A uniform set of accounting policies is adopted by those entities. All intra-group transactions, balances and unrealized gains on transactions between combining entities or businesses are eliminated.

2.4 Separate financial statements

Investments in subsidiaries are accounted for at cost less impairment. Cost includes direct attributable costs of investment. The results of subsidiaries are accounted for by the Company on the basis of dividend received and receivable.

Impairment testing of the investments in subsidiaries is required upon receiving a dividend from these investments if the dividend exceeds the total comprehensive income of the subsidiary in the period the dividend is declared or if the carrying amount of the investment in the separate financial statements exceeds the carrying amount in the financial statements of the investee's net assets including goodwill.

2.5 Segment reporting

Operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision maker.

The board of directors the Company assesses the financial performance and position of the Group and makes strategic decisions and is identified as the Chief Operating Decision Maker ("CODM") responsible for allocating resources and assessing performance of the operating segment.

2.6 Foreign currency translation

(i) Functional and presentation currency

Items included in Historical Financial Information of each of the Group's entities are measured using the currency of the primary economic environment in which the entity operates (the "functional currency"). The Company's functional currency is United States Dollar ("USD"). As the majority of the assets and operations of the Group are located in the PRC, the Historical Financial Information is presented in RMB. The Group's presentation currency differs from the Company's functional currency as management rely on management accounts prepared in RMB for review of the Group's historical financial performance and decision making.

(ii) Transactions and balances

Foreign currency transactions are translated into the functional currency using the exchange rates at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation of monetary assets and liabilities denominated in foreign currencies at year end exchange rates are generally recognised in profit or loss. They are deferred in equity if they relate to qualifying cash flow hedges and qualifying net investment hedges or are attributable to part of the net investment in a foreign operation.

(iii) Group companies

The results and financial position of foreign operations (none of which has the currency of a hyperinflationary economy) that have a functional currency different from the presentation currency are translated into the presentation currency as follows:

- assets and liabilities for each balance sheet presented are translated at the closing rate at the date of that balance sheet;
- income and expenses for each statement of profit or loss and statement of comprehensive income are translated at average exchange rates (unless this is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, in which case income and expenses are translated at the dates of the transactions); and
- all resulting exchange differences are recognised in other comprehensive income.

2.7 Property, plant and equipment

Property, plant and equipment are stated at historical cost less accumulated depreciation and impairment losses (if any). Historical cost includes expenditure that is directly attributable to the acquisition of the items.

Subsequent costs are included in the asset's carrying amount or recognised as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Group and the cost of the item can be measured reliably. The carrying amount of any component accounted for as a separate asset is derecognised when replaced. All other repairs and maintenance are charged to profit or loss during the reporting period in which they are incurred.

Depreciation is calculated using the straight-line method to allocate their cost, net of their residual values, over their estimated useful lives or, in the case of medical treatment and safety infrastructure and leasehold improvements, the shorter lease term, as follows:

Medical equipment	5 years
Electronic equipment	3-5 years
Office furniture and fixtures	5 years
Motor vehicles	4 years
Medical treatment and safety infrastructure and leasehold improvement	Shorter of remaining lease term or estimated useful life

The assets' residual values and useful lives are reviewed, and adjusted if appropriate, at the end of each reporting period.

An asset's carrying amount is written down immediately to its recoverable amount if the asset's carrying amount is greater than its estimated recoverable amount (Note 2.10).

Gains and losses on disposals are determined by comparing proceeds with carrying amount. These are included in profit or loss.

2.8 Intangible assets**(i) Software**

The software represents the purchased computer software which are capitalised on the basis of the costs incurred to acquire the specific software. Based on the current functionalities equipped by the software and the daily operation needs, the Group considers a useful life of 10 years is the best estimation under current business needs. Therefore, these costs are amortized over 10 years using the straight-line method.

(ii) Goodwill

Goodwill is measured as described in Note 2.3. Goodwill on acquisitions of subsidiaries is included in intangible assets. Goodwill is not amortised but it is tested for impairment annually, or more frequently if events or changes in circumstances indicate that it might be impaired, and is carried at cost less accumulated impairment losses (if any). Gains and losses on the disposal of an entity include the carrying amount of goodwill relating to the entity sold.

Goodwill is allocated to cash-generating units for the purpose of impairment testing. The allocation is made to those cash-generating units or groups of cash-generating units that are expected to benefit from the business combination in which the goodwill arose. The units or groups of units are identified at the lowest level at which goodwill is monitored for internal management purposes.

(iii) Trademarks

Separately acquired trademarks are shown at historical cost. Trademark as acquired in the business combination is recognised at its fair value at the acquisition date. All trademarks are amortised on a straight-line basis over their estimated useful lives of 10 to 11 years. Trademarks are carried at costs less accumulated amortisation and impairment losses (if any). When determining the estimated useful life, the Group considered the forecasted period during which the trademark can bring the incremental economic benefit to the Group and the operating history of the trademark.

2.9 Research and development

Research expenditure is recognised as an expense as incurred. Costs incurred on development projects (relating to the design and developing of new or improved products and processes) are recognised as intangible assets when it is probable that the project will be a success considering its commercial and technical feasibility and its costs can be measured reliably. Other development expenditures that do not meet these criteria are recognised as an expense when incurred. Development costs previously recognised as an expense are not recognised as an asset in a subsequent period.

Capitalised development cost is measured at cost less accumulated amortisation and accumulated impairment losses. Amortisation of capitalised development cost is calculated using the straight-line method over its expected useful life from the date they are available for use.

2.10 Impairment of non-financial assets

Goodwill is not subject to amortisation and are tested annually for impairment, or more frequently if events or changes in circumstances indicate that they might be impaired. Intangible assets that have an indefinite useful life are not subject to amortisation and are tested annually for impairment, or more frequently if events or changes in circumstances indicate that they might be impaired. Other assets are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognised for the amount by which the asset's carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset's fair value less costs of disposal and value in use. For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash inflows which are largely independent of the cash inflows from other assets or groups of assets (cash-generating units). Non-financial assets other than goodwill that suffered an impairment are reviewed for possible reversal of the impairment at the end of each reporting period.

2.11 Investments and other financial assets**(i) Classification**

The Group classifies its financial assets in the following measurement categories:

- those to be measured subsequently at fair value (either through other comprehensive income (“OCI”) or through profit or loss); and
- those to be measured at amortised cost.

The classification depends on the entity’s business model for managing the financial assets and the contractual terms of the cash flows.

For assets measured at fair value, gains and losses will either be recorded in profit or loss or OCI. For investments in equity instruments that are not held for trading, this will depend on whether the Group has made an irrevocable election at the time of initial recognition to account for the equity investment at fair value through other comprehensive income (“FVOCI”).

The Group reclassifies debt investments when and only when its business model for managing those assets changes.

(ii) Recognition and derecognition

Regular way purchases and sales of financial assets are recognised on trade-date, the date on which the Group commits to purchase or sell the asset. Financial assets are derecognised when the rights to receive cash flows from the financial assets have expired or have been transferred and the Group has transferred substantially all the risks and rewards of ownership.

(iii) Measurement

At initial recognition, the Group measures a financial asset at its fair value plus, in the case of a financial asset not at fair value through profit or loss (“FVPL”), transaction costs that are directly attributable to the acquisition of the financial asset. Transaction costs of financial assets carried at FVPL are expensed in profit or loss.

Financial assets with embedded derivatives are considered in their entirety when determining whether their cash flows are solely payment of principal and interest.

Debt instruments

Subsequent measurement of debt instruments depends on the Group’s business model for managing the asset and the cash flow characteristics of the asset. There are two measurement categories into which the Group classifies its debt instruments:

- **Amortised cost:** Assets that are held for collection of contractual cash flows where those cash flows represent solely payments of principal and interest are measured at amortised cost. Interest income from these financial assets is included in finance income using the effective interest rate method. Any gain or loss arising on derecognition is recognised directly in profit or loss and presented in other gains/(losses) together with foreign exchange gains and losses. Impairment losses are presented as separate line item in the statement of comprehensive income.
- **FVPL:** Assets that do not meet the criteria for amortised cost or FVOCI are measured at FVPL. A gain or loss on a debt investment that is subsequently measured at FVPL is recognised in profit or loss and presented net within other gains/(losses) in the period in which it arises.

Equity instruments

The Group subsequently measures all equity investments at fair value. Where the Group's management has elected to present fair value gains and losses on equity investments in OCI, there is no subsequent reclassification of fair value gains and losses to profit or loss following the derecognition of the investment. Dividends from such investments continue to be recognised in profit or loss as other income when the Group's right to receive payments is established.

Changes in the fair value of financial assets at FVPL are recognised in profit or loss and presented within other gains/(losses) in the statement of comprehensive income as applicable. Impairment losses (and reversal of impairment losses) on equity investments measured at FVOCI are not reported separately from other changes in fair value.

(iv) Impairment

The Group assesses on a forward-looking basis the expected credit losses associated with its debt instruments carried at amortised cost. The impairment methodology applied depends on whether there has been a significant increase in credit risk.

For trade receivables, the Group applies the simplified approach permitted by HKFRS 9, which requires expected lifetime losses to be recognised from initial recognition of the receivables, see Notes 18 and 3.1(c) for further details.

2.12 Offsetting financial instruments

Financial assets and liabilities are offset and the net amount is reported in the balance sheet where the Group currently has a legally enforceable right to offset the recognised amounts, and there is an intention to settle on a net basis or realise the asset and settle the liability simultaneously.

2.13 Inventories

Inventories are stated at the lower of cost and net realisable value. Cost is determined using the first-in, first-out (FIFO) method. Costs of purchased inventory are determined after deducting rebates and discounts. Net realisable value is the estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale.

2.14 Trade receivables

Trade receivables are amounts due from customers for goods sold or services performed in the ordinary course of business. They are generally due for settlement within one year and therefore all classified as current.

Trade receivables are recognised initially at the amount of consideration that is unconditional unless they contain significant financing components, when they are recognised at fair value. The Group holds the trade receivables with the objective of collecting the contractual cash flows and therefore measures them subsequently at amortised cost using the effective interest method. See Notes 18 and 3.1(c) for further information about the Group's accounting for trade receivables and Note 2.11 for a description of the Group's impairment policies.

2.15 Cash and cash equivalents

For the purpose of presentation in the statement of cash flows, cash and cash equivalents includes cash on hand, deposits held at call with financial institutions, other short-term, highly liquid investments with original maturities of three months or less that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value.

2.16 Share capital

Ordinary shares are classified as equity.

Incremental costs directly attributable to the issue of new shares or options are shown in equity as a deduction, net of tax, from the proceeds.

2.17 Trade and other payables

These amounts represent liabilities for goods and services provided to the Group prior to the end of financial year which are unpaid. The amounts are unsecured and are usually paid within 30 days of recognition. Trade and other payables are presented as current liabilities unless payment is not due within 12 months after the reporting period. They are recognised initially at their fair value and subsequently measured at amortised cost using the effective interest method.

2.18 Borrowings

Borrowings are initially recognised at fair value, net of transaction costs incurred. Borrowings are subsequently measured at amortised cost. Any difference between the proceeds (net of transaction costs) and the redemption amount is recognised in profit or loss over the period of the borrowings using the effective interest method. Fees paid on the establishment of loan facilities are recognised as transaction costs of the loan to the extent that it is probable that some or all of the facility will be drawn down. In this case, the fee is deferred until the draw down occurs. To the extent there is no evidence that it is probable that some or all of the facility will be drawn down, the fee is capitalised as a prepayment for liquidity services and amortized over the period of the facility to which it relates.

Borrowings are removed from the balance sheet when the obligation specified in the contract is discharged, cancelled or expired. The difference between the carrying amount of a financial liability that has been extinguished or transferred to another party and the consideration paid, including any non-cash assets transferred or liabilities assumed, is recognised in profit or loss as other income or finance costs.

Borrowings are classified as current liabilities unless the Group has an unconditional right to defer settlement of the liability for at least 12 months after the reporting period.

2.19 Current and deferred income tax

The income tax expense or credit for the period is the tax payable on the current period's taxable income based on the applicable income tax rate for each jurisdiction adjusted by changes in deferred income tax assets and liabilities attributable to temporary differences and to unused tax losses.

(i) Current income tax

The current income tax charge is calculated on the basis of the tax laws enacted or substantively enacted at the end of the reporting period in the countries where the Company and its subsidiaries operate and generate taxable income. Management periodically evaluates positions taken in tax returns with respect to situations in which applicable tax regulation is subject to interpretation. It establishes provisions where appropriate on the basis of amounts expected to be paid to the tax authorities.

(ii) Deferred income tax

Deferred income tax is provided in full, using the liability method, on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the consolidated financial statements. However, deferred income tax liabilities are not recognised if they arise from the initial recognition of goodwill. Deferred income tax is also not accounted for if it arises from initial recognition of an asset or liability in a transaction other than a business combination that at the time of the transaction affects neither accounting nor taxable profit or loss. Deferred income tax is determined using tax rates (and laws) that have been enacted or substantially enacted by the end of the reporting period and are expected to apply when the related deferred income tax asset is realised or the deferred income tax liability is settled.

Deferred income tax assets are recognised only if it is probable that future taxable amounts will be available to utilise those temporary differences, tax losses and tax credits.

Deferred income tax liabilities and assets are not recognised for temporary differences between the carrying amount and tax bases of investments in foreign operations where the Company is able to control the timing of the reversal of the temporary differences and it is probable that the differences will not reverse in the foreseeable future.

Deferred income tax assets and liabilities are offset where there is a legally enforceable right to offset current income tax assets and liabilities and where the deferred income tax balances relate to the same taxation authority. Current income tax assets and tax liabilities are offset where the entity has a legally enforceable right to offset and intends either to settle on a net basis, or to realise the asset and settle the liability simultaneously.

Current and deferred income tax is recognised in profit or loss, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. In this case, the tax is also recognised in other comprehensive income or directly in equity, respectively.

2.20 Employee benefits

(i) *Short-term obligations*

Liabilities for wages and salaries, including non-monetary benefits and accumulating sick leave that are expected to be settled wholly within 12 months after the end of the period in which the employees render the related service are recognised in respect of employees' services up to the end of the reporting period and are measured at the amounts expected to be paid when the liabilities are settled. The liabilities are presented as current employee benefit obligations in the balance sheet.

(ii) *Pension obligations*

The Group has only defined contribution plan in which the Group pays contributions to publicly or privately administered pension insurance plans on a mandatory, contractual or voluntary basis. The Group has no further payment obligations once the contributions have been paid. The contributions are recognised as employee benefit expense when they are due.

(iii) *Medical and other benefits*

The Group makes monthly contributions for medical and other benefits to the local authorities in accordance with relevant local regulations for the employees. The Group's liability in respect of employee medical benefits is limited to the contributions payable in each period.

(iv) *Housing benefits*

The employees of the Group are entitled to participate in various government-sponsored housing funds. The Group contributes on a monthly basis to these funds based on certain percentages of the salaries of the employees. The Group's liability in respect of these funds is limited to the contributions payable in each period.

2.21 Share-based compensation

Share-based compensation benefits are provided to employees, and information relating to these schemes is set out in Note 23.

The fair value of awarded shares granted to employees less amount paid by employees is recognised as an employee benefits expense over the relevant service period, being the vesting period of the shares, and the credit is recognised in equity in the share-based compensation reserve. The fair value of the shares is measured at the grant date. The number of shares expected to vest is estimated based on the non-market vesting conditions. The estimates are revised at the end of each reporting period and adjustments are recognised in profit or loss and the share-based compensation reserve. Where shares are forfeited due to a failure by the employee to satisfy the service conditions, any expenses previously recognised in relation to such shares are reversed effective at the date of the forfeiture.

2.22 Provisions

Provisions for legal claims are recognised when the Group has a present legal or constructive obligation as a result of past events, it is probable that an outflow of resources will be required to settle the obligation and the amount can be reliably estimated. Provisions are not recognised for future operating losses.

Where there are a number of similar obligations, the likelihood that an outflow will be required in settlement is determined by considering the class of obligations as a whole. A provision is recognised even if the likelihood of an outflow with respect to any one item included in the same class of obligations may be small.

Provisions are measured at the present value of management's best estimate of the expenditure required to settle the present obligation at the end of the reporting period. The discount rate used to determine the present value is a pre-tax rate that reflects current market assessments of the time value of money and the risks specific to the liability. The increase in the provision due to the passage of time is recognised as interest expense.

2.23 Revenue recognition

Revenues are recognised when, or as, the control of the goods or services is transferred to the customer. Depending on the terms of the contract and the laws applicable, control of the goods and services may be transferred over time or at a point in time. Control of the goods and services is transferred over time if the Group's performance:

- provides all the benefits received and consumed simultaneously by the customer;
- creates and enhances an asset that the customer controls as the Group performs; or
- does not create an asset with an alternative use to the Group and the Group has an enforceable right to payment for performance completed to date.

If control of the goods and services transfers over time, revenue is recognised over the period of the contract by reference to the progress towards complete satisfaction of that performance obligation. Otherwise, revenue is recognised at a point in time when the customer obtains control of the goods and services.

The progress towards complete satisfaction of performance obligation is measured based on direct measurements of the value of individual services transferred by the Group to the customer.

If contracts involve the sale of multiple goods, goods followed by related services, or multiple services, the transaction price will be allocated to each performance obligation based on their relative stand-alone selling prices. If the stand-alone selling prices are not directly observable, they are estimated based on expected cost plus a margin, depending on the availability of observable information.

When either party to a contract has performed, the Group presents the contract in the balance sheets as a contract asset or a contract liability, depending on the relationship between the entity's performance and the customer's payment.

The Group offers some discounts to the customers, and revenue is recognised based on the price specified in the contract, net of the discount.

If a customer pays consideration or the Group has a right to an amount of consideration that is unconditional, before the Group transfers a good or service to the customer, the Group presents the contract as a contract liability when the payment is made or the receivable is recorded (whichever is earlier). A contract liability is the Group's obligation to transfer goods or services to a customer for which the Group has received consideration (or an amount of consideration is due) from the customer.

A receivable is recorded when the Group has an unconditional right to consideration. A right to consideration is unconditional if only the passage of time is required before payment of that consideration is due.

A refund liability is the constructive obligation to refund some or all of the consideration received (or receivable) from the customer and is measured at the amount the Group ultimately expects it will have to return to the customer. The Group updates its estimates of refund liabilities (and the corresponding change in the transaction price) at the end of each reporting period.

The following is a description of the accounting policy for the principal revenue streams of the Group.

(i) Hair transplant

For hair transplant service, customers normally receive treatment which contains various treatment components (e.g. pre-surgery medical checking, surgery treatment and post-surgery cleaning) that are all highly relevant and regarded as one performance obligation. Revenue from provision of hair transplantation services recognised at a point in time when the services have been rendered to customers.

The Group usually receives the payment from customers in advance before the services are rendered. The majority of customers normally do not ask for a refund of payment and the services not yet rendered are recorded as contract liability. The Group has estimated the refund in respect of unsatisfactory services rendered based on the Group's past experience with customers and recognised as refund liabilities (see Note 4(a)). The contract liability is recognised as revenue when the related services are rendered.

Sales of hair transplant related goods are recognised when the Group has transferred the products to the customer, and the customer has obtained control of the products.

(ii) *Medical hair care*

The Group provides medical hair care services in package which is accounted as multiple elements of services. Revenue from medical hair care services is recognised over the period of the contract by reference to the progress towards complete satisfaction of the performance obligation. The progress towards the complete satisfaction of performance obligation is measured by direct measures of the value of individual service transferred to the customer. Normally, there is no expiry date for the packages while majority of the customers take up all the services in the packages within two years.

The Group usually receives the payment from customers in advance before the services are rendered. The majority of customers normally do not ask for a refund of payment and the services not yet rendered are recorded as contract liability. The Group has estimated the refund in respect of unsatisfactory services rendered based on the Group's past experience with customers and recognised as refund liabilities (see Note 4(a)). The contract liability is recognised as revenue when the related services are rendered.

Sales of goods related to medical hair care are recognised when the Group has transferred the products to the customer, and the customer has obtained control of the products.

(iii) *Others*

The Group also provides routine hair care services in package which is accounted as multiple elements of services. Revenue from routine hair care services is recognised over the period of the contract by reference to the progress towards complete satisfaction of the performance obligation. The progress towards the complete satisfaction of performance obligation is measured by direct measures of the value of individual service transferred to the customer. Normally, there is no expiry date for the packages while majority of the customers take up all the services in the packages within two years.

The Group usually receives the payment from customers in advance before the services are rendered. Customers normally do not ask for a refund of payment and the services not yet rendered are recorded as contract liability. The contract liability is recognised as revenue when the related services are rendered.

Sales of goods related to routine hair care are recognised when the Group has transferred the products to the customer, and the customer has obtained control of the products.

2.24 Earnings per share

(i) *Basic earnings per share*

Basic earnings per share is calculated by dividing:

- the profit attributable to owners of the Company, excluding any costs of servicing equity other than ordinary shares;
- by the weighted average number of ordinary shares outstanding during the financial year, adjusted for bonus elements in ordinary shares issued during the year and excluding treasury shares.

(ii) *Diluted earnings per share*

Diluted earnings per share adjusts the figures used in the determination of basic earnings per share to take into account:

- the after-income tax effect of interest and other financing costs associated with dilutive potential ordinary shares; and
- the weighted average number of additional ordinary shares that would have been outstanding assuming the conversion of all dilutive potential ordinary shares.

2.25 Leases

The Group leases buildings as lessee. Rental contracts are typically made for fixed periods of 1 to 15 years.

Leases are recognised as a right-of-use asset and a corresponding liability at the date at which the leased asset is available for use by the Group.

Contracts may contain both lease and non-lease components. The Group allocates the consideration in the contract to the lease and non-lease components based on their relative stand-alone prices.

Assets and liabilities arising from a lease are initially measured on a present value basis. Lease liabilities include the net present value of the following lease payments (if applicable):

- fixed payments (including in-substance fixed payments), less any lease incentives receivable;
- variable lease payment that are based on an index or a rate, initially measured using the index or rate as at the commencement date;
- amounts expected to be payable by the Group under residual value guarantees;
- the exercise price of a purchase option if the Group is reasonably certain to exercise that option; and payments of penalties for terminating the lease, if the lease term reflects the Group exercising that option.

Lease payments to be made under reasonably certain extension options are also included in the measurement of the liability.

The lease payments are discounted using the interest rate implicit in the lease. If that rate cannot be readily determined, which is generally the case for leases in the Group, the lessee's incremental borrowing rate is used, being the rate that the individual lessee would have to pay to borrow the funds necessary to obtain an asset of similar value to the right-of-use asset in a similar economic environment with similar terms, security and conditions.

To determine the incremental borrowing rate, the Group:

- where possible, uses recent third-party financing received by the individual lessee as a starting point, adjusted to reflect changes in financing conditions since third party financing was received;
- uses a build-up approach that starts with a risk-free interest rate adjusted for credit risk for leases held by the Company, which does not have recent third party financing, and makes adjustments specific to the lease, e.g. term, country, currency and security.

Lease payments are allocated between principal and finance cost. The finance cost is charged to profit or loss over the lease period so as to produce a constant periodic rate of interest on the remaining balance of the liability for each period.

Right-of-use assets are measured at cost comprising the following (if applicable):

- the amount of the initial measurement of lease liability;
- any lease payments made at or before the commencement date less any lease incentives received; and
- any initial direct costs.

Right-of-use assets are generally depreciated over the shorter of the asset's useful life and the lease term on a straight-line basis. If the Group is reasonably certain to exercise a purchase option, the right-of-use asset is depreciated over the underlying asset's useful life.

Payments associated with short-term leases and all leases of low-value assets are recognised on a straight-line basis as an expense in profit or loss. Short-term leases are leases with a lease term of 12 months or less.

A lessee normally recognises an asset and a lease liability when it enters into most leases under HKFRS 16. The Group considers the lease as a single transaction in which the asset and liability are integrally linked, so there is no net temporary difference at inception. Subsequently, as differences arise on settlement of the liability and the amortisation of the leased asset, there will be a net temporary difference on which deferred tax is recognised.

Amendment to HKFRS 16 provides a practical expedient for lessees to elect not to apply lease modification accounting for rent concessions arising as a direct consequence of the COVID-19 pandemic. The practical expedient applies only to rent concessions occurring as a direct consequence of the pandemic and only if (i) the change in lease payments results in revised consideration for the lease that is substantially the same as, or less than, the consideration for the lease immediately preceding the change; (ii) any reduction in lease payments affects only payments originally due on or before June 30, 2021; and (iii) there is no substantive change to other terms and conditions of the lease. The amendment is effective for annual periods beginning on or after June 1, 2020 with earlier application permitted and shall be applied retrospectively.

During the year ended December 31, 2020, certain monthly lease payments for the leases of the Group's workspaces have been reduced or waived by the lessors upon reducing the scale of production as a result of the COVID-19 pandemic and there are no other changes to the terms of the leases. The Group has early adopted the amendment on January 1, 2020 and elected not to apply lease modification accounting for all rent concessions granted by the lessors as a result of the pandemic during the year ended December 31, 2020. Accordingly, a reduction in the lease payments arising from the rent concessions of approximately RMB5,567,000 has been accounted for as a variable lease payment by derecognising part of the lease liabilities and crediting to profit or loss for the year ended December 31, 2020.

2.26 Dividend distribution

Dividend distribution to the shareholders is recognised as a liability in the Historical Financial Information in the year in which the dividends are approved by the entities' shareholders or directors, where appropriate.

2.27 Government grants

Grants from the government are recognised at their fair value where there is a reasonable assurance that the grant will be received and the Group will comply with all attached conditions.

Government grants relating to costs are deferred and recognised in the profit or loss over the period necessary to match them with the costs that they are intended to compensate.

Government grants relating to the purchase of property, plant and equipment and other non-current assets are included in the non-current liabilities and are credited to profit or loss on a straight-line basis over the expected lives of the related assets.

2.28 Interest income

Interest income is presented as finance income where it is earned from financial assets that are held for cash management purposes. Any other interest income is included in other income.

Interest income is calculated by applying the effective interest rate to the gross carrying amount of a financial asset except for financial assets that subsequently become credit-impaired. For credit-impaired financial assets the effective interest rate is applied to the net carrying amount of the financial asset (after deduction of the loss allowance).

3. FINANCIAL RISK MANAGEMENT

3.1 Financial risk factors

The Group's activities expose it to a variety of financial risks: market risk (including foreign currency risk and cash flow and fair value interest rate risk), credit risk and liquidity risk. The Group's overall risk management programme focuses on the unpredictability of financial markets and seeks to minimize potential adverse effects on the Group's financial performance. Risk management is carried out by the senior management of the Group and approved by the executive directors.

(a) Foreign currency risk

The functional currency of majority of the entities within the Group is RMB. Most of the Group's transactions are based and settled in RMB. Foreign currencies are used to settle the Group's revenue and borrowings out of Mainland China.

RMB is not freely convertible into other foreign currencies and conversion of RMB into foreign currencies is subject to rules and regulations of foreign exchange control promulgated by the PRC Government.

Details of the Group's cash and cash equivalents and borrowings as at June 30, 2021, denominated in foreign currencies, mainly USD, are disclosed in Notes 21 and 24 respectively.

The management of the Group monitors foreign exchange exposure and will consider hedging significant foreign exchange exposure should the need arises.

(b) Cash flow and fair value interest rate risk

The Group's income and operating cash flows are substantially independent of changes in market interest rates and the Group has no significant interest-bearing assets except for cash and cash equivalents, details of which have been disclosed in Note 21.

The Group has no long-term borrowings with variable rates, which expose the Group to cash flow interest rate risk. And lease liabilities expose the Group to fair value interest rate risk. The Group currently has not used any interest rate swap arrangements.

(c) Credit risk

(i) Risk management

The Group is exposed to credit risk primarily in relation to its cash and cash equivalents as well as trade receivables and other financial assets at amortised cost. The carrying amount of each class of the above financial assets represents the Group's maximum exposure to credit risk in relation to the corresponding class of financial assets.

To manage this risk, deposits are mainly placed with state-owned or reputable financial institutions in the PRC. There has been no recent history of default in relation to these financial institutions.

(ii) Impairment of financial assets

The Group has the following types of financial assets subject to expected credit loss model:

- trade receivables
- other financial assets at amortised cost

While cash and cash equivalents are also subject to the impairment requirements of HKFRS 9, the identified impairment loss was insignificant.

Trade receivables

The Group applies the HKFRS 9 simplified approach to measuring expected credit losses which uses a lifetime expected loss allowance for trade receivables.

To measure the expected credit losses, trade receivables have been grouped based on shared credit risk characteristics. The expected credit loss also incorporate forward looking information.

Other financial assets at amortised cost

Other financial assets at amortised cost include other receivables, and management makes periodic assessments as well as individual assessment on the recoverability based on historical settlement records and past experience. Forward-looking information incorporated in the expected credit loss model. The Group has performed historical analysis and identified the key economic variables impacting credit risk and expected credit loss. It considers available reasonable and supportive forwarding-looking information. Especially the following indicators are incorporated (if applicable):

- internal and external credit rating;
- actual or expected significant adverse changes in business, financial or economic conditions that are expected to cause a significant change to the debtor's ability to meet its obligations;
- actual or expected significant changes in the operating results of the debtor; and
- significant changes in the expected performance and behaviour of the debtor, including changes in the payment status of debtors in the Group and changes in the operating results of the debtor.

(iii) Net impairment losses on financial assets recognised in profit or loss

During the Track Record Period, the following losses were recognised in profit or loss in relation to impaired financial assets:

	Year ended December 31,			Six months ended June 30,	
	2018	2019	2020	2020	2021
	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
				(Unaudited)	
Impairment losses					
Movement in loss allowance for trade receivables (Note 18)	(66)	38	(51)	(7)	26
Movement in loss allowance for other receivables (Note 19)	(1,567)	(72)	(436)	(272)	(402)
Net impairment losses on financial assets	(1,633)	(34)	(487)	(279)	(376)

(d) Liquidity risk

The Group aims to maintain sufficient cash and cash equivalents. Due to the dynamic nature of the underlying businesses, the Group maintains flexibility in funding by maintaining adequate cash and cash equivalents.

The table below analyses the Group's non-derivative financial liabilities into relevant maturity grouping based on the remaining period at the end of each reporting period to the contractual maturity date. The amounts disclosed in the table are the contractual undiscounted cash flows.

	Less than 1 year	Between 1 and 2 years	Between 2 and 5 years	Over 5 years	Total	Carrying amount
	<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>
At December 31, 2018						
Trade and other payables*	31,574	–	–	–	31,574	31,574
Lease liabilities	78,110	74,310	186,250	142,851	481,521	400,313
	<u>109,684</u>	<u>74,310</u>	<u>186,250</u>	<u>142,851</u>	<u>513,095</u>	<u>431,887</u>
At December 31, 2019						
Borrowings	45,815	–	–	–	45,815	44,827
Trade and other payables*	38,944	–	–	–	38,944	38,944
Lease liabilities	99,770	94,100	238,266	187,088	619,224	508,040
	<u>184,529</u>	<u>94,100</u>	<u>238,266</u>	<u>187,088</u>	<u>703,983</u>	<u>591,811</u>
At December 31, 2020						
Borrowings	26,259	–	–	–	26,259	25,870
Trade and other payables*	63,600	–	–	–	63,600	63,600
Lease liabilities	151,785	154,069	398,048	299,310	1,003,212	829,930
	<u>241,644</u>	<u>154,069</u>	<u>398,048</u>	<u>299,310</u>	<u>1,093,071</u>	<u>919,400</u>
At June 30, 2021						
Borrowings	219,001	–	–	–	219,001	214,395
Trade and other payables*	117,235	–	–	–	117,235	117,235
Lease liabilities	162,324	154,177	383,843	257,649	913,993	802,360
	<u>498,560</u>	<u>154,177</u>	<u>383,843</u>	<u>257,649</u>	<u>1,294,229</u>	<u>1,133,990</u>

* Excluding non-financial liabilities of accrued employee benefits and tax payable.

3.2 Capital risk management

The Group's objectives on managing capital are to safeguard the Group's ability to continue as a going concern and support the sustainable growth of the Group in order to provide returns for shareholders and benefits for other stakeholders and to maintain an optimal capital structure to enhance equity holders' value in the long term.

In order to maintain or adjust the capital structure, the Group may adjust the amount of dividends paid to shareholders, issue new shares or sell assets to reduce debt.

The Group monitors capital on the basis of the asset-liability ratio. This ratio is calculated as total liabilities divided by total assets. The Group aims to maintain the asset-liability ratio at a reasonable level.

	As at December 31,			As at June 30,
	2018	2019	2020	2021
	<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>
Total liability	530,949	692,093	1,188,298	1,462,461
Total assets	734,445	931,213	1,594,356	1,996,794
The liability-to-asset ratio	72.29%	74.32%	74.53%	73.24%

4. CRITICAL ACCOUNTING ESTIMATES AND JUDGEMENTS

Estimates and judgements are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

The Group makes estimates and assumptions concerning the future. The resulting accounting estimates will, by definition, seldom equal the related actual results. The estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are addressed below.

(a) Estimation of variable consideration for refund to customers

The Group estimates variable considerations to be included in the transaction price for the refund to customers in respect of unsatisfactory services rendered.

The Group has estimated the refund which is based on the Group's past experience with customers. Any significant changes in experience as compared to historical patterns will impact the expected refund estimated by the Group. The Group updates its assessment of expected refund on a regular basis and the refund liabilities are adjusted accordingly. The amount recognised as refund liabilities for the expected refund was approximately RMB4 million, RMB5 million, RMB8 million and RMB11 million as at December 31, 2018, 2019 and 2020 and June 30, 2021, respectively (Note 25).

(b) Recognition of share-based compensation expenses

As mentioned in Note 23, an equity-settled share-based compensation plan was granted to the employees. The directors have used discounted cash flow method to determine the total fair value of the underlying shares granted to employees, which is to be expensed over the vesting period. Significant estimate on key assumptions, such as discount rate, risk-free interest rate, expected volatility and discount for lack of marketability, is required to be made by the directors in applying the discounted cash flow method.

As the awards granted in equity-settled share-based compensation plan are conditional on a Qualified Initial Public Offerings ("QIPO"). The directors have estimated the QIPO's probability and QIPO date when they calculated share-based compensation expenses at each reporting period end. Since QIPO condition is considered as vesting condition, the Group also needs to estimate on the basis of the most likely outcome.

(c) Income taxes

The Group is mainly subject to income taxes in the PRC. Significant judgment is required in determining the provision for income taxes. There are some transactions and calculations for which the ultimate tax determination is uncertain. Where the final tax outcome of these matters is different from the amounts that were initially recorded, such differences will impact the current income tax and deferred income tax provisions in the period in which such determination are made.

Yonghe Investment is qualified as "High and New Technology Enterprises" ("HNTEs") and is entitled to the preferential income tax rate of 15%. The qualification is valid 3 years, and upon expiry the Company is required to submit the application to relevant government authority to certify the HNTEs qualification. If the Company disqualified from the HNTEs certification, it cannot enjoy the preferential income tax, and the change in tax rate will affect the current and deferred income taxes in the period in which the change takes place.

Deferred income tax assets relating to tax losses and unused tax credits are recognised as management considers it is probable that future taxable profit will be available against which the tax losses and tax credits can be utilised. Future taxable profit includes the profit from operating results and taxable profits of future periods reversed of taxable temporary differences. Estimates and judgement are required in determining the timing and amount of future taxable profit generated. In case where the actual future taxable profit generated are less than expected, or change in facts and circumstances which result in revision of future taxable profit estimation, a material reversal or further recognition of deferred income tax assets may arise, which will be recognised in the profit or loss in the period in which such a reversal or further recognition takes place. As of the respective balance sheet date, the Group's unrecognised deferred income tax assets in respect of tax losses and tax credits have been set out in Note 12.

5. SEGMENT INFORMATION

Operating segments are reported in a manner consistent with the internal reporting provided to the CODM. The CODM, who is responsible for allocating resources and assessing performance of the operating segment, has been identified as the board of directors of the Company that make strategic decisions. The Group is principally engaged in the provision of hair transplant service which are subject to similar type of services, similar class of customers, similar regulatory environment and similar business risk. Resources are allocated based on what is beneficial to the Group in enhancing the value as a whole rather than any specific unit. Therefore, the CODM of the Company regards that there is only one operating segment for the Group.

The major operating entities of the Group are all domiciled in the PRC and major of the Group's revenue were derived in the PRC during the Track Record Period.

As at December 31, 2018, 2019 and 2020 and June 30, 2021, majority of non-current assets of the Group were located in the PRC.

There was no revenue derived from a single external customer accounting for 10% or more of the Group's revenue during the Track Record Period.

6. REVENUE FROM CONTRACTS WITH CUSTOMERS

	Year ended December 31,			Six months ended June 30,	
	2018	2019	2020	2020	2021
	<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i> (Unaudited)	<i>RMB'000</i>
Hair transplant	918,014	1,197,775	1,412,744	567,225	789,522
Medical hair care	—	15,060	213,214	30,687	254,189
Others	16,312	11,642	12,339	3,651	9,689
	<u>934,326</u>	<u>1,224,477</u>	<u>1,638,297</u>	<u>601,563</u>	<u>1,053,400</u>

	Year ended December 31,			Six months ended June 30,	
	2018	2019	2020	2020	2021
	RMB'000	RMB'000	RMB'000	RMB'000 (Unaudited)	RMB'000
Revenue from customer and recognised at a point time					
Hair transplant	918,014	1,197,775	1,412,744	567,225	789,522
Medical hair care – sale of goods	–	6,928	18,575	5,890	15,405
Others – sale of goods	1,683	2,162	5,390	1,457	4,888
	<u>919,697</u>	<u>1,206,865</u>	<u>1,436,709</u>	<u>574,572</u>	<u>809,815</u>
Revenue from customer and recognised over time					
Medical hair care – services	–	8,132	194,639	24,797	238,784
Others – services	14,629	9,480	6,949	2,194	4,801
	<u>14,629</u>	<u>17,612</u>	<u>201,588</u>	<u>26,991</u>	<u>243,585</u>
Total	<u>934,326</u>	<u>1,224,477</u>	<u>1,638,297</u>	<u>601,563</u>	<u>1,053,400</u>
	Year ended December 31,			Six months ended June 30,	
	2018	2019	2020	2020	2021
	RMB'000	RMB'000	RMB'000	RMB'000 (Unaudited)	RMB'000
Revenue from customer by region					
Mainland PRC	934,326	1,224,477	1,638,297	601,563	1,052,646
Hong Kong	–	–	–	–	754
	<u>934,326</u>	<u>1,224,477</u>	<u>1,638,297</u>	<u>601,563</u>	<u>1,053,400</u>

7. OTHER INCOME

	Year ended December 31,			Six months ended June 30,	
	2018	2019	2020	2020	2021
	RMB'000	RMB'000	RMB'000	RMB'000 (Unaudited)	RMB'000
VAT additional deduction (a)	–	938	1,802	629	1,640
Government grants (b)	24	505	4,082	601	493
Others	909	–	420	124	–
	<u>933</u>	<u>1,443</u>	<u>6,304</u>	<u>1,354</u>	<u>2,133</u>

- (a) The amounts represent the additional deduction of value-added tax applicable to certain subsidiaries of the Group providing hair care services since April 2019.

- (b) Government grants relating to income include various government subsidies received by the group entities from the relevant government bodies in connection with enterprise development, tax refund and employee related grants etc. All subsidies were recognised at the time when the Group fulfilled the relevant criteria and the related expenses were incurred.

8. OTHER GAINS AND LOSSES, NET

	Year ended December 31,			Six months ended June 30,	
	2018	2019	2020	2020	2021
	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
				(Unaudited)	
Gains on disposal of subsidiaries	2,400	1,100	–	–	–
Losses on disposal of property, plant and equipment	(5,704)	(1,849)	(3,984)	(3,597)	(451)
Compensation expenditure to customers	(394)	(297)	(2)	–	–
Donation	–	–	(1,000)	(1,000)	–
Compensation from the early-termination of a property lease	–	–	–	–	6,431
Others	(3,323)	(2,327)	(2,752)	(1,169)	1,231
	(7,021)	(3,373)	(7,738)	(5,766)	7,211

9. EXPENSES BY NATURE

Expenses included in cost of sales and services, selling and marketing expenses, general and administrative expenses and research and development expenses are further analysed as follows:

	Year ended December 31,			Six months ended June 30,	
	2018	2019	2020	2020	2021
	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
				(Unaudited)	
Promotion and marketing related expenses	328,092	458,139	507,667	148,507	389,436
Employee benefits expenses (Note 10)	264,846	370,289	494,886	194,646	330,022
Depreciation of right-of-use assets (Note i and 15)	51,800	72,967	82,990	38,657	52,949
Depreciation of property, plant and equipment (Note 14)	32,535	56,347	75,732	35,635	43,812
Cost of inventories and consumables	25,941	40,405	63,951	19,831	46,307
Utilities, maintenance fee and office expenses	28,509	40,492	35,749	14,078	23,176
Taxes and surcharges	10,589	17,353	30,103	6,629	19,732
Travelling and entertainment expenses	29,421	29,962	27,922	8,538	18,568
Rental expenses for short-term leases (Note 15(b))	9,823	10,750	13,956	6,515	6,076
Consulting service fee	816	678	3,268	2,920	1,168
Listing expenses	–	–	3,827	–	7,545
Technical fee	775	1,070	2,616	642	2,909
Auditors' remuneration	712	872	1,959	716	1,186
Amortisation of intangible assets (Note 16)	114	391	403	186	306
Other expenses	13,674	24,757	25,086	10,042	10,031
Total	797,647	1,124,472	1,370,115	487,542	953,223

- (i) The depreciation of right-of-use assets for the year ended December 31, 2020 and the six months ended June 30, 2020 as presented above have been net off the rental reduction or waivers due to COVID-19 of approximately RMB6 million and RMB4 million, respectively (Note 15(b)).

10. EMPLOYEE BENEFITS EXPENSES

	Year ended December 31,			Six months ended June 30,	
	2018	2019	2020	2020	2021
	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
				(Unaudited)	
Wages, salaries and bonuses	230,045	320,698	458,974	176,264	291,092
Share-based compensation expenses	–	–	3,606	3,513	92
Pension costs – defined contribution plans	16,811	19,605	1,914	1,914	16,743
Other social security costs	8,626	12,278	12,540	4,276	10,009
Housing benefits	5,937	8,783	11,255	4,800	7,524
Welfare and other expenses	3,427	8,925	6,597	3,879	4,562
	<u>264,846</u>	<u>370,289</u>	<u>494,886</u>	<u>194,646</u>	<u>330,022</u>

- (i) Employees of the Group are required to participate in a defined contribution plan administrated and operated by the local municipal government in the PRC. The Group contributes funds which are calculated on certain percentages of the employee salary as agreed by the local municipal government to the plan to fund the retirement benefits of the employees.
- (ii) Pension costs – defined contribution plans decreased in 2020, primarily due to the reduction and exemption policy of pension by the local municipal government due to COVID-19 outbreak in 2020.
- (iii) Five highest paid individuals

The five individuals whose emoluments are the highest in the Group for the years ended December 31, 2018, 2019 and 2020 and the six months ended June 30, 2020 and 2021 include 2, 0, 1, 1 and 1 directors respectively whose emoluments are reflected in the analysis shown in Note 32. The emoluments payable to the remaining 3, 5, 4, 4 and 4 individuals respectively during the Track Record Period are as follows:

	Year ended December 31,			Six months ended June 30,	
	2018	2019	2020	2020	2021
	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
				(Unaudited)	
Wages, salaries, bonuses, housing funds and other employees benefits	1,613	6,962	6,485	2,661	2,065
Share-based compensation expenses	–	–	7	3	6
	<u>1,613</u>	<u>6,962</u>	<u>6,492</u>	<u>2,664</u>	<u>2,071</u>

The emoluments of the 3, 5, 4, 4 and 4 individuals fell within the following bands:

	Year ended December 31,			Six months ended June 30,	
	2018	2019	2020	2020	2021
				(Unaudited)	
Emoluments bands:					
Nil to HK\$1,000,000	3	–	–	3	4
HK\$1,000,001 to HK\$1,500,000	–	2	–	1	–
HK\$1,500,001 to HK\$2,000,000	–	3	2	–	–
HK\$2,000,001 to HK\$2,500,000	–	–	2	–	–
	<u>3</u>	<u>5</u>	<u>4</u>	<u>4</u>	<u>4</u>

During the Track Record Period, no director or the five highest paid individuals received any emolument from the Group as an inducement to join, upon joining the Group, leave the Group or as compensation for loss of office.

11. FINANCE COSTS – NET

	Year ended December 31,			Six months ended June 30,	
	2018	2019	2020	2020	2021
	<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>
				(Unaudited)	
Finance income					
Interest income on bank deposits	139	210	941	218	2,408
Finance costs					
Interest expenses on bank borrowings	–	(1,275)	(1,488)	(1,025)	(1,150)
Interest expenses for lease liabilities	(17,808)	(25,453)	(34,800)	(14,982)	(21,528)
	<u>(17,808)</u>	<u>(26,728)</u>	<u>(36,288)</u>	<u>(16,007)</u>	<u>(22,678)</u>
Finance costs – net	<u>(17,669)</u>	<u>(26,518)</u>	<u>(35,347)</u>	<u>(15,789)</u>	<u>(20,270)</u>

12. INCOME TAX EXPENSES

	Year ended December 31,			Six months ended June 30,	
	2018	2019	2020	2020	2021
	<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>
				(Unaudited)	
Current income tax	68,883	44,836	75,715	34,435	52,197
Deferred income tax (<i>Note 27</i>)	(11,094)	(8,937)	(8,133)	(6,353)	(3,763)
Income tax expense	<u>57,789</u>	<u>35,899</u>	<u>67,582</u>	<u>28,082</u>	<u>48,434</u>

(a) Cayman Islands

The Company is incorporated as an exempted company with limited liability under the Companies Act of the Cayman Islands and is not subject to Cayman Islands income tax.

(b) Hong Kong Profits Tax

The subsidiary incorporated in Hong Kong is subject to Hong Kong profits tax at the rate of 16.5% on any estimated assessable profits arising in Hong Kong.

(c) PRC Enterprise Income Tax ("EIT")

Except as described below, the income tax provision of the Group in respect of its operations in the PRC was subject to statutory tax rate of 25% on the estimated assessable profits for the Track Record Period, based on the existing legislation, interpretations and practices in respect thereof.

On October 31, 2018, Yonghe Investment was qualified as HNTEs under the relevant PRC laws and regulations. This status is subject to a requirement that Yonghe Investment reapply for HNTEs status every three years.

The tax on the Group's profit before income tax differs from the theoretical amount that would arise using the statutory tax rate of 25% are as follows:

	Year ended December 31,			Six months ended June 30,	
	2018	2019	2020	2020	2021
	<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i> (Unaudited)	<i>RMB'000</i>
Profit before income tax	111,289	71,523	230,914	93,541	88,875
Tax calculated at statutory tax rate of 25%	27,822	17,881	57,729	23,385	22,219
Tax effects of:					
Unused tax credits for which no deferred income tax assets was recognised (i)	30,946	20,870	21,434	3,288	25,367
Expenses not deductible for tax purposes	1,711	1,183	1,400	143	245
Research and development tax credit	(141)	(542)	(2,180)	(1,023)	(1,085)
Tax losses for which no deferred income tax asset was recognised	466	487	1,064	743	833
Impact of preferential tax rates	(3,015)	(3,980)	(11,865)	1,546	(7,484)
Income tax of shares transfer of Beijing Haiyouyou in Reorganisation	—	—	—	—	8,339
	<u>57,789</u>	<u>35,899</u>	<u>67,582</u>	<u>28,082</u>	<u>48,434</u>

- (i) Pursuant to the EIT Law and related regulations, the pre-tax deduction for advertising expenses is limited to the 15% of the revenue in the current year, and the excess could be carried forward for deduction in the following years. Deferred income tax assets relating to unused tax credits of advertising expense are not recognised as management considers it is not probable to utilise these unrecognised tax credits in the foreseeable future because the Group will continue to invest on promotion and marketing activities to expand its businesses.

As at December 31, 2018, 2019 and 2020 and June 30, 2021, unused tax credits for which no deferred income tax assets has been recognised in respect of deductible advertising expense carried forward amounted to approximately RMB222 million, RMB305 million, RMB391 million, and RMB494 million, respectively.

	As at December 31,			As at
	2018	2019	2020	June 30,
	RMB'000	RMB'000	RMB'000	2021
Unused tax losses for which no deferred income tax assets has been recognised for entities subject to the income tax rate of 25%	2,289	2,889	2,946	6,277

The expiry dates of the unused tax losses as of the respective balance sheet dates are listed as below.

	As at December 31,			As at
	2018	2019	2020	June 30,
	RMB'000	RMB'000	RMB'000	2021
Year ended/ending:				
2020	10	10	–	–
2021	–	–	–	–
2022	413	413	413	413
2023	1,866	863	863	863
2024	–	1,603	722	722
2025	–	–	948	948
2026	–	–	–	3,331
	2,289	2,889	2,946	6,277

Pursuant to the Detailed Implementation Regulations for Implementation of the EIT Law issued on December 6, 2007, dividends distributed from the profits generated by the PRC companies after January 1, 2008 to their foreign investors shall be subject to withholding income tax at the rate of 10%, a lower 5% withholding income tax rate may be applied when the immediate holding companies of the subsidiaries in Mainland China are incorporated in Hong Kong and fulfill the requirements to the tax treaty arrangements between Mainland China and Hong Kong. The Group has not accrued any withholding income tax for the undistributed earnings of its subsidiaries in Mainland China as the Group does not have a plan to distribute these earnings from its subsidiaries in Mainland China.

13. EARNINGS PER SHARE**(a) Basic earnings per share**

Basic earnings per share is calculated by dividing:

- the profit attributable to owners of the company, excluding undistributed earnings attributable to unvested restricted shares during the vesting period (Note 23);
- by the weighted average number of ordinary shares outstanding during the financial year, adjusted for bonus elements in ordinary shares issued during the year and excluding shares held for employee share scheme (Note 23). The shares subscribed for the interests in the Company upon the Reorganization and the share split pursuant to the shareholders' resolution passed on November 12, 2021 as mentioned in Note 35 had been adjusted retrospectively as if those shares have been issued since January 1, 2018.

	Year ended December 31,			Six months ended June 30,	
	2018	2019	2020	2020	2021
				(Unaudited)	
Profit for the year/period attributable to owners of the Company (RMB'000)	53,500	35,624	163,332	65,459	40,441
Less: undistributed earnings attributable to unvested restricted shares during vesting period (RMB'000)	—	—	(16,368)	(4,373)	(1,077)
Profit attributable to the ordinary equity owners of the Company used in calculating basic earnings per share (RMB'000)	53,500	35,624	146,964	61,086	39,364
Weighted average number of ordinary equity shares in issue ('000)	400,000	400,000	375,890	383,912	378,241
Basic earnings per share for profit attributable to ordinary equity owners of the Company during the year/period (expressed in RMB per share)	0.13	0.09	0.39	0.16	0.10

(b) Diluted earnings per share

Diluted earnings per share adjusts the figures used in the determination of basic earnings per share to take into account:

- undistributed earnings attributable to unvested restricted shares during the vesting period added back to the numerator, and
- the weighted average number of additional ordinary shares that would have been outstanding assuming the conversion of all dilutive potential ordinary shares.

	Year ended December 31,			Six months ended June 30,	
	2018	2019	2020	2020	2021
				(Unaudited)	
Profit attributable to the ordinary equity owners of the Company used in calculating basic earnings per share (<i>RMB'000</i>)	53,500	35,624	146,964	61,086	39,364
Add: undistributed earnings attributable to unvested restricted shares during vesting period (<i>RMB'000</i>)	–	–	16,368	4,373	1,077
Profit attributable to the ordinary equity owners of the Company used in calculating diluted earnings per share (<i>RMB'000</i>)	53,500	35,624	163,332	65,459	40,441
Weighted average number of ordinary shares used as the denominator in calculating basic earnings per share (<i>'000</i>)	400,000	400,000	375,890	383,912	378,241
Adjustments for calculation of diluted earnings per share: Restricted shares (<i>'000</i>)	–	–	43,172	28,901	47,139
Weighted average number of ordinary shares and potential ordinary shares used as the denominator in calculating diluted earnings per share (<i>'000</i>)	400,000	400,000	419,062	412,813	425,380
Diluted earnings per share for profit attributable to owners of the Company during the year/period (expressed in RMB per share)	0.13	0.09	0.39	0.16	0.10

(c) **Information concerning the classification of securities**

Restricted shares granted to employees under share award schemes are not regarded as outstanding until they are vested. The restricted shares have not been included in the determination of basic earnings per share. Restricted shares are entitled to undistributed earnings during the vesting period, and the numerator should be adjusted for undistributed earnings attributable to unvested restricted shares. These shares are excluded from the weighted average number of ordinary shares for the calculation of basic earning per share.

Restricted shares have been included in the determination of diluted earnings per share. The adjustment to basic earnings per share are added back to the numerator in diluted earnings per share.

Details relating to the restricted shares are set out in Note 23.

14. PROPERTY, PLANT AND EQUIPMENT

	Medical equipment	Electronic equipment	Office furniture and fixtures	Motor vehicles	Medical treatment and safety infrastructure and leasehold improvement	Total
	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
Cost:						
At January 1, 2018 (Unaudited)	5,806	6,982	3,661	213	58,493	75,155
Additions	5,276	6,419	5,210	8	129,474	146,387
Disposal	(1,054)	(879)	(283)	–	(9,933)	(12,149)
At December 31, 2018	10,028	12,522	8,588	221	178,034	209,393
Additions	6,606	8,023	4,826	–	101,725	121,180
Disposal	(966)	(1,073)	(645)	(4)	(13,034)	(15,722)
At December 31, 2019	15,668	19,472	12,769	217	266,725	314,851
Additions	12,905	8,258	6,050	574	130,408	158,195
Disposal	(566)	(995)	(414)	–	(49,449)	(51,424)
At December 31, 2020	28,007	26,735	18,405	791	347,684	421,622
Acquisition of a subsidiary (Note 30)	–	228	–	–	34	262
Additions	7,622	5,095	3,140	4	99,505	115,366
Disposal	(537)	(798)	(537)	–	(5,582)	(7,454)
At June 30, 2021	35,092	31,260	21,008	795	441,641	529,796
Accumulated depreciation:						
At January 1, 2018 (Unaudited)	(1,448)	(1,636)	(398)	(4)	(11,354)	(14,840)
Depreciation	(1,371)	(2,512)	(1,024)	(113)	(27,515)	(32,535)
Disposal	711	579	178	–	4,672	6,140
At December 31, 2018	(2,108)	(3,569)	(1,244)	(117)	(34,197)	(41,235)
Depreciation	(2,308)	(4,788)	(2,033)	(53)	(47,165)	(56,347)
Disposal	834	785	223	1	12,024	13,867
At December 31, 2019	(3,582)	(7,572)	(3,054)	(169)	(69,338)	(83,715)
Depreciation	(3,858)	(6,512)	(3,062)	(72)	(62,228)	(75,732)
Disposal	267	685	214	–	46,096	47,262
At December 31, 2020	(7,173)	(13,399)	(5,902)	(241)	(85,470)	(112,185)
Depreciation	(2,991)	(3,648)	(1,932)	(69)	(35,172)	(43,812)
Disposal	367	642	330	–	5,582	6,921
At June 30, 2021	(9,797)	(16,405)	(7,504)	(310)	(115,060)	(149,076)

	Medical equipment	Electronic equipment	Office furniture and fixtures	Motor vehicles	Medical treatment and safety infrastructure and leasehold improvement	Total
	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
Net carrying amount:						
At December 31, 2018	7,920	8,953	7,344	104	143,837	168,158
At December 31, 2019	12,086	11,900	9,715	48	197,387	231,136
At December 31, 2020	20,834	13,336	12,503	550	262,214	309,437
At June 30, 2021	25,295	14,855	13,504	485	326,581	380,720

Depreciation expenses have been charged to profit or loss and presented in the consolidated statements of comprehensive income as follows:

	Year ended December 31,			Six months ended June 30,	
	2018	2019	2020	2020	2021
	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
				(Unaudited)	
Cost of sales and services	28,155	48,749	65,457	30,725	37,772
General and administrative expenses	1,404	1,919	2,607	1,356	1,519
Selling and marketing expenses	2,934	5,576	7,519	3,457	4,440
Research and development expenses	42	103	149	97	81
	32,535	56,347	75,732	35,635	43,812

15. LEASES

(a) Amounts recognised in the consolidated balance sheets

	As at December 31,			As at June 30,
	2018	2019	2020	2021
	RMB'000	RMB'000	RMB'000	RMB'000
Right-of-use assets (i)				
Leased buildings	398,862	494,985	810,653	761,324
Lease liabilities				
Current	75,381	96,868	147,051	157,979
Non-current	324,932	411,172	682,879	644,381
	400,313	508,040	829,930	802,360

- (i) The movement in right-of-use assets in the consolidated balance sheets are as follows:

	Year ended December 31,			Six months ended June 30,
	2018	2019	2020	2021
	RMB'000	RMB'000	RMB'000	RMB'000
Cost				
At beginning of the year/period	294,721	462,456	631,817	1,032,566
Additions	167,778	190,381	436,853	129,692
Lease expiration	(15)	(6,921)	(16,561)	(19,873)
Termination of lease contracts	(28)	(14,099)	(19,543)	(23,398)
Lease modification (Note)	–	–	–	(86,075)
At end of the year/period	462,456	631,817	1,032,566	1,032,912
Accumulated depreciation				
At beginning of the year/period	–	(63,594)	(136,832)	(221,913)
Depreciation charge for the year/period	(63,624)	(85,518)	(109,278)	(77,785)
Lease expiration	15	6,921	16,561	19,873
Termination of lease contracts	15	5,359	7,636	8,237
At end of the year/period	(63,594)	(136,832)	(221,913)	(271,588)
Net book amount				
At end of the year/period	398,862	494,985	810,653	761,324

Note:

The Group has leased a property for a new clinic in Beijing in May 2020 with a term of six years. Due to the change of the lessor, the Group needs to terminate this lease contract in July 2021 and then enters into another agreement with the new lessor. The change has no impact on the operation of the clinic. As at June 30, 2021, the termination contract with the original lessor was signed and becomes effective in July 2021.

- (b) Amounts recognised in the consolidated statements of comprehensive income

	Year ended December 31,			Six months ended June 30,	
	2018	2019	2020	2020	2021
	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
				(Unaudited)	
Depreciation charge of right-of-use assets	51,800	72,967	88,557	42,505	52,949
Rental reduction or waivers due to COVID-19 (Note 2.25)	–	–	(5,567)	(3,848)	–
Interest expense (Note 11)	17,808	25,453	34,800	14,982	21,528
Expense relating to short-term leases	9,823	10,750	13,956	6,515	6,076

(c) Depreciation of right-of-use assets are charged to the following categories:

	Year ended December 31,			Six months ended June 30,	
	2018	2019	2020	2020	2021
	<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i> (Unaudited)	<i>RMB'000</i>
Cost of sales and services	47,268	66,199	81,796	39,312	49,030
General and administrative expenses	3,257	3,257	3,208	1,575	1,534
Selling and marketing expenses	1,275	3,511	3,553	1,617	2,385
Subtotal	51,800	72,967	88,557	42,504	52,949
Capitalised as medical treatment and safety infrastructure and leasehold improvement	11,824	12,551	20,721	6,272	24,836
	<u>63,624</u>	<u>85,518</u>	<u>109,278</u>	<u>48,776</u>	<u>77,785</u>

(d) The total cash outflow for leases for the years ended December 31, 2018, 2019 and 2020 and the six months ended June 30, 2020 and 2021 are approximately RMB77 million, RMB106 million, RMB147 million, RMB79 million and RMB81 million, respectively.

16. INTANGIBLE ASSETS

	Software	Trademark	Goodwill	Total
	<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>
Cost:				
At January 1, 2018 (Unaudited)	495	–	–	495
Additions	<u>1,136</u>	<u>–</u>	<u>–</u>	<u>1,136</u>
At December 31, 2018	<u>1,631</u>	<u>–</u>	<u>–</u>	<u>1,631</u>
Additions	2,300	–	–	2,300
Disposal	<u>(198)</u>	<u>–</u>	<u>–</u>	<u>(198)</u>
At December 31, 2019	<u>3,733</u>	<u>–</u>	<u>–</u>	<u>3,733</u>
Additions	<u>643</u>	<u>–</u>	<u>–</u>	<u>643</u>
At December 31, 2020	<u>4,376</u>	<u>–</u>	<u>–</u>	<u>4,376</u>
Acquisition of a subsidiary (Note 30)	–	4,758	25,157	29,915
Additions	<u>549</u>	<u>443</u>	<u>–</u>	<u>992</u>
At June 30, 2021	<u>4,925</u>	<u>5,201</u>	<u>25,157</u>	<u>35,283</u>

	Software	Trademark	Goodwill	Total
	<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>
Accumulated amortisation:				
At January 1, 2018 (Unaudited)	(119)	–	–	(119)
Amortisation	(114)	–	–	(114)
At December 31, 2018	(233)	–	–	(233)
Amortisation	(391)	–	–	(391)
Disposal	198	–	–	198
At December 31, 2019	(426)	–	–	(426)
Amortisation	(403)	–	–	(403)
At December 31, 2020	(829)	–	–	(829)
Amortisation	(296)	(10)	–	(306)
At June 30, 2021	(1,125)	(10)	–	(1,135)
Net carrying amount:				
At December 31, 2018	1,398	–	–	1,398
At December 31, 2019	3,307	–	–	3,307
At December 31, 2020	3,547	–	–	3,547
At June 30, 2021	3,800	5,191	25,157	34,148

- (a) Amortisation expenses have been charged to profit or loss and presented in the consolidated statements of comprehensive income as follows:

	Year ended December 31,			Six months ended June 30,	
	2018	2019	2020	2020	2021
	<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>
				(Unaudited)	
General and administrative expenses	112	389	401	185	305
Selling and marketing expenses	2	2	2	1	1
	114	391	403	186	306

- (b) The goodwill of approximately RMB25 million arising from the acquisition of Nu/Hart Hair Solutions Limited (“NU/Hart”) on May 31, 2021 has been allocated to the cash generating unit (“CGU”) of NU/Hart for impairment testing. As at June 30, 2021, management performed an impairment assessment on the goodwill. The recoverable amounts of the hair transplant business operated by NU/Hart have been assessed by an independent valuer and determined based on value-in-use (“VIU”) calculation. The calculation used cash flow projections based on financial budgets covering a five-year period approved by management.

The following table sets forth each key assumption on which management has based its cash flow projections to undertake impairment testing of goodwill as at June 30, 2021:

Revenue 2021 (% annual growth rate)	6%
Revenue 2022 to 2025 (% annual growth rate)	15%
Revenue 2026 (% annual growth rate)	8%
Terminal growth rate	2%
Pre-tax discount rate	18.3%

As at June 30, 2021, the recoverable amount of the CGU of RMB32 million calculated based on VIU calculation exceeded its carrying value of RMB30 million by RMB2 million. Management has considered and assessed reasonably possible changes for other key assumptions and have not identified any instances that could cause the carrying amount to exceed their recoverable amount.

Management has undertaken sensitivity analysis on the impairment test of goodwill. The following table sets forth all possible changes to the key assumptions of the impairment test and the changes taken in isolation in the VIU calculations that would remove the remaining headroom as at June 30, 2021:

Annual revenue growth rate	-0.12%
Discount rate	+0.24%

The goodwill of approximately RMB25 million represents the excess of the acquisition consideration transferred over the fair value of the net identifiable assets acquired as at the acquisition date on May 31, 2021. As at June 30, 2021, the recoverable amount of the CGU in NU/Hart is estimated to exceed the carrying amount of the CGU by approximately RMB2 million. Such recoverable amount of the CGU is determined based on VIU calculations. The calculation requires the Group to estimate the future cash flow expected to arise from CGU and a suitable discount rate in order to calculate the present value. As at recoverable amount valuation date, it has been only one month since the acquisition date and no significant changes in expected future cash flows generated from the CGU as well as the discount rate, management expects that the recoverable amount would not increase significantly from the fair value of the net identifiable assets acquired as at the acquisition date. Therefore, the headroom only amounts to RMB2 million.

The directors of the Company considered there is no reasonably possible change in key parameters would cause the carrying amount of each CGU to exceed its recoverable amount.

By reference to the recoverable amount assessed by the independent valuer as at June 30, 2021, the directors of the Company determined that no impairment provision on goodwill for the six months ended June 30, 2021.

- (c) The trademark of approximately RMB5 million is identified in the acquisition of Nu/Hart on May 31, 2021. As of the valuation date, the revenue of NU/Hart mainly comes from hair transplant services with the Nu/Hart trademark. Management considered that NU/Hart will provide continuous service by using the trademark after acquisition and by reference to the valuation report, this trademark will make revenue contribution for 11 years and after that, the incremental economic benefit became immaterial.

17. FINANCIAL INSTRUMENTS BY CATEGORY

Financial assets	Note	As at December 31,			As at June 30, 2021
		2018	2019	2020	
		RMB'000	RMB'000	RMB'000	RMB'000
Financial assets at amortised cost:					
Trade receivables	18	9,805	5,859	10,330	6,929
Deposits and other receivables	19	25,508	36,426	52,038	59,940
Cash and cash equivalents	21	68,476	89,789	292,856	453,100
Restricted cash	24(b)	–	–	–	149,500
		<u>103,789</u>	<u>132,074</u>	<u>355,224</u>	<u>669,469</u>
Financial liabilities					
Financial liabilities	Note	As at December 31,			As at June 30, 2021
		2018	2019	2020	
		RMB'000	RMB'000	RMB'000	RMB'000
Financial liabilities at amortised cost:					
Borrowings	24	–	44,827	25,870	214,395
Trade and other payables (excluding tax payables and accrued employee benefits)	25	31,574	38,944	63,600	117,235
Lease liabilities	15	400,313	508,040	829,930	802,360
		<u>431,887</u>	<u>591,811</u>	<u>919,400</u>	<u>1,133,990</u>

The Group's exposure to various risks associated with the financial instruments is discussed in Note 3. The maximum exposure to credit risk at the end of the reporting period is the carrying amount of each class of financial assets mentioned above.

18. TRADE RECEIVABLES

	As at December 31,			As at June 30, 2021
	2018	2019	2020	
	RMB'000	RMB'000	RMB'000	RMB'000
Trade receivables from contracts with customers				
– Third parties	9,871	5,887	10,409	6,982
Less: allowance for impairment	(66)	(28)	(79)	(53)
	<u>9,805</u>	<u>5,859</u>	<u>10,330</u>	<u>6,929</u>

- (a) The Group usually receives the payment from customers in advance. The trade receivable is primarily the receivable from financial institutions or the third party payment platforms which the customers have already settled their payment through financial institutions or the third party payment platforms. The credit term given to the third party payment platforms are determined on an individual basis with normal credit period within 15 days. The ageing analysis of the trade receivables based on invoice date is as follows:

	As at December 31,			As at
	2018	2019	2020	June 30,
	RMB'000	RMB'000	RMB'000	2021
Up to 3 months	9,871	5,861	10,403	6,982
3 to 6 months	–	12	6	–
6 months to 1 year	–	14	–	–
	9,871	5,887	10,409	6,982
Less: allowance for impairment	(66)	(28)	(79)	(53)
Total	9,805	5,859	10,330	6,929

(b) **Fair values of trade receivables**

Due to the short-term nature of the current receivables, their carrying amounts are considered to be approximately the same as their fair values.

(c) **Impairment and risk exposure**

On the basis as described in Note 3.1(c), the loss allowance for trade receivables as at December 31, 2018, 2019 and 2020 and June 30, 2021 are determined as follows:

	As at December 31,						As at June 30,		
	2018		2019		2020		2021		
	Expected loss rate	Gross carrying amount	Loss allowance provision	Expected loss rate	Gross carrying amount	Loss allowance provision	Expected loss rate	Gross carrying amount	Loss allowance provision
	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
Trade receivables									
– Financial institutions	0.13%	5,199	7	0.14%	4,284	6	0.22%	8,191	18
– Third party payment platforms	1.26%	4,672	59	1.37%	1,603	22	2.75%	2,218	61
– Others	–	–	–	–	–	–	–	–	–
		9,871	66		5,887	28		10,409	79
								6,982	53

19. PREPAYMENTS, DEPOSITS AND OTHER RECEIVABLES

	As at December 31,			As at
	2018	2019	2020	June 30,
	RMB'000	RMB'000	RMB'000	2021
				RMB'000
Included in current assets				
Prepayments				
Advertising and information technology services fee	19,416	22,826	37,454	27,321
Rental and property management fees	6,602	2,982	5,342	13,559
Professional and agency service fees	5,654	1,038	2,315	5,939
Purchase of inventory	1,179	2,366	4,441	13,629
Capitalisation of listing expenses	–	–	–	2,339
Others	1,100	2,087	2,473	1,620
	33,951	31,299	52,025	64,407
Deductible input VAT	652	574	3,367	7,279
Other receivables				
Deposits (a)	22,468	28,828	43,606	54,954
Proceed receivables from disposal of subsidiaries	1,800	150	–	–
Cash advance to employees (b)	1,120	590	479	2,698
Amounts due from related parties	36	110	133	–
Others	2,054	8,790	10,298	5,168
	27,478	38,468	54,516	62,820
Less: provision for impairment of other receivables (c)	(1,970)	(2,042)	(2,478)	(2,880)
	25,508	36,426	52,038	59,940
Subtotal	60,111	68,299	107,430	131,626
Included in non-current assets				
Prepayments for property, plant and equipment	863	2,499	4,095	2,216
Total	60,974	70,798	111,525	133,842

(a) Deposits consists primarily of security deposits for rental.

(b) Cash advance to employees are unsecured, interest-free and repayable on demand.

(c) Impairment and risk exposure

On the basis as described in Note 3.1(c), the loss allowance for other financial assets at amortised cost as at December 31, 2018, 2019 and 2020 and June 30, 2021 are determined as follows:

	As at December 31,									As at June 30,		
	2018			2019			2020			2021		
	Expected	Gross	Loss	Expected	Gross	Loss	Expected	Gross	Loss	Expected	Gross	Loss
	loss rate	carrying amount	allowance provision	loss rate	carrying amount	allowance provision	loss rate	carrying amount	allowance provision	loss rate	carrying amount	allowance provision
		RMB'000	RMB'000		RMB'000	RMB'000		RMB'000	RMB'000		RMB'000	RMB'000
Other receivables												
– Deposits	7.73%	22,468	1,737	6.31%	28,828	1,819	5.14%	43,606	2,242	5.09%	54,954	2,799
– Proceed receivables from disposal of subsidiaries	2.44%	1,800	44	0.67%	150	1	–	–	–	–	–	–
– Cash advance to employees	0.89%	1,120	10	0.85%	590	5	0.84%	479	4	0.93%	2,698	25
– Amounts due from related parties	–	36	–	–	110	–	–	133	–	–	–	–
– Other receivables	8.71%	2,054	179	2.47%	8,790	217	2.25%	10,298	232	1.08%	5,168	56
		<u>27,478</u>	<u>1,970</u>		<u>38,468</u>	<u>2,042</u>		<u>54,516</u>	<u>2,478</u>		<u>62,820</u>	<u>2,880</u>

20. INVENTORIES

	As at December 31,			As at
	2018	2019	2020	June 30,
	RMB'000	RMB'000	RMB'000	2021
				RMB'000
Pharmaceuticals and medical consumables	9,618	7,355	11,305	13,788
Medical hair care consumables	729	956	8,621	14,493
Wash and hair care products	2,731	4,422	3,876	10,546
Others	<u>1,177</u>	<u>1,753</u>	<u>3,194</u>	<u>5,669</u>
	14,255	14,486	26,996	44,496
Less: allowance for impairment of inventories	<u>–</u>	<u>–</u>	<u>–</u>	<u>–</u>
	<u>14,255</u>	<u>14,486</u>	<u>26,996</u>	<u>44,496</u>

Inventories recognised as cost of sales and services during the years ended December 31, 2018, 2019 and 2020 and the six months ended June 30, 2020 and 2021 amounted to approximately RMB26 million, RMB40 million, RMB64 million, RMB20 million and RMB46 million, respectively.

21. CASH AND CASH EQUIVALENTS

The Group	As at December 31,			As at
	2018	2019	2020	June 30,
	<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>	2021
Bank deposits	68,260	89,705	292,763	452,898
Cash on hand	216	84	93	202
Cash and cash equivalents	<u>68,476</u>	<u>89,789</u>	<u>292,856</u>	<u>453,100</u>

The carrying amount of the Group's cash and cash equivalents are denominated in the following currencies:

	As at December 31,			As at
	2018	2019	2020	June 30,
	<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>	2021
RMB	68,476	89,789	292,856	356,726
USD	—	—	—	94,023
HKD	—	—	—	2,351
	<u>68,476</u>	<u>89,789</u>	<u>292,856</u>	<u>453,100</u>

The Company	As at	As at
	December 31,	June 30,
	2020	2021
	<i>RMB'000</i>	<i>RMB'000</i>
Bank deposits	—	92,355
Cash and cash equivalents	<u>—</u>	<u>92,355</u>

As at June 30, 2021, the carrying amount of the Company's cash and cash equivalents are denominated in USD.

22. SHARE CAPITAL AND OTHER RESERVES

(i) Share capital

On September 17, 2020, the Company was incorporated in the Cayman Islands as an exempted company with limited liability. As of the date of incorporation, the initial authorised share capital of the Company was US\$50,000 divided into 5,000,000,000 shares with a par value of US\$0.00001 each.

- (a) On September 17, 2020, Mr. Zhang Yu, Mr. Zhang Hui, Mr. Nie Lei, Mr. Geng Jiaqi, Ms. Duan Siqi, Mr. Tan Xu and Mr. Song Linfeng subscribed shares in the Company in proportion to their ultimate shareholdings in Beijing Haiyouyou respectively through their respective special purpose vehicles incorporated in the BVI. On January 29, 2021, Panmao Shanghai through Yonghe Hair Service Holdings Limited, its special purpose vehicle incorporated in BVI, CYH and Hu & Yan subscribed shares in the Company in proportion to their shareholdings in Beijing Haiyouyou respectively. The number of subscribed shares is 100,000,000 in total.

The cash considerations for the share subscriptions was fully settled on June 4, 2021 and the shares exchanges were completed on May 10, 2021.

- (b) On April 26, 2021, the Company issued 6,382,979 shares with a par value of US\$0.00001 each to ZY Investment Capital Ltd., representing approximately 6.0% of the shares of the Company in issue upon completion of the share issuance at a consideration of RMB89 million. Therefore, the share capital and other reserves were increased by RMB414 and RMB89 million, respectively. The consideration was fully paid on May 17, 2021.

	Number of ordinary shares	Share capital	
		USD	RMB
Authorized			
As at June 30, 2021	5,000,000,000	50,000	323,005
Issued and fully paid			
As at December 31, 2020	—	—	—
Issue of shares (a)	100,000,000	1,000	6,409
Issue of shares to ZY Investment Capital Ltd (b)	6,382,979	64	414
Issued and fully paid			
As at June 30, 2021	106,382,979	1,064	6,823

(ii) Other reserves

	Year ended December 31,			Six months ended June 30, 2021
	2018	2019	2020	
	RMB'000	RMB'000	RMB'000	RMB'000
At the beginning of year/period	150,365	150,365	150,365	153,971
Issue of shares to ZY Investment Capital Ltd.	—	—	—	88,689
Issue of shares	—	—	—	(7)
Currency translation differences	—	—	—	(947)
Share-based compensation	—	—	3,606	92
At the end of year/period	150,365	150,365	153,971	241,798

As at January 1, 2018, the other reserves comprised the capital reserves arisen from the capital contribution of Beijing Haiyouyou from Beijing Xunyi, CYH, Panxin Shanghai and Xizang Yonghe of RMB4,705,882, RMB36,242,647, RMB36,242,647 and RMB9,573,530, respectively, and the remaining balance mainly the reserves as arisen from the waiver of debt of approximately RMB64 million by Beijing Xunyi in 2017.

23. SHARE-BASED COMPENSATION

(a) Share award schemes

On March 31, 2020, the shareholders of the Beijing Haiyouyou communicated the details of the share-based compensation scheme including the performance criteria with the grantees, pursuant to which, 1) shareholders (other than Beijing Xunyi) of Beijing Haiyouyou who would convert to the shareholder of the Company would transfer in total 8% of the shares of the Company to Mr. Zhang Yu and 118 eligible employees at a consideration of RMB111 million (the “8% Employee Share Plan”); 2) the Company would issue approximately 6% of the shares of the Company to Mr. Zhang Yu at a consideration of RMB89 million (the “6% Employee Share Plan”). Accordingly, March 31, 2020 is considered as the grant date (the “grant date”) of the selected share-based compensation.

8% Employee Share Plan

On April 23, 2021, shareholders (other than Mr. Zhang Yu and Mr. Zhang Hui) of the Company (the “Transferors”) transferred in total 5,000,000 and 3,000,000 shares (representing 5% and 3% of the issued shares in the Company, respectively) to Yunuo Technology Holdings Limited and Zhirui Technology Holdings Limited, respectively, under the 8% Employee Share Plan. The shares transferred was in proportion to the Transferors respective shareholding in the Company.

Under the plan, Mr. Zhang Yu and 118 eligible employees (the “eligible employees”) were granted 5,000,000 and 3,000,000 shares, respectively. The shares granted to Mr. Zhang Yu would be vested when the consideration have been paid. The shares granted to eligible employees would be vested when such eligible employees complete a certain service period after QIPO. In which, 30% of these shares could be vested when such eligible employees complete a two-year service period after QIPO, 30% of these shares could be vested when such eligible employees complete a three-year service period after QIPO, and the remaining 40% could vest when such eligible employees complete a four-year service period after QIPO. If an eligible employee ceases the employment by the Company within this period, the awarded shares will be repurchased by employee incentive platform, at the price that the employees initially purchased, and if applicable, plus 4.5% per annum interest.

The total consideration for the shares calculated at the price of RMB13.89 per share of approximately RMB111 million were fully paid by Mr. Zhang Yu and those eligible employees in May 2021 and the shares granted to Mr. Zhang Yu had been vested.

Yunuo Technology Holdings Limited (the “Yunuo”) was incorporated in the BVI on January 15, 2021 and wholly owned by Mr. Zhang Yu. Zhirui Technology Holdings Limited (the “Zhirui”) was incorporated in the BVI as a limited company on January 15, 2021 as an employee incentive platform for the eligible employees, which is controlled by the controlling shareholders.

6% Employee Share Plan

On April 26, 2021, the Company issued 6,382,979 shares, representing approximately 6.0% of the shares of the Company, to ZY Investment Capital Ltd. under the 6% Employee Share Plan. ZY Investment Capital Ltd. was incorporated in the BVI and wholly owned by Mr. Zhang Yu. The share issued to Mr. Zhang Yu would be vested when the consideration have been paid.

The consideration of RMB89 million in total at an exercise price of RMB13.89 each share were paid in May 2021 and the shares granted had been vested.

The Group has applied discounted cash flow method to determine the fair value of the underlying shares of RMB14.19 per share under the respective Employee Share Plan on the grant dates. Best estimates of key assumptions, such as discount rate and projections of future performance, are required to be determined by management. Key assumptions used in determining the fair value of shares under the Employee Share Plans are as follows:

	8% Employee Share Plan	6% Employee Share Plan
Discount rate	13.5%	13.5%
Risk-free interest rate	3.21%	3.21%
Volatility	53%	53%
Discount for lack of marketability	10%	10%

(b) Set out below are the movement in the number of awarded shares under the Employee Share Plans:

	Year ended December 31,			Six months ended June 30,
	2018	2019	2020	2021
	RMB'000	RMB'000	RMB'000	RMB'000
At the beginning of year/period	–	–	–	14,382,979
Granted	–	–	14,382,979	–
Vested	–	–	–	(11,382,979)
At the end of year/period	–	–	14,382,979	3,000,000
Shares not yet granted at the end of year/period	–	–	–	–

(c) Expenses arising from share-based payment transactions

	Year ended December 31,			Six months ended June 30,	
	2018	2019	2020	2020	2021
	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
				(Unaudited)	
Share award schemes issued under the Employee Share Plans	–	–	3,606	3,513	92

As at June 30, 2021, the accumulated expenses arising from share-based payment transactions amounting to approximately RMB3.7 million, with the corresponding credit to the share-based compensation reserve.

24. BORROWINGS

The Group	As at December 31,			As at
	2018	2019	2020	June 30,
	RMB'000	RMB'000	RMB'000	2021
Short-term bank borrowings				
– Unsecured	–	44,827	25,870	94,173
– Secured	–	–	–	120,222
Total	–	44,827	25,870	214,395

The Company	As at December 31,	As at June 30,
	2020	2021
	RMB'000	RMB'000
Short-term bank borrowings		
– Secured	–	120,222

(a) As at December 31, 2019, the bank borrowings carried interest at fixed rate ranging from 4.35% to 6.50% per annum.

As at December 31, 2020, the bank borrowings carried interest at fixed rate ranging from 3.89% to 4.35% per annum.

As at June 30, 2021, the unsecured bank borrowings carries interest at fixed rate ranging from 4.00% to 4.90% per annum, and the secured bank borrowings carries interest at fixed rate of 1.79% per annum.

(b) As at December 31, 2019 and 2020, the bank borrowings were repayable within one year and were guaranteed by Mr. Zhang Yu and his spouse Ms. Li Qian.

As at June 30, 2021, the bank borrowings were repayable within one year and bank borrowings of RMB120.2 million were secured by restricted bank deposits with carrying amount of approximately RMB149.5 million and equity interests of certain subsidiaries.

(c) The fair value of borrowings approximated their carrying amounts as at December 31, 2019 and 2020 and June 30, 2021 due to the short maturities of these borrowings.

(d) The carrying amounts of the borrowings are denominated in the following currencies:

	As at December 31,			As at
	2018	2019	2020	June 30,
	RMB'000	RMB'000	RMB'000	2021
RMB	–	44,827	25,870	94,173
USD	–	–	–	120,222
	–	44,827	25,870	214,395

25. TRADE AND OTHER PAYABLES

	As at December 31,			As at
	2018	2019	2020	June 30,
	RMB'000	RMB'000	RMB'000	2021
Trade payable	16,574	22,545	44,676	66,645
Accrued employee benefits	26,856	32,226	71,077	74,962
Refund liabilities (i)	3,935	5,024	7,581	11,253
Accrued expenses	4,738	2,283	4,219	6,074
Tax payable	4,039	5,928	3,555	19,809
Security deposit	3,079	3,178	3,135	4,467
Amounts due to related parties (Note 31(c))	785	749	30	25,886
Others	2,463	5,165	3,959	2,910
	<u>62,469</u>	<u>77,098</u>	<u>138,232</u>	<u>212,006</u>

- (i) The Group has estimated the refund liabilities which is based on the Group's past experience with customers (Note 2.23).
- (ii) The carrying amounts of trade and other payables are considered to be approximated to their fair values, due to their short-term nature.
- (iii) Aging analysis of the trade payables based on invoice date at the end of each reporting period are as follows:

	As at December 31,			As at
	2018	2019	2020	June 30,
	RMB'000	RMB'000	RMB'000	2021
Up to 3 months	14,649	16,579	37,948	57,512
3 to 6 months	1,322	4,796	3,851	3,654
6 months to 1 year	400	845	2,344	4,307
1 to 2 years	138	260	408	1,172
Over 2 years	65	65	125	—
	<u>16,574</u>	<u>22,545</u>	<u>44,676</u>	<u>66,645</u>

26. CONTRACT LIABILITIES

	As at December 31,			As at
	2018	2019	2020	June 30,
	RMB'000	RMB'000	RMB'000	2021
Contract liabilities				
Hair transplant	6,223	8,375	11,196	11,850
Medical hair care	–	4,054	97,706	159,749
Others	10,669	10,925	11,521	10,193
	<u>16,892</u>	<u>23,354</u>	<u>120,423</u>	<u>181,792</u>

The Group classifies these contract liabilities as current because the Group does not have an unconditional right to defer for at least 12 months after the reporting period.

(i) Significant changes in contract liabilities

Contract liabilities for medical hair care contracts have increased as a result of business expansion.

(ii) Revenue recognised in relation to contract liabilities

The following table shows how much of the revenue recognised in the current reporting period relates to carried-forward contract liabilities:

	Year ended December 31,			Six months ended June 30,	
	2018	2019	2020	2020	2021
	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
				(Unaudited)	
Hair transplant	2,221	3,083	3,075	2,711	3,935
Medical hair care	–	–	3,285	2,563	64,902
Others	3,976	4,880	3,179	1,211	2,434
	<u>6,197</u>	<u>7,963</u>	<u>9,539</u>	<u>6,485</u>	<u>71,271</u>

(iii) Unsatisfied contracts

Management expects that the amount of approximately RMB8 million, RMB10 million, RMB61 million and RMB135 million of the transaction to unsatisfied obligations as at December 31, 2018, 2019 and 2020 and June 30, 2021 will be recognised as revenue within next one year. The remaining will be recognised in more than one year.

27. DEFERRED INCOME TAX

(a) The analysis of deferred income tax assets is as follows:

	As at December 31,			As at
	2018	2019	2020	June 30,
	<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>	2021
				<i>RMB'000</i>
Deferred income tax assets:				
– Deferred income tax assets to be recovered after more than 12 months	10,469	17,022	27,115	29,978
– Deferred income tax assets to be recovered within 12 months	2,578	4,345	2,076	2,953
	13,047	21,367	29,191	32,931
Set-off of deferred income tax liabilities pursuant to set-off provisions	(530)	(514)	(179)	(196)
Net deferred tax assets	12,517	20,853	29,012	32,735
Deferred income liabilities:				
– Deferred income tax liabilities to be settled after more than 12 months	671	247	67	786
– Deferred income tax liabilities to be settled within 12 months	653	460	331	374
	1,324	707	398	1,160
Set-off of deferred income tax assets pursuant to set-off provisions	(530)	(514)	(179)	(196)
Net deferred income tax liabilities	794	193	219	964

(b) The net movement on the deferred income tax account is as follows:

	Year ended December 31,			Six months ended
	2018	2019	2020	June 30,
	<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>	2021
				<i>RMB'000</i>
At beginning of the year/period	629	11,723	20,660	28,793
Credited to income tax expense (Note 12)	11,094	8,937	8,133	3,763
Acquisition of a subsidiary (Note 30)	–	–	–	(785)
At end of the year/period	11,723	20,660	28,793	31,771

- (c) The gross movements in deferred income tax assets and deferred income tax liabilities during the Track Record Period are as follows:

- (i) Deferred income tax assets:

	Tax losses	Leases	Refund liabilities	Provision for impairment of assets	Intra-group unrealised profit or loss	Share-based compensation	Total
	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
As at January 1, 2018 (Unaudited)	2,371	–	675	88	9	–	3,143
Credited to profit or loss	5,714	3,475	282	281	152	–	9,904
As at December 31, 2018	<u>8,085</u>	<u>3,475</u>	<u>957</u>	<u>369</u>	<u>161</u>	<u>–</u>	<u>13,047</u>
Credited to profit or loss	3,452	4,426	299	6	137	–	8,320
As at December 31, 2019	<u>11,537</u>	<u>7,901</u>	<u>1,256</u>	<u>375</u>	<u>298</u>	<u>–</u>	<u>21,367</u>
Credited to profit or loss	387	6,036	639	119	102	541	7,824
As at December 31, 2020	<u>11,924</u>	<u>13,937</u>	<u>1,895</u>	<u>494</u>	<u>400</u>	<u>541</u>	<u>29,191</u>
(Debited)/credited to profit or loss	(393)	3,497	447	219	(44)	14	3,740
As at June 30, 2021	<u>11,531</u>	<u>17,434</u>	<u>2,342</u>	<u>713</u>	<u>356</u>	<u>555</u>	<u>32,931</u>

- (ii) Deferred income tax liabilities:

	Leases	Intangible assets	Total
	RMB'000	RMB'000	RMB'000
As at January 1, 2018 (Unaudited)	2,514	–	2,514
Credited to profit or loss	(1,190)	–	(1,190)
As at December 31, 2018	<u>1,324</u>	<u>–</u>	<u>1,324</u>
Credited to profit or loss	(617)	–	(617)
As at December 31, 2019	<u>707</u>	<u>–</u>	<u>707</u>
Credited to profit or loss	(309)	–	(309)
As at December 31, 2020	<u>398</u>	<u>–</u>	<u>398</u>
Credited to profit or loss	(23)	–	(23)
Acquisition of a subsidiary (Note 30)	–	785	785
As at June 30, 2021	<u>375</u>	<u>785</u>	<u>1,160</u>

28. CASH FLOW INFORMATION

(a) Cash generated from operations

Reconciliation of profit before income tax to cash generated from operations for the Track Record Period:

Note	Year ended December 31,			Six months ended June 30,	
	2018	2019	2020	2020	2021
	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
				(Unaudited)	
Profit before income tax	111,289	71,523	230,914	93,541	88,875
Adjustments for:					
Depreciation and amortisation	9	84,449	129,705	159,125	74,478
Share-based compensation	10	–	–	3,606	3,513
Losses on disposal of property, plant and equipment	8	5,704	1,849	3,984	3,597
Finance costs	11	17,808	26,728	36,288	16,007
Finance income	11	(139)	(210)	(941)	(218)
Fair value change of financial assets		(333)	–	(131)	–
Gains on disposal of subsidiaries	8	(2,400)	(1,100)	–	–
Listing expenses		–	–	3,827	–
Net impairment losses on financial assets		1,633	34	487	279
Change in working capital:					
– Inventories		(8,763)	(231)	(12,510)	(3,198)
– Trade and other receivables, prepayments and deposits		8,583	(7,562)	(45,835)	(34,694)
– Trade and other payables		(4,870)	11,808	65,420	34,635
– Contract liabilities		(131)	6,462	97,069	25,879
Cash generated from operations		212,830	239,006	541,303	213,819
					290,650

(b) Non-cash financing activities

	Year ended December 31,			Six months ended June 30,	
	2018	2019	2020	2020	2021
	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
				(Unaudited)	
Addition of right-of-use assets	167,778	190,381	436,853	228,747	129,692
Reduction in right-of-use assets and lease liabilities due to lease modification (Note 15(a)(i))	–	–	–	–	(86,075)

(c) Net debt reconciliation

	Note	As at December 31,			As at
		2018	2019	2020	June 30,
		RMB'000	RMB'000	RMB'000	2021
					RMB'000
Cash and cash equivalents	21	68,476	89,789	292,856	453,100
Borrowings	24	–	(44,827)	(25,870)	(214,395)
Lease liabilities	15	(400,313)	(508,040)	(829,930)	(802,360)
Net debt		<u>(331,837)</u>	<u>(463,078)</u>	<u>(562,944)</u>	<u>(563,655)</u>
Cash and cash equivalents	21	68,476	89,789	292,856	453,100
Gross debt		<u>(400,313)</u>	<u>(552,867)</u>	<u>(855,800)</u>	<u>(1,016,755)</u>
Net debt		<u>(331,837)</u>	<u>(463,078)</u>	<u>(562,944)</u>	<u>(563,655)</u>
Liabilities from financing activities					
		Leases	Borrowings	Cash and cash equivalents	Total
		RMB'000	RMB'000	RMB'000	RMB'000
Net debt as at January 1, 2018					
(Unaudited)		(284,429)	–	46,387	(238,042)
Cash flows		69,689	–	22,089	91,778
New leases		(167,778)	–	–	(167,778)
Termination of lease contracts		13	–	–	13
Finance costs recognised		(17,808)	–	–	(17,808)
Net debt as at December 31, 2018		<u>(400,313)</u>	<u>–</u>	<u>68,476</u>	<u>(331,837)</u>
Cash flows		99,367	(44,827)	21,313	75,853
New leases		(190,381)	–	–	(190,381)
Termination of lease contracts		8,740	–	–	8,740
Finance costs recognised		(25,453)	–	–	(25,453)
Net debt as at December 31, 2019		<u>(508,040)</u>	<u>(44,827)</u>	<u>89,789</u>	<u>(463,078)</u>
Cash flows		132,289	18,957	203,067	354,313
New leases		(436,853)	–	–	(436,853)
Termination of lease contracts		11,907	–	–	11,907
Finance costs recognised		(34,800)	–	–	(34,800)
Rental reduction or waived due to COVID-19		5,567	–	–	5,567
Net debt as at December 31, 2020		<u>(829,930)</u>	<u>(25,870)</u>	<u>292,856</u>	<u>(562,944)</u>
Cash flows		77,554	(186,815)	159,481	50,220
New leases		(129,692)	–	–	(129,692)
Termination of lease contracts		15,161	–	–	15,161
Lease modification		86,075	–	–	86,075
Finance costs recognised		(21,528)	–	–	(21,528)
Exchange (losses)/gains		–	(1,710)	763	(947)
Net debt as at June 30, 2021		<u>802,360</u>	<u>(214,395)</u>	<u>453,100</u>	<u>(563,655)</u>

29. COMMITMENTS**(a) Capital commitments**

Significant capital expenditure contracted for at the end of the reporting period but not recognised as liabilities is as follows:

	Year ended December 31,			As at
	2018	2019	2020	June 30, 2021
	RMB'000	RMB'000	RMB'000	RMB'000
Medical treatment and safety infrastructure and leasehold improvement	11,672	13,099	72,346	25,863
Property, plant and equipment	2	151	1,112	125
Intangible assets	470	–	–	–
	<u>12,144</u>	<u>13,250</u>	<u>73,458</u>	<u>25,988</u>

(b) Lease commitments

The Group's future aggregate minimum lease payments due under short-term leases (which are exempted from recognising the related right-of-use assets and lease liabilities) are as follows:

	As at December 31,			As at
	2018	2019	2020	June 30, 2021
	RMB'000	RMB'000	RMB'000	RMB'000
Within 1 year	<u>8,113</u>	<u>8,248</u>	<u>3,774</u>	<u>5,799</u>

30. BUSINESS COMBINATION**(a) Summary of acquisition**

On May 31, 2021, the Group acquired 100% equity interest in NU/Hart, a renowned Hong Kong hair transplant service provider, with RMB30,000,000 as cash consideration, from Zhuhai Xinsiyu Management Service Co., Ltd. ("Xinsiyu"), a wholly-owned by Zhuhai Siyu Industrial Development Company Limited, which is in turn owned by Shenzhen Zhongxiu Xinsheng Investment Center (Limited Partners), a limited partnership managed by Citron PE Holdings Limited ("CPE").

The goodwill of approximately RMB25 million arising from the acquisition is attributable to the synergy of business combination arising from the Mainland China and Hong Kong. None of the goodwill recognised is expected to be deductible for income tax purpose.

Details of the purchase consideration, the net assets acquired and goodwill are as follows:

Purchase consideration (refer to (b) below):	RMB'000
Cash paid	6,000
Consideration payables (i)	<u>24,000</u>
Total purchase consideration	<u>30,000</u>

- (i) According to the purchase agreement, the remaining consideration will be paid from the expiration of six months after the completion day May 31, 2021 and until the expiration of eighteen months after May 31, 2021.

The assets and liabilities recognised as a result of the acquisition are as follows:

	<i>RMB'000</i>
Cash and cash equivalents	2,198
Prepayments, deposits and other receivables	729
Inventories	25
Property, plant and equipment	262
Intangible assets	4,758
Trade and other payables	(2,120)
Contract liabilities	(224)
Deferred income tax liabilities	(785)
	<hr/>
Net identifiable assets acquired	4,843
	<hr/>
Goodwill	25,157
	<hr/>

(b) Purchase consideration – cash outflow

	<i>RMB'000</i>
Outflow of cash to acquire subsidiary, net of cash acquired	
Cash consideration	6,000
Less: Cash and cash equivalents	(2,198)
	<hr/>
Net outflow of cash – investing activities	3,802
	<hr/>

NU/Hart contributed revenue of approximately RMB0.75 million and net profit of RMB0.02 million to the Group for the period from the acquisition date to June 30, 2021. If the acquisition had occurred on 1 January 2021, consolidated pro-forma revenue and profit for the six months ended June 30, 2021 of the Group would have been approximately RMB1,060 million and RMB43 million, respectively.

31. RELATED PARTY TRANSACTIONS

Parties are considered to be related if one party has the ability, directly or indirectly, control the other party or exercise significant influence over the other party in making financial and operation decisions. Parties are also considered to be related if they are under common control or joint control in the controlling shareholder's families. Members of key management and their close family member of the Group are also considered as related parties.

Same as those disclosed elsewhere in these Historical Financial Information, the following significant transactions were carried out between the Group and its related parties during the Track Record Period. In the opinion of the directors of the Company, the related party transactions were carried out in the normal course of business and at terms negotiated between the Group and the respective related parties. The Group's pricing policies of the transactions with related parties are determined on the basis of mutual negotiations between the relevant parties.

(a) Names and relationships with related parties

Name of related parties	Relationship with the Company
Mr. Zhang Yu	Beneficial shareholder and director of the Company
Mr. Zhang Hui	Beneficial shareholder and director of the Company
Yonghe Yuhui	Former shareholder of Beijing Haiyouyou
Beijing Xunyi	Former shareholder of Beijing Haiyouyou
Panxin Shanghai	Former shareholder of Beijing Haiyouyou
Xinsiyu	A company indirectly owned by a limited partnership managed by CPE, which is the shareholder of the general partner of Paomao Shanghai

(b) Significant transactions with related parties

	Year ended December 31,			Six months ended June 30,	
	2018	2019	2020	2020	2021
	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
				(Unaudited)	
<i>Purchase of training services</i>					
Panxin Shanghai	133	–	–	–	–
	<u>133</u>	<u>–</u>	<u>–</u>	<u>–</u>	<u>–</u>
<i>Acquisition of a subsidiary</i>					
Xinsiyu	–	–	–	–	30,000
	<u>–</u>	<u>–</u>	<u>–</u>	<u>–</u>	<u>30,000</u>

(c) Year ended balances with related parties

	As at December 31,			As at June 30,
	2018	2019	2020	2021
	RMB'000	RMB'000	RMB'000	RMB'000
Amounts due from related parties – non-trade				
Yonghe Yuhui	–	74	97	–
Beijing Xunyi	36	36	36	–
	<u>36</u>	<u>110</u>	<u>133</u>	<u>–</u>
Amounts due to related parties – non-trade				
Mr. Zhang Hui	785	749	30	–
Mr. Zhang Yu	–	–	–	27
Xinsiyu	–	–	–	25,859
	<u>–</u>	<u>–</u>	<u>–</u>	<u>25,886</u>

Save for the outstanding balance with Xinsiyu in relation to the acquisition of Nu/Hart, which was non-trade in nature, the Group plan to settle the outstanding balances with other related parties, which were non-trade in nature, before the Listing. The outstanding balance with Xinsiyu is expected to be settled upon the Listing using proceeds from the Listing.

(d) Guarantees

	As at December 31,			As at June 30,
	2018	2019	2020	2021
	RMB'000	RMB'000	RMB'000	RMB'000
Bank borrowings guaranteed by Mr. Zhang Yu (Note 24)	–	44,827	25,870	–
	<u>–</u>	<u>44,827</u>	<u>25,870</u>	<u>–</u>

(e) Key management personnel compensation

Key management includes director and senior officers. The compensations paid or payable to key management for employee services are shown below:

	Year ended December 31,			Six months ended June 30,	
	2018	2019	2020	2020	2021
	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
				(Unaudited)	
Wages, salaries and bonuses	1,823	3,217	5,086	2,017	2,464
Pension costs – defined contribution plans	183	191	36	36	144
Other social security costs	116	139	140	42	89
Housing benefits	116	128	171	77	99
Share-based compensation	–	–	3,484	3,473	11
	2,238	3,675	8,917	5,645	2,807

32. BENEFITS AND INTERESTS OF DIRECTORS

As the date of the report, the following directors were appointed:

Executive Directors

Mr. Zhang Yu (*Note (a)(i)*)

Mr. Zhang Hui (*Note (a)(i)*)

Non-executive Directors

Mr. Zhai Feng (*Note (a)(ii)*)

Mr. Geng Jiaqi (*Note (a)(ii)*)

Independent Non-executive Directors

Mr. Li Xiaopei (*Note (a)(iii)*)

Mr. Chan Peng Kuan (*Note (a)(iii)*)

Ms. Wang Jiping (*Note (a)(iii)*)

(a) Directors' emoluments

The directors received emoluments from the Group (in their role as senior management and employee before their appointment as directors respectively) for the years ended December 31, 2018, 2019 and 2020 and the six months ended June 30, 2020 and 2021 were set out below:

	<i>Note</i>	Salaries	Discretionary bonuses	Social security costs, housing benefits and other employee benefits	Share-based compensation expenses	Total
		<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>
For the year ended December 31, 2018						
Executive Directors						
Mr. Zhang Yu	(i)	455	—	125	—	580
Mr. Zhang Hui	(i)	429	36	103	—	568
		884	36	228	—	1,148

				Social security costs, housing benefits and other employee benefits	Share-based compensation expenses	
	Note	Salaries	Discretionary bonuses			Total
		RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
For the year ended December 31, 2019						
Executive Directors						
Mr. Zhang Yu	(i)	900	—	123	—	1,023
Mr. Zhang Hui	(i)	422	226	98	—	746
		1,322	226	221	—	1,769
For the year ended December 31, 2020						
Executive Directors						
Mr. Zhang Yu	(i)	1,200	251	69	3,467	4,987
Mr. Zhang Hui	(i)	422	226	63	5	716
		1,622	477	132	3,472	5,703
For the six months ended June 30, 2020 (Unaudited)						
Executive Directors						
Mr. Zhang Yu	(i)	600	—	32	3,467	4,099
Mr. Zhang Hui	(i)	211	53	25	2	291
		811	53	57	3,469	4,390
For the six months ended June 30, 2021						
Executive Directors						
Mr. Zhang Yu	(i)	630	—	63	—	693
Mr. Zhang Hui	(i)	211	53	63	3	330
		841	53	126	3	1,023

- (i) Mr. Zhang Yu and Mr. Zhang Hui were appointed as the Group's directors on September 17, 2020 and re-designated as executive directors on June 1, 2021.
- (ii) Mr. Zhai Feng and Mr. Geng Jiaqi were appointed as the Group's directors on September 17, 2020 and re-designated as non-executive directors on June 1, 2021. The emoluments of the non-executive director Mr. Zhai Feng and Mr. Geng Jiaqi in relation to their services rendered for the Group for the Track Record Period were not borne by the Group. Their emoluments were not allocated to the Group as the management of the Company considers there is no reasonable basis of allocation.
- (iii) Ms. Wang Jiping, Mr. Chan Peng Kuan and Mr. Li Xiaopei were appointed as the Group's independent non-executive directors on June 1, 2021. During the years ended December 31, 2018, 2019 and 2020 and the six months ended June 30, 2020 and 2021, these independent non-executive directors did not receive any remuneration.

(b) Directors' retirement and termination benefits

No retirement or termination benefits have been paid to the Company's directors for the years ended December 31, 2018, 2019 and 2020 and the six months ended June 30, 2020 and 2021.

(c) Consideration provided to third parties for making available directors' services

No consideration was provided to third parties for making available directors' services during the years ended December 31, 2018, 2019 and 2020 and the six months ended June 30, 2020 and 2021.

(d) Information about loans, quasi-loans or other dealings in favor of directors, controlled bodies corporate by and connected entities with such directors

No loans, quasi-loans or other dealings were entered into by the Company in favor of directors, controlled bodies corporate by and connected entities with such directors during the years ended December 31, 2018, 2019 and 2020 and the six months ended June 30, 2020 and 2021.

(e) Directors' material interests in transactions, arrangements or contracts

No significant transactions, arrangements and contracts in relation to the Group's business to which the Group was a party and in which a director of the Company had a material interest, whether directly or indirectly, subsisted at the end of the years or at any time during the years ended December 31, 2018, 2019 and 2020 and the six months ended June 30, 2020 and 2021.

33. CONTINGENCIES

The Group has been involved in some lawsuits arising in the ordinary course of business. Provision has been made for the probable losses to the Group on those claims when the management can reasonably estimate the outcome of the lawsuits taking into account of the legal advice. No provision has been made for those pending lawsuits where the management considered that the outcome of the lawsuits cannot be reasonably estimated or management believes the outflow of resources is not probable.

34. DIVIDEND

No dividend has been paid or declared by the Company or the companies now comprising the Group during each of the years ended December 31, 2018, 2019 and 2020 and the six months ended June 30, 2021.

35. EVENTS OCCURRING AFTER THE REPORTING PERIOD

On November 12, 2021, the shareholders of the Company resolved to conduct a share split (the "Share Split") on a one-for-four basis, and the nominal value of the Shares will be changed from US\$0.00001 each to US\$0.0000025 each. Immediately after such Share Split, the issued share capital of the Company is 425,531,916 shares of US\$0.0000025 each.

On November 12, 2021, the Company declared a cash dividend of RMB70 million, being approximately RMB0.1645 per share (after the Share Split). The dividend has been paid on November 25, 2021.

III. SUBSEQUENT FINANCIAL STATEMENTS

No audited financial statements have been prepared by the Company or any of its subsidiaries in respect of any period subsequent to June 30, 2021 and up to the date of this report. Except for the dividend of RMB70 million declared on November 12, 2021, no other dividend or distribution has been declared or made by the Company or any of the companies now comprising the Group in respect of any period subsequent to June 30, 2021 and up to the date of this report.

The information set out in Appendix II does not form part of the “Accountant’s Report” from the reporting accountant, PricewaterhouseCoopers, Certified Public Accountants, Hong Kong, as set out in Appendix I, and is included herein for illustrative purposes only. The unaudited pro forma financial information should be read in conjunction with the section entitled “Financial Information” in this prospectus and the “Accountant’s Report” set out in Appendix I to this prospectus.

A. UNAUDITED PRO FORMA STATEMENT OF ADJUSTED NET TANGIBLE ASSETS

The following unaudited pro forma statement of adjusted net tangible assets of the Group prepared in accordance with Rule 4.29 of the Listing Rules is for illustrative purposes only, and is set out below to illustrate the effect of the Global Offering on the consolidated net tangible assets of the Group attributable to the owners of the Company as of June 30, 2021 as if the Global Offering had taken place on June 30, 2021, assuming the over-allotment is not exercised.

This unaudited pro forma statement of adjusted net tangible assets has been prepared for illustrative purposes only, and because of its hypothetical nature, it may not give a true picture of the consolidated net tangible assets of the Group had the Global Offering been completed as of June 30, 2021 or at any future dates.

	Unadjusted audited consolidated net tangible assets of the Group attributable to the owners of the Company as at June 30, 2021	Estimated net proceeds from the Global Offering	Unaudited pro forma adjusted consolidated net tangible assets attributable to the owners of the Company as at June 30, 2021	Unaudited pro forma adjusted consolidated net tangible assets per Share as at June 30, 2021	
	RMB'000 (Note 1)	RMB'000 (Note 2)	RMB'000	RMB (Note 3)	HK\$ (Note 4)
Based on an Offer Price of					
HK\$15.80 per Share	500,185	1,113,829	1,614,014	3.10	3.78

Notes:

- (1) The unadjusted audited consolidated net tangible assets of the Group attributable to owners of the Company as at June 30, 2021 is extracted from the Accountant’s Report as set out in Appendix I to this prospectus, which is based on the audited consolidated net assets of the Group attributable to owners of the Company as at June 30, 2021 of RMB534,333,000 with an adjustment for the intangible assets attributable to owners of the Company as at June 30, 2021 of RMB34,148,000.

- (2) The estimated net proceeds from the Global Offering are based on 94,424,000 Shares at the indicative Offer Price of HK\$15.80 per share, after deduction of the estimated underwriting fees and other related expenses payable by the Company and takes no account of any shares which may be issued upon the exercise of the Over-allotment Option.
- (3) The unaudited pro forma adjusted consolidated net tangible assets per Share is arrived at after the adjustments referred to in the preceding paragraphs and on the basis that 519,955,916 Shares were in issue immediately upon completion of the Share Split and the Global Offering, which is assumed to be on June 30, 2021 for the purpose of the pro forma financial information, and takes no account of any Shares which may be issued upon exercise of the Over-allotment Option.
- (4) For the purpose of this unaudited pro forma adjusted net tangible assets, the amounts stated in Renminbi are converted into Hong Kong dollars at the rate of HK\$1.00 to RMB0.8210. No representation is made that Renminbi has been, could have been or may be converted to Hong Kong dollars, or vice versa, at that rate.
- (5) No adjustment has been made to reflect any trading result or other transactions of the Group entered into subsequent to June 30, 2021.
- (6) The unaudited pro forma adjusted consolidated net tangible assets of the Group have not taken into account the cash dividend of RMB70,000,000 approved by the Board and Shareholders on November 12, 2021. The unaudited pro forma adjusted consolidated net tangible assets per Share would have been HK\$3.62 (equivalent to RMB2.97) per Share based on the indicative Offer Price of HK\$15.80 after taking into account the declaration and payment of the cash dividend.

B. REPORT FROM THE REPORTING ACCOUNTANT ON THE UNAUDITED PRO FORMA FINANCIAL INFORMATION

The following is the text of a report received from PricewaterhouseCoopers, Certified Public Accountants, Hong Kong, for the purpose of incorporation in this prospectus.



羅兵咸永道

INDEPENDENT REPORTING ACCOUNTANT'S ASSURANCE REPORT ON THE COMPILATION OF UNAUDITED PRO FORMA FINANCIAL INFORMATION

To the Directors of Yonghe Medical Group Co., Ltd.

We have completed our assurance engagement to report on the compilation of unaudited pro forma financial information of Yonghe Medical Group Co., Ltd. (the "Company") and its subsidiaries (collectively the "Group") by the directors of the Company (the "Directors") for illustrative purposes only. The unaudited pro forma financial information consists of the unaudited pro forma statement of adjusted net tangible assets of the Group as at June 30, 2021, and related notes (the "Unaudited Pro Forma Financial Information") as set out on pages II-1 to II-2 of the Company's prospectus dated December 1, 2021, in connection with the proposed initial public offering of the shares of the Company (the "Prospectus"). The applicable criteria on the basis of which the Directors have compiled the Unaudited Pro Forma Financial Information are described on pages II-1 to II-2 of the Prospectus.

The Unaudited Pro Forma Financial Information has been compiled by the Directors to illustrate the impact of the proposed initial public offering on the Group's financial position as at June 30, 2021 as if the proposed initial public offering had taken place at June 30, 2021. As part of this process, information about the Group's financial position has been extracted by the Directors from the Group's financial information for the six months ended June 30, 2021, on which an accountant's report has been published.

Directors' Responsibility for the Unaudited Pro Forma Financial Information

The Directors are responsible for compiling the Unaudited Pro Forma Financial Information in accordance with paragraph 4.29 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules") and with reference to Accounting Guideline 7, *Preparation of Pro Forma Financial Information for Inclusion in Investment Circulars* ("AG 7") issued by the Hong Kong Institute of Certified Public Accountants ("HKICPA").

PricewaterhouseCoopers, 22/F Prince's Building, Central, Hong Kong
T: +852 2289 8888, F: +852 2810 9888, www.pwchk.com

Our Independence and Quality Control

We have complied with the independence and other ethical requirements of the Code of Ethics for Professional Accountants issued by the HKICPA, which is founded on fundamental principles of integrity, objectivity, professional competence and due care, confidentiality and professional behaviour.

Our firm applies Hong Kong Standard on Quality Control 1 issued by the HKICPA and accordingly maintains a comprehensive system of quality control including documented policies and procedures regarding compliance with ethical requirements, professional standards and applicable legal and regulatory requirements.

Reporting Accountant's Responsibilities

Our responsibility is to express an opinion, as required by paragraph 4.29(7) of the Listing Rules, on the Unaudited Pro Forma Financial Information and to report our opinion to you. We do not accept any responsibility for any reports previously given by us on any financial information used in the compilation of the Unaudited Pro Forma Financial Information beyond that owed to those to whom those reports were addressed by us at the dates of their issue.

We conducted our engagement in accordance with Hong Kong Standard on Assurance Engagements 3420, *Assurance Engagements to Report on the Compilation of Pro Forma Financial Information Included in a Prospectus*, issued by the HKICPA. This standard requires that the reporting accountant plans and performs procedures to obtain reasonable assurance about whether the Directors have compiled the Unaudited Pro Forma Financial Information in accordance with paragraph 4.29 of the Listing Rules and with reference to AG 7 issued by the HKICPA.

For purposes of this engagement, we are not responsible for updating or reissuing any reports or opinions on any historical financial information used in compiling the Unaudited Pro Forma Financial Information, nor have we, in the course of this engagement, performed an audit or review of the financial information used in compiling the Unaudited Pro Forma Financial Information.

The purpose of unaudited pro forma financial information included in a prospectus is solely to illustrate the impact of a significant event or transaction on unadjusted financial information of the entity as if the event had occurred or the transaction had been undertaken at an earlier date selected for purposes of the illustration. Accordingly, we do not provide any assurance that the actual outcome of the proposed initial public offering at June 30, 2021 would have been as presented.

A reasonable assurance engagement to report on whether the unaudited pro forma financial information has been properly compiled on the basis of the applicable criteria involves performing procedures to assess whether the applicable criteria used by the directors in the compilation of the unaudited pro forma financial information provide a reasonable basis for presenting the significant effects directly attributable to the event or transaction, and to obtain sufficient appropriate evidence about whether:

- The related pro forma adjustments give appropriate effect to those criteria; and
- The unaudited pro forma financial information reflects the proper application of those adjustments to the unadjusted financial information.

The procedures selected depend on the reporting accountant's judgment, having regard to the reporting accountant's understanding of the nature of the company, the event or transaction in respect of which the unaudited pro forma financial information has been compiled, and other relevant engagement circumstances.

The engagement also involves evaluating the overall presentation of the unaudited pro forma financial information.

We believe that the evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Our work has not been carried out in accordance with auditing standards or other standards and practices generally accepted in the United States of America or auditing standards of the Public Company Accounting Oversight Board (United States) or standards and practices of any professional body in any other overseas jurisdiction and accordingly should not be relied upon as if it had been carried out in accordance with those standards and practices.

Opinion

In our opinion:

- (a) the Unaudited Pro Forma Financial Information has been properly compiled by the Directors on the basis stated;
- (b) such basis is consistent with the accounting policies of the Group; and
- (c) the adjustments are appropriate for the purposes of the Unaudited Pro Forma Financial Information as disclosed pursuant to paragraph 4.29(1) of the Listing Rules.

PricewaterhouseCoopers
Certified Public Accountants
Hong Kong
December 1, 2021

SUMMARY OF THE CONSTITUTION OF THE COMPANY

1 Memorandum of Association

The Memorandum of Association of the Company was conditionally adopted on November 24, 2021 and states, inter alia, that the liability of the members of the Company is limited, that the objects for which the Company is established are unrestricted and the Company shall have full power and authority to carry out any object not prohibited by the Cayman Companies Act or any other law of the Cayman Islands.

The Memorandum of Association is available on display at the address specified in Appendix V in the section headed “Documents Delivered to the Registrar of Companies and Available on Display”.

2 Articles of Association

The Articles of Association of the Company were conditionally adopted on November 24, 2021 and include provisions to the following effect:

2.1 *Classes of Shares*

The share capital of the Company consists of ordinary shares. The authorized share capital of the Company at the date of adoption of the Articles is US\$50,000.00 divided into 20,000,000,000 shares of US\$0.0000025 each.

2.2 *Directors*

(a) Power to allot and issue Shares

Subject to the provisions of the Cayman Companies Act and the Memorandum and Articles of Association, the unissued shares in the Company (whether forming part of its original or any increased capital) shall be at the disposal of the Directors, who may offer, allot, grant options over or otherwise dispose of them to such persons, at such times and for such consideration, and upon such terms, as the Directors shall determine.

Subject to the provisions of the Articles of Association and to any direction that may be given by the Company in general meeting and without prejudice to any special rights conferred on the holders of any existing shares or attaching to any class of shares, any share may be issued with or have attached thereto such preferred, deferred, qualified or other special rights or restrictions, whether in regard to dividend, voting, return of capital or otherwise, and to such persons at such times and for such consideration as the Directors may determine. Subject to the Cayman Companies Act and to any special rights conferred on any shareholders or attaching to any class of shares, any share may, with the sanction of a special resolution, be issued on terms that it is, or at the option of the Company or the holder thereof, liable to be redeemed.

(b) Power to dispose of the assets of the Company or any subsidiary

The management of the business of the Company shall be vested in the Directors who, in addition to the powers and authorities by the Articles of Association expressly conferred

upon them, may exercise all such powers and do all such acts and things as may be exercised or done or approved by the Company and are not by the Articles of Association or the Cayman Companies Act expressly directed or required to be exercised or done by the Company in general meeting, but subject nevertheless to the provisions of the Cayman Companies Act and of the Articles of Association and to any regulation from time to time made by the Company in general meeting not being inconsistent with such provisions or the Articles of Association, provided that no regulation so made shall invalidate any prior act of the Directors which would have been valid if such regulation had not been made.

(c) Compensation or payment for loss of office

Payment to any Director or past Director of any sum by way of compensation for loss of office or as consideration for or in connection with his retirement from office (not being a payment to which the Director is contractually entitled) must first be approved by the Company in general meeting.

(d) Loans to Directors

There are provisions in the Articles of Association prohibiting the making of loans to Directors or their respective close associates which are equivalent to the restrictions imposed by the Companies Ordinance.

(e) Financial assistance to purchase Shares

Subject to all applicable laws, the Company may give financial assistance to Directors and employees of the Company, its subsidiaries or any holding company or any subsidiary of such holding company in order that they may buy shares in the Company or any such subsidiary or holding company. Further, subject to all applicable laws, the Company may give financial assistance to a trustee for the acquisition of shares in the Company or shares in any such subsidiary or holding company to be held for the benefit of employees of the Company, its subsidiaries, any holding company of the Company or any subsidiary of any such holding company (including salaried Directors).

(f) Disclosure of interest in contracts with the Company or any of its subsidiaries

No Director or proposed Director shall be disqualified by his office from contracting with the Company either as vendor, purchaser or otherwise nor shall any such contract or any contract or arrangement entered into by or on behalf of the Company with any person, company or partnership of or in which any Director shall be a member or otherwise interested be capable on that account of being avoided, nor shall any Director so contracting or being any member or so interested be liable to account to the Company for any profit so realized by any such contract or arrangement by reason only of such Director holding that office or the fiduciary relationship thereby established, provided that such Director shall, if his interest in such contract or arrangement is material, declare the nature of his interest at the earliest meeting of the board of Directors at which it is practicable for him to do so, either specifically or by way of a general notice stating that, by reason of the facts specified in the notice, he is to be regarded as interested in any contracts of a specified description which may be made by the Company.

A Director shall not be entitled to vote on (nor shall be counted in the quorum in relation to) any resolution of the Directors in respect of any contract or arrangement or any other proposal in which the Director or any of his close associates (or, if required by the Listing Rules, his other associates) has any material interest, and if he shall do so his vote shall not be counted (nor is he to be counted in the quorum for the resolution), but this prohibition shall not apply to any of the following matters, namely:

- (i) the giving to such Director or any of his close associates of any security or indemnity in respect of money lent or obligations incurred or undertaken by him or any of them at the request of or for the benefit of the Company or any of its subsidiaries;
- (ii) the giving of any security or indemnity to a third party in respect of a debt or obligation of the Company or any of its subsidiaries for which the Director or any of his close associates has himself/themselves assumed responsibility in whole or in part and whether alone or jointly under a guarantee or indemnity or by the giving of security;
- (iii) any proposal concerning an offer of shares, debentures or other securities of or by the Company or any other company which the Company may promote or be interested in for subscription or purchase where the Director or any of his close associates is/are or is/are to be interested as a participant in the underwriting or sub-underwriting of the offer;
- (iv) any proposal or arrangement concerning the benefit of employees of the Company or any of its subsidiaries including:
 - (A) the adoption, modification or operation of any employees' share scheme or any share incentive scheme or share option scheme under which the Director or any of his close associates may benefit; or
 - (B) the adoption, modification or operation of a pension or provident fund or retirement, death or disability benefits scheme which relates both to Directors, their close associates and employees of the Company or any of its subsidiaries and does not provide in respect of any Director or any of his close associates, as such any privilege or advantage not generally accorded to the class of persons to which such scheme or fund relates; and
- (v) any contract or arrangement in which the Director or any of his close associates is/are interested in the same manner as other holders of shares or debentures or other securities of the Company by virtue only of his/their interest in shares or debentures or other securities of the Company.

(g) Remuneration

The Directors shall be entitled to receive by way of remuneration for their services such sum as shall from time to time be determined by the Directors, or the Company in general meeting, as the case may be, such sum (unless otherwise directed by the resolution by which it is determined) to be divided amongst the Directors in such proportions and in such manner as they may agree, or failing agreement, equally, except that in such event any Director holding office for less than the whole of the relevant period in respect of which the remuneration is paid shall only rank in such division in proportion to the time during such period for which he has held office. Such remuneration shall be in addition to any other remuneration to which a Director who holds any salaried employment or office in the Company may be entitled by reason of such employment or office.

The Directors shall also be entitled to be paid all expenses, including travel expenses, reasonably incurred by them in or in connection with the performance of their duties as Directors including their expenses of traveling to and from board meetings, committee meetings or general meetings or otherwise incurred whilst engaged on the business of the Company or in the discharge of their duties as Directors.

The Directors may grant special remuneration to any Director who shall perform any special or extra services at the request of the Company. Such special remuneration may be made payable to such Director in addition to or in substitution for his ordinary remuneration as a Director, and may be made payable by way of salary, commission or participation in profits or otherwise as may be agreed.

The remuneration of an executive Director or a Director appointed to any other office in the management of the Company shall from time to time be fixed by the Directors and may be by way of salary, commission or participation in profits or otherwise or by all or any of those modes and with such other benefits (including share option and/or pension and/or gratuity and/or other benefits on retirement) and allowances as the Directors may from time to time decide. Such remuneration shall be in addition to such remuneration as the recipient may be entitled to receive as a Director.

(h) Retirement, appointment and removal

The number of Directors shall not be less than two.

The Directors shall have power at any time and from time to time to appoint any person to be a Director, either to fill a casual vacancy or as an addition to the existing Directors. Any Director so appointed shall hold office only until the next general meeting of the Company and shall then be eligible for re-election at that meeting.

The Company may by ordinary resolution remove any Director (including a Managing Director or other executive Director) before the expiration of his period of office notwithstanding anything in the Articles of Association or in any agreement between the Company and such Director (but without prejudice to any claim for compensation or

damages payable to him in respect of the termination of his appointment as Director or of any other appointment of office as a result of the termination of this appointment as Director).

The Company may by ordinary resolution appoint another person in his place. Any Director so appointed shall hold office during such time only as the Director in whose place he is appointed would have held the same if he had not been removed. The Company may also by ordinary resolution elect any person to be a Director, either to fill a casual vacancy or as an addition to the existing Directors. Any Director so appointed shall hold office only until the next following general meeting of the Company and shall then be eligible for re-election but shall not be taken into account in determining the number of Directors and which Directors who are to retire by rotation at such meeting.

No person shall, unless recommended by the Board, be eligible for election to the office of Director at any general meeting unless, during the period, which shall be at least seven days, commencing no earlier than the day after the dispatch of the notice of the meeting appointed for such election and ending no later than seven days prior to the date of such meeting, there has been given to the Secretary of the Company notice in writing by a member of the Company (not being the person to be proposed) entitled to attend and vote at the meeting for which such notice is given of his intention to propose such person for election and also notice in writing signed by the person to be proposed of his willingness to be elected.

There is no shareholding qualification for Directors nor is there any specified age limit for Directors. The office of a Director shall be vacated:

- (i) if he resigns his office by notice in writing to the Company at its registered office or its principal office in Hong Kong;
- (ii) if an order is made by any competent court or official on the grounds that he is or may be suffering from mental disorder or is otherwise incapable of managing his affairs and the Directors resolve that his office be vacated;
- (iii) if, without leave, he is absent from meetings of the Directors (unless an alternate Director appointed by him attends) for 12 consecutive months, and the Directors resolve that his office be vacated;
- (iv) if he becomes bankrupt or has a receiving order made against him or suspends payment or compounds with his creditors generally;
- (v) if he ceases to be or is prohibited from being a Director by law or by virtue of any provision in the Articles of Association;
- (vi) if he is removed from office by a notice in writing served upon him signed by not less than three-fourths in number (or, if that is not a round number, the nearest lower round number) of the Directors (including himself) for the time being then in office; or

- (vii) if he shall be removed from office by an ordinary resolution of the members of the Company under the Articles of Association.

At every annual general meeting of the Company one-third of the Directors for the time being, or, if their number is not three or a multiple of three, then the number nearest to, but not less than, one-third, shall retire from office by rotation, provided that every Director (including those appointed for a specific term) shall be subject to retirement by rotation at least once every three years. A retiring Director shall retain office until the close of the meeting at which he retires and shall be eligible for re-election thereat. The Company at any annual general meeting at which any Directors retire may fill the vacated office by electing a like number of persons to be Directors.

(i) Borrowing powers

The Directors may from time to time at their discretion exercise all the powers of the Company to raise or borrow or to secure the payment of any sum or sums of money for the purposes of the Company and to mortgage or charge its undertaking, property and assets (present and future) and uncalled capital or any part thereof.

(j) Proceedings of the Board

The Directors may meet together for the dispatch of business, adjourn and otherwise regulate their meetings and proceedings as they think fit in any part of the world. Questions arising at any meeting shall be determined by a majority of votes. In the case of an equality of votes, the chairman of the meeting shall have a second or casting vote.

2.3 *Alteration to constitutional documents*

No alteration or amendment to the Memorandum or Articles of Association may be made except by special resolution.

2.4 *Variation of rights of existing shares or classes of shares*

If at any time the share capital of the Company is divided into different classes of shares, all or any of the rights attached to any class of shares for the time being issued (unless otherwise provided for in the terms of issue of the shares of that class) may, subject to the provisions of the Cayman Companies Act, be varied or abrogated either with the consent in writing of the holders of not less than three-fourths in nominal value of the issued shares of that class or with the sanction of a special resolution passed at a separate meeting of the holders of the shares of that class. To every such separate meeting all the provisions of the Articles of Association relating to general meetings shall mutatis mutandis apply, but so that the quorum for the purposes of any such separate meeting and of any adjournment thereof shall be a person or persons together holding (or representing by proxy or duly authorized representative) at the date of the relevant meeting not less than one-third in nominal value of the issued shares of that class.

The special rights conferred upon the holders of shares of any class shall not, unless otherwise expressly provided in the rights attaching to or the terms of issue of such shares, be deemed to be varied by the creation or issue of further shares ranking *pari passu* therewith.

2.5 *Alteration of capital*

The Company may, from time to time, whether or not all the shares for the time being authorized shall have been issued and whether or not all the shares for the time being issued shall have been fully paid up, by ordinary resolution, increase its share capital by the creation of new shares, such new capital to be of such amount and to be divided into shares of such respective amounts as the resolution shall prescribe.

The Company may from time to time by ordinary resolution:

- (a) consolidate and divide all or any of its share capital into shares of a larger amount than its existing shares. On any consolidation of fully paid shares and division into shares of larger amount, the Directors may settle any difficulty which may arise as they think expedient and in particular (but without prejudice to the generality of the foregoing) may as between the holders of shares to be consolidated determine which particular shares are to be consolidated into each consolidated share, and if it shall happen that any person shall become entitled to fractions of a consolidated share or shares, such fractions may be sold by some person appointed by the Directors for that purpose and the person so appointed may transfer the shares so sold to the purchaser thereof and the validity of such transfer shall not be questioned, and so that the net proceeds of such sale (after deduction of the expenses of such sale) may either be distributed among the persons who would otherwise be entitled to a fraction or fractions of a consolidated share or shares ratably in accordance with their rights and interests or may be paid to the Company for the Company's benefit;
- (b) cancel any shares which at the date of the passing of the resolution have not been taken or agreed to be taken by any person, and diminish the amount of its share capital by the amount of the shares so canceled subject to the provisions of the Cayman Companies Act; and
- (c) sub-divide its shares or any of them into shares of smaller amount than is fixed by the Memorandum of Association, subject nevertheless to the provisions of the Cayman Companies Act, and so that the resolution whereby any share is sub-divided may determine that, as between the holders of the shares resulting from such sub-division, one or more of the shares may have any such preferred or other special rights, over, or may have such deferred rights or be subject to any such restrictions as compared with the others as the Company has power to attach to unissued or new shares.

The Company may by special resolution reduce its share capital or any capital redemption reserve in any manner authorized and subject to any conditions prescribed by the Cayman Companies Act.

2.6 *Special resolution — majority required*

A “special resolution” is defined in the Articles of Association to have the meaning ascribed thereto in the Cayman Companies Act, for which purpose, the requisite majority shall be not less than three-fourths of the votes of such members of the Company as, being entitled to do so, vote in person or, where proxies are allowed, by proxy or, in the case of corporations, by their duly authorized representatives, at a general meeting of which notice specifying the intention to propose the resolution as a special resolution has been duly given and includes a special resolution signed by all members for the time being entitled to receive notice of and to attend and vote at general meetings (or being corporations by their duly appointed representatives), and any such resolution shall be deemed to have been passed at a meeting held on the date on which it was signed by the last member to sign.

In contrast, an “ordinary resolution” is defined in the Articles of Association to mean a resolution passed by a simple majority of the votes of such members of the Company as, being entitled to do so, vote in person or, where proxies are allowed, by proxy or, in the case of corporations, by their duly authorized representatives, at a general meeting held in accordance with the Articles of Association and includes an ordinary resolution approved in writing by all the members of the Company aforesaid.

2.7 *Voting rights*

Subject to any special rights, privileges or restrictions as to voting for the time being attached to any class or classes of shares, at any general meeting on a poll every member present in person (or, in the case of a member being a corporation, by its duly authorized representative) or by proxy shall have one vote for each share registered in his name in the register of members of the Company.

Where any member is, under the Listing Rules, required to abstain from voting on any particular resolution or restricted to voting only for or only against any particular resolution, any votes cast by or on behalf of such member in contravention of such requirement or restriction shall not be counted.

In the case of joint registered holders of any share, any one of such persons may vote at any meeting, either personally or by proxy, in respect of such share as if he were solely entitled thereto; but if more than one of such joint holders be present at any meeting personally or by proxy, that one of the said persons so present being the most or, as the case may be, the more senior shall alone be entitled to vote in respect of the relevant joint holding and, for this purpose, seniority shall be determined by reference to the order in which the names of the joint holders stand on the register in respect of the relevant joint holding.

A member of the Company in respect of whom an order has been made by any competent court or official on the grounds that he is or may be suffering from mental disorder or is otherwise incapable of managing his affairs may vote by any person authorized in such circumstances to do so and such person may vote by proxy.

Save as expressly provided in the Articles of Association or as otherwise determined by the Directors, no person other than a member of the Company duly registered and who shall have paid all sums for the time being due from him payable to the Company in respect of his shares shall be entitled to be present or to vote (save as proxy for another member of the Company), or to be reckoned in a quorum, either personally or by proxy at any general meeting.

At any general meeting a resolution put to the vote of the meeting shall be decided by way of a poll save that the chairman of the meeting may allow a resolution which relates purely to a procedural or administrative matter as prescribed under the Listing Rules to be voted on by a show of hands.

If a recognized clearing house (or its nominee(s)) is a member of the Company it may authorize such person or persons as it thinks fit to act as its proxy(ies) or representative(s) at any general meeting of the Company or at any general meeting of any class of members of the Company provided that, if more than one person is so authorized, the authorization shall specify the number and class of shares in respect of which each such person is so authorized. A person authorized pursuant to this provision shall be entitled to exercise the same rights and powers on behalf of the recognized clearing house (or its nominee(s)) which he represents as that recognized clearing house (or its nominee(s)) could exercise as if it were an individual member of the Company holding the number and class of shares specified in such authorization, including, where a show of hands is allowed, the right to vote individually on a show of hands.

2.8 Annual general meetings and extraordinary general meetings

The Company shall hold a general meeting as its annual general meeting each year, within a period of not more than 15 months after the holding of the last preceding annual general meeting (or such longer period as the Stock Exchange may authorize). The annual general meeting shall be specified as such in the notices calling it.

Extraordinary general meetings may be convened on the requisition of two or more shareholders (or any one member which is a recognized clearing house (or its nominee(s)) holding, at the date of deposit of the requisition, not less than one-tenth of the paid up capital of the Company having the right of voting at general meetings.

2.9 Accounts and audit

The Directors shall cause to be kept such books of account as are necessary to give a true and fair view of the state of the Company's affairs and to show and explain its transactions and otherwise in accordance with the Cayman Companies Act.

The Directors shall from time to time determine whether, and to what extent, and at what times and places and under what conditions or regulations, the accounts and books of the Company, or any of them, shall be open to the inspection by members of the Company (other than officers of the Company) and no such member shall have any right of inspecting any accounts or books or documents of the Company except as conferred by the Cayman Companies Act or any other relevant law or regulation or as authorized by the Directors or by the Company in general meeting.

The Directors shall, commencing with the first annual general meeting, cause to be prepared and to be laid before the members of the Company at every annual general meeting a profit and loss account for the period, in the case of the first account, since the incorporation of the Company and, in any other case, since the preceding account, together with a statement of financial position as at the date to which the profit and loss account is made up and a Director's report with respect to the profit or loss of the Company for the period covered by the profit and loss account and the state of the Company's affairs at the end of such period, an auditor's report on such accounts and such other reports and accounts as may be required by law. Copies of those documents to be laid before the members of the Company at an annual general meeting shall not less than 21 days before the date of the meeting, be sent in the manner in which notices may be served by the Company as provided in the Articles of Association to every member of the Company and every holder of debentures of the Company provided that the Company shall not be required to send copies of those documents to any person of whose address the Company is not aware or to more than one of the joint holders of any shares or debentures.

The Company shall at every annual general meeting appoint an auditor or auditors of the Company who shall hold office until the next annual general meeting. The removal of an auditor before the expiration of his period of office shall require the approval of an ordinary resolution of the members in general meeting. The remuneration of the auditors shall be fixed by the Company at the annual general meeting at which they are appointed provided that in respect of any particular year the Company in general meeting may delegate the fixing of such remuneration to the Directors.

2.10 Notice of meetings and business to be conducted thereat

An annual general meeting shall be called by not less than 21 days' notice in writing and any extraordinary general meeting shall be called by not less than 14 days' notice in writing. The notice shall be exclusive of the day on which it is served or deemed to be served and of the day for which it is given, and shall specify the time, place and agenda of the meeting, particulars of the resolutions and the general nature of the business to be considered at the meeting. The notice convening an annual general meeting shall specify the meeting as such, and the notice convening a meeting to pass a special resolution shall specify the intention to propose the resolution as a special resolution. Notice of every general meeting shall be given to the auditors and all members of the Company (other than those who, under the provisions of the Articles of Association or the terms of issue of the shares they hold, are not entitled to receive such notice from the Company).

Notwithstanding that a meeting of the Company is called by shorter notice than that mentioned above, it shall be deemed to have been duly called if it is so agreed:

- (a) in the case of a meeting called as an annual general meeting, by all members of the Company entitled to attend and vote thereat or their proxies; and
- (b) in the case of any other meeting, by a majority in number of the members having a right to attend and vote at the meeting, being a majority together holding not less than 95% in nominal value of the shares giving that right.

2.11 Transfer of shares

Transfers of shares may be effected by an instrument of transfer in the usual common form or in such other form as the Directors may approve which is consistent with the standard form of transfer as prescribed by the Stock Exchange.

The instrument of transfer shall be executed by or on behalf of the transferor and, unless the Directors otherwise determine, the transferee, and the transferor shall be deemed to remain the holder of the share until the name of the transferee is entered in the register of members of the Company in respect thereof. All instruments of transfer shall be retained by the Company.

The Directors may, in its absolute discretion, and without assigning any reason, refuse to register any transfer of any share which is not fully paid up or on which the Company has a lien. The Directors may also decline to register any transfer of any shares unless:

- (a) the instrument of transfer is lodged with the Company accompanied by the certificate for the shares to which it relates (which shall upon the registration of the transfer be canceled) and such other evidence as the Directors may reasonably require to show the right of the transferor to make the transfer;
- (b) the instrument of transfer is in respect of only one class of shares;
- (c) the instrument of transfer is properly stamped (in circumstances where stamping is required);
- (d) in the case of a transfer to joint holders, the number of joint holders to whom the share is to be transferred does not exceed four;
- (e) the shares concerned are free of any lien in favor of the Company; and
- (f) a fee of such amount not exceeding the maximum amount as the Stock Exchange may from time to time determine to be payable (or such lesser sum as the Directors may from time to time require) is paid to the Company in respect thereof.

If the Directors refuse to register a transfer of any share they shall, within two months after the date on which the transfer was lodged with the Company, send to each of the transferor and the transferee notice of such refusal.

The registration of transfers may, on 10 business days' notice (or on 6 business days' notice in the case of a rights issue) being given by advertisement published on the Stock Exchange's website, or, subject to the Listing Rules, by electronic communication in the manner in which notices may be served by the Company by electronic means as provided in the Articles of Association or by advertisement published in the newspapers, be suspended and the register of members of the Company closed at such times for such periods as the Directors may from time to time determine, provided that the registration of transfers shall not be suspended or the register

closed for more than 30 days in any year (or such longer period as the members of the Company may by ordinary resolution determine provided that such period shall not be extended beyond 60 days in any year).

2.12 Power of the Company to purchase its own shares

The Company is empowered by the Cayman Companies Act and the Articles of Association to purchase its own shares subject to certain restrictions and the Directors may only exercise this power on behalf of the Company subject to the authority of its members in general meeting as to the manner in which they do so and to any applicable requirements imposed from time to time by the Stock Exchange and the Securities and Futures Commission of Hong Kong. Shares which have been repurchased will be treated as canceled upon the repurchase. The holder of the shares being purchased shall be bound to deliver up to the Company at its principal place of business in Hong Kong or such other place as the Directors shall specify the certificate(s) thereof, if any, for cancellation and thereupon the Company shall pay to him the purchase or redemption monies in respect thereof.

2.13 Power of any subsidiary of the Company to own shares

There are no provisions in the Articles of Association relating to the ownership of shares by a subsidiary.

2.14 Dividends and other methods of distribution

Subject to the Cayman Companies Act and the Articles of Association, the Company in general meeting may declare dividends in any currency but no dividends shall exceed the amount recommended by the Directors. No dividend may be declared or paid other than out of profits and reserves of the Company lawfully available for distribution, including share premium.

Unless and to the extent that the rights attached to any shares or the terms of issue thereof otherwise provide, all dividends shall (as regards any shares not fully paid throughout the period in respect of which the dividend is paid) be apportioned and paid pro rata according to the amounts paid up on the shares during any portion or portions of the period in respect of which the dividend is paid. For these purposes no amount paid up on a share in advance of calls shall be treated as paid up on the share.

The Directors may from time to time pay to the members of the Company such interim dividends as appear to the Directors to be justified by the profits of the Company. The Directors may also pay half-yearly or at other intervals to be selected by them any dividend which may be at a fixed rate if they are of the opinion that the profits available for distribution justify the payment.

The Directors may retain any dividends or other monies payable on or in respect of a share upon which the Company has a lien, and may apply the same in or towards satisfaction of the debts, liabilities or engagements in respect of which the lien exists. The Directors may also deduct from any dividend or other monies payable to any member of the Company all sums of money (if any) presently payable by him to the Company on account of calls, installments or otherwise.

No dividend shall carry interest against the Company.

Whenever the Directors or the Company in general meeting have resolved that a dividend be paid or declared on the share capital of the Company, the Directors may further resolve: (a) that such dividend be satisfied wholly or in part in the form of an allotment of shares credited as fully paid up on the basis that the shares so allotted are to be of the same class as the class already held by the allottee, provided that the members of the Company entitled thereto will be entitled to elect to receive such dividend (or part thereof) in cash in lieu of such allotment; or (b) that the members of the Company entitled to such dividend will be entitled to elect to receive an allotment of shares credited as fully paid up in lieu of the whole or such part of the dividend as the Directors may think fit on the basis that the shares so allotted are to be of the same class as the class already held by the allottee. The Company may upon the recommendation of the Directors by ordinary resolution resolve in respect of any one particular dividend of the Company that notwithstanding the foregoing a dividend may be satisfied wholly in the form of an allotment of shares credited as fully paid without offering any right to members of the Company to elect to receive such dividend in cash in lieu of such allotment.

Any dividend, interest or other sum payable in cash to a holder of shares may be paid by cheque or warrant sent through the post addressed to the registered address of the member of the Company entitled, or in the case of joint holders, to the registered address of the person whose name stands first in the register of members of the Company in respect of the joint holding or to such person and to such address as the holder or joint holders may in writing direct. Every cheque or warrant so sent shall be made payable to the order of the holder or, in the case of joint holders, to the order of the holder whose name stands first on the register of members of the Company in respect of such shares, and shall be sent at his or their risk and the payment of any such cheque or warrant by the bank on which it is drawn shall operate as a good discharge to the Company in respect of the dividend and/or bonus represented thereby, notwithstanding that it may subsequently appear that the same has been stolen or that any endorsement thereon has been forged. The Company may cease sending such cheques for dividend entitlements or dividend warrants by post if such cheques or warrants have been left uncashed on two consecutive occasions. However, the Company may exercise its power to cease sending cheques for dividend entitlements or dividend warrants after the first occasion on which such a cheque or warrant is returned undelivered. Any one of two or more joint holders may give effectual receipts for any dividends or other monies payable or property distributable in respect of the shares held by such joint holders.

Any dividend unclaimed for six years from the date of declaration of such dividend may be forfeited by the Directors and shall revert to the Company.

Whenever the Directors or the Company in general meeting have resolved that a dividend may be paid or declared, the Directors may further resolve that such dividend be satisfied wholly or in part by the distribution of specific assets of any kind, and in particular of paid up shares, debentures or warrants to subscribe securities of any other company, and where any difficulty arises in regard to such distribution the Directors may settle it as they think expedient, and in particular may disregard fractional entitlements, round the same up or down or provide that the same shall accrue to the benefit of the Company, and may fix the value for distribution of such specific assets and may determine that cash payments shall be made to any members of the Company upon the footing of the value so fixed in order to adjust the rights of all parties, and may vest any such specific assets in trustees as may seem expedient to the Directors.

2.15 Proxies

Any member of the Company entitled to attend and vote at a meeting of the Company shall be entitled to appoint another person who must be an individual as his proxy to attend and vote instead of him and a proxy so appointed shall have the same right as the member to speak at the meeting. A proxy need not be a member of the Company.

Instruments of proxy shall be in common form or in such other form as the Directors may from time to time approve provided that it shall enable a member to instruct his proxy to vote in favor of or against (or in default of instructions or in the event of conflicting instructions, to exercise his discretion in respect of) each resolution to be proposed at the meeting to which the form of proxy relates. The instrument of proxy shall be deemed to confer authority to vote on any amendment of a resolution put to the meeting for which it is given as the proxy thinks fit. The instrument of proxy shall, unless the contrary is stated therein, be valid as well for any adjournment of the meeting as for the meeting to which it relates provided that the meeting was originally held within 12 months from such date.

The instrument appointing a proxy shall be in writing under the hand of the appointor or his attorney authorized in writing or if the appointor is a corporation either under its seal or under the hand of an officer, attorney or other person authorized to sign the same.

The instrument appointing a proxy and (if required by the Directors) the power of attorney or other authority (if any) under which it is signed, or a notarially certified copy of such power or authority, shall be delivered at the registered office of the Company (or at such other place as may be specified in the notice convening the meeting or in any notice of any adjournment or, in either case, in any document sent therewith) not less than 48 hours before the time appointed for holding the meeting or adjourned meeting at which the person named in the instrument proposes to vote or, in the case of a poll taken subsequently to the date of a meeting or adjourned meeting, not less than 48 hours before the time appointed for the taking of the poll and in default the instrument of proxy shall not be treated as valid. No instrument appointing a proxy shall be valid after the expiration of 12 months from the date named in it as the date of its execution. Delivery of any instrument appointing a proxy shall not preclude a member of the Company from attending and voting in person at the meeting or poll concerned and, in such event, the instrument appointing a proxy shall be deemed to be revoked.

2.16 Calls on shares and forfeiture of shares

The Directors may from time to time make calls upon the members of the Company in respect of any monies unpaid on their shares (whether on account of the nominal amount of the shares or by way of premium or otherwise) and not by the conditions of allotment thereof made payable at fixed times and each member of the Company shall (subject to the Company serving upon him at least 14 days' notice specifying the time and place of payment and to whom such payment shall be made) pay to the person at the time and place so specified the amount called on his shares. A call may be revoked or postponed as the Directors may determine. A person upon whom a call is made shall remain liable on such call notwithstanding the subsequent transfer of the shares in respect of which the call was made.

A call may be made payable either in one sum or by installments and shall be deemed to have been made at the time when the resolution of the Directors authorizing the call was passed. The joint holders of a share shall be jointly and severally liable to pay all calls and installments due in respect of such share or other monies due in respect thereof.

If a sum called in respect of a share shall not be paid before or on the day appointed for payment thereof, the person from whom the sum is due shall pay interest on the sum from the day appointed for payment thereof to the time of actual payment at such rate, not exceeding 15% per annum, as the Directors may determine, but the Directors shall be at liberty to waive payment of such interest wholly or in part.

If any call or installment of a call remains unpaid on any share after the day appointed for payment thereof, the Directors may at any time during such time as any part thereof remains unpaid serve a notice on the holder of such shares requiring payment of so much of the call or installment as is unpaid together with any interest which may be accrued and which may still accrue up to the date of actual payment.

The notice shall name a further day (not being less than 14 days from the date of service of the notice) on or before which, and the place where, the payment required by the notice is to be made, and shall state that in the event of non-payment at or before the time and at the place appointed, the shares in respect of which such call was made or installment is unpaid will be liable to be forfeited.

If the requirements of such notice are not complied with, any share in respect of which such notice has been given may at any time thereafter, before payment of all calls or installments and interest due in respect thereof has been made, be forfeited by a resolution of the Directors to that effect. Such forfeiture shall include all dividends and bonuses declared in respect of the forfeited shares and not actually paid before the forfeiture. A forfeited share shall be deemed to be the property of the Company and may be re-allotted, sold or otherwise disposed of.

A person whose shares have been forfeited shall cease to be a member of the Company in respect of the forfeited shares but shall, notwithstanding the forfeiture, remain liable to pay to the Company all monies which at the date of forfeiture were payable by him to the Company in respect of the shares, together with (if the Directors shall in their discretion so require) interest thereon at such rate not exceeding 15% per annum as the Directors may prescribe from the date of forfeiture until payment, and the Directors may enforce payment thereof without being under any obligation to make any allowance for the value of the shares forfeited, at the date of forfeiture.

2.17 Inspection of register of members

The register of members of the Company shall be kept in such manner as to show at all times the members of the Company for the time being and the shares respectively held by them. The register may, on 10 business days' notice (or on 6 business days' notice in the case of a rights issue) being given by advertisement published on the Stock Exchange's website, or, subject to the Listing Rules, by electronic communication in the manner in which notices may be served by the Company by electronic means as provided in the Articles of Association or by advertisement published in the newspapers, be closed at such times and for such periods as the Directors may from time to time

determine either generally or in respect of any class of shares, provided that the register shall not be closed for more than 30 days in any year (or such longer period as the members of the Company may by ordinary resolution determine provided that such period shall not be extended beyond 60 days in any year).

Any register of members kept in Hong Kong shall during normal business hours (subject to such reasonable restrictions as the Directors may impose) be open to inspection by any member of the Company without charge and by any other person on payment of a fee of such amount not exceeding the maximum amount as may from time to time be permitted under the Listing Rules as the Directors may determine for each inspection.

2.18 Quorum for meetings and separate class meetings

No business shall be transacted at any general meeting unless a quorum is present when the meeting proceeds to business, but the absence of a quorum shall not preclude the appointment of a chairman which shall not be treated as part of the business of the meeting.

Two members of the Company present in person or by proxy shall be a quorum provided always that if the Company has only one member of record the quorum shall be that one member present in person or by proxy.

A corporation being a member of the Company shall be deemed for the purpose of the Articles of Association to be present in person if represented by its duly authorized representative being the person appointed by resolution of the directors or other governing body of such corporation or by power of attorney to act as its representative at the relevant general meeting of the Company or at any relevant general meeting of any class of members of the Company.

The quorum for a separate general meeting of the holders of a separate class of shares of the Company is described in paragraph 2.4 above.

2.19 Rights of minorities in relation to fraud or oppression

There are no provisions in the Articles of Association concerning the rights of minority shareholders in relation to fraud or oppression.

2.20 Procedure on liquidation

If the Company shall be wound up, and the assets available for distribution amongst the members of the Company as such shall be insufficient to repay the whole of the paid-up capital, such assets shall be distributed so that, as nearly as may be, the losses shall be borne by the members of the Company in proportion to the capital paid up, or which ought to have been paid up, at the commencement of the winding up on the shares held by them respectively. If in a winding up the assets available for distribution amongst the members of the Company shall be more than sufficient to repay the whole of the capital paid up at the commencement of the winding up, the excess shall be distributed amongst the members of the Company in proportion to the capital paid up at the commencement of the winding up on the shares held by them respectively. The foregoing is without prejudice to the rights of the holders of shares issued upon special terms and conditions.

If the Company shall be wound up, the liquidator may with the sanction of a special resolution of the Company and any other sanction required by the Cayman Companies Act, divide amongst the members of the Company in specie or kind the whole or any part of the assets of the Company (whether they shall consist of property of the same kind or not) and may, for such purpose, set such value as he deems fair upon any property to be divided as aforesaid and may determine how such division shall be carried out as between the members or different classes of members of the Company. The liquidator may, with the like sanction, vest the whole or any part of such assets in trustees upon such trusts for the benefit of the members of the Company as the liquidator, with the like sanction and subject to the Cayman Companies Act, shall think fit, but so that no member of the Company shall be compelled to accept any assets, shares or other securities in respect of which there is a liability.

2.21 *Untraceable members*

The Company shall be entitled to sell any shares of a member of the Company or the shares to which a person is entitled by virtue of transmission on death or bankruptcy or operation of law if: (a) all cheques or warrants, not being less than three in number, for any sums payable in cash to the holder of such shares have remained uncashed for a period of 12 years; (b) the Company has not during that time or before the expiry of the three month period referred to in (d) below received any indication of the whereabouts or existence of the member; (c) during the 12 year period, at least three dividends in respect of the shares in question have become payable and no dividend during that period has been claimed by the member; and (d) upon expiry of the 12 year period, the Company has caused an advertisement to be published in the newspapers or subject to the Listing Rules, by electronic communication in the manner in which notices may be served by the Company by electronic means as provided in the Articles of Association, giving notice of its intention to sell such shares and a period of three months has elapsed since such advertisement and the Stock Exchange has been notified of such intention. The net proceeds of any such sale shall belong to the Company and upon receipt by the Company of such net proceeds it shall become indebted to the former member for an amount equal to such net proceeds.

SUMMARY OF CAYMAN ISLANDS COMPANY LAW AND TAXATION

1 Introduction

The Cayman Companies Act is derived, to a large extent, from the older Companies Acts of England, although there are significant differences between the Cayman Companies Act and the current Companies Act of England. Set out below is a summary of certain provisions of the Cayman Companies Act, although this does not purport to contain all applicable qualifications and exceptions or to be a complete review of all matters of corporate law and taxation which may differ from equivalent provisions in jurisdictions with which interested parties may be more familiar.

2 Incorporation

The Company was incorporated in the Cayman Islands as an exempted company with limited liability on 17 September 2020 under the Cayman Companies Act. As such, its operations must be conducted mainly outside the Cayman Islands. The Company is required to file an annual return each year with the Registrar of Companies of the Cayman Islands and pay a fee which is based on the size of its authorized share capital.

3 Share Capital

The Cayman Companies Act permits a company to issue ordinary shares, preference shares, redeemable shares or any combination thereof.

The Cayman Companies Act provides that where a company issues shares at a premium, whether for cash or otherwise, a sum equal to the aggregate amount of the value of the premia on those shares shall be transferred to an account called the “share premium account”. At the option of a company, these provisions may not apply to premia on shares of that company allotted pursuant to any arrangement in consideration of the acquisition or cancelation of shares in any other company and issued at a premium. The Cayman Companies Act provides that the share premium account may be applied by a company, subject to the provisions, if any, of its memorandum and articles of association, in such manner as the company may from time to time determine including, but without limitation:

- (a) paying distributions or dividends to members;
- (b) paying up unissued shares of the company to be issued to members as fully paid bonus shares;
- (c) in the redemption and repurchase of shares (subject to the provisions of section 37 of the Cayman Companies Act);
- (d) writing-off the preliminary expenses of the company;
- (e) writing-off the expenses of, or the commission paid or discount allowed on, any issue of shares or debentures of the company; and
- (f) providing for the premium payable on redemption or purchase of any shares or debentures of the company.

No distribution or dividend may be paid to members out of the share premium account unless immediately following the date on which the distribution or dividend is proposed to be paid the company will be able to pay its debts as they fall due in the ordinary course of business.

The Cayman Companies Act provides that, subject to confirmation by the Grand Court of the Cayman Islands, a company limited by shares or a company limited by guarantee and having a share capital may, if so authorized by its articles of association, by special resolution reduce its share capital in any way.

Subject to the detailed provisions of the Cayman Companies Act, a company limited by shares or a company limited by guarantee and having a share capital may, if so authorized by its articles of association, issue shares which are to be redeemed or are liable to be redeemed at the option of the company or a shareholder. In addition, such a company may, if authorized to do so by its articles of association, purchase its own shares, including any redeemable shares. The manner of such a purchase must be authorized either by the articles of association or by an ordinary resolution of the company. The articles of association may provide that the manner of purchase may be determined by the directors of the

company. At no time may a company redeem or purchase its shares unless they are fully paid. A company may not redeem or purchase any of its shares if, as a result of the redemption or purchase, there would no longer be any member of the company holding shares. A payment out of capital by a company for the redemption or purchase of its own shares is not lawful unless immediately following the date on which the payment is proposed to be made, the company shall be able to pay its debts as they fall due in the ordinary course of business.

There is no statutory restriction in the Cayman Islands on the provision of financial assistance by a company for the purchase of, or subscription for, its own or its holding company's shares. Accordingly, a company may provide financial assistance if the directors of the company consider, in discharging their duties of care and to act in good faith, for a proper purpose and in the interests of the company, that such assistance can properly be given. Such assistance should be on an arm's-length basis.

4 Dividends and Distributions

With the exception of section 34 of the Cayman Companies Act, there are no statutory provisions relating to the payment of dividends. Based upon English case law which is likely to be persuasive in the Cayman Islands in this area, dividends may be paid only out of profits. In addition, section 34 of the Cayman Companies Act permits, subject to a solvency test and the provisions, if any, of the company's memorandum and articles of association, the payment of dividends and distributions out of the share premium account (see paragraph 3 above for details).

5 Shareholders' Suits

The Cayman Islands courts can be expected to follow English case law precedents. The rule in *Foss v. Harbottle* (and the exceptions thereto which permit a minority shareholder to commence a class action against or derivative actions in the name of the company to challenge (a) an act which is ultra vires the company or illegal, (b) an act which constitutes a fraud against the minority where the wrongdoers are themselves in control of the company, and (c) an action which requires a resolution with a qualified (or special) majority which has not been obtained) has been applied and followed by the courts in the Cayman Islands.

6 Protection of Minorities

In the case of a company (not being a bank) having a share capital divided into shares, the Grand Court of the Cayman Islands may, on the application of members holding not less than one-fifth of the shares of the company in issue, appoint an inspector to examine into the affairs of the company and to report thereon in such manner as the Grand Court shall direct.

Any shareholder of a company may petition the Grand Court of the Cayman Islands which may make a winding up order if the court is of the opinion that it is just and equitable that the company should be wound up.

Claims against a company by its shareholders must, as a general rule, be based on the general laws of contract or tort applicable in the Cayman Islands or their individual rights as shareholders as established by the company's memorandum and articles of association.

The English common law rule that the majority will not be permitted to commit a fraud on the minority has been applied and followed by the courts of the Cayman Islands.

7 Disposal of Assets

The Cayman Companies Act contains no specific restrictions on the powers of directors to dispose of assets of a company. As a matter of general law, in the exercise of those powers, the directors must discharge their duties of care and to act in good faith, for a proper purpose and in the interests of the company.

8 Accounting and Auditing Requirements

The Cayman Companies Act requires that a company shall cause to be kept proper books of account with respect to:

- (a) all sums of money received and expended by the company and the matters in respect of which the receipt and expenditure takes place;
- (b) all sales and purchases of goods by the company; and
- (c) the assets and liabilities of the company.

Proper books of account shall not be deemed to be kept if there are not kept such books as are necessary to give a true and fair view of the state of the company's affairs and to explain its transactions.

9 Register of Members

An exempted company may, subject to the provisions of its articles of association, maintain its principal register of members and any branch registers at such locations, whether within or without the Cayman Islands, as its directors may from time to time think fit. There is no requirement under the Cayman Companies Act for an exempted company to make any returns of members to the Registrar of Companies of the Cayman Islands. The names and addresses of the members are, accordingly, not a matter of public record and are not available for public inspection.

10 Inspection of Books and Records

Members of a company will have no general right under the Cayman Companies Act to inspect or obtain copies of the register of members or corporate records of the company. They will, however, have such rights as may be set out in the company's articles of association.

11 Special Resolutions

The Cayman Companies Act provides that a resolution is a special resolution when it has been passed by a majority of at least two-thirds of such members as, being entitled to do so, vote in person or, where proxies are allowed, by proxy at a general meeting of which notice specifying the intention to propose the resolution as a special resolution has been duly given, except that a company may in its articles of association specify that the required majority shall be a number greater than two-thirds, and may additionally so provide that such majority (being not less than two-thirds) may differ as between matters required to be approved by a special resolution. Written resolutions signed by all the members entitled to vote for the time being of the company may take effect as special resolutions if this is authorized by the articles of association of the company.

12 Subsidiary Owning Shares in Parent

The Cayman Companies Act does not prohibit a Cayman Islands company acquiring and holding shares in its parent company provided its objects so permit. The directors of any subsidiary making such acquisition must discharge their duties of care and to act in good faith, for a proper purpose and in the interests of the subsidiary.

13 Mergers and Consolidations

The Cayman Companies Act permits mergers and consolidations between Cayman Islands companies and between Cayman Islands companies and non-Cayman Islands companies. For these purposes, (a) “merger” means the merging of two or more constituent companies and the vesting of their undertaking, property and liabilities in one of such companies as the surviving company, and (b) “consolidation” means the combination of two or more constituent companies into a consolidated company and the vesting of the undertaking, property and liabilities of such companies to the consolidated company. In order to effect such a merger or consolidation, the directors of each constituent company must approve a written plan of merger or consolidation, which must then be authorized by (a) a special resolution of each constituent company and (b) such other authorization, if any, as may be specified in such constituent company’s articles of association. The written plan of merger or consolidation must be filed with the Registrar of Companies of the Cayman Islands together with a declaration as to the solvency of the consolidated or surviving company, a list of the assets and liabilities of each constituent company and an undertaking that a copy of the certificate of merger or consolidation will be given to the members and creditors of each constituent company and that notification of the merger or consolidation will be published in the Cayman Islands Gazette. Dissenting shareholders have the right to be paid the fair value of their shares (which, if not agreed between the parties, will be determined by the Cayman Islands court) if they follow the required procedures, subject to certain exceptions. Court approval is not required for a merger or consolidation which is effected in compliance with these statutory procedures.

14 Reconstructions

There are statutory provisions which facilitate reconstructions and amalgamations approved by a majority in number representing 75% in value of shareholders or creditors, depending on the circumstances, as are present at a meeting called for such purpose and thereafter sanctioned by the Grand Court of the Cayman Islands. Whilst a dissenting shareholder would have the right to express to the Grand Court his view that the transaction for which approval is sought would not provide the shareholders with a fair value for their shares, the Grand Court is unlikely to disapprove the transaction on that ground alone in the absence of evidence of fraud or bad faith on behalf of management and if the transaction were approved and consummated the dissenting shareholder would have no rights comparable to the appraisal rights (i.e. the right to receive payment in cash for the judicially determined value of his shares) ordinarily available, for example, to dissenting shareholders of United States corporations.

15 Take-overs

Where an offer is made by a company for the shares of another company and, within four months of the offer, the holders of not less than 90% of the shares which are the subject of the offer accept, the offeror may at any time within two months after the expiration of the said four months, by notice require the dissenting shareholders to transfer their shares on the terms of the offer. A dissenting shareholder may apply to the Grand Court of the Cayman Islands within one month of the notice objecting to the transfer. The burden is on the dissenting shareholder to show that the Grand Court should exercise its discretion, which it will be unlikely to do unless there is evidence of fraud or bad faith or collusion as between the offeror and the holders of the shares who have accepted the offer as a means of unfairly forcing out minority shareholders.

16 Indemnification

Cayman Islands law does not limit the extent to which a company's articles of association may provide for indemnification of officers and directors, except to the extent any such provision may be held by the Cayman Islands courts to be contrary to public policy (e.g. for purporting to provide indemnification against the consequences of committing a crime).

17 Liquidation

A company may be placed in liquidation compulsorily by an order of the court, or voluntarily (a) by a special resolution of its members if the company is solvent, or (b) by an ordinary resolution of its members if the company is insolvent. The liquidator's duties are to collect the assets of the company (including the amount (if any) due from the contributories (shareholders)), settle the list of creditors and discharge the company's liability to them, ratably if insufficient assets exist to discharge the liabilities in full, and to settle the list of contributories and divide the surplus assets (if any) amongst them in accordance with the rights attaching to the shares.

18 Stamp Duty on Transfers

No stamp duty is payable in the Cayman Islands on transfers of shares of Cayman Islands companies except those which hold interests in land in the Cayman Islands.

19 Taxation

Pursuant to section 6 of the Tax Concessions Act (2018 Revision) of the Cayman Islands, the Company may obtain an undertaking from the Financial Secretary of the Cayman Islands:

- (a) that no law which is enacted in the Cayman Islands imposing any tax to be levied on profits, income, gains or appreciations shall apply to the Company or its operations; and
- (b) in addition, that no tax to be levied on profits, income, gains or appreciations or which is in the nature of estate duty or inheritance tax shall be payable:
 - (i) on or in respect of the shares, debentures or other obligations of the Company; or

- (ii) by way of the withholding in whole or in part of any relevant payment as defined in section 6(3) of the Tax Concessions Act (2018 Revision).

The Cayman Islands currently levy no taxes on individuals or corporations based upon profits, income, gains or appreciations and there is no taxation in the nature of inheritance tax or estate duty. There are no other taxes likely to be material to the Company levied by the Government of the Cayman Islands save certain stamp duties which may be applicable, from time to time, on certain instruments executed in or brought within the jurisdiction of the Cayman Islands. The Cayman Islands are not party to any double tax treaties that are applicable to any payments made by or to the Company.

20 Exchange Control

There are no exchange control regulations or currency restrictions in the Cayman Islands.

21 Economic Substance Requirements

Pursuant to the International Tax Cooperation (Economic Substance) Act, 2018 (“**ES Law**”) that came into force on 1 January 2019, a “relevant entity” is required to satisfy the economic substance test set out in the ES Law. A “relevant entity” includes an exempted company incorporated in the Cayman Islands as is the Company; however, it does not include an entity that is tax resident outside the Cayman Islands. Accordingly, if an exempted company incorporated in the Cayman Islands is tax resident outside the Cayman Islands, it will not be required to satisfy the economic substance test set out in the ES Law.

22 General

Campbells, the Company’s legal advisers on Cayman Islands law, have sent to the Company a letter of advice summarizing aspects of Cayman Islands company law. This letter, together with a copy of the Cayman Companies Act, is available on display as referred to in the section headed “Documents Delivered to the Registrar of Companies and Available on Display” in Appendix V. Any person wishing to have a detailed summary of Cayman Islands company law or advice on the differences between it and the laws of any jurisdiction with which he/she is more familiar is recommended to seek independent legal advice.

A. FURTHER INFORMATION ABOUT OUR GROUP**1. Incorporation of Our Company**

We were incorporated in the Cayman Islands on September 17, 2020 under the Companies Act as an exempted company with limited liability. Accordingly, our corporate structure and Articles of Association are subject to the relevant laws of the Cayman Islands. A summary of certain aspects of the Cayman Islands company law and a summary of certain provisions of our Articles of Associations are set out in the section headed “Summary of the Constitution of the Company and Cayman Islands Company Law” in Appendix III to this prospectus.

Our registered place of business in Hong Kong is at Level 54, Hopewell Centre, 183 Queen’s Road East, Hong Kong. We were registered as a non-Hong Kong Company under Part 16 of the Companies Ordinance on May 11, 2021. Ms. Kam Mei Ha Wendy (甘美霞) and Ms. Leung Ching Ching (梁晶晶) of Level 54, Hopewell Centre, 183 Queen’s Road East, Hong Kong have been appointed as our authorized representatives for the acceptance of service of process and notices in Hong Kong.

2. Changes in the Share Capital of Our Company

As of the date of incorporation of our Company, our Company was authorized to issue 5,000,000,000 Shares of US\$0.00001 each. On November 12, 2021, the shareholders of the Company resolved to conduct share split on a one-for-four basis, and the nominal value of the Shares changed from US\$0.00001 each to US\$0.0000025 each. Immediately after such share split, the authorized share capital of the Company is 20,000,000,000 Shares of US\$0.0000025 each.

The following sets out the changes in the share capital of our Company during the two years immediately preceding the date of this prospectus:

On September 17, 2020, Sertus Nominees (Cayman) Limited transferred the one share of our Company to ZhangYu Hair Service Holdings Limited at par value.

On February 1, 2021, Hu & Yan Healthcare Investment Limited transferred 5,350,000 shares to Ever Horizon Developments Limited for nil consideration.

On April 22, 2021, ZhangYu Hair Service Holdings Limited transferred 34,000,000 shares to ZY Investment Capital Ltd.

On April 22, 2021, ZhangHui Hair Service Holdings Limited transferred 6,000,000 shares to ZH Investment Capital Ltd.

On April 23, 2021, NieLei Hair Service Holdings Limited transferred 90,834 shares to Yunuo Technology Holdings Limited for a consideration of RMB1,261,268.

On April 23, 2021, NieLei Hair Service Holdings Limited transferred 54,500 shares to Zhirui Technology Holdings Limited for a consideration of RMB756,756.

On April 23, 2021, JiaQi Hair Service Holdings Limited transferred 15,833 shares to Yunuo Technology Holdings Limited for a consideration of RMB219,848.

On April 23, 2021, JiaQi Hair Service Holdings Limited transferred 9,500 shares to Zhirui Technology Holdings Limited for a consideration of RMB131,911.

On April 23, 2021, SiQi Hair Service Holdings Limited transferred 15,833 shares to Yunuo Technology Holdings Limited for a consideration of RMB219,848.

On April 23, 2021, SiQi Hair Service Holdings Limited transferred 9,500 shares to Zhirui Technology Holdings Limited for a consideration of RMB131,911.

On April 23, 2021, TanXu Hair Service Holdings Limited transferred 7,500 shares to Yunuo Technology Holdings Limited for a consideration of RMB104,141.

On April 23, 2021, TanXu Hair Service Holdings Limited transferred 4,500 shares to Zhirui Technology Holdings Limited for a consideration of RMB62,484.

On April 23, 2021, LinFeng Hair Service Holdings Limited transferred 7,500 shares to Yunuo Technology Holdings Limited for a consideration of RMB104,141.

On April 23, 2021, LinFeng Hair Service Holdings Limited transferred 4,500 shares to Zhirui Technology Holdings Limited for a consideration of RMB62,484.

On April 23, 2021, Yonghe Hair Service Holdings Limited transferred 2,208,333 shares to Yunuo Technology Holdings Limited for a consideration of RMB30,663,624.

On April 23, 2021, Yonghe Hair Service Holdings Limited transferred 1,325,000 shares to Zhirui Technology Holdings Limited for a consideration of RMB18,398,177.

On April 23, 2021, CYH Cosmetic Medical Holdings Limited transferred 2,208,333 shares to Yunuo Technology Holdings Limited for a consideration of RMB30,663,624.

On April 23, 2021, CYH Cosmetic Medical Holdings Limited transferred 1,325,000 shares to Zhirui Technology Holdings Limited for a consideration of RMB18,398,177.

On April 23, 2021, Ever Horizon Developments Limited transferred 445,834 shares to Yunuo Technology Holdings Limited for a consideration of RMB6,190,591.

On April 23, 2021, Ever Horizon Developments Limited transferred 267,500 shares to Zhirui Technology Holdings Limited for a consideration of RMB3,714,350.

The following table sets out the details of all the issuance of our Shares taken place within two years immediately preceding the date of this prospectus:

Date of Shares issuance	Name of Shareholders	Number of Shares	Consideration Paid
September 17, 2020	Sertus Nominees (Cayman) Limited	1	par value
September 17, 2020	ZhangYu Hair Service Holdings Limited	33,999,999	par value
September 17, 2020	ZhangHui Hair Service Holdings Limited	6,000,000	par value
September 17, 2020	NieLei Hair Service Holdings Limited	1,090,000	par value
September 17, 2020	JiaQi Hair Service Holdings Limited	190,000	par value
September 17, 2020	SiQi Hair Service Holdings Limited	190,000	par value
September 17, 2020	TanXu Hair Service Holdings Limited	90,000	par value
September 17, 2020	LinFeng Hair Service Holdings Limited	90,000	par value
January 29, 2021	Yonghe Hair Service Holdings Limited	26,500,000	RMB70,235,414.5
January 29, 2021	CYH Cosmetic Medical Holdings Limited	26,500,000	Equity interests in Beijing Haiyouyou through share exchange
January 29, 2021	Hu & Yan Healthcare Investment Limited	5,350,000	Equity interests in Beijing Haiyouyou through share exchange
April 26, 2021	ZY Investment Capital Ltd	6,382,979	RMB88,630,000

Immediately following completion of the Global Offering (without taking into account any Share which may be issued upon any exercise of the Over-allotment Option, our issued share capital will be US\$1,299.88979 divided into 519,955,916 Shares, all fully paid or credited as fully paid.

Save as disclosed above, there has been no alteration in our share capital within the two years immediately preceding the date of this prospectus.

3. Changes in the Share Capital of Our Subsidiary

The list of our major subsidiaries is set out under the financial statements in the Accountant's Report as included in Appendix I to this Prospectus. The following alteration in the share capital of our subsidiary has taken place within the two years immediately preceding the date of this prospectus:

Beijing Haiyouyou

In June, 2020, Beijing Haiyouyou passed a shareholders' resolution for Tianjin Yonghe Yuhui to transfer 5.349% equity interests in Beijing Haiyouyou to Hu & Yan Healthcare Investment Limited for a consideration of RMB31,625,000.

On May 10, 2021, Beijing Haiyouyou passed a shareholders' resolution for Beijing Xunyi, CYH, Panmao Shanghai, Hu&Yan and Tianjin Yonghe Yuhui to transfer 40%, 26.5%, 26.5%, 5.349% and 1.651% equity interests in Beijing Haiyouyou, respectively, to Yonghe Medical for the consideration of RMB106,015,720 or equivalent, RMB70,235,414.5 or equivalent USD, 26,500,000 Shares of our Company, 5,350,000 Shares of our Company and RMB4,375,798.8 or equivalent USD, respectively.

Yonghe Investment

On November 27, 2020, Yonghe Investment passed a shareholders' resolution to increase its registered capital from RMB10,000,000 to RMB14,285,714.3. The increase of RMB4,285,714.3 is contributed by Beijing Xunyi.

Beijing Maoduoduo

On October 22, 2020, Beijing Maoduoduo passed a shareholders' resolution for Yonghe Investment to transfer 100% equity interests in Beijing Maoduoduo to Beijing Yunyihui for a consideration of RMB5 million.

Beijing Yunmao

On November 3, 2020, Beijing Yunmao passed a shareholders' resolution for Yonghe Investment to transfer 100% equity interests in Beijing Yunmao to Yonghe Research Laboratory for a consideration of RMB5 million.

Yonghe Research Laboratory

On December 7, 2020, Yonghe Research Laboratory passed a shareholders' resolution for Yonghe Investment to transfer 100% equity interests in Yonghe Research Laboratory to Beijing Haiyouyou for a consideration of RMB500,000.

Jinan Yongxin Medical Technology Company Limited

On March 17, 2021, Jinan Yongxin Medical Technology Company Limited passed a shareholders' resolution for Yonghe Investment to transfer 100% equity interests in Jinan Yongxin to Yonghe Research Laboratory for nil consideration.

Chengdu Yonghe

On November 17, 2020, Chengdu Yonghe passed a shareholders' resolution for Yonghe Investment to transfer 100% equity interests Chengdu Yonghe to Beijing Haiyouyou for a consideration of RMB500,000.

On January 5, 2021, Chengdu Yonghe passed a shareholders' resolution to increase its registered capital from RMB500,000 to RMB555,556. The increase of RMB55,556 is contributed by Beijing Xunyi.

Save as disclosed above, there has been no alteration in the share capital of our subsidiaries within the two years immediately preceding the date of this prospectus.

4. Resolutions of the Shareholders of the Company Passed on November 24, 2021

Pursuant to the resolutions passed at a duly convened general meeting of our Shareholders on November 24, 2021, it was resolved, among others:

- (a) the Memorandum and Articles of Association were approved and adopted, and will come into effect upon Listing;
- (b) conditional on (1) the Listing Committee granting the listing of, and permission to deal in, the Shares in issue and to be issued as mentioned in this prospectus; and (2) the obligations of the Underwriters under the Underwriting Agreements becoming unconditional and the Underwriting Agreements not being terminated in accordance with the terms therein or otherwise:
 - (i) the Global Offering and the Over-allotment Option were approved and our Directors were authorized to effect the same, and to allot and issue the Offer Shares pursuant to the Global Offering and the Over-allotment Option;
 - (ii) the grant of the Over-allotment Option by our Company to the International Underwriters to allot and issue up to 15% of the Offer Shares initially available under the Global Offering to cover, among other things, the over-allocations in the International Offering was approved; and
 - (iii) the proposed Listing was approved, and our Directors were authorized to implement such Listing.
- (c) a general unconditional mandate was granted to our Directors to allot, issue and deal with Shares, and to make or grant offers, agreements, or options which might require such Shares to be allotted and issued or dealt with at any time subject to the requirement that the aggregate nominal value of the Shares so allotted and issued or agreed conditionally or unconditionally to be allotted and issued, shall not exceed 20% of the aggregate nominal value of the share capital of our Company in issue immediately following completion of the Global Offering.

This mandate does not cover Shares to be allotted, issued, or dealt with under a rights issue or scrip dividend scheme or similar arrangements, or a specific authority granted by our Shareholders or upon the exercise of the Over-allotment Option. This general mandate to issue Shares will remain in effect until:

- (i) the conclusion of the next annual general meeting of our Company;
- (ii) the expiration of the period within which the next annual general meeting of our Company is required to be held under the applicable laws or the Articles of Association; or
- (iii) it is varied or revoked by an ordinary resolution of our Shareholders at a general meeting of our Company;

whichever is the earliest;

- (d) a general unconditional mandate was granted to our Directors to exercise all powers of our Company to repurchase Shares with an aggregate nominal value of not more than 10% of the aggregate nominal value of the share capital of our Company in issue immediately following completion of the Global Offering (excluding Shares which may be allotted and issued upon the exercise of the Over-allotment Option).

This mandate only relates to repurchase made on the Stock Exchange or on any other stock exchange on which the Shares may be listed (and which is recognized by the SFC and the Stock Exchange for this purpose) and made in accordance with all applicable laws and regulations and the requirements of the Listing Rules. This general mandate to repurchase Shares will remain in effect until:

- (i) the conclusion of the next annual general meeting of our Company;
- (ii) the expiration of the period within which the next annual general meeting of our Company is required to be held under any applicable laws or the Articles of Association; or
- (iii) it is varied or revoked by an ordinary resolution of our Shareholders at a general meeting of our Company;

whichever is the earliest; and

- (e) the general unconditional mandate as mentioned in paragraph (c) above would be extended by the addition to the aggregate nominal value of the Shares which may be allotted and issued or agreed to be allotted and issued by our Directors pursuant to such general mandate of an amount representing the aggregate nominal value of the Shares purchased by our Company pursuant to the mandate to repurchase Shares referred to in paragraph (d) above (up to 10% of the aggregate nominal value of the Shares in issue immediately following completion of the Global Offering, excluding any Shares which may fall to be allotted and issued pursuant to the exercise of the Over-allotment Option).

5. Restrictions on Repurchase

This section sets out information required by the Stock Exchange to be included in this prospectus concerning the repurchase by us of our own Shares.

(a) Provisions of the Listing Rules

The Listing Rules permit companies with a primary listing on the Stock Exchange to repurchase their own Shares on the Stock Exchange subject to certain restrictions, the more important of which are summarized below:

(i) Shareholders' Approval

All proposed repurchase of Shares (which must be fully paid up in the case of shares) by a company with a primary listing on the Stock Exchange must be approved in advance by an ordinary resolution of the shareholders, either by way of general mandate or by specific approval of a particular transaction.

(ii) *Source of Funds*

Repurchases must be funded out of funds legally available for the purpose in accordance with the constitutive documents of a listed company, the laws of the jurisdiction in which the listed company is incorporated or otherwise established. A listed company may not repurchase its own securities on the Stock Exchange for a consideration other than cash or for settlement otherwise than in accordance with the trading rules of the Stock Exchange from time to time. Subject to the foregoing, any repurchases by a listed company may be made out of the funds which would otherwise be available for dividend or distribution or out of the proceeds of a new issue of shares made for the purpose of the repurchase. Any amount of premium payable on the purchase over the par value of the shares to be repurchased must be out of the funds which would otherwise be available for dividend or distribution or from sums standing to the credit of our share premium account.

(b) *Reasons for Repurchase*

Our Directors believe that it is in the best interest of us and our Shareholders for our Directors to have general authority from the Shareholders to enable us to repurchase Shares in the market. Such repurchases may, depending on market conditions and funding arrangements at the time, lead to an enhancement of the net asset value per Share and/or earnings per Share and will only be made where our Directors believe that such repurchases will benefit us and our Shareholders.

(c) *Funding of Repurchases*

In repurchasing securities, we may only apply funds legally available for such purpose in accordance with the Memorandum of Association and Articles of Association, the Companies Act or other applicable laws of Cayman Islands and the Listing Rules. On the basis of our current financial condition as disclosed in this prospectus and taking into account our current working capital position, our Directors consider that, if the Repurchase Mandate were to be exercised in full, it might have a material adverse effect on our working capital and/or our gearing position as compared with the position disclosed in this prospectus. However, our Directors do not propose to exercise the repurchase mandate to such an extent as would, in the circumstances, have a material adverse effect on our working capital requirements or the gearing levels which in the opinion of our Directors are from time to time appropriate for us.

(d) *General*

Exercise in full of the current repurchase mandate, on the basis of 519,955,916 Shares in issue after completion of the Global Offering (without taking into account of the Shares which may be allotted and issued pursuant to the exercise of the Over-allotment Option), could accordingly result in up to 51,995,591 Shares being repurchased by us during the period prior to:

- (i) the conclusion of our next annual general meeting;
- (ii) the expiration of the period within which the next annual general meeting of our Company is required by any applicable law or the Articles of Association to be held; or
- (iii) the date on which the repurchase mandate is varied or revoked by an ordinary resolution of our Shareholders in general meeting, whichever is the earliest.

None of our Directors nor, to the best of their knowledge having made all reasonable enquiries, any of their close associates (as defined in the Listing Rules) currently intends to sell any Shares to us or our subsidiaries. Our Directors have undertaken with the Stock Exchange that, so far as the same may be applicable, they will exercise the repurchase mandate in accordance with the Listing Rules, the Memorandum of Association and Articles of Association, the Companies Act or any other applicable laws of the Cayman Islands.

If, as a result of a repurchase of our Shares pursuant to the repurchase mandate, a Shareholder's proportionate interest in our voting rights is increased, such increase will be treated as an acquisition for the purpose of the Takeovers Code. Accordingly, a Shareholder or a group of Shareholders acting in concert could obtain or consolidate control of us and become obliged to make a mandatory offer in accordance with Rule 26 of the Takeovers Code. Save as aforesaid, our Directors are not aware of any consequences which would arise under the Takeovers Code as a consequence of any repurchases pursuant to the repurchase mandate. Any repurchase of Shares which results in the number of Shares held by the public being reduced to less than 25% of our Shares then in issue could only be implemented with the approval of the Hong Kong Stock Exchange to waive the Listing Rules requirements regarding the public shareholding referred to above. It is believed that a waiver of this provision would not normally be given other than in exceptional circumstances.

No core connected person, as defined in the Listing Rules, has notified us that he/she or it has a present intention to sell his/her or its Shares to us, or has undertaken not to do so, if the repurchase mandate is exercised.

B. FURTHER INFORMATION ABOUT THE BUSINESS OF THE COMPANY

1. Summary of Material Contracts

The following contracts (not being contracts entered into in the ordinary course of business) were entered into by our Group within the two years preceding the date of this prospectus and are or may be material:

- (1) an exclusive operation services agreement dated January 6, 2021 and entered into among Beijing Haiyouyou, Beijing Xunyi, the Registered Shareholders, Yonghe Investment, 62 Medical Institutions⁽¹⁾ wholly-owned by Yonghe Investment and Chengdu Yonghe, pursuant to which, among others, Yonghe Investment, 62 Medical Institutions⁽¹⁾ wholly-owned by Yonghe Investment, Chengdu Yonghe, the Registered Shareholders and Beijing Xunyi agreed to engage Beijing Haiyouyou as their exclusive operational service consultant and service provider to provide operational services in return for service fees;
- (2) an exclusive purchase option agreement dated January 6, 2021 and entered into among Beijing Haiyouyou, the Registered Shareholders and Beijing Xunyi, pursuant to which, among others, each of the Registered Shareholders irrevocably and unconditionally granted Beijing Haiyouyou or its designated person an exclusive purchase option to purchase all or part of his equity interests in Beijing Xunyi and Beijing Xunyi irrevocably and unconditionally granted Beijing Haiyouyou or its designated person an exclusive purchase option to purchase all or part of Beijing Xunyi's assets, each at the minimum purchase price permitted under PRC law;

- (3) an exclusive purchase option agreement dated January 6, 2021 and entered into among Beijing Haiyouyou, Beijing Xunyi, Yonghe Investment, 62 Medical Institutions⁽¹⁾ wholly-owned by Yonghe Investment and Chengdu Yonghe, pursuant to which, among others, (i) Beijing Xunyi irrevocably and unconditionally granted Beijing Haiyouyou or its designated person an exclusive purchase option to purchase all or part of its equity interests in Yonghe Investment and Chengdu Yonghe; (ii) Yonghe Investment irrevocably and unconditionally granted Beijing Haiyouyou or its designated person an exclusive purchase option to purchase all or part of its equity interests in 62 Medical Institutions wholly-owned by Yonghe Investment⁽¹⁾; and (iii) each of Yonghe Investment, the 62 Medical Institutions⁽¹⁾ wholly-owned by Yonghe Investment and Chengdu Yonghe irrevocably and unconditionally granted Beijing Haiyouyou or its designated person an exclusive purchase option to purchase all or part of their respective assets, each at the minimum purchase price permitted under PRC law;
- (4) a shareholders' rights entrustment agreement dated January 6, 2021 and entered into among Beijing Haiyouyou, the Registered Shareholders and Beijing Xunyi, pursuant to which, among others, each of the Registered Shareholders irrevocably authorized and entrusted Beijing Haiyouyou (and its successors or liquidators) or its designated natural person to exercise all his rights and powers as the shareholder of Beijing Xunyi;
- (5) a shareholders' rights entrustment agreement dated January 6, 2021 and entered into among Beijing Haiyouyou, Beijing Xunyi, Yonghe Investment, 62 Medical Institutions⁽¹⁾ wholly-owned by Yonghe Investment and Chengdu Yonghe, pursuant to which, among others, (i) Beijing Xunyi irrevocably authorized and entrusted Beijing Haiyouyou (and its successors or liquidators) or its designated natural person to exercise all its rights and powers as the shareholder of Yonghe Investment and Chengdu Yonghe (as applicable), and (ii) Yonghe Investment irrevocably authorized and entrusted Beijing Haiyouyou (and its successors or liquidators) or its designated natural person to exercise all its rights and powers as the shareholder of its wholly-owned 62 Medical Institutions⁽¹⁾;
- (6) an equity pledge agreement dated January 6, 2021 and entered into among Beijing Haiyouyou, the Registered Shareholders and Beijing Xunyi, pursuant to which, each of the Registered Shareholders unconditionally and irrevocably agreed to pledge and grant first priority security interests over all of his equity interest and rights in Beijing Xunyi to Beijing Haiyouyou;
- (7) an equity pledge agreement January 6, 2021 and entered into among Beijing Haiyouyou, Beijing Xunyi, Yonghe Investment and Chengdu Yonghe, pursuant to which, Beijing Xunyi unconditionally and irrevocably agreed to pledge and grant first priority security interests over all of its equity interest and rights in Yonghe Investment and Chengdu Yonghe to Beijing Haiyouyou;
- (8) an exclusive operation services agreement dated April 8, 2021 and entered into among Beijing Haiyouyou, Beijing Xunyi, the Registered Shareholders, Yonghe Investment and Guiyang Yonghe Jimei Medical Beauty Clinic Co., Ltd. ("**Guiyang Yonghe Jimei**"), pursuant to which, among others, Yonghe Investment, Guiyang Yonghe Jimei, the Registered

Note:

- (1) The 62 Medical Institutions includes No.2 to No.62 Medical Institutions (both inclusive) listed in note 9 to "History – Our Corporate Structure – Corporate Structure Before the Global Offering" in this prospectus and Fuzhou Yonghe Meidu Medical Beauty Clinic Co., Ltd. (福州雍禾美度醫療美容門診部有限公司) (which was deregistered on June 3, 2021).

Shareholders and Beijing Xunyi agreed to engage Beijing Haiyouyou as their exclusive operational service consultant and service provider to provide operational services in return for service fees;

- (9) an exclusive purchase option agreement dated April 8, 2021 and entered into among Beijing Haiyouyou, Beijing Xunyi, Yonghe Investment and Guiyang Yonghe Jimei, pursuant to which, among others, (i) Beijing Xunyi irrevocably and unconditionally granted Beijing Haiyouyou or its designated person an exclusive purchase option to purchase all of the equity interest it owns in Yonghe Investment, and (ii) each of Yonghe Investment and Guiyang Yonghe Jimei irrevocably and unconditionally granted Beijing Haiyouyou or its designated person an exclusive purchase option to purchase all of their assets, each at the minimum purchase price permitted under PRC law;
- (10) a shareholders' rights entrustment agreement dated April 8, 2021 and entered into among Beijing Haiyouyou, Beijing Xunyi, Yonghe Investment and Guiyang Yonghe Jimei, pursuant to which, among others, (i) Beijing Xunyi irrevocably authorized and entrusted Beijing Haiyouyou (and its successors or liquidators) or its designated natural person to exercise all its rights and powers as the shareholder of Yonghe Investment, and (ii) Yonghe Investment irrevocably authorized and entrusted Beijing Haiyouyou (and its successors or liquidators) or its designated natural person to exercise all its rights and powers as the shareholder of Guiyang Yonghe Jimei;
- (11) an exclusive operation services agreement dated August 17, 2021 and entered into among Beijing Haiyouyou, Beijing Xunyi, the Registered Shareholders, Yonghe Investment and Yantai Yonghe Medical Beauty Clinic Co., Ltd. ("**Yantai Yonghe**"), pursuant to which, among others, Yonghe Investment, Yantai Yonghe, the Registered Shareholders and Beijing Xunyi agreed to engage Beijing Haiyouyou as their exclusive operational service consultant and service provider to provide operational services in return for service fees;
- (12) an exclusive purchase option agreement dated August 17, 2021 and entered into among Beijing Haiyouyou, Beijing Xunyi, Yonghe Investment and Yantai Yonghe, pursuant to which, among others, (i) Beijing Xunyi irrevocably and unconditionally granted Beijing Haiyouyou or its designated person an exclusive purchase option to purchase all of the equity interest it owns in Yonghe Investment, and (ii) each of Yonghe Investment and Yantai Yonghe irrevocably and unconditionally granted Beijing Haiyouyou or its designated person an exclusive purchase option to purchase all of their assets, each at the minimum purchase price permitted under PRC law;
- (13) a shareholders' rights entrustment agreement dated August 17, 2021 and entered into among Beijing Haiyouyou, Beijing Xunyi, Yonghe Investment and Yantai Yonghe, pursuant to which, among others, (i) Beijing Xunyi irrevocably authorized and entrusted Beijing Haiyouyou (and its successors or liquidators) or its designated natural person to exercise all its rights and powers as the shareholder of Yonghe Investment, and (ii) Yonghe Investment irrevocably authorized and entrusted Beijing Haiyouyou (and its successors or liquidators) or its designated natural person to exercise all its rights and powers as the shareholder of Yantai Yonghe;

- (14) an exclusive operation services agreement dated September 30, 2021 and entered into among Beijing Haiyouyou, Beijing Xunyi, the Registered Shareholders, Yonghe Investment and Shenzhen Niufeisi Medical Beauty Clinic (“**Shenzhen Niufeisi**”), pursuant to which, among others, Yonghe Investment, Shenzhen Niufeisi, the Registered Shareholders and Beijing Xunyi agreed to engage Beijing Haiyouyou as their exclusive operational service consultant and service provider to provide operational services in return for service fees;
- (15) an exclusive purchase option agreement dated September 30, 2021 and entered into among Beijing Haiyouyou, Beijing Xunyi, Yonghe Investment and Shenzhen Niufeisi, pursuant to which, among others, (i) Beijing Xunyi irrevocably and unconditionally granted Beijing Haiyouyou or its designated person an exclusive purchase option to purchase all of the equity interest it owns in Yonghe Investment, and (ii) each of Yonghe Investment and Shenzhen Niufeisi irrevocably and unconditionally granted Beijing Haiyouyou or its designated person an exclusive purchase option to purchase all of their assets, each at the minimum purchase price permitted under PRC law;
- (16) a shareholders’ rights entrustment agreement dated September 30, 2021 and entered into among Beijing Haiyouyou, Beijing Xunyi, Yonghe Investment and Shenzhen Niufeisi, pursuant to which, among others, (i) Beijing Xunyi irrevocably authorized and entrusted Beijing Haiyouyou (and its successors or liquidators) or its designated natural person to exercise all its rights and powers as the shareholder of Yonghe Investment, and (ii) Yonghe Investment irrevocably authorized and entrusted Beijing Haiyouyou (and its successors or liquidators) or its designated natural person to exercise all its rights and powers as the shareholder of Shenzhen Niufeisi;
- (17) an exclusive operation services agreement dated October 12, 2021 and entered into among Beijing Haiyouyou, Beijing Xunyi, the Registered Shareholders, Yonghe Investment and Shenzhen Svenson Clinic (“**Shenzhen Svenson**”), pursuant to which, among others, Yonghe Investment, Shenzhen Svenson, the Registered Shareholders and Beijing Xunyi agreed to engage Beijing Haiyouyou as their exclusive operational service consultant and service provider to provide operational services in return for service fees;
- (18) an exclusive purchase option agreement dated October 12, 2021 and entered into among Beijing Haiyouyou, Beijing Xunyi, Yonghe Investment and Shenzhen Svenson, pursuant to which, among others, (i) Beijing Xunyi irrevocably and unconditionally granted Beijing Haiyouyou or its designated person an exclusive purchase option to purchase all of the equity interest it owns in Yonghe Investment, and (ii) each of Yonghe Investment and Shenzhen Svenson irrevocably and unconditionally granted Beijing Haiyouyou or its designated person an exclusive purchase option to purchase all of their assets, each at the minimum purchase price permitted under PRC law;

- (19) a shareholders' rights entrustment agreement dated October 12, 2021 and entered into among Beijing Haiyouyou, Beijing Xunyi, Yonghe Investment and Shenzhen Svenson, pursuant to which, among others, (i) Beijing Xunyi irrevocably authorized and entrusted Beijing Haiyouyou (and its successors or liquidators) or its designated natural person to exercise all its rights and powers as the shareholder of Yonghe Investment, and (ii) Yonghe Investment irrevocably authorized and entrusted Beijing Haiyouyou (and its successors or liquidators) or its designated natural person to exercise all its rights and powers as the shareholder of Shenzhen Svenson;
- (20) an exclusive operation services agreement dated October 20, 2021 and entered into among Beijing Haiyouyou, Beijing Xunyi, the Registered Shareholders, Yonghe Investment and Guangzhou Svenson Clinic Co., Ltd. ("**Guangzhou Svenson**"), pursuant to which, among others, Yonghe Investment, Guangzhou Svenson, the Registered Shareholders and Beijing Xunyi agreed to engage Beijing Haiyouyou as their exclusive operational service consultant and service provider to provide operational services in return for service fees;
- (21) an exclusive purchase option agreement dated October 20, 2021 and entered into among Beijing Haiyouyou, Beijing Xunyi, Yonghe Investment and Guangzhou Svenson, pursuant to which, among others, (i) Beijing Xunyi irrevocably and unconditionally granted Beijing Haiyouyou or its designated person an exclusive purchase option to purchase all of the equity interest it owns in Yonghe Investment, and (ii) each of Yonghe Investment and Guangzhou Svenson irrevocably and unconditionally granted Beijing Haiyouyou or its designated person an exclusive purchase option to purchase all of their assets, each at the minimum purchase price permitted under PRC law;
- (22) a shareholders' rights entrustment agreement dated October 20, 2021 and entered into among Beijing Haiyouyou, Beijing Xunyi, Yonghe Investment and Guangzhou Svenson, pursuant to which, among others, (i) Beijing Xunyi irrevocably authorized and entrusted Beijing Haiyouyou (and its successors or liquidators) or its designated natural person to exercise all its rights and powers as the shareholder of Yonghe Investment, and (ii) Yonghe Investment irrevocably authorized and entrusted Beijing Haiyouyou (and its successors or liquidators) or its designated natural person to exercise all its rights and powers as the shareholder of Guangzhou Svenson;
- (23) a cornerstone investment agreement dated November 29, 2021 entered into among our Company, NCC China A-share Master Fund, Morgan Stanley Asia Limited, China International Capital Corporation Hong Kong Securities Limited, pursuant to which NCC China A-share Master Fund agreed to subscribe for Shares at the Offer Price in the aggregate amount of the Hong Kong dollar equivalent of US\$20,000,000;
- (24) a cornerstone investment agreement dated November 29, 2021 entered into among our Company, Yi Fang Da Hadar Investment Limited, Morgan Stanley Asia Limited, China International Capital Corporation Hong Kong Securities Limited, pursuant to which Yi Fang Da Hadar Investment Limited agreed to subscribe for Shares at the Offer Price in the aggregate amount of the Hong Kong dollar equivalent of US\$10,000,000;

- (25) a cornerstone investment agreement dated November 29, 2021 entered into among our Company, Enreal China Master Fund, Forreal China Value Fund, Morgan Stanley Asia Limited, China International Capital Corporation Hong Kong Securities Limited, pursuant to which Enreal China Master Fund and Forreal China Value Fund agreed to subscribe for Shares at the Offer Price in the aggregate amount of the Hong Kong dollar equivalent of US\$10,000,000;
- (26) a cornerstone investment agreement dated November 29, 2021 entered into among our Company, Hudson Bay Master Fund Ltd, Morgan Stanley Asia Limited, China International Capital Corporation Hong Kong Securities Limited, pursuant to which Hudson Bay Master Fund Ltd agreed to subscribe for Shares at the Offer Price in the aggregate amount of the Hong Kong dollar equivalent of US\$10,000,000;
- (27) a cornerstone investment agreement dated November 29, 2021 entered into among our Company, Lake Bleu Prime Healthcare Master Fund Limited, Morgan Stanley Asia Limited, China International Capital Corporation Hong Kong Securities Limited, pursuant to which Lake Bleu Prime Healthcare Master Fund Limited agreed to subscribe for Shares at the Offer Price in the aggregate amount of the Hong Kong dollar equivalent of US\$10,000,000;
- (28) a cornerstone investment agreement dated November 29, 2021 entered into among our Company, LAV Star Limited, LAV Star Opportunities Limited, Morgan Stanley Asia Limited, China International Capital Corporation Hong Kong Securities Limited, pursuant to which LAV Star Limited and LAV Star Opportunities Limited agreed to subscribe for Shares at the Offer Price in the aggregate amount of the Hong Kong dollar equivalent of US\$10,000,000;
- (29) a cornerstone investment agreement dated November 29, 2021 entered into among our Company, WT Asset Management Limited, Morgan Stanley Asia Limited, China International Capital Corporation Hong Kong Securities Limited, pursuant to which WT Asset Management Limited agreed to procure certain funds which it has discretionary investment management power to subscribe for Shares at the Offer Price in the aggregate amount of the Hong Kong dollar equivalent of US\$10,000,000;
- (30) a cornerstone investment agreement dated November 29, 2021 entered into among our Company, IvyRock Asset Management (HK) Limited, Morgan Stanley Asia Limited, China International Capital Corporation Hong Kong Securities Limited, pursuant to which IvyRock Asset Management (HK) Limited agreed to procure certain funds which it has discretionary investment management power to subscribe for Shares at the Offer Price in the aggregate amount of the Hong Kong dollar equivalent of US\$7,000,000;
- (31) a cornerstone investment agreement dated November 29, 2021 entered into among our Company, Athos Asia Event Driven Master Fund, Morgan Stanley Asia Limited, China International Capital Corporation Hong Kong Securities Limited, pursuant to which Athos Asia Event Driven Master Fund agreed to subscribe for Shares at the Offer Price in the aggregate amount of the Hong Kong dollar equivalent of US\$5,000,000;

(32) a cornerstone investment agreement dated November 29, 2021 entered into among our Company, York Asian Opportunities Investments Master Fund, L.P., Morgan Stanley Asia Limited, China International Capital Corporation Hong Kong Securities Limited, pursuant to which York Asian Opportunities Investments Master Fund, L.P. agreed to subscribe for Shares at the Offer Price in the aggregate amount of the Hong Kong dollar equivalent of US\$5,000,000; and





(33) the Hong Kong Underwriting Agreement.

2. Our Material Intellectual Property Rights


(a) Trademarks

As of the Latest Practicable Date, our material registered trademarks were as follows:

No.	Trademark	Place of registration	Name of registered proprietor	Registration no.	Class	Expiry date
1		PRC	Yonghe Investment	26129403	10	September 20, 2028
2		PRC	Yonghe Investment	26124318	42	December 06, 2028
3		PRC	Yonghe Investment	26110014	44	October 27, 2029
4		PRC	Yonghe Investment	5905100	44	February 20, 2030
5		PRC	Yonghe Investment	8565083	5	September 06, 2031
6		PRC	Yonghe Investment	8565120	10	August 13, 2031
7		PRC	Yonghe Investment	26128547	35	September 20, 2028
8		PRC	Yonghe Investment	26115835	44	September 20, 2028
9		PRC	Yonghe Investment	26108693	42	September 20, 2028
10		PRC	Yonghe Investment	27147415	35	October 27, 2028
11		PRC	Yonghe Investment	27142770	10	October 27, 2028
12		PRC	Yonghe Investment	27125374	44	November 06, 2028
13		PRC	Yonghe Investment	42486837	44	July 27, 2030
14		PRC	Yonghe Investment	42467394	44	November 27, 2030

No.	Trademark	Place of registration	Name of registered proprietor	Registration no.	Class	Expiry date
15		PRC	Svenson Beijing	7603644	20	November 20, 2030
16		PRC	Svenson Beijing	7600362	35	December 13, 2030
17		PRC	Svenson Beijing	4672133	44	December 27, 2028
18		PRC	Svenson Beijing	932686	5	January 20, 2027

As of the Latest Practicable Date, we have applied for the registration of the following trademarks which have been published to the public and we consider to be material to our business:

No.	Trademark	Place of registration	Name of applicant	Application no.	Class	Application date
1	雍禾毛发	PRC	Yonghe Investment	53525374	44	February 3, 2021
2		PRC	Yonghe Investment	52448090	35	December 24, 2020
3	雍禾毛发管家	PRC	Yonghe Investment	50638217	35	October 22, 2020

(b) Patents

As of the Latest Practicable Date, our material registered patents were as follows:

No.	Patient No.	Description	Patent type	Place of Registration	Registered owner	Application date
1.	ZL201930685346.3	Operating room communication trolley	Design	PRC	Yonghe Investment	December 9, 2019
2.	ZL201930685445.1	Hair testing machine	Design	PRC	Yonghe Investment	December 9, 2019
3.	ZL201930555554.1	Hair testing machine	Design	PRC	Yonghe Investment	October 12, 2019

No.	Patient No.	Description	Patent type	Place of Registration	Registered owner	Application date
4.	ZL201921693956.9	A testing device	Utility model	PRC	Yonghe Investment	October 10, 2019
5.	ZL201820622564.2	Hair transplant punch and hair transplant surgery equipment	Utility model	PRC	Yonghe Investment	April 27, 2018
6.	ZL201730131657.6	Hair follicles extract needles	Design	PRC	Yonghe Investment	April 19, 2017
7.	ZL201720102689.8	A hair follicles extract needle	Utility model	PRC	Yonghe Investment	February 2, 2017
8.	ZL202130288308.1	Postoperative effect imaging contraster	Design	PRC	Yonghe Investment	May 14, 2021

For material patents of our Group as of the Latest Practicable Date, please refer to the paragraph headed “Business — Intellectual Property” in this prospectus for more details.

(c) Domain Names

As of the Latest Practicable Date, our material domain names were as follows:

No.	Domain name	Registrant	Date of registration	Expiry date
1.	zhifa.cc	Yonghe Investment	December 30, 2009	December 30, 2021
2.	yonghegroup.cn	Beijing Yonghe	November 30, 2020	November 30, 2022

(d) Software Copyrights

As of the Latest Practicable Date, our material software copyrights were as follows:

No.	Registered owner	Description	Type	Registration No.	Registration Institution	Registration Date
1.	Yonghe Investment	Yonghe Hair Transplant Hair Manager Software Abbreviation: Hair Manager V1.0 (雍禾植發毛發管家軟件[簡稱：毛髮管家]V1.0)	Computer Software	2020SR0331600	NCAC	April 14, 2020
2.	Yonghe Investment	Hair Professional Testing and Analysis System V1.0 (毛髮專業檢測分析系統V1.0)	Computer Software	2020SR0654780	NCAC	June 19, 2020

No.	Registered owner	Description	Type	Registration No.	Registration Institution	Registration Date
3.	Yonghe Investment	Hair Transplant Patient Self-service Platform Abbreviation: Hair Transplant Patient Self-service Platform V1.2 (植發患者自主服務平臺[簡稱：植發患者自主平臺]V1.2)	Computer Software	2018SR654146	NCAC	August 16, 2018
4.	Yonghe Investment	Yongxianghui Pro Content Sharing Platform App Abbreviation: Yongxianghui Pro V1.1.1 (雍享匯Pro 內容分享平臺APP[簡稱：雍享Pro] V1.1.1)	Computer Software	2019SR1040615	NCAC	October 14, 2019

Save as aforesaid, as of the Latest Practicable Date, there were no other trade or service marks, patents, intellectual or industrial property rights which were material in relation to our business.

C. FURTHER INFORMATION ABOUT DIRECTORS AND SUBSTANTIAL SHAREHOLDERS

1. Disclosure of Interests

(a) *Interests and short positions of the Directors and chief executive of the Company in the Shares, underlying Shares and debentures of our Company and our associated corporations*

The following table sets out the interests and short positions of our Directors and chief executive of our Company immediately following completion of the Global Offering (without taking into account the Shares which may be allotted and issued pursuant to the exercise of the Over-allotment Option) in our Shares, underlying Shares or debentures of our Company or any of our associated corporations (within the meaning of Part XV of the SFO) which will have to be notified to us and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests and short positions in which they are taken or deemed to have under such provisions of the SFO), or which will be required, pursuant to section 352 of the SFO, to be entered in the register referred to therein, or which will be required to be notified to us and the Stock Exchange pursuant to the Model Code for Securities Transactions by Directors of Listed Issuers contained in the Listing Rules, once our Shares are listed:

Name of Director/ Chief Executive	Capacity/nature of interest	Number of Shares immediately after the completion of the Listing	Approximate percentage of shareholding in the total share capital of our Company after the Global Offering (assuming no exercise of the Over-allotment Option)	Approximate percentage of shareholding in the total share capital of our Company after the Global Offering (assuming the Over-allotment Option is fully exercised) ⁽¹⁾
Mr. Zhang ⁽²⁾⁽³⁾	Founder and beneficiary of a discretionary trust	181,531,916	34.91%	33.99%
Zhang Hui ⁽⁴⁾	Founder and beneficiary of a discretionary trust	24,000,000	4.62%	4.49%
Geng Jiaqi ⁽⁵⁾	Interest in controlled corporation	658,668	0.13%	0.12%

Notes:

- (1) The calculation is based on the total number of 519,955,916 Shares in issue immediately after completion of the Global Offering (without taking into account the Shares which may be issued upon the exercise of the Over-allotment Option).

- (2) ZY Investment Capital Ltd is an investment holding company incorporated in BVI. The entire share capital of ZY Investment Capital Ltd is wholly owned by ZY Ventures Ltd. The entire share capital of ZY Ventures Ltd is wholly owned by Trident Trust Company (Singapore) Pte Limited as the trustee of The ZY Trust. The ZY Trust is a discretionary trust set up by Mr. Zhang as the settlor on March 25, 2021 for benefit of Mr. Zhang and certain of his family members. Mr. Zhang (as the founder of the ZY Trust) and Trident Trust Company (Singapore) Pte Limited are taken to be interest in 40,382,979 Shares held by ZY Investment Capital Ltd under the SFO.
- (3) Yunuo Technology Holdings Limited is an investment holding company incorporated in the BVI and is wholly owned by Shanghai Yuxin Technology Partnership Company (Limited Partnership) (上海予信科技合夥企業(企業合夥)). The limited partner of Shanghai Yuxin Technology Partnership Company (Limited Partnership) is Mr. Zhang, and the general partner is Shanghai Yuhe Technology Partnership Company (Limited Partnership) (上海予赫科技合夥企業(企業合夥)). Therefore, Mr. Zhang is deemed to be interested in 5,000,000 Shares held by Yunuo Technology Holdings Limited under the SFO.
- (4) ZH Investment Capital Ltd is an investment holding company incorporated in BVI. The entire share capital of ZH Investment Capital Ltd is wholly owned by ZH Ventures Ltd. The entire share capital of ZH Ventures Ltd is wholly owned by Trident Trust Company (Singapore) Pte Limited as the trustee of The ZH Trust. The ZH Trust is a discretionary trust set up by Mr. Zhang Hui as the settlor on March 25, 2021 for benefit of Mr. Zhang Hui and certain of his family members. Mr. Zhang Hui (as the founder of the ZH Trust) and Trident Trust Company (Singapore) Pte Limited are taken to be interest in 6,000,000 Shares held by ZH Investment Capital Ltd under the SFO.
- (5) Jiaqi Hair Service Limited is an investment holding company incorporated in BVI. The entire share capital of Jiaqi Hair Service Limited is wholly owned by Geng Jiaqi, a non-executive Director. Accordingly, Geng Jiaqi is deemed to be interested in the Shares held by Jiaqi Hair Service Limited.

(b) Interests of the substantial shareholders in the Shares

Save as disclosed in the section headed “Substantial Shareholders”, immediately following the completion of the Global Offering and without taking into account any Shares which may be issued pursuant to the exercise of the Over-allotment Option, our Directors are not aware of any other person (not being a Director or chief executive of our Company) who will have an interest or short position in the Shares or the underlying Shares which would fall to be disclosed to us and the Stock Exchange under the provisions of Divisions 2 and 3 of Part XV of the SFO, or who is, directly or indirectly, interested in 10% or more of the issued voting shares of our Company.

2. Particulars of Directors’ Service Contracts and Letters of Appointment

Each of our executive Directors has entered into a service contract with our Company and we have issued letters of appointment to our non-executive Director and each of our independent non-executive Directors. The principal particulars of these service contracts and letters of appointment are (a) for a term of 3 years commencing from the Listing Date and (b) are subject to termination in accordance with their respective terms. The term of the service contracts and the letters of appointment may be renewed in accordance with our Articles of Association and the applicable Listing Rules.

Save as disclosed above, none of our Directors has entered, or has proposed to enter, a service contract with any member of our Group (other than contracts expiring or determinable by the employer within one year without the payment of compensation (other than statutory compensation)).

3. Emoluments of Directors

The aggregate amount of emoluments which was paid to our Directors for the three financial years ended December 31, 2018, 2019, 2020 and the six months ended June 30, 2021 were approximately RMB1.1 million, RMB1.8 million, RMB5.7 million and RMB1.0 million, respectively.

It is estimated that emoluments and benefits in kind equivalent to approximately RMB2.2 million in aggregate will be paid and granted to our Directors by us in respect of the three financial year ending December 31, 2021 under arrangements in force at the date of this prospectus.

The aggregate amount of remuneration which were paid by the Group to our five highest paid individual (including both employees and Directors) for the three financial years ended December 31, 2018, 2019, 2020 and the six months ended June 30, 2021 were RMB2.8 million, RMB7.0 million, RMB11.5 million and RMB2.8 million, respectively.

None of our Directors or any past directors of any member of the Group has been paid any sum of money for each of the three financial years ended December 31, 2018, 2019 and 2020 as (a) an inducement to join or upon joining the Company; or (b) for loss of office as a director of any member of the Group or of any other office in connection with the management of the affairs of any member of the Group.

There has been no arrangement under which a Director has waived or agreed to waive any emoluments for each of the three financial years ended December 31, 2018, 2019 and 2020.

4. Disclaimers

Save as disclosed in this prospectus:

- (a) none of our Directors or our chief executive has any interest or short position in the Shares, underlying Shares or debentures of us or any of our associated corporations (within the meaning of Part XV the SFO) which will have to be notified to us and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO, or which will be required, pursuant to section 352 of the SFO, to be entered in the register referred to therein, or which will be required to be notified to us and the Stock Exchange pursuant to Model Code for Securities Transactions by Directors of Listed Issuers once the Shares are listed on the Stock Exchange;
- (b) none of our Directors is aware of any person (not being a Director or chief executive of the Company) who will, immediately following completion of the Global Offering (without taking into account any Shares which may be allotted and issued pursuant to the exercise of the Over-allotment Option), have an interest or short position in the Shares or underlying Shares which would fall to be disclosed to us under the provisions of Divisions 2 and 3 of Part XV of the SFO or who is interested, directly or indirectly, in 10% or more of the issued voting shares of any member of our Group; and

- (c) so far as is known to our Directors, none of our Directors, their respective close associates (as defined under the Listing Rules) or Shareholders who own more than 5% of the number of issued shares of the Company have any interests in the five largest customers or the five largest suppliers of the Group.

D. OTHER INFORMATION

1. Estate Duty

Our Directors have been advised that no material liability for estate duty is likely to fall on our Company or any of our subsidiaries.

2. Litigation

Except as disclosed in this prospectus, as of the Latest Practicable Date, we were not engaged in any litigation, arbitration or claim of material importance and no litigation, arbitration or claim of material importance is known to our Directors to be pending or threatened by or against any member of our Group, that would have a material adverse effect on our Group's results of operations or financial condition, taken as a whole.

3. Preliminary expenses

As of the Latest Practicable Date, our Company has not incurred any material preliminary expenses.

4. Promoter

Our Company has no promoter for the purpose of the Listing. Within the two years preceding the date of this prospectus, no cash, securities or other benefit has been paid, allotted or given or is proposed to be paid, allotted or given to any promoter in connection with the Global Offering and the related transactions described in this prospectus.

5. Taxation of Holders of Shares

(1) Hong Kong

Dealings in Shares registered on our Company's Hong Kong branch register of members will be subject to Hong Kong stamp duty. The sale, purchase and transfer of Shares are subject to Hong Kong stamp duty. The current rate charged on each of the purchaser and seller is 0.1% of the consideration or, if higher, the value of the Shares being sold or transferred. Dividends paid on Shares will not be subject to tax in Hong Kong and no tax is imposed in Hong Kong in respect of capital gains. However, profits from dealings in the Shares derived by persons carrying on a business of trading or dealings in securities in Hong Kong arising in or derived from Hong Kong may be subject to Hong Kong profits tax. The Revenue (Abolition of Estate Duty) Ordinance 2005 came into effect on February 11, 2006 in Hong Kong. No Hong Kong estate duty is payable and no estate duty clearance papers are needed for a grant of representation in respect of holders of Shares whose death occurs on or after February 11, 2006.

(2) Cayman Islands

There is no stamp duty payable in the Cayman Islands on transfers of shares of Cayman Islands companies save for those which hold interests in land in the Cayman Islands.

(3) Consultation with professional advisers

Potential investors in the Global Offering are urged to consult their professional tax advisers if they are in any doubt as to the taxation implications of subscribing for, purchasing, holding or disposing of or dealing in our Shares (or exercising rights attached to them). None of us, the Joint Sponsors, the Joint Global Coordinators, the Joint Bookrunners, the Joint Lead Managers, or any other person or party involved in the Global Offering accept responsibility for any tax effects on, or liabilities of, any person, resulting from the subscription, purchase, holding or disposal of, dealing in or the exercise of any rights in relation to our Shares.

6. Application for Listing

The Joint Sponsors has made an application on behalf of our Company to the Listing Committee of the Stock Exchange for the listing of, and permission to deal in, the Shares in issue and to be issued as mentioned in this prospectus. All necessary arrangements have been made to enable the securities to be admitted into CCASS.

7. No Material Adverse Change

Our Directors up to the date of this prospectus, there has been no material adverse change in the financial or trading position or prospect of our Group since June 30, 2021 (being the date to which the latest audited consolidated financial statements of our Group were prepared).

8. Qualifications of Experts

The qualifications of the experts (as defined under the Listing Rules and the Companies (Winding Up and Miscellaneous Provisions) Ordinance) who have given their opinion and/or advice in this prospectus are as follows:

Name	Qualifications
Morgan Stanley Asia Limited	Licensed corporation under the SFO for Type 1 (dealing in securities), Type 4 (advising on securities), Type 5 (advising on futures contracts), Type 6 (advising on corporate finance) and Type 9 (asset management) regulated activities as defined under the SFO

Name	Qualifications
China International Capital Corporation Hong Kong Securities Limited	A licensed corporation under the SFO to conduct Type 1 (dealing in securities), Type 2 (dealing in futures contracts), Type 4 (advising on securities), Type 5 (advising on futures contracts) and Type 6 (advising on corporate finance) regulated activities as defined under the SFO
PricewaterhouseCoopers	Certified Public Accountants under Professional Accountants Ordinance (Cap. 50) Registered Public Interest Entity Auditor under Financial Reporting Council Ordinance (Cap. 588)
Campbells	Cayman legal adviser
Tian Yuan Law Firm	PRC legal adviser
Frost & Sullivan (Beijing) Inc., Shanghai Branch Co.	Industry consultant
Protiviti Shanghai Co., Ltd.	Internal control expert

As of the Latest Practicable Date, none of the experts named above had any shareholding interest in our Company or any of our subsidiaries or the right (whether legally enforceable or not) to subscribe for or to nominate persons to subscribe for securities in any member of our Group.

9. Consents

Each of the experts named in paragraph headed “8. Qualifications of Experts” above has given and has not withdrawn their respective written consents to the issue of this prospectus with the inclusion of their reports and/or letters and/or the references to their names included herein in the form and context in which they are respectively included.

10. Joint Sponsors’ Independence

The Joint Sponsors satisfy the independence criteria applicable to sponsors set out in Rule 3A.07 of the Listing Rules.

The Joint Sponsors’ fees payable by us in respect of the Joint Sponsors’ services as sponsor for the Listing are USD1 million in total.

11. Binding Effect

This prospectus shall have the effect, if an application is made in pursuance of it, of rendering all persons concerned bound by all of the provisions (other than the penal provisions) of sections 44A and 44B of the Companies (Winding Up and Miscellaneous Provisions) Ordinance so far as applicable.

12. Miscellaneous

Save as otherwise disclosed in this prospectus:

- (a) within the two years preceding the date of this prospectus, no share or loan capital of the Company or any of its subsidiaries has been issued or has been agreed to be issued fully or partly paid either for cash or for a consideration other than cash;
- (b) no share or loan capital of the Company or any of its subsidiaries is under option or is agreed conditionally or unconditionally to be put under option;
- (c) no founder, management or deferred shares of the Company or any of its subsidiaries have been issued or have been agreed to be issued;
- (d) none of the equity and debt securities of the Company is listed or dealt in on any stock exchange (other than the Stock Exchange) nor is any listing or permission to deal being or proposed to be sought;
- (e) the Group has no outstanding convertible debt securities or debentures;
- (f) there is no arrangement under which future dividends are waived or agreed to be waived;
- (g) the English text of this prospectus and the Application Forms shall prevail over their respective Chinese text;
- (h) there has not been any interruption in the business of the Group which may have or has had a significant effect on the financial position of the Group in the 12 months preceding the date of this prospectus;
- (i) within the two years preceding the date of this prospectus, no commission has been paid or is payable (except commissions to sub-underwriters) for subscribing or agreeing to subscribe, or procuring or agreeing to procure the subscriptions, for any Shares in our Company;
- (j) none of our Directors or experts referred to in the paragraph headed “D. Other Information 8. Qualifications of Experts” of this appendix has any direct or indirect interest in the promotion of us, or in any assets which have within the two years immediately preceding the date of this prospectus been acquired or disposed of by or leased to any member of our Group, or are proposed to be acquired or disposed of by or leased to any member of our Group;
- (k) none of our Directors or experts referred to in the paragraph headed “D. Other Information 8. Qualifications of Experts” of this appendix is materially interested in any contract or arrangement subsisting at the date of this prospectus which is significant in relation to the business of our Group taken as a whole; and
- (l) within the two years preceding the date of this prospectus, no commission has been paid or is payable (except commissions to sub-underwriters) for subscribing or agreeing to subscribe, or procuring or agreeing to procure the subscriptions, for any Shares in our Company.

DOCUMENTS DELIVERED TO THE REGISTRAR OF COMPANIES

The documents attached to a copy of this prospectus and delivered to the Registrar of Companies in Hong Kong for registration were (i) a copy of the **GREEN** Application Form; (ii) copies of each of the material contracts referred to in the section headed “Appendix IV — Statutory and General Information — B. Further Information about the Business of the Company — 1. Summary of material contracts”; and (iii) the written consents issued by each of the experts and referred to in section headed “Appendix IV — Statutory and General Information — D. Other information — 8. Qualifications of Experts”.

DOCUMENTS AVAILABLE ON DISPLAY

Copies of the following documents will be available on display on the website of the Stock Exchange at www.hkexnews.hk and our website at www.yonghegroup.cn during a period of 14 days from the date of this prospectus:

- (a) the Memorandum of Association and Articles of Association;
- (b) the accountant’s report of the Group for the years ended December 31, 2018, 2019 and 2020 and the six months ended June 30, 2021 from PricewaterhouseCoopers, the text of which is set out in Appendix I to this prospectus;
- (c) the audited consolidated financial statements of our Group for the years ended December 31, 2018, 2019 and 2020 and the six months ended June 30, 2021;
- (d) the report from PricewaterhouseCoopers on the unaudited pro forma financial information of our Group, the text of which is set out in Appendix II to this prospectus;
- (e) the PRC legal opinions issued by Tian Yuan Law Firm, our legal advisers on PRC law, in respect of our general matters and property interests;
- (f) the letter issued by Campbells, our legal advisers on Cayman Islands laws, summarizing certain aspects of Companies Act referred to in the section headed “Appendix III — Summary of the Constitution of the Company and Cayman Islands Company Law”;
- (g) the industry report prepared by Frost & Sullivan referred to in the section headed “Industry Overview” in this Prospectus;
- (h) the report for internal control review over the non-compliance incidents referred to in the paragraph headed “Licenses, Permits, Approvals and Compliance” in the section headed “Business” in this prospectus prepared by Protiviti;
- (i) the Companies Act;
- (j) the material contracts referred to in the section headed “Appendix IV — Statutory and General Information — B. Further Information about the Business of the Company — 1. Summary of Material Contracts”;

- (k) the service agreements and letters of appointment referred to in “Appendix IV — Statutory and General Information — C. Further Information about Directors and Substantial Shareholders — 2. Particulars of Directors’ Service Contracts and Letters of Appointment”; and
- (l) the written consents referred to in the section headed “Appendix IV — Statutory and General Information — D. Other Information — 9. Consents”.

YONGHE MEDICAL GROUP CO., LTD.
雍禾醫療集團有限公司